PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	TEPPER, RI; COFFMAN, RL; LEDER, P				TEPPER, RI; COFFMAN, RL; LEDER, P			AN EOSINOPHIL-DEPENDENT MECHANISM FOR THE ANTITUMOR EFFECT OF INTERLEUKIN-4	SCIENCE			English	Article							LYMPHOCYTES	Murine interleukin-4 (IL-4) exhibits potent antitumor activity when present at the site of tumor cell challenge. Associated with tumor cell death is the appearance of an inflammatory infiltrate comprised predominantly of eosinophils and macrophages, but with few lymphocytes. Antibodies that specifically block the accumulation of granulocytes at the site of inflammation were injected in vivo to define the cell type responsible for the antitumor action of IL-4. These studies implicate eosinophils in IL-4-mediated tumor cytotoxicity. The lymphoid-independent nature of IL-4 action is supported by the analysis of mutant mouse strains with defined lymphocyte immunodeficiencies. The observed regression of established tumor masses by localized IL-4 action provides a rationale for exploring IL-4-mediated tumor killing as a potential therapy for human malignant disorders.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	TEPPER, RI (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114, USA.							COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COLEY DG, 1972, EXP PARASITOL, V32, P520; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; PENNLINE KJ, 1990, CYTOMETRY, V11, P823; SCHREIBER H, 1989, FUNDAMENTAL IMMUNOLO, P927; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2	8	505	514	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					548	551		10.1126/science.1636093	http://dx.doi.org/10.1126/science.1636093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636093				2022-12-24	WOS:A1992JE75500035
J	FRANCES, R; FRANKLIN, JE				FRANCES, R; FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOPAMINE-D2 RECEPTOR GENE; ALCOHOLISM; ASSOCIATION; DISORDER				FRANCES, R (corresponding author), UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103, USA.							BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS CE, 1991, JAMA-J AM MED ASSOC, V266, P1793; DULIT RA, 1990, AM J PSYCHIAT, V147, P1002; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; GALANTER M, 1991, AM J DRUG ALCOHOL AB, V17, P1, DOI 10.3109/00952999108992805; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GEORGE DT, 1990, ACTA PSYCHIAT SCAND, V82, P1, DOI 10.1111/j.1600-0447.1990.tb01345.x; HUGHES JR, 1991, ARCH INTERN MED, V151, P1993, DOI 10.1001/archinte.151.10.1993; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685; METZGER D, 1991, AM J PSYCHIAT, V148, P636; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P655; ORFORD J, 1991, BRIT J MED PSYCHOL, V64, P189, DOI 10.1111/j.2044-8341.1991.tb01656.x; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P653; SCHRAGER L, 1991, PUBLIC HEALTH REP, V106, P78; SCHWAB S, 1991, AM J HUM GENET, V49, P203; UHL GR, 1992, ARCH GEN PSYCHIAT, V49, P157; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1991, JAMA-J AM MED ASSOC, V266, P3133; 1991, AM J PSYCHIAT, V148, P1291	24	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					330	332						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613907				2022-12-24	WOS:A1992JC35200017
J	OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT				OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT			VENTRICULAR ARRHYTHMIAS IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; NON-CARDIAC SURGERY; CIGARETTE-SMOKING; RISK; STRESS; INDEX	Objective.-To determine the incidence, clinical predictors and prognostic importance of perioperative ventricular arrhythmias. Design.-Prospective cohort study (Study of Perioperative Ischemia). Setting.-University-affiliated Department of Veterans Affairs Medical Center, San Francisco, Calif. Subjects.-A consecutive sample of 230 male patients, with known coronary artery disease (46%) or at high risk of coronary artery disease (54%), undergoing major noncardiac surgical procedures. Measurements.-We recorded cardiac rhythm throughout the preoperative (mean=21 hours), intraoperative (mean=6 hours), and postoperative (mean=38 hours) periods using continuous ambulatory electrocardiographic monitoring. Adverse cardiac outcomes were noted by physicians blinded to information about arrhythmias. Main Results.-Frequent or major ventricular arrhythmias (>30 ventricular ectopic beats per hour, ventricular tachycardia) occurred in 44% of our patients: 21% preoperatively, 16% intraoperatively, and 36% postoperatively. Compared with the preoperative baseline, the severity of arrhythmia increased in only 2% of patients intraoperatively but in 10% postoperatively. Preoperative ventricular arrhythmias were more common in smokers (odds ratio [OR], 4.1; 95% confidence interval [CI], 1.2 to 15.0), those with a history of congestive heart failure (OR, 4.1; 95% CI, 1.9 to 9.0), and those with electrocardiographic evidence of myocardial ischemia (OR, 2.2; 95% CI, 1. 1 to 4.7). Preoperative arrhythmias were associated with the occurrence of intraoperative and postoperative arrhythmias (OR, 7.3; 95% CI, 3.3 to 16.0, and OR, 6.4; 95% CI, 2.7 to 15.0, respectively). Nonfatal myocardial infarction or cardiac death occurred in nine men; these outcomes were not significantly more frequent in those with prior perioperative arrhythmias, albeit with wide CIs (OR, 1.6; 95% CI, 0.4 to 6.2). Conclusion.-Almost half of all high-risk patients undergoing noncardiac surgery have frequent ventricular ectopic beats or nonsustained ventricular tachycardia. Our results suggest that these arrhythmias, when they occur without other signs or symptoms of myocardial infarction, may not require aggressive monitoring or treatment during the perioperative period.	DEPT VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; DEPT VET AFFAIRS MED CTR,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DEPT ANESTHESIA,SAN FRANCISCO,CA	University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, P01HL025847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25847, HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERTRAND CA, 1971, J AMER MED ASSOC, V216, P1615, DOI 10.1001/jama.216.10.1615; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DAVIS MJE, 1984, AM J CARDIOL, V54, P282, DOI 10.1016/0002-9149(84)90183-8; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DODD RB, 1962, SURGERY, V51, P440; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; HENNEKENS CH, 1980, AM J EPIDEMIOL, V112, P93, DOI 10.1093/oxfordjournals.aje.a112980; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HOLLIFIELD JW, 1989, AM J CARDIOL, V63, pG22, DOI 10.1016/0002-9149(89)90214-2; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; KIMBROUGH HM, 1975, J UROLOGY, V113, P846, DOI 10.1016/S0022-5347(17)59596-8; Kjekshus J, 1990, AM J CARDIOL, V65, P421, DOI DOI 10.1084/JEM.20051151; KNOEBEL SB, 1989, CIRCULATION, V79, P206, DOI 10.1161/01.CIR.79.1.206; KUNER J, 1967, DIS CHEST, V52, P580, DOI 10.1378/chest.52.5.580; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MASSIE B M, 1992, Journal of the American College of Cardiology, V19, p78A; MORGANROTH J, 1987, AM J CARDIOL, V59, pE32, DOI 10.1016/0002-9149(87)90199-8; MYERS MG, 1988, CHEST, V93, P14, DOI 10.1378/chest.93.1.14; NADEMANEE K, 1990, CIRCULATION, V82, P1054, DOI 10.1161/01.CIR.82.3.1054; PODRID PJ, 1989, EUR HEART J, V10, P66, DOI 10.1093/eurheartj/10.suppl_E.66; PRATT CM, 1985, NEW ENGL J MED, V313, P1444, DOI 10.1056/NEJM198512053132304; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VANIK PE, 1968, ANESTH ANAL CURR RES, V47, P299; 1978, MANUAL OPERATIONS, V2	34	75	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					217	221		10.1001/jama.268.2.217	http://dx.doi.org/10.1001/jama.268.2.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608140				2022-12-24	WOS:A1992JB27900028
J	KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L				KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH STREPTOKINASE IN ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORCESTER HEART-ATTACK; MORTALITY; PROGNOSIS; RATES	Background. There is a lack of consensus among cardiologists about the potential benefit of thrombolytic therapy for suspected acute myocardial infarction in older patients. To investigate this issue, we constructed a decision-analytic model for patients 75 years of age or older who present with ST-segment elevation within six hours of the onset of symptoms suggesting acute myocardial infarction. Methods. The variables incorporated in this model were the probability that the patient has an acute myocardial infarction, the probability of in-hospital death among patients with acute myocardial infarction who do not receive thrombolytic therapy, the probability of a fatal or incapacitating complication resulting from thrombolytic therapy, and the expected relative reduction in the risk of death associated with thrombolytic therapy in patients with acute myocardial infarction. Our analyses were based primarily on the use of streptokinase as the thrombolytic agent. Results. Given our base-line assumptions, the probability of dying in the hospital was 21.4 percent if thrombolytic therapy was given and 24.4 percent if it was not given. In one-way sensitivity analyses, thrombolytic therapy decreased the risk of dying if the probability that the patient had an acute myocardial infarction was assumed to be greater than 9 percent, if the probability of dying in the hospital after an acute myocardial infarction without thrombolytic therapy was assumed to be greater than 3 percent, if the rate of fatal or incapacitating complications due to thrombolytic therapy was assumed to be 4 percent or less, or if the relative reduction in the risk of death associated with thrombolytic therapy was assumed to be greater than 1 percent. On the basis of our base-line assumptions, our estimate of the cost effectiveness of streptokinase therapy (the cost per year of life saved) for an 80-year-old patient with suspected acute myocardial infarction was $21,200. For a wide range of assumptions about risks, benefits, and costs, the cost per year of life saved remained less than $55,000. Conclusions. Within the limitations imposed by the assumptions used in our analysis, thrombolytic therapy with streptokinase was found to be a beneficial and cost-effective treatment for suspected acute myocardial infarction in elderly patients in a wide variety of clinical circumstances.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DIV CARDIOVASC, NASHVILLE, TN 37240 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University			, Harlan/AAI-2875-2020		AHRQ HHS [1P01HS06341, 1R01HS06452, 1R01HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; Hodgson T A, 1984, Health Care Financ Rev, V5, P1; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1232; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOX RG, 1988, LANCET, V2, P525; 1988, AGING AM TRENDS PROJ; 1991, CIRCULATION S2, V84, P230	26	160	160	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					7	13		10.1056/NEJM199207023270102	http://dx.doi.org/10.1056/NEJM199207023270102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598117				2022-12-24	WOS:A1992JA76100002
J	LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D				LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D			A BEDSIDE DECISION INSTRUMENT TO ELICIT A PATIENTS PREFERENCE CONCERNING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						DECISION MAKING; BREAST NEOPLASMS; ANTINEOPLASTIC AGENTS; QUALITY OF LIFE PATIENT SATISFACTION	THERAPY; QUALITY; LIFE	The objective of this study was to develop an instrument to help clinicians inform patients with breast cancer of risks and benefits of adjuvant chemotherapy as derived from clinical trials and to help the informed patient decide whether she prefers treatment or no treatment. The instrument consists of a visual aid (called the decision board) and written material. It provides detailed information on a patient's choices (chemotherapy or no chemotherapy), outcomes (recurrence or not), probabilities of outcomes and their meaning, and quality of life associated with treatment choice and outcome. The validity and reliability of the instrument were evaluated in 30 healthy female volunteers. It was first administered using standard estimates of recurrence for node-negative breast cancer (15% risk of recurrence without treatment, which is reduced to 10% with chemotherapy). A preference for treatment (or no treatment) was then elicited. The validity was evaluated by changing the information provided on risks and benefits and determining whether the preference changed in a predictable manner. To test for reliability, the instrument was administered 2 weeks later. Seventeen women chose chemotherapy and 13 chose no chemotherapy. In the former group, 14 women (82%) switched preference when the magnitude of benefit was reduced, and 16 (94%) switched when the toxicity of treatment was increased. For those women who chose not to receive chemotherapy, 12 (92%) switched when the benefit was increased and 100% switched when toxicity was eliminated. The reliability was excellent (kappa = 0.86). The instrument has been used to elicit treatment preferences in 37 newly presenting patients with high-risk, node-negative breast cancer and has been found to be acceptable and helpful to the patient.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	LEVINE, MN (corresponding author), HAMILTON REG CANC CTR, 699 CONCESS ST, HAMILTON L8V 5C3, ONTARIO, CANADA.							BONADONNA G, 1985, J CLIN ONCOL, V3, P259, DOI 10.1200/JCO.1985.3.2.259; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; BUDESCU DV, 1990, ORGAN BEHAV HUM DEC, V46, P240, DOI 10.1016/0749-5978(90)90031-4; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; GAFNI A, 1990, NEW ENGL J MED, V323, P1354; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; HENDERSON IC, 1987, CURR PROB CANCER, V11, P127; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HUGHES TE, 1991, MED CARE, V29, P297, DOI 10.1097/00005650-199103000-00011; LEVINE MN, 1988, J CLIN ONCOL, V6, P1798, DOI 10.1200/JCO.1988.6.12.1798; LEVINE MN, 1991, J CLIN ONCOL, V9, P348, DOI 10.1200/JCO.1991.9.2.348; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MEHREZ A, 1991, MED DECIS MAKING, V11, P140, DOI 10.1177/0272989X9101100212; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; MEHREZ A, 1990, SOC SCI MED, V31, P1281, DOI 10.1016/0277-9536(90)90137-H; NORMAN GR, 1986, PDQ STATISTICS; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; ROSE G, 1990, BRIT MED J, V301, P683, DOI 10.1136/bmj.301.6754.683; SIMINOFF LA, 1989, MED DECIS MAKING, V9, P262, DOI 10.1177/0272989X8900900406; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192	26	230	231	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					53	58		10.7326/0003-4819-117-1-53	http://dx.doi.org/10.7326/0003-4819-117-1-53			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596048				2022-12-24	WOS:A1992JA43500010
J	PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL				PRAS, E; AKSENTIJEVICH, I; GRUBERG, L; BALOW, JE; PROSEN, L; DEAN, M; STEINBERG, AD; PRAS, M; KASTNER, DL			MAPPING OF A GENE CAUSING FAMILIAL MEDITERRANEAN FEVER TO THE SHORT ARM OF CHROMOSOME-16	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LINKAGE ANALYSIS; DNA; AMYLOIDOSIS; IDENTIFICATION; POLYSEROSITIS; C5A-INHIBITOR; LOCALIZATION; ARMENIANS; FREQUENCY; COMMITTEE	Background. Familial Mediterranean fever is an autosomal-recessive disease characterized by acute attacks of fever with sterile peritonitis, pleurisy, or synovitis. The biochemical basis of the disease is unknown, but determining the chromosomal location of the gene for the disorder should be a first step toward defining the biochemical events. Methods and Results. As part of a systematic genome-wide search, we sought evidence of linkage between familial Mediterranean fever and chromosome 16 DNA markers in 27 affected non-Ashkenazi Jewish families from Israel. Two loci from the subtelomeric region of the short arm of chromosome 16 (16p) had lod scores sufficient to establish linkage (a score greater-than-or-equal-to 3). One DNA marker (D16S84) gave a maximal lod score of 9.17 (odds of 10(9.17) to 1 in favor of linkage) at a recombination frequency (theta) of 0.04. A probe associated with the hemoglobin-alpha complex (5'HVR) gave a maximal lod score of 14.47 at a theta of 0.06. Multipoint linkage analysis indicated that the following was the most likely gene order: the centromere, the gene for familial Mediterranean fever, D16S84, hemoglobin-alpha, and the telomere. The maximal multipoint lod score was 19.86. There was a striking degree of homozygosity at chromosome 16p loci in the affected offspring of eight consanguineous couples. Conclusions. The gene that causes familial Mediterranean fever in non-Ashkenazi Jews maps to the short arm of chromosome 16.	NIAMSD,ARTHRITIS & RHEUMATISM BRANCH,BLDG 6,RM 112,BETHESDA,MD 20892; CHAIM SHEBA MED CTR,DEPT MED,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL; NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Chaim Sheba Medical Center; Chaim Sheba Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012; Aksentijevich, Ivona/AAF-1335-2019	Dean, Michael C/0000-0003-2234-0631; 				AKSENTIJEVICH I, 1991, AM J HUM GENET, V49, P335; ANDERSON MA, 1984, IN VITRO CELL DEV B, V20, P856; AYESH SK, 1990, J IMMUNOL, V144, P3066; BARAKAT MH, 1986, Q J MED, V60, P837; Battey, 1986, BASIC METHODS MOL BI; CAVENEE W, 1984, AM J HUM GENET, V36, P10; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONNEALLY PM, 1985, CYTOGENET CELL GENET, V40, P356, DOI 10.1159/000132186; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; DIAMOND JM, 1987, NATURE, V329, P105, DOI 10.1038/329105a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRADKIN A, 1985, ISRAEL J MED SCI, V21, P757; GERMINO GG, 1990, AM J HUM GENET, V46, P925; GRUBERG L, 1991, CYTOGENET CELL GENET, V58, P2113; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JULIER C, 1990, GENOMICS, V6, P419, DOI 10.1016/0888-7543(90)90471-6; KASTNER DL, 1991, CYTOGENET CELL GENET, V58, P2115; Kosambi D. D., 1944, ANN EUGENICS, V12, P172; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MEYERHOFF J, 1980, MEDICINE, V59, P66, DOI 10.1097/00005792-198001000-00004; MULLEY JC, 1990, CYTOGENET CELL GENET, V53, P175, DOI 10.1159/000132923; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P3122, DOI 10.1093/nar/16.7.3122; OTT J, 1985, ANAL HUMAN GENETIC L, P27; OZDEMIR A I, 1969, American Journal of Gastroenterology, V51, P311; PRAS M, 1982, JOHNS HOPKINS MED J, V150, P22; PRITCHARD MA, 1991, GENOMICS, V10, P801, DOI 10.1016/0888-7543(91)90466-R; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REEDERS S T, 1988, Genomics, V3, P150, DOI 10.1016/0888-7543(88)90146-2; REEDERS ST, 1989, CYTOGENET CELL GENET, V51, P299, DOI 10.1159/000132796; REEDERS ST, 1991, CYTOGENET CELL GENET, V58, P643, DOI 10.1159/000133176; REIMANN HA, 1954, JAMA-J AM MED ASSOC, V154, P1254, DOI 10.1001/jama.1954.02940490018005; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; SCHLESINGER M, 1984, TISSUE ANTIGENS, V24, P65; SCHWABE AD, 1974, MEDICINE, V53, P453, DOI 10.1097/00005792-197411000-00005; SCHWABE AD, 1987, JPN J MED, V26, P370, DOI 10.2169/internalmedicine1962.26.370; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; WILSON D E, 1989, American Journal of Human Genetics, V45, pA168	41	228	236	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 4	1992	326	23					1509	1513		10.1056/NEJM199206043262301	http://dx.doi.org/10.1056/NEJM199206043262301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW972	1579134				2022-12-24	WOS:A1992HW97200001
J	TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI				TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI			ANIMAL-MODEL OF GAUCHERS-DISEASE FROM TARGETED DISRUPTION OF THE MOUSE GLUCOCEREBROSIDASE GENE	NATURE			English	Article							CELLS; MUTATIONS	GAUCHER's disease is the most prevalent lysosomal storage disorder in humans and results from an autosomally inherited deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase) 1-6, which is responsible for degrading the sphingolipid glucocerebroside. An animal model for Gaucher's disease would be important for investigating its phenotypic diversity and pathogenesis and for evaluating therapeutic approaches. A naturally occurring canine model has been reported but not propagated 7. Attempts to mimic the disease in animals by inhibiting glucocerebrosidase have been inadequate 8. Here we generate an animal model for Gaucher's disease by creating a null allele in embryonic stem cells through gene targeting and using these genetically modified cells to establish a mouse strain carrying the mutation 9,10. Mice homozygous for this mutation have < 4% Of normal glucocerebrosidase activity, die within twenty-four hours of birth and store glucocerebroside in lysosomes of cells of the reticuloendothelial system.	NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; NICHHD,MAMMALIAN GENES & DEV LAB,BETHESDA,MD 20892; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Erasmus University Rotterdam				Zablocka, Barbara/0000-0003-3116-7295				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BEUTLER E, 1970, LANCET, V1, P612; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DEBRUIJN WC, 1976, HISTOCHEM J, V8, P121, DOI 10.1007/BF01007164; FREDRICKSON DS, 1978, METABOLIC BASIS INHE, P731; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; HARTLEY WJ, 1982, HDB ANIMAL MODELS HU; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Kanfer J N, 1982, Prog Clin Biol Res, V95, P627; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; Lee R E, 1982, Prog Clin Biol Res, V95, P177; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin B M, 1989, Adv Pediatr, V36, P277; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SUN CC, 1984, PATHOL RES PRACT, V179, P101, DOI 10.1016/S0344-0338(84)80069-2; SVENNERHOLM L, 1982, GAUCHER DIS CENTURY, P231; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILLEMSEN R, 1988, ULTRASTRUCT PATHOL, V12, P471, DOI 10.3109/01913128809032232	25	246	251	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					407	410		10.1038/357407a0	http://dx.doi.org/10.1038/357407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594045				2022-12-24	WOS:A1992HX17200064
J	BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA				BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA			INCIDENCE OF LEUKEMIA AND OTHER CANCERS IN BIRTH AND SCHOOLS COHORTS IN THE DOUNREAY AREA	BRITISH MEDICAL JOURNAL			English	Article							WEST CUMBRIA; CHILDHOOD LEUKEMIA; CHILDREN BORN; YOUNG-PEOPLE; SEASCALE; FOLLOW	Objective - To determine whether a raised incidence of leukaemia in the Dounreay area occurred in children born to local mothers (birth cohort) or in those who moved to the area after birth (schools cohort) and also whether any cases of cancer have occurred in children born near Dounreay who may have moved elsewhere. Design - Follow up study. Setting - Dounreay area of Caithness, Scotland. Subjects - 4144 children born in the area in the period 1969-88 and 1641 children who attended local schools in the same period but who had been born elsewhere. Main outcome measures - Cancer registration records linked to birth and schools records with computerised probability matching methods. Results - Five cancer registrations were traced from the birth cohort compared with 5.8 expected on the basis of national rates (observed to expected ratio 0.9, 95% confidence interval 0.3 to 2.0). Atl five cases were of leukaemia (2.3, 0.7 to 5.4). In the schools cohort three cases were found (2.1, 0.4 to 6.2), all of which were of leukaemia (6.7, 1.4 to 19.5). All eight children were resident in the Dounreay area at the time of diagnosis; thus no cases were found in children who were born in or had attended school in the study area but who subsequently moved away. Conclusion - The raised incidence of leukaemia in both the birth and schools cohorts suggests that place of birth is not a more important factor than place of residence in the series of cases of leukaemia observed near Dounreay area.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	BLACK, RJ (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.							Baldwin JA, 1987, TXB MED RECORD LINKA; BELL AG, 1989, REPORT DOUNREAY EDRP; BLACK D, 1984, INVESTIGATION POSSIB; Breslow NE, 1987, SCI PUBLICATIONS, VII; DRAPER GJ, 1988, SCI PUBLICATION, V87; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GLASS S, 1987, LEUKEMIA RES, V2, P881; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; KINLEN L, 1988, LANCET, V2, P1323; Newcombe H. B., 1988, HDB RECORD LINKAGE; STILLER CA, 1988, SCI PUBLICATION, V87; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, COMARE2ND COMM MED A	17	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1401	1405		10.1136/bmj.304.6839.1401	http://dx.doi.org/10.1136/bmj.304.6839.1401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628012	Green Published, Bronze			2022-12-24	WOS:A1992HX08200015
J	ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD				ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD			HIGH-EFFICIENCY EXPRESSION AND SOLUBILIZATION OF FUNCTIONAL T-CELL ANTIGEN RECEPTOR HETERODIMERS	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; CYTOCHROME-C; DEGRADATION; RECOGNITION; IA; COMPLEX; CHAINS; GENE; ZETA; BETA	The T cell receptor (TCR) zeta-chain was attached to the TCR-alpha and beta-extracellular domains to induce efficient expression of alpha-beta-heterodimers that can recognize complexes of antigen with major histocompatibility complex (MHC) molecules. Chimeric constructs expressed in RBL-2H3 cells were efficiently transported to the cell surface uniquely as disulfide-linked heterodimers. Transfectants were activated by specific antigen-MHC complexes, which demonstrated that the expressed-alpha-beta was functional and that CD3 was not required for antigen-MHC binding. Constructs with thrombin cleavage sites were efficiently cleaved to soluble disulfide-linked heterodimers. Thus, attachment of TCR-zeta-domains and protease cleavage sites to TCR-alpha and beta induces expression of demonstrably functional heterodimers that can be solubilized.			ENGEL, I (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HANSBURG D, 1983, J IMMUNOL, V131, P319; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI C, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743	30	76	94	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1318	1321		10.1126/science.1598575	http://dx.doi.org/10.1126/science.1598575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598575				2022-12-24	WOS:A1992HW13500033
J	GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR				GIORDANO, A; LEE, JH; SCHEPPLER, JA; HERRMANN, C; HARLOW, E; DEUSCHLE, U; BEACH, D; FRANZA, BR			CELL-CYCLE REGULATION OF HISTONE-H1 KINASE-ACTIVITY ASSOCIATED WITH THE ADENOVIRAL PROTEIN-E1A	SCIENCE			English	Article							CONTROL GENE CDC2+; FISSION YEAST; E1A PROTEINS; DIVISION CYCLE; DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL DOMAINS; TRANSFORMATION; GROWTH; EXPRESSION	Several cellular proteins form stable complexes with the proteins encoded by the adenovirus early region 1A (E1A) gene in extracts derived from adenovirus infected or transformed cells. Two of the cellular proteins that bind to E1A have been identified; one, a 105-kilodalton protein (pRb), is the product of the retinoblastoma gene, and the other, a 60-kilodalton protein, is a human cyclin A. Two other proteins that bind E1A have now been shown to be related to p34cdc2. This E1A complex displayed histone H1-specific kinase activity; the kinase activity was modulated during the cell division cycle, and association of pRb with E1A apparently was not required for this activity.	COLD SPRING HARBOR LAB,FREEMAN LAB CANC CELL BIOL,COLD SPRING HARBOR,NY 11724; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, UNPUB; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; STEPHENS C, 1986, CANCER CELL, V4, P429; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	53	93	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 13	1991	253	5025					1271	1275		10.1126/science.1653969	http://dx.doi.org/10.1126/science.1653969			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE689	1653969				2022-12-24	WOS:A1991GE68900038
J	SAMPEDRO, J; GUERRERO, I				SAMPEDRO, J; GUERRERO, I			UNRESTRICTED EXPRESSION OF THE DROSOPHILA GENE PATCHED ALLOWS A NORMAL SEGMENT POLARITY	NATURE			English	Article							PATTERN-FORMATION; BODY PATTERN; EMBRYOS; REQUIREMENTS; WINGLESS; PROTEIN; CUTICLE; LARVAL	IN the Drosophila embryo, mutations in the segment polarity gene patched (ptc) cause the replacement of the middle region of each segment by a mirror-image duplication of the remaining structures, including the parasegmental border 1-3. This gene, which encodes a transmembrane protein, is initially expressed in a generalized way at blastoderm, but later stops being transcribed in cells expressing the engrailed gene, and even later in cells in the middle of the parasegment 2-4. The genes engrailed (en) and wingless (wg) are also segment-polarity genes, and they are expressed in adjacent stripes flanking the parasegment borders in the embryo 5; in ptc mutants wg expression extends anteriorly and an ectopic stripe of en expression is induced 6,7. The suggestion has been made that ptc must be transcribed in a specific subset of cells to prevent en expression anterior to the wg-expressing stripe 4. Here we report that unrestricted expression of ptc from a heat-shock promoter has no adverse effect on development of Drosophila embryos. The heat-shock construct can also rescue ptc mutants, restoring wg expression to its normal narrow stripe. The ectopic en stripe fails to appear, but the normal one remains unaffected. The results imply that, despite its localized requirement, the restricted expression of ptc does not itself allocate positional information.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Guerrero, Isabel/K-2518-2014	Guerrero, Isabel/0000-0001-6761-1218				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; COHEN SM, 1989, EMBO J, V8, P2045, DOI 10.1002/j.1460-2075.1989.tb03613.x; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DiNardo S, 1990, Semin Cell Biol, V1, P173; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM P, 1985, NATURE, V317, P634, DOI 10.1038/317634a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	19	31	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					187	190		10.1038/353187a0	http://dx.doi.org/10.1038/353187a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653907				2022-12-24	WOS:A1991GE73100060
J	SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK				SAFRIN, S; BERGER, TG; GILSON, I; WOLFE, PR; WOFSY, CB; MILLS, J; BIRON, KK			FOSCARNET THERAPY IN 5 PATIENTS WITH AIDS AND ACYCLOVIR-RESISTANT VARICELLA-ZOSTER VIRUS-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						VARICELLA ZOSTER VIRUS; ACQUIRED IMMUNODEFICIENCY SYNDROME; FOSCARNET; ACYCLOVIR; HUMAN IMMUNODEFICIENCY VIRUS	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HERPES-ZOSTER	Objective: To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS). Design: Open-label study. Setting. Three university medical centers. Patients: Five patients with AIDS who were infected with thymidine-kinase-deficient or -altered strains of varicella-zoster virus. Intervention: Foscarnet, 40 mg/kg body weight every 8 hours in 1-hour infusions for 10 or more days. Main Results: Four patients had healing in response to foscarnet therapy, and each of four tested patients became culture negative for virus during foscarnet therapy. Results of fluorescent antigen testing remained positive during therapy in two patients; one of these patients had concomitant clinical failure but the other patient healed fully. One patient had complete healing despite the emergence of resistance to foscarnet in serial specimens obtained during foscarnet therapy. Conclusion: Foscarnet is a potentially effective and tolerable antiviral agent for patients with acyclovir-resistant, varicella-zoster virus infection; however, the optimal dosage and duration of therapy require further study, as does the relation between clinical findings and in-vitro susceptibility results.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94110 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	University of California System; University of California San Francisco; Burroughs Wellcome Fund								BABA M, 1986, TOHOKU J EXP MED, V148, P275, DOI 10.1620/tjem.148.275; FRIEDMANKIEN AE, 1986, J AM ACAD DERMATOL, V14, P1023, DOI 10.1016/S0190-9622(86)70127-8; GILSON IH, 1989, J AM ACAD DERMATOL, V20, P637, DOI 10.1016/S0190-9622(89)70076-1; HOPPENJANS WB, 1990, ARCH DERMATOL, V126, P1048, DOI 10.1001/archderm.126.8.1048; JACOBSON MA, 1990, ANN INTERN MED, V112, P187, DOI 10.7326/0003-4819-112-3-187; JANIER M, 1988, J AM ACAD DERMATOL, V18, P584, DOI 10.1016/S0190-9622(88)80295-0; LINNEMANN CC, 1990, AIDS, V4, P577, DOI 10.1097/00002030-199006000-00014; PAHWA S, 1988, JAMA-J AM MED ASSOC, V260, P2879, DOI 10.1001/jama.260.19.2879; SAFRIN S, 1990, J INFECT DIS, V161, P1078, DOI 10.1093/infdis/161.6.1078; WEIGLE KA, 1983, J INFECT DIS, V148, P630, DOI 10.1093/infdis/148.4.630	10	165	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1991	115	1					19	21		10.7326/0003-4819-115-1-19	http://dx.doi.org/10.7326/0003-4819-115-1-19			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FT937	1646585				2022-12-24	WOS:A1991FT93700004
J	INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J				INGLES, CJ; SHALES, M; CRESS, WD; TRIEZENBERG, SJ; GREENBLATT, J			REDUCED BINDING OF TFIID TO TRANSCRIPTIONALLY COMPROMISED MUTANTS OF VP16	NATURE			English	Article							FUNCTIONAL DISSECTION; ACTIVATION DOMAIN; MAMMALIAN-CELLS; RNA-POLYMERASE; PROTEINS; EXPRESSION; YEAST; GENE	ACTIVATOR proteins that control transcription initiation by RNA polymerase II 1,2 usually have two domains: one binds to DNA, and the other activates transcription 3,4. A particularly potent acidic 5,6 activation domain at the C terminus of the herpes simplex virus protein VP16 7-9 binds directly and selectively to the human and yeast TATA box-binding factor TFIID 10. We have now investigated the biological significance of this in vitro interaction by using mutant forms of VP16 11. For changes at the critical phenylalanine residue at position 442 of VP16 there was a good correlation between transactivation activity in vivo and the binding of VP16 to TFIID in vitro. In contrast, mutants with reduced negative charge were more defective for binding than for activation.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University	INGLES, CJ (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO M5G 1L6,ONTARIO,CANADA.			Triezenberg, Steven/0000-0003-4184-5221				BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718	17	292	297	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					588	590		10.1038/351588a0	http://dx.doi.org/10.1038/351588a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646402				2022-12-24	WOS:A1991FR03400066
J	EPHRUSSI, A; LEHMANN, R				EPHRUSSI, A; LEHMANN, R			INDUCTION OF GERM-CELL FORMATION BY OSKAR	NATURE			English	Article							POSTERIOR DETERMINANT NANOS; SEGMENTATION GENE HUNCHBACK; DROSOPHILA POLAR GRANULES; MATERNAL GENE; ANTERIOR PATTERN; MESSENGER-RNA; LOCALIZATION; PROTEIN; EMBRYO; PLASM	The oskar gene directs germ plasm assembly and controls the number of germ cell precursors formed at the posterior pole of the Drosophila embryo. Mislocalization of oskar RNA to the anterior pole leads to induction of germ cells at the anterior. Of the eight genes necessary for germ cell formation at the posterior, only three, oskar, vasa and tudor, are essential at an ectopic site.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST BIOMED RES,DEPT BIOL,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Ephrussi, Anne/ABD-4393-2021; Ephrussi, Anne/AAG-4075-2020	Ephrussi, Anne/0000-0002-5061-4620; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; BULL AL, 1966, J EXP ZOOL, V161, P221, DOI 10.1002/jez.1401610207; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; EDDY EM, 1975, INT REV CYTOL, V43, P229; ELDON ED, 1991, DEVELOPMENT, V111, P367; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAY B, 1988, DEVELOPMENT, V103, P625; HAY B, 1990, DEVELOPMENT, V109, P425; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KRAUT R, 1991, DEVELOPMENT, V111, P601; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LEHMANN R, IN PRESS CURR OPIN G; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACDONALD PM, 1986, NATURE, V324, P672; MAHOWALD AP, 1971, J EXP ZOOL, V176, P329, DOI 10.1002/jez.1401760308; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1985, COLD SPRING HARB SYM, V50, P105, DOI 10.1101/SQB.1985.050.01.015; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; Rabinowitz M, 1941, J MORPHOL, V69, P1, DOI 10.1002/jmor.1050690102; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SPRADLING AC, 1960, DROSOPHILA PRACTICAL, P175; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	41	514	522	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					387	392		10.1038/358387a0	http://dx.doi.org/10.1038/358387a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641021				2022-12-24	WOS:A1992JF85300046
J	GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM				GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM			RECOGNITION OF ANGIOTENSIN-II - ANTIBODIES AT DIFFERENT LEVELS OF AN IDIOTYPIC NETWORK ARE SUPERIMPOSABLE	SCIENCE			English	Article							HEAVY-CHAIN GENES; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; REGION GENE; DIVERSITY; COMPLEX; ANTIGEN; IDENTIFICATION; GENERATION; EXPRESSION	Genetic and sequence information are reported for an angiotensin II-reactive antibody (Ab1, MAb 110) and an anti-anti-idiotypic antibody (Ab3, MAb 131) that have identical antigen binding properties and that are related by an anti-idiotypic antibody (Ab2-beta) that satisfies accepted biochemical criteria for an internal image-bearing antibody. The sequences of the variable regions of the Ab3 and of the Abl are nearly identical, even though the Ab1 is an antibody to a peptide and the Ab3 is an antibody to a globular protein. Significantly, amino acid residues that make critical contacts with antigen in the crystal structure of the Ab3-antigen complex are highly conserved in Ab1, suggesting that the epitopes of the Ab2-beta recognized by the Ab3 do indeed resemble the bound structure of the antigen.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University			Ronco, Pierre/AAC-8390-2022	Amzel, L. Mario/0000-0002-0129-9572	PHS HHS [6M 44692] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; CLARKE SH, 1990, J IMMUNOL, V144, P2795; COSENZA H, 1976, EUR J IMMUNOL, V6, P114, DOI 10.1002/eji.1830060208; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GARCIA KC, UNPUB; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOFLER R, 1988, J IMMUNOL, V140, P4031; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; MARGET M, 1988, GENE, V74, P335, DOI 10.1016/0378-1119(88)90167-9; MARION TN, 1990, J IMMUNOL, V145, P2322; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MITCHELL T J, 1990, Peptide Research, V3, P277; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PICARD C, 1986, IMMUNOLOGY, V57, P19; PONTILLON F, 1988, J IMMUNOL, V140, P3052; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SAKANO H, 1979, NATURE, V280, P603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	36	47	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					528	531		10.1126/science.1636087	http://dx.doi.org/10.1126/science.1636087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636087				2022-12-24	WOS:A1992JE75500028
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF ENVELOPE V3 LOOP AS THE MAJOR DETERMINANT OF CD4 NEUTRALIZATION SENSITIVITY OF HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; AIDS-RELATED COMPLEX; MONONUCLEAR PHAGOCYTES; T4 ANTIGEN; ANTIBODIES; RECEPTOR; TYPE-1; GP120; RETROVIRUS	Laboratory isolates of human immunodeficiency virus type-1 (HIV-1) such as HTLV-IIIB are generally T cell line-tropic and highly sensitive to neutralization by soluble CD4 (sCD4), a potential antiviral agent that is undergoing clinical trial. However, many primary HIV-1 isolates are macrophage-tropic and sCD4-resistant. Envelope V3 loop sequences derived from primary HIV-1 isolates were sufficient to confer on HTLV-IIIB not only the tissue tropism but also the degree of sCD4 neutralization resistance characteristic of their HIV-1 strains of origin. Single amino acid changes in the V3 loop enhanced sCD4 resistance by up to tenfold. These observations suggest that the tissue tropism and sCD4 neutralization sensitivity of HIV-1 isolates are regulated by similar mechanisms.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert Kim/AAX-4925-2020; Lyerly, Herbert K/B-6528-2014	Lyerly, Herbert Kim/0000-0002-0063-4770; Lyerly, Herbert K/0000-0002-0063-4770	NIAID NIH HHS [AI28233, AI28662] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028662, R29AI028233] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BYRN RA, 1989, J VIROL, V63, P4370, DOI 10.1128/JVI.63.10.4370-4375.1989; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEAN KC, 1988, NATURE, V331, P82; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAMATOS PJ, 1990, J IMMUNOL, V144, P4183; GARTNER S, 1990, AIDS RES HUM RETROV, V6, P1017, DOI 10.1089/aid.1990.6.1017; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HUSSEY RE, 1988, NATURE, V331, P80; HWANG S, UNPUB; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	48	115	117	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					535	537		10.1126/science.1636088	http://dx.doi.org/10.1126/science.1636088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636088				2022-12-24	WOS:A1992JE75500030
J	HAN, TM; RUNNEGAR, B				HAN, TM; RUNNEGAR, B			MEGASCOPIC EUKARYOTIC ALGAE FROM THE 2.1-BILLION-YEAR-OLD NEGAUNEE IRON-FORMATION, MICHIGAN	SCIENCE			English	Article							CARBONACEOUS MEGAFOSSILS; BACILLUS-SUBTILIS; RIBOSOMAL-RNA; ORIGIN; CHINA; EVOLUTION; BACTERIA	Hundreds of specimens of spirally coiled, megascopic, carbonaceous fossils resembling Grypania spiralis (Walcott), have been found in the 2.1 billion-year-old Negaunee Iron-Formation Formation at the Empire Mine, near Marquette, Michigan. This occurrence of Grypania is 700 million to 1 000 million years older than fossils from previously known sites in Montana, China, and India. As Grypania appears to have been a photosynthetic alga, this discovery places the origin of organelle-bearing eukaryotic cells prior to 2.1 billion years ago.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90024; CLIFFS MIN SERV CO MICHIGAN,ISHPEMING,MI 49849; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								Beer EJ., 1919, REC GEOL SURV INDIA, V50, P139; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CLOUD P, 1979, PRECAMBRIAN RES, V10, P73, DOI 10.1016/0301-9268(79)90020-2; CRAWFORD AR, 1971, J GEOL SOC LONDON, V125, P351; DOOLITTLE RF, 1989, HIERARCHY LIFE, P73; DU RL, 1985, PRECAMBRIAN RES, V29, P5, DOI 10.1016/0301-9268(85)90055-5; DU RL, 1986, ACTA GEOL SINICA, P115; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; Gerlach DC., 1988, EOS, V69, P1515; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAN TM, 1975, 769 US GEOL SURV PRO, P76; Hayes JM., 1983, EARTHS EARLIEST BIOS, P291; HENDERSON E, 1984, SCIENCE, V225, P510, DOI 10.1126/science.6429855; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANNASCH HW, 1989, NATURE, V342, P834, DOI 10.1038/342834a0; KABNICK S, 1991, AM SCI, V70, P34; KANDLER O, 1990, P NATL ACAD SCI USA, V87, P4576; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MENDELSON NH, 1989, J BACTERIOL, V171, P1055, DOI 10.1128/jb.171.2.1055-1062.1989; Peel J.S., 1988, RAPP GRPHINLANDS GEO, V137, P5; RIDING R, 1984, GEOL MAG, V121, P205, DOI 10.1017/S0016756800028260; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; RUNNEGAR B, UNPUB; Runnegar B, 1991, PALAEOGEOGR PALAEOCL, V97, P97, DOI 10.1016/0031-0182(91)90186-U; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; SCHOPF JW, 1992, MAJOR EVENTS IN THE HISTORY OF LIFE, P29; SMITH CR, 1989, NATURE, V341, P27, DOI 10.1038/341027a0; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SONG XL, 1984, GEOL MAG, V121, P179; Starr M. P., 1981, PROKARYOTES; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; SUMMONS RE, 1990, AM J SCI, V290A, P212; TANDON K K, 1977, Geophytology, V7, P126; TANDON KK, 1977, CURR SCI INDIA, V46, P563; VIDAL G, 1989, LETHAIA, V22, P375, DOI 10.1111/j.1502-3931.1989.tb01437.x; WALTER MR, 1976, J PALEONTOL, V50, P872; WALTER MR, 1990, AM J SCI, V290A, P133; WANG F, 1981, NATURE, V294, P74; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	45	310	342	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					232	235		10.1126/science.1631544	http://dx.doi.org/10.1126/science.1631544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631544				2022-12-24	WOS:A1992JC58500036
J	JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC				JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC			INCREASED OSTEOCLAST DEVELOPMENT AFTER ESTROGEN LOSS - MEDIATION BY INTERLEUKIN-6	SCIENCE			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCITONIN RECEPTORS; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS; MARROW CULTURES; TRABECULAR BONE; PREVENTION; RATS; MICE	Osteoclasts, the cells that resorb bone, develop from hematopoietic precursors of the bone marrow under the control of factors produced in their microenvironment. The cytokine interleukin-6 can promote hematopoiesis and osteoclastogenesis. Interleukin-6 production by bone and marrow stromal cells is suppressed by 17-beta-estradiol in vitro. In mice, estrogen loss (ovariectomy) increased the number of colony-forming units for granulocytes and macrophages, enhanced osteoclast development in ex vivo cultures of marrow, and increased the number of osteoclasts in trabecular bone. These changes were prevented by 17-beta-estradiol or an antibody to interleukin-6. Thus, estrogen loss results in an interleukin-6-mediated stimulation of osteoclastogenesis, which suggests a mechanism for the increased bone resorption in postmenopausal osteoporosis.	DEPT VET AFFAIRS MED CTR,ENDOCRINOL & METAB SECT,INDIANAPOLIS,IN 46202; ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285; DNAX RES INST CELLULAR & MOLEC BIOL,PALO ALTO,CA 94304; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,CTR ONCOL,INDIANAPOLIS,IN 46202	Eli Lilly; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Passeri, Giovanni/0000-0002-4039-1160	NCI NIH HHS [CA36464] Funding Source: Medline; NIAID NIH HHS [AI21761] Funding Source: Medline; NIAMS NIH HHS [AR41313] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464, R01CA036464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041313] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARZEL US, 1988, AM J MED, V85, P847; BATAILLE, 1991, J CLIN INVEST, V88, P62; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GRAVES L, 1990, J CELL PHYSIOL, V145, P102, DOI 10.1002/jcp.1041450115; GRAY TK, 1989, BIOCHEM BIOPH RES CO, V158, P407, DOI 10.1016/S0006-291X(89)80062-2; HATTERSLEY G, 1989, ENDOCRINOLOGY, V125, P1606, DOI 10.1210/endo-125-3-1606; HATTERSLEY G, 1991, ENDOCRINOLOGY, V128, P259, DOI 10.1210/endo-128-1-259; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KLEIN B, 1991, BLOOD, V78, P1198; KURIHARA N, 1991, J BONE MINER RES, V6, P257; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; LINDSAY R, 1976, LANCET, V1, P1038; LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211; OTSUKA T, 1991, EXP HEMATOL, V19, P1042; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POJDA Z, 1990, EXP HEMATOL, V18, P1034; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; ULICH TR, 1991, J IMMUNOL, V146, P2316; WILLIAMS D, IN PRESS CONN TISS R; WONG GG, 1988, J IMMUNOL, V140, P3040	30	1209	1291	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					88	91		10.1126/science.1621100	http://dx.doi.org/10.1126/science.1621100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621100				2022-12-24	WOS:A1992JC16500036
J	DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF				DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF			ANTIBODY AND HIV-1 GP120 RECOGNITION OF CD4 UNDERMINES THE CONCEPT OF MIMICRY BETWEEN ANTIBODIES AND RECEPTORS	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; IDIOTYPIC ANTIBODIES; REOVIRUS RECEPTOR; MEMBRANE-PROTEIN; CELL-SURFACE; IDENTIFICATION; EXPRESSION; DIVERSITY; ANTIGEN; BINDING	IT has been proposed that antibodies can mimic the binding of a receptor to its ligand and that anti-idiotype antibodies raised against such antibodies can be used to identify the receptor 1-3. A large number of antibodies have been raised against CD4, the receptor on T cells for the envelope glycoprotein gp120 of the human immunodeficiency virus, and the site at which gp120 binds to CD4 has been delineated 4. It has therefore become possible to contrast the fine specificities of a natural ligand (gp120) and antibodies that interact with the receptor at the same site. Here we report that out of a panel of 225 anti-CD4 antibodies, only one showed fine binding specificity that was broadly like that of gp120, but the evidence was against this being an exact mimic. Thus the data indicate that the production of antibody mimics will occur very rarely or not at all and that the anti-idiotype approach is unlikely to be useful. This contention is supported by a review of the results of attempts to use this approach. Taking strict criteria for success, there is no example for which the anti-idiotype approach has led to the discovery of a previously undescribed receptor or other protein of interest.	BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY	University of Cambridge; University of Munich	DAVIS, SJ (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND.							BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANH TC, 1987, P NATL ACAD SCI USA, V84, P3891, DOI 10.1073/pnas.84.11.3891; CHOI AHC, 1988, VIROLOGY, V163, P191, DOI 10.1016/0042-6822(88)90246-2; CO MS, 1985, P NATL ACAD SCI USA, V82, P5315, DOI 10.1073/pnas.82.16.5315; DALGLEISH AG, 1987, LANCET, V2, P1047; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; EICHMANN K, 1974, EUR J IMMUNOL, V4, P296, DOI 10.1002/eji.1830040413; Estess P, 1990, CURRENT RES PROTEIN, P499; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GENTSCH JR, 1987, VIROLOGY, V161, P245, DOI 10.1016/0042-6822(87)90192-9; HEALEY DG, 1991, EUR J IMMUNOL, V21, P1491, DOI 10.1002/eji.1830210624; KRETH HW, 1973, EUR J IMMUNOL, V3, P141, DOI 10.1002/eji.1830030306; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MASON DW, 1980, BIOCHEM J, V187, P1; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; REEVES JP, 1991, AIDS RES HUM RETROV, V7, P55, DOI 10.1089/aid.1991.7.55; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCHOCKMEL GA, 1992, J EXP MED, V175, P301, DOI 10.1084/jem.175.1.301; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; STAUDT LM, 1983, J EXP MED, V157, P687, DOI 10.1084/jem.157.2.687; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; WILKS D, 1991, J INFECT DIS, V163, P389, DOI 10.1093/infdis/163.2.389	31	66	73	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					76	79		10.1038/358076a0	http://dx.doi.org/10.1038/358076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614536				2022-12-24	WOS:A1992JB34100058
J	KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS				KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS			THE SAFETY OF FOODS DEVELOPED BY BIOTECHNOLOGY	SCIENCE			English	Article							ENZYMES		US FDA,CTR FOOD SAFETY & APPL NUTR,DIV FOOD & COLOR ADDIT,ROCKVILLE,MD 20857; US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	KESSLER, DA (corresponding author), US FDA,POLICY,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							BERKOWITZ DB, 1990, BIO-TECHNOL, V8, P819, DOI 10.1038/nbt0990-819; HOPKINS DD, 1991, MUTABLE FEAST ASSURI; JAFFE WG, 1973, TOXICANTS OCCURRING, P106; PARIZA MW, 1983, J FOOD PROTECT, V46, P453, DOI 10.4315/0362-028X-46.5.453; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; 1992, FED REG         0529, V57, P22984; 1989, APPROACHES ASSESSING; IN PRESS REPORT FOOD; 1990, REGUL TOXICOL PHAR 2, V12; 1991, FOOD NEW BIOTECHNOLO; 1991, STRATEGIES ASSESSING	11	82	84	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1747	&		10.1126/science.1615315	http://dx.doi.org/10.1126/science.1615315			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615315				2022-12-24	WOS:A1992JA43400011
J	REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA				REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA			MUTATIONS AT THE 3' SPLICE SITE CAN BE SUPPRESSED BY COMPENSATORY BASE CHANGES IN U1 SNRNA IN FISSION YEAST	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SIGNAL RECOGNITION PARTICLE; SCHIZOSACCHAROMYCES-POMBE; INTRON SEQUENCES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN INTRONS; LARIAT FORMATION; GENE; BINDING	U1 snRNA is an essential splicing factor known to base pair with 5' splice sites of premessenger RNAs. We demonstrate that pairing between the universally conserved CU just downstream from the 5' junction interaction region and the 3' splice site AG contributes to efficient splicing of Schizosaccharomyces pombe introns that typify the AG-dependent class described in mammals. Strains carrying mutations in the 3' AG of an artificial intron accumulate linear precursor, indicative of a first step block. Lariat formation is partially restored in these mutants by compensatory changes in nucleotides C-7 and U8 of U1 snRNA. ConsiStent with a general role in fission yeast splicing, mutations at C-7 are lethal, while U8 mutants are growth impaired and accumulate linear, unspliced precursor to U6 snRNA. U1 RNA-mediated recognition of the 3' splice site may have origins in analogous intramolecular interactions in an ancestral self-splicing RNA.			REICH, CI (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA.							AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BACH ML, 1987, CURR GENET, V12, P527, DOI 10.1007/BF00419562; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; DUCHENE M, 1988, NUCLEIC ACIDS RES, V16, P7233, DOI 10.1093/nar/16.15.7233; FOUSER LA, 1987, MOL CELL BIOL, V7, P225, DOI 10.1128/MCB.7.1.225; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GATERMANN KB, 1989, MOL CELL BIOL, V9, P1526, DOI 10.1128/MCB.9.4.1526; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HIMMELSPACH M, 1991, MOL CELL BIOL, V11, P1258, DOI 10.1128/MCB.11.3.1258; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; LAZAR E, 1982, NUCLEIC ACIDS RES, V10, P1193, DOI 10.1093/nar/10.4.1193; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOUNT SM, 1981, NUCLEIC ACIDS RES, V9, P6351, DOI 10.1093/nar/9.23.6351; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PORTER G, 1990, MOL CELL BIOL, V10, P2874, DOI 10.1128/MCB.10.6.2874; POTASHKIN J, 1989, NUCLEIC ACIDS RES, V17, P7821, DOI 10.1093/nar/17.19.7821; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; REDDY R, 1989, METHOD ENZYMOL, V180, P521; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; REICH C, 1990, MOL CELL BIOL, V10, P5548, DOI 10.1128/MCB.10.10.5548; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1986, EMBO J, V5, P3517, DOI 10.1002/j.1460-2075.1986.tb04677.x; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOGIN ML, 1989, INT CONGR SER, V824, P133; STEITZ JA, 1988, STRUCTURE FUNCTION M, P71; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TATEI K, 1987, J BIOL CHEM, V262, P11667; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1991, METHOD ENZYMOL, V194, P405; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZILLMANN M, 1987, MOL CELL BIOL, V7, P2877, DOI 10.1128/MCB.7.8.2877	65	102	102	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1159	1169		10.1016/0092-8674(92)90637-R	http://dx.doi.org/10.1016/0092-8674(92)90637-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617727				2022-12-24	WOS:A1992JA43100010
J	BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD				BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD			EFFECTS OF LONG-TERM OCTREOTIDE ON GALL STONE FORMATION AND GALL-BLADDER FUNCTION	BRITISH MEDICAL JOURNAL			English	Article							SOMATOSTATIN		ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,CTR SLEEP DISORDERS,CAMPERDOWN,NSW 2050,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney	BIGGWITHER, GW (corresponding author), ST VINCENTS HOSP,DEPT RADIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				AHRENDT SA, 1991, AM J SURG, V161, P177, DOI 10.1016/0002-9610(91)90381-M; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; LIESSUM PA, 1989, J CLIN ENDOCR METAB, V69, P557; SASSOLAS G, 1990, J CLIN ENDOCR METAB, V71, P391, DOI 10.1210/jcem-71-2-391	5	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1611	1612		10.1136/bmj.304.6842.1611	http://dx.doi.org/10.1136/bmj.304.6842.1611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628089	Green Published, Bronze			2022-12-24	WOS:A1992JA43600024
J	HOLMVANG, G				HOLMVANG, G			USEFULNESS OF MRI IN AORTIC DISSECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note																			0	0	0	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1670	1670						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588980				2022-12-24	WOS:A1992HY62800005
J	CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M				CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M			NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY - THE SOCIAL AND PSYCHOLOGICAL EFFECTS OF A RECENT DIAGNOSIS OF EPILEPSY	BRITISH MEDICAL JOURNAL			English	Article							PROGNOSIS; SEIZURES	Objectives - To determine the nature and extent of psychosocial problems in epilepsy and their associations. Design - A postal survey was used drawing data from prospective consecutive cases. Data on demographic, medical, and social backgrounds were collected. A specially designed, validated attitude questionnaire examined 14 areas of psychosocial adjustment to epilepsy. Setting - 124 primary care general practices. Subjects - Adults (aged over 17) with a recent diagnosis of epilepsy (within previous 36 months). They were registered with the national general practice study of epilepsy and had a confirmed diagnosis according to the usual criteria. 216 subjects were approached for the survey by their general practitioners; 192 returned questionnaires. Results - Problems in at least one area were experienced by 175 (91%) of the 192 subjects. Problems were generally mild, which contrasts strongly with findings in chronic cases. The areas of greatest concern were fear of seizures (80% of cases; 72% moderate or severe) and fear of stigma in employment (69% of cases; 40% moderate or severe). A highly significant relation was found between psychosocial effects and the frequency and recency of seizures. Conclusions-In the early stages of epilepsy psychosocial effects are closely related to the severity of the medical condition, suggesting that the argument for the stigmatising effect of the diagnosis by itself is less important than previously thought. The findings also suggest that problems may evolve as the condition becomes chronic.	INST NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London	CHAPLIN, JE (corresponding author), CITY UNIV LONDON,CTR REHABIL RESOURCE,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND.		Shorvon, Simon D/A-2019-2009; Chaplin, John/AAI-8584-2020	Chaplin, John/0000-0001-8128-4225				CHAPLIN JE, 1990, NEUROEPIDEMIOLOGY, V9, P151, DOI 10.1159/000110765; DODRILL CB, 1984, EPILEPSIA, V25, P168, DOI 10.1111/j.1528-1157.1984.tb04173.x; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; LEVIN R, 1988, EPILEPSIA, V29, P805, DOI 10.1111/j.1528-1157.1988.tb04238.x; Nunnally J. C, 1981, PSYCHOMETRIC THEORY; RODIN EA, 1972, EPILEPSIA, V13, P121, DOI 10.1111/j.1528-1157.1972.tb04559.x; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; WRIGHT GN, 1978, NEW DIMENSIONS REHAB, P492	10	61	61	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1416	1418		10.1136/bmj.304.6839.1416	http://dx.doi.org/10.1136/bmj.304.6839.1416			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628019	Green Published, Bronze			2022-12-24	WOS:A1992HX08200023
J	IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A				IKURA, M; CLORE, GM; GRONENBORN, AM; ZHU, G; KLEE, CB; BAX, A			SOLUTION STRUCTURE OF A CALMODULIN-TARGET PEPTIDE COMPLEX BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							LIGHT CHAIN KINASE; NUCLEAR-MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; MEMBRANE CA-2+ PUMP; BINDING DOMAIN; 3-DIMENSIONAL STRUCTURE; DISTANCE GEOMETRY; HETERONUCLEAR NMR; PROTEIN-KINASE; CENTRAL HELIX	The three-dimensional solution structure of the complex between calcium-bound calmodulin (Ca2+-CaM) and a 26-residue synthetic peptide comprising the CaM binding domain (residues 577 to 602) of skeletal muscle myosin light chain kinase, has been determined using multidimensional heteronuclear filtered and separated nuclear magnetic resonance spectroscopy. The two domains of CaM (residues 6 to 73 and 83 to 146) remain essentially unchanged upon complexation. The long central helix (residues 65 to 93), however, which connects the two domains in the crystal structure of Ca2+-CaM, is disrupted into two helices connected by a long flexible loop (residues 74 to 82), thereby enabling the two domains to clamp residues 3 to 21 of the bound peptide, which adopt a helical conformation. The overall structure of the complex is globular, approximating an ellipsoid of dimensions 47 by 32 by 30 angstroms. The helical peptide is located in a hydrophobic channel that passes through the center of the ellipsoid at an angle of approximately 45-degrees with its long axis. The complex is mainly stabilized by hydrophobic interactions which, from the CaM side, involve an unusually large number of methionines. Key residues of the peptide are Trp4 and Phe17, which serve to anchor the amino- and carboxyl-terminal halves of the peptide to the carboxyl- and amino-terminal domains of CaM, respectively. Sequence comparisons indicate that a number of peptides that bind CaM with high affinity share this common feature containing either aromatic residues or long-chain hydrophobic ones separated by a stretch of 12 residues, suggesting that they interact with CaM in a similar manner.	NIDDKD, CHEM PHYS LAB, BLDG 2, BETHESDA, MD 20892 USA; UNIV MARYLAND, CHEM PHYS PROGRAM, COLLEGE PK, MD 20740 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Maryland; University of Maryland College Park; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525; Ikura, Mitsuhiko/0000-0002-9524-1303				ALA A, 1991, BIOCHEMISTRY-US, V30, P5498; ANDERSON SR, 1986, CALCIUM CELL FUNCTIO, V6, P1; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, IN PRESS BIOCHEMISTR; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; BLUMENTHAL DK, 1987, METHOD ENZYMOL, V139, P115; BLUMENTHAL DK, 1988, MOL ASPECTS CELLULAR, V5, P341; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; COX JA, 1985, J BIOL CHEM, V260, P2527; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEGRADO WF, 1988, ADV PROTEIN CHEM, V39, P51; DEGRADO WF, 1985, J CELL BIOCHEM, V29, P83, DOI 10.1002/jcb.240290204; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FORSEN HJ, 1966, CALCIUM CELL FUNCTIO, V6, P113; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GUERINI D, 1991, ADV PROT PHOSPHATASE, V6, P391; HANLEY RM, 1987, SCIENCE, V237, P293, DOI 10.1126/science.3037704; HEIDORN DB, 1989, BIOCHEMISTRY-US, V28, P6757, DOI 10.1021/bi00442a032; HUBBAD MJ, 1989, BIOCHEMISTRY-US, V28, P1867; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4569; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P1188, DOI 10.1021/bi00219a004; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KLEE CB, UNPUB; KLEVIT RE, 1985, BIOCHEMISTRY-US, V24, P8152, DOI 10.1021/bi00348a047; KRETSINGER RH, 1986, J INORG BIOCHEM, V28, P289, DOI 10.1016/0162-0134(86)80093-9; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; KWIATKOWSKI AP, 1989, BIOCHEMISTRY-US, V28, P5380, DOI 10.1021/bi00439a010; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATSUSHIMA N, 1989, J BIOCHEM, V105, P883, DOI 10.1093/oxfordjournals.jbchem.a122773; MCDOWELL L, 1985, BIOCHEMISTRY-US, V24, P2979, DOI 10.1021/bi00333a026; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ONEIL KT, 1989, J BIOL CHEM, V264, P14571; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; ONO T, 1989, J BIOL CHEM, V264, P2081; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; PRECHEUR B, 1992, BIOCHEMISTRY-US, V31, P229, DOI 10.1021/bi00116a032; ROTH SM, 1991, BIOCHEMISTRY-US, V30, P10078, DOI 10.1021/bi00106a003; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SEEHOLZER SH, 1989, BIOCHEMISTRY-US, V28, P4011, DOI 10.1021/bi00435a057; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; TREWHELLA J, 1990, BIOCHEMISTRY-US, V29, P9316, DOI 10.1021/bi00492a003; VERMA AK, 1988, J BIOL CHEM, V263, P14152; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZHU G, 1990, J MAGN RESON, V90, P405, DOI 10.1016/0022-2364(90)90150-8; ZUIDERWEG ERP, 1991, J AM CHEM SOC, V113, P370, DOI 10.1021/ja00001a060; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	89	1191	1202	3	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					632	638		10.1126/science.1585175	http://dx.doi.org/10.1126/science.1585175			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585175				2022-12-24	WOS:A1992HR18500024
J	GRANT, A; HODDINOTT, C				GRANT, A; HODDINOTT, C			JOINT REPLACEMENT, DENTAL SURGERY, AND ANTIBIOTIC-PROPHYLAXIS	BRITISH MEDICAL JOURNAL			English	Article									CARDIFF ROYAL INFIRM,DEPT ORTHOPAED SURG,CARDIFF CF2 1SZ,S GLAM,WALES	Cardiff Royal Infirmary								JACOBSON JJ, 1987, ORAL SURG ORAL MED O, V63, P122, DOI 10.1016/0030-4220(87)90352-5; LINQVIST C, 1985, ACTA ORTHOP SCAND, V56, P506; NELSON JP, 1990, J BONE JOINT SURG AM, V72A, P1; SULLIVAN PM, 1990, J BONE JOINT SURG AM, V72A, P121, DOI 10.2106/00004623-199072010-00019; THYNE GM, 1991, J BONE JOINT SURG BR, V73, P191, DOI 10.1302/0301-620X.73B2.2005136	5	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	959		10.1136/bmj.304.6832.959	http://dx.doi.org/10.1136/bmj.304.6832.959			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581718	Green Published, Bronze			2022-12-24	WOS:A1992HP06400022
J	TEANBY, D				TEANBY, D			UNDERREPORTING OF PEDESTRIAN ROAD ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Road accidents to pedestrians caused 1706 deaths and 58 374 injuries in Great Britain during 1989.(1) These figures and other data used for road planning and safety campaigns are derived from accident data supplied by the police. I assessed the completeness of police recording by comparing their figures on accidents to pedestrians with data from a regional database of trauma care.			TEANBY, D (corresponding author), WARRINGTON GEN HOSP,MERSEY REG TRAUMA SURVEY,WARRINGTON WA5 1QG,ENGLAND.							BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; 1990, ROAD ACCIDENTS GREAT, P47	2	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 15	1992	304	6824					422	422		10.1136/bmj.304.6824.422	http://dx.doi.org/10.1136/bmj.304.6824.422			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HE389	1637379	Green Published, Bronze			2022-12-24	WOS:A1992HE38900021
J	BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT				BELONGIA, EA; GOODMAN, JL; HOLLAND, EJ; ANDRES, CW; HOMANN, SR; MAHANTI, RL; MIZENER, MW; ERICE, A; OSTERHOLM, MT			AN OUTBREAK OF HERPES-GLADIATORUM AT A HIGH-SCHOOL WRESTLING CAMP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SIMPLEX VIRUS TYPE-1	Background and Methods. Herpes simplex virus type 1 (HSV-1) has been identified as a cause of cutaneous or ocular infection among athletes involved in contact sports; in this context it is known as herpes gladiatorum. In July 1989, we investigated an outbreak among 175 high-school wrestlers attending a four-week intensive-training camp. Cases of infection were identified by review of medical records, interview and examination of the wrestlers, and culture of skin lesions. Oropharyngeal swabs were obtained for HSV-1 culture, and serum samples for HSV-1 serologic studies. HSV-1 isolates were compared by restriction-endonuclease analysis. Results. HSV-1 infection was diagnosed in 60 wrestlers (34 percent). The lesions were on the head in 73 percent of the wrestlers, the extremities in 42 percent, and the trunk in 28 percent. HSV-1 was isolated from 21 wrestlers (35 percent), and in 39 (65 percent) infection was identified by clinical criteria. Five had conjunctivitis or blepharitis; none had keratitis. Constitutional symptoms were common, including fever (25 percent), chills (27 percent), sore throat (40 percent), and headache (22 percent). The attack rate varied significantly among the three practice groups, ranging from 25 percent for practice group 1 (lightweights) to 67 percent for group 3 (heavyweights). Restriction-endonuclease analysis identified four strains of HSV-1 among the 21 isolates. All 10 isolates from practice group 3 were identical (strain A), and 5 of 7 isolates from practice group 2 (middleweights) were identical (strain B), which suggested concurrent transmission of different strains within different groups. HSV-1 was not isolated from any oropharyngeal swabs. Conclusions. Herpes gladiatorum may cause substantial morbidity among wrestlers, and it is primarily transmitted by direct skin-to-skin contact. Prompt identification and exclusion of wrestlers with skin lesions may reduce transmission.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,717 SE DELAWARE ST,BOX 9441,MINNEAPOLIS,MN 55440; CTR DIS CONTROL,DIV FIELD SERV,ATLANTA,GA 30333; UNIV MINNESOTA HOSP & CLIN,MINNEAPOLIS,MN 55455	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital				Belongia, Edward/0000-0001-7478-0415				BECKER TM, 1988, AM J SPORT MED, V16, P665, DOI 10.1177/036354658801600620; DYKE LM, 1965, J AMER MED ASSOC, V194, P1001, DOI 10.1001/jama.194.9.1001; GOODMAN JL, 1986, VIRUS RES, V5, P191, DOI 10.1016/0168-1702(86)90017-1; LIESEGANG TJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1160, DOI 10.1001/archopht.1989.01070020226030; PORTER PS, 1965, J AMER MED ASSOC, V194, P998, DOI 10.1001/jama.194.9.998; SELLING B, 1964, NEW ENGL J MED, V270, P979, DOI 10.1056/NEJM196405072701903; SOSIN DM, 1989, AM J SPORT MED, V17, P828, DOI 10.1177/036354658901700618; WALBOOMERS JMM, 1976, VIROLOGY, V74, P256, DOI 10.1016/0042-6822(76)90151-3; WHEELER CE, 1965, J AMER MED ASSOC, V194, P993; WHITE WB, 1984, JAMA-J AM MED ASSOC, V252, P533	10	90	91	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	1991	325	13					906	910		10.1056/NEJM199109263251302	http://dx.doi.org/10.1056/NEJM199109263251302			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GF856	1652687				2022-12-24	WOS:A1991GF85600002
J	PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS				PEREIRA, BJG; MILFORD, EL; KIRKMAN, RL; LEVEY, AS			TRANSMISSION OF HEPATITIS-C VIRUS BY ORGAN-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A; LIVER-DISEASE; RENAL-TRANSPLANTATION; HEPATOCELLULAR-CARCINOMA; HEMODIALYSIS-PATIENTS; CYTOMEGALO-VIRUS; VIRAL-HEPATITIS; ANTIBODIES; RECIPIENTS	Background. Liver disease is a frequent and major complication after organ transplantation. We sought to determine whether hepatitis C virus (HCV) is transmitted by organ transplantation and whether it causes post-transplantation liver disease. Methods. Serum samples from all cadaver organ donors to the New England Organ Bank between 1986 and 1990 were screened retrospectively for antibodies to HCV (anti-HCV) by enzyme-linked immunosorbent assay (ELISA). We reviewed the hospital records of all recipients of organs from anti-HCV-positive donors for evidence of liver disease. Serum samples from recipients obtained before transplantation and during follow-up were analyzed for anti-HCV. Results. Of 716 organ donors, 13 (1.8 percent) were positive for anti-HCV. Their organs (19 kidneys, 6 hearts, and 4 livers) went to 29 recipients. Non-A, non-B hepatitis developed after transplantation in 14 of the 29 (48 percent), for a prevalence 7.4 times the 6.5 percent prevalence after transplantation from untested donors that was previously reported by two institutions in the organ bank (P < 0.0001). The liver disease began a mean of 3.8 months after transplantation and became chronic in 12 patients; the other 2 had subfulminant hepatic failure. Liver disease was more frequent in the patients who had received antilymphocyte preparations (P = 0.04). HCV was the cause of the post-transplantation liver disease in 12 of the 13 recipients (92 percent) for whom serum samples were available. Anti-HCV was detected by ELISA in eight and enzyme immunoassay in one; in three others, HCV RNA was detected by polymerase chain reaction in serum samples obtained after transplantation. Conclusions. Organ transplantation can transmit hepatitis C. This raises serious questions about the continued acceptance of organs from donors positive for anti-HCV.	NEW ENGLAND ORGAN BANK INC,138 HARVARD ST,BROOKLINE,MA 02146									ALTER MJ, 1987, AM J EPIDEMIOL, V125, P133, DOI 10.1093/oxfordjournals.aje.a114496; ANDRES A, 1990, J AM SOC NEPHROL, V1, P754; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; BOYCE NW, 1988, AM J KIDNEY DIS, V11, P307, DOI 10.1016/S0272-6386(88)80135-5; BRAUN WE, 1990, KIDNEY INT, V37, P1363, DOI 10.1038/ki.1990.123; BRUIX J, 1989, LANCET, V2, P1004; CHEESEMAN SH, 1979, NEW ENGL J MED, V300, P1345, DOI 10.1056/NEJM197906143002401; CHEESEMAN SH, 1980, ANN INTERN MED, V93, P39, DOI 10.7326/0003-4819-93-1-39; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLOMBO M, 1989, LANCET, V2, P1006; Debure A, 1988, Adv Nephrol Necker Hosp, V17, P375; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P743; ESTABAN JI, 1989, LANCET, V2, P294; FERNANDEZ JA, 1990, J AM SOC NEPHROL, V1, P757; GILLI P, 1990, LANCET, V336, P243, DOI 10.1016/0140-6736(90)91766-4; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HARNETT JD, 1987, TRANSPLANTATION, V44, P369, DOI 10.1097/00007890-198709000-00009; HESS G, 1989, LANCET, V2, P987; JEFFERS LJ, 1990, KIDNEY INT, V38, P320, DOI 10.1038/ki.1990.203; KIDD S, 1990, 8TH INT C VIR BERL; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LAQUAGLIA MP, 1981, TRANSPLANTATION, V32, P504, DOI 10.1097/00007890-198112000-00011; MAHONY JF, 1989, TRANSPLANT P, V21, P1433; MASIH AS, 1988, AM J SURG PATHOL, V12, P362, DOI 10.1097/00000478-198805000-00004; MONDELLI MU, 1990, LANCET, V336, P244; MORTIMER PP, 1989, LANCET, V2, P798; PAR A, 1990, LANCET, V336, P123, DOI 10.1016/0140-6736(90)91644-P; PARFREY PS, 1985, TRANSPLANTATION, V39, P610, DOI 10.1097/00007890-198506000-00007; PARKER RL, 1946, JAMA-J AM MED ASSOC, V131, P95, DOI 10.1001/jama.1946.02870190019005; PEREZROMERO M, 1990, ANN INTERN MED, V113, P411, DOI 10.7326/0003-4819-113-5-411; RIESTRA S, 1990, ANN INTERN MED, V113, P411; ROGGENDORF M, 1989, LANCET, V2, P324; RUBIN RH, 1989, TRANSPL P, V21, P1440; SCHLIPKOTER U, 1990, LANCET, V335, P1409, DOI 10.1016/0140-6736(90)91296-M; SHERLOCK S, 1989, DISEASES LIVER BILIA, V32, P339; SOPKO J, 1978, AM J MED, V64, P139, DOI 10.1016/0002-9343(78)90190-0; TREPO C, 1990, 8TH INT C VIR BERL; WARE AJ, 1979, ANN INTERN MED, V91, P364, DOI 10.7326/0003-4819-91-3-364; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WEIR MR, 1985, KIDNEY INT, V28, P839, DOI 10.1038/ki.1985.206; WILLIAMS AE, 1990, ANN CLIN LAB SCI, V20, P192; YAMAGUCHI K, 1990, LANCET, V335, P1409; ZELDIS JB, 1990, ANN INTERN MED, V112, P958, DOI 10.7326/0003-4819-112-12-958	45	354	354	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					454	460		10.1056/NEJM199108153250702	http://dx.doi.org/10.1056/NEJM199108153250702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649402				2022-12-24	WOS:A1991GA76300002
J	GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD				GLASS, DJ; NYE, SH; HANTZOPOULOS, P; MACCHI, MJ; SQUINTO, SP; GOLDFARB, M; YANCOPOULOS, GD			TRKB MEDIATES BDNF/NT-3-DEPENDENT SURVIVAL AND PROLIFERATION IN FIBROBLASTS LACKING THE LOW AFFINITY NGF RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; GENE-TRANSFER; FACTOR FAMILY; PC12 CELLS; MAMMALIAN-CELLS; EXPRESSION; BRAIN; DIFFERENTIATION	The neurotrophins (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], neurotrophin-3 [NT-3], and neurotrophin-4 [NT-4]) have been defined by their ability to support neuronal survival. These factors utilize the Trk family of receptor tyrosine kinases, perhaps in conjunction with a second component known as the low affinity NGF receptor (LNGFR). Here we demonstrate that TrkB mediates survival and proliferation in response to both BDNF and NT-3 when expressed in a particular strain of NIH 3T3 fibroblasts, with BDNF the more potent ligand. Furthermore, the BDNF dose dependency displayed by these TrkB-expressing fibroblasts is similar to that required to support the survival of primary neurons. The LNGFR is not expressed in our fibroblast system, implying that this receptor is not essential for responses to physiological concentrations of the neurotrophins. We discuss our findings in the context of neurotrophin signaling pathways and mechanisms of neuronal cell death.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591	Regeneron	GLASS, DJ (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BERND P, 1984, J BIOL CHEM, V259, P5509; BOTHWELL M, 1991, CURR TOP MICROBIOL, V165, P63; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOLBOOK F, 1991, NEURON, V6, P845; HOSANG M, 1985, J BIOL CHEM, V260, P655; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; LINDSAY RM, 1985, DEV BIOL, V112, P30, DOI 10.1016/0012-1606(85)90116-2; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARUYAMA K, 1987, ONCOGENE, V1, P361; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MURPHY AJM, 1987, P NATL ACAD SCI USA, V84, P8277, DOI 10.1073/pnas.84.23.8277; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHECHTER AL, 1981, CELL, V24, P867, DOI 10.1016/0092-8674(81)90112-4; SEHGAL A, 1988, MOL CELL BIOL, V8, P2242, DOI 10.1128/MCB.8.5.2242; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SUTTER A, 1979, J BIOL CHEM, V254, P5972; SUTTER A, 1979, TRANSMEMBRANE SIGNAL, P659; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1987, ONCOGENE, V1, P369; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541	46	280	293	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					405	413		10.1016/0092-8674(91)90629-D	http://dx.doi.org/10.1016/0092-8674(91)90629-D			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649703				2022-12-24	WOS:A1991FY71200020
J	THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B				THISSE, C; PERRINSCHMITT, F; STOETZEL, C; THISSE, B			SEQUENCE-SPECIFIC TRANSACTIVATION OF THE DROSOPHILA TWIST GENE BY THE DORSAL GENE-PRODUCT	CELL			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VENTRAL POLARITY; BICOID PROTEIN; NUCLEAR-LOCALIZATION; DORSOVENTRAL PATTERN; REL ONCOGENE; EMBRYO; CELLS; EXPRESSION	The maternal gene dorsal encodes a nuclear protein acting as a morphogen that determines the size and fate of regions along the dorsal-ventral axis of the Drosophila embryo. From previous genetic and biochemical studies it was hypothesized that dorsal might be responsible for the activation of the zygotic gene twist. In this report, regulatory sequences required for correct spatial and quantitative expression of twist are defined, by using phenotypic rescue and studying twist-beta-galactosidase expression. In addition, by transient cotransfection assays, we show that the dorsal protein specifically activates expression from the twist promoter. We demonstrate that dorsal is a sequence-specific DNA-binding protein that recognizes a motif similar to that recognized by the mammalian transcriptional activator NF-kappa-B.			THISSE, C (corresponding author), FAC MED STRASBOURG, INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB, INSERM,U184, 11 RUE HUMANN, F-67085 STRASBOURG, FRANCE.			THISSE, Christine/0000-0002-8684-1681				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOUROUIS M, 1983, EMBO J, V2, P1099, DOI 10.1002/j.1460-2075.1983.tb01552.x; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELMESSAL M, 1987, THESIS U L PASTEUR S; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IP YT, 1991, CELL, V64, P439; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEPTIN M, 1990, DEVELOPMENT, V110, P73; LEVINE M, 1988, CELL, V52, P785, DOI 10.1016/0092-8674(88)90418-7; LIN HC, 1985, ANAL BIOCHEM, V147, P114, DOI 10.1016/0003-2697(85)90016-8; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MARTIN M, 1988, J INSECT PHYSIOL, V34, P691, DOI 10.1016/0022-1910(88)90079-0; N?sslein-Volhard C., 1979, DETERMINANTS SPATIAL, P185; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; NUSSLEINVOLHARD C, 1989, CIBA F SYMP, V144, P37; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTAMARIA P, 1983, EMBO J, V2, P1695, DOI 10.1002/j.1460-2075.1983.tb01644.x; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SCHUPBACH T, 1986, DEV BIOL, V113, P443, DOI 10.1016/0012-1606(86)90179-X; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIMPSON P, 1983, GENETICS, V105, P615; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1984, NATURE, V311, P262, DOI 10.1038/311262a0; STEWARD R, 1985, COLD SPRING HARB SYM, V50, P223, DOI 10.1101/SQB.1985.050.01.028; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; THISSE B, 1987, GENE DEV, V1, P709, DOI 10.1101/gad.1.7.709; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; VAUGHN JL, 1986, TCA MANUAL, V3, P527; WAKIMOTO BT, 1984, DEV BIOL, V102, P147, DOI 10.1016/0012-1606(84)90182-9	55	214	215	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 28	1991	65	7					1191	1201		10.1016/0092-8674(91)90014-P	http://dx.doi.org/10.1016/0092-8674(91)90014-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648449				2022-12-24	WOS:A1991FU89900011
J	BARBEE, RA				BARBEE, RA			BRONCHIAL REACTIVITY - HYPORESPONSIVENESS VS HYPERRESPONSIVENESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							POPULATION; RESPONSIVENESS; METHACHOLINE				BARBEE, RA (corresponding author), UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724, USA.							COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; HOPP RJ, 1985, J ALLERGY CLIN IMMUN, V76, P609, DOI 10.1016/0091-6749(85)90783-3; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62	4	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					802	802						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640589				2022-12-24	WOS:A1992JG66600041
J	BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL				BOMAN, AL; TAYLOR, TC; MELANCON, P; WILSON, KL			A ROLE FOR ADP-RIBOSYLATION FACTOR IN NUCLEAR VESICLE DYNAMICS	NATURE			English	Article							GTP-BINDING PROTEINS; BREFELDIN-A; MEMBRANE-VESICLES; FORMATION INVITRO; GOLGI-APPARATUS; ENVELOPE; COMPONENTS; TRANSPORT; TARGETS; EGGS	Two distinct steps in nuclear envelope assembly can be assayed in vitro1-3: the protein-mediated binding4 of nuclear-specific vesicles to chromatin, and the subsequent fusion5 of these vesicles to enclose the chromatin within a double nuclear membrane. Nuclear vesicle fusion, like fusion in the secretory pathway6,7, requires ATP8,9 and cytosol1,3,5 and is inhibited by nonhydrolysable GTP analogues1,2. The sensitivity of nuclear vesicle fusion to GTP-gamma-S requires a GTP-dependent soluble factor, the properties of which are strikingly similar to a GTP-dependent Golgi binding factor (GCBF) that inhibits Golgi vesicle fusion in the presence of GTP-gamma-S and belongs to the ADP-ribosylation factor (ARF) family of small GTPases10,11. In the presence of GTP-gamma-S, ARF proteins and alpha-, beta-, gamma-, delta-COP ('coatomer') subunits are associated with Golgi transport vesicles 6,12,13, but the exact roles of ARF proteins in secretion are not vet understood. We report here that purified ARF1 and GGBF have GTP-dependent soluble factor activity in the nuclear vesicle fusion assay. Our results show that the function of ARF is not limited to the Golgi apparatus, and indicate that there may be a link between the formation of nuclear vesicles during mitosis and proteins involved in secretion.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,725 N WOLFE ST,BALTIMORE,MD 21205; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Johns Hopkins University; University of Colorado System; University of Colorado Boulder			Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032				BALCH WE, 1992, J BIOL CHEM, V267, P13053; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DONALDSON JG, IN PRESS P NATN ACAD; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4637; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; ORCI L, 1991, CELL, V64, P1183; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WEISS O, 1989, J BIOL CHEM, V264, P21066; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57	30	104	105	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					512	514		10.1038/358512a0	http://dx.doi.org/10.1038/358512a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641041				2022-12-24	WOS:A1992JG73900053
J	KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD				KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD			RAPID SUPPRESSION OF SPONTANEOUS VENTRICULAR ARRHYTHMIAS DURING ORAL AMIODARONE LOADING	ANNALS OF INTERNAL MEDICINE			English	Article						AMIODARONE; ARRHYTHMIA; VENTRICULAR FIBRILLATION; TACHYCARDIA; EXTRASYSTOLE	CLASS-1A ANTIARRHYTHMIC AGENT; PROGRAMMED STIMULATION; MYOCARDIAL CONCENTRATIONS; TACHYCARDIA INDUCTION; CARDIAC-ARRHYTHMIAS; CLINICAL EFFICACY; THERAPY; COMBINATION; SAFETY; PLASMA	Objective: To determine the time course of effects of amiodarone during an oral loading period. Design: A prospective, nonrandomized study. Setting: Arrhythmia referral center at a university hospital. Patients: Fifty patients with refractory sustained ventricular tachycardia (n = 44) or ventricular fibrillation (n = 6) and frequent (greater-than-or-equal-to 30/h) ventricular premature complexes. Intervention: Oral amiodarone, 1200 mg/d for 14 days and 400 mg/d thereafter. Measurements: Ambulatory electrocardiographic monitorings, 12-lead electrocardiograms, and amiodarone blood levels on days 3, 5, 7, 9, 11, 13, and 28. Results: Dramatic reductions of ventricular arrhythmias were noted during the first 72 hours of the therapy. Average ventricular premature complexes/h, couplets/h, and nonsustained ventricular tachycardias/24 h were 524 +/- 1224/h, 16 +/- 61 /h, and 167 +/- 611/24 h, respectively, at baseline, and reduced to 140 +/- 243/h, 11 +/- 50/h, and 33 +/- 117/24 h, respectively, on day 3 (P < 0.05 for all). Subsequent reductions of ventricular arrhythmias from day 3 to day 13 were more gradual but were still significant (P < 0.05). A significant reduction of ventricular arrhythmias (greater-than-or-equal-to 70% reduction of ventricular premature complexes and greater-than-or-equal-to 90% reduction of nonsustained ventricular tachycardias) was noted in 50% of patients on day 3, in 65% on day 7, and in 83% on day 13. Prolongation of the OT interval exhibited a similar time course. There were no further differences in reduction of ventricular premature complexes or OT intervals between day 13 and day 28. Conclusions: Oral amiodarone given in loading doses produces rapid and dramatic reductions in spontaneous ventricular arrhythmias within 72 hours. Subsequent reductions of spontaneous arrhythmia were gradual and less dramatic.	MONTEFIORE MED CTR, DEPT MED, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	KIM, SG (corresponding author), MONTEFIORE MED CTR, DIV CARDIOL, 111 E 210TH ST, BRONX, NY 10467 USA.			Fisher, John/0000-0003-2748-8715				[Anonymous], 1986, Am J Cardiol, V57, P91; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BORBOLA J, 1988, AM HEART J, V115, P1202, DOI 10.1016/0002-8703(88)90009-9; DEBBAS NMG, 1984, BRIT HEART J, V51, P316; ESCOUBET B, 1985, AM J CARDIOL, V55, P696, DOI 10.1016/0002-9149(85)90139-0; GREENSPON AJ, 1988, J AM COLL CARDIOL, V11, P117, DOI 10.1016/0735-1097(88)90176-3; HAFFAJEE CI, 1983, AM HEART J, V106, P935, DOI 10.1016/0002-8703(83)90019-4; KIM SG, 1987, AM J CARDIOL, V60, P288, DOI 10.1016/0002-9149(87)90229-3; KIM SG, 1988, AM J CARDIOL, V62, P7; KIM SG, 1987, CIRCULATION, V76, P1, DOI 10.1161/01.CIR.76.1.1; KIM SG, 1985, AM J CARDIOL, V56, P84, DOI 10.1016/0002-9149(85)90571-5; KIM SG, 1987, J AM COLL CARDIOL, V9, P398, DOI 10.1016/S0735-1097(87)80395-9; KIM SG, 1987, AM J CARDIOL, V59, P1314, DOI 10.1016/0002-9149(87)90911-8; MARCHLINSKI FE, 1985, AM J CARDIOL, V55, P709, DOI 10.1016/0002-9149(85)90141-9; MASON JW, 1991, CIRCULATION, V84, P348; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; MORADY F, 1986, J AM COLL CARDIOL, V7, P148, DOI 10.1016/S0735-1097(86)80273-X; MORGANROTH J, 1978, CIRCULATION, V58, P408, DOI 10.1161/01.CIR.58.3.408; MOSTOW ND, 1984, AM J CARDIOL, V54, P569, DOI 10.1016/0002-9149(84)90250-9; MOSTOW ND, 1986, CIRCULATION, V73, P1231, DOI 10.1161/01.CIR.73.6.1231; NADEMANEE K, 1982, CIRCULATION, V66, P200; RAKITA L, 1983, JAMA-J AM MED ASSOC, V250, P1293, DOI 10.1001/jama.250.10.1293; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; ROSENFELD LE, 1987, AM HEART J, V114, P1367, DOI 10.1016/0002-8703(87)90538-2; SIDDOWAY LA, 1983, AM HEART J, V106, P951, DOI 10.1016/0002-8703(83)90021-2; SINGH BN, 1984, PACE, V7, P109, DOI 10.1111/j.1540-8159.1984.tb04867.x; VELTRI EP, 1985, J AM COLL CARDIOL, V6, P806, DOI 10.1016/S0735-1097(85)80487-3; VELTRI EP, 1985, AM J CARDIOL, V55, P375, DOI 10.1016/0002-9149(85)90379-0; WELLENS HJJ, 1984, CIRCULATION, V69, P120, DOI 10.1161/01.CIR.69.1.120; WINKLE RA, 1978, CIRCULATION, V57, P1116, DOI 10.1161/01.CIR.57.6.1116	31	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					197	201		10.7326/0003-4819-117-3-197	http://dx.doi.org/10.7326/0003-4819-117-3-197			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616213				2022-12-24	WOS:A1992JF30400004
J	BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG				BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG			TRANSFORMING GROWTH-FACTOR-BETA IN LEISHMANIAL INFECTION - A PARASITE ESCAPE MECHANISM	SCIENCE			English	Article							INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; IFN-GAMMA; EXPRESSION; FACTOR-BETA-1; MACROPHAGES; LYMPHOKINE; ANTIGENS; SUBSETS; CELLS	The course of infection with the protozoan parasite Leishmania is determined in part by their early replication in macrophages, the exclusive host cells for these organisms. Although factors contributing to the survival of Leishmania are not well understood, cytokines influence the course of infection. Transforming growth factor-beta (TGF-beta) is a multipotential cytokine with diverse effects on cells of the immune system, including down-regulation of certain macrophage functions. Leishmanial infection induced the production of active TGF-beta, both in vitro and in vivo. TGF-beta was important for determining in vivo susceptibility to experimental leishmanial infection.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; FED UNIV BAHIA,SCH MED,BR-40140 SALVADOR,BA,BRAZIL; CELTRIX LABS INC,PALO ALTO,CA 94303; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Center for Infectious Disease Research; Bristol-Myers Squibb; Cornell University			Barral-Netto, Manoel/B-3904-2009; Barral, Aldina/B-4191-2009	Barral-Netto, Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X	FIC NIH HHS [TW-00018] Funding Source: Medline; NIAID NIH HHS [AI-25038, AI-16282] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025038, P01AI016282] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DING A, 1990, J IMMUNOL, V145, P940; HARMS G, 1989, LANCET, V1, P1287; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; MULE JJ, 1988, CANCER IMMUNOL IMMUN, V26, P95; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NELSON BJ, 1991, J IMMUNOL, V146, P1849; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1988, J IMMUNOL, V140, P3026	21	395	406	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					545	548		10.1126/science.1636092	http://dx.doi.org/10.1126/science.1636092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636092				2022-12-24	WOS:A1992JE75500034
J	TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K				TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K			CLONING OF THE GAMMA-CHAIN OF THE HUMAN IL-2 RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; HUMAN T-CELLS; BETA-CHAIN; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; LIGAND-BINDING; EXPRESSION; PROTEINS	A third subunit, the gamma-chain, of the human interleukin-2 receptor (IL-2R) was identified, and a complementary DNA clone encoding this member of the cytokine receptor family was isolated. The gamma-chain is necessary for the formation of the high- and intermediate-affinity receptors, which consist of alpha-beta-gamma-heterotrimers and beta-gamma-heterodimers, respectively. The IL-2R on murine fibroblastoid cells can be internalized after binding IL-2 only if the gamma-chain is present; alpha and beta are insufficient for internalization. Thus, the gamma-chain is an indispensable component of the functional IL-2R.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM 2,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University			Takeshita, Toshikazu/AAL-1382-2021	Ishii, Naoto/0000-0002-0549-8245				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATAKEYAMA M, 1985, NATURE, V317, P467; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERRMANN F, 1985, J EXP MED, V162, P1111, DOI 10.1084/jem.162.3.1111; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ISHII T, 1987, BIOCHEM J, V242, P211, DOI 10.1042/bj2420211; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Suzuki J, 1989, Int Immunol, V1, P373, DOI 10.1093/intimm/1.4.373; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TAKESHITA T, 1992, J IMMUNOL, V148, P2157; TANAKA Y, 1985, MICROBIOL IMMUNOL, V29, P959, DOI 10.1111/j.1348-0421.1985.tb02960.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; TSUDO M, 1990, J IMMUNOL, V145, P599; VOSS SD, 1990, J EXP MED, V172, P1101, DOI 10.1084/jem.172.4.1101; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	35	877	924	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					379	382		10.1126/science.1631559	http://dx.doi.org/10.1126/science.1631559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631559				2022-12-24	WOS:A1992JD67400032
J	RANDALL, LL				RANDALL, LL			PEPTIDE BINDING BY CHAPERONE SECB - IMPLICATIONS FOR RECOGNITION OF NONNATIVE STRUCTURE	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; TRANSLOCATION; PREPROTEIN; MEMBRANE; INVITRO	The molecular basis for recognition of nonnative proteins by the molecular chaperone SecB was investigated with an in vitro assay based on the protection of SecB from proteolysis when a ligand is bound. The SecB tetramer has multiple binding sites for positively charged peptides. When the peptide binding sites are occupied, the complex undergoes a conformational change to expose hydrophobic sites that bind the fluorescent probe 1-anilino-naphthalene-8-sulfonate. A model is proposed for interaction of nonnative polypeptides with both hydrophilic and hydrophobic sites on SecB.			RANDALL, LL (corresponding author), WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAVIDSON B, 1967, BIOCHEMISTRY-US, V6, P1616, DOI 10.1021/bi00858a008; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1992, ANTON LEEUW INT J G, V61, P93, DOI 10.1007/BF00580613; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ICHIMURA S, 1977, BIOPOLYMERS, V16, P1449, DOI 10.1002/bip.1977.360160706; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; LYNN J, 1968, BIOCHEM BIOPH RES CO, V33, P327, DOI 10.1016/0006-291X(68)90788-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Park K.- Y., UNPUB; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	16	110	114	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					241	245		10.1126/science.1631545	http://dx.doi.org/10.1126/science.1631545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631545				2022-12-24	WOS:A1992JC58500039
J	MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM				MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM			LONG-TERM CARDIAC PROGNOSIS FOLLOWING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL VASCULAR-DISEASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; INDEX	Objective.-To determine the long-term (2-year) cardiac prognosis of high-risk patients undergoing noncardiac surgery and to determine the predictors of long-term adverse cardiac outcome. Design.-Prospective cohort study. Historical, clinical, and laboratory data were collected during the in-hospital period, and at 6 months, 1 year, and 2 years following surgery. Data were analyzed using proportional hazards models. Setting.-University-affiliated Veterans Affairs medical center. Population.-A consecutive sample of 444 patients with or at high risk for coronary artery disease who had undergone elective noncardiac surgery and were discharged from the hospital in stable condition. Main Outcome Measures.-Cardiac death, myocardial infarction, unstable angina, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty, and new unstable angina requiring hospitalization. Results.-Forty-seven patients (11%) had major cardiovascular complications during a 728-day (median) follow-up period: 24 had cardiac death; 11, nonfatal myocardial infarction; six, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty; and six, new unstable angina requiring hospitalization. Thirty percent of outcomes occurred within 6 months of surgery and 64% within 1 year. Five independent predictors of long-term outcome were identified. Three predictors reflected the preexisting chronic disease state: (1) the presence of known vascular disease (hazard ratio, 6.1; 95% confidence interval [CI], 2.5 to 15.0; P<.0001); (2) a history of congestive heart failure (hazard ratio, 5.0; 95% CI, 2.0 to 12.0; P<.0005); and (3) known coronary artery disease (hazard ratio, 3.7; 95% CI, 1.7 to 8.0; P<.0007). Two predictors reflected acute postoperative ischemic events: (1) myocardial infarction/unstable angina (hazard ratio, 20; 95% CI, 7.5 to 53.0; P<.0001) and (2) myocardial ischemia (hazard ratio, 2.2; 95% CI, 1.1 to 4.3; P<.03). Patients surviving a postoperative in-hospital myocardial infarction had a 28-fold increase in the rate of subsequent cardiac complications within 6 months following surgery, a 15-fold increase within 1 year, and a 14-fold increase within 2 years (95% CI, 5.8 to 32; P<.00001). Seventy percent of all long-term adverse outcomes were preceded by in-hospital postoperative ischemia that occurred at least 30 days (median, 282 days) before the long-term event. The development of congestive heart failure or ventricular tachycardia (without ischemia) during hospitalization was not associated with adverse long-term outcome. Conclusions.-The incidence of long-term adverse cardiac outcomes following noncardiac surgery is substantial. At increased risk are patients with chronic cardiovascular disease; at highest risk are patients with acute perioperative ischemic events. We conclude that survivors of in-hospital perioperative ischemic events, specifically myocardial infarction, unstable angina, and postoperative ischemia, warrant more aggressive long-term follow-up and treatment than is currently practiced.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MANGANO, DT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR 129,DEPT ANESTHESIA,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.			Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; CRAWFORD ES, 1981, SURGERY, V90, P1055; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; FORSTER ED, 1986, ANN THORAC SURG, V41, P42; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P156; HARRISON DC, 1985, AM J CARDIOL, V56, pC10, DOI 10.1016/S0002-9149(85)80003-5; HERTZER NR, 1980, ANN SURG, V192, P667; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HERTZER NR, 1982, CLEVELAND CLIN Q, V49, P1; HERTZER NR, 1981, ANN SURG, V193, P493; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KANNEL WB, 1984, CIRCULATION, V70, P331, DOI 10.1161/01.CIR.70.3.331; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; MACKEY WC, 1990, J VASC SURG, V11, P226, DOI 10.1067/mva.1990.17574; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1990, NEW ENGL J MED, V323, P1171; MEHTA J, 1985, J LAB CLIN MED, V106, P661; RABY KE, 1990, AM J CARDIOL, V66, P1309, DOI 10.1016/0002-9149(90)91159-4; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SEVERI S, 1989, AM J CARDIOL, V64, P889, DOI 10.1016/0002-9149(89)90837-0; SILICIANO D, 1990, OPIOIDS ANESTHESIA, V2, P164; STONE PH, 1986, J AM COLL CARDIOL, V8, P1007, DOI 10.1016/S0735-1097(86)80374-6; TOMATIS LA, 1972, SURGERY, V71, P429; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; 1989, PHS891232 US DEP HLT; 1978, MANUAL OPERATIONS, V2; 1983, NEW ENGL J MED, V309, P331	38	249	256	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					233	239		10.1001/jama.268.2.233	http://dx.doi.org/10.1001/jama.268.2.233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608143				2022-12-24	WOS:A1992JB27900031
J	WALLACE, A; SALUZ, H				WALLACE, A; SALUZ, H			BEYOND SILVER STAINING	NATURE			English	Article							POLYACRYLAMIDE GELS; PROTEINS; DNA				WALLACE, A (corresponding author), IST RIC BIOL MOLEC,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY.							ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASKINS BS, 1976, APPL OPTICS, V15, P2860, DOI 10.1364/AO.15.002860; DEMPSTER DT, 1978, THESIS ROCHESTER I T; FYSON JR, 1980, J PHOTOGR SCI, V28, P194; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V2; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V1; IRIE S, 1982, ANAL BIOCHEM, V126, P350, DOI 10.1016/0003-2697(82)90526-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; OWUNWANNE A, 1982, J APPL PHOTOGR ENG, V8, P104; SMITH AG, 1985, J IMAGING TECHNOL, V11, P27; SMITHYMAN K, 1985, LANDFALL, V39, P8; SUZUKI S, 1952, J SOC SCI PHOTO 1109; THACKRAY M, 1974, AUTORADIOGRAPHY RADI; VACHON D, 1980, J APPL PHOTOGR ENG, V6, P141; WALLACE A, 1992, ANAL BIOCHEM, V203, P27, DOI 10.1016/0003-2697(92)90038-9	17	4	4	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					608	609		10.1038/357608a0	http://dx.doi.org/10.1038/357608a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608474				2022-12-24	WOS:A1992HZ11200064
J	BEWLEY, S				BEWLEY, S			THE LAW, MEDICAL-STUDENTS, AND ASSAULT	BRITISH MEDICAL JOURNAL			English	Article											BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6AU,ENGLAND.			bewley, susan/0000-0001-8064-652X				BEWLEY S, 1992, IN PRESS 26TH P BRIT; BRAZIER M, 1987, MED PATIENTS LAW, P55; CHAMBERLAIN G, 1990, AVOID MEDICOLEGAL PR, P16; Corbett J., 1990, METRO            JUL, p54e71; CORBETT J, 1990, METRO            SEP, P124; Dyer C, 1991, GUARDIAN        0916, P2; PHILLIPS A, 1991, GUARDIAN        0122, P34; ROBINSON J, 1985, J MED ETHICS, V11, P15; SKEGG PDG, 1984, LAW ETHICS MED, P95; WINKLER F, 1988, NEEDLE           JUN, P10; 1981, LAW SOC GAZETTE, V78, P1341; 1986, WOMEN MED        MAY, P8	12	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1551	1553		10.1136/bmj.304.6841.1551	http://dx.doi.org/10.1136/bmj.304.6841.1551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628058	Green Published, Bronze			2022-12-24	WOS:A1992HZ17800029
J	LI, TY; ETLER, DA				LI, TY; ETLER, DA			NEW MIDDLE PLEISTOCENE HOMINID CRANIA FROM YUNXIAN IN CHINA	NATURE			English	Article							HOMO-SAPIENS; ORIGIN; SKULL	Two fossil human crania have been found in Middle Pleistocene terrace deposits of the Han River in Yun county (Yunxian), Hubei province, China (Figs 1 and 2) 1. These damaged but relatively complete adult specimens show a mixture of features associated both with Homo erectus and with 'archaic H. sapiens'. The Yunxian crania (Figs 3 and 4), although crushed and distorted to varying degrees, are unusual in having major elements of the basicranium, palate, face and cranial vault preserved together. The specimens reveal many details of facial and basicranial anatomy rarely seen in hominid crania of comparable antiquity. Moreover, they are the most complete crania of such great age discovered on the Asian mainland. They consequently throw new light on Middle Pleistocene hominid diversity and the relationships among regionally disparate Middle Pleistocene hominids.	UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley	LI, TY (corresponding author), HUBEI INST ARCHEOL,67 DONGHU RD,WUHAN 430077,PEOPLES R CHINA.							Aiello L, 1990, INTRO HUMAN EVOLUTIO; BLACK DAVIDSON, 1931, PALAEONTOLOGIA SINICA SER D, V7, P1; Brauer G., 1990, Acta Anthropologica Sinica, V9, P350; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CONTROY GC, 1978, NATURE, V276, P67; DAY MH, 1980, NATURE, V284, P55, DOI 10.1038/284055a0; Dong X., 1989, EARLY HUMANKIND CHIN, P9; Howell F.C., 1978, P154; HUBLIN JJ, 1984, ANTHROPOS BRNO, V23, P175; KENNEDY GE, 1991, J HUM EVOL, V20, P375, DOI 10.1016/0047-2484(91)90006-H; Maier W., 1984, Courier Forschungsinstitut Senckenberg, V69, P123; Murrill R.I., 1975, Zeitschrift Morph Anthrop, V66, P176; POPE GG, 1991, J HUM EVOL, V21, P189, DOI 10.1016/0047-2484(91)90061-Y; RAK Y, 1986, J HUM EVOL, V15, P151, DOI 10.1016/S0047-2484(86)80042-2; RIGHTMIRE GP, 1990, EVOLUTION H ERECTUS; Sartono S., 1975, P327; SOHN S, 1990, ACTA ANTHR SINICA, V9, P359; Stringer C.B., 1984, Courier Forschungsinstitut Senckenberg, V69, P131; STRINGER CB, 1979, J ARCHAEOL SCI, V6, P235, DOI 10.1016/0305-4403(79)90002-5; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Wang Z., 1991, JIANGHAN KAOGU, V39, P1; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; WEIDENREICH F, 1936, PALAEONTOLOGICA SI D, V7, P1; Weidenreich F., 1951, ANTHROPOLOGICAL PAPE, V43, P205; Woo J., 1959, PALEOVERTEBR PALEOAN, V1, P159; WOO JK, 1965, SCI SINICA, V14, P1032; Wu, 1990, ACTA ANTHR SINICA, V9, P312; Wu RK., 1988, ACTA ANTHROPOL SIN, V7, P97; Wu RK, 1982, ACTA ANTHR SIN, V1, P2; WU XZ, 1981, SCI SINICA, V24, P530; Xinzhi W., 1988, ACTA ANTHROPOL SIN, V7, P287	32	81	98	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					404	407						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX172	1594044				2022-12-24	WOS:A1992HX17200063
J	HJORTDAHL, P; LAERUM, E				HJORTDAHL, P; LAERUM, E			CONTINUITY OF CARE IN GENERAL-PRACTICE - EFFECT ON PATIENT SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; META-ANALYSIS; DIMENSIONS	Objective-To evaluate the influence of continuity of care on patient satisfaction with consultations. Design-Directed and episodic specific evaluation of patient satisfaction with recent consultation. Setting and subjects-A representative sample of 3918 Norwegian primary care patients were asked to evaluate their consultations by filling in a questionnaire. The response rate was 78%. Main outcome measures-The patient's overall satisfaction with the consultation was rated on a six point scale. Continuity of care was recorded as the duration and intensity of the present patient-doctor relationship and as patients' perception of the present doctor being their personal doctor or not. Results-The multivariate analysis indicated that an overall personal patient-doctor relationship increased the odds of the patient being satisfied with the consultation sevenfold (95% confidence interval 4.9 to 9.9) as compared with consultations where no such relationships existed. The duration of the patient-doctor relationship had a weak but significant association with patient satisfaction, while the intensity of contacts showed no such association. Conclusion-Personal, continuous care is linked with patient satisfaction. If patient satisfaction is accepted as an integral part of quality health care, reinforcing personal care may be one way of increasing this quality.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY.							[Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; HARRIS RT, 1978, J APPL BEHAV SCI, V14, P382, DOI 10.1177/002188637801400313; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1989, FAM PRACT, V6, P292, DOI 10.1093/fampra/6.4.292; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; Lamberts H., 1987, ICPC INT CLASSIFICAT; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McWhinney IR, 1989, TXB FAMILY MED; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; PENDLETON D, 1984, CONSULTATON APPROACH; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; RUTLE O, 1983, 11983 STAT I FOLK RE; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006	22	263	268	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1287	1290		10.1136/bmj.304.6837.1287	http://dx.doi.org/10.1136/bmj.304.6837.1287			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606434	Green Published, Bronze			2022-12-24	WOS:A1992HV08600026
J	ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A				ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A			LATERALIZATION OF PHONETIC AND PITCH DISCRIMINATION IN SPEECH PROCESSING	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN AUDITORY-CORTEX; CORTICAL AREAS; ORGANIZATION; PERCEPTION; LOCALIZATION; LANGUAGE; MEMORY; BRAIN	Cerebral activation was measured with positron emission tomography in ten human volunteers. The primary auditory cortex showed increased activity in response to noise bursts, whereas acoustically matched speech syllables activated secondary auditory cortices bilaterally. Instructions to make judgments about different attributes of the same speech signal resulted in activation of specific lateralized neural systems. Discrimination of phonetic structure led to increased activity in part of Broca's area of the left hemisphere, suggesting a role for articulatory recoding in phonetic perception. Processing changes in pitch produced activation of the right prefrontal cortex, consistent with the importance of right-hemisphere mechanisms in pitch perception.			ZATORRE, RJ (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,MCCONNELL BRAIN IMAGING CTR,MONTREAL H3A 2B4,QUEBEC,CANADA.		Gjedde, Albert/I-2452-2019; Gjedde, Albert/U-3751-2019	Gjedde, Albert/0000-0002-3756-7401				Alajouanine T., 1939, SYNDROME DESINTEGRAT; BLUMSTEIN SE, 1977, NEUROPSYCHOLOGIA, V15, P19, DOI 10.1016/0028-3932(77)90111-7; BLUMSTEIN SE, 1987, MOTOR SENSORY PROCES, P257; BRUGGE JF, 1985, CEREB CORTEX, V4, P229; BUB D, 1991, J CEREBRAL BLOOD S2, V11, pS850; CELESIA GG, 1976, BRAIN, V99, P403, DOI 10.1093/brain/99.3.403; CHAVIS DA, 1976, BRAIN RES, V117, P379; CHERTKOW H, 1991, Neurology, V41, P300; COLOMBO M, 1990, SCIENCE, V247, P336, DOI 10.1126/science.2296723; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; EVANS AC, IN PRESS NEUROLMAGE; FITZPATRICK KA, 1982, CORTICAL SENSORY ORG, V3, P71; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GESCHWIN.N, 1970, SCIENCE, V170, P940, DOI 10.1126/science.170.3961.940; LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3; LECOURS AR, 1976, BRAIN LANG, V3, P88, DOI 10.1016/0093-934X(76)90008-0; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIEGEOISCHAUVEL C, 1991, BRAIN, V114, P139; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MEYER E, 1988, Society for Neuroscience Abstracts, V14, P917; MILNER B, 1962, INTERHEMISPHER RELAT, P177; OJEMANN G, 1979, SCIENCE, V205, P1401, DOI 10.1126/science.472757; Ombredane A, 1951, SURFACE DYSLEXIA; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PAUS T, UNPUB; Penfield W., 1959, SPEECH BRAIN MECHANI; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; SHALLICE T, 1990, NEUROPSYCHOLOGICAL I, pCH1; Tailarach J., 1988, COPLANAR STEREOTAXIC; Taylor L. B, 1979, FUNCTIONAL NEUROSURG, P165; WHITFIELD IC, 1985, CEREB CORTEX, P329; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; WOOD CC, 1971, SCIENCE, V173, P1248, DOI 10.1126/science.173.4003.1248; WORSLEY KJ, IN PRESS J CEREB BLO; ZATORRE RJ, 1991, BRAIN, V114, P2403, DOI 10.1093/brain/114.6.2403; ZATORRE RJ, 1988, J ACOUST SOC AM, V84, P566, DOI 10.1121/1.396834	43	1170	1189	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					846	849		10.1126/science.1589767	http://dx.doi.org/10.1126/science.1589767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589767				2022-12-24	WOS:A1992HT23500048
J	BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER				BAILEY, CH; CHEN, M; KELLER, F; KANDEL, ER			SEROTONIN-MEDIATED ENDOCYTOSIS OF APCAM - AN EARLY STEP OF LEARNING-RELATED SYNAPTIC GROWTH IN APLYSIA	SCIENCE			English	Article							REGULATES NEURITE OUTGROWTH; LONG-TERM SENSITIZATION; SENSORY NEURONS INVITRO; STRUCTURAL-CHANGES; RECEPTOR; SURFACE; FACILITATION; MORPHOLOGY; MEMBRANE; CELLS	The long-term facilitation of synaptic efficacy that is induced by serotonin in dissociated cell cultures of sensory and motor neurons of Aplysia is accompanied by the growth of new synaptic connections. This growth is associated with a down-regulation in the sensory neuron of Aplysia cell adhesion molecules (apCAMs). To examine the mechanisms of this down-regulation, thin-section electron microscopy was combined with immunolabeling by gold-conjugated monoclonal antibodies specific to apCAM. Within 1 hour, serotonin led to a 50% decrease in the density of gold-labeled complexes at the surface membrane of the sensory neuron. This down-regulation was achieved by a heterologous, protein synthesis-dependent activation of the endosomal pathway, which leads to internalization and apparent degradation of apCAM. The internalization is particularly prominent at sites where the processes of the sensory neurons contact one another and may act there to destabilize process-to-process contacts that normally inhibit growth. In turn, the endocytic activation may lead to a redistribution of membrane components to sites where new synapses form.	NEW YORK STATE PSYCHIAT INST & HOSP, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	New York State Psychiatry Institute; Columbia University; Howard Hughes Medical Institute	BAILEY, CH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, 722 W 168 ST, NEW YORK, NY 10032 USA.			Keller, Flavio/0000-0002-6449-6960	NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BACKER JM, 1991, BIOCHEM PHARMACOL, V41, P1267, DOI 10.1016/0006-2952(91)90097-O; BAILEY CC, UNPUB; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; CHENG TPO, 1985, J CELL BIOL, V101, P1473, DOI 10.1083/jcb.101.4.1473; CONNOLLY JL, 1984, J CELL BIOL, V98, P457, DOI 10.1083/jcb.98.2.457; CONNOLLY JL, 1985, J NEUROSCI RES, V13, P183, DOI 10.1002/jnr.490130113; COVAULT J, 1991, MOL BRAIN RES, V11, P11, DOI 10.1016/0169-328X(91)90015-P; DADABAY CY, 1991, J CELL BIOL, V112, P1151, DOI 10.1083/jcb.112.6.1151; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HELIN K, 1991, J BIOL CHEM, V266, P8363; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; Hu Y., UNPUB; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MAXFIELD FR, 1991, ACIDIFICATION ORGANE, P157; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; PFENNINGER KH, 1982, AXOPLASMIC TRANSPORT, P52; SHEPPARD A, 1991, BIOCHIM BIOPHYS ACTA, V1076, P156, DOI 10.1016/0167-4838(91)90234-Q; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; WALL DA, 1981, J CELL BIOL, V90, P687, DOI 10.1083/jcb.90.3.687; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633	37	294	298	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					645	649		10.1126/science.1585177	http://dx.doi.org/10.1126/science.1585177			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585177				2022-12-24	WOS:A1992HR18500026
J	SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C				SENTENAC, H; BONNEAUD, N; MINET, M; LACROUTE, F; SALMON, JM; GAYMARD, F; GRIGNON, C			CLONING AND EXPRESSION IN YEAST OF A PLANT POTASSIUM-ION TRANSPORT-SYSTEM	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; COMPLEMENTARY-DNA; ESCHERICHIA-COLI; PLASMA-MEMBRANE; GATED CHANNEL; PROTEIN; SEQUENCE; CAMP	A membrane polypeptide involved in K+ transport in a higher plant was cloned by complementation of a yeast mutant defective in K+ uptake with a complementary DNA library from Arabidopsis thaliana. A 2.65-kilobase complementary DNA conferred ability to grow on media with K+ concentration in the micromolar range and to absorb K+ (or Rb-86(+)) at rates similar to those in wild-type yeast. The predicted amino acid sequence (838 amino acids) has three domains: a channel-forming region homologous to animal K+ channels, a cyclic nucleotide-binding site, and an ankyrin-like region.	CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE; INRA,MICROBIOL IPV,F-34060 MONTPELLIER 1,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; INRAE	SENTENAC, H (corresponding author), ECOLE NATL SUPER AGRON MONTPELLIER,INRA,CNRS,URA 573,F-34060 MONTPELLIER,FRANCE.			Sentenac, Herve/0000-0003-3641-4822				AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HEDRICH R, 1989, ANNU REV PLANT PHYS, V40, P539, DOI 10.1146/annurev.pp.40.060189.002543; HESSE JE, 1984, P NATL ACAD SCI-BIOL, V81, P4746, DOI 10.1073/pnas.81.15.4746; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JAN LY, 1990, NATURE, V345, P673; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; Luttge U., 1989, Progress in Botany, V50, P51; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MINET M, IN PRESS PLANT J; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; SANDERS D, 1986, J MEMBRANE BIOL, V90, P67, DOI 10.1007/BF01869687; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SPITERI A, 1989, PLANT PHYSIOL, V91, P624, DOI 10.1104/pp.91.2.624; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STEVENS CF, 1991, NATURE, V349, P657, DOI 10.1038/349657a0; SUSSMAN MR, 1989, PLANT CELL, V1, P953, DOI 10.1105/tpc.1.10.953; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0	32	566	625	4	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					663	665		10.1126/science.1585180	http://dx.doi.org/10.1126/science.1585180			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585180				2022-12-24	WOS:A1992HR18500031
J	ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J				ESTEBAN, JI; LOPEZTALAVERA, JC; GENESCA, J; MADOZ, P; VILADOMIU, L; MUNIZ, E; MARTINVEGA, C; ROSELL, M; ALLENDE, H; VIDAL, X; GONZALEZ, A; HERNANDEZ, JM; ESTEBAN, R; GUARDIA, J			HIGH-RATE OF INFECTIVITY AND LIVER-DISEASE IN BLOOD-DONORS WITH ANTIBODIES TO HEPATITIS-C VIRUS	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, CHRONIC ACTIVE; HEPATITIS-C VIRUS; LIVER CIRRHOSIS; BLOOD DONORS; HEPATITIS ANTIBODIES	NON-B-HEPATITIS; NON-A-HEPATITIS; HEPATOCELLULAR-CARCINOMA; VIRAL SEQUENCES; FRACTIONATION; PLASMA	Objective: To determine the epidemiologic, clinical, serologic, and histologic importance of antibodies to hepatitis C virus (anti-HCV) in blood donors. Design: Cross-sectional identification and prospective evaluation of seropositive donors; retrospective assessment of infectivity; and nested case-control study for risk factors. Setting: Liver unit of a referral-based university hospital. Subjects: Of 30 231 consecutive donors, 368 (1.2%) were found to be anti-HCV-reactive by enzyme-linked immunosorbent assay (ELISA). Two hundred and fifty-four of these 368 donors were evaluated for risk factors by comparison with 284 age- and sex-matched controls. Eighty-six spouses of seropositive donors were also evaluated. Measurements and Main Results: Twenty-four percent of the seropositive donors had a history of percutaneous exposure to blood. This rate increased to 45% when only those donors confirmed to be anti-HCV positive by a second-generation recombinant immunoblot assay (RIBA-2) were considered. A family history of liver disease (odds ratio, 2.8; 95% Cl, 1.6 to 4.8), previous blood transfusion (odds ratio, 6.1; 95% Cl, 3 to 12.5), and a history of tattooing or intravenous drug abuse (odds ratio, 8.4; 95% Cl, 2.3 to 31) were associated with anti-HCV seropositivity. An elevated alanine aminotransferase (ALT) level was found in 58% of the seropositive donors. Of the 150 donors tested, 104 (69%; Cl, 62% to 77%) were confirmed by RIBA-2 to be anti-HCV positive. Of the 105 donors who had a biopsy, 16% had normal histologic findings, 11% had minimal changes, 21% had chronic persistent hepatitis, 45% had chronic active hepatitis, and 7% had active cirrhosis. All 77 donors with RIBA-2-confirmed seropositivity had histologic abnormalities. Of 43 donors evaluated in an infectivity study, 82% were implicated in previous HCV transmission. Only 2.3% of the spouses were anti-HCV positive. The ELISA, RIBA-2, and ALT results correlated with infectivity and abnormal histologic findings. Conclusions: In our geographic area, almost 70% of donors who are anti-HCV positive by ELISA are confirmed to be positive by RIBA-2; most of these donors appear to be chronic carriers of HCV and have substantial liver disease.	HOSP SANTA CRUZ & SAN PABLO, BLOOD BANK, E-08025 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, INST CATALA SALUT, BLOOD BANK, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT PATHOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT CLIN PHARMACOL, E-08035 BARCELONA, SPAIN; HOSP GEN UNIV VALL HEBRON, DEPT MED, HEMATOL HEMOTHERAPY SERV, E-08035 BARCELONA, SPAIN	Fundacio Banc Sang Teixits de les Illes Balears; Fundacio Banc Sang Teixits de les Illes Balears; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron; Hospital Universitari Vall d'Hebron	ESTEBAN, JI (corresponding author), HOSP GEN UNIV VALL HEBRON, DEPT MED, LIVER UNIT, PASSEIG VALL HEBRON S-N, E-08035 BARCELONA, SPAIN.		Vidal, Xavier/I-5958-2019; Genesca, Joan/H-7467-2019	Vidal, Xavier/0000-0001-6705-4298; Genesca, Joan/0000-0002-0831-8422; Viladomiu, Lluis/0000-0002-3434-9847; esteban, rafael/0000-0001-5280-392X				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRUIX J, 1989, LANCET, V2, P1004; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; FINLAYSON JS, 1990, LANCET, V335, P1274, DOI 10.1016/0140-6736(90)91335-8; FORTUNY C, 1991, VIRAL HEPATITIS LIVE; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GIOVANNINI M, 1990, LANCET, V335, P1166, DOI 10.1016/0140-6736(90)91174-9; HABIBI B, 1990, LANCET, V335, P855, DOI 10.1016/0140-6736(90)90968-B; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; QUAN S, 1990, 2ND P INT S HCV LOS; VANDERPOEL CL, 1990, LANCET, V335, P558, DOI 10.1016/0140-6736(90)90347-8; VARGAS V, 1990, ANN INTERN MED, V112, P232, DOI 10.7326/0003-4819-112-3-232_2; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; [No title captured]; 1989, 1ST P INT S HEP C VI, P25; 1989, 1ST P INT S HEP C VI, P9	18	314	316	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					443	449		10.7326/0003-4819-115-6-443	http://dx.doi.org/10.7326/0003-4819-115-6-443			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651674				2022-12-24	WOS:A1991GE81000005
J	ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J				ALDRICH, CJ; HAMMER, RE; JONESYOUNGBLOOD, S; KOSZINOWSKI, U; HOOD, L; STROYNOWSKI, I; FORMAN, J			NEGATIVE AND POSITIVE SELECTION OF ANTIGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES-T AFFECTED BY THE ALPHA-3 DOMAIN OF MHC-I MOLECULES	NATURE			English	Article							HISTOCOMPATIBILITY COMPLEX ANTIGENS; CELLS; CD8; EXPRESSION; HLA-A2	THE alpha-1 and alpha-2 domains of major histocompatibility complex (MHC) class I molecules function in the binding and presentation of foreign peptides to the T-cell antigen receptor and control both negative and positive selection of the T-cell repertoire 1-3. Although the alpha-3 domain of class I is not involved in peptide binding, it does interact with the T-cell accessory molecule, CD8 (refs 4, 5). CD8 is important in the selection of T cells as anti-CD8 antibody injected into perinatal mice interferes with this process 6. We previously used a hybrid class I molecule with the alpha-1/alpha-2 domains from L(d) and the alpha-3 domain from Q7b and showed that this molecule binds an L(d)-restricted peptide but does not interact with CD8-dependent cytotoxic T lymphocytes 7. Expression of this molecule in transgenic mice fails to negatively select a subpopulation of anti-L(d) cytotoxic T lymphocytes. In addition, positive selection of virus-specific L(d)-restricted cytotoxic T lymphocytes does not occur. We conclude that besides the alpha-1/alpha-2 domains of class I, the alpha-3 domain plays an important part in both positive and negative selection of antigen-specific cells.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV ULM,VIROL ABT,W-7900 ULM,GERMANY; CALTECH,DEPT BIOL,PASADENA,CA 91125	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Ulm University; California Institute of Technology	ALDRICH, CJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.			Hammer, Robert E./0000-0001-5487-7551				ALDRICH CJ, 1991, J IMMUNOL, V146, P3082; ALDRICH CJ, 1986, J IMMUNOL, V136, P383; ALEXANDER MA, 1991, J EXP MED, V173, P849, DOI 10.1084/jem.173.4.849; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BUDD RC, 1987, J IMMUNOL, V138, P1009; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; KOSZINOWSKI UH, 1987, J EXP MED, V166, P289, DOI 10.1084/jem.166.1.289; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; MACDONALD HR, 1982, IMMUNOL REV, V68, P89, DOI 10.1111/j.1600-065X.1982.tb01061.x; MARUSICGALESIC S, 1988, NATURE, V333, P180, DOI 10.1038/333180a0; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SPRENT J, 1990, IMMUNOL REV, V117, P213, DOI 10.1111/j.1600-065X.1990.tb00574.x; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	24	84	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					718	721		10.1038/352718a0	http://dx.doi.org/10.1038/352718a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652099	Green Submitted			2022-12-24	WOS:A1991GC06400059
J	WOODS, DF; BRYANT, PJ				WOODS, DF; BRYANT, PJ			THE DISKS-LARGE TUMOR SUPPRESSOR GENE OF DROSOPHILA ENCODES A GUANYLATE KINASE HOMOLOG LOCALIZED AT SEPTATE JUNCTIONS	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; AFFECTING IMAGINAL DISKS; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; RECESSIVE ONCOGENE; MEMBRANE-PROTEINS; EPITHELIAL-CELLS	Mutations of the lethal(1)discs large-1 (dlg) tumor suppressor gene of Drosophila cause neoplastic overgrowth of the imaginal discs. Sequencing of a near full-length cDNA predicts a protein containing a domain homologous to yeast guanylate kinase and a region homologous to SH3, a putative regulatory motif in nonreceptor protein tyrosine kinases and other signal transduction proteins. Immunofluorescence analysis using antibodies directed against fusion peptides shows that the dlg gene product is localized in an apical belt of the lateral cell membrane, at the position of the septate junction. The results suggest that a signal transduction process involving guanine nucleotides occurs at the septate junction and is necessary for cell proliferation control in Drosophila epithelia.			WOODS, DF (corresponding author), UNIV CALIF IRVINE,CTR DEV BIOL,IRVINE,CA 92717, USA.							ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BISHOP JG, 1988, GENE DEV, V2, P567, DOI 10.1101/gad.2.5.567; BOS JL, 1989, CANCER RES, V49, P4682; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; BRYANT PJ, 1971, DEV BIOL, V24, P233, DOI 10.1016/0012-1606(71)90097-2; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEQUIN R, 1984, DEV BIOL, V104, P37, DOI 10.1016/0012-1606(84)90034-4; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DOMENIGHINI M, 1990, MOL MICROBIOL, V4, P787, DOI 10.1111/j.1365-2958.1990.tb00649.x; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; EICHENBERGERGLINZ S, 1979, ROUX ARCH DEV BIOL, V186, P333, DOI 10.1007/BF00848457; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; GATEFF E, 1989, Critical Reviews in Oncogenesis, V1, P221; GATEFF E, 1974, ROUXS ARCH, V176, P23; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Goebel S.J., 1990, VIROLOGY, V179, P517; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HANRATTY WP, 1984, ROUX ARCH DEV BIOL, V193, P98, DOI 10.1007/BF00848637; HERZLINGER DA, 1984, J CELL BIOL, V98, P1777, DOI 10.1083/jcb.98.5.1777; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JURSNICH VA, 1990, DEV BIOL, V140, P413, DOI 10.1016/0012-1606(90)90090-6; KLAMBT C, 1989, DEV BIOL, V133, P425, DOI 10.1016/0012-1606(89)90046-8; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN P, 1977, DEV BIOL, V55, P213, DOI 10.1016/0012-1606(77)90168-3; MARTIN PF, 1982, J EXP ZOOL, V222, P97, DOI 10.1002/jez.1402220113; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; MERZ R, 1990, ENVIRON HEALTH PERSP, V88, P163, DOI 10.2307/3431068; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY C, 1974, DEV BIOL, V39, P23, DOI 10.1016/S0012-1606(74)80005-9; Noirot-Timothee C., 1980, International Review of Cytology, V63, P97, DOI 10.1016/S0074-7696(08)61758-1; PAWSON T, 1988, ONCOGENE, V3, P491; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; PISAM M, 1976, J CELL BIOL, V71, P907, DOI 10.1083/jcb.71.3.907; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; POODRY CA, 1970, ROUX ARCH DEV BIOL, V166, P1, DOI 10.1007/BF00576805; POODRY CA, 1990, ROUX ARCH DEV BIOL, V199, P219, DOI 10.1007/BF01682081; Potts W M, 1988, Oncogene Res, V3, P343; RAMIREZ F, 1990, ANN NY ACAD SCI, V580, P74, DOI 10.1111/j.1749-6632.1990.tb17919.x; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WEINER J, 1990, J CELL BIOL, V22, P587; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; ZIOMEK CA, 1980, J CELL BIOL, V86, P849, DOI 10.1083/jcb.86.3.849	75	781	793	0	29	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					451	464		10.1016/0092-8674(81)90009-X	http://dx.doi.org/10.1016/0092-8674(81)90009-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651169				2022-12-24	WOS:A1991GA94100007
J	BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J				BOLLINGER, JM; EDMONDSON, DE; HUYNH, BH; FILLEY, J; NORTON, JR; STUBBE, J			MECHANISM OF ASSEMBLY OF THE TYROSYL RADICAL DINUCLEAR IRON CLUSTER COFACTOR OF RIBONUCLEOTIDE REDUCTASE	SCIENCE			English	Article							ESCHERICHIA-COLI; DIPHOSPHATE REDUCTASE; HYDROGEN-PEROXIDE; SMALL SUBUNIT; MOSSBAUER; SPECTROSCOPY; PROTEIN-B2; ACTIVATION; RESONANCE; ENZYME	Incubation of the apoB2 subunit of Escherichia coli ribonucleotide reductase with Fe2+ and O2 produces native B2, which contains the tyrosyl radical-dinuclear iron cluster cofactor required for nucleotide reduction. The chemical mechanism of this reconstitution reaction was investigated by stopped-flow absorption spectroscopy and by rapid freeze-quench EPR (electron paramagnetic resonance) spectroscopy. Two novel intermediates have been detected in the reaction. The first exhibits a broad absorption band centered at 565 nanometers. Based on known model chemistry, this intermediate is proposed to be a mu-peroxodiferric complex. The second intermediate exhibits a broad absorption band centered at 360 nanometers and a sharp, isotropic EPR signal with g = 2.00. When the reaction is carried out with Fe-57(2+), this EPR signal is broadened, demonstrating that the intermediate is an iron-coupled radical. Variation of the ratio of Fe2+ to B2 in the reaction and comparison of the rates of formation and decay of the intermediates to the rate of formation of the tyrosyl radical (.Y122) suggest that both intermediates can generate .Y122. This conclusion is supported by the fact that both intermediates exhibit an increased lifetime in a mutant B2 subunit (B2-Y122F) lacking the oxidizable Y122. Based on these kinetic and spectroscopic data, a mechanism for the reaction is proposed. Unlike reactions catalyzed by heme-iron peroxidases, oxygenases, and model complexes, the reconstitution reaction appears not to involve high-valent iron intermediates.	EMORY UNIV,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,DEPT PHYS,ATLANTA,GA 30322; COLORADO STATE UNIV,DEPT CHEM,FT COLLINS,CO 80523	Emory University; Emory University; Colorado State University	BOLLINGER, JM (corresponding author), MIT,DEPT CHEM & BIOL,CAMBRIDGE,MA 02139, USA.		Bollinger, Joseph/C-1425-2016; Filley, Jon/AAI-6208-2020		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029595, R01GM029595, R01GM029433, R01GM032187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29433, GM32187, GM29595] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKIN CL, 1973, J BIOL CHEM, V248, P7464; BALLOU DP, 1974, ANAL CHEM, V46, P1248, DOI 10.1021/ac60345a034; BOLLINGER JM, IN PRESS J AM CHEM S; BUNKER G, 1987, BIOCHEMISTRY-US, V26, P4708, DOI 10.1021/bi00389a017; CHIN DH, 1980, J AM CHEM SOC, V102, P4344, DOI 10.1021/ja00533a009; DOLPHIN D, 1971, P NATL ACAD SCI USA, V68, P614, DOI 10.1073/pnas.68.3.614; EHRENBERG A, 1972, J BIOL CHEM, V247, P3485; ERIKSSON S, 1989, ALLOSTERIC ENZYMES, P189; ERMAN JE, 1989, BIOCHEMISTRY-US, V28, P7992, DOI 10.1021/bi00446a004; FONTECAVE M, 1990, BIOCHEM BIOPH RES CO, V168, P659, DOI 10.1016/0006-291X(90)92371-6; FOX BG, 1988, J BIOL CHEM, V263, P10553; FOX BG, 1989, J BIOL CHEM, V264, P17698; LYNCH JB, 1989, J BIOL CHEM, V264, P8091; MCCORMICK JM, IN PRESS NEW J CHEM; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MENAGE S, 1990, J AM CHEM SOC, V112, P6423, DOI 10.1021/ja00173a055; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; PETERSSON L, 1980, J BIOL CHEM, V255, P6706; QUE L, 1990, PROG INORG CHEM, V38, P97; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1989, BIOCHEMISTRY-US, V28, P2618, DOI 10.1021/bi00432a039; SALOWE SP, 1986, J BACTERIOL, V165, P363, DOI 10.1128/jb.165.2.363-366.1986; SANDERSLOEHR J, 1988, OXIDASES RELATED RED, P193; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; SJOBERG BM, 1982, BIOCHEMISTRY-US, V21, P96; SJOBERG BM, 1985, FEBS LETT, V183, P99, DOI 10.1016/0014-5793(85)80962-5; SJOBERG BM, 1977, J BIOL CHEM, V252, P536; STUBBE J, 1983, J BIOL CHEM, V258, P1625; STUBBE J, 1989, ADV ENZYMOL RELAT AR, V63, P349; STUBBE JA, 1990, J BIOL CHEM, V265, P5329; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004	36	342	343	0	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 19	1991	253	5017					292	298		10.1126/science.1650033	http://dx.doi.org/10.1126/science.1650033			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FX224	1650033				2022-12-24	WOS:A1991FX22400033
J	HORVITZ, HR; STERNBERG, PW				HORVITZ, HR; STERNBERG, PW			MULTIPLE INTERCELLULAR SIGNALING SYSTEMS CONTROL THE DEVELOPMENT OF THE CAENORHABDITIS-ELEGANS VULVA	NATURE			English	Article							SPECIFIES CELL FATES; EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; C-ELEGANS; EMBRYONIC-DEVELOPMENT; LATERAL INHIBITION; DROSOPHILA-NOTCH; GENETIC PATHWAY; TYROSINE KINASE; NERVOUS-SYSTEM	Developmental, genetic and molecular studies indicate that multiple intercellular signalling systems interact to specify the types and spatial patterns of cells generated during the formation of the vulva of the nematode Caenorhabditis elegans. Two classes of evolutionarily conserved transmembrane receptors and a Ras protein function in these signalling systems. The biology of vulval development provides a framework for understanding how cell interactions control the development of animals as diverse as nematodes, insects and mammals.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute	HORVITZ, HR (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sternberg, Paul/0000-0002-7699-0173				ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; Barbacid M., 1987, REV BIOCH, V56, P779; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1989, TRENDS GENET, V5, P237, DOI 10.1016/0168-9525(89)90094-2; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GURDON JB, 1987, DEVELOPMENT, V99, P285; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1984, GENETICS, V108, P165; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORVITZ HR, 1980, GENETICS, V96, P435; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; LEWIS J, 1977, J THEOR BIOL, V65, P575; LI C, 1990, NEURON, V4, P681, DOI 10.1016/0896-6273(90)90195-L; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; NISHIDA H, 1989, DEV BIOL, V132, P355, DOI 10.1016/0012-1606(89)90232-7; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RABBITTS T, 1990, NATURE, V348, P418; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SHANKLAND M, 1987, TRENDS GENET, V3, P314, DOI 10.1016/0168-9525(87)90279-4; SIMPSON P, 1990, DEVELOPMENT, V109, P509; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEINBERG RA, 1991, J NIH RES, V3, P45; WHITE J, 1988, NEMATODE CAENORHABDI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	60	229	245	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 13	1991	351	6327					535	541		10.1038/351535a0	http://dx.doi.org/10.1038/351535a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FR034	1646401				2022-12-24	WOS:A1991FR03400048
J	BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF				BAKKEN, LL; CASE, KL; CALLISTER, SM; BOURDEAU, NJ; SCHELL, RF			PERFORMANCE OF 45 LABORATORIES PARTICIPATING IN A PROFICIENCY TESTING PROGRAM FOR LYME-DISEASE SEROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; ANTIBODY; SERODIAGNOSIS	Objective.-We show that significant interlaboratory and intralaboratory variations exist in Lyme disease proficiency testing. Design.-Six case-defined Lyme serum samples and three serum samples from individuals with no history of Lyme disease were randomized in four shipments and distributed to 45 participating laboratories. Results.-Interlaboratory and intralaboratory performances were highly variable. Approximately 4% to 21% of laboratories failed to identify correctly positive serum samples with titers of 512 or more using polyvalent serum or immunoglobulin G conjugates. With lower levels of anti-Borrelia burgdorferi antibody in the serum sample, approximately 55% of participating laboratories did not identify a case-defined serum. There was also a striking inability of many laboratories to reproduce their results on split samples from the same individual. In addition, 2% to 7% of laboratories identified serum samples from individuals with no known exposure to B burgdorferi as positive using polyvalent serum. The false positivity rate increased to 27% with the use of immunoglobulin G conjugate. Conclusions.-Our results indicate that there is an urgent need for standardization of current testing methodologies. Until a national commitment is made, serological testing for Lyme disease will be of questionable value for the diagnosis of the disease.	UNIV WISCONSIN,WISCONSIN STATE LAB HYG,465 HENRY MALL,MADISON,WI 53706; UNIV WISCONSIN,DEPT MED MICROBIOL & IMMUNOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; GUNDERSON MED FDN,LA CROSSE,WI; LUTHERAN HOSP,LA CROSSE,WI	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Gundersen Lutheran Medical Center								AFZELIUS A, 1990, ARCH DERAMTOL SYPH, V101, P405; BERGSTROM S, 1991, EUR J CLIN MICROBIOL, V10, P422, DOI 10.1007/BF01968022; CALLISTER SM, 1988, J CLIN MICROBIOL, V26, P2632, DOI 10.1128/JCM.26.12.2632-2636.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDBERG CW, 1990, ARCH INTERN MED, V150, P732; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; LANE RS, 1990, J CLIN MICROBIOL, V28, P1774, DOI 10.1128/JCM.28.8.1774-1779.1990; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; QUAN TJ, 1991, 1ST P NAT C LYM DIS, P61; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SCRIMENTI RJ, 1970, ARCH DERMATOL, V102, P104, DOI 10.1001/archderm.102.1.104; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; 1991, MMWR, V40, P417	17	119	119	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					891	895		10.1001/jama.268.7.891	http://dx.doi.org/10.1001/jama.268.7.891			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640618				2022-12-24	WOS:A1992JH58800040
J	BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E				BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E			ELEVATED ARTERIAL BLOOD-PRESSURE IN CARDIAC-TAMPONADE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR DIASTOLIC COLLAPSE; VASCULAR SMOOTH-MUSCLE; ECHOCARDIOGRAPHIC SIGN; PERICARDIAL TAMPONADE; PULSUS PARADOXUS; MEDICAL PATIENTS; HYPERTENSION; COMPRESSION; RESISTANCE	Background. In cardiac tamponade cardiac output falls, but peripheral vascular resistance increases, so that systemic blood pressure may be maintained at normal or near-normal levels. We recently observed a patient with cardiac tamponade whose blood pressure was markedly elevated. Methods. To determine the frequency of elevated blood pressure in patients with cardiac tamponade and their hemodynamic characteristics, we studied 18 consecutive patients with cardiac tamponade from a variety of causes using right heart catheterization. Results. Six of the 18 patients had systolic arterial blood pressures ranging from 150 to 210 mm Hg (mean [+/-SD], 176+/-26) and diastolic pressures ranging from 100 to 130 mm Hg (mean, 113+/-14). All six had previously been hypertensive. After pericardiocentesis there was a significant decrease in blood pressure (to 139+/-13 mm Hg systolic, P<0.05; and 83+/-6 mm Hg diastolic, P<0.01) and peripheral vascular resistance (from 2150+/-588 to 1207+/-345 dyn . sec . cm-5, P<0.01). Cardiac output increased in all six. The other 12 patients, 3 of whom had a history of hypertension, had significant increases in cardiac output and systolic blood pressure (from 119+/-13 to 127+/-7 mm Hg, P<0.05) after pericardiocentesis, whereas peripheral vascular resistance decreased. Both groups had similar degrees of cardiac tamponade, as indicated by measurements of cardiac output and intrapericardial, right atrial, and pulmonary-artery wedge pressures. Conclusions. Elevated blood pressure may occur in some patients with cardiac tamponade who have preexisting hypertension. Moreover, blood pressure may fall after pericardiocentesis in patients who have elevated blood pressure associated with tamponade.			BROWN, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HARLEM HOSP CTR,DEPT MED,DIV CARDIOL,506 LENOX AVE,NEW YORK,NY 10032, USA.							ARMSTRONG WF, 1982, CIRCULATION, V65, P1491, DOI 10.1161/01.CIR.65.7.1491; Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; BOHR DF, 1984, AM J MED, V77, P3, DOI 10.1016/S0002-9343(84)80032-7; COGSWELL TL, 1985, CIRCULATION, V72, P1076, DOI 10.1161/01.CIR.72.5.1076; COGSWELL TL, 1986, AM J PHYSIOL, V251, pR916, DOI 10.1152/ajpregu.1986.251.5.R916; ENGEL PJ, 1982, AM J CARDIOL, V50, P1018, DOI 10.1016/0002-9149(82)90411-8; FOWLER NO, 1969, J CLIN INVEST, V48, P502, DOI 10.1172/JCI106007; FOWLER NO, 1978, MOD CONC CARDIOV DIS, V47, P115; FOWLER NO, 1978, CIRCULATION, V57, P563, DOI 10.1161/01.CIR.57.3.563; GASCHO JA, 1981, AM J PHYSIOL, V240, pH49, DOI 10.1152/ajpheart.1981.240.1.H49; GEER M, 1984, CLIN RES, V32, pA331; GILLAM LD, 1983, CIRCULATION, V68, P294, DOI 10.1161/01.CIR.68.2.294; GUBERMAN BA, 1981, CIRCULATION, V64, P633, DOI 10.1161/01.CIR.64.3.633; HANCOCK EW, 1971, CIRCULATION, V43, P183, DOI 10.1161/01.CIR.43.2.183; HOLLOWAY ET, 1973, CIRC RES, V33, P678, DOI 10.1161/01.RES.33.6.678; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M, P105; KERBER RE, 1982, NEW ENGL J MED, V307, P929, DOI 10.1056/NEJM198210073071506; KRONZON I, 1983, J AM COLL CARDIOL, V2, P770, DOI 10.1016/S0735-1097(83)80318-0; KULKARNI P, 1986, CHEST, V89, pS496; LEIMGRUBER PP, 1983, CIRCULATION, V68, P612, DOI 10.1161/01.CIR.68.3.612; LEVINE MJ, 1991, J AM COLL CARDIOL, V17, P59, DOI 10.1016/0735-1097(91)90704-D; LORELL BH, 1988, HEART DISEASE TXB CA, P1497; MILLER SW, 1982, AM J CARDIOL, V50, P1287, DOI 10.1016/0002-9149(82)90465-9; NYBORG NCB, 1988, HYPERTENSION, V11, P635, DOI 10.1161/01.HYP.11.6.635; PEGRAM BL, 1975, CARDIOVASC RES, V9, P707, DOI 10.1093/cvr/9.6.707; REDDY PS, 1978, CIRCULATION, V58, P265, DOI 10.1161/01.CIR.58.2.265; SCHILLER NB, 1977, CIRCULATION, V56, P774, DOI 10.1161/01.CIR.56.5.774; SCHULTE KL, 1988, HYPERTENSION, V11, P320, DOI 10.1161/01.HYP.11.4.320; SHABETAI R, 1979, PROG CARDIOVASC DIS, V22, P107, DOI 10.1016/0033-0620(79)90017-3; SHARP JT, 1960, AM J MED, V29, P640, DOI 10.1016/0002-9343(60)90097-8; SHEBATAI R, 1970, AM J CARDIOL, V26, P480; SINGH S, 1984, CIRCULATION, V70, P966, DOI 10.1161/01.CIR.70.6.966; SINGH S, 1986, AM J CARDIOL, V57, P652, DOI 10.1016/0002-9149(86)90853-2; SIVERTSSON R, 1968, LIFE SCI PT 1 PHYSI, V7, P1291, DOI 10.1016/0024-3205(68)90244-0; SPODICK DH, 1968, DIS CHEST, V54, P62, DOI 10.1378/chest.54.1.62	35	34	35	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					463	466		10.1056/NEJM199208133270704	http://dx.doi.org/10.1056/NEJM199208133270704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625736				2022-12-24	WOS:A1992JH34000004
J	METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A				METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A			THYROID-NODULES IN THE POPULATION LIVING AROUND CHERNOBYL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; ULTRASONOGRAPHY; NODULARITY; RADIATION; IRRADIATION; MANAGEMENT; CHILDHOOD; CHILDREN	Objective.-To determine the baseline incidence, prevalence, and characteristics of thyroid nodules in the population living around the Chernobyl nuclear power plant and to compare the findings with unexposed populations. Design.-Prevalence study. Population samples from seven highly contaminated villages were compared with six nearby control villages of the same size and type. The data were obtained as part of the International Chernobyl Project conducted in 1990. Setting.-The study was conducted 4.5 years after the Chernobyl reactor accident that released large quantities of radionuclides, including radioiodine. Patients or Other Participants.-Population samples of approximately 100 persons residing in both highly contaminated villages and control villages since the accident were compared. Individuals were selected on the basis of birth date as being 5, 10, 40, or 60 years old at the time of the study. All persons selected underwent a thyroid examination. Interventions.-None. Main Outcome Measures.-Two main outcome measures were used, both for thyroid nodularity: clinical palpation and high-resolution ultrasonography. Results.-There was no significant difference in thyroid nodularity between the study groups. Nodules were palpated in 0.7% of children and 2.9% of adults. Discrete nodules were found by ultrasonography in 0.5% of children and 14.9% of adults. Multinodular goiter was found in 3% of adults. Nodules were more common in females. Conclusions.-Four and a half years after the Chernobyl accident, the incidence, prevalence, and characteristics of thyroid nodules were the same in population samples from both highly contaminated and control settlements and similar to results reported for unexposed populations in other countries.	WASHINGTON UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO 63110; CORNELL UNIV,MED CTR,NEW YORK HOSP,SCH MED,DEPT NUCL MED,NEW YORK,NY 10021; ROYAL BRISBANE HOSP,SCH MED,DEPT NUCL MED,BRISBANE,QLD 4029,AUSTRALIA; UNIV BIRMINGHAM,SCH MED,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND; UNIV CINCINNATI HOSP,MED CTR RADIOISOTOPE LAB,CINCINNATI,OH; RADIAT EFFECT RES FDN,NAGASAKI,JAPAN; ACAD MED SCI OBINSK,INST MED RADIOL,OBNINSK,USSR; MINIST PUBL HLTH USSR,INST BIOPHYS,MOSCOW,USSR; KIEV UNION SCI CTR RADIAT MED,KIEV,UKRAINE,USSR	Washington University (WUSTL); Cornell University; NewYork-Presbyterian Hospital; Royal Brisbane & Women's Hospital; University of Birmingham; Radcliffe Infirmary; University of Oxford; University System of Ohio; University of Cincinnati; Radiation Effects Research Foundation - Japan; National Academy of Medical Sciences of Ukraine; National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine	METTLER, FA (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT RADIOL,ALBUQUERQUE,NM 87131, USA.							ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P216, DOI 10.1002/hed.2890030309; BANDER A, 1991, RADIOLOGY, V181, P683; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CARROLL BA, 1982, AM J ROENTGENOL, V133, P499; HAY ID, 1984, LANCET, V1, P916; HAY ID, 1988, CURR MED, V5, P22; HAYASHI N, 1986, Acta Radiologica Diagnosis, V27, P403; HORLOCKER T, 1986, THYROIDOLOGY, P1309; ILYIN L A, 1990, Journal of Radiological Protection, V10, P3, DOI 10.1088/0952-4746/10/1/001; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KATZ JF, 1984, RADIOLOGY, V151, P741, DOI 10.1148/radiology.151.3.6718735; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; NAGATAKI S, 1989, RAD THYROID, P1; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; ROBBINS J, 1989, RAD THYROID, P11; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; SCHIBLE W, 1979, RADIOLOGY, V133, P413; SHORE R, 1984, J NATL CANCER I, V74, P1177; STARK DD, 1983, SURGERY, V94, P863; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; WANG ZY, 1990, JNCI-J NATL CANCER I, V82, P478, DOI 10.1093/jnci/82.6.478; WOESTYN J, 1985, BRIT J RADIOL, V58, P1179, DOI 10.1259/0007-1285-58-696-1179; 1991, TECHNICAL REPORT INT	27	59	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					616	619		10.1001/jama.268.5.616	http://dx.doi.org/10.1001/jama.268.5.616			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629989				2022-12-24	WOS:A1992JF47300026
J	LI, JM; SHORE, GC				LI, JM; SHORE, GC			REVERSAL OF THE ORIENTATION OF AN INTEGRAL PROTEIN OF THE MITOCHONDRIAL OUTER-MEMBRANE	SCIENCE			English	Article							INNER MEMBRANE; PRECURSOR PROTEINS; SIGNAL SEQUENCE; IMPORT; INSERTION; POLYPEPTIDE; RESIDUES; INVITRO; DOMAIN; PORIN	The NH2-terminus of the signal-anchor sequence of an integral, bitopic protein of the outer mitochondrial membrane was extended both in amino acid length (from 11 to 38 amino acids) and net charge (from +4 to +8)-changes that confer on the NH2-terminus characteristics of a strong matrix-targeting signal. The protein was inserted into the outer membrane but in an inverted orientation (N(cyto)-C(in)). These findings suggest that, in common with other membrane systems, the orientation of a protein in the outer mitochondrial membrane can be determined by a signal that causes retention of the NH2-terminus on the cytosolic side of the membrane.			LI, JM (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,QUEBEC,CANADA.							BAKKER EP, 1978, BIOCHEMISTRY-US, V17, P2899, DOI 10.1021/bi00607a031; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FREITAG H, 1982, EUR J BIOCHEM, V126, P197, DOI 10.1111/j.1432-1033.1982.tb06766.x; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLICK B, 1991, ANNU REV GENET, V25, P21; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; Li J. P. H., UNPUB; MCBRIDE H, UNPUB; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NGUYEN M, 1986, J BIOL CHEM, V261, P800; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKERJANC IS, 1988, J BIOL CHEM, V263, P17233; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	24	52	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1815	1817		10.1126/science.1615327	http://dx.doi.org/10.1126/science.1615327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615327				2022-12-24	WOS:A1992JA43400035
J	BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC				BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC			PARENTAL ALCOHOL-USE, PROBLEM DRINKING, AND CHILDRENS INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - Millions of US children are exposed to parents who are problem drinkers, yet there is little evidence about the effect of parental alcohol consumption on children's health. The aim of this study was to assess the association between children's injuries and parental drinking. Design. - Survey of a nationally representative sample of the US population by household interview. Participants. - 12360 children and parents from single-family households, with data from the Alcohol and Child Health supplements to the 1988 National Health Interview Survey. Main Outcome Measure. - Serious injuries-injuries resulting in hospitalization, surgical treatment, missed school, one half day or more in bed. Results. - Children of mothers categorized as problem drinkers had 2.1 times the risk of serious injury as children of mothers who were nondrinkers (95% CI, 1.3 to 3.5). Other measures of mothers' alcohol consumption (ie, average, maximum, and self-rated consumption) were unrelated to child injuries, as were all measures of fathers' drinking. Children of women who were problem drinkers married to men rated as moderate or heavy drinkers had a relative risk of serious injury of 2.7 (95% CI, 0.8 to 8.6) compared with children of nondrinkers. Conclusion. - Children of women who are problem drinkers have an elevated injury risk; children with two parents who are problem drinkers are at higher risk. Further research is needed on potential mechanisms and interventions. Primary prevention might be enhanced if physicians elicited information about parental drinking, helped secure appropriate treatment, and participated in public health efforts to reduce the deleterious effects of alcohol.	NICHHD, ROCKVILLE, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	BIJUR, PE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, ROOM 920, ROSE F KENNEDY CTR, BRONX, NY 10461 USA.				NICHD NIH HHS [R01-HD25416-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025416] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PF, 1989, VITAL HLTH STAT, V10, P173; BEYER JM, 1981, J DRUG ISSUES, V11, P233, DOI 10.1177/002204268101100205; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; CHAFETZ ME, 1971, Q J STUD ALCOHOL, V32, P687; CLAIR D, 1987, J STUD ALCOHOL, V48, P345, DOI 10.15288/jsa.1987.48.345; DAWSON DA, 1991, J MARRIAGE FAM, V53, P573, DOI 10.2307/352734; ELGUEBALY N, 1977, AM J PSYCHIAT, V134, P357; FAMULARO R, 1986, AM J ORTHOPSYCHIAT, V56, P481, DOI 10.1111/j.1939-0025.1986.tb03480.x; KAMMEIER SM, 1971, Q J STUD ALCOHOL, V32, P364; KAPLAN SJ, 1983, J AM ACAD CHILD PSY, V22, P238, DOI 10.1016/S0002-7138(09)60371-X; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298; LINDEN W, 1986, J CONSULT CLIN PSYCH, V54, P309, DOI 10.1037/0022-006X.54.3.309; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MARGOLIS LH, 1986, PEDIATRICS, V77, P870; Obuchowska I., 1974, INT MENTAL HLTH RES, V16, P2; ORFORD J, 1990, RES ADV ALCOHOL DRUG, V10, P81; PUTNAM S, 1987, NOV AM MED C UN INJ; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; SCHOENBORN CA, 1991, ADV DATA, V205; SHAH BV, 1989, SUDAAN PROCEDURES DE; WALLER JA, 1985, INJURY CONTROL GUIDE, P467; WILLIAMS GD, 1986, PUBLIC HEALTH REP, V101, P593; 1987, DIAGNOSTIC STATISTIC; 1972, US DHEW HSM721050 NA; [No title captured]; 1984, ALCOHOL HLTH RES WOR, V8, P1	28	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3166	3171		10.1001/jama.267.23.3166	http://dx.doi.org/10.1001/jama.267.23.3166			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX918	1593737				2022-12-24	WOS:A1992HX91800025
J	YOUNG, MP; YAMANE, S				YOUNG, MP; YAMANE, S			SPARSE POPULATION CODING OF FACES IN THE INFEROTEMPORAL CORTEX	SCIENCE			English	Article							TEMPORAL CORTEX; NEURONS; MONKEY; PERCEPTION; RESPONSES; DIRECTION; IDENTITY; FEATURES	How does the brain represent objects in the world? A proportion of cells in the temporal cortex of monkeys responds specifically to objects, such as faces, but the type of coding used by these cells is not known. Population analysis of two sets of such cells showed that information is carried at the level of the population and that this information relates, in the anterior inferotemporal cortex, to the physical properties of face stimuli and, in the superior temporal polysensory area, to other aspects of the faces, such as their familiarity. There was often sufficient information in small populations of neurons to identify particular faces. These results suggest that representations of complex stimuli in the higher visual areas may take the form of a sparse population code.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL INFORMAT PROC LAB,WAKO,SAITAMA 351,JAPAN; ELECTROTECH LAB,DIV NEUROSCI,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST)	YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1985, Q J EXP PSYCHOL-A, V37, P121, DOI 10.1080/14640748508400927; BAYLIS GC, 1985, BRAIN RES, V342, P91, DOI 10.1016/0006-8993(85)91356-3; Dasser V., 1988, MACHIAVELLIAN INTELL, P85; Edgington E. S., 1980, RANDOMIZATION TESTS; FREE WJ, 1975, MASS ACTION NERVOUS; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1984, DYNAMIC ASPECTS NEOC; Gower J.C, 1971, MATH ARCHAEOLOGICAL, P138; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; Konorski J., 1967, INTEGRATIVE ACTIVITY; LEHKY SR, 1990, J NEUROSCI, V10, P2281; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1987, TRENDS NEUROSCI, V10, P358, DOI 10.1016/0166-2236(87)90071-3; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; RHODES G, 1988, PERCEPTION, V17, P43, DOI 10.1068/p170043; SCHONEMANN PH, 1970, PSYCHOMETRIKA, V35, P245, DOI 10.1007/BF02291266; SHEPARD RN, 1980, SCIENCE, V210, P390, DOI 10.1126/science.210.4468.390; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1990, THESIS U ST ANDREWS	22	418	421	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1327	1331		10.1126/science.1598577	http://dx.doi.org/10.1126/science.1598577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW135	1598577				2022-12-24	WOS:A1992HW13500036
J	KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J				KLEIJMEER, MJ; KELLY, A; GEUZE, HJ; SLOT, JW; TOWNSEND, A; TROWSDALE, J			LOCATION OF MHC-ENCODED TRANSPORTERS IN THE ENDOPLASMIC-RETICULUM AND CIS-GOLGI	NATURE			English	Article							CLASS-I MOLECULES; HLA-B ANTIGENS; MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELLS; INFLUENZA NUCLEOPROTEIN; REGION; BIOSYNTHESIS; RECOGNITION; ASSOCIATION; PEPTIDES	IMMUNE recognition of intracellular proteins is mediated by major histocompatibility complex (MHC) class I molecules that present short peptides to cytotoxic T cells 1-4. Evidence suggests that peptides arise by cleavage of proteins in the cytoplasm and are transported by a signal-independent mechanism into a pre-Golgi region of the cell, where they take part in the assembly of class I heavy chains with beta-2-microglobulin (reviewed in refs 5-7). Analysis of cells that have defects in class I molecule assembly and antigen presentation 8-14 has shown that this phenotype can result from mutations in either of the two ABC transporter genes located in the class II region of the MHC 15-22. This suggested that the protein complex encoded by these two genes 20,22 transports peptides from the cytosol into the endoplasmic reticulum. Here we report additional evidence by showing that the transporter complex is located in the endoplasmic reticulum membrane and is probably oriented with its ATP-binding domains in the cytosol.	IMPERIAL CANC RES FUND,HUMAN IMMUNOGENET LAB,LONDON WC2A 3PX,ENGLAND; JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	Cancer Research UK; University of Oxford	KLEIJMEER, MJ (corresponding author), UNIV UTRECHT,SCH MED,DEPT CELL BIOL,UTRECHT,NETHERLANDS.			Townsend, Alain/0000-0002-3702-0107				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRACIALE TJ, 1991, IMMUNOL TODAY, V12, P124, DOI 10.1016/0167-5699(91)90096-C; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOBBERSTEIN B, 1992, NATURE, V355, P109, DOI 10.1038/355109a0; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SALTER RD, 1986, EMBO J, V5, P943, DOI 10.1002/j.1460-2075.1986.tb04307.x; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	41	197	198	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					342	344		10.1038/357342a0	http://dx.doi.org/10.1038/357342a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589036				2022-12-24	WOS:A1992HW13200052
J	STACEY, GN; BOLTON, BJ; DOYLE, A				STACEY, GN; BOLTON, BJ; DOYLE, A			DNA FINGERPRINTING TRANSFORMS THE ART OF CELL AUTHENTICATION	NATURE			English	Article							QUALITY-CONTROL; MARKERS; LINES	The increasing diversity of new cell cultures is seriously stretching the capabilities of traditional methods of identification. DNA fingerprinting is set to play an important role in increasing confidence in the authenticity of cultures in research and industry.			STACEY, GN (corresponding author), PUBL HLTH LAB SERV APPL MICROBIOL & RES,EUROPEAN COLLECT ANIM CELL CULTURES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							HALTON DM, 1983, IN VITRO CELL DEV B, V19, P16, DOI 10.1007/BF02617989; HANLAN CR, 1989, CYTOGENETICS ANIMALS, pR11; HAY RJ, 1988, ANAL BIOCHEM, V171, P225, DOI 10.1016/0003-2697(88)90480-0; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1985, NATURE, V316, P76, DOI 10.1038/316076a0; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; MOWLES JM, 1990, CYTOTECHNOLOGY, V3, P107, DOI 10.1007/BF00143670; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NELSONRE.WA, 1974, SCIENCE, V184, P1093, DOI 10.1126/science.184.4141.1093; NELSONREES WA, 1976, SCIENCE, V195, P1343; OBRIEN SJ, 1980, IN VITRO CELL DEV B, V16, P119; STACEY GN, 1991, DNA FINGERPRINTING A; STACEY GN, IN PRESS CYTOTECHNOL; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; THACKER J, 1988, SOMAT CELL MOLEC GEN, V14, P519, DOI 10.1007/BF01535307	15	39	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					261	262		10.1038/357261a0	http://dx.doi.org/10.1038/357261a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589025				2022-12-24	WOS:A1992HV19500061
J	WHITMAN, M; MELTON, DA				WHITMAN, M; MELTON, DA			INVOLVEMENT OF P21RAS IN XENOPUS MESODERM INDUCTION	NATURE			English	Article							HA-RAS MUTATION; GROWTH-FACTORS; ACTIVIN-A; EMBRYOS; CELLS; DIFFERENTIATION; EMBRYOGENESIS; GASTRULATION; LAEVIS; GENES	DURING early vertebrate embryogenesis, mesoderm is specified by a signal emanating from prospective endoderm. This signal can respecify Xenopus prospective ectoderm as mesoderm, and can be mimicked by members of the fibroblast growth factor and transforming growth factor-beta families 1,2. In other systems, the p21c-ras proto-oncogene product has been implicated in signal transduction for various polypeptide growth factors. We report here that a dominant inhibitory ras mutant blocks the mesoderm-inducing activity of fibroblast growth factor and activin, as well as the endogenous inducing activity of prospective endoderm. A constitutively active ras mutant partially mimics these activities. These results indicate that p21ras may have a central role in the transduction of the mesoderm inductive signal. Basic fibroblast growth factor 3,4 and activin 5-8 have emerged as candidates for endogenous mesoderm-inducing molecules. The character of the mesoderm induced by these two factors is overlapping but distinct when assessed both by histological and molecular criteria 9,10. The signal transduction pathways used during induction by these factors are unknown. We used messenger RNA microinjection of Xenopus eggs to express a dominant inhibitory mutant ras, p21(Asn 17)Ha-ras, in cells competent to respond to inducing factors to examine the role of p21ras in this response. This mutant, which has a reduced affinity for GTP relative to GDP 11, blocks a variety of mitogenic signals in 3T3 fibroblasts 12 as well as the differentiation of pheochromocytoma cells in response to nerve growth factor 13.	DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138				Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Barbacid M., 1987, REV BIOCH, V56, P779; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GODSAVE SF, 1988, DEVELOPMENT, V102, P555; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; JAMRICH M, 1987, GENE DEV, V1, P124, DOI 10.1101/gad.1.2.124; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Ruiz i Altaba A, 1989, Nature, V341, P33; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SYMES K, 1987, DEVELOPMENT, V101, P339; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; WHITMAN M, 1989, ANNU REV CELL BIOL, V5, P93; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054	29	181	182	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					252	254		10.1038/357252a0	http://dx.doi.org/10.1038/357252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589022				2022-12-24	WOS:A1992HV19500058
J	BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG				BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG			IS HELICOBACTER-PYLORI THE CAUSE OF DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-LIKE ORGANISMS; UPPER GASTROINTESTINAL SYMPTOMS; FOLLOW-UP EXAMINATIONS; NON-ULCER DYSPEPSIA; CHRONIC GASTRITIS; MUCOSAL HISTOLOGY; BIOPSY SPECIMENS; PREVALENCE; INFECTION; DIAGNOSIS	Objective-To determine the association between infection with Helicobacter pylori and dyspepsia. Design-Cross sectional study of dyspeptic subjects and age and sex matched controls identified by a questionnaire survey of all inhabitants aged 20-69. (Endoscopy, histological examination, and microbiological examinations of biopsies from the gastric mucosa were performed blind.) Setting-Population based survey in Sorreisa, Norway. Subjects-All 782 dyspeptic subjects (excluding those with a previous history of peptic ulcer, gall stones or kidney stones, and coronary heart disease) and controls were offered an endoscopy, of whom 309 dyspeptic subjects and 310 controls attended. Main outcome measures-Prevalences of endoscopic and histological diagnoses and of cultures positive for H pylori. Results-A high prevalence of positive cultures, increasing with age, was found in both dyspeptic subjects (48%) and non-dyspeptic controls (36%) (p = 0.004). Positive cultures in both dyspeptic subjects and controls were strongly associated with histological gastritis (70%, 95% confidence interval 65.5 to 85.3; 60%, 52.7 to 67.7, respectively) and peptic ulcer (92%, 61.5 to 99.8; 64.1, 9.4 to 99.2, respectively). Only 3% of subjects with a histologically non-inflamed gastric mucosa had this infection (dyspeptic subjects 2%, 0.2 to 7.0; controls 4%; 1.2 to 8.8). Conclusions-The relation between dyspeptic symptoms and H pylori is dubious; H pylori seems to have a pathogenetic role in gastritis and may be a contributing factor but not a cause of peptic ulcer.	UNIV TROMSO,INST COMMUNITY MED,N-9001 TROMSO,NORWAY; UNIV TROMSO HOSP,GASTROENTEROL,N-9012 TROMSO,NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway								ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BARTHEL JS, 1988, ARCH INTERN MED, V148, P1149, DOI 10.1001/archinte.148.5.1149; BARTLETT JG, 1988, GASTROENTEROLOGY, V94, P229, DOI 10.1016/0016-5085(88)90634-8; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1988, LANCET, V1, P576; Doenges JL, 1938, P SOC EXP BIOL MED, V38, P536; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Fleiss JL, 1981, STAT METHODS RATES P; Freedberg A. S., 1940, AM J DIG DIS, V7, P443, DOI DOI 10.1007/BF02997393; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; HEATLEY RV, 1987, LANCET, V2, P779; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; LANGENBERG ML, 1984, LANCET, V1, P1348; LAWSON HH, 1964, LANCET, V1, P469; LOFFELD RJLF, 1989, GUT, V30, P1206, DOI 10.1136/gut.30.9.1206; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NESLAND AA, 1985, SCAND J GASTROENTERO, V20, P222, DOI 10.3109/00365528509089661; OWEN DA, 1979, PATHOL ANNU, V1, P247; PETERSON WL, 1986, GASTROENTEROLOGY, V90, P1585; PETTROSS CW, 1988, DIGEST DIS SCI, V33, P649, DOI 10.1007/BF01540425; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SAVARY M, 1977, OESOPHAGUS LEHRBUCH; SIURALA M, 1988, GUT, V29, P909, DOI 10.1136/gut.29.7.909; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TATSUTA M, 1986, DIGEST DIS SCI, V31, P7, DOI 10.1007/BF01347902; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814; WARREN JR, 1983, LANCET, V1, P1273; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701	37	142	142	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1276	1279		10.1136/bmj.304.6837.1276	http://dx.doi.org/10.1136/bmj.304.6837.1276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606428	Green Published, Bronze			2022-12-24	WOS:A1992HV08600019
J	ADAM, SA; GERACE, L				ADAM, SA; GERACE, L			CYTOSOLIC PROTEINS THAT SPECIFICALLY BIND NUCLEAR LOCATION SIGNALS ARE RECEPTORS FOR NUCLEAR IMPORT	CELL			English	Article							LARGE-T-ANTIGEN; RAT-LIVER NUCLEI; ASP-GLU-ASP; PORE COMPLEX; SEQUENCE REQUIREMENTS; TRANSPORT SIGNALS; MAMMALIAN-CELLS; LOCALIZATION; TRANSLOCATION; ENVELOPE	We have purified two major polypeptides of 54 and 56 kd from bovine erythrocytes that specifically bind the nuclear location sequence (NLS) of the SV40 large T antigen. When added to a permeabilized cell system for nuclear import, the purified proteins increase by 2- to 3-fold the nuclear accumulation of a fluorescent protein containing the large T antigen NLS. The import stimulation is saturable and dependent upon the presence of cytosol. Nuclear protein accumulation in vitro is sensitive to inactivation by N-ethylmaleimide (NEM). NEM inactivation can be overcome by addition of the purified NLS-binding proteins to the import system. NEM treatment of the purified proteins abolishes their ability to stimulate import but does not affect NLS binding. Our results indicate that the NLS-binding proteins are NEM-sensitive receptors for nuclear import. At least one other NEM-sensitive cytosolic activity and an NEM-insensitive cytosolic activity are also necessary for protein import in vitro.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	ADAM, SA (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA.			Adam, Stephen/0000-0003-3444-7655				ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; DALES S, 1973, VIROLOGY, V56, P465, DOI 10.1016/0042-6822(73)90050-0; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; IMAMOTOSONOBE N, 1988, P NATL ACAD SCI USA, V85, P3426, DOI 10.1073/pnas.85.10.3426; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1988, MOL CELL BIOL, V8, P2722, DOI 10.1128/MCB.8.7.2722; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MANDELL RB, 1990, J CELL BIOL, V111, P1175; MARKLAND W, 1987, MOL CELL BIOL, V7, P4255, DOI 10.1128/MCB.7.12.4255; MARTIN K, 1991, J VIROL, V65, P232, DOI 10.1128/JVI.65.1.232-244.1991; MEHLIN H, 1988, CELL BIOL INT REP, V12, P729, DOI 10.1016/0309-1651(88)90086-0; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARNAIK VK, 1990, MOL CELL BIOL, V10, P1287, DOI 10.1128/MCB.10.3.1287; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; TOGNON M, 1981, J VIROL, V40, P870, DOI 10.1128/JVI.40.3.870-880.1981; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WHITE EM, 1989, J CELL BIOL, V109, P1983, DOI 10.1083/jcb.109.5.1983; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1988, SCIENCE, V242, P275, DOI 10.1126/science.3051382; YONEDA Y, 1987, EXP CELL RES, V170, P439, DOI 10.1016/0014-4827(87)90319-3	61	370	378	1	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					837	847		10.1016/0092-8674(91)90431-W	http://dx.doi.org/10.1016/0092-8674(91)90431-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653647				2022-12-24	WOS:A1991GE46000004
J	HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG				HOUCK, MA; CLARK, JB; PETERSON, KR; KIDWELL, MG			POSSIBLE HORIZONTAL TRANSFER OF DROSOPHILA GENES BY THE MITE PROCTOLAELAPS-REGALIS	SCIENCE			English	Article							SCAPTOMYZA-PALLIDA DROSOPHILIDAE; P-TRANSPOSABLE ELEMENTS; SALTANS SPECIES GROUPS; HYBRID DYSGENESIS; ENZYMATIC AMPLIFICATION; HOMOLOGOUS SEQUENCES; MELANOGASTER GENOME; OBSCURA GROUP; DNA; POPULATIONS	There is strong inferential evidence for recent horizontal gene transfer of the P (mobile) element to Drosophila melanogaster from a species of the Drosophila willistoni group. One potential vector of this transfer is a semiparasitic mite, Proctolaelaps regalis DeLeon, whose morphology, behavior, and co-occurrence with Drosophila are consistent with the properties necessary for such a vector. Southern blot hybridization, polymerase chain reaction (PCR) amplification, and DNA sequencing showed that samples of P. regalis associated with a P strain of D. melanogaster carried P element sequences. Similarly, Drosophila ribosomal DNA sequences were identified in P. regalis samples that had been associated with Drosophila cultures. These result, have potentially important evolutionary implications, not only for understanding the mechanisms by which genes may be transferred between reproductively isolated species, but also for improved detection of some host-parasite and predator-prey relationships.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721; UNIV ARIZONA,DEPT ECOL & EVOLUT BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					PHS HHS [36715] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; ANXOLABEHERE D, 1985, GENET SEL EVOL, V17, P579, DOI 10.1186/1297-9686-17-4-579; APPENZELLER T, 1990, SCIENCE, V247, P1030, DOI 10.1126/science.2309117; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BROOKFIELD JFY, 1984, NATURE, V310, P330, DOI 10.1038/310330a0; Cantelo WW, 1973, DROSOPHILA INF SERV, V50, P163; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; DANIELS SB, 1987, GENETICS, V115, P711; DANIELS SB, 1986, J MOL EVOL, V23, P138, DOI 10.1007/BF02099908; DANIELS SB, 1990, GENETICS, V129, P399; DELEON D, FLA ENTOMOL, V196; Ehrman L., 1982, Genetics and Biology of Drosophila, V3b, P193; Engels W.R, 1989, MOBILE DNA, P437; Evans G. O, 1961, TERRESTRIAL ACARI BR, V1; GOOD AG, 1989, GENETICS, V122, P387; HAGEMANN S, 1990, J MOL EVOL, V31, P478, DOI 10.1007/BF02102074; Hammen L, 1964, ZOOLOGISCHE VERHANDE, V71; IWANO M, 1984, JPN J GENET, V59, P403, DOI 10.1266/jjg.59.403; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KIYASU PK, 1984, GENET RES, V44, P251, DOI 10.1017/S0016672300026495; KONDO S, 1985, P NATL ACAD SCI USA, V82, P6236; Krantz GW, 1978, MANUAL ACAROLOGY; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; TAUTZ D, 1988, MOL BIOL EVOL, V5, P366; Woolley TA, 1988, ACAROLOGY MITES HUMA	32	202	208	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1125	1129		10.1126/science.1653453	http://dx.doi.org/10.1126/science.1653453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653453				2022-12-24	WOS:A1991GD80800028
J	GOODWIN, FK				GOODWIN, FK			DIAZEPAM AND MEMORY LOSS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J DRUG ALCOHOL AB, V17, P129	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-24	WOS:A1991GB97500006
J	RAPRAEGER, AC; KRUFKA, A; OLWIN, BB				RAPRAEGER, AC; KRUFKA, A; OLWIN, BB			REQUIREMENT OF HEPARAN-SULFATE FOR BFGF-MEDIATED FIBROBLAST GROWTH AND MYOBLAST DIFFERENTIATION	SCIENCE			English	Article							PLASMINOGEN-ACTIVATOR PRODUCTION; SKELETAL-MUSCLE MYOBLASTS; PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; SWISS-3T3 CELLS; FACTOR RECEPTOR; AFFINITY; BINDING; CLONING; IDENTIFICATION	Basic fibroblast growth factor (bFGF) binds to heparan sulfate proteoglycans at the cell surface and to receptors with tyrosine kinase activity. Prevention of binding between cell surface heparan sulfate and bFGF (i) substantially reduces binding of fibroblast growth factor to its cell-surface receptors, (ii) blocks the ability of bFGF to support the growth of Swiss 3T3 fibroblasts, and (iii) induces terminal differentiation of MM14 skeletal muscle cells, which is normally repressed by fibroblast growth factor. These results indicate that cell surface heparan sulfate is directly involved in bFGF cell signaling.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	RAPRAEGER, AC (corresponding author), UNIV WISCONSIN,DEPT PATHOL,MADISON,WI 53706, USA.		Olwin, Bradley B/A-1333-2014	Krufka, Alison/0000-0002-8921-6291	NIAMS NIH HHS [AR39467, R01 AR039467] Funding Source: Medline; NICHD NIH HHS [HD21881] Funding Source: Medline; PHS HHS [5T32H007118] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R23HD021881, R01HD021881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039467, R01AR039467] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRUS LW, 1989, J BIOL CHEM, V264, P18647; CARPENTER G, 1976, J CELL PHYSIOL, V88, P227, DOI 10.1002/jcp.1040880212; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FARLEY JR, 1978, ARCH BIOCHEM BIOPHYS, V185, P376, DOI 10.1016/0003-9861(78)90180-7; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HUANG SS, 1986, BIOCHEM BIOPH RES CO, V139, P619, DOI 10.1016/S0006-291X(86)80035-3; KELLER JM, 1987, BIOCHIM BIOPHYS ACTA, V926, P139, DOI 10.1016/0304-4165(87)90230-3; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KRUFKA A, 1990, Journal of Cell Biology, V111, p223A; KRUFKA A, UNPUB; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LORIES V, 1989, J BIOL CHEM, V264, P7009; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; OLWIN BB, UNPUB; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAPRAEGER AC, UNPUB; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; SENO M, 1990, EUR J BIOCHEM, V188, P239, DOI 10.1111/j.1432-1033.1990.tb15395.x; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	1420	1462	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 21	1991	252	5013					1705	1708		10.1126/science.1646484	http://dx.doi.org/10.1126/science.1646484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT114	1646484				2022-12-24	WOS:A1991FT11400046
J	JOHNSON, E				JOHNSON, E			NEUROPSYCHOLOGICAL IMPAIRMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, AM J DRUG ALCOHOL AB, V192, P131	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH588	1640596				2022-12-24	WOS:A1992JH58800009
J	STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH				STAMPFER, MJ; MALINOW, MR; WILLETT, WC; NEWCOMER, LM; UPSON, B; ULLMANN, D; TISHLER, PV; HENNEKENS, CH			A PROSPECTIVE-STUDY OF PLASMA HOMOCYST(E)INE AND RISK OF MYOCARDIAL-INFARCTION IN UNITED-STATES PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BETA-SYNTHASE DEFICIENCY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ENDOTHELIAL-CELL INJURY; VASCULAR-DISEASE; HOMOCYSTEINE; HOMOCYSTINURIA; HYPERHOMOCYST(E)INEMIA; PREVALENCE; CAROTENE	Objective.-To assess prospectively the risk of coronary heart disease associated with elevated plasma levels of homocyst(e)ine. Design.-Nested case-control study using prospectively collected blood samples. Setting.-Participants in the Physicians' Health Study. Participants.-A total of 14916 male physicians, aged 40 to 84 years, with no prior myocardial infarction (MI) or stroke provided plasma samples at baseline and were followed up for 5 years. Samples from 271 men who subsequently developed MI were analyzed for homocyst(e)ine levels together with paired controls, matched by age and smoking. Main Outcome Measure.-Acute MI or death due to coronary disease. Results.-Levels of homocyst(e)ine were higher in cases than in controls (11.1+/-4.0 [SD] vs 10.5+/-2.8 nmol/mL; P=.03). The difference was attributable to an excess of high values among men who later had MIs. The relative risk for the highest 5% vs the bottom 90% of homocyst(e)ine levels was 3.1 (95% confidence interval, 1.4 to 6.9; P=.005). After additional adjustment for diabetes, hypertension, aspirin assignment, Quetelet's Index, and total/high-density lipoprotein cholesterol, this relative risk was 3.4 (95% confidence interval, 1.3 to 8.8) (P=.01). Thirteen controls and 31 cases (11%) had values above the 95th percentile of the controls. Conclusions.- Moderately high levels of plasma homocyst(e)ine are associated with subsequent risk of MI independent of other coronary risk factors. Because high levels can often be easily treated with vitamin supplements, homocyst(e)ine may be an independent, modifiable risk factor.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; OREGON REG PRIMATE RES CTR,BEAVERTON,OR 97006; OREGON HLTH SCI UNIV,DEPT MED,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT COMMUNITY & PREVENT MED,PORTLAND,OR 97201; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Harvard University; Harvard Medical School	STAMPFER, MJ (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,CHANNING LAB,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA042182] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595] Funding Source: NIH RePORTER; NCI NIH HHS [CA42182] Funding Source: Medline; NHLBI NIH HHS [HL26490, HL34595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, NEW ENGL J MED, V321, P129; BRATTSTROM L, 1988, METABOLISM, V37, P175, DOI 10.1016/S0026-0495(98)90014-2; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOT PG, 1983, EUR J CLIN INVEST, V13, P405, DOI 10.1111/j.1365-2362.1983.tb00121.x; GENEST JJ, 1990, J AM COLL CARDIOL, V16, P1114, DOI 10.1016/0735-1097(90)90542-W; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; KANG SS, 1991, AM J HUM GENET, V48, P536; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; KANG SS, 1987, METABOLISM, V36, P458, DOI 10.1016/0026-0495(87)90043-6; KATRANGI N, 1984, J LIPID RES, V25, P400; MALINOW MR, 1990, CIRCULATION, V81, P2004, DOI 10.1161/01.CIR.81.6.2004; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MALINOW MR, 1990, CORONARY ARTERY DIS, V1, P215, DOI 10.1097/00019501-199003000-00010; MALINOW MR, 1992, NUTR METAB CARDIOVAS, V1, P166; MANORE MM, 1989, AM J CLIN NUTR, V50, P339, DOI 10.1093/ajcn/50.2.339; MEREAURICHARD C, 1991, CLIN CHEM, V37, P126; Mudd Sh, 1989, METABOLIC BASIS INHE, V1, P693; MURPHYCHUTORIAN DR, 1985, J AM COLL CARDIOL, V6, P725, DOI 10.1016/S0735-1097(85)80473-3; Polansky M. M., 1985, METHODS VITAMIN ASSA, P417; REED T, 1991, CLIN GENET, V39, P425; RUBBA P, 1990, METABOLISM, V39, P1191, DOI 10.1016/0026-0495(90)90093-R; SMOLIN LA, 1981, J PEDIATR-US, V99, P467, DOI 10.1016/S0022-3476(81)80352-6; SMOLIN LA, 1988, ANAL BIOCHEM, V168, P374, DOI 10.1016/0003-2697(88)90332-6; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1985, STAT MED, V4, P111, DOI 10.1002/sim.4780040202; STARKEBAUM G, 1986, J CLIN INVEST, V77, P1370, DOI 10.1172/JCI112442; STORER BE, 1983, APPL STAT-J ROY ST C, V32, P172; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; UELAND PM, 1989, J LAB CLIN MED, V114, P473; WALL RT, 1980, THROMB RES, V18, P113, DOI 10.1016/0049-3848(80)90175-9; WILCKEN DEL, 1985, METABOLISM, V34, P1115, DOI 10.1016/0026-0495(85)90156-8; WILCKEN DEL, 1976, J CLIN INVEST, V57, P1079, DOI 10.1172/JCI108350; WILLIAMS RR, 1990, CORONARY ARTERY DIS, V1, P681, DOI 10.1097/00019501-199011000-00008; 1971, 5TH WORK GROUP COP	36	1391	1455	2	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					877	881		10.1001/jama.268.7.877	http://dx.doi.org/10.1001/jama.268.7.877			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640615				2022-12-24	WOS:A1992JH58800037
J	ROSOVE, MH; BREWER, PMC				ROSOVE, MH; BREWER, PMC			ANTIPHOSPHOLIPID THROMBOSIS - CLINICAL COURSE AFTER THE 1ST THROMBOTIC EVENT IN 70 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article						FIBRINOLYTIC AGENTS; THROMBOEMBOLISM; ANTIPHOSPHOLIPID SYNDROME; LUPUS ERYTHEMATOSUS, SYSTEMIC PURPURA, THROMBOCYTOPENIC, IDIOPATHIC	SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTI-CARDIOLIPIN ANTIBODIES; ANTICARDIOLIPIN ANTIBODIES; CIRCULATING ANTICOAGULANT; HABITUAL ABORTION; FETAL LOSSES; PREVALENCE; ASSOCIATION; WOMEN; PREDNISONE	Objective: To determine the clinical course and influence of antithrombotic therapy in patients with lupus anticoagulant or anticardiolipin antibodies, or both, after the first thromboembolic event. Design: Retrospective survey of consecutive patients treated according to their physician's best judgment. Setting: Secondary and tertiary referral practice. Patients: Seventy patients (48 women [69%]) with a mean age (+/-SD) of 45.5 +/- 17.3 years. The antiphospholipid syndrome was primary in 51 patients (73%) and secondary to systemic lupus erythematosus in 14 patients (20%) and to chronic idiopathic thrombocytopenic purpura in 5 patients (7%). Measurements: Site of initial and recurrent thrombotic events (venous or arterial), as well as kind (aspiring, heparin, or warfarin) and intensity of anticoagulation. Results: Total follow-up after the first thrombotic event was 361.0 patient-years (mean [+/-SD], 5.2 +/- 5.6 years per patient). Thirty-seven patients (53%) had 54 recurrent events, with 2 patients experiencing fatal events. Arterial events were followed by arterial events, and venous events by venous events, in 49 of 54 instances (91%). Recurrence rates during "no treatment;" aspirin therapy; or low-, intermediate-, or high-intensity warfarin therapy (international normalized ratios [INRs] less-than-or-equal-to 1.9, 2.0 to 2.9, and greater-than-or-equal-to 3.0, respectively, or rabbit brain thromboplastin prothrombin time ratios of approximately <1.3, 1.3 to 1.5, and >1.5, respectively) were 0.19, 0.32, 0.57, 0.07 (P = 0.12), and 0.00 (P < 0.001) per patient-year. The follow-up periods for the five types of therapy were 161.2, 37.8, 11.3, 40.9, and 110.2 patient-years, respectively. The highest INR coincident with thrombosis was 2.6. Five warfarin-treated patients had five significant bleeding events (0.031 per patient-year). Conclusions: Recurrent thrombosis is a potentially serious problem for patients with lupus anticoagulant or anticardiolipin antibodies or both. The site of the first event (arterial or venous) tended to predict the site of subsequent events. Intermediate- to high-intensity warfarin therapy may confer better antithrombotic protection than low- to intermediate-intensity warfarin therapy or aspirin therapy. Further studies are needed to define more precisely the rethrombosis rate and optimal type, intensity, and duration of antithrombotic therapy.			ROSOVE, MH (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, 100 UCLA MED PLAZA, SUITE 550, LOS ANGELES, CA 90024 USA.							ALARCONSEGOVIA D, 1989, MEDICINE, V68, P353, DOI 10.1097/00005792-198911000-00003; BOEY ML, 1983, BMJ-BRIT MED J, V287, P1021, DOI 10.1136/bmj.287.6398.1021; BRANCH DW, 1985, NEW ENGL J MED, V313, P1322, DOI 10.1056/NEJM198511213132104; BREY RL, 1990, NEUROLOGY, V40, P1190, DOI 10.1212/WNL.40.8.1190; CANOSO RT, 1988, AM J HEMATOL, V27, P272, DOI 10.1002/ajh.2830270408; CARRERAS LO, 1982, THROMB HAEMOSTASIS, V48, P38; CERVERA R, 1990, ANN RHEUM DIS, V49, P109, DOI 10.1136/ard.49.2.109; COWCHOCK S, 1986, AM J OBSTET GYNECOL, V155, P1002, DOI 10.1016/0002-9378(86)90335-2; DERKSEN RHWM, 1986, ARTHRITIS RHEUM, V29, P1295, DOI 10.1002/art.1780291021; EDELMAN P, 1986, HUM REPROD, V1, P295, DOI 10.1093/oxfordjournals.humrep.a136408; ELDRUPJORGENSEN J, 1989, J VASC SURG, V9, P334, DOI 10.1067/mva.1989.vs0090334; ELIAS M, 1984, ARCH INTERN MED, V144, P510, DOI 10.1001/archinte.144.3.510; FEINSTEIN DI, 1985, NEW ENGL J MED, V313, P1348, DOI 10.1056/NEJM198511213132109; FRANCOIS A, 1988, ANN INTERN MED, V109, P993, DOI 10.7326/0003-4819-109-12-993; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HARRIS EN, 1983, LANCET, V2, P1211; ISHII Y, 1990, ANN RHEUM DIS, V49, P387, DOI 10.1136/ard.49.6.387; KALUNIAN KC, 1988, AM J MED, V85, P602; KHAMASHTA MA, 1990, LANCET, V335, P1541, DOI 10.1016/0140-6736(90)91373-I; LEUNG WH, 1990, AM J MED, V89, P411, DOI 10.1016/0002-9343(90)90368-N; LOCKSHIN MD, 1985, NEW ENGL J MED, V313, P152, DOI 10.1056/NEJM198507183130304; LOCKSHIN MD, 1989, AM J OBSTET GYNECOL, V160, P439, DOI 10.1016/0002-9378(89)90468-7; LOCKWOOD CJ, 1989, AM J OBSTET GYNECOL, V161, P369, DOI 10.1016/0002-9378(89)90522-X; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LUBBE WF, 1983, LANCET, V1, P1361; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MUEH JR, 1980, ANN INTERN MED, V92, P156, DOI 10.7326/0003-4819-92-2-156; NILSSON IM, 1975, ACTA MED SCAND, V197, P153; PALARETI G, 1991, THROMB HAEMOSTASIS, V65, P452; PETRI M, 1987, ARTHRITIS RHEUM, V30, P601, DOI 10.1002/art.1780300601; ROSOVE MH, 1986, BLOOD, V68, P472; ROSOVE MH, 1990, OBSTET GYNECOL, V75, P630; ROSOVE MH, 1989, AM J HEMATOL, V32, P148, DOI 10.1002/ajh.2830320215; SANTIAGO MB, 1989, CLIN RHEUMATOL, V8, P23, DOI 10.1007/BF02031064; SHAPIRO SS, 1982, PROG HEMOST THROMB, V6, P263; SHI W, 1990, AUST NZ J MED, V20, P231, DOI 10.1111/j.1445-5994.1990.tb01025.x; STEGNAR M, 1991, THROMB RES, V63, P433, DOI 10.1016/0049-3848(91)90230-T; STIMMLER MM, 1989, ARCH INTERN MED, V149, P1833, DOI 10.1001/archinte.149.8.1833; TAYLOR M, 1990, AM J REPROD IMMUNOL, V23, P33, DOI 10.1111/j.1600-0897.1990.tb00666.x; UNANDER AM, 1987, AM J OBSTET GYNECOL, V156, P114, DOI 10.1016/0002-9378(87)90218-3; WANG Y, 1990, RHEUMATOL INT, V10, P75, DOI 10.1007/BF02274787	41	579	586	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					303	308		10.7326/0003-4819-117-4-303	http://dx.doi.org/10.7326/0003-4819-117-4-303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637025				2022-12-24	WOS:A1992JH46400006
J	FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK				FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK			IMPLICATIONS OF 3RD HEART SOUNDS IN PATIENTS WITH VALVULAR HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR VOLUME; ORIGIN; FAILURE; DOGS	Background. The presence of third heart sounds in patients with valvular heart disease is often regarded as a sign of heart failure, but it may also depend on the type of valvular disease. Methods. We assessed the prevalence of third heart sounds and the relation between third heart sounds and cardiac function in 1281 patients with six types of valvular heart disease. Results. The prevalence of third heart sounds was higher in patients with mitral regurgitation (46 percent) or aortic regurgitation (28 percent) than in those with aortic stenosis (11 percent) or mitral stenosis (8 percent). The left ventricular ejection fraction was significantly lower (P<0.001) when a third heart sound was detected in patients with aortic stenosis (0.38, vs. 0.56 in those without third heart sounds) or mixed aortic valve disease (0.40 vs. 0.55). However, the ejection fraction was only slightly lower in patients with mitral regurgitation and third heart sounds (0.51 vs. 0.57, P = 0.03). The pulmonary-capillary wedge pressure was higher (P<0.001) when a third heart sound was detected in patients with aortic stenosis (18.6 mm Hg, vs. 12.1 mm Hg in those without third heart sounds). There was no association between the wedge pressure and third heart sounds in patients with mitral regurgitation. The prevalence of third heart sounds increased with the severity of mitral regurgitation. Conclusions. In patients with mitral regurgitation, third heart sounds are common but do not necessarily reflect left ventricular systolic dysfunction or increased filling pressure. In patients with aortic stenosis, third heart sounds are uncommon but usually indicate the presence of systolic dysfunction and elevated filling pressure.	VET AFFAIRS MED CTR,RES SERV,BOSTON,MA; VET AFFAIRS MED CTR,RES SERV,HINES,IL; VET AFFAIRS MED CTR,RES SERV,DENVER,CO; VET AFFAIRS MED CTR,RES SERV,TUCSON,AZ	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System								ABDULLA AM, 1981, CIRCULATION, V64, P464, DOI 10.1161/01.CIR.64.3.464; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1040; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRAYZEL J, 1960, AM J MED, V28, P578, DOI 10.1016/0002-9343(60)90152-2; HAMMERMEISTER KE, 1974, CIRCULATION, V49, P739; ISHIMITSU T, 1985, J AM COLL CARDIOL, V5, P268, DOI 10.1016/S0735-1097(85)80046-2; ISHMAIL AA, 1987, CHEST, V91, P870, DOI 10.1378/chest.91.6.870; KENNEDY JW, 1970, AM HEART J, V80, P343, DOI 10.1016/0002-8703(70)90099-2; KUO PT, 1957, J CLIN INVEST, V36, P1035, DOI 10.1172/JCI103499; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; NIXON PG, 1961, BRIT HEART J, V23, P677; OZAWA Y, 1983, CIRCULATION, V67, P399, DOI 10.1161/01.CIR.67.2.399; OZAWA Y, 1983, CIRCULATION, V67, P393, DOI 10.1161/01.CIR.67.2.393; SHAH PM, 1968, NEW ENGL J MED, V278, P753, DOI 10.1056/NEJM196804042781402; SHAH PM, 1969, AM HEART J, V78, P823, DOI 10.1016/0002-8703(69)90450-5; VANDEWERF F, 1984, J CLIN INVEST, V73, P1400, DOI 10.1172/JCI111344; VANDEWERF F, 1984, CIRCULATION, V69, P1070, DOI 10.1161/01.CIR.69.6.1070; 1985, CONTROLLED CLIN TRIA, V6, P51	19	34	35	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					458	462		10.1056/NEJM199208133270703	http://dx.doi.org/10.1056/NEJM199208133270703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625735				2022-12-24	WOS:A1992JH34000003
J	RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A				RIDLEY, AJ; PATERSON, HF; JOHNSTON, CL; DIEKMANN, D; HALL, A			THE SMALL GTP-BINDING PROTEIN RAC REGULATES GROWTH-FACTOR INDUCED MEMBRANE RUFFLING	CELL			English	Article								The function of rac, a ras-related GTP-binding protein, was investigated in fibroblasts by microinjection. In confluent serum-starved Swiss 3T3 cells, rac1 rapidly stimulated actin filament accumulation at the plasma membrane, forming membrane ruffles. Several growth factors and activated H-ras also induced membrane ruffling, and this response was prevented by a dominant inhibitory mutant rac protein, N17rac1. This suggests that endogenous rac proteins are required for growth factor-induced membrane ruffling. In addition to membrane ruffling, a later response to both rac1 microinjection and some growth factors was the formation of actin stress fibers, a process requiring endogenous rho proteins. Using N17rac1 we have shown that these growth factors act through rac to stimulate this rho-dependent response. We propose that rac and rho are essential components of signal transduction pathways linking growth factors to the organization of polymerized actin.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST, INST CANC RES, FULHAM RD, LONDON SW3 6JB, ENGLAND.			Tapon, Dagmar/0000-0003-3837-4764; Ridley, Anne/0000-0001-8186-5708				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BARSAGI D, 1987, J CELL PHYSIOL, P69; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KELLER HU, 1990, J CELL SCI, V96, P99; KELLER HU, 1990, J CELL PHYSIOL, V145, P465, DOI 10.1002/jcp.1041450311; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MOLL J, 1991, ONCOGENE, V6, P863; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; ROZENGURT E, 1989, BRIT MED BULL, V45, P515, DOI 10.1093/oxfordjournals.bmb.a072339; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOBUE K, 1988, P NATL ACAD SCI USA, V85, P482, DOI 10.1073/pnas.85.2.482; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	45	3172	3239	3	102	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					401	410		10.1016/0092-8674(92)90164-8	http://dx.doi.org/10.1016/0092-8674(92)90164-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643658	Bronze			2022-12-24	WOS:A1992JH12400005
J	BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D				BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D			MITRAL ANNULAR CALCIFICATION AND THE RISK OF STROKE IN AN ELDERLY COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATCHED CONTROL SUBJECTS; ANULAR CALCIUM; CARDIAC ABNORMALITIES; ISCHEMIC ATTACKS; ECHOCARDIOGRAPHY; DISEASE; FIBROSUS; VALVE	Background. Previous clinical studies have suggested that there is an association between mitral annular calcification and the risk of stroke, but it is unclear whether this association is independent of the traditional risk factors for stroke. We examined the relation between mitral annular calcification and the incidence of stroke in a population-based study. Methods. Subjects in the Framingham Study receiving a routine examination underwent M-mode echocardiography to determine the presence and severity (thickness in millimeters) of mitral annular calcification. The incidence of stroke during eight years of follow-up was analyzed with a proportional-hazards model adjusting for the calcification, age, sex, systolic blood pressure, diabetes mellitus, cigarette smoking, atrial fibrillation, and coronary heart disease or congestive heart failure. Results. Among 1159 subjects whose echocardiograms could be assessed for mitral annular calcification and who had no history or current evidence of stroke at the index examination (51 percent of all subjects), the prevalence of mitral annular calcification was 10.3 percent in the men and 15.8 percent in the women. Multivariate analysis demonstrated that the presence of mitral annular calcification was associated with a relative risk of stroke of 2.10 (95 percent confidence interval, 1.24 to 3.57; P = 0.006). There was a continuous relation between the incidence of stroke and the severity of mitral annular calcification; each millimeter of thickening as shown on the echocardiogram represented a relative risk of stroke of 1.24 (95 percent confidence interval, 1.1 2 to 1.37; P<0.001). Furthermore, even when subjects with coronary heart disease or congestive heart failure were excluded from the analysis, subjects with mitral annular calcification still had twice the risk of stroke. Conclusions. In an elderly, longitudinally followed population-based cohort, mitral annular calcification was associated with a doubled risk of stroke, independently of traditional risk factors for stroke. Whether such calcification contributes causally to the risk of stroke or is merely a marker of increased risk because of its association with other precursors of stroke remains unknown.	BOSTON CITY HOSP,DEPT CARDIOL,BOSTON,MA 02118; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; NHLBI,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; DARTMOUTH HITCHCOCK MED CTR,CARDIOL SECT,LEBANON,NH	Boston Medical Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	BENJAMIN, EJ (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-09] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALWLESS JF, 1982, STATISTICAL MODELS M, P359; Barnett H J, 1983, Neurol Clin, V1, P291; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; Bonniger M, 1908, DEUT MED WOCHENSCHR, V34, P2292; BONNIGER M, 1908, DTSCH MED WCHNSCHR, V34, P2293; BURNSIDE JW, 1972, ANN INTERN MED, V76, P615, DOI 10.7326/0003-4819-76-4-615; CUPPLES LA, 1988, NIH882969 PUBL; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEBONO DP, 1979, LANCET, V2, P383; FULKERSON PK, 1979, AM J MED, V66, P967, DOI 10.1016/0002-9343(79)90452-2; FURLAN AJ, 1984, STROKE, V15, P801, DOI 10.1161/01.STR.15.5.801; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GREENLAND P, 1981, ANN INTERN MED, V95, P51, DOI 10.7326/0003-4819-95-1-51; GUTHRIE J, 1963, BRIT HEART J, V25, P137; JESPERSEN CM, 1987, ACTA MED SCAND, V222, P37; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KANNEL WB, 1983, JAMA-J AM MED ASSOC, V250, P2942, DOI 10.1001/jama.250.21.2942; KIRK RS, 1969, BRIT HEART J, V31, P684; KORN D, 1962, NEW ENGL J MED, V267, P900, DOI 10.1056/NEJM196211012671802; LIN CS, 1987, ARCH PATHOL LAB MED, V111, P411; MELLINO M, 1982, AM HEART J, V103, P222, DOI 10.1016/0002-8703(82)90495-1; NAIR CK, 1989, AM J CARDIOL, V63, P465, DOI 10.1016/0002-9149(89)90321-4; NAIR CK, 1984, AM J CARDIOL, V54, P1286, DOI 10.1016/S0002-9149(84)80082-X; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; POMERANCE A, 1970, J CLIN PATHOL, V23, P354, DOI 10.1136/jcp.23.4.354; REM JA, 1985, STROKE, V16, P950, DOI 10.1161/01.STR.16.6.950; RIDOLFI RL, 1976, ARCH PATHOL LAB MED, V100, P117; ROBERTS WC, 1972, ANN INTERN MED, V77, P939, DOI 10.7326/0003-4819-77-6-939; RYTAND DA, 1946, ARCH INTERN MED, V78, P544, DOI 10.1001/archinte.1946.00220050049003; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SAVAGE DD, 1983, AM J CARDIOL, V51, P1375, DOI 10.1016/0002-9149(83)90315-6; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; TODNEM K, 1986, ACTA NEUROL SCAND, V74, P323; ZAK FG, 1949, AM J MED SCI, V218, P510, DOI 10.1097/00000441-194911000-00004; 1992, ANN INTERN MED, V116, P6; 1988, APPLIED REGRESSION A, P297; 1990, NEW ENGL J MED, V323, P1505	39	300	305	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					374	379		10.1056/NEJM199208063270602	http://dx.doi.org/10.1056/NEJM199208063270602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625711				2022-12-24	WOS:A1992JG35600002
J	BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M				BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M			PSYCHIATRIC IMPLICATIONS OF MISSILE ATTACKS ON A CIVILIAN POPULATION - ISRAELI LESSONS FROM THE PERSIAN-GULF-WAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEBANON WAR	Objective.-To determine the proportion of hospitalized patients who had stress reactions as a result of missile attacks during the Persian Gulf War and evaluate the factors that influenced their evacuation. Design.-Review of medical records of patients hospitalized as a result of missile attacks. Setting.-During the Persian Gulf War in the winter of 1991, Israel received 18 missile attacks involving 39 surface-to-surface Scud missiles. The uncertainty in time, place, and type of warhead, conventional or chemical, was a source of chronic stress and the immediate cause for many traumatic stress reactions at or near the missile attack sites. Participants.-Data from victims who were injured after each missile attack were available through a central hookup between 12 local hospitals and the Medical Corps of the Israeli Defence Force. Main Outcome Measure.-The number of persons diagnosed in the hospital as psychological casualties after each missile attack. Results.-Approximately 43% of the 773 casualties evacuated to hospitals were diagnosed as psychological casualties, and an additional 27% had mistakenly injected themselves with atropine. Data also indicated that triage of psychological casualties to hospitals was more a function of the rescue team's training and preparation than the severity or extent of injury or damage. Conclusions.-Optimal treatment during events that cause mass casualties requires proper preparation of rescue teams as well as reorganization of the hospital' s psychiatric services. The threat of chemical warfare affected the number and nature of stress reactions.	TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL; TEL AVIV UNIV,SHAPEL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; BAR ILAN UNIV,DEPT PSYCHOL,RAMAT GAN,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Bar Ilan University	BLEICH, A (corresponding author), ISRAEL DEF FORCES,MED CORPS,DEPT MENTAL HLTH,MIL POB 02149,JERUSALEM,ISRAEL.							BELENKY GL, 1987, PSYCHIAT ANN, V17, P528, DOI 10.3928/0048-5713-19870801-06; BURKLE F M JR, 1991, Emergency Medicine Clinics of North America, V9, P87; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; DUNN CL, 1952, EMERGENCY MED SERVIC, V1, P170; HISS J, 1992, BRIT MED J, V304, P92, DOI 10.1136/bmj.304.6819.92; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; Kormos HR, 1978, STRESS DISORDERS VIE, P3; NEWHOUSE P, 1987, CONT STUDIES COMBAT, P185; NOY S, 1984, ISRAEL J MED SCI, V20, P360; OBALLANCE E, 1988, GULF WAR, P103; RACHMAN SJ, 1990, FEAR COURAGE, P25; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613	13	67	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					613	615		10.1001/jama.268.5.613	http://dx.doi.org/10.1001/jama.268.5.613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF473	1629988				2022-12-24	WOS:A1992JF47300025
J	ISEMAN, MD				ISEMAN, MD			A LEAP OF FAITH - WHAT CAN WE DO TO CURTAIL INTRAINSTITUTIONAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTION CONTROL; ULTRAVIOLET RAYS; CROSS INFECTION	ULTRAVIOLET AIR DISINFECTION	Large-scale, epidemic transmission of tuberculosis to patients, nonprofessional staff, nurses, and physicians has been documented recently in hospitals, clinics, acquired immunodeficiency syndrome (AIDS) residencies, and correctional facilities. Prominent factors in these outbreaks have included human immunodeficiency virus (HIV) infection and AIDS, delayed diagnosis of tuberculosis, multidrug-resistant strains of tuberculosis that resulted in protracted shedding of mycobacteria, and ventilation patterns in buildings that resulted in the accumulation of infectious particles. Multiple deaths from tuberculosis have resulted. Various strategies, including vaccines, masks, augmented ventilation, air filters, and ultraviolet irradiation have been proposed to control this situation. Although no well-controlled studies exist to document the utility of any of these modalities, ultraviolet germicidal irradiation seems both the best theoretical model and the most practical tactic. Ultraviolet systems should be widely deployed throughout high-risk institutions.	UNIV COLORADO, SCH MED, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DIV INFECT DIS, CLIN MYCOBACTERIOL SERV, 1400 JACKSON ST, DENVER, CO 80206 USA.							CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; Riley R.L., 1961, MOL MED MICROBIOLOGY, P1; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1980, B INT UNION TUBERC, V55, P14; 1990, MMWR, V39, P1	16	52	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					251	253		10.7326/0003-4819-117-3-251	http://dx.doi.org/10.7326/0003-4819-117-3-251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616220				2022-12-24	WOS:A1992JF30400013
J	HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA				HOLLAND, KN; BRILL, RW; CHANG, RKC; SIBERT, JR; FOURNIER, DA			PHYSIOLOGICAL AND BEHAVIORAL THERMOREGULATION IN BIGEYE TUNA (THUNNUS-OBESUS)	NATURE			English	Article							FISH; MOVEMENTS	TUNA are unique among teleost fishes in being thermoconserving. Vascular counter-current heat exchangers maintain body temperatures above ambient water temperature, thereby improving locomotor muscle efficiency, especially at burst speeds and when pursuing prey below the thermocline1-6. Because tuna also occasionally swim rapidly in warm surface waters, it has been hypothesized that tuna thermoregulate to accommodate changing activity levels or ambient temperatures7. But previous field experiments have been unable to demonstrate definitively short-latency, mammalian-type physiological thermoregulation8,9. Here we show using telemetered data that free-ranging bigeye tuna (Thunnus obesus) can rapidly alter whole-body thermal conductivity by two orders of magnitude. The heat exchangers are disengaged to allow rapid warming as the tuna ascend from cold water into warmer surface waters, and are reactivated to conserve heat when they return into the depths. Combining physiological and behavioural thermoregulation expands the foraging space of bigeye tuna into otherwise prohibitively cold, deep water.	NATL MARINE FISHERIES SERV,HONOLULU LAB,HONOLULU,HI 96822; OTTER RES LTD,NANAIMO,BC,CANADA	National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA	HOLLAND, KN (corresponding author), HAWAII INST MARINE BIOL,POB 1346,COCONUT ISL,KANEOHE,HI 96744, USA.		Holland, Kim/ABH-1490-2021					[Anonymous], 1978, FISH PHYSL; AXELSSON M, 1986, J EXP BIOL, V126, P225; CAREY FG, 1973, SCI AM, V228, P36, DOI 10.1038/scientificamerican0273-36; CAREY FG, 1973, COMP BIOCHEM PHYSIOL, V44, P375, DOI 10.1016/0300-9629(73)90490-8; CAREY FG, 1987, PHYSIOL ZOOL, V60, P138, DOI 10.1086/physzool.60.1.30158635; CAREY FG, 1990, MAR BIOL, V106, P329, DOI 10.1007/BF01344309; Carey FG, 1990, PLANNING FUTURE BILL, P103; DIZON AE, 1979, AM ZOOL, V19, P249; DIZON AE, 1976, J THERM BIOL, V1, P18; Graham J.B., 1978, P113; Graham J.B., 1983, P248; GRAHAM JB, 1975, FISH B-NOAA, V73, P219; GRAHAM JB, 1981, PHYSIOL ZOOL, V54, P470, DOI 10.1086/physzool.54.4.30155840; GREIWANK A, 1991, AUTOMATIC DIFFERENTI; HOLLAND K, 1985, MAR FISH REV, V47, P26; HOLLAND KN, 1990, FISH B-NOAA, V88, P493; NEILL W H, 1976, Environmental Biology of Fishes, V1, P61, DOI 10.1007/BF00761729; NEILL WS, 1974, SCIENCE, V184, P8; STEFFEL S, 1976, T AM FISH SOC, V105, P558; STEVENS ED, 1974, J EXP BIOL, V61, P145; 1991, AUTODIF A C PLUS PLU	21	180	190	5	58	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					410	412		10.1038/358410a0	http://dx.doi.org/10.1038/358410a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641023				2022-12-24	WOS:A1992JF85300054
J	LAURENCE, J; HODTSEV, AS; POSNETT, DN				LAURENCE, J; HODTSEV, AS; POSNETT, DN			SUPERANTIGEN IMPLICATED IN DEPENDENCE OF HIV-1 REPLICATION IN T-CELLS ON TCR V-BETA EXPRESSION	NATURE			English	Article							MOLECULAR ANALYSIS; CLONAL ANERGY; LYMPHOCYTES-T; ENTEROTOXIN-B; INFECTION; INDUCTION; MICE	IN the pathogenesis of AIDS it is not yet understood whether the small fraction of CD4+ T cells (approximately 1%) infected with the human immunodeficiency virus (HIV) are randomly targeted or not. Here we present evidence that human CD4 T-cell lines expressing selected T-cell antigen receptor V-beta gene products can all be infected in vitro with HIV-1, but give markedly different titres of HIV-1 virion production. For example, V-beta-12 T-cell lines from several unrelated donors reproducibly yielded up to 100-fold more gag gene product (p24gag antigen) than V-beta-6.7a lines. This is consistent with a superantigen effect, because the V-beta selectivity was observed with several divergent HIV-1 isolates, was dependent on antigen-presenting cells and on major histocompatibility complex (MHC) class II but was not MHC class II-restricted. The in vivo significance of these findings is supported by the preferential stimulation of V-beta-12+ T cells by freshly obtained irradiated antigen-presenting cells from some HIV-1-seropositive but not HIV-1-negative donors. Moreover, cells from patients positive for viral antigen (gp120) were enriched in the V-beta-12 subpopulation. V-beta-12+ T cells were not deleted in AIDS patients, however, raising the possibility that a variety of mechanisms contribute to T-cell depletion. Our results indicate that a superantigen targets a subpopulation of CD4+ cells for viral replication.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,1300 YORK AVE,BOX 56,NEW YORK,NY 10021	Cornell University								ACUTO O, 1985, J EXP MED, V161, P1326, DOI 10.1084/jem.161.6.1326; BIGLER RD, 1983, J EXP MED, V158, P1000, DOI 10.1084/jem.158.3.1000; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; LAURENCE J, 1991, J VIROL, V65, P213, DOI 10.1128/JVI.65.1.213-219.1991; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; ONEILL H, 1991, CELL IMMUNOL, V6136, P54; PRASHAR Y, 1991, J IMMUNOL, V147, P3441; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	164	170	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					255	259		10.1038/358255a0	http://dx.doi.org/10.1038/358255a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630494				2022-12-24	WOS:A1992JD58700060
J	STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A				STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A			IMPAIRMENT OF RENAL-FUNCTION WITH INCREASING BLOOD LEAD CONCENTRATIONS IN THE GENERAL-POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE; EXPOSURE; CADMIUM; PRESSURE; HYPERTENSION; WORKERS	Background. Nephropathy is known to occur in persons with heavy exposure to lead. Whether exposure to lead in the general population leads to impaired renal function is not known. Methods. We studied renal function and indexes ot lead exposure in a random population sample of 965 men and 1016 women (age range, 20 to 88 years). In all the subjects we measured creatinine clearance and blood concentrations of lead and zinc protoporphyrin (an indirect measure of blood lead level). Results. The mean (+/-SD) creatinine clearance rate was 99+/-30 ml per minute in the men and 80+/-25 ml per minute in the women. In the men the geometric mean blood lead concentration was 114-mu-g per liter (0.55-mu-mol per liter) (range, 23 to 725-mu-g per liter [0.11 to 3.5-mu-mol per liter]), and in the women 75-mu-g per liter (0.36-mu-mol per liter) (range, 17 to 603-mu-g per liter [0.08 to 2.9-mu-mol per liter]); the zinc protoporphyrin values in blood averaged 1.0 and 1.1-mu-g per gram ot hemoglobin, respectively. The creatinine clearance rate was inversely correlated with blood lead and zinc protoporphyrin values in the men and the women both before and after adjustments for age, body-mass index, and diuretic treatment. A 10-fold increase in blood lead concentration was associated with a reduction of 10 to 13 ml per minute in creatinine clearance. We also found a positive correlation between serum beta-2-microglobulin (which is inversely related to the glomerular filtration rate) and blood lead in men, between serum beta-2-microglobulin and zinc protoporphyrin in both sexes, and between serum creatinine and zinc protoporphyrin in men. Conclusions. Exposure to lead may impair renal function in the general population. The alternative hypothesis that renal impairment may lead to an increase in the blood lead concentration cannot be excluded. however.	CATHOLIC UNIV LEUVEN,HYPERTENS & CARDIOVASC REHABIL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT PATHOPHYSIOL,NEPHROL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,IND TOXICOL & OCCUPAT MED UNIT,B-3000 LOUVAIN,BELGIUM; STATE UNIV LIEGE,ENVIRONM TOXICOL UNIT,B-4000 LIEGE,BELGIUM	KU Leuven; KU Leuven; KU Leuven; University of Liege			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				[Anonymous], 1988, BMJ, V297, P319; BARTELS H, 1971, CLIN CHIM ACTA, V32, P81, DOI 10.1016/0009-8981(71)90467-0; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BERNARD A, 1984, EXPERIENTIA, V40, P143, DOI 10.1007/BF01963577; BERNARD AM, 1983, CLIN CHEM, V29, P1007; BUCHET JP, 1980, J OCCUP ENVIRON MED, V22, P741; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; CHISOLM JJ, 1962, J PEDIATR-US, V60, P1, DOI 10.1016/S0022-3476(62)80002-X; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CRAMER K, 1974, BRIT J IND MED, V31, P113; EMMERSON BT, 1991, NEPHRON, V58, P233, DOI 10.1159/000186421; EMMERSON BT, 1963, AUSTRALAS ANN MED, V12, P139, DOI 10.1111/imj.1963.12.2.139; EMMERSON BT, 1971, AUST NZ J MED, V1, P353, DOI 10.1111/j.1445-5994.1971.tb02545.x; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; KARLSSON FA, 1980, SCAND J CLIN LAB INV, V40, P27; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1991, J HUM HYPERTENS, V5, P485; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; 1987, WORLD HLTH ORG REGIO, V23, P242; 1934, MED J AUSTRALIA, V1, P600	29	175	180	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					151	156		10.1056/NEJM199207163270303	http://dx.doi.org/10.1056/NEJM199207163270303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608406	Green Published			2022-12-24	WOS:A1992JD31900003
J	VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM				VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM			FATTY-ACID BIOSYNTHESIS REDIRECTED TO MEDIUM CHAINS IN TRANSGENIC OILSEED PLANTS	SCIENCE			English	Article							ARABIDOPSIS; TRANSFORMATION; TRANSPORT; CLONING; PROTEIN; MUTANTS	Medium-chain fatty acids (FAs), found in storage lipids of certain plants, are an important renewable resource. Seeds of undomesticated California bay accumulate laurate (12:0), and a 12:0-acyl-carrier protein thioesterase (BTE) has been purified from this tissue. Sequencing of BTE enabled the cloning of a complementary DNA coding for a plastid-targeted preprotein. Expression of the complementary DNA in the seeds of Arabidopsis thaliana resulted in BTE activity, and medium chains accumulated at the expense of long-chain (greater-than-or-equal-to 16) FAs. Laurate became the most abundant FA species and was deposited in the storage triacylglycerols. These results demonstrate a mechanism for medium-chain FA synthesis in plants.			VOELKER, TA (corresponding author), CALGENE INC,1920 5TH ST,DAVIS,CA 95616, USA.							AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; BATTEY JF, 1989, TRENDS BIOTECHNOL, V7, P122, DOI 10.1016/0167-7799(89)90088-7; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; DAVIES H, UNPUB; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; KNUTZON DS, COMMUNICATION; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LUTCKE HA, 1987, EMBO J, V6, P44; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; POLLARD MR, 1991, ARCH BIOCHEM BIOPHYS, V284, P1; ROSNER MR, 1982, J CELL BIOCHEM, V18, P37, DOI 10.1002/jcb.1982.240180105; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; TURPEN T H, 1986, Biotechniques, V4, P14; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	23	313	368	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					72	74		10.1126/science.1621095	http://dx.doi.org/10.1126/science.1621095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621095				2022-12-24	WOS:A1992JC16500031
J	MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH				MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH			A PROSPECTIVE-STUDY OF EXERCISE AND INCIDENCE OF DIABETES AMONG UNITED-STATES MALE PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; POLYNESIAN POPULATION; PREVALENCE; MELLITUS; PACIFIC; RISK	Objective.-To examine prospectively the association between regular exercise and the subsequent development of non-insulin-dependent diabetes mellitus (NIDDM). Design.-Prospective cohort study including 5 years of follow-up. Participants.-21 271 US male physicians participating in the Physicians' Health Study, aged 40 to 84 years and free of diagnosed diabetes mellitus, myocardial infarction, cerebrovascular disease, and cancer at baseline. Morbidity follow-up was 99.7% complete. Main Outcome Measure.-Incidence of NIDDM. Results.-At baseline, information was obtained about frequency of vigorous exercise and other risk indicators. During 105 141 person-years of follow-up, 285 new cases of NIDDM were reported. The age-adjusted incidence of NIDDM ranged from 369 cases per 1 00 000 person-years in men who engaged in vigorous exercise less than once weekly to 214 cases per 1 00 000 person-years in those exercising at least five times per week (P, trend, <.001). Men who exercised at least once per week had an age-adjusted relative risk (RR) of NIDDM of 0.64 (95% Cl, 0.51 to 0.82; P=.0003) compared with those who exercised less frequently. The age-adjusted RR of NIDDM decreased with increasing frequency of exercise: 0.77 for once weekly, 0.62 for two to four times per week, and 0.58 for five or more times per week (P, trend, .0002). A significant reduction in risk of NIDDM persisted after adjustment for both age and body-mass index: RR, 0.71 (95% Cl, 0.56 to 0.91; P=.006) for at least once per week compared with less than once weekly, and P, trend, .009, for increasing frequency of exercise. Further control for smoking, hypertension, and other coronary risk factors did not materially alter these associations. The inverse relation of exercise to risk of NIDDM was particularly pronounced among overweight men. Conclusions.-Exercise appears to reduce the development of NIDDM even after adjusting for body-mass index. Increased physical activity may be a promising approach to the primary prevention of NIDDM.	HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET RES CTR,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BECKNIELSEN H, 1989, DIABETES METAB REV, V5, P487, DOI 10.1002/dmr.5610050602; BJORNTORP P, 1982, RECENT TREND DIABETE, P115; BURSTEIN R, 1985, DIABETES, V34, P756, DOI 10.2337/diabetes.34.8.756; CEDERHOLM J, 1985, ACTA MED SCAND, V217, P373; DAHM GL, 1987, AM J PHYSIOL, V252, pE170; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; FRISCH RE, 1986, DIABETES, V35, P1101, DOI 10.2337/diabetes.35.10.1101; HARRIS MI, 1985, DIABETES AM DIABETES, V6, P1; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLLOSZY JO, 1986, ACTA MED SCAND S, V711, P55; HUGHES T, 1987, MMWR-MORBID MORTAL W, V36, P195; JARRETT RJ, 1986, DIABETIC MED, V3, P549, DOI 10.1111/j.1464-5491.1986.tb00813.x; KING H, 1986, MED J AUSTRALIA, V145, P505, DOI 10.5694/j.1326-5377.1986.tb139452.x; KING H, 1984, AM J EPIDEMIOL, V119, P396, DOI 10.1093/oxfordjournals.aje.a113758; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONDON CE, 1980, AM J PHYSIOL, V239, pE169, DOI 10.1152/ajpendo.1980.239.3.E169; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RUDERMAN N, 1990, DIABETES CARE, V13, P1163, DOI 10.2337/diacare.13.11.1163; SCHNEIDER SH, 1984, DIABETOLOGIA, V26, P355, DOI 10.1007/BF00266036; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; STERN JS, 1987, RECENT ADV OBESITY R, P337; TAYLOR R, 1984, DIABETOLOGIA, V27, P578, DOI 10.1007/BF00276971; TAYLOR RJ, 1983, DIABETES CARE, V6, P334, DOI 10.2337/diacare.6.4.334; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45; ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203; 1985, NIH851468 US DEP HLT	35	500	515	3	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					63	67		10.1001/jama.268.1.63	http://dx.doi.org/10.1001/jama.268.1.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608115				2022-12-24	WOS:A1992JA16500024
J	HADORN, DC; MCCORMICK, K; DIOKNO, A				HADORN, DC; MCCORMICK, K; DIOKNO, A			AN ANNOTATED ALGORITHM APPROACH TO CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT-CARE; MEDICINE	The Urinary Incontinence in Adults Guideline Panel facilitated the ready elucidation of its guideline's management recommendations through the use of an annotated algorithm approach. The algorithms created as part of this guideline differ from previous algorithms in two ways: (1) they employ systematic annotation to link explicitly the algorithms' recommendations to the literature, and (2) they contain patient counseling and decision nodes to depict the major preference-dependent decision or branch points in the algorithm. We believe that these two innovations can help ensure the clinical validity of guidelines' algorithms while preserving appropriate clinical flexibility and respecting patient preferences.	WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; RAND CORP, SANTA MONICA, CA 90406 USA; NIA, GERIATR RES CTR, BETHESDA, MD 20892 USA	Beaumont Health; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					AHRQ HHS [T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1982, CRITERIA STANDARDS Q; Field MJ, 1990, CLIN PRACTICE GUIDEL; Gottlieb L K, 1990, QRB Qual Rev Bull, V16, P80; GREENFIELD S, 1981, MED CARE, V19, P255, DOI 10.1097/00005650-198103000-00002; GREENFIELD S, 1990, PROVIDING QUALITY CA; GRIMM RH, 1975, NEW ENGL J MED, V292, P507, DOI 10.1056/NEJM197503062921005; KASSIRER JP, 1990, HOSP PRACT, P23; KOMAROFF AL, 1982, AM J PUBLIC HEALTH, V72, P10, DOI 10.2105/AJPH.72.1.10; KOMAROFF AL, 1974, NEW ENGL J MED, V290, P307, DOI 10.1056/NEJM197402072900605; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; PALMER RH, 1984, MED CARE, V22, P632, DOI 10.1097/00005650-198407000-00005; SOX HC, 1973, NEW ENGL J MED, V288, P818, DOI 10.1056/NEJM197304192881605; 1992, AHCPR920038 AG HLTH	13	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3311	3314		10.1001/jama.267.24.3311	http://dx.doi.org/10.1001/jama.267.24.3311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597913				2022-12-24	WOS:A1992HY94400030
J	ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ				ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ			HYDROGEN-EXCHANGE MEASUREMENT OF THE FREE-ENERGY OF STRUCTURAL AND ALLOSTERIC CHANGE IN HEMOGLOBIN	SCIENCE			English	Article							DIMER-TETRAMER ASSOCIATION; TEMPERATURE-DEPENDENCE; RIBONUCLEASE-S; RESOLUTION; PROTEINS; HELIX	The inability to localize and measure the free energy of protein structure and structure change severely limits protein structure-function investigations. The local unfolding model for protein hydrogen exchange quantitatively relates the free energy of local structural stability with the hydrogen exchange rate of concerted sets of structurally related protons. In tests with a number of modified hemoglobin forms, the loss in structural free energy obtained locally from hydrogen exchange results matches the loss in allosteric free energy measured globally by oxygen-binding and subunit dissociation experiments.	UNIV COLORADO,DEPT BIOCHEM,BOULDER,CO 80309; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University of Colorado System; University of Colorado Boulder; Washington University (WUSTL)	ENGLANDER, SW (corresponding author), UNIV PENN,JOHNSON RES FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NIGMS NIH HHS [R01 GM031847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALLEWELL NM, 1983, J BIOCHEM BIOPH METH, V7, P345, DOI 10.1016/0165-022X(83)90060-X; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BERGER ARIEH, 1957, ARCH BIOCHEM AND BIOPHYS, V69, P106, DOI 10.1016/0003-9861(57)90478-2; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ENGLANDER JJ, 1983, J MOL BIOL, V169, P325, DOI 10.1016/S0022-2836(83)80186-7; ENGLANDER JJ, 1985, ANAL BIOCHEM, V147, P234, DOI 10.1016/0003-2697(85)90033-8; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.bb.21.060192.001331; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1980, BIOPHYS J, V32, P577, DOI 10.1016/S0006-3495(80)84991-5; ENGLANDER SW, 1983, STRUCTURE DYNAMICS N, P421; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IP SHC, 1977, J BIOL CHEM, V252, P82; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUWAJIMA K, 1983, J MOL BIOL, V169, P299, DOI 10.1016/S0022-2836(83)80185-5; LOUIE G, 1988, J MOL BIOL, V201, P755, DOI 10.1016/0022-2836(88)90472-X; LOUIE G, 1988, J MOL BIOL, V201, P765, DOI 10.1016/0022-2836(88)90473-1; MAIN EL, 1980, J BIOL CHEM, V255, P10695; MCKINNIE RE, 1991, CHEM PHYS, V158, P283, DOI 10.1016/0301-0104(91)87072-4; MILLS FC, 1979, J BIOL CHEM, V254, P2881; MONOD J, 1965, J MOL BIOL, V12, P33; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RAY J, 1986, BIOCHEMISTRY-US, V25, P3000, DOI 10.1021/bi00358a040; ROGERO JR, 1986, METHOD ENZYMOL, V131, pL508; ROSA JJ, 1979, J MOL BIOL, V133, P399, DOI 10.1016/0022-2836(79)90400-5; TURNER GL, 1989, THESIS J HOPKINS U B; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	29	83	83	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1684	1687		10.1126/science.256.5064.1684	http://dx.doi.org/10.1126/science.256.5064.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609279	Green Accepted			2022-12-24	WOS:A1992HZ17400046
J	MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L				MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L			ASSESSING FOR ABUSE DURING PREGNANCY - SEVERITY AND FREQUENCY OF INJURIES AND ASSOCIATED ENTRY INTO PRENATAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHYSICAL ABUSE; VIOLENCE; CONFLICT; WOMEN	Objective. - To assess the occurrence, frequency, and severity of physical abuse during pregnancy and associated initiation of prenatal care. Design. - Stratified, prospective cohort analysis. Setting. - Public prenatal clinics in Houston, Tex, and Baltimore, Md. Participants. - Total population-based sample of 691 black, Hispanic, and white pregnant women. All of the women were urban residents and most of the Hispanic women were Mexican American. All participants were invited into the study at the first prenatal visit and were followed up until delivery. Main Outcome Measure. - Identification of abuse status. Results. - A three-question Abuse Assessment Screen detected a 17% (1/6) prevalence of physical or sexual abuse during pregnancy, which is more than double all previous published reports. When evaluated against nationally tested research instruments, the three-question screen that was asked at the first prenatal visit was sensitive and specific to abuse status. Abuse was recurrent, with 60% of abused women reporting two or more episodes of assault. Location of abuse focused on the head. Frequency and severity of abuse and potential danger of homicide was appreciably worse for white women. Abused women were twice as likely as nonabused women to begin prenatal care during the third trimester. Conclusions. - A simple clinical assessment screen completed by the health care provider in a private setting and with the male partner absent is as effective as research instruments in identifying abused women. Straightforward, routine clinical assessment is recommended as essential in preventing potential trauma, interrupting existing abuse, and protecting health.	UNIV MARYLAND,BALTIMORE,MD 21201; UNIV OTAGO,DUNEDIN,NEW ZEALAND	University System of Maryland; University of Maryland Baltimore; University of Otago	MCFARLANE, J (corresponding author), TEXAS WOMANS UNIV,1130 MD ANDERSON BLVD,HOUSTON,TX 77030, USA.				PHS HHS [R49/CCR603514-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BERENSON A, 1991, AM J OBSTET GYNECOL, V164, P491; CAMPBELL J, IN PRESS RES NURS HL; CAMPBELL JC, 1986, ADV NURS SCI, V8, P36, DOI 10.1097/00012272-198607000-00006; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; JORGENSEN SR, 1977, J MARRIAGE FAM, V39, P653, DOI 10.2307/350472; LAZARRO M, 1991, J NURS ADMIN, V21, P24; MCFARLANE J, 1989, WOMEN HEALTH, V15, P69, DOI 10.1300/J013v15n03_06; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1991, VIOLENCE WOMEN NURSI; MCFARLANE J, 1991, DATING VIOLENCE YOUN; Parker B, 1991, MCN Am J Matern Child Nurs, V16, P161, DOI 10.1097/00005721-199105000-00013; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; Steinmetz S., 1977, CYCLE VIOLENCE ASSER; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; STRAUS MA, 1981, CLOSED DOORS VIOLENC; 1988, ABUSED WOMAN; 1986, SURGEON GENERALS WOR; 1989, BATTERED WOMAN	22	715	727	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3176	3178		10.1001/jama.267.23.3176	http://dx.doi.org/10.1001/jama.267.23.3176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593739				2022-12-24	WOS:A1992HX91800027
J	DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S				DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S			UNNECESSARY HOSPITALIZATION IN A PSYCHIATRIC REHABILITATION UNIT	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	DICK, PH (corresponding author), ROYAL LIFF HOSP,DUNDEE PSYCHIAT REHABIL SERV,DUNDEE DD2 5NF,SCOTLAND.							AFFLECK JW, 1984, BRIT J PSYCHIAT, V145, P517, DOI 10.1192/bjp.145.5.517; Dick P H, 1990, Int J Rehabil Res, V13, P119, DOI 10.1097/00004356-199006000-00003; MCCREADIE RG, 1983, BRIT J PSYCHIAT, V143, P564, DOI 10.1192/bjp.143.6.564; MCCREADIE RG, 1991, BRIT J PSYCHIAT, V158, P398, DOI 10.1192/bjp.158.3.398; 1989, CARING PEOPLE COMMUN	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1544	1544		10.1136/bmj.304.6841.1544	http://dx.doi.org/10.1136/bmj.304.6841.1544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ178	1628055	Green Published, Bronze			2022-12-24	WOS:A1992HZ17800026
J	LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A				LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A			PURIFICATION, SEQUENCE, AND CELLULAR-LOCALIZATION OF A NOVEL CHROMOSOMAL PROTEIN THAT BINDS TO METHYLATED DNA	CELL			English	Article							MOUSE SATELLITE DNA; GENE-EXPRESSION; CHROMATIN STRUCTURE; DENOVO METHYLATION; PROMOTER; CELLS; 5-METHYLCYTOSINE; IDENTIFICATION; DEMETHYLATION; ORGANIZATION	Methylation of mammalian DNA can lead to repression of transcription and alteration of chromatin structure. Recent evidence suggests that both effects are the result of an interaction between the methylated sites and methyl-CpG-binding proteins (MeCPs). MeCP1 has previously been detected in crude nuclear extracts. Here we report the identification, purification, and cDNA cloning of a novel MeCP called MeCP2. Unlike MeCP1, the new protein is able to bind to DNA that contains a single methyl-CpG pair. By staining with an antibody, we show that the distribution of MeCP2 along the chromosomes parallels that of methyl-CpG. In mouse, for example, MeCP2 is concentrated in pericentromeric heterochromatin, which contains a large fraction (about 40%) of all genomic 5-methylcytosine.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; GENENTECH INC,S SAN FRANCISCO,CA 94080; ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,A-1121 VIENNA,AUSTRIA; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV VIENNA,INST BOT,A-1010 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Roche Holding; Genentech; University of Edinburgh; University of Vienna	LEWIS, JD (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.			Bird, Adrian/0000-0002-8600-0372; Meehan, Richard/0000-0001-6471-6882; Henzel, William/0000-0003-2940-3797	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; COMINGS DE, 1973, EXP CELL RES, V77, P469, DOI 10.1016/0014-4827(73)90601-0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P683, DOI 10.1093/nar/9.3.683; HUBSCHER U, 1987, NUCLEIC ACIDS RES, V15, P5486, DOI 10.1093/nar/15.13.5486; JEPPESEN PN, 1991, CHROMOSOMA, V101, P322; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JONES KW, 1970, NATURE, V225, P912, DOI 10.1038/225912a0; JOSEPH A, 1989, EXP CELL RES, V183, P494, DOI 10.1016/0014-4827(89)90408-4; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIT S, 1961, J MOL BIOL, V3, P711, DOI 10.1016/S0022-2836(61)80075-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; MANSON MM, 1981, CARCINOGENESIS, V2, P661, DOI 10.1093/carcin/2.7.661; MANUELIDIS L, 1981, FEBS LETT, V129, P25, DOI 10.1016/0014-5793(81)80746-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; REEVES R, 1990, J BIOL CHEM, V265, P8573; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RICKWOOD D, 1975, EUR J BIOCHEM, V51, P593, DOI 10.1111/j.1432-1033.1975.tb03961.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID M, 1984, HUM GENET, V67, P257, DOI 10.1007/BF00291352; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEIN R, 1982, P NATL ACAD SCI USA, V79, P4418; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG RYH, 1986, NUCLEIC ACIDS RES, V14, P9843, DOI 10.1093/nar/14.24.9843; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252	52	1040	1077	3	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					905	914		10.1016/0092-8674(92)90610-O	http://dx.doi.org/10.1016/0092-8674(92)90610-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606614				2022-12-24	WOS:A1992HY79200003
J	NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L				NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L			EXPRESSION CLONING OF A DIPHTHERIA-TOXIN RECEPTOR - IDENTITY WITH A HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR PRECURSOR	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; BACTERIAL TOXINS; SIGNAL SEQUENCE; FACTOR-ALPHA; B-FRAGMENT; ZETA-CHAIN; LOW PH; CELLS	A monkey cDNA (pDTS) encoding a diphtheria toxin (DT) sensitivity determinant was isolated by expression cloning in mouse L-M cells. Mouse cells are naturally resistant to DT, because they lack functional cell surface receptors for the toxin. Unlike wild-type L-M cells, pDTS-transfected mouse cells are extremely toxin sensitive and specifically bind radioiodinated DT. Intoxication of the transfected cells requires receptor-mediated endocytosis of the bound toxin. The cDNA is predicted to encode an integral membrane protein that is identical to the precursor of a heparin-binding EGF-like growth factor. The DT sensitivity protein is thus a growth factor precursor that DT exploits as a receptor.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	NAGLICH, JG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Russell, David/0000-0002-0277-403X	NATIONAL CANCER INSTITUTE [F32CA008398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08398] Funding Source: Medline; NIAID NIH HHS [AI-16805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EIDELS L, 1982, INFECT IMMUN, V37, P1054, DOI 10.1128/IAI.37.3.1054-1058.1982; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1980, INTRO MACROMOLECULES, V1, P3; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTHEWS LS, 1991, CELL, V65, P973; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOEHRING TJ, 1974, BIOCHEM BIOPH RES CO, V60, P1446, DOI 10.1016/0006-291X(74)90360-X; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; NAGLICH JG, 1990, P NATL ACAD SCI USA, V87, P7250, DOI 10.1073/pnas.87.18.7250; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PROIA RL, 1981, J BIOL CHEM, V256, P4991; PROIA RL, 1980, J BIOL CHEM, V255, P2025; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROBBINS AR, 1987, METHOD ENZYMOL, V138, P458; ROLF JM, 1990, J BIOL CHEM, V265, P7331; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J., 1989, MOL CLONING LAB MANU; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STENMARK H, 1988, J BIOL CHEM, V263, P13449; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649	67	470	492	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1051	1061		10.1016/0092-8674(92)90623-K	http://dx.doi.org/10.1016/0092-8674(92)90623-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606612				2022-12-24	WOS:A1992HY79200016
J	SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH				SUH, I; SHATEN, BJ; CUTLER, JA; KULLER, LH			ALCOHOL-USE AND MORTALITY FROM CORONARY HEART-DISEASE - THE ROLE OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY DISEASE; ALCOHOL DRINKING; LIPOPROTEINS, HDL CHOLESTEROL; MORTALITY; DOSE-RESPONSE RELATIONSHIP, DRUG	CARDIOVASCULAR MORTALITY; CONSUMPTION; MEN; SUBFRACTIONS; FRAMINGHAM; DRINKING	Objective: To study the association between alcohol consumption and death from coronary heart disease and to determine the extent to which the association can be explained by the high-density lipoprotein (HDL) cholesterol level. Design: A cohort study involving men enrolled in the Multiple Risk Factor Intervention Trial (MRFIT). Setting: Community-based study. Participants: Men (n = 11 688) at high risk for developing coronary heart disease but without clinical evidence of it. More than 90% of the men were white, and the average age was 46 years. Five percent of the men abstained from alcohol during the trial, 81% consumed fewer than 21 alcoholic drinks per week, and 14% consumed more than 21 alcoholic drinks per week. Measurements: Average alcohol intake over 7 years was calculated for MRFIT participants who were alive at the end of the trial and who had at least three follow-up records of alcohol consumption. Post-trial mortality during a 3.8-year period was assessed. Results: The adjusted relative risk for death from coronary heart disease for each increase of 7 drinks per week was 0.89 (95% Cl, 0.80 to 1.00), with an apparent dose-response relationship. The average HDL level was associated with the average alcohol intake in a least-squares regression model (beta = -0.0074; P < 0.01). When the average HDL level was included in the proportional hazards model for mortality from coronary heart disease, the absolute value of the coefficient for average drinks per week declined 45%, yielding an adjusted relative risk for each additional 7 drinks per week of 0.94 (Cl, 0.84 to 1.05). Conclusion: In middle-aged men who are light to moderate drinkers, the inverse association between alcohol consumption and death from coronary heart disease can be explained, in large part, by the HDL cholesterol level, which increases with alcohol consumption. However, alcohol consumption cannot be recommended because of the known adverse effects of excess alcohol use.	UNIV MINNESOTA, SCH PUBL HLTH,DIV BIOSTAT, COORDINATING CTR BIOMETR RES,2221 UNIV AVE SE, SUITE 200, MINNEAPOLIS, MN 55414 USA; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20814 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15261 USA	University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HC22971] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC022971] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		COLDITZ GA, 1985, AM HEART J, V109, P886, DOI 10.1016/0002-8703(85)90654-4; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1987, ACTA MED SCAND, P73; DAVIDSON DM, 1989, WESTERN J MED, V151, P430; DYER AR, 1980, PREV MED, V9, P78, DOI 10.1016/0091-7435(80)90060-2; FERRENCE RG, 1986, J STUD ALCOHOL, V47, P394, DOI 10.15288/jsa.1986.47.394; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GORDON T, 1983, AM HEART J, V105, P667, DOI 10.1016/0002-8703(83)90492-1; GORDON T, 1981, CIRCULATION, V64, P63; HARTUNG GH, 1990, METABOLISM, V39, P81, DOI 10.1016/0026-0495(90)90152-3; HULLEY SB, 1981, CIRCULATION, V64, P57; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KULLER LH, 1983, AM J EPIDEMIOL, V117, P406, DOI 10.1093/oxfordjournals.aje.a113559; LANGER RD, 1988, AM J EPIDEMIOL, V128, P916; LUPIEN PJ, 1988, CAN J CARDIOL, V4, P102; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER NE, 1988, J EPIDEMIOL COMMUN H, V42, P220, DOI 10.1136/jech.42.3.220; PETERSSON B, 1982, BRIT MED J, V285, P1457, DOI 10.1136/bmj.285.6353.1457; REGAN TJ, 1990, JAMA-J AM MED ASSOC, V264, P377, DOI 10.1001/jama.264.3.377; SHAPER AG, 1988, LANCET, V2, P1267; SHATEN BJ, 1991, PREV MED, V20, P655, DOI 10.1016/0091-7435(91)90061-8; STEINBERG D, 1991, ANN INTERN MED, V114, P967, DOI 10.7326/0003-4819-114-11-967; WANNAMETHEE G, 1988, INT J EPIDEMIOL, V17, P307, DOI 10.1093/ije/17.2.307; 1974, DHEW2ND REP, P68; 1989, J AM COLL CARDIOL, V13, pA11	29	270	272	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					881	887		10.7326/0003-4819-116-11-881	http://dx.doi.org/10.7326/0003-4819-116-11-881			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580443				2022-12-24	WOS:A1992HW13700001
J	HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP				HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP			A TRANSCRIPTIONAL ENHANCER WHOSE FUNCTION IMPOSES A REQUIREMENT THAT PROTEINS TRACK ALONG DNA	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BINDING PROTEIN; REPLICATION APPARATUS; PROMOTER SEARCH; GENE; EXPRESSION; ACTIVATOR; DISTANCE; SITE	Transcriptional regulation of the bacteriophage T4 late genes requires the participation of three DNA polymerase accessory proteins that are encoded by T4 genes 44, 62, and 45, and that act at an enhancer-like site. Transcriptional activation by these DNA replication proteins also requires the function of an RNA polymerase-bound coactivator protein that is encoded by T4 gene 33 and a promoter recognition protein that is encoded by T4 gene 55. Transcriptional activation in DNA constructs, in which the enhancer and a T4 late promoter can be segregated on two rings of a DNA catenane, has now been analyzed. The ability of an interposed DNA-binding protein to affect communication between the enhancer and the promoter was also examined. Together, these experiments demonstrate that this transcription-activating signal is conveyed between its enhancer and a T4 late promoter by a DNA-tracking mechanism. Alternative activation mechanisms relying entirely on through-space interactions of enhancer-bound and promoter-bound proteins are excluded.	UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ADHYA S, 1989, ANNU REV GENET, V23, P207; ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GEIDUSCHEK EP, 1983, BACTERIOPHAGE T, V4, P189; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREENSTEIN D, 1908, J MOL BIOL, V197, P157; GRUIDL ME, 1991, VIROLOGY, V184, P359, DOI 10.1016/0042-6822(91)90852-3; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P3977; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAGASANIK B, 1989, New Biologist, V1, P247; Maniatis T., 1982, MOL CLONING; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, P NATL ACAD SCI-BIOL, V78, P3428, DOI 10.1073/pnas.78.6.3428; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SCARLATO V, 1989, VIROLOGY, V171, P475, DOI 10.1016/0042-6822(89)90617-X; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; SELICK HE, 1987, UCLA S MOL CELL BIOL, V26, P183; SINGER P, 1987, J BIOL CHEM, V262, P14178; SINGER PT, 1988, J BIOL CHEM, V263, P4208; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WILLIAMS KJ, 1991, THESIS U CALIFORNIA; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	51	116	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1298	1303		10.1126/science.1598572	http://dx.doi.org/10.1126/science.1598572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598572				2022-12-24	WOS:A1992HW13500026
J	VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR				VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR			CIS-ACTING SEQUENCES REGULATING EXPRESSION OF THE HUMAN ALPHA-GLOBIN CLUSTER LIE WITHIN CONSTITUTIVELY OPEN CHROMATIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LOCUS ACTIVATION REGION; CPG-RICH ISLANDS; CELL-SPECIFIC ENHANCER; I SENSITIVE DOMAIN; GENE-CLUSTER; TRANSGENIC MICE; HYPERSENSITIVE SITES; CHICKEN LYSOZYME; MESSENGER-RNAS	Current models suggest that tissue-specific genes are arranged in discrete, independently controlled segments of chromatin referred to as regulatory domains. Transition from a closed to open chromatin structure may be an important step in the regulation of gene expression. To determine whether the human alpha-globin cluster, like the beta-globin cluster, lies within a discrete, erythroid-specific domain, we have examined the long-range genomic organization and chromatin structure around this region. The alpha-genes lie adjacent to at least four widely expressed genes. The major alpha-globin regulatory element lies 40 kb away from the cluster within an intron of one of these genes. Therefore, unlike the beta-cluster, cis-acting sequences controlling alpha-gene expression are dispersed within a region of chromatin that is open in both erythroid and nonerythroid cells. This implies a difference in the hierarchical control of alpha- and beta-globin expression.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Oxford	VYAS, P (corresponding author), JOHN RADCLIFFE HOSP,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Vyas, Paresh/B-5708-2009	Vyas, Paresh/0000-0003-3931-0914	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALBITAR M, 1989, BLOOD, V74, P629; ALEVY MC, 1984, BIOCHEMISTRY-US, V23, P2309, DOI 10.1021/bi00305a034; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BICKMORE WA, 1989, TRENDS GENET, V5, P144, DOI 10.1016/0168-9525(89)90055-3; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODNAR JW, 1988, J THEOR BIOL, V132, P479, DOI 10.1016/S0022-5193(88)80086-9; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHENSOLAL MM, 1982, DNA-J MOLEC CELL BIO, V1, P355, DOI 10.1089/dna.1982.1.355; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; ECCLES S, 1990, New Biologist, V2, P801; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRAME MC, 1984, BRIT J CANCER, V49, P269, DOI 10.1038/bjc.1984.44; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GEY GO, 1952, CANCER RES, V12, P264; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HANSON IM, 1991, GENOMICS, V10, P417, DOI 10.1016/0888-7543(91)90327-B; HATTON CSR, 1990, BLOOD, V76, P221; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; HUXLEY C, 1990, MOL CELL BIOL, V10, P605, DOI 10.1128/MCB.10.2.605; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1989, HEMOGLOBIN SWITCHI B, P33; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; KLEIN E, 1967, LANCET, V2, P1068; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LAWSON GM, 1980, BIOCHEMISTRY-US, V19, P4403, DOI 10.1021/bi00560a004; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; LEUNG SO, 1989, NUCLEIC ACIDS RES, V17, P8283, DOI 10.1093/nar/17.20.8283; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; LIEBHABER SA, 1990, P NATL ACAD SCI USA, V87, P9431, DOI 10.1073/pnas.87.23.9431; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCCORMICK D, 1983, BRIT J EXP PATHOL, V64, P103; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; ROMAO L, 1991, BLOOD, V78, P1589; Sambrook J., 1989, MOL CLONING LAB MANU; SARGENT CA, 1989, EMBO J, V8, P2305, DOI 10.1002/j.1460-2075.1989.tb08357.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P8573; SPIES T, 1989, P NATL ACAD SCI USA, V86, P8955, DOI 10.1073/pnas.86.22.8955; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMPSON S, 1984, J CELL SCI, V72, P37; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; WILSON JT, 1980, J BIOL CHEM, V255, P2807; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108	92	155	155	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					781	793		10.1016/0092-8674(92)90290-S	http://dx.doi.org/10.1016/0092-8674(92)90290-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591777				2022-12-24	WOS:A1992HW83800009
J	BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D				BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D			RISK OF 2ND BRAIN-TUMOR AFTER CONSERVATIVE SURGERY AND RADIOTHERAPY FOR PITUITARY-ADENOMA	BRITISH MEDICAL JOURNAL			English	Article							NERVOUS-SYSTEM; IRRADIATION; CANCER; CHILDHOOD; COMPLICATIONS	Objective-To assess the risk of second brain tumour in patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Design-Long term follow up of a cohort of patients with pituitary adenoma and comparison of tumour occurrence with population incidence rates. Setting-The Royal Marsden Hospital. Subjects-334 patients with pituitary adenoma treated with conservative surgery and radiotherapy (median dose 45 Gy) and followed up for 3760 person years. Main outcome measures-Second intracranial tumour and systemic malignancy. Results-Five patients developed a second brain tumour: two had astrocytoma, two meningioma, and one meningeal sarcoma. The cumulative risk of developing a second brain tumour over the first 10 years after treatment was 1.3% (95% confidence interval 0.4% to 3.9%) and over 20 years 1.9% (0.7% to 5.0%). The relative risk of a second brain tumour compared with the incidence in the normal population was 9.38 (3.05 to 21.89). There was no excess risk of any other type of second primary malignancy. Conclusions-There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Although radiation is likely to be the most important factor contributing to the excess risk, further study is required in a cohort of similar patients not receiving radiation.	INST CANC RES,ACAD UNIT RADIOTHERAPY & ONCOL,SUTTON SM2 5PX,SURREY,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	BRADA, M (corresponding author), INST CANC RES,NEUROONCOL UNIT,SUTTON SM2 5PX,SURREY,ENGLAND.			Bliss, Judith/0000-0001-7957-7424				Albo V, 1985, P AN M AM SOC CLIN, V4, P172; AMENDOLA BE, 1985, CANCER INVEST, V3, P507, DOI 10.3109/07357908509039812; ARISTIZABAL S, 1977, INT J RADIAT ONCOL, V2, P667, DOI 10.1016/0360-3016(77)90046-3; BERNSTEIN M, 1991, RAD INJURY NERVOUS, P480; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P69; COLEMAN MP, 1989, PERSON YEARS USER MA; DOWSETT RJ, 1990, INT J RADIAT ONCOL, V19, P453, DOI 10.1016/0360-3016(90)90557-Z; EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FEEK CM, 1984, CLIN ENDOCRINOL, V20, P401, DOI 10.1111/j.1365-2265.1984.tb03435.x; FLICKINGER JC, 1989, CANCER, V63, P2409, DOI 10.1002/1097-0142(19890615)63:12<2409::AID-CNCR2820631206>3.0.CO;2-M; GRIGSBY PW, 1989, INT J RADIAT ONCOL, V16, P1411, DOI 10.1016/0360-3016(89)90942-5; HALBERG FE, 1987, ENDOCRIN METAB CLIN, V16, P667, DOI 10.1016/S0889-8529(18)30468-7; HARRIS JR, 1976, RADIOLOGY, V120, P167, DOI 10.1148/120.1.167; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KAPLAN EL, 1978, J AM STAT ASSOC, V54, P457; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; KLIBANSKI A, 1991, NEW ENGL J MED, V324, P822; PARKER RG, 1990, INT J RADIAT ONCOL, V18, P993, DOI 10.1016/0360-3016(90)90432-J; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; ROSS DA, 1988, J NEUROSURG, V68, P854, DOI 10.3171/jns.1988.68.6.0854; SOFFER D, 1983, J NEUROSURG, V59, P1048, DOI 10.3171/jns.1983.59.6.1048; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203	24	329	332	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1343	1346		10.1136/bmj.304.6838.1343	http://dx.doi.org/10.1136/bmj.304.6838.1343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611331	Bronze, Green Published			2022-12-24	WOS:A1992HW41700021
J	SMITH, TF; WATERMAN, MS				SMITH, TF; WATERMAN, MS			THE CONTINUING CASE OF THE FLORIDA DENTIST	SCIENCE			English	Editorial Material									UNIV SO CALIF,DEPT MATH,LOS ANGELES,CA 90089	University of Southern California	SMITH, TF (corresponding author), BOSTON UNIV,BIOMOLEC ENGN RES CTR,BOSTON,MA 02215, USA.							[Anonymous], 1992, DNA TECHNOLOGY FOREN; BARINAGA M, 1992, SCIENCE, V255, P686, DOI 10.1126/science.1738842; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; MCCABE ERB, 1992, J PEDIATR-US, V120, P499, DOI 10.1016/S0022-3476(05)82475-8; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PALCA J, 1992, SCIENCE, V255, P392, DOI 10.1126/science.1734515; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1990, MORB MORTAL WKLY REP, V39, P489	9	32	32	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1155	1156		10.1126/science.256.5060.1155	http://dx.doi.org/10.1126/science.256.5060.1155			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589795				2022-12-24	WOS:A1992HV19200023
J	STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ				STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ			USE OF LUCOZADE AND GLUCAGON BY AMBULANCE STAFF FOR TREATING HYPOGLYCEMIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article									SCOTTISH AMBULANCE SERV, EDINBURGH EH10 5SA, SCOTLAND		STEEL, JM (corresponding author), ROYAL INFIRM, DEPT DIABET, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							COLLIER A, 1987, DIABETES CARE, V10, P712, DOI 10.2337/diacare.10.6.712; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; MULHAUSER I, 1985, DIABETES CARE S1, V8, P39; WESTON C, 1990, BRIT MED J, V300, P908, DOI 10.1136/bmj.300.6729.908-a; YAXLEY L, 1991, DIABETIC MED S1, V8, P71	5	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1992	304	6837					1283	1284		10.1136/bmj.304.6837.1283	http://dx.doi.org/10.1136/bmj.304.6837.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606430	Green Published, Bronze			2022-12-24	WOS:A1992HV08600022
J	BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R				BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R			SYNAPTOTAGMIN - A CALCIUM SENSOR ON THE SYNAPTIC VESICLE SURFACE	SCIENCE			English	Article							PROTEIN-KINASE-C; MEMBRANE-PROTEIN; PHASE-SEPARATION; BINDING PROTEIN; POLYLYSINE; CELLS	Neurons release neurotransmitters by calcium-dependent exocytosis of synaptic vesicles. However, the molecular steps transducing the calcium signal into membrane fusion are still an enigma. It is reported here that synaptotagmin, a highly conserved synaptic vesicle protein, binds calcium at physiological concentrations in a complex with negatively charged phospholipids. This binding is specific for calcium and involves the cytoplasmic domain of synaptotagmin. Calcium binding is dependent on the intact oligomeric structure of synaptotagmin (it is abolished by proteolytic cleavage at a single site). These results suggest that synaptotagmin acts as a cooperative calcium receptor in exocytosis.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Petrenko, Alexander/0000-0002-6689-6546; Jahn, Reinhard/0000-0003-1542-3498				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BIRRELL GB, 1976, BIOCHEMISTRY-US, V15, P2925, DOI 10.1021/bi00658a035; BOGGS JM, 1976, BIOCHEMISTRY-US, V15, P5420; CARRIER D, 1986, BIOCHEMISTRY-US, V25, P4167, DOI 10.1021/bi00362a027; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; FOHR KJ, IN PRESS METHODS ENZ; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HARTMANN W, 1978, BIOCHIM BIOPHYS ACTA, V509, P474, DOI 10.1016/0005-2736(78)90241-9; IKEDA T, 1990, BIOCHIM BIOPHYS ACTA, V1026, P105, DOI 10.1016/0005-2736(90)90339-P; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIFARO JM, 1989, NEUROSCIENCE, V29, P1, DOI 10.1016/0306-4522(89)90327-8; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	27	795	802	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1021	1025		10.1126/science.1589771	http://dx.doi.org/10.1126/science.1589771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589771				2022-12-24	WOS:A1992HU22400039
J	HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG				HARWOOD, AJ; HOPPER, NA; SIMON, MN; DRISCOLL, DM; VERON, M; WILLIAMS, JG			CULMINATION IN DICTYOSTELIUM IS REGULATED BY THE CAMP-DEPENDENT PROTEIN-KINASE	CELL			English	Article							DIFFERENTIATION INDUCING FACTOR; PRESTALK GENE-EXPRESSION; CELLULAR SLIME-MOLD; ANTERIOR-LIKE CELLS; STALK CELLS; CYCLIC-AMP; DISCOIDEUM; MORPHOGEN; DIF; TRANSFORMATION	We placed a specific inhibitor of cyclic AMP-dependent protein kinase (PKA) under the control of a prestalk-specific promoter. Cells containing this construct form normally patterned slugs, but under environmental conditions that normally trigger immediate culmination, the slugs undergo prolonged migration. Slugs that eventually enter culmination do so normally but arrest as elongated, hairlike structures that contain neither stalk nor spore cells. Mutant cells do not migrate to the stalk entrance when codeveloped with wild-type cells and show greatly reduced inducibility by DIF, the stalk cell morphogen. These results suggest that the activity of PKA is necessary for the altered pattern of movement of prestalk cells at culmination and their differentiation into stalk cells. We propose a model whereby a protein repressor, under the control of PKA, inhibits precocious induction of stalk cell differentiation by DIF and so regulates the choice between slug migration and culmination.	INST PASTEUR,UNITE BIOCHIM CELLULAIRE,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	HARWOOD, AJ (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.		Harwood, Adrian/A-4350-2010	Harwood, Adrian/0000-0003-3124-5169				ABE K, 1983, DEV BIOL, V95, P200, DOI 10.1016/0012-1606(83)90018-0; BERKS M, 1990, DEVELOPMENT, V110, P977; BERKS M, 1988, DEV BIOL, V125, P108; BONNER JT, 1952, AM NAT, V86, P79, DOI 10.1086/281707; BONNER JT, 1985, J EMBRYOL EXP MORPH, V87, P207; CECCARELLI A, 1991, CELL, V65, P983, DOI 10.1016/0092-8674(91)90550-I; DEGUNZBURG J, 1982, EMBO J, V1, P1063, DOI 10.1002/j.1460-2075.1982.tb01297.x; DINGERMANN T, 1989, GENE, V85, P353, DOI 10.1016/0378-1119(89)90428-9; EARLY AE, 1987, GENE, V59, P99, DOI 10.1016/0378-1119(87)90270-8; EARLY AE, 1988, MOL CELL BIOL, V8, P3458, DOI 10.1128/MCB.8.8.3458; FIRTEL RA, 1990, GENE DEV, V4, P18, DOI 10.1101/gad.4.1.18; GEORGE RP, 1972, J GEN MICROBIOL, V70, P477, DOI 10.1099/00221287-70-3-477; GROSS JD, 1983, NATURE, V303, P244, DOI 10.1038/303244a0; HARWOOD AJ, 1991, DIFFERENTIATION, V46, P7, DOI 10.1111/j.1432-0436.1991.tb00860.x; HARWOOD AJ, 1991, IN PRESS DEV BIOL; INOUYE K, 1988, DEVELOPMENT, V104, P669; JERMYN KA, 1991, DEVELOPMENT, V111, P779; JERMYN KA, 1989, NATURE, V340, P144, DOI 10.1038/340144a0; JERMYN KA, 1987, DEVELOPMENT, V100, P745; KAKUTANI T, 1986, DEV BIOL, V115, P439, DOI 10.1016/0012-1606(86)90264-2; KAY RR, 1982, P NATL ACAD SCI-BIOL, V79, P3228, DOI 10.1073/pnas.79.10.3228; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KREFFT M, 1983, EXP CELL RES, V147, P235, DOI 10.1016/0014-4827(83)90291-4; KWONG L, 1988, DIFFERENTIATION, V37, P1, DOI 10.1111/j.1432-0436.1988.tb00789.x; KWONG L, 1990, DEVELOPMENT, V110, P303; MAEDA M, 1988, DEV GROWTH DIFFER, V30, P573; MCROBBIE SJ, 1988, DEV BIOL, V125, P59, DOI 10.1016/0012-1606(88)90058-9; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MERKLE RK, 1984, CELL DIFFER DEV, V14, P257, DOI 10.1016/0045-6039(84)90014-9; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MUTZEL R, 1987, P NATL ACAD SCI USA, V84, P6, DOI 10.1073/pnas.84.1.6; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; NEWELL PC, 1982, J GEN MICROBIOL, V128, P1639; RAPER K, 1940, J E MITCHELL SCI SOC, V59, P241; RAPER KENNETH B., 1952, BULL TORREY BOT CLUB, V79, P25, DOI 10.2307/2482103; RILEY BB, 1990, DEVELOPMENT, V109, P715; SCHAAP P, 1985, DEV BIOL, V111, P51, DOI 10.1016/0012-1606(85)90434-8; SCHINDLER J, 1977, J MOL BIOL, V116, P161, DOI 10.1016/0022-2836(77)90124-3; SIEGERT F, 1991, PHYSICA D, V49, P224, DOI 10.1016/0167-2789(91)90210-Z; SIMON MN, 1989, EMBO J, V8, P2039, DOI 10.1002/j.1460-2075.1989.tb03612.x; STERNFELD J, 1981, DIFFERENTIATION, V20, P10, DOI 10.1111/j.1432-0436.1981.tb01150.x; STERNFELD J, 1982, DEV BIOL, V93, P111, DOI 10.1016/0012-1606(82)90244-5; SUSSMAN M, 1978, EXP CELL RES, V116, P217, DOI 10.1016/0014-4827(78)90078-2; SUSSMAN M, 1977, FRB FIGGRTRNYISYION, P31; TAKEUCHI I, 1977, DEV DIFFERENTIATION, P1; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; WANG M, 1989, DEVELOPMENT, V105, P569; WANG M, 1990, DEV BIOL, V140, P182, DOI 10.1016/0012-1606(90)90065-Q; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; WILLIAMS JG, 1989, DEVELOPMENT, V7, P91	51	129	130	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					615	624		10.1016/0092-8674(92)90225-2	http://dx.doi.org/10.1016/0092-8674(92)90225-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586944				2022-12-24	WOS:A1992HV08900006
J	YOST, HJ				YOST, HJ			REGULATION OF VERTEBRATE LEFT RIGHT ASYMMETRIES BY EXTRACELLULAR-MATRIX	NATURE			English	Article							XENOPUS-LAEVIS; PROSPECTIVE AREAS; FIBRONECTIN; GASTRULATION; HANDEDNESS; MOVEMENTS; MIGRATION; NEURULA; EMBRYOS; LAYER	THE vertebrate body is organized along three geometric axes: anterior-posterior, dorsal-ventral and left-right. Left-right axis formation, displayed in heart and gut development, is the least understood, even though it has been studied for many years 1-4. In Xenopus laevis gastrulae, a fibronectin-rich extracellular matrix is deposited on the basal surface of ectoderm cells 5,6 over which cardiac and visceral primordia move during development. Here I report experiments in which localized perturbation of a small patch of extracellular matrix by microsurgery was correlated with localized randomization of left-right asymmetries. Global perturbation of the extracellular matrix by microinjection of Arg-Gly-Asp peptides or heparinase into the blastocoel resulted in global randomization of left-right asymmetries. From these observations, I suggest that left-right axial information is contained in the extracellular matrix early in development and is independently transmitted to cardiac and visceral primordia.			YOST, HJ (corresponding author), UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,4-135 JACKSON HALL,321 CHURCH ST SE,MINNEAPOLIS,MN 55455, USA.							BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BRICKMAN M, 1990, J CELL BIOL, V111, P484; BRIVANLOU AH, 1989, DEVELOPMENT, V106, P611; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; Clark RAF, 1989, CURR OPIN CELL BIOL, V1, P1000, DOI 10.1016/0955-0674(89)90072-0; FEY J, 1990, DIFFERENTIATION, V42, P144, DOI 10.1111/j.1432-0436.1990.tb00755.x; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; GALLOWAY J, 1990, NATURE, V346, P223, DOI 10.1038/346223a0; GERHART J, 1989, DEVELOPMENT, V107, P37; Keller R., 1990, Seminars in Developmental Biology, V1, P25; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KELLER RE, 1985, J EMBRYOL EXP MORPH, V89, P185; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LINASK KK, 1988, DEV BIOL, V129, P315, DOI 10.1016/0012-1606(88)90378-8; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OPPENHEIMER JM, 1974, AM ZOOL, V15, P867; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHEFLER WC, 1968, STATISTICS BIOL SCI, P1; Spemann Hans., 1906, VERH DEUT ZOOL GES, V16, P195; Takaya H., 1953, Annotationes Zoologicae Japonenses, V26, P38; VONWOELLWARTH C, 1950, ROUX ARCH ENTWICKLUN, V144, P178; WEHRMAKER A, 1969, ROUX ARCH DEV BIOL, V163, P1; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1991, BIOL ASYMMETRY HANDE, P165	28	110	110	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					158	161		10.1038/357158a0	http://dx.doi.org/10.1038/357158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579165				2022-12-24	WOS:A1992HU12200058
J	BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V				BAKHEIT, AMO; BEHAN, PO; DINAN, TG; GRAY, CE; OKEANE, V			POSSIBLE UP-REGULATION OF HYPOTHALAMIC 5-HYDROXYTRYPTAMINE RECEPTORS IN PATIENTS WITH POSTVIRAL FATIGUE SYNDROME	BRITISH MEDICAL JOURNAL			English	Article							PROLACTIN; BUSPIRONE; SEROTONIN; MUSCLE	Objective - To study the dynamic function of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Design - Prospective comparison of patients with postviral fatigue syndrome with two control groups. Setting - Department of neurology, University of Glasgow, Southern General Hospital; department of psychiatry, St James's Hospital, Dublin. Subjects - 15 patients with postviral fatigue syndrome, 13 age and sex matched healthy subjects, and 13 patients with primary depression. Main outcome measures - Serum prolactin concentrations before and one, two, and three hours after administration of buspirone. Results - Because of the effects of sex hormones on prolactin secretion data for men and women were analysed separately. There was no significant difference in baseline prolactin concentrations between patients with postviral fatigue syndrome and healthy subjects or those with primary depression. However, the percentage difference between peak and baseline values was significantly higher in patients with postviral fatigue syndrome than the control groups (one way analysis of variance: women, p = 0.003; men, p = 0.004). Conclusions - The results suggest upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome but not in those with primary depression. The buspirone challenge test may therefore be useful in distinguishing these two conditions. Larger studies are required to explore the potential value of drugs acting on central 5-hydroxytryptamine receptors in the treatment of patients with the postviral fatigue syndrome.	GLASGOW ROYAL INFIRM,GLASGOW G4 0SF,SCOTLAND; ST JAMES HOSP,PSYCHIAT,DUBLIN 8,IRELAND; UNIV GLASGOW,NEUROL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; Trinity College Dublin; University of Glasgow			Dinan, Timothy/ABA-8284-2020	Dinan, Timothy/0000-0002-2316-7220; o'keane, veronica/0000-0002-1519-099X				ACHESON ED, 1959, AM J MED, V26, P569, DOI 10.1016/0002-9343(59)90280-3; ARCHARD LC, 1988, J ROY SOC MED, V81, P326, DOI 10.1177/014107688808100608; ARNOLD DL, 1984, LANCET, V1, P1367; BEHAN PO, 1985, J INFECTION, V10, P211, DOI 10.1016/S0163-4453(85)92488-0; BEHAN PO, 1988, CRIT REV NEUROBIOL, V4, P157; BEHAN PO, 1991, BRIT MED BULL, V47, P793, DOI 10.1093/oxfordjournals.bmb.a072511; BROWNSTEIN MJ, 1976, BRAIN RES, V117, P287, DOI 10.1016/0006-8993(76)90736-8; CLUFF E, 1991, REV INFECT DIS S1, V13, P138; FAGAN KG, 1983, J R COLL GEN PRACT, V33, P335; GOLD PW, 1988, NEW ENGL J MED, V319, P413, DOI 10.1056/NEJM198808183190706; GOW JW, 1991, BRIT MED BULL, V47, P872, DOI 10.1093/oxfordjournals.bmb.a072517; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; GREGORY CA, 1990, PSYCHOPHARMACOLOGY, V100, P283, DOI 10.1007/BF02244420; GROSSER BI, 1987, J CLIN PSYCHIAT, V48, P3; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLMES GP, 1988, ANN INTERN MED, V18, P378; JAMAL GA, 1989, EUR NEUROL, V29, P272; KATO Y, 1974, J CLIN ENDOCR METAB, V38, P695, DOI 10.1210/jcem-38-4-695; MELTZER HY, 1983, ARCH GEN PSYCHIAT, V40, P1099; NEUHAUSER H, 1988, PSYCHOPHARMACOLOGY S, V96, P393; QUATTRONE A, 1983, BRIT J CLIN PHARMACO, V16, P471, DOI 10.1111/j.1365-2125.1983.tb02202.x; YATHAM LN, 1989, LANCET, V1, P1447; 1987, DIAGNOSTIC STATISTIC	23	153	153	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1010	1012		10.1136/bmj.304.6833.1010	http://dx.doi.org/10.1136/bmj.304.6833.1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586780	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200016
J	SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M				SMITH, J; CROWE, C; JOHNSON, C; DONOVAN, M			TRANSFERS FROM PRISON FOR URGENT PSYCHIATRIC-TREATMENT - A STUDY OF SECTION-48 ADMISSIONS	BRITISH MEDICAL JOURNAL			English	Article											DONOVAN, M (corresponding author), LANGDON HOSP,BUTLER CLIN,DAWLISH EX7 0NR,DEVON,ENGLAND.							GROUNDS A, 1990, PRINCIPLES PRACTICE; Joseph P L, 1990, Health Trends, V22, P51; MCCLURE GMG, 1987, BRIT J PSYCHIAT, V150, P309, DOI 10.1192/bjp.150.3.309; Smith J, 1991, J FORENSIC PSYCHIATR, V2, P95; 1990, WORKING PARTY REPORT; 1990, 6690 HOM OFF CIRC	6	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					967	969		10.1136/bmj.304.6832.967	http://dx.doi.org/10.1136/bmj.304.6832.967			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HP064	1581722	Bronze, Green Published			2022-12-24	WOS:A1992HP06400027
J	MACEJAK, DG; SARNOW, P				MACEJAK, DG; SARNOW, P			INTERNAL INITIATION OF TRANSLATION MEDIATED BY THE 5' LEADER OF A CELLULAR MESSENGER-RNA	NATURE			English	Article							CAP-BINDING-PROTEIN; SECONDARY STRUCTURE; NONCODING REGION; POLIOVIRUS; VIRUS; CELLS; GENE; CONSERVATION; INVOLVEMENT; ADENOVIRUS	A RIBOSOME-SCANNING model has been proposed to explain the initiation of eukaryotic messenger RNAs 1 in which binding of the 43S ternary ribosomal subunit near or at the 5' end of the mRNA is facilitated by an interaction between the methylated cap-structure at the end of the mRNA and the cap-binding protein complex eIF-4F (refs 2, 3). But picornaviral mRNAs do not have a 5' terminal cap structure and are translated by internal ribosome binding 4-7. A cellular mRNA, encoding the immunoglobulin heavy-chain binding protein, can be translated in poliovirus-infected cells at a time when cap-dependent translation of host cell mRNAs is inhibited 8. We report here that the 5' leader of the binding protein mRNA can directly confer internal ribosome binding to an mRNA in mammalian cells, indicating that translation initiation by an internal ribosome-binding mechanism is used by eukaryotic mRNAs.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	MACEJAK, DG (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,MOLEC BIOL PROGRAM,DENVER,CO 80262, USA.			Sarnow, Peter/0000-0002-2043-2770				Ausubel F, 1989, MOL REPROD DEV, V1, P146; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BENERJEE AK, 1980, MICROBIOL REV, V44, P175; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; CALZONE FJ, 1982, NUCLEIC ACIDS RES, V10, P2145, DOI 10.1093/nar/10.6.2145; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KATZE MG, 1986, J VIROL, V60, P1027, DOI 10.1128/JVI.60.3.1027-1039.1986; KIRKEGAARD K, 1986, CELL, V47, P433, DOI 10.1016/0092-8674(86)90600-8; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAUGHON A, 1986, MOL CELL BIOL, V6, P4676, DOI 10.1128/MCB.6.12.4676; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SONENBERG N, 1987, ADV VIRUS RES, V33, P175, DOI 10.1016/S0065-3527(08)60318-8; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275	24	462	711	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 5	1991	353	6339					90	94		10.1038/353090a0	http://dx.doi.org/10.1038/353090a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD805	1652694				2022-12-24	WOS:A1991GD80500067
J	GOODWIN, FK				GOODWIN, FK			COCAINE WITHDRAWAL AND THE BRAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							1991, AM J PSYCHIAT, V148, P621	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	GB975	1650851				2022-12-24	WOS:A1991GB97500007
J	DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A				DETHE, H; LAVAU, C; MARCHIO, A; CHOMIENNE, C; DEGOS, L; DEJEAN, A			THE PML-RAR-ALPHA FUSION MESSENGER-RNA GENERATED BY THE T(15-17) TRANSLOCATION IN ACUTE PROMYELOCYTIC LEUKEMIA ENCODES A FUNCTIONALLY ALTERED RAR	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; V-ERBA; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL EXPRESSION; RESPONSIVE ELEMENT; ESTROGEN-RECEPTOR; GENE-EXPRESSION; VIRUS TYPE-1; ZINC FINGER	We have previously shown that the t(15; 17) translocation specifically associated with acute promyelocytic leukemia (APL) fuses the retinoic acid receptor-alpha (RAR-alpha) locus to an as yet unknown gene, initially called myl and now renamed PML. We report here that this gene product contains a novel zinc finger motif common to several DNA-binding proteins. The PML-RAR-alpha mRNA encodes a predicted 106 kd chimeric protein containing most of the PML sequences fused to a large part of RAR-alpha, including its DNA- and hormone-binding domains. In transient expression assays, the hybrid protein exhibits altered transactivating properties if compared with the wild-type RAR-alpha progenitor. Identical PML-RAR-alpha fusion points are found in several patients. These observations suggest that in APL, the t(15;17) translocation generates an RAR mutant that could contribute to leukemogenesis through interference with promyelocytic differentiation.	UNIV PARIS 07,BIOL CELLULAIRE HEMATOPOET LAB,F-75221 PARIS 05,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,F-75010 PARIS,FRANCE; HOP ST LOUIS,SERV MED NUCL,F-75010 PARIS,FRANCE; HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	DETHE, H (corresponding author), INST PASTEUR,INSERM,U163,UNITE RECOMBINAISON & EXPRESS GENET,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Lavau, Catherine/Q-2928-2019; Dejean, Anne/L-5145-2018	CHOMIENNE, Christine/0000-0001-5513-5752; Lavau, Catherine/0000-0003-4800-1320				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1981, BLOOD, V57, P1000; BROCKES J, 1990, NATURE, V345, P766, DOI 10.1038/345766a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHANET R, 1988, GENE, V74, P543, DOI 10.1016/0378-1119(88)90187-4; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1991, CELL, V66; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOEFFLER HP, 1985, CHRONIC ACUTE LEUKEM, P27; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANOTTE M, 1991, BLOOD, V77, P1080; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBERTS AB, 1984, RETINOIDS, V2, P209; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	62	1245	1264	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					675	684		10.1016/0092-8674(91)90113-D	http://dx.doi.org/10.1016/0092-8674(91)90113-D			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652369				2022-12-24	WOS:A1991GC74500008
J	BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P				BASILE, AS; HUGHES, RD; HARRISON, PM; MURATA, Y; PANNELL, L; JONES, EA; WILLIAMS, R; SKOLNICK, P			ELEVATED BRAIN CONCENTRATIONS OF 1,4-BENZODIAZEPINES IN FULMINANT HEPATIC-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BENZODIAZEPINE RECEPTOR LIGANDS; GAMMA-AMINOBUTYRIC-ACID; ANIMAL-MODEL; RABBIT MODEL; ANTAGONIST FLUMAZENIL; ENCEPHALOPATHY; COMPLEX; REVERSAL; DIAZEPAM; POTATO	Background. Increased gamma-aminobutyric acid (GABA) neurotransmission has been implicated in the pathogenesis of hepatic encephalopathy. The mechanism by which GABA-ergic activity is increased in hepatic failure is unclear, but recent studies in animals with encephalopathy due to fulminant hepatic failure suggest that GABA-ergic neurotransmission may be increased by the presence of elevated concentrations of benzodiazepine agonists such as diazepam and N-desmethyldiazepam. Methods and Results. Samples of frontal cortex were obtained at autopsy from 11 patients with hepatic encephalopathy who died of acetaminophen-induced fulminant hepatic failure and 8 patients who died of cardiovascular disease or trauma. None of the 19 patients had received benzodiazepines while hospitalized. Chromatographic analyses of extracts of these samples revealed 4 to 19 peaks representing substances that inhibited the binding of a radiolabeled imidazobenzodiazepine ([H-3]flumazenil) to its receptors. Several of these peaks had retention times corresponding to those of known 1,4-benzodiazepines. Ultraviolet- and mass-spectroscopic analysis confirmed that two of these peaks represented diazepam and N-desmethyldiazepam. The patients who died of fulminant hepatic failure could be divided into two groups: six who had had significantly elevated brain concentrations (2-fold to 10-fold higher than normal) of substances inhibiting the binding of [H-3]flumazenil and five who had normal concentrations. Conclusions. Brain concentrations of substances inhibiting the binding of [H-3]flumazenil to its receptors are increased in some patients with hepatic encephalopathy due to fulminant hepatic failure. The origin of these substances is unknown, but these findings provide a rational basis for trials of benzodiazepine-receptor antagonists in the management of this disorder.	NIDDKD,DIGEST DIS BRANCH,BIOORGAN CHEM LAB,BETHESDA,MD 20892; NIDDKD,DIGEST DIS BRANCH,LIVER DIS SECT,BETHESDA,MD 20892; UNIV LONDON KINGS COLL,SCH MED & DENT,LIVER UNIT,LONDON WC2R 2LS,ENGLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of London; King's College London	BASILE, AS (corresponding author), NIDDKD,DIGEST DIS BRANCH,NEUROSCI LAB,BLDG 8,RM 111,BETHESDA,MD 20892, USA.		Harrison, Phillip M/D-5374-2009	opoku, anita/0000-0001-7243-8157				BANSKY G, 1989, GASTROENTEROLOGY, V97, P744, DOI 10.1016/0016-5085(89)90647-1; BASILE AS, 1989, J NEUROCHEM, V53, P1057, DOI 10.1111/j.1471-4159.1989.tb07395.x; BASILE AS, 1990, NEUROPSYCHOPHARMACOL, V3, P61; BASILE AS, 1991, SYNAPSE, V7, P141, DOI 10.1002/syn.890070208; BASILE AS, 1988, J NEUROSCI, V8, P2414; BASILE AS, 1990, P NATL ACAD SCI USA, V87, P5263, DOI 10.1073/pnas.87.14.5263; BASILE AS, 1991, PHARMACOL REV, V43, P28; BASSETT ML, 1987, GASTROENTEROLOGY, V93, P1069, DOI 10.1016/0016-5085(87)90571-3; BASSETT ML, 1990, GASTROENTEROLOGY, V98, P747, DOI 10.1016/0016-5085(90)90298-F; Conn HO, 1978, HEPATIC COMA SYNDROM; FERENCI P, 1989, GASTROENTEROLOGY, V96, P240, DOI 10.1016/0016-5085(89)90787-7; FOERSTER EH, 1978, J ANAL TOXICOL, V2, P50, DOI 10.1093/jat/2.2.50; GAMMAL SH, 1990, HEPATOLOGY, V11, P371, DOI 10.1002/hep.1840110307; Greenblatt DJ, 1987, PSYCHOPHARMACOLOGY 3, P1377; GRIMM G, 1988, LANCET, V2, P1392; JONES EA, 1988, LIVER BIOL PATHOBIOL, P985; LUCKNER M., 1984, SECONDARY METABOLISM, DOI DOI 10.1007/978-3-662-09838-7; MEDINA JH, 1988, BIOCHEM BIOPH RES CO, V152, P534, DOI 10.1016/S0006-291X(88)80070-6; MENNINI T, 1983, BENZODIAZEPINE RECOG, P189; MULLEN KD, 1989, METAB BRAIN DIS, V4, P253, DOI 10.1007/BF00999771; MULLEN KD, 1990, LANCET, V336, P81, DOI 10.1016/0140-6736(90)91594-Z; OLASMAA M, 1990, J NEUROCHEM, V55, P2015, DOI 10.1111/j.1471-4159.1990.tb05790.x; OLASMAA M, 1989, LANCET, V1, P491; OSSELTON MD, 1977, J FORENSIC SCI SOC, V17, P189, DOI 10.1016/S0015-7368(77)71147-8; SANGAMESWARAN L, 1986, P NATL ACAD SCI USA, V83, P9236, DOI 10.1073/pnas.83.23.9236; SCHAFER DF, 1982, LANCET, V1, P18, DOI 10.1016/S0140-6736(82)92559-4; SCHENKER S, 1988, HEPATIC ENCEPHALOPAT, P15; SCOLLOLAVIZZARI G, 1985, LANCET, V1, P1324; SKOLNICK P, 1988, ISI ATLAS-PHARMACOL, V2, P19; STEINDL P, 1990, Gastroenterology, V98, pA636; UNSELD E, 1990, BIOCHEM PHARMACOL, V39, P210, DOI 10.1016/0006-2952(90)90668-B; WILDMANN J, 1987, J NEURAL TRANSM, V70, P383, DOI 10.1007/BF01253613; WILDMANN J, 1988, BIOCHEM PHARMACOL, V37, P3549, DOI 10.1016/0006-2952(88)90384-X; WILDMANN J, 1988, BIOCHEM BIOPH RES CO, V157, P1436, DOI 10.1016/S0006-291X(88)81036-2; 1985, DISEASES LIVER BILIA, P91	35	144	145	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					473	478		10.1056/NEJM199108153250705	http://dx.doi.org/10.1056/NEJM199108153250705			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649403	Bronze			2022-12-24	WOS:A1991GA76300005
J	HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M				HIRANO, S; KIMOTO, N; SHIMOYAMA, Y; HIROHASHI, S; TAKEICHI, M			IDENTIFICATION OF A NEURAL ALPHA-CATENIN AS A KEY REGULATOR OF CADHERIN FUNCTION AND MULTICELLULAR ORGANIZATION	CELL			English	Article							CELL-ADHESION MOLECULE; CYTOPLASMIC DOMAIN; EXPRESSION; UVOMORULIN; CDNA; EMBRYOS; REGION	The function of cadherin cell adhesion molecules is thought to be regulated by a group of cytoplasmic proteins, including alpha-catenin. We identified a subtype of alpha-catenin, termed alpha-catenin, which is associated with N-cadherin and expressed mainly in the nervous system. cDNA transfection experiments showed that alpha-N-catenin can also bind with E-cadherin. To investigate the role of alpha-N-catenin, we transfected lung carcinoma PC9 cells, which express E-cadherin and beta-catenin but neither alpha- nor alpha-N-catenin, with alpha-N-catenin cDNA. While parental PC9 grew as isolated cells, the transfectant lines formed aggregates in which cells were tightly adhered to each other, showing epithelial arrangements, and they occasionally gave rise to cystic spheres. These results suggest that alpha-N-catenin is crucial not only for cadherin function but also for organization of multicellular structures.	NATL CANC CTR, RES INST, DIV PATHOL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan	HIRANO, S (corresponding author), KYOTO UNIV, FAC SCI, DEPT BIOPHYS, SAKYO KU, KYOTO 606, JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				COUTU MD, 1988, P NATL ACAD SCI USA, V85, P8535, DOI 10.1073/pnas.85.22.8535; FUJIMORI T, 1990, DEVELOPMENT, V110, P97; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KINJO M, 1979, BRIT J CANCER, V39, P15, DOI 10.1038/bjc.1979.3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1992, IN PRESS J CELL BIOL; SANTERRE RF, 1984, GENE, V30, P147, DOI 10.1016/0378-1119(84)90115-X; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; WHEELOCK MJ, 1991, DIFFERENTIATION, V46, P35, DOI 10.1111/j.1432-0436.1991.tb00863.x	33	530	539	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					293	301		10.1016/0092-8674(92)90103-J	http://dx.doi.org/10.1016/0092-8674(92)90103-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638632				2022-12-24	WOS:A1992JE75700012
J	ZUGER, A				ZUGER, A			MONDAY MORNING CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619737				2022-12-24	WOS:A1992JD47200009
J	RUBIN, SM; CUMMINGS, SR				RUBIN, SM; CUMMINGS, SR			RESULTS OF BONE DENSITOMETRY AFFECT WOMENS DECISIONS ABOUT TAKING MEASURES TO PREVENT FRACTURES	ANNALS OF INTERNAL MEDICINE			English	Article						BONE DENSITY; ESTROGEN REPLACEMENT THERAPY; OSTEOPOROSIS; DENSITOMETRY; HEALTH BEHAVIOR; WOMENS HEALTH	HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; CALCIUM SUPPLEMENTATION; REPLACEMENT THERAPY; DIETARY CALCIUM; ESTROGEN; RISK; CALCITONIN; DENSITY	Objective: To describe how the results of bone densitometry affect women's decisions about measures to prevent fractures and to determine whether labeling women as having below-normal bone density has adverse effects. Design: Mail survey of a random sample of women. Setting: Four community hospitals in the San Francisco Bay area. Patients: A total of 261 women (response rate, 81.3%) who had undergone bone densitometry. Measurements: Bone densitometry and self-report of changes in attitude and behaviors. Results: Fifty-three percent of the women reported that their first bone density measurements were below normal, and 44% said that they were diagnosed as having osteoporosis on the basis of their test results. Women who reported that their bone density measurements were below normal were much more likely than women with normal results to begin some type of measure to prevent fractures (94% compared with 56%; P < 0.01), to start hormone therapy (38% compared with 8%; P < 0.01), and to take precautions to avoid falling (50% compared with 9%; P < 0.01). Women reporting low bone density, however, also became more fearful of falling (38% compared with 2%; P < 0.01) and limited their activities to avoid falling (24% compared with 2%; P < 0.01). Conclusions: The results of bone densitometry substantially influence women's decisions about beginning estrogen replacement therapy and other preventive measures for osteoporotic fractures. The potential effects of labeling a women as having below-normal bone density need to be considered before densitometry is widely used for unselective screening of women.			RUBIN, SM (corresponding author), UNIV CALIF SAN FRANCISCO, PREVENT SCI GRP, BOX 0886, SAN FRANCISCO, CA 94143 USA.							ALDERMAN MH, 1990, J CLIN EPIDEMIOL, V43, P195, DOI 10.1016/0895-4356(90)90185-R; ALOIA JF, 1978, ANN INTERN MED, V89, P356, DOI 10.7326/0003-4819-89-3-356; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CHESTNUT CH, 1988, OSTEOPOROSIS ETIOLOG, P403; CUMMINGS SR, 1990, ANN INTERN MED, V113, P565, DOI 10.7326/0003-4819-113-8-565; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1986, ANN INTERN MED, V104, P817, DOI 10.7326/0003-4819-104-6-817; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; EASTELL R, 1988, OSTEOPOROSIS ETIOLOG, P373; ERNSTER VL, 1988, PREV MED, V17, P201, DOI 10.1016/0091-7435(88)90064-3; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; ETTINGER B, 1987, AM J OBSTET GYNECOL, V156, P1298, DOI 10.1016/0002-9378(87)90168-2; FATOURECHI V, 1987, ANN INTERN MED, V107, P923, DOI 10.7326/0003-4819-107-6-923; FELDMAN W, 1990, Journal of General Internal Medicine, V5, pS50, DOI 10.1007/BF02600842; Frame P S, 1975, J Fam Pract, V2, P29; GENANT HK, 1989, RADIOLOGY, V170, P817, DOI 10.1148/radiology.170.3.2916037; HILLNER BE, 1986, AM J MED, V80, P1115, DOI 10.1016/0002-9343(86)90674-1; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; JOHNSTON CC, 1989, J BONE MINER RES S2, V4, P1; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KOCHERSBERGER G, 1987, ARCH INTERN MED, V147, P1951, DOI 10.1001/archinte.147.11.1951; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141, DOI 10.1093/oxfordjournals.aje.a113388; LEFEBVRE RC, 1988, ARCH INTERN MED, V148, P1993, DOI 10.1001/archinte.148.9.1993; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LINDSAY R, 1980, LANCET, V2, P1151; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MACINTYRE I, 1988, LANCET, V1, P900; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P155; MeltonIII L. J., 1988, OSTEOPOROSIS ETIOLOG, P133; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; Morrison AS., 1985, SCREENING CHRONIC DI; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PARISIEN M, 1990, ENDOCRIN METAB CLIN, V19, P19, DOI 10.1016/S0889-8529(18)30337-2; REGINSTER JY, 1987, LANCET, V2, P1481; RICHARDSON ML, 1986, SKELETAL RADIOL, V15, P85, DOI 10.1007/BF00350200; RIGGS BL, 1988, ANN INTERN MED, V108, P293, DOI 10.7326/0003-4819-108-2-293; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; THOMAS DB, 1990, MENOPAUSE BIOL CLIN, P101; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; WASNICH RD, 1987, OSTEOPOROSIS UPDATE, P123; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102; WHITE LJ, 1987, ANN INTERN MED, V107, P932, DOI 10.7326/0003-4819-107-6-932; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1989, GUIDE CLIN PREVENTIV, P239; 1979, CAN MED ASS J, V121, P1193; 1984, JAMA-J AM MED ASSOC, P799	58	146	147	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				990	995		10.7326/0003-4819-116-12-990	http://dx.doi.org/10.7326/0003-4819-116-12-990			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586110				2022-12-24	WOS:A1992HY79300007
J	SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM				SELLICK, JA; LONGBINE, D; SCHIFELING, R; MYLOTTE, JM			SCREENING HOSPITAL EMPLOYEES FOR MEASLES IMMUNITY IS MORE COST-EFFECTIVE THAN BLIND IMMUNIZATION	ANNALS OF INTERNAL MEDICINE			English	Article						MEASLES; COST-BENEFIT ANALYSIS; HEALTH PERSONNEL; IMMUNIZATION	TRANSMISSION	Objective: To examine alternative strategies in developing a cost-effective program to assure measles immunity among hospital employees. Design: Observational. Setting: Referral teaching hospital. Participants: Eighteen hundred "established" hospital employees with potential patient contact and 630 newly hired hospital employees. Interventions: Established employees born after 1 January 1957 and all newly hired employees were screened for serologic evidence of measles immunity and immunized if necessary. Measurements: Cost analysis. Results: The cost of screening and directed immunization of established employees was $3.98 per employee compared with a potential cost $10.03 to $42.80 per employee if all employees were "blindly" immunized with monovalent measles vaccine or trivalent mumps-measles-rubella vaccine. The cost of the screening and directed immunization of new employees was $2.42 per employee compared with potential costs $8.30 to $39.34 per employee for blind immunization. These analyses assumed that varying percentages of employees would be able to produce documentation of having received a previous dose of vaccine or of having had measles. Conclusions: In a large referral hospital, screening for measles immunity followed by directed immunization was considerably less expensive than immunizing all potentially susceptible employees.	BUFFALO GEN HOSP, DEPT EMPLOYEE HLTH, BUFFALO, NY 14203 USA; SUNY BUFFALO, BUFFALO, NY 14260 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	SELLICK, JA (corresponding author), BUFFALO GEN HOSP, DEPT MED, 100 HIGH ST, BUFFALO, NY 14203 USA.							ATKINSON WL, 1991, AM J MED, V91, pS320, DOI 10.1016/0002-9343(91)90389-F; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BRAUNSTEIN H, 1990, AM J DIS CHILD, V144, P296, DOI 10.1001/archpedi.1990.02150270046024; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; DAVIS RM, 1986, JAMA-J AM MED ASSOC, V255, P1295, DOI 10.1001/jama.255.10.1295; MATHIAS RG, 1989, AM J PUBLIC HEALTH, V79, P475, DOI 10.2105/AJPH.79.4.475; NEUMANN PW, 1985, J CLIN MICROBIOL, V22, P296, DOI 10.1128/JCM.22.2.296-298.1985; SUBBARAO EK, 1991, J INFECT DIS, V163, P876, DOI 10.1093/infdis/163.4.876; WEBER DJ, 1991, J PEDIATR-US, V119, P322, DOI 10.1016/S0022-3476(05)80753-X; WHARTON M, 1990, ARCH INTERN MED, V150, P47, DOI 10.1001/archinte.150.1.47; 1991, MMWR, V40, P369; 1989, MMWR, V38, P1	12	17	18	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				982	984		10.7326/0003-4819-116-12-982	http://dx.doi.org/10.7326/0003-4819-116-12-982			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586108				2022-12-24	WOS:A1992HY79300005
J	NOLLER, HF; HOFFARTH, V; ZIMNIAK, L				NOLLER, HF; HOFFARTH, V; ZIMNIAK, L			UNUSUAL RESISTANCE OF PEPTIDYL TRANSFERASE TO PROTEIN EXTRACTION PROCEDURES	SCIENCE			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI RIBOSOMES; PEPTIDYLTRANSFERASE ACTIVITY; A-SITES; P-SITES; SUBUNITS; CHLORAMPHENICOL; RECONSTITUTION; IDENTIFICATION; NUCLEOTIDES	Peptidyl transferase, the ribosomal activity responsible for catalysis of peptide bond formation, is resistant to vigorous procedures that are conventionally employed to remove proteins from protein-nucleic acid complexes. When the "fragment reaction" was used as a model assay for peptide bond formation, Escherichia coli ribosomes or 50S subunits retained 20 to 40 percent activity after extensive treatment with proteinase K and SDS, but lost activity after extraction with phenol or exposure to EDTA. Ribosomes from the thermophilic eubacterium Thermus aquaticus remained more than 80 percent active after treatment with proteinase K and SDS, which was followed by vigorous extraction with phenol. This activity is attributable to peptidyl transferase, as judged by specific inhibition by the peptidyl transferase-specific antibiotics chloramphenicol and carbomycin. In contrast, activity is abolished by treatment with ribonuclease T1. These findings support the possibility that 23S ribosomal RNA participates in the peptidyl transferase function.			NOLLER, HF (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON RE, UNPUB; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BURMA DP, 1985, ARCH BIOCHEM BIOPHYS, V239, P427, DOI 10.1016/0003-9861(85)90708-8; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CERNA J, 1973, EUR J BIOCHEM, V34, P551, DOI 10.1111/j.1432-1033.1973.tb02794.x; Chambliss G., 1980, RIBOSOMES STRUCTURE, P357; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HELD WA, 1973, J BIOL CHEM, V248, P5720; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; NIERHAUS KH, 1973, P NATL ACAD SCI USA, V70, P1931, DOI 10.1073/pnas.70.7.1931; NIERHAUS KH, 1982, CURR TOP MICROBIOL, V97, P81; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PARISH JH, 1966, BIOCHIM BIOPHYS ACTA, V129, P554, DOI 10.1016/0005-2787(66)90070-0; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; STAEHELIN T, 1969, COLD SPRING HARB SYM, V34, P39, DOI 10.1101/SQB.1969.034.01.008; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; 1989, CATALOGUE BACTERIA B	33	608	629	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1992	256	5062					1416	1419		10.1126/science.1604315	http://dx.doi.org/10.1126/science.1604315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604315				2022-12-24	WOS:A1992HX33700026
J	MCCULLOCH, P				MCCULLOCH, P			GASTRIC-CANCER	BRITISH MEDICAL JOURNAL			English	Article											MCCULLOCH, P (corresponding author), NATL CANC CTR,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN.			McCulloch, Peter/0000-0002-3210-8273					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1372	1373		10.1136/bmj.304.6838.1372	http://dx.doi.org/10.1136/bmj.304.6838.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611340	Green Published, Bronze			2022-12-24	WOS:A1992HW41700033
J	TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA				TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA			SURVEY OF 3765 CARDIOPULMONARY RESUSCITATIONS IN BRITISH HOSPITALS (THE BRESUS STUDY) - METHODS AND OVERALL RESULTS	BRITISH MEDICAL JOURNAL			English	Article							BASIC LIFE SUPPORT; CARDIAC-ARREST; INTENSIVE-CARE; EMERGENCY; SURVIVAL; ACCIDENT; GUIDELINES	Objective-To determine the circumstances, incidence, and outcome of cardiopulmonary resuscitation in British hospitals. Design-Hospitals registered all cardiopulmonary resuscitation attempts for 12 months or longer and followed survival to one year. Setting-12 metropolitan, provincial, teaching, and non-teaching hospitals across Britain. Subjects-3765 patients in whom a resuscitation attempt was performed, including 927 in whom the onset of arrest was outside the hospital. Main outcome measure-Survival after initial resuscitation, at 24 hours, at discharge from hospital, and at one year, calculated by the life table method. Results-There were 417 known survivors at one year, with 214 lost to follow up. By life table analysis for every eight attempted resuscitations there were three immediate survivors, two at 24 hours, 1.5 leaving hospital alive, and one alive at one year. Survival at one year was 12.5% including out of hospital cases and 15.0% not including these cases. Each hospital year averaged 30 survivors at one year: three who had an arrest outside hospital, seven who had one in the accident and emergency department, seven in the cardiac care unit, 10 in the general wards, and three in other, non-ward areas. Within the hospitals survival rates were best in those who had an arrest in the accident and emergency department, the cardiac care unit, or other specialised units. Outcome varied 12-fold in subgroups defined by age, type of arrest, and place of arrest. Conclusion-71% of the mortality at one year in patients undergoing attempted resuscitation occurred during the initial arrest. Hospital resuscitation is life saving and cost effective and warrants appropriate attention, training, coordination, and equipment.	UNIV SUSSEX,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND; ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND; PINDERFIELDS HOSP,ACCID & EMERGENCY MED,WAKEFIELD,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND	University of Sussex; University of Brighton; Pinderfields Hospital; University of Oxford; Imperial College London	TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COPE AR, 1987, J ROY SOC MED, V80, P746, DOI 10.1177/014107688708001207; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; DELOOZ HH, 1989, RESUSCITATION, V17, pS1, DOI 10.1016/0300-9572(89)90085-3; EVANS TR, 1990, ABC RESUSCITATION; GEORGE AL, 1989, AM J MED, V87, P28; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KAYE W, 1981, HEART LUNG, V10, P860; MARSDEN AK, 1989, BRIT MED J, V299, P442, DOI 10.1136/bmj.299.6696.442; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; ROBERTSON CE, 1984, ARCH EMERG MED, V1, P17; ROSER LA, 1967, ARCH SURG-CHICAGO, V95, P658; SCOTT RPF, 1981, ANAESTHESIA, V36, P526, DOI 10.1111/j.1365-2044.1981.tb10290.x; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; SMITH GB, 1987, INTENS CARE MED, V13, P260, DOI 10.1007/BF00265115; SULJAGAPECHTEL K, 1984, RESUSCITATION, V12, P77, DOI 10.1016/0300-9572(84)90061-3; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WARDROPE J, 1986, ARCH EMERG MED, V3, P183; WILDSMITH JA, 1972, BRIT J ANAESTH, V44, P716; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198; ZIDEMAN DA, 1985, J WORLD ASS EMERGENC, V1, P291; 1980, JAMA-J AM MED ASSOC, V244, P453; 1987, J R COLL PHYSICIANS, V21, P1	28	233	237	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1347	1351		10.1136/bmj.304.6838.1347	http://dx.doi.org/10.1136/bmj.304.6838.1347			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611332	Green Published, Bronze			2022-12-24	WOS:A1992HW41700022
J	NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W				NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W			DESIGNED ENEDIYNES - A NEW CLASS OF DNA-CLEAVING MOLECULES WITH POTENT AND SELECTIVE ANTICANCER ACTIVITY	SCIENCE			English	Article							NEOCARZINOSTATIN CHROMOPHORE ANALOGS; ESPERAMICIN-CALICHEMICIN CLASS; CHROMIUM-MEDIATED CLOSURES; 10-MEMBERED RING ANALOGS; DIELS-ALDER ROUTE; ANTITUMOR ANTIBIOTICS; CALICHEAMICIN-ESPERAMICIN; BICYCLIC CORE; DYNEMICIN-A; GENERAL METHODOLOGY	The rational design and biological actions of a new class of DNA-cleaving molecules with potent and selective anticancer activity are reported. These relatively simple enediyne-type compounds were designed from basic chemical principles to mimic the actions of the rather complex naturally occurring enediyne anticancer antibiotics, particularly dynemicin A. Equipped with locking and triggering devices, these compounds damage DNA in vitro and in vivo on activation by chemical or biological means. Their damaging effects are manifested in potent anticancer activity with remarkable selectivities. Their mechanism of action involves intracellular unlocking and triggering of a Bergman reaction, leading to highly reactive benzenoid diradicals that cause severe DNA damage. The results of these studies demonstrate the potential of these de novo designed molecules as biotechnology tools and anticancer agents.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.		Dai, Wei-Min/B-6981-2008	Dai, Wei-Min/0000-0001-5688-7606				BERGMAN RG, 1973, ACCOUNTS CHEM RES, V6, P25, DOI 10.1021/ar50061a004; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BORMAN S, 1991, CHEM ENG NEWS, V69, P11, DOI 10.1021/cen-v069n035.p011; CABAL MP, 1990, J AM CHEM SOC, V112, P3253, DOI 10.1021/ja00164a079; CHIKASHITA H, 1991, J ORG CHEM, V56, P1962; DANISHEFSKY SJ, 1988, TETRAHEDRON LETT, V29, P4681, DOI 10.1016/S0040-4039(00)80579-1; DANISHEFSKY SJ, 1988, J AM CHEM SOC, V110, P6890, DOI 10.1021/ja00228a051; DARBY N, 1971, J CHEM SOC CHEM COMM, P1516, DOI 10.1039/c29710001516; DOI T, 1991, J ORG CHEM, V56, P3465, DOI 10.1021/jo00011a002; DOYLE TW, 22ND P ANN CANC S AN, V1; DRAK J, 1991, P NATL ACAD SCI USA, V88, P7464, DOI 10.1073/pnas.88.17.7464; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GOLIK J, 1987, J AM CHEM SOC, V109, P3462, DOI 10.1021/ja00245a049; HASELTINE JN, 1989, J AM CHEM SOC, V111, P7638, DOI 10.1021/ja00201a068; HASELTINE JN, 1991, J AM CHEM SOC, V113, P3850, DOI 10.1021/ja00010a030; HASELTINE JN, 1990, J ORG CHEM, V55, P2576, DOI 10.1021/jo00296a007; HIRAMA M, 1989, J AM CHEM SOC, V111, P4120, DOI 10.1021/ja00193a065; HIRAMA M, 1991, J AM CHEM SOC, V113, P9851, DOI 10.1021/ja00026a022; JONES RR, 1972, J AM CHEM SOC, V94, P660, DOI 10.1021/ja00757a071; KONISHI M, 1990, J AM CHEM SOC, V112, P3715, DOI 10.1021/ja00165a097; KREBS A, 1990, TETRAHEDRON LETT, V31, P3533, DOI 10.1016/S0040-4039(00)94435-6; LEE MD, 1987, J AM CHEM SOC, V109, P3464, DOI 10.1021/ja00245a050; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LEE MD, 1987, J AM CHEM SOC, V109, P3466, DOI 10.1021/ja00245a051; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4082, DOI 10.1021/ja00404a018; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4091, DOI 10.1021/ja00404a019; MAGNUS P, 1989, J CHEM SOC CHEM COMM, P916, DOI 10.1039/c39890000916; MAGNUS P, 1989, TETRAHEDRON LETT, V30, P1905, DOI 10.1016/S0040-4039(00)99609-6; MAGNUS P, 1990, J ORG CHEM, V55, P1709, DOI 10.1021/jo00293a009; MAGNUS P, 1988, J AM CHEM SOC, V110, P6921, DOI 10.1021/ja00228a071; MAGNUS P, 1990, J AM CHEM SOC, V112, P4986, DOI 10.1021/ja00168a068; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P544, DOI 10.1039/c39910000544; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P541, DOI 10.1039/c39910000541; MANTLO NB, 1989, J ORG CHEM, V54, P2781, DOI 10.1021/jo00273a002; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MYERS AG, 1989, J AM CHEM SOC, V111, P9130, DOI 10.1021/ja00207a036; MYERS AG, 1991, J AM CHEM SOC, V113, P694, DOI 10.1021/ja00002a059; MYERS AG, 1989, J AM CHEM SOC, V111, P8057, DOI 10.1021/ja00202a079; NAGATA R, 1989, TETRAHEDRON LETT, V30, P4995, DOI 10.1016/S0040-4039(01)80564-5; NAGATA R, 1990, TETRAHEDRON LETT, V31, P2907, DOI 10.1016/0040-4039(90)80181-K; NICOLAOU KC, 1992, ANGEW CHEM INT EDIT, V31, P340, DOI 10.1002/anie.199203401; NICOLAOU KC, 1990, ANGEW CHEM INT EDIT, V29, P1064, DOI 10.1002/anie.199010641; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P7247, DOI 10.1021/ja00229a068; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1032, DOI 10.1002/anie.199110321; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P3106, DOI 10.1021/ja00008a045; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P4866, DOI 10.1021/ja00222a077; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7416, DOI 10.1021/ja00176a064; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P9878, DOI 10.1021/ja00026a039; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1387, DOI 10.1002/anie.199113873; NICOLAOU KC, 1989, ANGEW CHEM INT EDIT, V28, P1272, DOI 10.1002/anie.198912721; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7825, DOI 10.1021/ja00177a070; NICOLAOU KC, IN PRESS ANGEW CHEM; NICOLAOU KC, UNPUB; NISHIKAWA T, 1991, CHEM LETT, P1271, DOI 10.1246/cl.1991.1271; NISHIKAWA T, 1991, SYNLETT, P393; PORCO JA, 1990, J AM CHEM SOC, V112, P7410, DOI 10.1021/ja00176a060; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SAKAI Y, 1991, TETRAHEDRON LETT, V32, P4363, DOI 10.1016/S0040-4039(00)92171-3; SCHOENEN FJ, 1989, TETRAHEDRON LETT, V30, P3765, DOI 10.1016/S0040-4039(01)80649-3; SCHREIBER SL, 1988, J AM CHEM SOC, V110, P631, DOI 10.1021/ja00210a071; SCHREIBER SL, 1989, TETRAHEDRON LETT, V30, P433, DOI 10.1016/S0040-4039(00)95220-1; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH AL, 1992, J AM CHEM SOC, V114, P3134, DOI 10.1021/ja00034a068; TOMIOKA K, 1989, TETRAHEDRON LETT, V30, P851, DOI 10.1016/S0040-4039(01)80634-1; TOSHIMA K, 1991, TETRAHEDRON LETT, V32, P391, DOI 10.1016/S0040-4039(00)92636-4; WEHLAGE T, 1990, TETRAHEDRON LETT, V31, P6625, DOI 10.1016/S0040-4039(00)97131-4; WENDER PA, 1990, J AM CHEM SOC, V112, P5369, DOI 10.1021/ja00169a065; WENDER PA, 1988, TETRAHEDRON LETT, V29, P909, DOI 10.1016/S0040-4039(00)82479-X; WENDER PA, 1991, J AM CHEM SOC, V113, P2311, DOI 10.1021/ja00006a065	69	331	348	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1172	1178		10.1126/science.256.5060.1172	http://dx.doi.org/10.1126/science.256.5060.1172			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589797				2022-12-24	WOS:A1992HV19200026
J	KOCH, C; ZADOR, A; BROWN, TH				KOCH, C; ZADOR, A; BROWN, TH			DENDRITIC SPINES - CONVERGENCE OF THEORY AND EXPERIMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; CALCIUM; STIMULATION; ENHANCEMENT; MECHANISM; NEURONS		YALE UNIV,NEUROSCI PROGRAM,NEW HAVEN,CT 06520; YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University; Yale University	KOCH, C (corresponding author), CALTECH,COMP & NEURAL SYST PROGRAM,PASADENA,CA 91125, USA.			Zador, Anthony/0000-0002-8431-9136; Koch, Christof/0000-0001-6482-8067				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BRADLEY P, 1979, BRAIN RES, V162, P148, DOI 10.1016/0006-8993(79)90764-9; BROWN T H, 1988, P201; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COSS RG, 1985, BEHAV NEURAL BIOL, V44, P151, DOI 10.1016/S0163-1047(85)90170-0; COSS RG, 1978, SCIENCE, V200, P787, DOI 10.1126/science.644322; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DESMOND N L, 1988, P265; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; GREENOUGH WT, 1985, SYNAPTIC PLASTICITY, P335; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1989, HIPPOCAMPUS NEW VIST, P32; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; LARKMAN AU, 1991, J COMP NEUROL, V306, P320, DOI 10.1002/cne.903060208; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; PERKEL DH, 1985, BRAIN RES, V325, P331, DOI 10.1016/0006-8993(85)90334-8; PURPURA DP, 1974, SCIENCE, V186, P1126, DOI 10.1126/science.186.4169.1126; Rall W., 1974, CELLULAR MECH SUBSER, P13; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; RINZEL J, 1982, SOME MATH QUESTIONS, P7; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; SHEPHERD GM, 1985, P NATL ACAD SCI USA, V82, P2192, DOI 10.1073/pnas.82.7.2192; VANHARREVELD A, 1975, EXP NEUROL, V49, P736, DOI 10.1016/0014-4886(75)90055-2; WILSON CJ, 1984, J NEUROSCI, V4, P281; WILSON CJ, 1983, J NEUROSCI, V3, P383; XIANG Z, 1991, Society for Neuroscience Abstracts, V17, P1330; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	35	80	81	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					973	974		10.1126/science.1589781	http://dx.doi.org/10.1126/science.1589781			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589781				2022-12-24	WOS:A1992HU22400025
J	ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ				ALEXANDER, JM; GRANT, AM; CAMPBELL, MJ			RANDOMIZED CONTROLLED TRIAL OF BREAST SHELLS AND HOFFMAN EXERCISES FOR INVERTED AND NON-PROTRACTILE NIPPLES	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine the value of recommending breast shells or Hoffman's exercises, or both, to pregnant women with inverted or non-protractile nipples who intend to breast feed. Design - Randomised controlled trial with a two treatment by two level factorial design. Setting - Antenatal clinics in a district general hospital and the community. Subjects - 96 nulliparous women recruited between 25 and 35 completed weeks in a singleton pregnancy with at least one inverted or non-protractile nipple. Main outcome measures - Anatomical change of nipples, judged blindly before first breast feeding, and success of breast feeding reported by postal questionnaire six weeks postnatally. Results - Sustained improvement in nipple anatomy was more common in the untreated groups but the differences were not significant (52% (25/48) shells v 60% (29/48) no shells; difference -8% (95% confidence interval -28% to 11%) and 54% (26/48) exercises v 58% (28/48) no exercises; -4% (-24% to 16%)). 24 (50%) women not recommended shells and 14 (29%) recommended shells (21%; 40% to 2%) were breast feeding six weeks after delivery (p = 0.05), reflecting more women recommended shells both deciding to bottle feed before delivery and discontinuing breast feeding. The same number of women in exercise and no exercise groups were successfully breast feeding (0%; -20% to 20%). 13% of women approached about the trial (and planning to breast feed) did not attempt breast feeding. Conclusions - Recommending nipple preparation with breast shells may reduce the chances of successful breast feeding. While there is no clear evidence that the treatments offered are effective antenatal nipple examination should be abandoned.	NATL PERINATAL EPIDEMIOL UNIT,PERINATAL TRIALS SERV,OXFORD OX2 6HE,ENGLAND	University of Oxford	ALEXANDER, JM (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,DEPT NURSING STUDIES,SOUTHAMPTON S09 4XY,ENGLAND.		Campbell, Michael J/I-4253-2014	Campbell, Michael J/0000-0003-3529-2739				AKRE J, 1990, B WHO S, V67, P47; AKRE J, 1990, B WHO S, V67, P55; AKRE J, 1990, B WHO S, V67, P19; ALEXANDER J, 1991, THESIS U SOUTHAMPTON; BLAIKLEY J, 1953, J OBSTET GYN BRIT EM, V60, P657; CHALMERS I, 1982, EFFECTIVENESS SATISF, P209; COCHRAN WG, 1957, EXPT DESIGNS, P148; DELEE JB, 1947, PRINCIPLES PRACTICE, P99; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GUNTHER M, 1973, INFANT FEEDING, P104; HOFFMAN JB, 1953, AM J OBSTET GYNECOL, V66, P346; HYTTEN FE, 1958, LANCET, V1, P1201; HYTTEN FE, 1954, BMJ-BRIT MED J, V2, P1447, DOI 10.1136/bmj.2.4902.1447; INCH S, 1989, EFFECTIVE CARE PREGN, P335; LARSEN LLV, 1990, INT J CHILDBIRTH FEB, P33; LESPERANCE CM, 1980, BIRTH FAM J, V7, P21, DOI 10.1111/j.1523-536X.1980.tb01361.x; MARTIN J, 1988, INFANT FEEDING 1985; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P138; POOLE K, 1987, NEW GENERATION, V6, P33; RENFREW MJ, 1992, WOMENS HLTH MATTERS, P81; RIORDAN J, 1983, PRACTICAL GUIDE BREA; WALLER H, 1946, ARCH DIS CHILD, V21, P1, DOI 10.1136/adc.21.105.1; [No title captured]; 1944, 91 MIN HLTH PUBL HLT	24	45	45	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1030	1032		10.1136/bmj.304.6833.1030	http://dx.doi.org/10.1136/bmj.304.6833.1030			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586788	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200024
J	NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P				NUNNARI, JM; ZIMMERMAN, DL; OGG, SC; WALTER, P			CHARACTERIZATION OF THE ROUGH ENDOPLASMIC-RETICULUM RIBOSOME-BINDING ACTIVITY	NATURE			English	Article							MICROSOMAL-MEMBRANES; IDENTIFICATION; TRANSLOCATION; PROTEINS	THE rough endoplasmic reticulum membranes of mammalian cells contain specific ribosome-binding sites 1. A purification to apparent homogeneity of a negatively charged protein (ERpl80) of relative molecular mass 180,000 (180 K) was reported which was proposed to function as a rough endoplasmic reticulum ribosome receptor 2 We report here that ribosome-binding site activity quantitatively solubilized from rough endoplasmic reticulum membranes does not cofractionate with ERpl80. By contrast, ribosome-binding site activity fractionates as a much smaller, positively charged protein.			NUNNARI, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Ogg, Stephen/0000-0003-4157-1654				BORGESE N, 1974, J MOL BIOL, V88, P559, DOI 10.1016/0022-2836(74)90408-2; COLLINS PG, IN PRESS J CELL BIOL; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; TAZAWA S, 1991, J BIOCHEM-TOKYO, V109, P89; WALTER P, 1983, METHOD ENZYMOL, V96, P682; YOSHIDA H, 1987, BIOCHEM J, V245, P811, DOI 10.1042/bj2450811	8	31	31	2	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					638	640		10.1038/352638a0	http://dx.doi.org/10.1038/352638a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650916				2022-12-24	WOS:A1991GB21100061
J	GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R				GRODEN, J; THLIVERIS, A; SAMOWITZ, W; CARLSON, M; GELBERT, L; ALBERTSEN, H; JOSLYN, G; STEVENS, J; SPIRIO, L; ROBERTSON, M; SARGEANT, L; KRAPCHO, K; WOLFF, E; BURT, R; HUGHES, JP; WARRINGTON, J; MCPHERSON, J; WASMUTH, J; LEPASLIER, D; ABDERRAHIM, H; COHEN, D; LEPPERT, M; WHITE, R			IDENTIFICATION AND CHARACTERIZATION OF THE FAMILIAL ADENOMATOUS POLYPOSIS-COLI GENE	CELL			English	Article							COLORECTAL CANCERS; POINT MUTATIONS; HUMAN DNA; POLYMORPHISMS; CHROMOSOME-5; INHERITANCE; DELETION	DNA from 61 unrelated patients with adenomatous polyposis coli (APC) was examined for mutations in three genes (DP1, SRP19, and DP2.5) located within a 100 kb region deleted in two of the patients. The intron-exon boundary sequences were defined for each of these genes, and single-strand conformation polymorphism analysis of exons from DP2.5 identified four mutations specific to APC patients. Each of two aberrant alleles contained a base substitution changing an amino acid to a stop codon in the predicted peptide; the other mutations were small deletions leading to frameshifts. Analysis of DNA from parents of one of these patients showed that his 2 bp deletion is a new mutation; furthermore, the mutation was transmitted to two of his children. These data have established that DP2.5 is the APC gene.	UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT PATHOL,SALT LAKE CITY,UT 84132; UNIV UTAH,HLTH SCI CTR,DEPT MED,DIV GASTROENTEROL,SALT LAKE CITY,UT 84132; ST MARKS HOSP,SALT LAKE CITY,UT 84117; UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of California System; University of California Irvine	GRODEN, J (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84132, USA.		Pillay, Nischalan/F-9536-2012; McPherson, John D/D-2633-2017	McPherson, John D/0000-0001-8049-9347; Le Paslier, Denis/0000-0003-4335-9956	NATIONAL CANCER INSTITUTE [T32CA009602] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040886] Funding Source: NIH RePORTER; NCI NIH HHS [5T32 CA09602] Funding Source: Medline; NHGRI NIH HHS [HG-00320] Funding Source: Medline; NIGMS NIH HHS [R01-GM40886-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOURNE HR, 1991, NATURE, V351, P188, DOI 10.1038/351188a0; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; Maniatis T., 1982, MOL CLONING; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RIVERA H, 1990, J MED GENET, V27, P267, DOI 10.1136/jmg.27.4.267; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X	28	2345	2415	2	62	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					589	600		10.1016/0092-8674(81)90021-0	http://dx.doi.org/10.1016/0092-8674(81)90021-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651174				2022-12-24	WOS:A1991GA94100019
J	HOYT, MA; TOTIS, L; ROBERTS, BT				HOYT, MA; TOTIS, L; ROBERTS, BT			SACCHAROMYCES-CEREVISIAE GENES REQUIRED FOR CELL-CYCLE ARREST IN RESPONSE TO LOSS OF MICROTUBULE FUNCTION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DIVISION CYCLE; YEAST; KINASE; DNA; MUTATIONS; MUTANTS	We have identified mutant strains of S. cerevisiae that fail to properly arrest their cell cycles at mitosis in response to the loss of microtubule function. New bud emergence and DNA replication (but not cytokinesis) occur with high efficiency in the mutants under conditions that inhibit these events in wild-type cells. The inability to halt cell cycle progression is specific for impaired microtubule function; the mutants respond normally to other cell cycle-blocking treatments. Under microtubule-disrupting conditions, the mutants neither achieve nor maintain the high level of histone H-1 kinase activity characteristic of wild-type cells. Our studies have defined three genes required for normal cell cycle arrest. These findings are consistent with the existence of a surveillance system that halts the cell cycle in response to microtubule perturbation.			HOYT, MA (corresponding author), JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA.				NCRR NIH HHS [S07RR07041] Funding Source: Medline; NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007041] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Dustin P., 1984, MICROTUBULES; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; HUTTER KJ, 1978, A VAN LEEUW J MICROB, V44, P269, DOI 10.1007/BF00394305; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LANGE P, 1980, MOL GEN GENET, V180, P605, DOI 10.1007/BF00268067; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RIEDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1983, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3	36	951	978	2	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 9	1991	66	3					507	517		10.1016/0092-8674(81)90014-3	http://dx.doi.org/10.1016/0092-8674(81)90014-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651171	hybrid			2022-12-24	WOS:A1991GA94100012
J	SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF				SOPPET, D; ESCANDON, E; MARAGOS, J; MIDDLEMAS, DS; REID, SW; BLAIR, J; BURTON, LE; STANTON, BR; KAPLAN, DR; HUNTER, T; NIKOLICS, K; PARADA, LF			THE NEUROTROPHIC FACTORS BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3 ARE LIGANDS FOR THE TRKB TYROSINE KINASE RECEPTOR	CELL			English	Article							NERVE GROWTH-FACTOR; PDGF BETA-RECEPTOR; MOLECULAR-CLONING; FACTOR FAMILY; SIGNALING COMPLEX; MESSENGER-RNA; GENE-TRANSFER; EXPRESSION; ONCOGENE; CELLS	Neurotrophic factors are essential for neuronal survival and function. Recent data have demonstrated that the product of the tyrosine kinase trk protooncogene binds NGF and is a component of the high affinity NGF receptor. Analysis of the trkB gene product, gp145trkB, in NIH 3T3 cells indicates that this tyrosine kinase receptor is rapidly phosphorylated on tyrosine residues upon exposure to the NGF-related neurotrophic factors BDNF and NT-3. Furthermore, gp145trkB specifically binds BDNF and NT-3 in NIH 3T3 cells and in hippocampal cells,but does not bind NGF. Thus, the trk family of receptors are likely to be important signal transducers of NGF-related trophic signals in the formation and maintenance of neuronal circuits.	NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; GENENTECH INC,DEPT DEV BIOL,S SAN FRANCISCO,CA 94080; SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Roche Holding; Genentech; Salk Institute	SOPPET, D (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,MOLEC EMBRYOL SECT,FREDERICK,MD 21702, USA.		Parada, luis F/B-9400-2014		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; Black I.B., 1990, Current Topics in Developmental Biology, V24, P161; BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHAO MV, 1990, HDB EXPT PHARM, P135; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ESCANDON E, 1990, DEV BIOL, V142, P293, DOI 10.1016/0012-1606(90)90350-R; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HIGASHIYAMA S, 1991, SCIENCE, V251, P72; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM UH, 1991, J BIOL CHEM, V266, P1359; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MARTINZANCA D, 1990, AVIAN MODEL IN DEVELOPMENT BIOLOGY : FROM ORGANISM TO GENES, P291; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; Ramon y Cajal S., 1909, HISTOLOGIE SYSTEME N, DOI [DOI 10.5962/BHL.TITLE.48637, 10.5962/bhl.title.48637]; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSENTHAL A, 1991, IN PRESS ENDOCRINOLO; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SUTTER A, 1979, J BIOL CHEM, V254, P5972; VETTER ML, 1991, IN PRESS P NATL ACAD	56	716	744	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					895	903		10.1016/0092-8674(91)90396-G	http://dx.doi.org/10.1016/0092-8674(91)90396-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645620				2022-12-24	WOS:A1991FP51600019
J	MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H				MILUNSKY, A; ULCICKAS, M; ROTHMAN, KJ; WILLETT, W; JICK, SS; JICK, H			MATERNAL HEAT EXPOSURE AND NEURAL-TUBE DEFECTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-PREGNANCY; HYPERTHERMIA; SAUNA; TERATOGEN; FEVER; ABNORMALITIES; EMBRYOS; WOMEN	Objective.-To determine if exposure to hot tub, sauna, fever, or electric blanket during early pregnancy was associated with an increased risk for neural tube defects (NTDs). Design.-Prospective follow-up study. Setting.-Mostly private obstetric practices, primarily in New England. Participants.-A cohort of 23491 women having serum alpha-fetoprotein screening or an amniocentesis were identified. Complete exposure and outcome information was available for 97% of these women. Outcome Measures.-Relative risks (RRs) were used to compare incidence of NTD in those exposed to heat with those who were not exposed to any heat. Crude RRs were calculated directly from the data. Unconfounded RRs were calculated using logistic regression. Results.-Women reporting any heat exposure (sauna, hot tub, fever, or electric blanket) in early pregnancy had a crude risk of their fetuses developing NTD of 1.6 (95% CI [confidence interval], 0.9 to 2.9). Women reporting exposure to sauna, hot tub, or fever in early pregnancy had a crude risk of their fetuses developing NTD 2.2 times that of women without heat exposure (95% CI, 1.2 to 4.1). For hot tub use, the crude RR was 2.9 (95% CI, 1.4 to 6.3); for sauna, 2.6 (95% CI, 0.7 to 10.1); for fever, 1.9 (95% CI, 0.8 to 4.1); and for electric blanket, 1.2 (95% CI, 0.5 to 2.6). Multivariate adjusted RRs for individual heat sources, after controlling for maternal age, folic acid supplements, family history of NTD, and exposure to other heat sources, were for hot tub use, 2.8 (95% CI, 1.2 to 6.5); sauna, 1.8 (95% CI, 0.4 to 7.9); fever, 1.8 (95% CI, 0.8 to 4.1); and electric blanket, 1.2 (95% CI, 0.5 to 2.6). When only hot tub, sauna, and fever were considered and the women's exposure to each tallied, compared with no heat exposure, the RR for NTDs increased from 1.9 (95% CI, 0.9 to 3.7) after one type of heat exposure to 6.2 (95% CI, 2.2 to 17.2) after two types of heat exposure. Conclusions.-Exposure to heat in the form of hot tub, sauna, or fever in the first trimester of pregnancy was associated with an increased risk for NTDs. Hot tub exposure appeared to have the strongest effect of any single heat exposure. Exposure to electric blanket was not materially associated with increased risk for NTDs.	BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED & EPIDEMIOL,BOSTON,MA 02118; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	MILUNSKY, A (corresponding author), BOSTON UNIV,SCH MED,CTR HUMAN GENET,80 E CONCORD ST,BOSTON,MA 02118, USA.			Rothman, Kenneth/0000-0003-2398-1705; Milunsky, Aubrey/0000-0003-2114-4823; Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992	NINDS NIH HHS [NS 19561] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019561] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARORA KL, 1979, TERATOLOGY, V19, P251, DOI 10.1002/tera.1420190216; BRINSMADE A B, 1957, Beitr Pathol Anat, V117, P154; CHANCE PF, 1978, LANCET, V1, P769; COCKROFT DL, 1978, TERATOLOGY, V17, P277, DOI 10.1002/tera.1420170306; EDWARDS MJ, 1972, LANCET, V1, P320; EDWARDS MJ, 1974, J EMBRYOL EXP MORPH, V32, P593; EDWARDS MJ, 1967, ARCH PATHOL, V84, P42; EDWARDS MJ, 1986, TERATOGEN CARCIN MUT, V6, P563, DOI 10.1002/tcm.1770060610; FISHER NL, 1981, PEDIATRICS, V68, P480; FRASER FC, 1978, LANCET, V2, P634; GERMAN J, 1984, AM J MED, V76, P293, DOI 10.1016/0002-9343(84)90788-5; GRAHAM JM, 1988, TERATOLOGY, V37, P461; HARTLEY WJ, 1974, TERATOLOGY, V9, P299, DOI 10.1002/tera.1420090309; HARVEY MAS, 1981, CAN MED ASSOC J, V125, P50; HENDRICKX AG, 1979, TERATOLOGY, V19, P177, DOI 10.1002/tera.1420190208; HUNTER AGW, 1984, AM J MED GENET, V19, P45, DOI 10.1002/ajmg.1320190108; KILHAM L, 1976, TERATOLOGY, V14, P323, DOI 10.1002/tera.1420140307; KLEINEBRECHT J, 1979, LANCET, V1, P1403; LAYDE PM, 1980, TERATOLOGY, V21, P105, DOI 10.1002/tera.1420210114; LIPSON A, 1988, AM J MED GENET, V29, P117, DOI 10.1002/ajmg.1320290114; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILLER P, 1978, LANCET, V1, P519; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; NILSEN NO, 1984, TERATOLOGY, V30, P237, DOI 10.1002/tera.1420300211; PLEET H, 1981, PEDIATRICS, V67, P785; SAXEN L, 1982, TERATOLOGY, V25, P309, DOI 10.1002/tera.1420250307; SHIOTA K, 1982, AM J MED GENET, V12, P281, DOI 10.1002/ajmg.1320120306; SMITH DW, 1978, J PEDIATR-US, V92, P878, DOI 10.1016/S0022-3476(78)80352-7; SOHAR E, 1976, ISRAEL J MED SCI, V12, P1275; SPRAGGETT K, 1982, TERATOLOGY, V25, pA78; SUPERNEAU DW, 1985, AM J MED GENET, V21, P575, DOI 10.1002/ajmg.1320210319; UHARI M, 1979, BRIT MED J, V1, P1216, DOI 10.1136/bmj.1.6172.1216; UMPIERRE CC, 1978, TERATOLOGY, V16, P155; WANNER RA, 1976, J PATHOL, V118, P235, DOI 10.1002/path.1711180406; WARKANY J, 1986, TERATOLOGY, V33, P365, DOI 10.1002/tera.1420330316; WEBSTER WS, 1984, TERATOLOGY, V29, P417, DOI 10.1002/tera.1420290313; 1978, BMJ, V2, P1586; 1978, LANCET, V2, P560	38	188	194	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					882	885		10.1001/jama.268.7.882	http://dx.doi.org/10.1001/jama.268.7.882			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640616				2022-12-24	WOS:A1992JH58800038
J	DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK				DANIELSON, C; LYON, JL; EGGER, M; GOODENOUGH, GK			HIP-FRACTURES AND FLUORIDATION IN UTAH ELDERLY POPULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WATER FLUORIDATION; BONE; COMMUNITIES; WOMEN; OSTEOPOROSIS; DENSITY; OLDER	Objective.-To test the effect of water fluoridated to 1 ppm on the incidence of hip fractures in the elderly. Design.-Ecological cohort. Setting.-The incidence of femoral neck fractures in patients 65 years of age or older was compared in three communities in Utah, one with and two without water fluoridated to 1 ppm. Patients.-All patients with hip fractures who were 65 years of age and older over a 7-year period in the three communities, excluding (1) those with revisions of hip fractures, (2) those in whom the hip fracture was anything but a first diagnosis, (3) those in whom metastatic disease was present, or (4) those in whom the fracture was a second fracture (n=246). Outcome Measure.-Rate of hospital discharge for hip fracture. Results.-The relative risk for hip fracture for women in the fluoridated area was 1.27 (95% confidence interval [Cl]=1.08 to 1.46) and for men was 1.41 (95% Cl=1.00 to 1.81) relative to the nonfluoridated areas. Conclusions.-We found a small but significant increase in the risk of hip fracture in both men and women exposed to artificial fluoridation at 1 ppm, suggesting that low levels of fluoride may increase the risk of hip fracture in the elderly.			DANIELSON, C (corresponding author), UNIV UTAH,DEPT FAMILY & PREVENT MED,50 N MED DR,SALT LAKE CITY,UT 84132, USA.							ALHAVA EM, 1980, ACTA ORTHOP SCAND, V51, P413, DOI 10.3109/17453678008990817; ANSEL BM, 1965, ANN RHEUM DIS, V25, P67; ARNALA I, 1986, ACTA ORTHOP SCAND, V57, P433; BERNSTEI.DS, 1966, J AMER MED ASSOC, V198, P499, DOI 10.1001/jama.198.5.499; Chiang C, 1961, VITAL STAT SPEC REP, P47; COOPER C, 1990, J EPIDEMIOL COMMUN H, V44, P17, DOI 10.1136/jech.44.1.17; COOPER C, 1991, JAMA-J AM MED ASSOC, V266, P513, DOI 10.1001/jama.266.4.513; EVANS FG, 1976, ACTA ORTHOP SCAND, V47, P489, DOI 10.3109/17453677608988726; ISKRANT AP, 1968, AM J PUBLIC HEALTH N, V58, P485, DOI 10.2105/AJPH.58.3.485; JACOBSEN SJ, 1990, JAMA-J AM MED ASSOC, V264, P500, DOI 10.1001/jama.264.4.500; KENDALL MG, 1977, ADV THEORY STATISTIC, V1; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LEONE NC, 1955, AMER J ROENTGENOL RA, V74, P874; Lindsay R, 1988, Clin Geriatr Med, V4, P411; MADANS J, 1983, AM J PUBLIC HEALTH, V73, P296, DOI 10.2105/AJPH.73.3.296; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; PHIPPS KR, 1990, J DENT RES, V69, P1256, DOI 10.1177/00220345900690060601; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; SAVILLE PD, 1966, JAMA-J AM MED ASSOC, V199, P105; SIMONEN O, 1985, LANCET, V2, P432; SOWERS MR, 1991, AM J EPIDEMIOL, V133, P649, DOI 10.1093/oxfordjournals.aje.a115940; 1989, CDC898411 US DEP HLT, P76	23	78	79	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					746	748						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640574				2022-12-24	WOS:A1992JG66600015
J	PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP				PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP			PRESERVED INSULIN-SECRETION AND INSULIN INDEPENDENCE IN RECIPIENTS OF ISLET AUTOGRAFTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							I DIABETIC RECIPIENTS; PANCREATIC-POLYPEPTIDE; AUTO-TRANSPLANTATION; INDUCED HYPOGLYCEMIA; ADRENERGIC-BLOCKADE; GLUCAGON-RELEASE; CANINE PANCREAS; NERVOUS-SYSTEM; CYCLOSPORIN; PLASMA	Background. Transplantation of pancreatic islets, rather than whole pancreas, has been introduced as a treatment for diabetes mellitus. We studied five patients ranging in age from 12 to 37 years who had severe chronic pancreatitis for which they underwent total pancreatectomy followed by isolation and hepatic transplantation of their own islets. Methods. All patients had remained insulin-independent for 1 to 7 1/2 years after transplantation. The numbers of islets transplanted ranged from 110,000 to 412,000. Islet function was assessed by measuring the plasma insulin responses to intravenous glucose and arginine and the plasma glucagon responses to hypoglycemia and arginine. In one patient, islet function was studied during catheterization of the hepatic vein, portal vein, and splenic artery and by analysis of a liver-biopsy specimen. Results. After transplantation, the mean (+/-SD)fasting plasma glucose concentration was 122+/-47 mg per deciliter (6.8+/-2.6 mmol per liter) and the hemoglobin A1c concentration was 6.0+/-0.8 percent in the five patients. The values were most abnormal - 214 mg per deciliter (11.9 mmol per liter) and 7.3 percent, respectively - in the patient who received only 110,000 islets. The acute plasma insulin responses to glucose and to arginine in the five patients were 23+/-13 and 26+/-10-mu-U per milliliter (168+/-94 and 184+/-70 pmol per liter), respectively, as compared with 58+/-6 and 37+/-8-mu-U per milliliter (416+/-44 and 267+/-61 pmol per liter) in the normal subjects. The peak plasma glucagon responses to insulin and arginine were 21+/-4 and 65+/-36 pg per millilter, respectively, as compared with 125+/-28 and 156+/-99 pg per milliliter in the normal subjects. All five patients had plasma epinephrine but not pancreatic polypeptide responses to hypoglycemia. The results of the hepatic-vein catheterization in one patient indicated that the transplanted islets released insulin and glucagon in response to arginine. Immunoperoxidase staining of this patient's liver-biopsy specimen showed that the islets contained insulin, glucagon, and somatostatin but not pancreatic polypeptide. Conclusions. Intrahepatic transplantation of as few as 265,000 islets can result in the release of insulin and glucagon at appropriate times and in prolonged periods of insulin independence.	UNIV MINNESOTA, CTR DIABET, BOX 101 UMHC, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT MED, DIV ENDOCRINOL & METAB, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT SURG, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MICHIGAN, DEPT MED, ANN ARBOR, MI 48109 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Roberston, R Paul/AAX-5613-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039994, T32DK007203] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00400] Funding Source: Medline; NIDDK NIH HHS [R01 DK 39994, 5T32 DK 07203] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMERON JL, 1980, SURGERY, V87, P397; CHESNEY TMC, 1969, DIABETES, V18, P627, DOI 10.2337/diab.18.9.627; DIEM P, 1990, J CLIN INVEST, V86, P2008, DOI 10.1172/JCI114936; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; DUNNING BE, 1990, AM J PHYSIOL, V258, pE436, DOI 10.1152/ajpendo.1990.258.3.E436; FARNEY AC, 1991, SURGERY, V110, P427; GERSELL DJ, 1979, DIABETES, V28, P11, DOI 10.2337/diabetes.28.1.11; GILLISON SL, 1989, DIABETES, V38, P465, DOI 10.2337/diabetes.38.4.465; GLASER B, 1983, METABOLISM, V32, P57, DOI 10.1016/0026-0495(83)90156-7; GUNNARSSON R, 1983, LANCET, V2, P571; HARRIS M, 1979, DIABETES, V28, P1039; HAVEL PJ, 1989, ENDOCR REV, V10, P332, DOI 10.1210/edrv-10-3-332; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVERSEN J, 1971, J CLIN INVEST, V50, P2123, DOI 10.1172/JCI106706; LARGIADER F, 1980, TRANSPLANTATION, V29, P76, DOI 10.1097/00007890-198001000-00017; LYGREN I, 1983, SCAND J GASTROENTERO, V18, P155, DOI 10.3109/00365528309181576; MARLISS EB, 1973, EUR J CLIN INVEST, V3, P16; MIRALLES P, 1990, DIABETES, V39, P996, DOI 10.2337/diabetes.39.8.996; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAJARIAN JS, 1980, ANN SURG, V192, P526, DOI 10.1097/00000658-198010000-00011; NIELSEN JH, 1986, DIABETES, V35, P1049, DOI 10.2337/diabetes.35.9.1049; PALMER JP, 1979, METABOLISM, V28, P549, DOI 10.1016/0026-0495(79)90196-3; PALMER JP, 1976, J CLIN INVEST, V57, P522, DOI 10.1172/JCI108305; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; RUSSELL AE, 1989, J AUTONOM NERV SYST, V26, P85, DOI 10.1016/0165-1838(89)90111-2; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; SUTHERLAND DER, 1981, DIABETOLOGIA, V20, P435; TRIMBLE ER, 1980, DIABETES, V29, P341, DOI 10.2337/diabetes.29.5.341; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; WALTER RM, 1974, J CLIN INVEST, V54, P1214, DOI 10.1172/JCI107864; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857; WEIR GC, 1990, DIABETES, V39, P401, DOI 10.2337/diabetes.39.4.401	35	133	139	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					220	226		10.1056/NEJM199207233270402	http://dx.doi.org/10.1056/NEJM199207233270402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614463	Bronze			2022-12-24	WOS:A1992JE38100002
J	THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR				THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR			ASSOCIATION OF PRIOR INFECTION WITH CHLAMYDIA-PNEUMONIAE AND ANGIOGRAPHICALLY DEMONSTRATED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; PATHOGENESIS; TWAR; HERPESVIRUS; FINLAND; CELLS	Objective.-To evaluate the association between prior infection with Chlamydia Pneumoniae, as measured by IgG antibody, and coronary artery disease. Design.-A population-based, case-control study. Setting.-Group Health Cooperative of Puget Sound, a Seattle-based health maintenance organization. Participants.-Men 55 years of age and younger and women 65 years of age and younger. Cases (n=171) were members of Group Health Cooperative undergoing diagnostic coronary angiography who had at least one coronary artery lesion occupying 50% or more of the luminal diameter. The population controls (n=120) were Group Health Cooperative members without known coronary heart disease. Main Outcome Measure.-The adjusted odds ratio (OR) for coronary artery disease associated with prior C pneumoniae infection as measured by the presence of IgG antibody. Results.-After adjusting for age, gender, and calendar quarter of blood drawing, the OR for coronary artery disease associated with the presence of antibody was 2.6 (95% confidence interval, 1.4 to 4.8). The association was limited to cigarette smokers, in whom the OR was 3.5 (95% confidence interval, 1.7 to 7.0). Among never-smokers, the OR was 0.8 (95% confidence interval, 0.3 to 1.9). When cases and controls were restricted to those assayed concurrently, the adjusted OR (smokers and nonsmokers combined) was 4.2 (95% confidence interval, 1.8 to 10.0). Adjustment for serum cholesterol, hypertension, alcohol use, diabetes, and socioeconomic status did not change these results. Only a weak association was found when cases were compared with 63 subjects whose angiographic results were normal (OR, 1.2; 95% confidence interval, 0.6 to 2.2). Conclusions.-These results generally support the previously reported association between C pneumoniae infection and coronary heart disease. However, caution should be used in interpreting the basis for this association.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	THOM, DH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DIV FAMILY & COMMUNITY MED,703 WELCH RD,SUITE G-1,STANFORD,CA 94305, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021885] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-F32-HL-08194-01] Funding Source: Medline; NIAID NIH HHS [AI-21885] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLIE EE, 1979, CLIN CHEM, V25, P817; BOOZE CF, 1987, AVIAT SPACE ENVIR MD, V58, P297; Breslow N, 1980, STATISTICAL METHODS, V32; CHIRGWIN K, 1991, J INFECT DIS, V163, P757, DOI 10.1093/infdis/163.4.757; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FABRICANT CG, 1981, AM J PATHOL, V105, P176; GRAYSTON JT, 1985, REV INFECT DIS, V7, P717; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KRON J, 1983, ARCH INTERN MED, V143, P1466; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MIKLOZEK CL, 1988, AM HEART J, V115, P768, DOI 10.1016/0002-8703(88)90877-0; Osler W, 1908, MODERN MED ITS PRACT, P429; Patnode D, 1990, CHLAMYDIAL INFECTION, P406; PATTON DL, 1987, J INFECT DIS, V155, P1292, DOI 10.1093/infdis/155.6.1292; PUOLAKKAINEN M, 1989, EPIDEMIOL INFECT, V102, P287, DOI 10.1017/S0950268800029964; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WANG SP, 1984, 1983 INT S MED VIR, P87; Warnick G R, 1986, Methods Enzymol, V129, P101; YAMAZAKI T, 1990, J INFECT DIS, V162, P1390, DOI 10.1093/infdis/162.6.1390	29	369	388	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					68	72		10.1001/jama.268.1.68	http://dx.doi.org/10.1001/jama.268.1.68			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608116				2022-12-24	WOS:A1992JA16500025
J	LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH			SWI6 PROTEIN IS REQUIRED FOR TRANSCRIPTION OF THE PERIODICALLY EXPRESSED DNA-SYNTHESIS GENES IN BUDDING YEAST	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; REGULATORS	IN budding yeast many genes are expressed under cell-cycle control in late G1. These include a large group of DNA synthesis genes 1, the HO gene 2 involved in mating-type switching, CTS1 (chitinase) 3 and also CLN1 and CLN2 (ref. 4) encoding G1 cyclins. Two factors, encoded by the SWI4 and SWI6 genes, are required for HO (ref. 5), CLN (refs 6, 7) and CTS1 (ref. 3) gene expression and, at least in the HO promoter, bind to CACGA4 upstream sequences 5,7-9 (CCBs). This motif is not found upstream of the DNA synthesis genes, which instead have a hexamer element, ACGCGT 1 (MCB), an MluI restriction site, that is recognized by a cell-cycle regulated transcription complex DSC1 (ref. 1). This MluI-activation system consisting of the MCBs and DSC1 is conserved in fission yeast where a DSC1-like complex controls the cdc22+ ribonucleotide reductase gene 10. The Schizosaccharomyces pombe cdc10+ gene encodes a component of DSC1 (ref. 10) and, significantly, this has homology with both the Swi4 and Swi6 proteins 8,11. Here we show that Swi6 is an essential component of DSC1 and that deletion of SWI6 impairs the cell-cycle regulation of the DNA synthesis genes, as well as CLN1 and CLN2. Thus Swi6 is the common factor in regulation of all the above genes and may therefore be responsible for the timing of their expression in late G1.	NATL INST MED RES,YEAST GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	MRC National Institute for Medical Research; Fred Hutchinson Cancer Center			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427; Breeden, Linda/0000-0001-7337-5434				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; DOHRMANN PR, IN PRESS GENES DEV; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JOHNSTON LH, IN PRESS COLD SPRING; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1992, TRENDS GENET, V8, P79, DOI 10.1016/0168-9525(92)90183-5; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; SIMANIS V, 1989, J CELL SCI, V92, P51; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	23	148	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					505	508		10.1038/357505a0	http://dx.doi.org/10.1038/357505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608450				2022-12-24	WOS:A1992HY05200066
J	ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP				ABRAMSON, SV; BURKE, JF; KELLY, JJ; KITCHEN, JG; DOUGHERTY, MJ; YIH, DF; MCGEEHIN, FC; SHUCK, JW; PHIAMBOLIS, TP			PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERTENSION; TRICUSPID VALVE INSUFFICIENCY; CARDIOMYOPATHY, CONGESTIVE; ECHOCARDIOGRAPHY; HEART FAILURE, CONGESTIVE	CONGESTIVE HEART-FAILURE; TRICUSPID REGURGITATION; NONINVASIVE ESTIMATION; DOPPLER ULTRASOUND; SYSTOLIC PRESSURE; PULSED DOPPLER; PROGNOSIS; ECHOCARDIOGRAPHY; SURVIVAL; DETERMINANTS	Objective: To ascertain whether pulmonary hypertension, as assessed noninvasively by continuous-wave Doppler of tricuspid regurgitation, can be an important independent factor in the prognosis of patients with ischemic or idiopathic dilated cardiomyopathy. Design: Cohort study of consecutive patients with dilated cardiomyopathy in whom follow-up was obtained on all survivors for 28 months. Setting: Outpatient cardiology private practice office in a tertiary care center. Patients: Consecutive sample of 108 patients who presented for a scheduled office visit during a 15-month period. Measurements: M-mode, two-dimensional, and Doppler echocardiographic examinations were done on all patients at entry into the study and on survivors 1 year later. All examinations included extensive pulsed- and continuous-wave Doppler evaluation for tricuspid regurgitation. Main Outcome Measures: Overall mortality, mortality due to myocardial failure, and hospitalization for congestive heart failure. Results: Twenty-eight patients had a high velocity of tricuspid regurgitation (> 2.5 m/s), and 80 patients had a low velocity (less-than-or-equal-to 2.5 m/s). After 28 months of follow-up, the mortality rate was 57% in patients with a high velocity compared with 17% in patients with a low velocity (difference of 40%, 95% Cl, 20% to 60%). Hospitalization for congestive heart failure occurred in 75% and 26% of patients, respectively (difference of 49%, Cl, 30% to 68%). Eighty-nine percent of patients with a high velocity either died or were hospitalized compared with only 32% of patients with a low velocity (difference of 57%, Cl, 42% to 72%). The peak velocity of tricuspid regurgitation was the only prognostic variable selected using stepwise logistic regression models for the three outcome events. Conclusion: Noninvasive assessment of pulmonary hypertension using continuous-wave Doppler of tricuspid regurgitation can predict morbidity and mortality in patients with ischemic or idiopathic dilated cardiomyopathy.	LANKENAU HOSP, ECHOCARDIOG LAB, SUITE 356 LANKENAU MED BLDG E, 100 LANCASTER AVE W CITY LINE, WYNNEWOOD, PA 19096 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA	Lankenau Medical Center; Jefferson University								ABBASI AS, 1980, CIRCULATION, V61, P143, DOI 10.1161/01.CIR.61.1.143; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; CLELAND JGF, 1987, BRIT HEART J, V58, P572; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DIAZ RA, 1987, BRIT HEART J, V58, P393; DOUGLAS PS, 1989, J AM COLL CARDIOL, V13, P311, DOI 10.1016/0735-1097(89)90504-4; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GRADMAN A, 1989, J AM COLL CARDIOL, V14, P564, DOI 10.1016/0735-1097(89)90093-4; HATLE L, 1981, BRIT HEART J, V45, P157; IKRAM H, 1987, BRIT HEART J, V57, P521; Kannel W B, 1989, Cardiol Clin, V7, P1; KATZ AM, 1990, NEW ENGL J MED, V322, P100; KELLY TL, 1990, AM HEART J, V119, P1111, DOI 10.1016/S0002-8703(05)80242-X; LEE WH, 1986, CIRCULATION, V73, P257, DOI 10.1161/01.CIR.73.2.257; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; MASSIE BM, 1987, CIRCULATION, V75, P11; MIKAMI T, 1984, AM J CARDIOL, V53, P160, DOI 10.1016/0002-9149(84)90702-1; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; PACKER M, 1987, CIRCULATION, V75, P55; POLAK JF, 1983, J AM COLL CARDIOL, V2, P217, DOI 10.1016/S0735-1097(83)80156-9; ROMEO F, 1989, CLIN CARDIOL, V12, P387, DOI 10.1002/clc.4960120708; SIMONSON JS, 1988, J AM COLL CARDIOL, V11, P557, DOI 10.1016/0735-1097(88)91531-8; STEWART RAH, 1990, Q J MED, V74, P309; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; WILSON JR, 1987, CIRCULATION, V75, P64; WYATT HL, 1980, CIRCULATION, V61, P1119, DOI 10.1161/01.CIR.61.6.1119; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657; YOSHIDA K, 1988, CIRCULATION, V78, P840, DOI 10.1161/01.CIR.78.4.840	32	248	256	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					888	895		10.7326/0003-4819-116-11-888	http://dx.doi.org/10.7326/0003-4819-116-11-888			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580444				2022-12-24	WOS:A1992HW13700002
J	HAWTON, K; FAGG, J				HAWTON, K; FAGG, J			TRENDS IN DELIBERATE SELF POISONING AND SELF INJURY IN OXFORD, 1976-90	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; PARASUICIDE; EDINBURGH	Objective - To review trends in deliberate self poisoning and self injury (attempted suicide) over 15 years (1976-90) on the basis of general hospital referrals. Design - Prospective data collection by computerised monitoring system. Setting - Teaching general hospital. Subjects - All patients aged 15 and over (n = 9605) referred to the hospital after episodes (n = 13 340) of deliberate self poisoning or self injury. Main outcome measures - Rates based on population of Oxford city; changes in substances used for self poisoning; history and repetition of attempts; and rates of admission to the hospital and of referral to the psychiatric service. Results - Attempted suicide rates for women declined during the late 1970s and early 1980s but increased again during the late 1980s. Those for men remained relatively steady throughout the period. Highest mean annual rates occurred in women aged 15-19 (711/100 000) and in 20-34 year old men (334/100 000). The proportion of overdoses with paracetamol increased from 14.3% (125/873) in 1976 to 42% (365/869) in 1990 (chi-2 for trend = 481, p < 0.01). Throughout the period the proportions of referred patients admitted to hospital and of those attempting suicide for the first time (over two thirds) did not decrease. Annual rates of repetition of attempts by women declined from 15.1% (257/1700) in 1976-8 to 11.9% (161/1356) in 1987-9 (chi-2 for trend = 7.8, p < 0.01). Lower repetition rates occurred in women admitted to hospital and referred to the psychiatric service (431/4585, 9.4%) than in those not referred (42/235, 17.9%; chi-2 = 17.2, p < 0.0001). Conclusions - Rates of attempted suicide declined in the 1970s and early 1980s, in women, but there are probably at least 100 000 hospital referrals a year in England and Wales because of this problem. Prevention of paracetamol self poisoning requires urgent attention, and psychosocial assessment should be conducted with as many of those who attempt suicide as possible.			HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							ALDERSON MR, 1974, LANCET, V1, P1040; [Anonymous], 1984, MANAGEMENT DELIBERAT; BANCROFT JHJ, 1975, BRIT J PREV SOC MED, V29, P170; BLACK D, 1988, J ROY SOC MED, V81, P97, DOI 10.1177/014107688808100216; BLAKE DR, 1978, BRIT MED J, V1, P1032, DOI 10.1136/bmj.1.6119.1032; BREWER C, 1985, BRIT MED J, V290, P391, DOI 10.1136/bmj.290.6465.391; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P657; HAWTON K, 1979, BRIT MED J, V2, P1040, DOI 10.1136/bmj.2.6197.1040; HAWTON K, 1987, ATTEMPTED SUICIDE; HAWTON K, 1989, CURRENT RES SUICIDE, P180; KREITMAN N, 1979, PSYCHOL MED, V9, P469, DOI 10.1017/S0033291700032013; OWENS DW, 1988, BRIT J PSYCHIAT, V152, P830, DOI 10.1192/bjp.152.6.830; PLATT S, 1988, PSYCHOL MED, V18, P405, DOI 10.1017/S0033291700007959; SKRIMSHIRE AM, 1976, J BIOSOC SCI, V8, P85, DOI 10.1017/S0021932000010531	14	130	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1409	1411		10.1136/bmj.304.6839.1409	http://dx.doi.org/10.1136/bmj.304.6839.1409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628014	Bronze, Green Published			2022-12-24	WOS:A1992HX08200017
J	CORMACK, BP; STRUHL, K				CORMACK, BP; STRUHL, K			THE TATA-BINDING PROTEIN IS REQUIRED FOR TRANSCRIPTION BY ALL 3 NUCLEAR-RNA POLYMERASES IN YEAST-CELLS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; PROMOTER ELEMENT; MOLECULAR MECHANISMS; ACTIVATOR PROTEIN; ESCHERICHIA-COLI; DNA-SEQUENCES; GENE; INVITRO; INITIATION	Using temperature- and proteolytically sensitive derivatives to inactivate the function of the yeast TATA-binding protein (TBP) in vivo, we investigated the requirement of TBP for transcription by the three nuclear RNA polymerases in yeast cells. TBP is required for RNA polymerase II (pol II) transcription from promoters containing conventional TATA elements as well as functionally distinct promoters that lack TATA-like sequences. TBP is also required for transcription of the U6 snRNA and two different tRNA genes mediated by RNA pol III as well as transcription of ribosomal RNA mediated by RNA pol I. For all promoters tested, transcription decreases rapidly and specifically upon inactivation of TBP, strongly suggesting that TBP is directly involved in the transcription process. These observations suggest that TBP is required for transcription of all nuclearly encoded genes in yeast, although distinct molecular mechanisms are probably involved for the three RNA polymerase transcription machineries.			CORMACK, BP (corresponding author), HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030186, R37GM030186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BUTT TR, 1988, J BIOL CHEM, V263, P16364; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CASHEL M, 1975, ANNU REV MICROBIOL, V29, P301, DOI 10.1146/annurev.mi.29.100175.001505; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHEN W, 1989, EMBO J, V8, P261, DOI 10.1002/j.1460-2075.1989.tb03372.x; CHEN W, 1988, P NATL ACAD SCI USA, V85, P2691, DOI 10.1073/pnas.85.8.2691; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELION EA, 1986, MOL CELL BIOL, V6, P2089, DOI 10.1128/MCB.6.6.2089; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; FIRE A, 1984, J BIOL CHEM, V259, P2509; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HOMA FL, 1988, GENE DEV, V2, P40, DOI 10.1101/gad.2.1.40; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KAMBADUR R, 1990, P NATL ACAD SCI USA, V87, P9168, DOI 10.1073/pnas.87.23.9168; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KEMPERSVEENSTRA AE, 1986, EMBO J, V5, P2703, DOI 10.1002/j.1460-2075.1986.tb04554.x; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; MEMET S, 1988, J BIOL CHEM, V263, P10048; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NICOLET CM, 1991, METHOD ENZYMOL, V194, P710; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARK EC, 1992, P NATL ACAD SCI USA, V89, P1249, DOI 10.1073/pnas.89.4.1249; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REINBERG D, 1987, J BIOL CHEM, V262, P3310; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SINGER VL, 1990, GENE DEV, V4, P636, DOI 10.1101/gad.4.4.636; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; STRUHL K, 1986, MOL CELL BIOL, V6, P3847, DOI 10.1128/MCB.6.11.3847; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313	74	325	328	1	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 15	1992	69	4					685	696		10.1016/0092-8674(92)90232-2	http://dx.doi.org/10.1016/0092-8674(92)90232-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586947				2022-12-24	WOS:A1992HV08900013
J	MICHELSON, HB; WONG, RKS				MICHELSON, HB; WONG, RKS			EXCITATORY SYNAPTIC RESPONSES MEDIATED BY GABA(A) RECEPTORS IN THE HIPPOCAMPUS	SCIENCE			English	Article							SOMATOSTATIN-LIKE IMMUNOREACTIVITY; CENTRAL-NERVOUS-SYSTEM; PYRAMIDAL CELLS; GABAERGIC NEURONS; RAT; INTERNEURONS; ANTAGONISTS; SUBTYPES; SLICES; ACID	Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the cortex. Activation of postsynaptic GABA(A) receptors hyperpolarizes cells and inhibits neuronal activity. Synaptic responses mediated by GABA(A) receptors also strongly excited hippocampal neurons. This excitatory response was recorded in morphologically identified interneurons in the presence of 4-aminopyridine or after elevation of extracellular potassium concentrations. The synaptic excitation sustained by GABA(A) receptors synchronized the activity of inhibitory interneurons. This synchronized discharge of interneurons in turn elicited large-amplitude inhibitory postsynaptic potentials in pyramidal and granule cells. Excitatory synaptic responses mediated by GABA(A) receptors may thus provide a mechanism for the recruitment of GABAergic interneurons through their recurrent connections.			MICHELSON, HB (corresponding author), SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203, USA.							ALGER BE, 1982, J PHYSIOL-LONDON, V328, P105, DOI 10.1113/jphysiol.1982.sp014255; ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P608, DOI 10.1152/jn.1964.27.4.608; ARAM J, 1989, BRIT J PHARMACOL, V96, P82; ARAM JA, 1991, J NEUROPHYSIOL, V65, P1034, DOI 10.1152/jn.1991.65.5.1034; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; KNOWLES WD, 1981, J NEUROSCI, V1, P318; KOSAKA T, 1988, EXP BRAIN RES, V71, P388; LACAILLE JC, 1988, J NEUROSCI, V8, P1411; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; Lux H D, 1986, Adv Neurol, V44, P619; MILES R, 1987, J PHYSIOL-LONDON, V388, P611, DOI 10.1113/jphysiol.1987.sp016634; MILES R, 1990, J PHYSIOL-LONDON, V423, P95; MULLER W, 1990, J NEUROPHYSIOL, V64, P46, DOI 10.1152/jn.1990.64.1.46; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; PERREAULT P, 1989, Society for Neuroscience Abstracts, V15, P1213; SLOVITER RS, 1987, J COMP NEUROL, V256, P42, DOI 10.1002/cne.902560105; SOMOGYI P, 1984, J NEUROSCI, V4, P2590; STEWART WW, 1981, NATURE, V292, P17, DOI 10.1038/292017a0; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WONG RKS, 1982, J NEUROPHYSIOL, V48, P938, DOI 10.1152/jn.1982.48.4.938; WONG RKS, 1982, SCIENCE, V216, P745	25	271	271	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1420	1423		10.1126/science.1654594	http://dx.doi.org/10.1126/science.1654594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654594				2022-12-24	WOS:A1991GF85100042
J	OSTERGAARD, HL; TROWBRIDGE, IS				OSTERGAARD, HL; TROWBRIDGE, IS			NEGATIVE REGULATION OF CD45 PROTEIN TYROSINE PHOSPHATASE-ACTIVITY BY IONOMYCIN IN T-CELLS	SCIENCE			English	Article							LEUKOCYTE-COMMON ANTIGEN; ACTIVATION; PHOSPHORYLATION; CALCIUM; KINASE; EXPRESSION; FLUORESCENCE; RESPONSES; MEMBRANE; ALTERS	CD45 is a leukocyte-specific, transmembrane protein tyrosine phosphatase (PTPase) required for T cell responsiveness. How the activity of PTPases is regulated in vivo is unclear. Treatment of murine thymocytes and a variety of murine T cell lines with the calcium ionophore ionomycin decreased CD45 PTPase activity. Ionomycin treatment also led to a decreased phosphorylation of serine residues in CD45. These results indicate that increased intracellular calcium modulates CD45 PTPase activity, demonstrating regulation of CD45 PTPase activity in vivo, and also implicate serine dephosphorylation as a possible mechanism.	SALK INST,DEPT CANC BIOL,SAN DIEGO,CA 92186	Salk Institute					NATIONAL CANCER INSTITUTE [R01CA017733, R37CA017733] Funding Source: NIH RePORTER; NCI NIH HHS [CA-17733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT PR, 1985, J BIOL CHEM, V260, P8746; ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; AUTERO M, 1987, EUR J IMMUNOL, V17, P1503, DOI 10.1002/eji.1830171018; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DEBER CM, 1986, BIOCHEM BIOPH RES CO, V134, P731, DOI 10.1016/S0006-291X(86)80481-8; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; OMARY MB, 1980, J BIOL CHEM, V255, P1662; OSTERGAARD H, 1987, J IMMUNOL, V139, P3573; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OSTERGAARD HL, UNPUB; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1991, ADV PROT PHOSPHATASE, V6, P227; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; YAMADA A, 1990, EUR J IMMUNOL, V20, P1655, DOI 10.1002/eji.1830200806	30	109	110	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 20	1991	253	5026					1423	1425		10.1126/science.1654595	http://dx.doi.org/10.1126/science.1654595			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GF851	1654595				2022-12-24	WOS:A1991GF85100043
J	FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R				FERNS, GAA; RAINES, EW; SPRUGEL, KH; MOTANI, AS; REIDY, MA; ROSS, R			INHIBITION OF NEOINTIMAL SMOOTH-MUSCLE ACCUMULATION AFTER ANGIOPLASTY BY AN ANTIBODY TO PDGF	SCIENCE			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN ATHEROSCLEROTIC PLAQUES; CORONARY ANGIOPLASTY; CELL-PROLIFERATION; DIFFERENT ISOFORMS; LESION FORMATION; GENE-EXPRESSION; ARTERIAL INJURY; PLATELET; RAT	Approximately 30 to 40 percent of atherosclerotic coronary arteries treated by angioplasty or by bypass surgery occlude as a result of restenosis. This restenosis is due principally to the accumulation of neointimal smooth muscle cells, which is also a prominent feature of the advanced lesions of atherosclerosis. The factors responsible for the accumulation of intimal smooth muscle cells have not been identified. Platelet-derived growth factor (PDGF) is a potent smooth muscle chemoattractant and mitogen. It is present in platelets and can be formed by endothelium, smooth muscle, and monocyte-derived macrophages. The development of an intimal lesion in the carotid artery of athymic nude rats induced by intraarterial balloon catheter deendothelialization was inhibited by a polyclonal antibody to PDGF. These data demonstrate that endogenous PDGF is involved in the accumulation of neointimal smooth muscle cells associated with balloon injury and may be involved in restenosis after angioplasty, and perhaps in atherogenesis as well.	ST BARTHOLOMEWS HOSP,COLL MED,WILLIAM HARVEY RES INST,LONDON EC1M 6BQ,ENGLAND; ZYMOGENET INC,SEATTLE,WA 98105	University of London; Queen Mary University London; Zymogenet Inc.			Ghayour-Mobarhan, Majid/AAY-5963-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-03174, HL-18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BAUMGART.HR, 1966, PATHOL MICROBIOL, V29, P393, DOI 10.1159/000161922; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; CLOWES AW, 1983, LAB INVEST, V49, P327; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; FELLSTROM B, 1989, TRANSPLANT P, V21, P3689; FERNS GAA, UNPUB; Ferns GAA, 1990, GROWTH FACTORS, V3, P315, DOI 10.3109/08977199009003674; FESTING MFW, 1978, NATURE, V274, P365, DOI 10.1038/274365a0; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FRENS GAA, 1991, AM J PATHOL, V138, P1045; FRIEDMAN RJ, 1977, J CLIN INVEST, V60, P1191, DOI 10.1172/JCI108872; GOLDEN MA, 1991, J CLIN INVEST, V87, P406, DOI 10.1172/JCI115011; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; JAWIEN A, 1991, FASEB J, V55, pA1246; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIMGRUBER PP, 1986, CIRCULATION, V73, P710, DOI 10.1161/01.CIR.73.4.710; LINDNER V, 1991, CIRC RES, V68, P103; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; RAINES E, UNPUB; RAINES EW, 1982, J BIOL CHEM, V257, P5154; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; REIDY MA, 1985, LAB INVEST, V53, P513; REIDY MA, 1981, LAB INVEST, V44, P301; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; STEMERMAN MB, 1972, J EXP MED, V136, P769, DOI 10.1084/jem.136.4.769; VAESSEN LMB, 1986, SCAND J IMMUNOL, V24, P223, DOI 10.1111/j.1365-3083.1986.tb02089.x; WIJNS W, 1985, AM J CARDIOL, V55, P357, DOI 10.1016/0002-9149(85)90375-3; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	40	1012	1107	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1129	1132		10.1126/science.1653454	http://dx.doi.org/10.1126/science.1653454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653454				2022-12-24	WOS:A1991GD80800029
J	KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B				KERNAN, MJ; KURODA, MI; KREBER, R; BAKER, BS; GANETZKY, B			NAPTS, A MUTATION AFFECTING SODIUM-CHANNEL ACTIVITY IN DROSOPHILA, IS AN ALLELE OF MLE, A REGULATOR OF X-CHROMOSOME TRANSCRIPTION	CELL			English	Article							SENSITIVE PARALYTIC MUTANTS; DOSAGE COMPENSATION; MEMBRANE EXCITABILITY; NERVOUS-SYSTEM; MELANOGASTER; BINDING; GENE; RNA; DNA; CONDUCTION	nap(ts) is a recessive mutation that affects the level of sodium channel activity and, at high temperature, causes paralysis associated with a loss of action potentials. We show, by genetic complementation tests, germline transformation, and analysis of mutations, that nap(ts) is a gain-of-function mutation of mle, a gene required for X chromosome dosage compensation and male viability. Molecular analyses of nap and mle mutations indicate that mle+, nap+, and nap(ts) activities are encoded by the same open reading frame and suggest that nap(ts) is due to a single amino acid substitution. Although nap(ts) is known to act via para+, an X-linked sodium channel structural gene, its effect is not due to a simple defect in para+ dosage compensation.	UNIV WISCONSIN,GENET LAB,MADISON,WI 53706; STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94306	University of Wisconsin System; University of Wisconsin Madison; Stanford University	KERNAN, MJ (corresponding author), UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093, USA.			Kernan, Maurice/0000-0002-1546-6159	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015390] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BACHILLER D, 1986, DEV BIOL, V118, P379, DOI 10.1016/0012-1606(86)90007-2; BAKER BS, 1983, ANNU REV GENET, V17, P345, DOI 10.1146/annurev.ge.17.120183.002021; BELOTE JM, 1980, NATURE, V285, P573, DOI 10.1038/285573a0; BELOTE JM, 1980, GENETICS, V96, P165; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; COLQUHOUN D, 1972, J PHYSIOL-LONDON, V221, P533, DOI 10.1113/jphysiol.1972.sp009766; COMPANY M, 1991, NATURE, V349, P497; ELKINS T, 1990, J NEUROGENET, V6, P207, DOI 10.3109/01677069009107111; FUKUNAGA A, 1975, GENETICS, V81, P135; GANETZKY B, 1986, ANNU REV GENET, V20, P13; GANETZKY B, 1984, GENETICS, V108, P897; GANETZKY B, 1982, GENETICS, V100, P597; GOLUBOVSKY MD, 1972, DROS INF SERV, V49, P117; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P8413, DOI 10.1093/nar/17.21.8413; HALL JC, 1982, Q REV BIOPHYS, V15, P223, DOI 10.1017/S0033583500004844; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; JACKSON FR, 1984, NATURE, V308, P189, DOI 10.1038/308189a0; JAFFE E, 1986, TRENDS GENET, V2, P316, DOI 10.1016/0168-9525(86)90287-8; KAUVAR LM, 1982, MOL GEN GENET, V187, P172, DOI 10.1007/BF00384402; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LOUGHNEY K, 1989, MOL BIOL NEURORECEPT, P201; LOVERRE A, 1980, DROS INF SERV, V55, P88; LUCCHESI J C, 1982, Genetics, V100, pS42; LUCCHESI JC, 1987, ADV GENET, V24, P371, DOI 10.1016/S0065-2660(08)60013-9; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MYERS RM, 1985, SCIENCE, V230, P1242, DOI 10.1126/science.4071043; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; ODOWD DK, 1988, J NEUROSCI, V8, P3633; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERN M, 1990, GENETICS, V124, P133; SUZUKI DT, 1971, P NATL ACAD SCI USA, V68, P890, DOI 10.1073/pnas.68.5.890; UCHIDA S, 1981, JPN J GENET, V56, P523, DOI 10.1266/jjg.56.523; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WU CF, 1980, NATURE, V286, P814, DOI 10.1038/286814a0; WU CF, 1983, J NEUROSCI, V3, P1888; WU CF, 1978, P NATL ACAD SCI USA, V75, P4047, DOI 10.1073/pnas.75.8.4047	40	104	108	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					949	959		10.1016/0092-8674(91)90440-A	http://dx.doi.org/10.1016/0092-8674(91)90440-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653649				2022-12-24	WOS:A1991GE46000013
J	HEALY, B				HEALY, B			ON GENE PATENTING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; 1991, OTABA494 OFF TECHN A; 1991, REPORT NATIONAL BIOT; 1992, IBA POSITION PAPER R	5	29	29	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					664	668		10.1056/NEJM199208273270930	http://dx.doi.org/10.1056/NEJM199208273270930			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JK204	1640972	Bronze			2022-12-24	WOS:A1992JK20400034
J	RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG				RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG			THE SERUM-ASCITES ALBUMIN GRADIENT IS SUPERIOR TO THE EXUDATE-TRANSUDATE CONCEPT IN THE DIFFERENTIAL-DIAGNOSIS OF ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC LIVER-DISEASE; PROTEIN-CONCENTRATION; CIRRHOTIC ASCITES; OPSONIC ACTIVITY; MENSTRUAL-CYCLE; FLUID; DIURESIS; BACTERASCITES; SPECTRUM	Objective: To compare the serum-ascites albumin gradient to the exudate-transudate concept in the classification of ascites. Design: Prospective collection of ascitic fluid data from patients with well-characterized causes of ascites. Setting. Hepatology inpatient and outpatient ward and consult service of a large, urban hospital. Patients: A total of 901 paired serum and ascitic fluid samples were collected from consecutive patients with all forms of ascites. Interventions: None. Main Outcome Measures: The utility of the serum-ascites albumin gradient and the old exudate-transudate concept (as defined by ascitic fluid total protein concentration [AFTP]) were compared for their ability in discriminating the cause for ascites formation. Results: The albumin gradient correctly differentiated causes of ascites due to portal hypertension from those that were not due to portal hypertension 96.7% of the time. The AFTP, when used as defined in the old exudate-transudate concept, classified the causes of ascites correctly only 55.6% of the time. This resulted in part because the AFTP of most spontaneously infected samples (traditionally expected to be exudates) was low, and the AFTP of most cardiac ascites samples (traditionally expected to be transudates) was high. Conclusions: The exudate-transudate concept should be discarded in the classification of ascites. The serum-ascites albumin gradient is far more useful than the AFTP as a marker for portal hypertension, but the latter remains a useful adjunct in the differential diagnosis of ascites.	UNIV IOWA, IOWA CITY, IA 52242 USA; UNIV SO CALIF, LIVER UNIT, LOS ANGELES, CA 90089 USA	University of Iowa; University of Southern California								AKRIVIADIS EA, 1990, GASTROENTEROLOGY, V98, P127, DOI 10.1016/0016-5085(90)91300-U; BOUCKAERT PXJM, 1986, J REPROD FERTIL, V77, P329; BOYER TD, 1978, ARCH INTERN MED, V138, P1103, DOI 10.1001/archinte.138.7.1103; BURACK WR, 1960, AM J MED, V28, P510, DOI 10.1016/0002-9343(60)90145-5; CHESON BD, 1985, CLIN LAB MED, V5, P195, DOI 10.1016/S0272-2712(18)30865-5; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; HOEFS JC, 1985, DM-DIS MON, V31, P1, DOI 10.1016/0011-5029(85)90002-1; HOEFS JC, 1983, J LAB CLIN MED, V102, P260; HOEFS JC, 1981, HEPATOLOGY, V1, P249, DOI 10.1002/hep.1840010310; KAJANI MA, 1990, DIGEST DIS SCI, V35, P33, DOI 10.1007/BF01537219; MAATHUIS JB, 1978, J ENDOCRINOL, V76, P123, DOI 10.1677/joe.0.0760123; MAUER K, 1988, DIGEST DIS SCI, V33, P1208, DOI 10.1007/BF01536667; MAUK PM, 1988, ARCH INTERN MED, V148, P1577, DOI 10.1001/archinte.148.7.1577; PARE P, 1983, GASTROENTEROLOGY, V85, P240; POCKROS PJ, 1988, HEPATOLOGY, V8, P1450; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RECTOR WG, 1984, AM J MED, V77, P83, DOI 10.1016/0002-9343(84)90440-6; ROCCO VK, 1986, ANN INTERN MED, V105, P573, DOI 10.7326/0003-4819-105-4-573; ROVELSTAD RA, 1958, GASTROENTEROLOGY, V34, P436; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; RUNYON BA, 1988, J CLIN GASTROENTEROL, V10, P410, DOI 10.1097/00004836-198808000-00013; RUNYON BA, 1986, ARCH INTERN MED, V146, P2173, DOI 10.1001/archinte.146.11.2173; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; RUNYON BA, 1985, HEPATOLOGY, V5, P257, DOI 10.1002/hep.1840050217; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; RUNYON BA, 1984, HEPATOLOGY, V4, P1209, DOI 10.1002/hep.1840040619; RUNYON BA, 1986, HEPATOLOGY, V6, P396, DOI 10.1002/hep.1840060311; RUNYON BA, 1989, GASTROENTEROLOGY, V97, P158, DOI 10.1016/0016-5085(89)91430-3; RUNYON BA, 1987, J CLIN GASTROENTEROL, V9, P172, DOI 10.1097/00004836-198704000-00012; RUNYON BA, 1990, HEPATOLOGY, V12, P710, DOI 10.1002/hep.1840120415; RUNYON BA, 1991, TXB GASTROENTEROLOGY, P846; SAMPLINER RE, 1974, AM J MED SCI, V267, P275, DOI 10.1097/00000441-197405000-00003; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; SPAK I, 1960, ACTA CHIR SCAND    S, V261, P7; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403	35	382	403	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					215	220		10.7326/0003-4819-117-3-215	http://dx.doi.org/10.7326/0003-4819-117-3-215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616215				2022-12-24	WOS:A1992JF30400007
J	BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L				BERGER, SL; PINA, B; SILVERMAN, N; MARCUS, GA; AGAPITE, J; REGIER, JL; TRIEZENBERG, SJ; GUARENTE, L			GENETIC ISOLATION OF ADA2 - A POTENTIAL TRANSCRIPTIONAL ADAPTER REQUIRED FOR FUNCTION OF CERTAIN ACIDIC ACTIVATION DOMAINS	CELL			English	Article							RNA POLYMERASE-II; TATA BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ACCURATE INITIATION; REGULATORY PROTEIN; S-CEREVISIAE; YEAST GENE; BOX FACTOR; CYC1 GENE; DNA	We have devised a genetic strategy to isolate the target of acidic activation domains of transcriptional activators based on toxicity in yeast cells of the chimeric activator, GAL4-VP16. Toxicity required the integrity of both the VP16 acidic activation domain and the GAL4 DNA-binding domain, suggesting that inhibition resulted from trapping of general transcription factors at genomic sites. Mutations that break the interaction between GAL4-VP16 and general factors would alleviate toxicity and identify transcriptional adaptors, if adaptors bridged the interaction between activators and general factors. We thus identified ADA1, ADA2, and ADA3. Mutations in ADA2 reduced the activity of GAL4-VP16 and GCN4 in vivo. ada2 mutant extracts exhibited normal basal transcription, but were defective in responding to GAL4-VP16, GCN4, or the dA:dT activator. Strikingly, the mutant extract responded like wild type to GAL4-HAP4. We conclude that ADA2 potentiates the activity of one class of acidic activation domain but not a second class.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, GENET PROGRAM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University	BERGER, SL (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.		Piña, Benjamin/A-1671-2011	Piña, Benjamin/0000-0001-9216-2768; Silverman, Neal/0000-0002-4259-456X; Triezenberg, Steven/0000-0003-4184-5221; Berger, Shelley/0000-0001-5398-4400	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027323, R21AI027323] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27323] Funding Source: Medline; NIGMS NIH HHS [GM 30454-10] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DEZELEE S, 1989, EMBO J, V8, P3437, DOI 10.1002/j.1460-2075.1989.tb08508.x; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; FASSLER JS, 1988, GENETICS, V118, P203; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GERSTER T, 1988, P NATL ACAD SCI USA, V85, P6347, DOI 10.1073/pnas.85.17.6347; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HINNEBUSCH AG, 1985, P NATL ACAD SCI USA, V82, P498, DOI 10.1073/pnas.82.2.498; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAUGHON A, 1984, MOL CELL BIOL, V4, P260, DOI 10.1128/MCB.4.2.260; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MATSUI T, 1980, J BIOL CHEM, V255, P1992; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOREAU P, 1981, NUCLEIC ACIDS RES, V9, P6047, DOI 10.1093/nar/9.22.6047; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OHARE P, 1988, EMBO J, V7, P4231, DOI 10.1002/j.1460-2075.1988.tb03320.x; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OLESEN J, 1987, CELL, V51, P953, DOI 10.1016/0092-8674(87)90582-4; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; OSBORNE BI, 1988, GENE DEV, V2, P766, DOI 10.1101/gad.2.6.766; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PRESTON CM, 1988, CELL, V52, P425, DOI 10.1016/S0092-8674(88)80035-7; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; ROSE M, 1983, J MOL BIOL, V170, P883, DOI 10.1016/S0022-2836(83)80193-4; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WINSTON F, 1984, GENETICS, V107, P179; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	83	389	409	2	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					251	265		10.1016/0092-8674(92)90100-Q	http://dx.doi.org/10.1016/0092-8674(92)90100-Q			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638630				2022-12-24	WOS:A1992JE75700009
J	LI, E; BESTOR, TH; JAENISCH, R				LI, E; BESTOR, TH; JAENISCH, R			TARGETED MUTATION OF THE DNA METHYLTRANSFERASE GENE RESULTS IN EMBRYONIC LETHALITY	CELL			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DENOVO METHYLATION; RETROVIRAL GENOMES; STEM-CELLS; HOMOLOGOUS RECOMBINATION; DETERMINES METHYLATION; SEQUENCE SPECIFICITY; TRANSGENIC MICE; EXPRESSION; MOUSE	Gene targeting in embryonic stem (ES) cells has been used to mutate the murine DNA methyltransferase gene. ES cell lines homozygous for the mutation were generated by consecutive targeting of both wild-type alleles; the mutant cells were viable and showed no obvious abnormalities with respect to growth rate or morphology, and had only trace levels of DNA methyltransferase activity. A quantitative end-labeling assay showed that the level of m5C in the DNA of homozygous mutant cells was about one-third that of wild-type cells, and Southern blot analysis after cleavage of the DNA with a methylation-sensitive restriction endonuclease revealed substantial demethylation of endogenous retroviral DNA. The mutation was introduced into the germline of mice and found to cause a recessive lethal phenotype. Homozygous embryos were stunted, delayed in development, and did not survive past midgestation. The DNA of homozygous embryos showed a reduction of the level of m5C similar to that of homozygous ES cells. These results indicate that while a 3-fold reduction in levels of genomic m5C has no detectable effect on the viability or proliferation of ES cells in culture, a similar reduction of DNA methylation in embryos causes abnormal development and embryonic lethality.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,HUMAN REPROD & REPROD BIOL LAB,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	LI, E (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043565] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339-05] Funding Source: Medline; NIGMS NIH HHS [GM43565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2536; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JONES PA, 1983, RECENT RES CANCER, V84, P202; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; MANN JR, 1988, DEVELOPMENT, V103, P129; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1987, DEVELOPMENT, V99, P371; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; PFEIFER GP, 1986, BIOCHIM BIOPHYS ACTA, V868, P238, DOI 10.1016/0167-4781(86)90059-X; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHWARZ MB, 1962, J BIOL CHEM, V237, P1961; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STUHLMANN H, 1981, CELL, V26, P221, DOI 10.1016/0092-8674(81)90305-6; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	58	3116	3353	8	212	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					915	926		10.1016/0092-8674(92)90611-F	http://dx.doi.org/10.1016/0092-8674(92)90611-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606615				2022-12-24	WOS:A1992HY79200004
J	ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ				ROTH, J; KEMPF, A; REUTER, G; SCHAUER, R; GEHRING, WJ			OCCURRENCE OF SIALIC ACIDS IN DROSOPHILA-MELANOGASTER	SCIENCE			English	Article							CELL-ADHESION MOLECULE; POLYSIALIC ACID; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; LIMAX-FLAVUS; WILMS TUMOR; GLYCOPROTEINS; LOCALIZATION; ANTIGENS; LECTIN	Sialylated oligosaccharides, which are cell type-specific and developmentally regulated, have been implicated in a variety of complex biological events. Their broad functional importance is reflected by their presence in a wide variety of phyla extending from Echinodermata through higher vertebrates. Here, sialic acids are detected throughout development in an insect, Drosophila. Homopolymers of alpha-2,8-linked sialic acid, polysialic acid, are developmentally regulated and only expressed during early Drosophila development.	UNIV BASEL,BIOCTR,DEPT CELL BIOL,CH-4056 BASEL,SWITZERLAND; UNIV KIEL,INST BIOCHEM,W-2300 KIEL 1,GERMANY	University of Basel; University of Kiel								ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; BERG EL, 1991, J BIOL CHEM, V266, P14869; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CORFIELD AP, 1982, SIALIC ACIDS CHEM ME, P5; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6167, DOI 10.1021/bi00239a013; DAVIDSON DJ, 1991, BIOCHEMISTRY-US, V30, P6689, DOI 10.1021/bi00241a008; DENNIS RD, 1988, J NEUROCHEM, V51, P1490, DOI 10.1111/j.1471-4159.1988.tb01116.x; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FINNE J, 1985, J BIOL CHEM, V260, P1265; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; HALL AK, 1985, DEV BIOL, V110, P39, DOI 10.1016/0012-1606(85)90061-2; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HOFF SD, 1989, CANCER RES, V49, P6883; HUSMANN M, 1990, J HISTOCHEM CYTOCHEM, V38, P209, DOI 10.1177/38.2.1688896; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; KRAUSS JH, 1988, ARCH MICROBIOL, V150, P584, DOI 10.1007/BF00408254; LACKIE PM, 1990, DEVELOPMENT, V110, P933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LIVINGSTON B D, 1990, Glycobiology, V1, P39, DOI 10.1093/glycob/1.1.39; MCKRAKEN GH, 1974, LANCET, V2, P246; MILLER RL, 1982, J BIOL CHEM, V257, P7574; MITCHISON TJ, 1983, DEV BIOL, V99, P261, DOI 10.1016/0012-1606(83)90275-0; MOMOI T, 1986, J BIOL CHEM, V261, P6270; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; NORJIRI H, 1986, P NATL ACAD SCI USA, V83, P782; NUDELMAN ED, 1989, J BIOL CHEM, V264, P18719; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAVINDRANATH MH, 1985, J BIOL CHEM, V260, P8850; REUTER G, 1986, ANAL BIOCHEM, V157, P39, DOI 10.1016/0003-2697(86)90193-4; ROGERS GN, 1985, J BIOL CHEM, V260, P7362; ROGERS GN, 1983, VIROLOGY, V127, P361, DOI 10.1016/0042-6822(83)90150-2; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; ROTH J, 1981, J HISTOCHEM CYTOCHEM, V29, P663, DOI 10.1177/29.5.6166664; ROTH J, 1984, J HISTOCHEM CYTOCHEM, V32, P1167, DOI 10.1177/32.11.6208237; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SHUKLA AK, 1982, J CHROMATOGR, V244, P81, DOI 10.1016/S0021-9673(00)80124-7; SILVER RP, 1981, NATURE, V289, P696, DOI 10.1038/289696b0; TAATJES DJ, 1987, HISTOCHEM J, V19, P235, DOI 10.1007/BF01680634; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISGERBER C, 1991, Glycobiology, V1, P357, DOI 10.1093/glycob/1.4.357	50	146	147	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					673	675		10.1126/science.1585182	http://dx.doi.org/10.1126/science.1585182			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585182				2022-12-24	WOS:A1992HR18500035
J	INGHAM, PW; TAYLOR, AM; NAKANO, Y				INGHAM, PW; TAYLOR, AM; NAKANO, Y			ROLE OF THE DROSOPHILA PATCHED GENE IN POSITIONAL SIGNALING	NATURE			English	Article							SEGMENT POLARITY GENE; SPATIAL-DISTRIBUTION; EMBRYONIC PATTERN; FUSHI-TARAZU; PROTEIN; EXPRESSION; WINGLESS; BLASTODERM; REGION	AFTER cellularization of the Drosophila embryo, positional differences within each primordial segment are maintained and elaborated by processes that require cell interactions. The best-documented examples 1,2 of such intercellular signalling are the mutual interactions between neighbouring cells expressing the homeodomain protein engrailed 3 and the secreted glycoprotein encoded by wingless 4, the Drosophila homologue of the murine Wnt-1 gene 5. Little is known about the molecular basis of these signalling mechanisms but the activities of several other genes, notably patched and hedgehog, have been implicated in the process 1,2. Here we show that the role of patched in positional signalling is permissive rather than instructive, its activity being required to suppress wingless transcription in cells predisposed to express the latter. According to this view, expression of wingless is normally maintained only in those cells receiving an extrinsic signal, encoded by hedgehog, that antagonizes the repressive activity of patched. We suggest that the patched protein may itself be the receptor for this signal, implying that this is an unusual mechanism of ligand-dependent receptor inactivation.			INGHAM, PW (corresponding author), IMPERIAL CANC RES FUND, DEPT ZOOL, DEV BIOL UNIT, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip William/AAH-5884-2020; Ingham, Philip W/G-9903-2011; Ingham, Philip W/E-6710-2010	Ingham, Philip William/0000-0001-8224-9958; Ingham, Philip W/0000-0001-8224-9958; 				ARIAS AM, 1988, DEVELOPMENT, V103, P157; ARIAS AM, 1989, TRENDS GENET, V5, P262, DOI 10.1016/0168-9525(89)90099-1; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; DINARDO S, 1987, GENE DEV, V1, P1212, DOI 10.1101/gad.1.10.1212; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; HOWARD K, 1986, CELL, V44, P949, DOI 10.1016/0092-8674(86)90018-8; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	22	381	399	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 12	1991	353	6340					184	187		10.1038/353184a0	http://dx.doi.org/10.1038/353184a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653906				2022-12-24	WOS:A1991GE73100059
J	LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA				LOEB, DM; MARAGOS, J; MARTINZANCA, D; CHAO, MV; PARADA, LF; GREENE, LA			THE TRK PROTOONCOGENE RESCUES NGF RESPONSIVENESS IN MUTANT NGF-NONRESPONSIVE PC12 CELL-LINES	CELL			English	Article							NERVE GROWTH-FACTOR; FACTOR RECEPTOR; GENE-TRANSFER; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; EXPRESSION; DIFFERENTIATION; SURVIVAL; AFFINITY; RESPOND	The trk tyrosine kinase proto-oncogene product gp140prototrk binds nerve growth factor (NGF) and is rapidly and selectively activated by this neurotrophic factor. To determine whether gp140prototrk is involved in transducing a functional NGF signal, PC12 cell mutants (PC12nnr) deficient in high affinity NGF binding and unresponsive to NGF were used. Northern analysis revealed that these mutant cells have greatly reduced levels of trk expression. PC12nnr cultures were transiently transfected with expression vectors encoding the full-length rat trk cDNA and assessed for responsiveness to NGF. Expression of exogenous trk rescued the capacity for NGF-promoted neurite outgrowth, cellular hypertrophy, and serum-free survival by these cells. These results indicate that gp140prototrk is necessary for functional NGF signal transduction.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032	Columbia University	LOEB, DM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032, USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744	NINDS NIH HHS [NS 27680, NS 21072, NS 16036] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016036, P50NS027680, R01NS021072, P01NS027680] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GORIN PD, 1979, P NATL ACAD SCI USA, V76, P5382, DOI 10.1073/pnas.76.10.5382; GREEN SH, 1986, J BIOL CHEM, V261, P5316; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GREENE LA, 1991, IN PRESS CULTURING N; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LEVI A, 1991, ANNU REV PHARMACOL, V31, P205; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MANIATIS T, 1982, MOL CLONING LABORATO, P383; MARTINEZ HJ, 1985, P NATL ACAD SCI USA, V82, P7777, DOI 10.1073/pnas.82.22.7777; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RUIT KG, 1990, J NEUROSCI, V10, P2412; RUKENSTEIN A, 1991, IN PRESS J NEUROSCI; SOPPET D, 1991, CELL, V65, P895, DOI 10.1016/0092-8674(91)90396-G; VOLONTE C, 1989, J CELL BIOL, V109, P2395, DOI 10.1083/jcb.109.5.2395; Volonte C, 1990, GROWTH FACTORS, V2, P321; YAN Q, 1988, J NEUROSCI, V8, P3481	41	242	243	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 6	1991	66	5					961	966		10.1016/0092-8674(91)90441-Z	http://dx.doi.org/10.1016/0092-8674(91)90441-Z			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GE460	1653650				2022-12-24	WOS:A1991GE46000014
J	FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH				FARCI, P; ALTER, HJ; WONG, D; MILLER, RH; SHIH, JW; JETT, B; PURCELL, RH			A LONG-TERM STUDY OF HEPATITIS-C VIRUS-REPLICATION IN NON-A, NON-B HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODIES; GENOME; BLOOD; CDNA; CHIMPANZEES; SEQUENCE; ANTIGEN; RNA; PCR	Background. Although antibodies to the hepatitis C virus (HCV) are known to be associated with non-A, non-B hepatitis, little is known about the pattern of HCV replication, its relation to antibody levels, and the clinical course of non-A, non-B hepatitis. Methods. We measured HCV RNA in serial serum samples from five patients with post-transfusion non-A, non-B hepatitis who were followed for 1 0 to 14 years after transfusion. We also studied four chimpanzees that were experimentally infected with serum from four of these patients. Serum HCV RNA was detected by a "nested" polymerase-chain-reaction (PCR) assay that used two sets of primers derived from the third (NS3) and fourth (NS4) nonstructural gene regions of the HCV genome. Results. HCV sequences were detected by PCR in only two of the five patients and two of the four chimpanzees with the set of primers corresponding to the NS3 region, but in all five patients (and in all four chimpanzees) with the primers from the NS4 region. Serum HCV RNA was first detected within three weeks of transfusion in all five patients and within one week in three patients. The viremia lasted less than 4 months in the patient (and two chimpanzees) with acute, self-limited hepatitis, whereas it persisted for 10 to 14 years in the four patients (and for 1 and 3 years in two chimpanzees) with chronic non-A, non-B hepatitis. Antibodies to HCV were first detected at week 12 to 14; they disappeared after nine years in the patient with self-limited disease and became borderline after five years in one of the patients with chronic disease. Conclusions. During the early phase of primary HCV infection, there is a period of several months of seronegativity during which HCV RNA is the only diagnostic marker of infection. The disappearance of HCV RNA from serum appears to correlate with the resolution of non-A, non-B hepatitis, whereas viremia persists in patients whose disease progresses to chronic hepatitis. In contrast, antibody levels do not necessarily remain elevated in patients with chronic disease.	NIH,BIOMED ENGN & INSTRUMENTAT BRANCH,WARREN G MAGNUSON CLIN CTR,DEPT TRANSFUS MED,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA	FARCI, P (corresponding author), NIAID,INFECT DIS LAB,HEPATITIS VIRUSES SECT,BLDG 7,RM 202,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Jett, Betsy/AAT-5154-2021					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER HJ, 1978, LANCET, V1, P459; ALTER HJ, 1989, CURRENT PERSPECTIVES, P83; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1989, LANCET, V2, P294; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; GARSON JA, 1990, LANCET, V336, P1022, DOI 10.1016/0140-6736(90)92487-3; HOUGHTON M, 1988, Patent No. 883109225; KANEKO S, 1990, LANCET, V335, P976, DOI 10.1016/0140-6736(90)91042-9; KATO N, 1989, P JPN ACAD B-PHYS, V65, P219, DOI 10.2183/pjab.65.219; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KUBO Y, 1989, NUCLEIC ACIDS RES, V17, P10367, DOI 10.1093/nar/17.24.10367; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, NATURE, V339, P490; MAKRIS M, 1990, LANCET, V335, P1117, DOI 10.1016/0140-6736(90)91124-S; MIYAMURA T, 1990, P NATL ACAD SCI USA, V87, P983, DOI 10.1073/pnas.87.3.983; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; VANDERPOEL CL, 1989, LANCET, V2, P297; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266	25	494	511	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	1991	325	2					98	104		10.1056/NEJM199107113250205	http://dx.doi.org/10.1056/NEJM199107113250205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FV522	1646962				2022-12-24	WOS:A1991FV52200005
J	EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S				EGEBJERG, J; BETTLER, B; HERMANSBORGMEYER, I; HEINEMANN, S			CLONING OF A CDNA FOR A GLUTAMATE RECEPTOR SUBUNIT ACTIVATED BY KAINATE BUT NOT AMPA	NATURE			English	Article							AMINO-ACID RECEPTORS; FUNCTIONAL EXPRESSION; XENOPUS-OOCYTES; KAINIC ACID; NERVOUS-SYSTEM; BINDING-SITES; PHARMACOLOGY; QUISQUALATE; FAMILY; SEQUENCE	FAST excitatory transmission in the vertebrate central nervous system is mediated mainly by L-glutamate. On the basis of pharmacological, physiological and agonist binding properties, the ionotropic glutamate receptors are classified into NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate) and kainate subtypes 1. Sequence homology between complementary DNA clones encoding non-NMDA glutamate receptor subunits reveals at least two subunit classes: the GluR1 to GluR4 class 2-6 and the GluR5 class 7. Here we report the cloning and expression of a functional rat glutamate receptor subunit cDNA, GluR6, which has a very different pharmacology from that of the GluR1-GluR4 class. Receptors generated from the GluR1-GluR4 class have a higher apparent affinity for AMPA than for kainate 3-6. When expressed in Xenopus oocytes the homomeric GluR6 receptor is activated by kainate, quisqualate and L-glutamate but not by AMPA, and the apparent affinity for kainate is higher than for receptors from the GluR1-GluR4 class. Desensitization of the receptor was observed with continuous application of agonist. The homomeric GluR6 glutamate receptor exhibits an outwardly rectifying current-voltage relationship. In situ hybridizations reveal a pattern of GluR6 gene expression reminiscent of the binding pattern obtained with [H-3]kainate.			EGEBJERG, J (corresponding author), SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA.		bettler, bernhard/AAO-8018-2020	Bettler, Bernhard/0000-0003-0842-8207				BENARI Y, 1988, J PHYSIOL-LONDON, V404, P365, DOI 10.1113/jphysiol.1988.sp017294; BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; DAWSON TL, 1990, MOL PHARMACOL, V38, P779; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FOSTER AC, 1984, BRAIN RES REV, V7, P103, DOI 10.1016/0165-0173(84)90020-1; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; MEYER ML, 1989, P NATL ACAD SCI USA, V86, P1411; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; ROBINSON JH, 1981, BRAIN RES, V221, P117, DOI 10.1016/0006-8993(81)91067-2; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; VERDOORN TA, 1988, MOL PHARMACOL, V34, P298; VERDOORN TA, 1989, MOL PHARMACOL, V35, P360; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0	22	581	593	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 27	1991	351	6329					745	748		10.1038/351745a0	http://dx.doi.org/10.1038/351745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648177				2022-12-24	WOS:A1991FU20100064
J	GOODWIN, FK				GOODWIN, FK			PEER-REARED MONKEYS ALCOHOL-PRONE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							HIGHLEY JD, IN PRESS P NATL ACAD	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR835	1646339				2022-12-24	WOS:A1991FR83500007
J	JOHNSON, E				JOHNSON, E			ELEVATED VASOPRESSIN AND BULIMIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1992, J CLIN ENDOCRINOLOGY, V74, P1277	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-24	WOS:A1992JH58800011
J	RIVLIN, RS				RIVLIN, RS			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER		CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	RIVLIN, RS (corresponding author), MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUNK MJ, 1989, P SOC EXP BIOL MED, V190, P379; COWDEN WB, 1987, T ROY SOC TROP MED H, V81, P533, DOI 10.1016/0035-9203(87)90395-6; DOWLING HJ, 1991, CLIN RES, V39, pA645; DUTTA P, 1991, J PROTOZOOL, V38, P479, DOI 10.1111/j.1550-7408.1991.tb04820.x; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HOUMARD JA, 1991, INT J OBESITY, V15, P181; NEWMARK HL, 1991, AM J CLIN NUTR, V54, pS209, DOI 10.1093/ajcn/54.1.209S; RIVLIN RS, 1991, AM J CLIN NUTR, V54, pS177; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SERES DS, 1991, NUTR RES, V11, P337, DOI 10.1016/S0271-5317(05)80309-4; WEINHOUSE S, 1991, CA-CANCER J CLIN, V41, P334, DOI 10.3322/canjclin.41.6.334	12	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					382	383		10.1001/jama.268.3.382	http://dx.doi.org/10.1001/jama.268.3.382			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613928				2022-12-24	WOS:A1992JC35200040
J	YOUNG, MP				YOUNG, MP			OBJECTIVE ANALYSIS OF THE TOPOLOGICAL ORGANIZATION OF THE PRIMATE CORTICAL VISUAL-SYSTEM	NATURE			English	Article							RHESUS-MONKEY; CORTEX; CONNECTIONS; MACAQUE; PATHWAYS; AREAS	THE primate cortical visual system is composed Of many structurally and functionally distinct areas 1-3, each receiving and sending about 10 projections from and to other cortical areas 1. The visual cortex is thus served by many cortico-cortical connections to form a network of considerable complexity. Thus the gross organization of this cortical processing system presents a formidable topological problem: although the spatial Position of the areas in the brain is reasonably well established, the gross 'processing architecture' defined by the connections, is less well understood. Here I report an optimization approach that gives both qualitative and quantitative insight into the connectional topology of the primate cortical visual system. This approach supports suggestions that the system is divided into a dorsal 'stream' and a ventral 'stream' with limited cross-talk, that these two streams reconverge in the region of the principal sulcus (area 46) and in the superior temporal polysensory areas, that the system is hierarchically organized, and that the majority of the connections are from 'nearest-neighbour' and 'next-door-but-one' areas.			YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							BAIZER JS, 1991, J NEUROSCI, V11, P168; BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; CROCK F, 1991, COLD SPRING HARB SYM, V55, P953; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Edgington E. S., 1980, RANDOMIZATION TESTS; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GOWER JC, 1975, PSYCHOMETRIKA, V40, P33, DOI 10.1007/BF02291478; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; Norusis M.J., 1990, SPSS BASE SYSTEM USE; PETERS A, 1985, CEREBRAL CORTEX; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHONEMAN P, 1970, PSYCHOMETRIKA, V31, P1; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; SHEPARD RN, 1962, PSYCHOMETRIKA, V27, P125, DOI 10.1007/BF02289630; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; Young F. W., 1990, SPSS BASE SYSTEM USE, P396; YOUNG FW, 1979, MULTIDIMENSIONAL SCA; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1990, THESIS ST ANDREWS U; YOUNG MP, 1991, SOC NEUR ABS, V17; YOUNG MP, IN PRESS J NEUROPHYS; YOUNG MP, IN PRESS BRAIN MECHA; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	30	337	346	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					152	155		10.1038/358152a0	http://dx.doi.org/10.1038/358152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614547				2022-12-24	WOS:A1992JC58300052
J	NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH				NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH			INVIVO CALCIUM ELEVATIONS IN THYMOCYTES WITH T-CELL RECEPTORS THAT ARE SPECIFIC FOR SELF LIGANDS	SCIENCE			English	Article							TRANSGENIC MICE; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; TOLERANCE; EXPRESSION; REACTIVITY; SELECTION; PRODUCTS; DELETION; IMMATURE	Selection of the T cell receptor (TCR) repertoire in the thymus probably involves TCR-mediated signals transduced in developing thymocytes after interaction with thymic stromal cells bearing self ligands. TCR-transduced signals should have identifiable consequences that would distinguish thymocytes whose TCRs have been engaged by self ligands from those whose TCRs have not. Among thymocytes expressing a transgenic TCR of defined specificity, a large number had elevated intracellular calcium concentrations but only when resident in a negatively selecting thymus in which their self ligand was expressed. Thus, developing thymocytes are stimulated by endogenous ligands in vivo to mobilize intracellular calcium, and increased intracellular calcium concentrations may reflect the consequences of intrathymic signaling associated with thymic negative selection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10 ROOM 4B-17,BETHESDA,MD 20892; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy			Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; Nakayama T, UNPUB; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Singer A., 1986, PROG IMMUNOL, V6, P60; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z	20	68	70	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					96	99		10.1126/science.1621102	http://dx.doi.org/10.1126/science.1621102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621102				2022-12-24	WOS:A1992JC16500039
J	ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S				ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S			PRIMARY VENTRICULAR-TACHYCARDIA IN ACUTE MYOCARDIAL-INFARCTION - CLINICAL CHARACTERISTICS AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; TACHYCARDIA; HEART VENTRICLE; DEATH, SUDDEN; HEMODYNAMICS	FIBRILLATION; PROGNOSIS; ARRHYTHMIAS; REPERFUSION	Objective: To examine the immediate and long-term clinical and prognostic significance of primary ventricular tachycardia, defined as tachycardia of ventricular origin occurring within 48 hours of acute myocardial infarction in patients without hemodynamic compromise (Killip class I). Design: Prospective cohort study. Setting: Intensive coronary care units in eight regional, referral, and university hospitals. Patients: A total of 162 patients with primary ventricular tachycardia, both sustained and nonsustained (study group), and 2578 counterparts without ventricular tachycardia (reference group). Measurements: In-hospital rates of atrial fibrillation, atrioventricular block, congestive heart failure, cardiogenic shock, and cardiac arrest. In-hospital and 1-year follow-up rates of sudden death, nonsudden cardiac death, and noncardiac death. Results: The study and reference groups had similar mortality (in-hospital, 6.8% and 9.6%, P > 0.2 and at 1 year after discharge, 3.7% and 5.4%, P > 0.2, respectively) and in-hospital complication rates (atrioventricular block, 13.0% and 9.7%, P > 0.2; cardiogenic shock, 3.7% and 3.0%, P > 0.2; cardiac arrest, 1.8% and 4.4%, P > 0.2, respectively). Patients with sustained ventricular tachycardia (28 patients) compared with those with nonsustained ventricular tachycardia (134 patients) had higher rates of polymorphic tachycardia (50% compared with 6%, P = 0.001), in-hospital total cardiac mortality (21 % compared with 4%, P = 0.003) and sudden-death mortality (14% compared with 2%, P = 0.001); they also showed a trend toward a higher in-hospital mortality than the reference group (21.4% compared with 9.6%, P = 0.15) but had no increased mortality 1 year after discharge (4.6% compared with 5.4%, P > 0.2). Conclusions: As a group, patients with primary ventricular tachycardia do not differ from counterparts without primary ventricular tachycardia in their in-hospital clinical course and 1-year prognosis. Primary sustained ventricular tachycardia is often polymorphic and carries worse in-hospital prognosis than nonsustained tachycardia. However, it does not predict recurrent ventricular tachycardia or increased sudden-death rates during the next year.			ELDAR, M (corresponding author), CHAIM SHEBA MED CTR, NEUFELD CARDIAC RES CTR, NEUFELD CARDIAC RES INST, IL-52621 TEL HASHOMER, ISRAEL.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BEHAR S, 1990, AM J CARDIOL, V66, P1208, DOI 10.1016/0002-9149(90)91101-B; BEHAR S, 1988, EUR HEART J, V9, P354; Bishop YM., 2007, DISCRETE MULTIVARIAT; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOROWITZ LN, 1981, CIRCULATION, V63, P1120, DOI 10.1161/01.CIR.63.5.1120; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; LAWRIE DM, 1968, LANCET, V2, P523; LIE K I, 1974, European Journal of Cardiology, V1, P379; MILLER FC, 1986, AM HEART J, V112, P928, DOI 10.1016/0002-8703(86)90302-9; NICOD P, 1988, J AM COLL CARDIOL, V11, P464, DOI 10.1016/0735-1097(88)91518-5; TCHOU P, 1989, Journal of the American College of Cardiology, V13, p21A; TOFLER GH, 1987, AM J CARDIOL, V60, P755, DOI 10.1016/0002-9149(87)91018-6; TYE KH, 1979, AM J CARDIOL, V44, P632, DOI 10.1016/0002-9149(79)90280-7; VOLPI A, 1987, NEW ENGL J MED, V317, P257, DOI 10.1056/NEJM198707303170501; VOLPI A, 1989, AM J CARDIOL, V63, P1174, DOI 10.1016/0002-9149(89)90174-4; 1985, SAS USERS GUIDE STAT, P403; 1985, SAS USERS GUIDE STAT, P171	22	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					31	36		10.7326/0003-4819-117-1-31	http://dx.doi.org/10.7326/0003-4819-117-1-31			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596045				2022-12-24	WOS:A1992JA43500005
J	PHILPOTT, A; LENO, GH				PHILPOTT, A; LENO, GH			NUCLEOPLASMIN REMODELS SPERM CHROMATIN IN XENOPUS EGG EXTRACTS	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HISTONE COMPLEXES; LAEVIS OOCYTES; ACIDIC PROTEIN; NUCLEI; FERTILIZATION; DNA; REPLICATION; TRANSITIONS; CLEAVAGE	Nucleoplasmin is necessary and sufficient for the initial stage of Xenopus sperm decondensation in egg extracts. In this article we show that sperm decondensation is accompanied by loss of two sperm-specific basic proteins (X and Y) and gain of histones H2A and H2B, resulting in nucleosome formation. Purified nucleoplasmin alone removes X and Y and assembles purified H2A and H2B on decondensing sperm chromatin, forming nucleosome cores. Immunodepletion of nucleoplasmin from extract prevents removal of X and Y and addition of H2A and H2B, while adding back nucleoplasmin restores decondensation and X and Y removal. Thus, nucleoplasmin acts as both an assembly and a disassembly factor for remodeling sperm chromatin at fertilization.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOLS NC, 1972, CAN J ZOOLOG, V50, P171, DOI 10.1139/z72-026; BOLS NC, 1973, CAN J ZOOL, V51, P203, DOI 10.1139/z73-029; DEAN J, 1983, DEV BIOL, V99, P210, DOI 10.1016/0012-1606(83)90269-5; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; GORDON K, 1985, EXP CELL RES, V157, P409, DOI 10.1016/0014-4827(85)90126-0; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; POCCIA D, 1984, DEV BIOL, V104, P274, DOI 10.1016/0012-1606(84)90083-6; POCCIA D, 1981, DEV BIOL, V82, P287, DOI 10.1016/0012-1606(81)90452-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P769; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	32	202	210	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					759	767		10.1016/0092-8674(92)90288-N	http://dx.doi.org/10.1016/0092-8674(92)90288-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591776				2022-12-24	WOS:A1992HW83800007
J	JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP				JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP			TARGETING ASTHMA CARE IN GENERAL-PRACTICE USING A MORBIDITY INDEX	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; MANAGEMENT; MORTALITY; PATIENT; TRENDS; RATES; AUDIT	Objectives-To evaluate a morbidity index as a postal surveillance tool in defining previously diagnosed asthmatic patients needing extra education or management; to determine the accuracy of a computerised asthma register in general practice. Design-Postal questionnaire survey of asthmatic patients identified from a computer register. Questionnaire comprised three morbidity questions, two questions about current asthma status, and one about treatments. Setting-Urban general practice of 8400 patients linked to academic unit. Subjects-853 asthmatic patients of all ages. Main outcome measures-Numbers of patients with low, medium, and high morbidity; associations of these groups with age, asthma status, and drugs taken. Results-Two mailings yielded 621 replies (73%); 28 patients (5%) had moved away, leaving 593 for analysis. Attempts were subsequently made to contact 20% sample of non-respondents. 234 respondents (40%) were in the "low morbidity" group, 149 (25%) in the "medium morbidity" group, and 210 (35%) in the "high morbidity" category. 53% of patients perceiving themselves as currently asthmatic (193/362) were in the high morbidity group, but 7% (11/153) who said they were no longer asthmatic and 8% (6/78) who did not believe they had ever been asthmatic were also in that group. High morbidity was also found in 10% (18/185) of those on no treatment, 38% (59/154) of those on bronchodilators alone, and 54% (119/220) of those on inhaled corticosteroids. 25 patients (4%) were wrongly identified as asthmatic; when combined with returns marked "gone away" this gave a disease register accuracy of 91%. Conclusions-This exercise identified subgroups of previously diagnosed asthmatic patients with high morbidity in general practice who might benefit from extra education and management and revealed some misclassification on the asthma disease register.			JONES, KP (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6ST,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P651; ASTHMA, 1992, ARCH DIS CHILD, V67, P240; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1991, THORAX, V46, P574, DOI 10.1136/thx.46.8.574; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P256; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; JONES K, 1991, BRIT J GEN PRACT, V41, P224; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; JONES KP, 1992, BRIT MED J, V304, P361, DOI 10.1136/bmj.304.6823.361; JONES KP, 1991, THORAX, V46; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STANLEY PH, 1991, BRIT MED J, V303, P971, DOI 10.1136/bmj.303.6808.971; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1990, BMJ, V301, P797	34	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1353	1356		10.1136/bmj.304.6838.1353	http://dx.doi.org/10.1136/bmj.304.6838.1353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611335	Green Published, Bronze			2022-12-24	WOS:A1992HW41700026
J	MACKIE, RM; HOLE, D				MACKIE, RM; HOLE, D			AUDIT OF PUBLIC-EDUCATION CAMPAIGN TO ENCOURAGE EARLIER DETECTION OF MALIGNANT-MELANOMA	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To evaluate a public campaign to encourage earlier referral and treatment of primary cutaneous malignant melanoma and thus reduce mortality related to melanoma. Design - Production and distribution of educational material aimed at adults. Update information sent to general practitioners before campaign. Analysis of data on melanoma before and after campaign in June 1985. Setting - West of Scotland, population 2.7 million. Main outcome measures - Total numbers of referrals per month to melanoma clinic, numbers of melanomas diagnosed, change in distribution of thickness, and mortality before and after introducing the campaign. Results - Referrals to the pigmented lesion clinic increased by 278%, from five a week in June-July 1984 to 19 a week in June-July 1985. Twice as many women as men were referred to the clinic (49% of referrals were of women aged under 65). The numbers of newly diagnosed primary cutaneous melanoma were 63 (12/month) in January-May 1985 and 146 (21/month) in June-December 1985, an increase of 131%. The percentage of tumours detected that were less than 1.5 mm thick rose significantly by 16% (95% confidence interval 11% to 19%), from 38% (328) in 1979-84 to 54% (592) in 1985-9. Mortality began to fall in women from 1988. Conclusions - The public education campaign succeeded in reducing the absolute number of thick tumours and melanoma related mortality in women.	GREATER GLASGOW HLTH BOARD,CANC SURVEILLANCE UNIT,GLASGOW,SCOTLAND		MACKIE, RM (corresponding author), UNIV GLASGOW,DEPT DERMATOL,GLASGOW G12 8QQ,SCOTLAND.							Cox DR., 1970, ANAL BINARY DATA; DOHERTY VR, 1986, BRIT MED J, V292, P987, DOI 10.1136/bmj.292.6526.987; DOHERTY VR, 1988, BRIT MED J, V297, P388, DOI 10.1136/bmj.297.6645.388; FIELD SI, 1987, J AM ACAD DERMATOL, V16, P578, DOI 10.1016/S0190-9622(87)70077-2; MACKIE RM, IN PRESS LANCET; MCLEOD GR, 1988, PIGMENT CELL, V9, P131; SMITH T, 1979, BRIT MED J, V1, P253, DOI 10.1136/bmj.1.6158.253	7	166	167	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1012	1015		10.1136/bmj.304.6833.1012	http://dx.doi.org/10.1136/bmj.304.6833.1012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586781	Green Published			2022-12-24	WOS:A1992HQ14200017
J	RUTALA, WA; WEBER, DJ				RUTALA, WA; WEBER, DJ			INFECTIOUS WASTE - MISMATCH BETWEEN SCIENCE AND POLICY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; MICROBIAL-CONTAMINATION; HOSPITAL INCINERATOR; HOUSEHOLD REFUSE; UNITED-STATES; MANAGEMENT; EMISSION; BACTERIA; HIV-1				RUTALA, WA (corresponding author), UNIV N CAROLINA,CHAPEL HILL,NC 27599, USA.							ALLEN RJ, 1989, JAPCA J AIR WASTE MA, V39, P164, DOI 10.1080/08940630.1989.10466516; ALTHAUS H, 1983, ZBL BAKT MIK HYG B, V178, P1; BARBA PD, 1987, NOV MID AIR POLL CON; BECK M, 1989, NEWSWEEK        1127, P75; Beck Melinda, 1989, NEWSWEEK, P66; BLENKHARN JI, 1989, J HOSP INFECT, V14, P73, DOI 10.1016/0195-6701(89)90137-0; COOPER RC, 1975, WATER RES, V9, P733, DOI 10.1016/0043-1354(75)90065-2; DONNELLY JA, 1984, EPA600824119 MUN ENV; DRIVER JH, 1989, 1989 P INT C U CAL I; ENGELBRECHT RS, 1974, VIRUS SURVIVAL WATER, P201; GARNER JS, 1985, INFECTIVE WASTE GUID; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAGER E, 1989, ZBL HYG UMWELTMED, V188, P343; KALNOWSKI G, 1983, ZBL BAKT MIK HYG B, V178, P364; KARPIAK J, 1991, AM J INFECT CONTROL, V19, P8, DOI 10.1016/0196-6553(91)90155-6; LEE HH, 1990, J INFECT DIS, V162, P347, DOI 10.1093/infdis/162.2.347; MARCHESE JT, 1990, 3RD INT C NOS INF AT; MOSE JR, 1985, ZBL BAKT MIK HYG B, V181, P98; OHARA K, 1989, TRASH AM BEACHES NAT; PAHREN HR, 1987, CRC CRIT R ENVIRON, V7, P187; RESNICK L, 1986, JAMA-J AM MED ASSOC, V255, P1887, DOI 10.1001/jama.255.14.1887; RICHARDSON JH, 1988, HHS NIH888395 DEP HL; RUTALA WA, 1989, JAMA-J AM MED ASSOC, V262, P1635, DOI 10.1001/jama.262.12.1635; RUTALA WA, 1983, INFECT CONT HOSP EP, V4, P198, DOI 10.1017/S0195941700058227; RUTALA WA, 1987, ASEPSIS, V9, P2; RUTALA WA, 1987, CLIN CRITICAL CARE M, V12, P131; SLADE JS, 1989, WATER SCI TECHNOL, V21, P55, DOI 10.2166/wst.1989.0078; SLAVIK N, 1988, HLTH FACILITIES  SEP, P22; SOBSEY MD, 1978, AM J PUBLIC HEALTH, V68, P858, DOI 10.2105/AJPH.68.9.858; SOBSEY MD, 1975, APPL MICROBIOL, V30, P565, DOI 10.1128/AEM.30.4.565-574.1975; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; 1990, PUBLIC HLTH IMPLICAT; 1988, STATE INFECTIOUS WAS; 1990, OTA0459 OFF TECHN AS; 1989, INVENTORY MED WASTE; 1986, EPA530SW86014 REP; 1989, FED REGISTER, V54, P12326; 1990, EPA530SW90087A INT R; 1990, EPA530SW90051A INT R; 1987, MMWR S2S, V36, P3; 1988, INVESTIGATION SOURCE; 1989, SUMMARY POTENTIAL RI	42	24	24	1	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 22	1991	325	8					578	582		10.1056/NEJM199108223250811	http://dx.doi.org/10.1056/NEJM199108223250811			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB447	1649972	Green Submitted			2022-12-24	WOS:A1991GB44700011
J	SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE				SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE			HIGH-RISK OF ACTIVE TUBERCULOSIS IN HIV-INFECTED DRUG-USERS WITH CUTANEOUS ANERGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; AIDS EPIDEMIC; PROGRAM	Objectives.-To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results. Design and Setting.-Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31 -month study period ended December 31, 1990. Methods.-Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4+ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status. Results.-Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4+ cells (median 0.33 vs 0.56 x 10(9)/L, P<.01) compared with tuberculin reactors, although neither clinical status nor CD4+ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n=18) or of unknown (n=34) HIV serological status developed active tuberculosis during the study period (P<.05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [CI], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 1 00 person-years (95% CI, 2.6 to 24.7; P=0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% CI, 1.3 to 18.0). Conclusion.-Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,BRONX,NY 10461	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [R01DA04347] Funding Source: Medline; PHS HHS [U62/CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BIRX D, 1989, 5 INT C AIDS MONTR; BLATT SP, 1991, 7TH INT C AIDS FLOR; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; COHEN J, 1990, 6TH INT C AIDS SAN F; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; MARKOWITZ N, 1991, 7 INT C AIDS FLOR; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1990, MMWR, V39, P718; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P214; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1991, NEW YORK STATE J MED, V91, P233; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1990, 6TH INT C AIDS SAN F; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WADHAWAN D, 1990, 6TH INT C AIDS SAN F; WIERZBA TP, 1991, 7TH INT C AIDS FLOR; 1991, MMWR, V40, P649; 1990, MMWR SRR17, V39, P1; 1987, MMWR, V36, P785; 1989, MMWR, V38, P236; 1991, MMWR, V40, P585; 1990, MMWR SRR8, V39, P1; 1991, MMWR SRR5, V40, P27; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1990, TUBERCULOSIS NEW YOR; 1990, MMWR, V39, P638	39	261	265	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					504	509		10.1001/jama.268.4.504	http://dx.doi.org/10.1001/jama.268.4.504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619742				2022-12-24	WOS:A1992JD47200025
J	WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U				WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U			HSP90 CHAPERONES PROTEIN FOLDING INVITRO	NATURE			English	Article							HEAT-SHOCK PROTEINS; LIGHT-CHAIN	THE heat-shock protein Hsp90 is the most abundant constitutively expressed stress protein in the cytosol of eukaryotic cells 1,2, where it participates in the maturation of other proteins, modulation of protein activity in the case of hormone-free steroid receptors, and intracellular transport of some newly synthesized kinases 3-5. A feature of all these processes could be their dependence on the formation of protein structure. If Hsp90 is a molecular chaperone involved in maintaining a certain subset of cellular proteins in an inactive form, it should also be able to recognize and bind non-native proteins, thereby influencing their folding to the native state. Here we investigate whether Hsp90 can influence protein folding in vitro and show that Hsp90 suppresses the formation of protein aggregates by binding to the target proteins at a stoichiometry of one Hsp90 dimer to one or two substrate molecule(s). Furthermore, the yield of correctly folded and functional protein is increased significantly. The action of Hsp90 does not depend on the presence of nucleoside triphosphates, so it may be that Hsp90 uses a novel molecular mechanism to assist protein folding in vivo.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM,BIOCHEM ABT 2,W-3400 GOTTINGEN,GERMANY	University of Regensburg; University of Gottingen			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SCHMIDT M, IN PRESS J BIOL CHEM; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P4367; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WEST SM, 1988, BIOCHEM J, V251, P135, DOI 10.1042/bj2510135; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	18	441	452	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					169	170		10.1038/358169a0	http://dx.doi.org/10.1038/358169a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614549				2022-12-24	WOS:A1992JC58300059
J	ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ				ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ			SHIGELLA-FLEXNERI INDUCES APOPTOSIS IN INFECTED MACROPHAGES	NATURE			English	Article							LISTERIA-MONOCYTOGENES; PLASMID; SPREAD; GROWTH; CELLS; ACTIN	THE Gram-negative bacterial pathogen Shigella flexneri causes dysentery by invading the human colonic mucosa 1. Bacteria are phagocytosed by enterocytes 2, escape from the phagosome into the cytoplasm 3 and spread to adjacent cells 4. After crossing the epithelium, Shigella reaches the lamina propria of intestinal villi, the first line of defence. This tissue is densely populated with phagocytes that are killed in great numbers, resulting in abscesses 5,6. The genes required for cell invasion 7 and macrophage killing 2 are located on a 220-kilobase plasmid. We report here on the mechanism of cytotoxicity used by S. flexneri to kill macrophages. Each of four different strains was tested for its capacity to induce cell death. An invasive strain induced programmed cell death (apoptosis 8,9), whereas its non-invasive, plasmid-cured isogenic strain was not toxic; neither was a mutant in ipa B (ref. 10) (invasion protein antigen), a gene necessary for entry. A non-invasive strain expressing the haemolysin operon of Escherichia coli 11 induced accidental cell death (necrosis), demonstrating that other bacterial cytotoxic mechanisms do not lead to apoptosis. This is the first evidence that an invasive bacterial pathogen can induce suicide in its host cells.	INST PASTEUR, INSERM,U199,UNITE PATHOGENIE MICROBIENNE MOLEC, 25-28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CENT MICROSCOPIE ELECTR STN, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ANAND BS, 1986, GASTROENTEROLOGY, V90, P654, DOI 10.1016/0016-5085(86)91120-0; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CLERC PL, 1987, INFECT IMMUN, V55, P521, DOI 10.1128/IAI.55.3.521-527.1987; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MATHAN MM, 1991, REV INFECT DIS, V13, pS314; NOEGEL A, 1979, MOL GEN GENET, V175, P343, DOI 10.1007/BF00397234; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; Tanenbaum SW, 1978, CYTOCHALASINS BIOCH; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WARING P, 1990, J BIOL CHEM, V265, P14476; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	18	757	808	10	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					167	169		10.1038/358167a0	http://dx.doi.org/10.1038/358167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614548				2022-12-24	WOS:A1992JC58300058
J	MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J				MORCOS, SK; ELNAHAS, AM; BROWN, P; HAYLOR, J			EFFECT OF IODINATED WATER-SOLUBLE CONTRAST-MEDIA ON URINARY PROTEIN ASSAYS	BRITISH MEDICAL JOURNAL			English	Letter							TESTS				MORCOS, SK (corresponding author), NO GEN HOSP,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.							DAWSON P, 1985, BRIT J RADIOL, V58, P785, DOI 10.1259/0007-1285-58-692-785-b; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mutzel W, 1989, Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd, V128, P101; SHANAHAN JC, 1985, BRIT J RADIOL, V58, P389, DOI 10.1259/0007-1285-58-688-389-b	4	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					29	29		10.1136/bmj.305.6844.29-a	http://dx.doi.org/10.1136/bmj.305.6844.29-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638196	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JC79900029
J	KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR				KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR			RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE	NATURE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PROTEIN; CLONING; ENZYME; CELLS	THE macrolide rapamycin induces cell cycle G1 arrest in yeast and in mammalian cells 1-3, which suggests that an evolutionarily conserved, rapamycin-sensitive pathway may regulate entry into S phase. In mammals, rapamycin inhibits interleukin-2 receptor-induced S phase entry and subsequent T-cell proliferation 4-6, resulting in immunosuppression. Here we show that interleukin-2 selectively stimulates the phosphorylation and activation of p70 S6 kinase but not the erk-encoded MAP kinases and rsk-encoded S6 kinases 7,8. Rapamycin completely and rapidly inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase at concentrations comparable to those blocking S phase entry of T cells (0.05-0.2 nM). The structurally related macrolide FK506 competitively antagonizes the actions of rapamycin, indicating that these effects are mediated by FKBP, which binds the transition-state mimic structure common to both rapamycin and FK506 (refs 4, 6, 9-11). The selective blockade of the p70 S6 kinase activation cascade by the rapamycin-FKBP complex implicates this signalling pathway in the regulation of T cell entry into S phase.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	KUO, CJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305, USA.			Fiorentino, David/0000-0001-7951-3674; Kuo, Calvin/0000-0002-7427-5985				BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1991, CANCER CELL, V3, P1; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, IN PRESS CELL; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0	23	582	596	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					70	73		10.1038/358070a0	http://dx.doi.org/10.1038/358070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614535				2022-12-24	WOS:A1992JB34100056
J	OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP				OKEEFFE, ST; TSAPATSARIS, NP; BEETHAM, WP			INCREASED PREVALENCE OF MIGRAINE AND CHEST PAIN IN PATIENTS WITH PRIMARY RAYNAUD DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						RAYNAUDS DISEASE; MIGRAINE; CHEST PAIN; VASOCONSTRICTION; HEADACHE	VARIANT ANGINA; FIBROMYALGIA; POPULATION; HEADACHES; DISORDER; SPASM	Objective: To investigate the prevalence of headaches and recurrent chest pain in patients with primary Raynaud disease. Design: Postal survey. Setting: Raynaud disease clinic at the Lahey Clinic Medical Center, a tertiary care hospital. Participants: A consecutive series of 120 patients with primary Raynaud disease who had been observed for at least 2 years, 97 of whom received and 93 of whom completed the questionnaire, and a control group of 93 age- and sex-matched hospital employees with Raynaud phenomenon. Results: Migraine was diagnosed in 57 (61%) patients with primary Raynaud disease and in 21 (23%) of the control group (odds ratio, 5.4; 95% Cl, 2.8 to 10.3). Migraine with aura and migraine without aura were more common in patients with Raynaud disease than in the control subjects (27% compared with 5%; P < 0.001 and 34% compared with 17%; P = 0.008, respectively). Nonmigrainous headaches were more common in the control group (51% compared with 25%; P = 0.003). Chest pains were reported by 44 (47%) of the patients with Raynaud disease and by 15 (16%) of the control group (odds ratio, 4.4; Cl, 2.4 to 9.3). Chest pains were more frequently reported by patients with Raynaud disease who had migraine (34 of 57, 60%) than by patients without migraine (10 of 36, 28%; P = 0.003). Conclusions: An increased prevalence of migraine was found in patients with primary Raynaud disease. Chest pain, often diagnosed as musculoskeletal or nonspecific, was common in patients with primary Raynaud phenomenon, especially in patients who had coexisting migraine.	LAHEY CLIN MED CTR, VASC MED & HYPERTENS SECT, 41 MALL RD, BURLINGTON, MA 01805 USA	Lahey Hospital & Medical Center				O'Keeffe, Shaun/0000-0002-7682-5004				APPENZELLER O, 1963, J NEUROL NEUROSUR PS, V26, P447, DOI 10.1136/jnnp.26.5.447; COFFMAN JD, 1975, PROG CARDIOVASC DIS, V18, P123, DOI 10.1016/0033-0620(75)90002-X; COFFMAN JD, 1989, RAYNAUDS PHENOMENON, P3; DALESSANDRO R, 1988, J NEUROL NEUROSUR PS, V51, P21, DOI 10.1136/jnnp.51.1.21; FAM AG, 1985, CAN MED ASSOC J, V133, P379; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; ISENBERG DA, 1982, ANN RHEUM DIS, V41, P30, DOI 10.1136/ard.41.1.30; LEPPERT J, 1987, ANGIOLOGY, V38, P871, DOI 10.1177/000331978703801201; LEVINE PR, 1989, SOUTHERN MED J, V82, P580, DOI 10.1097/00007611-198905000-00010; MARICQ HR, 1986, J CHRON DIS, V39, P423, DOI 10.1016/0021-9681(86)90109-8; MARKUS HS, 1992, J NEUROL, V239, P39, DOI 10.1007/BF00839210; MASERI A, 1987, J AM COLL CARDIOL, V9, P249, DOI 10.1016/S0735-1097(87)80372-8; MILLER D, 1981, NEW ENGL J MED, V304, P763, DOI 10.1056/NEJM198103263041306; OLESEN J, 1987, ARCH NEUROL-CHICAGO, V44, P321, DOI 10.1001/archneur.1987.00520150061023; PAL B, 1989, ANN RHEUM DIS, V48, P312, DOI 10.1136/ard.48.4.312; PELLEGRINO MJ, 1990, ARCH PHYS MED REHAB, V71, P526; PRIOLLET P, 1987, AM J MED, V83, P494, DOI 10.1016/0002-9343(87)90760-1; RASKIN NH, 1988, HEADACHE, P99; ROBERTSON D, 1978, LANCET, V1, P452; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P645; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; SILMAN A, 1990, BMJ-BRIT MED J, V301, P590, DOI 10.1136/bmj.301.6752.590; TAYLOR PJ, 1970, BRIT J IND MED, V27, P364; WATERS WE, 1975, J NEUROL NEUROSUR PS, V38, P613, DOI 10.1136/jnnp.38.6.613; WELCH KMA, 1987, ARCH NEUROL-CHICAGO, V44, P323, DOI 10.1001/archneur.1987.00520150063024; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; ZAHAVI I, 1984, ARCH INTERN MED, V144, P742, DOI 10.1001/archinte.144.4.742	27	53	53	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				985	989		10.7326/0003-4819-116-12-985	http://dx.doi.org/10.7326/0003-4819-116-12-985			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586109				2022-12-24	WOS:A1992HY79300006
J	GEIST, V				GEIST, V			ENDANGERED SPECIES AND THE LAW	NATURE			English	Editorial Material											GEIST, V (corresponding author), UNIV CALGARY,FAC ENVIRONM DESIGN,CALGARY T2N 1N4,ALBERTA,CANADA.							BARTOS L, 1981, ZOOL ANZ, V207, P260; BARTOS L, 1981, ZOOL ANZEIGER JENA, V208, P30; BARTOS L, 1981, ZOOL ANZEIGER JENA, V207, P217; GEIST V, 1991, CAN J ZOOL, V69, P706, DOI 10.1139/z91-103; GEIST V, 1991, ARCTIC, V44, P287; GITTLEMAN JL, 1991, NATURE, V351, P524, DOI 10.1038/351524a0; HALTENORTH T, 1963, HDB ZOOLOGIE, V1, P1; HARRINGTON S, 1982, I FOREST, V30, P64; HIRSCH J, 1976, SAG RAC REL ABSTR, V6, P1; LEHMAN N, 1991, EVOLUTION, V45, P104, DOI 10.1111/j.1558-5646.1991.tb05270.x; NADLER C F, 1973, Zeitschrift fuer Saeugetierkunde, V38, P109; OBRIEN SJ, 1991, SCIENCE, V251, P1187, DOI 10.1126/science.251.4998.1187; RENNIE J, 1991, SCI AM, V256, P18; SMITH MH, 1986, J MAMMAL, V67, P103, DOI 10.2307/1381006; SMITH MH, 1985, WHITE TAILED DEER, P119; WAYNE RK, 1991, NATURE, V351, P565, DOI 10.1038/351565a0	16	32	40	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 28	1992	357	6376					274	276		10.1038/357274a0	http://dx.doi.org/10.1038/357274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW132	1589032				2022-12-24	WOS:A1992HW13200018
J	HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H				HOCH, B; MAIER, RM; APPEL, K; IGLOI, GL; KOSSEL, H			EDITING OF A CHLOROPLAST MESSENGER-RNA BY CREATION OF AN INITIATION CODON	NATURE			English	Article							NUCLEOTIDE-SEQUENCE; PLANT-MITOCHONDRIA; GENE ORGANIZATION; DNA-SEQUENCE; GENOME; MAIZE; MAP	PRIMARY mRNA transcripts in several systems are edited by single base substitutions, small deletions or insertions to yield functional messenger RNA species 1,2. Mitochondrial mRNAs in particular, including those from plants 3-5, seem to be the subject of extensive editing, unlike mRNAs encoded by chloroplast DNA, for which the prediction of amino-acid sequence from the corresponding gene sequence is generally unambiguous 6-8. Occasionally, however, an ACG codon appears at the 5' terminus of chloroplast genes, where the initiation codon ATG would be expected. Here we present evidence for a C --> U editing that is responsible for the conversion of the ACG codon to an AUG initiation codon in the mRNA transcript from the rpl2 gene of the maize plastome, showing that mRNA editing can also occur in chloroplasts.			HOCH, B (corresponding author), UNIV FREIBURG,INST BIOL 3,SCHANZLE STR 1,W-7800 FREIBURG,GERMANY.		/ABF-9144-2020					ANSORGE W, 1986, J BIOCHEM BIOPH METH, V13, P315, DOI 10.1016/0165-022X(86)90038-2; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; FOX TD, 1981, CELL, V26, P315, DOI 10.1016/0092-8674(81)90200-2; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; KAVOUSI M, 1990, NUCLEIC ACIDS RES, V18, P4244, DOI 10.1093/nar/18.14.4244; LARRINUA IM, 1983, PLANT MOL BIOL, V2, P129, DOI 10.1007/BF01578513; LONSDALE DM, 1983, CELL, V34, P1007, DOI 10.1016/0092-8674(83)90558-5; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; PRUITT KD, 1991, CURR GENET, V19, P191, DOI 10.1007/BF00336486; SCHUSTER W, 1991, PHYSIOL PLANTARUM, V81, P437, DOI [10.1111/j.1399-3054.1991.tb08754.x, 10.1034/j.1399-3054.1991.810321.x]; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; STERN DB, 1982, NATURE, V299, P698, DOI 10.1038/299698a0; STERN DB, 1986, NUCLEIC ACIDS RES, V14, P5651, DOI 10.1093/nar/14.14.5651; [No title captured]	18	263	290	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					178	180		10.1038/353178a0	http://dx.doi.org/10.1038/353178a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653905				2022-12-24	WOS:A1991GE73100057
J	MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM				MANGELSDORF, DJ; UMESONO, K; KLIEWER, SA; BORGMEYER, U; ONG, ES; EVANS, RM			A DIRECT REPEAT IN THE CELLULAR RETINOL-BINDING PROTEIN TYPE-II GENE CONFERS DIFFERENTIAL REGULATION BY RXR AND RAR	CELL			English	Article							ACID-RESPONSIVE ELEMENT; THYROID-HORMONE; NUCLEAR RECEPTORS; SMALL-INTESTINE; BETA-GENE; EXPRESSION; IDENTIFICATION; CLONING	The vitamin A derivative retinoic acid exerts its effects on transcription through two distinct classes of nuclear receptors, the retinoic acid receptor (RAR) and the retinoid X receptor (RXR). We provide evidence that expression of the gene for cellular retinol-binding protein type II (CRBPII), a key protein in the intestinal absorption of vitamin A, is dramatically up-regulated by retinoic acid in the presence of RXR but not RAR. This regulation is conferred through a specific cis element in the CRBPII promoter that contains five nearly perfect tandem repeats of the sequence AGGTCA spaced by a single nucleotide. The discovery of this new RX response element provides a means for distinguishing between the two retinoid receptor systems and suggests that an RXR-mediated pathway exists for modulating vitamin A metabolism.	SALK INST BIOL STUDIES,LA JOLLA,CA 92186	Salk Institute	MANGELSDORF, DJ (corresponding author), HOWARD HUGHES MED INST,LA JOLLA,CA 92186, USA.		Evans, Ronald/AAF-4001-2019; Borgmeyer, Uwe/D-4662-2012	Evans, Ronald/0000-0002-9986-5965; Borgmeyer, Uwe/0000-0003-3727-4083; Mangelsdorf, David/0000-0002-4355-0796				BETTLER B, 1990, NEURON, V5, P583, DOI 10.1016/0896-6273(90)90213-Y; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; DEMMER LA, 1987, J BIOL CHEM, V262, P2458; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1991, TRANSCRIPTIONAL REGU; ONG DE, 1987, ARCH DERMATOL, V123, P1693, DOI 10.1001/archderm.123.12.1693; ONG DE, 1987, J BIOL CHEM, V262, P2729; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; Sporn M.B., 1984, RETINOIDS, V1-2; SPORN MB, 1984, RETINOIDS, V2; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559	29	622	659	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					555	561		10.1016/0092-8674(81)90018-0	http://dx.doi.org/10.1016/0092-8674(81)90018-0			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651173				2022-12-24	WOS:A1991GA94100016
J	JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC				JUSTEMENT, LB; CAMPBELL, KS; CHIEN, NC; CAMBIER, JC			REGULATION OF B-CELL ANTIGEN RECEPTOR SIGNAL TRANSDUCTION AND PHOSPHORYLATION BY CD45	SCIENCE			English	Article							PROTEIN TYROSINE PHOSPHORYLATION; LEUKOCYTE-COMMON ANTIGEN; MURINE LYMPHOCYTES-B; HUMAN T-CELLS; MOLECULAR-COMPONENTS; ACTIVATION; IGM; PHOSPHATASE; ANTIBODIES; T200	CD45 is a member of a family of membrane proteins that possess phosphotyrosine phosphatase activity, and is the source of much of the tyrosine phosphatase activity in lymphocytes. In view of its enzymatic activity and high copy number, it seems likely that CD45 functions in transmembrane signal transduction by lymphocyte receptors that arc coupled to activation of tyrosine kinases. The B cell antigen receptor was found to transduce a Ca2+-mobilizing signal only if cells expressed CD45. Also, both membrane immunoglobulin M (mIgM) and CD45 were lost from the surface of cells treated with antibody to CD45, suggesting a physical interaction between these proteins. Finally, CD45 dephosphorylated a complex of mIg-associated proteins that appears to function in signal transduction by the antigen receptor. These data indicate that CD45 occurs as a component of a complex of proteins associated with the antigen receptor, and that CD45 may regulate signal transduction by modulating the phosphorylation state of the antigen receptor subunits.	UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver			Campbell, Kerry S./T-1381-2019	Cambier, John/0000-0002-7803-242X; Justement, Louis/0000-0001-7058-867X	NIAID NIH HHS [AI20519, AI21768] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021768, R01AI020519] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRAMEAS S, 1979, J IMMUNOL, V122, P648; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P399; CAMBIER JC, 1991, J IMMUNOL, V146, P2075; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, IN PRESS P NATL ACAD; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GRUBER MF, 1989, J IMMUNOL, V142, P4144; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HOMBACH J, 1990, EUR J IMMUNOL, V20, P2795, DOI 10.1002/eji.1830201239; JOHNSON P, 1989, J EXP MED, V169, P1179, DOI 10.1084/jem.169.3.1179; JUSTEMENT LB, 1990, J IMMUNOL, V144, P3272; JUSTEMENT LB, UNPUB; KIENER PA, 1989, J IMMUNOL, V143, P23; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LANE PJL, 1990, J IMMUNOL, V144, P3684; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; MIRE AR, 1985, BIOCHIM BIOPHYS ACTA, V847, P159, DOI 10.1016/0167-4889(85)90169-7; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; NISHIBE S, 1990, SCIENCE, V250, P153; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297; WIENANDS J, 1990, EMBO J, V9, P449, DOI 10.1002/j.1460-2075.1990.tb08130.x; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	35	308	314	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1839	1842		10.1126/science.1648262	http://dx.doi.org/10.1126/science.1648262			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648262				2022-12-24	WOS:A1991FU06100037
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			THE VECTOR OF THE LYME-DISEASE SPIROCHETE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,W-1000 BERLIN 33,GERMANY.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					542	542						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635568				2022-12-24	WOS:A1992JJ45700007
J	CATES, W; HINMAN, AR				CATES, W; HINMAN, AR			AIDS AND ABSOLUTISM - THE DEMAND FOR PERFECTION IN PREVENTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; METHADONE TREATMENT; HIV INFECTION; NOTIFICATION; RISK				CATES, W (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; ANGELL M, 1991, NEW ENGL J MED, V325, P811; BRANDT EN, 1988, PUBLIC HEALTH REP, V103, P339; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; Francois-Marie Arouet, 1764, DICT PHILOS; Gerstein D., 1990, TREATING DRUG PROBLE; HOUSTON S, 1991, NEW ENGL J MED, V325, P810; LAMBERT B, 1990, NY TIMES, P1; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; NEWMEYER JA, 1988, J PSYCHOACTIVE DRUGS, V20, P159, DOI 10.1080/02791072.1988.10524488; NOBLE RC, 1991, NEWSWEEK        0401, P8; OHI G, 1988, LANCET, V2, P947; PERRY S, 1989, HOSP COMMUNITY PSYCH, V40, P158; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; ROTHENBERG RB, 1990, SEXUALLY TRANSMITTED, P1081; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SCHLESINGER AM, 1989, BROWN ALUMNI MONTHLY, V42, P37; SIEGEL JE, 1991, AM J PUBLIC HEALTH, V81, P1273, DOI 10.2105/AJPH.81.10.1273; TOOMEY KE, 1988, NEW ENGL J MED, V319, P442; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VLAHOV D, 1991, EPIDEMIOLOGY, V2, P444, DOI 10.1097/00001648-199111000-00010; WYKOFF RF, 1991, SEX TRANSM DIS, V18, P217, DOI 10.1097/00007435-199110000-00004; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1990, METHADONE MAINTENANC, P30; 1991, MMWR MORB MORTAL WKL, V40	29	43	44	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					492	494		10.1056/NEJM199208133270711	http://dx.doi.org/10.1056/NEJM199208133270711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH340	1625740				2022-12-24	WOS:A1992JH34000011
J	JAGADEESH, B; GRAY, CM; FERSTER, D				JAGADEESH, B; GRAY, CM; FERSTER, D			VISUALLY EVOKED OSCILLATIONS OF MEMBRANE-POTENTIAL IN CELLS OF CAT VISUAL-CORTEX	SCIENCE			English	Article							DEPENDENT NEURONAL OSCILLATIONS; RESPONSES; MODEL	In response to visual stimulation, cells of the cat visual cortex fire rhythmically at frequencies between 30 and 60 hertz. This rhythmic firing can be synchronized among cells in widespread areas of the visual cortex. The visual stimulus conditions under which this process occurs suggest that the synchronization may contribute to the integration of information across broadly displaced parts of the visual field. An intricate mechanism must control the regularity of firing and its synchronization. In vivo whole-cell patch recordings from cells in area 17 have now shown that robust oscillations of membrane potential underlie the regularity of firing seen extracellularly. In the cells studied, the characteristics of the oscillations of membrane potential suggest that such oscillations are produced by rhythmic activity in synaptic inputs. These rhythmic synaptic inputs form the most likely mechanism for the synchronization of activity in neighboring cortical cells.	SALK INST BIOL STUDIES,SAN DIEGO,CA 92138	Salk Institute	JAGADEESH, B (corresponding author), NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208, USA.				NATIONAL EYE INSTITUTE [R29EY008686, R01EY004726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY04726, R29 EY08686] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; ARIEL M, 1983, VISION RES, V23, P1485, DOI 10.1016/0042-6989(83)90160-8; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; FERSTER D, 1990, VISUAL NEUROSCI, V4, P115, DOI 10.1017/S0952523800002285; FERSTER D, 1983, J PHYSIOL-LONDON, V342, P181, DOI 10.1113/jphysiol.1983.sp014846; FERSTER D, 1992, J NEUROSCI, V12, P1262; Freeman WJ, 1975, MASS ACTION NERVOUS; FUSTER JOAQUIN M., 1965, Z VER GLEICHENDE PHYSIOL, V49, P605, DOI 10.1007/BF00367161; GHOSE GM, 1990, SOC NEUR ABSTR, V16, P523; GRAY CM, 1990, EUR J NEUROSCI, V2, P607, DOI 10.1111/j.1460-9568.1990.tb00450.x; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; GRAY CM, 1992, INDUCED RHYTHMS BRAI, P29; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAGADEESH B, UNPUB; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; LLINAS RR, 1991, P NATL ACAD SCI USA, V88, P897, DOI 10.1073/pnas.88.3.897; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VANDERMALSBURG C, 1985, BER BUNSEN PHYS CHEM, V89, P703; VANDERMALSBURG C, 1981, CORRELATION THEORY B; VANDERMALSBURG C, 1986, BRAIN THEORY, P161; WILSON HR, 1972, BIOPHYS J, V12, P1, DOI 10.1016/S0006-3495(72)86068-5	31	128	131	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					552	554		10.1126/science.1636094	http://dx.doi.org/10.1126/science.1636094			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636094				2022-12-24	WOS:A1992JE75500036
J	MELDRUM, FC; HEYWOOD, BR; MANN, S				MELDRUM, FC; HEYWOOD, BR; MANN, S			MAGNETOFERRITIN - INVITRO SYNTHESIS OF A NOVEL MAGNETIC PROTEIN	SCIENCE			English	Article							FE(OH)2 SUSPENSIONS; AIR OXIDATION; IRON(II) ION; FERRITIN; FE3O4	The iron storage protein ferritin consists of a spherical polypeptide shell (apoferritin) surrounding a 6-nanometer inorganic core of the hydrated iron oxide ferrihydrite (5Fe2O3.9H2O). Previous studies have shown that the in vitro reconstitution of apoferritin yields mineral cores essentially identical to those of the native proteins. A magnetic mineral was synthesized within the nanodimensional cavity of horse spleen ferritin by the use of controlled reconstitution conditions. Transmission electron microscopy and electron diffraction analysis indicate that the entrapped mineral particles are discrete 6-nanometer spherical single crystals of the ferrimagnetic iron oxide magnetite (Fe3O4). The resulting magnetic protein, "magnetoferritin," could have uses in biomedical imaging, cell labeling, and separation procedures.	UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath			Mann, Stephen/D-1332-2012; Meldrum, Fiona C/E-2726-2014	Mann, Stephen/0000-0003-3012-8964; Meldrum, Fiona/0000-0001-9243-8517				BUTLER RF, 1975, J GEOPHYS RES, V80, P4049, DOI 10.1029/JB080i029p04049; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; KEMP W, 1986, NMR CHEM MULTINUCLEA, P154; KIYAMA M, 1974, B CHEM SOC JPN, V47, P1646, DOI 10.1246/bcsj.47.1646; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIVNE E, 1986, J HISTOCHEM CYTOCHEM, V34, P167, DOI 10.1177/34.2.3944455; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MANN S, 1989, J CHEM SOC FARAD T 1, V85, P3033, DOI 10.1039/f19898503033; Mann S., 1989, BIOMINERALIZATION CH; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, UNPUB; MOLDAY RS, 1977, NATURE, V268, P437, DOI 10.1038/268437a0; OZAKI M, 1985, J COLLOID INTERF SCI, V107, P199, DOI 10.1016/0021-9797(85)90162-6; TAMAURA Y, 1983, J CHEM SOC DALTON, P189, DOI 10.1039/dt9830000189; TAMAURA Y, 1981, J CHEM SOC DALTON, P1807, DOI 10.1039/dt9810001807; TAYLOR RM, 1984, CLAY CLAY MINER, V32, P167, DOI 10.1346/CCMN.1984.0320302; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; ZHAO XK, 1990, J PHYS CHEM-US, V94, P2373	20	503	530	3	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					522	523		10.1126/science.1636086	http://dx.doi.org/10.1126/science.1636086			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636086				2022-12-24	WOS:A1992JE75500025
J	BRADLEY, DJ; KJELLBOM, P; LAMB, CJ				BRADLEY, DJ; KJELLBOM, P; LAMB, CJ			ELICITOR-INDUCED AND WOUND-INDUCED OXIDATIVE CROSS-LINKING OF A PROLINE-RICH PLANT-CELL WALL PROTEIN - A NOVEL, RAPID DEFENSE RESPONSE	CELL			English	Article							NODULIN TRANSCRIPT ENOD2; PARENCHYMA INNER CORTEX; SOYBEAN ROOT-NODULES; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; PHASEOLUS-VULGARIS; GLYCOPROTEIN GENE; SALICYLIC-ACID; EXPRESSION; PEA	Treatment of bean or soybean cells with fungal elicitor or glutathione causes a rapid insolubilization of preexisting (hydroxy)proline-rich structural proteins in the cell wall. This insolubilization, which involves H2O2-mediated oxidative cross-linking, is initiated within 2 min and is complete within 10 min under optimal conditions, and hence, precedes the expression of transcription-dependent defenses. Cross-linking is also under developmental control during hypocotyl growth and in tissues subject to mechanical stress such as the stem-petiole junction. Stimulus-dependent oxidative cross-linking of wall structural proteins is a novel site of cellular regulation with potentially important functions in cell maturation and toughening of cell walls in the initial stages of plant defense.	SALK INST BIOL STUDIES,PLANT BIOL LAB,LA JOLLA,CA 92037	Salk Institute			poinssot, benoit/B-2569-2009	poinssot, benoit/0000-0001-5890-4318				APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; AYERS AR, 1976, PLANT PHYSIOL, V57, P760, DOI 10.1104/pp.57.5.760; BIGGS KJ, 1990, PLANT PHYSIOL, V92, P197, DOI 10.1104/pp.92.1.197; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; CORBIN DR, 1987, MOL CELL BIOL, V7, P4337, DOI 10.1128/MCB.7.12.4337; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; CRAMER CL, 1985, EMBO J, V4, P285, DOI 10.1002/j.1460-2075.1985.tb03627.x; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; Dixon R A, 1990, Adv Genet, V28, P165; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HONG JC, 1989, PLANT CELL, V1, P937, DOI 10.1105/tpc.1.9.937; HONG JC, 1990, J BIOL CHEM, V265, P2470; Hurn B A, 1980, Methods Enzymol, V70, P104; KELLER B, 1989, P NATL ACAD SCI USA, V86, P1529, DOI 10.1073/pnas.86.5.1529; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KELLER B, 1988, EMBO J, V7, P3625, DOI 10.1002/j.1460-2075.1988.tb03243.x; KELLER B, 1989, EMBO J, V8, P1309, DOI 10.1002/j.1460-2075.1989.tb03510.x; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; NORMAN PM, 1986, PLANTA, V167, P452, DOI 10.1007/BF00391220; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SAUER N, 1990, PLANT CELL ENVIRON, V13, P257, DOI 10.1111/j.1365-3040.1990.tb01310.x; SCHEEL D, 1991, ADV MOL GENETICS PLA, V1, P373; SEQUEIRA L, 1983, ANNU REV MICROBIOL, V37, P51, DOI 10.1146/annurev.mi.37.100183.000411; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SHENG J, 1991, PLANT J, V3, P345; SMITH JA, 1991, PHYSIOL MOL PLANT P, V38, P232; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH KA, 1989, EMBO J, V8, P335, DOI 10.1002/j.1460-2075.1989.tb03382.x; VANDEWIEL C, 1990, EMBO J, V9, P1; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206	47	981	1053	2	120	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					21	30		10.1016/0092-8674(92)90530-P	http://dx.doi.org/10.1016/0092-8674(92)90530-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623521				2022-12-24	WOS:A1992JC95700005
J	SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B				SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B			DISTRIBUTED NEURAL NETWORK UNDERLYING MUSICAL SIGHT-READING AND KEYBOARD PERFORMANCE	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; AGRAPHIA; ALEXIA; LOCALIZATION; ACTIVATION; COMPOSER; APHASIA	Music, like other forms of expression, requires specific skills for its production, and the organization and representation of these skills in the human brain are not well understood. With the use of positron emission tomography and magnetic resonance imaging, the functional neuroanatomy of musical sight-reading and keyboard performance was studied in ten professional pianists. Reading musical notations and translating these notations into movement patterns on a keyboard resulted in activation of cortical areas distinct from, but adjacent to, those underlying similar verbal operations. These findings help explain why brain damage in musicians may or may not affect both verbal and musical functions depending on the size and location of the damaged area.			SERGENT, J (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,COGNIT NEUROSCI LAB,MONTREAL H3A 2B4,QUEBEC,CANADA.							ALAJOUANINE T, 1948, BRAIN, V71, P229, DOI 10.1093/brain/71.3.229; [Anonymous], 1977, MUSIC BRAIN; BASSO A, 1985, J NEUROL NEUROSUR PS, V48, P407, DOI 10.1136/jnnp.48.5.407; Benton AL, 1977, MUSIC AND THE BRAIN, P378; BERNSTEIN L., 1976, UNANSWERED QUESTION; BRUST JCM, 1980, BRAIN, V103, P367, DOI 10.1093/brain/103.2.367; Damasio H, 1989, LESION ANAL NEUROPSY; DELIEGE C, 1984, FONDEMENTS MUSIQUE T; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1991, J CEREBR BLOOD F MET, V11, pA79, DOI 10.1038/jcbfm.1991.41; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JUDD T, 1983, BRAIN, V106, P435, DOI 10.1093/brain/106.2.435; Lerdahl F., 1983, GENERATIVE GRAMMAR T; LURIA AL, 1965, J NEUROL SCI, P288; Marin O., 1982, PSYCHOL MUSIC, P453; MARIN OSM, 1980, DEEP DYSLEXIA, P407; Marnat Marcel, 1986, RAVEL; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROELTGEN DP, 1984, BRAIN, V107, P811, DOI 10.1093/brain/107.3.811; ROSENTHAL M, 1987, MONDE MUS, V103, P114; SERGENT J, 1992, CEREB CORTEX, V2, P68, DOI 10.1093/cercor/2.1.68; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SERGENT J, 1989, HDB NEUROPSYCHOLOGY, P69; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SIGNORET JL, 1987, REV NEUROL-FRANCE, V143, P172; SLOBODA J, 1978, PSYCHOL MUSIC, V9, P1; Sloboda J. A., 1985, MUSICAL MIND COGNITI; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; Weiskrantz L., 1968, ANAL BEHAV CHANGE, P400	41	197	198	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					106	109		10.1126/science.1621084	http://dx.doi.org/10.1126/science.1621084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	JC165	1621084				2022-12-24	WOS:A1992JC16500042
J	FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T				FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T			THE DROSOPHILA HOMOLOG OF THE IMMUNOGLOBULIN RECOMBINATION SIGNAL BINDING-PROTEIN REGULATES PERIPHERAL NERVOUS-SYSTEM DEVELOPMENT	CELL			English	Article							SMALL AUTOSOMAL REGION; LARGE TRANSPOSING ELEMENT; SCUTE GENE-COMPLEX; LOOP-HELIX PROTEINS; ALCOHOL-DEHYDROGENASE; STRUCTURAL GENE; NEGATIVE REGULATOR; MELANOGASTER; DNA; MUTATIONS	The J(kappa) RBP binds to the immunoglobulin recombination signal sequence flanking the kappa-type J segment. We previously isolated the highly conserved homolog of the J(kappa) RBP gene from D. melanogaster, which is not thought to have immunoglobulin molecules. Using many deficiency mutants and in situ hybridization, we mapped the Drosophila J(kappa) RBP gene in a region containing two recessive lethal mutations, i.e., br26 and br7, which shows the dominant Suppressor of Hairless (Su(H)) phenotype in heterozygotes. All six Su(H) alleles analyzed at the DNA level contained mutations in the Drosophila J(kappa) RBP gene. Since the Su(H) mutation affects peripheral nervous system development, the Drosophila J(kappa) RBP gene product is involved in gene regulation of peripheral nervous system development. The results also imply that the immunoglobulin recombination signal sequence and the target sequence of the Drosophila J(kappa) RBP protein might have a common evolutionary origin.			FURUKAWA, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ASHBURNER M, 1982, GENETICS, V102, P401; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1982, GENETICS, V101, P447; ASHBURNER M, 1983, GENETICS, V104, P405; ASHBURNER M, 1982, GENETICS, V102, P421; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANG AG, 1991, DEVELOPMENT, V111, P89; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GUBB D, 1986, GENETICS, V112, P551; GUBB D, 1985, CHROMOSOMA, V92, P116, DOI 10.1007/BF00328463; GUBB D, 1984, CHROMOSOMA, V91, P54, DOI 10.1007/BF00286485; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KAWAICHI M, 1991, J BIOL CHEM, V266, P18387; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P844, DOI 10.1073/pnas.82.3.844; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P2082, DOI 10.1073/pnas.82.7.2082; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1984, GENETICS, V106, P249; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NASH D, 1990, GENETICS, V64, P471; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; ODONNELL JD, 1977, GENETICS, V86, P533; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAGER J, 1988, EMBO J, V7, P2409, DOI 10.1002/j.1460-2075.1988.tb03086.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WOODRUFF RC, 1979, GENETICS, V92, P133; WOODRUFF RC, 1979, GENETICS, V92, P117	50	114	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1191	1197		10.1016/0092-8674(92)90640-X	http://dx.doi.org/10.1016/0092-8674(92)90640-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617729				2022-12-24	WOS:A1992JA43100013
J	POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM				POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM			3-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 BY MULTIDIMENSIONAL HETERONUCLEAR MAGNETIC-RESONANCE SPECTROSCOPY	SCIENCE			English	Article							RESTRAINED MOLECULAR-DYNAMICS; CYTOKINE RECEPTOR SUPERFAMILY; CELL-STIMULATING FACTOR; 2D NMR-SPECTRA; DISTANCE GEOMETRY; FACTOR-I; COUPLING-CONSTANTS; HYDROGEN-EXCHANGE; PROTEINS; ASSIGNMENT	The three-dimensional solution structure of recombinant human interleukin-4, a protein of 133 residues and 15.4 kilodaltons that plays a key role in the immune and inflammatory systems, has been solved by multidimensional heteronuclear magnetic resonance spectroscopy. The structure is dominated by a left-handed four-helix bundle with an unusual topology comprising two overhand connections. The linker elements between the helices are formed by either long loops, small helical turns, or short strands. The overall topology is remarkably similar to that of growth hormone and granulocyte-macrophage colony stimulating factor, despite the absence of any sequence homology, and substantial differences in the relative lengths of the helices, the length and nature of the various connecting elements, and the pattern of disulfide bridges. These three proteins, however, bind to cell surface receptors belonging to the same hematopoietic superfamily, which suggests that interleukin-4 may interact with its receptor in an analogous manner to that observed in the crystal structure of the growth hormone-extracellular receptor complex.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA; IMMUNEX CORP, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Immunex Corporation			Powers, Robert/AAK-3431-2020; Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018	Powers, Robert/0000-0001-9948-6837; Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI KI, 1990, ANNU REV BIOCHEM, V59, P7983; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHICHE L, 1990, P NATL ACAD SCI USA, V87, P3240, DOI 10.1073/pnas.87.8.3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GARRETT DS, 1992, BIOCHEMISTRY-US, V31, P4347, DOI 10.1021/bi00132a027; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; POWERS R, 1992, BIOCHEMISTRY-US, V31, P4334, DOI 10.1021/bi00132a026; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	50	150	164	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1673	1677		10.1126/science.256.5064.1673	http://dx.doi.org/10.1126/science.256.5064.1673			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609277	Green Published			2022-12-24	WOS:A1992HZ17400043
J	DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL				DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL			INVOLVEMENT OF P21RAS IN ACTIVATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE-2	NATURE			English	Article							INSULIN; PHOSPHORYLATES; STIMULATION	MANY growth factors upon stimulation of their receptors induce the activity of extracellular signal-regulated kinases, ERKs, also known as MAP kinases 1,2. Several of these growth factors also activate the ras proto-oncogene product, p21ras (Ras), by stimulating the conversion of the inactive GDP-bound form of Ras to the active GTP-bound form 3-6. We have shown that direct introduction of p21ras oncoprotein into cells in the absence of growth factors activates ERKs within five minutes 7, which indicates that normal p21ras may be involved in the activation of ERKs by growth factors. Here we use a recombinant vaccinia virus expressing an interfering mutant of p21ras, Ras(Asn17), to investigate this question. In NIH3T3 cells that overexpress the insulin receptor, this recombinant virus inhibits insulin-induced activation of ERK2 completely, but there is no inhibition of insulin-induced activation of phosphatidyl-inositol-3-kinase. In rat-1 cells the recombinant virus inhibited ERK2 activity induced by platelet-derived growth factor (PDGF) but not by phorbol ester. We conclude that p21ras mediates insulin- and PDGF-induced activation of ERK2.	CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK	DEVRIESSMITS, AMM (corresponding author), UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Mackett M., 1985, DNA CLONING PRACTICA, P191; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OSTEROP APR, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STACEY DW, 1991, ONCOGENE, V6, P2297; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0	23	387	388	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					602	604		10.1038/357602a0	http://dx.doi.org/10.1038/357602a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608472				2022-12-24	WOS:A1992HZ11200058
J	RICE, WR				RICE, WR			SEXUALLY ANTAGONISTIC GENES - EXPERIMENTAL-EVIDENCE	SCIENCE			English	Article								When selection differs between the sexes, a mutation beneficial to one sex may be harmful to the other (sexually antagonistic). Because the sexes share a common gene pool, selection in one sex can interfere with the other's adaptive evolution. Theory predicts that sexually antagonistic mutations should accumulate in tight linkage with a new sex-determining gene, even when the harm to benefit ratio is high. Genetic markers and artificial selection were used to make a pair of autosomal genes segregate like a new pair of sex-determining genes in a Drosophila melanogaster model system. A 29-generation study provides experimental evidence that sexually antagonistic genes may be common in nature and will accumulate in response to a new sex-determining gene.			RICE, WR (corresponding author), UNIV CALIF SANTA CRUZ,BIOL BOARD STUDIES,SANTA CRUZ,CA 95064, USA.							Bull J. J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH D, 1980, GENET RES, V35, P205, DOI 10.1017/S0016672300014051; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; KIDWELL JF, 1973, GENETICS, V85, P171; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANDEL SPH, 1971, HEREDITY, V26, P49, DOI 10.1038/hdy.1971.5; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; SPEITH HT, 1983, GENETICS BIOL DROSOP, V3, pCH23	10	239	240	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1436	1439		10.1126/science.1604317	http://dx.doi.org/10.1126/science.1604317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604317				2022-12-24	WOS:A1992HX33700033
J	TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ				TOKARS, JI; BELL, DM; CULVER, DH; MARCUS, R; MENDELSON, MH; SLOAN, EP; FARBER, BF; FLIGNER, D; CHAMBERLAND, ME; MCKIBBEN, PS; MARTONE, WJ			PERCUTANEOUS INJURIES DURING SURGICAL-PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-B; RISK; TRANSMISSION; OPERATIONS; INFECTION; SURGEONS	Objective. --To study the numbers and circumstances of percutaneous injuries (eg, needle sticks, cuts) that occur during surgical procedures. Surgical personnel risk infection with blood-borne pathogens from percutaneous injuries; some injuries might also place patients at risk by exposing them to a health care worker's blood. Design. --Observers present at 1382 surgical procedures recorded information about the procedure, the personnel present, and percutaneous injuries that occurred. Setting. --Four US teaching hospitals during 1990. Participants. --Operating room personnel in five surgical specialties. Main Outcome Measures. --Numbers and circumstances of percutaneous injuries among surgical personnel and instances in which surgical instruments that had injured a worker recontacted the patient's surgical wound. Results. --Ninety-nine injuries occurred during 95 (6.9%) of the 1382 procedures. Seventy-six injuries (77%) were caused by suture needles and affected the nondominant hand (62 injuries [63%]), especially the distal forefinger. The risk of injury adjusted for confounding variables by logistic regression was higher during vaginal hysterectomy (odds ratio [OR], 3.5; 95% confidence interval [Cl], 1.6 to 7.5) and lower during certain orthopedic procedures (OR, 0.2; Cl, 0.1 to 0.7) than during 11 other types of procedures (reference group; OR, 1.0). Use of fingers rather than an instrument to hold the tissue being sutured was associated with 35 injuries (35%). Eighty-eight injuries (89%) were sustained by resident or attending surgeons; in 28 (32%) of the 88 injuries in surgeons, the sharp object that caused the injury recontacted the patient. Conclusion. --Percutaneous injuries occur regularly during surgery, placing surgical personnel and, to a lesser extent, patients at risk for infection with blood-borne pathogens. Many such injuries may be preventable with changes in devices, techniques, or protective equipment; all such measures require careful evaluation to determine their efficacy in reducing injury and their effect on patient care.	N SHORE UNIV HOSP,CORNELL UNIV MED COLL,DEPT MED,DIV INFECT DIS,MANHASSET,NY 11030; CHRIST HOSP,DEPT EMERGENCY MED,OAK LAWN,IL; CUNY MT SINAI SCH MED,DEPT MED,DIV INFECT DIS,NEW YORK,NY 10029; COOK CTY HOSP,DEPT EMERGENCY MED,CHICAGO,IL 60612	Cornell University; Northwell Health; North Shore University Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; John H Stroger Junior Hospital Cook County	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.			Marcus, Ruthanne/0000-0002-9094-0674				Bell DM, 1991, AM J MED S3B, V91, P294; BESSINGER CD, 1988, SURG GYNECOL OBSTET, V167, P287; BICKEL JT, 1990, J FORENSIC SCI, V35, P12; DIAZBUXO JA, 1991, SURG GYNECOL OBSTET, V172, P312; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HUSSAIN SA, 1988, BRIT J SURG, V75, P314, DOI 10.1002/bjs.1800750407; LETTAU LA, 1986, JAMA-J AM MED ASSOC, V255, P934, DOI 10.1001/jama.255.7.934; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; POPEJOY SL, 1991, SURG GYNECOL OBSTET, V172, P480; QUEBBEMAN EJ, 1991, ANN SURG, V214, P614, DOI 10.1097/00000658-199111000-00012; SERRANO CW, 1991, OBSTET GYNECOL, V77, P525; TELFORD GL, 1987, SURG ROUNDS, V10, P30; WELCH J, 1989, LANCET, V1, P205; WRIGHT JG, 1991, JAMA-J AM MED ASSOC, V266, P1668, DOI 10.1001/jama.266.12.1668; 1991, MMWR, V40, P309; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS3	19	196	199	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2899	2904		10.1001/jama.267.21.2899	http://dx.doi.org/10.1001/jama.267.21.2899			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583758				2022-12-24	WOS:A1992HW13300026
J	POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A				POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A			PREVENTION OF AUTOIMMUNE DIABETES IN THE BB RAT BY INTRATHYMIC ISLET TRANSPLANTATION AT BIRTH	SCIENCE			English	Article							LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; SELF-TOLERANCE; CELLS; EXPRESSION; RECEPTOR; SUBSETS	Spontaneous diabetes in the BioBreeding (BB) rat, like human type I diabetes, results from the destruction of pancreatic islets by autoreactive T lymphocytes recognizing beta-cell-specific antigens. T cell tolerance is in part mediated by interactions of maturing thymocytes with antigens expressed in the thymic microenvironment; islets were therefore implanted into the thymus of neonatal diabetes-prone BB rats to determine whether exposure of T cell precursors to beta-cell antigens could influence the development of diabetes. This treatment completely prevented diabetes and insulitis in the native pancreas. The effect may be the result of specific modulation of diabetogenic T cells maturing in an islet-bearing thymus.	HOSP UNIV PENN,DEPT SURG,4 SILVERSTEIN,3400 SPRUCE ST,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034878, R01DK026007, R37DK026007, R01DK034878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34878, DK26007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL MC, 1989, DIABETOLOGIA, V32, pA461; DEAN BM, 1985, DIABETOLOGIA, V28, P464, DOI 10.1007/BF00280892; GEORGIOU HM, 1988, J EXP MED, V167, P132, DOI 10.1084/jem.167.1.132; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; JAWORSKI MA, 1986, DIABETES RES CLIN EX, V3, P1; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIKE AA, 1986, DIABETES, V35, pA74; LIKE AA, 1986, J EXP MED, V164, P1145, DOI 10.1084/jem.164.4.1145; LIKE AA, 1979, SCIENCE, V206, P1421, DOI 10.1126/science.388619; MASON DW, 1983, IMMUNOL REV, V74, P57, DOI 10.1111/j.1600-065X.1983.tb01084.x; MCKEEVER U, 1990, P NATL ACAD SCI USA, V87, P7618, DOI 10.1073/pnas.87.19.7618; MORDES JP, 1987, DIABETES METAB REV, V3, P725, DOI 10.1002/dmr.5610030307; MORDES JP, 1987, DIABETOLOGIA, V30, P22, DOI 10.1007/BF01788902; MURASE N, 1990, DIABETES, V39, P1584, DOI 10.2337/diabetes.39.12.1584; NAJI A, 1983, J IMMUNOL, V130, P2168; NAJI A, 1981, SCIENCE, V213, P1390, DOI 10.1126/science.6791286; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; POSSELT AM, 1991, ANN SURG, V214, P363, DOI 10.1097/00000658-199110000-00001; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROSSINI AA, 1984, J CLIN INVEST, V74, P36; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5	24	133	136	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1321	1324		10.1126/science.1598576	http://dx.doi.org/10.1126/science.1598576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598576				2022-12-24	WOS:A1992HW13500034
J	ZHANG, JP; STEPHENS, RS				ZHANG, JP; STEPHENS, RS			MECHANISM OF C-TRACHOMATIS ATTACHMENT TO EUKARYOTIC HOST-CELLS	CELL			English	Article							CHLAMYDIA-TRACHOMATIS; HEPARAN-SULFATE; LEISHMANIA-DONOVANI; BINDING PROTEINS; MCCOY CELLS; PSITTACI; GLYCOSAMINOGLYCAN; BIOSYNTHESIS; SEQUENCE; HELA	A novel trimolecular mechanism of microbial attachment to mammalian host cells was characterized for the obligate intracellular pathogen Chlamydia trachomatis. Using purified glycosaminoglycans (GAGs) and specific GAG lyases, we demonstrated that a heparan sulfate-like GAG present on the surface of chlamydia organisms is required for attachment to host cells. These observations were supported by inhibition of attachment following binding of heparan sulfate receptor analogs to chlamydiae and by demonstrating that chlamydiae synthesize a unique heparan sulfate-like GAG. Furthermore, exogenous heparan sulfate, as an adhesin analog, restored attachment and infectivity to organisms that had lost these attributes following treatment with heparan sulfate lyase. These data suggest that a GAG adhesin ligand mediates attachment by bridging mutual GAG receptors on the host cell surface and on the chlamydial outer membrane surface.	UNIV CALIF SAN FRANCISCO,FRANCIS I PROCTOR FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ZHANG, JP (corresponding author), UNIV CALIF BERKELEY,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY007757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029432] Funding Source: NIH RePORTER; NEI NIH HHS [EY07757] Funding Source: Medline; NIAID NIH HHS [AI29432] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN J, 1988, J BACTERIOL, V171, P285; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BECKER Y, 1969, ISRAEL J MED SCI, V5, P121; BILOZUR ME, 1990, J BIOL CHEM, V265, P19697; BUTCHER BA, 1990, EXP PARASITOL, V71, P49, DOI 10.1016/0014-4894(90)90007-Y; BYRNE GI, 1976, INFECT IMMUN, V14, P645, DOI 10.1128/IAI.14.3.645-651.1976; BYRNE GI, 1978, INFECT IMMUN, V19, P598, DOI 10.1128/IAI.19.2.598-606.1978; CARDIN AD, 1984, ANAL BIOCHEM, V137, P368, DOI 10.1016/0003-2697(84)90099-X; CERI H, 1986, INFECT IMMUN, V51, P1; DAWSON CR, 1985, REV INFECT DIS, V7, P768; EISSENBERG LG, 1983, INFECT IMMUN, V40, P741, DOI 10.1128/IAI.40.2.741-751.1983; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; HATCH TP, 1981, J GEN MICROBIOL, V125, P273; HODINKA RL, 1986, INFECT IMMUN, V54, P885; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON AP, 1983, BRIT J VENER DIS, V59, P369; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KUO CC, 1976, INFECT IMMUN, V13, P1103, DOI 10.1128/IAI.13.4.1103-1109.1976; KURE S, 1986, J IMMUNOL, V137, P3900; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; MOULDER JW, 1988, MICROBIOLOGY CHLAMYD, P3; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P517, DOI 10.1042/bj2640517; OFEK I, 1982, J BACTERIOL, V149, P426, DOI 10.1128/JB.149.2.426-433.1982; OKAZAKI K, 1991, VIROLOGY, V181, P666, DOI 10.1016/0042-6822(91)90900-V; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PAUL G, 1987, J BIOL CHEM, V262, P9587; SCHACHTER J, 1988, MICROBIOLOGY CHLAMYD, P153; SODERLUND G, 1983, INFECT IMMUN, V40, P534; STEPHENS RS, 1986, J BACTERIOL, V168, P1277, DOI 10.1128/jb.168.3.1277-1282.1986; STEPHENS RS, 1982, J CLIN MICROBIOL, V16, P4, DOI 10.1128/JCM.16.1.4-7.1982; STEPHENS RS, 1989, INTRACELLULAR PARASI, P51; STORZ J, 1989, MICROBIOLOGY CHLAMYD, P167; TROY FA, 1979, ANNU REV MICROBIOL, V33, P519, DOI 10.1146/annurev.mi.33.100179.002511; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VRETOU E, 1989, J GEN MICROBIOL, V135, P3229; WIELAND F, 1980, FEBS LETT, V120, P110, DOI 10.1016/0014-5793(80)81058-1; WINER MA, 1989, J REPROD FERTIL, V87, P337, DOI 10.1530/jrf.0.0870337; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; WYRICK PB, 1989, INFECT IMMUN, V57, P2378, DOI 10.1128/IAI.57.8.2378-2389.1989	52	206	211	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					861	869		10.1016/0092-8674(92)90296-O	http://dx.doi.org/10.1016/0092-8674(92)90296-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591780				2022-12-24	WOS:A1992HW83800015
J	CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G				CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G			INVESTIGATION OF QT INTERVAL IN ADULT CELIAC-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									S ORSOLA UNIV HOSP,DEPT MED PATHOL & CLIN MED 1,I-40138 BOLOGNA,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna	CORAZZA, GR (corresponding author), UNIV LAQUILA,DEPT MED,I-67100 LAQUILA,ITALY.		Corazza, Gino Roberto/K-8500-2016	Corazza, Gino Roberto/0000-0001-9532-0573				CHAMBERS JB, 1985, LANCET, V2, P1308; GREEN PA, 1960, GASTROENTEROLOGY, V38, P399; ISNER JM, 1985, ANN INTERN MED, V102, P49, DOI 10.7326/0003-4819-102-1-49; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1285		10.1136/bmj.304.6837.1285	http://dx.doi.org/10.1136/bmj.304.6837.1285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606432	Bronze, Green Published			2022-12-24	WOS:A1992HV08600024
J	MEHLIN, H; DANEHOLT, B; SKOGLUND, U				MEHLIN, H; DANEHOLT, B; SKOGLUND, U			TRANSLOCATION OF A SPECIFIC PREMESSENGER RIBONUCLEOPROTEIN PARTICLE THROUGH THE NUCLEAR-PORE STUDIED WITH ELECTRON-MICROSCOPE TOMOGRAPHY	CELL			English	Article							CHIRONOMUS-TENTANS; BALBIANI RINGS; PROTEIN IMPORT; RNA TRANSPORT; COMPLEX; ENVELOPE; OOCYTES; BINDING; GENES; CELL	A specific premessenger ribonucleoprotein (RNP) particle in the salivary glands of the dipteran Chironomus tentans was studied with electron microscope tomography during translocation from the cell nucleus to the cytoplasm. The RNP particle consists of a thin RNP fiber tightly folded into a ribbon, which is bent into a ring-like structure. Upon translocation through the pore, the particle is first orientated in a specific manner at the pore entrance, and subsequently the bent ribbon is gradually straightened and transported through the pore with the 5' end of the RNA in the lead. Concomitantly, the elementary RNP fiber constituting the ribbon is gradually unpacked and will appear more or less extended on the cytoplasmic side of the pore complex. The ordered nature of the process suggests a specific recognition of the RNP particle at the nuclear pore.			MEHLIN, H (corresponding author), KAROLINSKA INST,MED NOBEL INST,DEPT MOLEC GENET,S-10401 STOCKHOLM 60,SWEDEN.		Skoglund, Ulf/B-5829-2015	Skoglund, Ulf/0000-0002-3407-0053				AGUTTE PS, 1976, NATURE, V263, P165, DOI 10.1038/263165a0; Agutter P S, 1984, Subcell Biochem, V10, P281; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; ANDERSSON K, 1980, EXP CELL RES, V130, P313, DOI 10.1016/0014-4827(80)90008-7; BEERMANN W, 1962, MAI C GES SCHAFT PHY, P64; CASE ST, 1983, J BIOL CHEM, V258, P7793; CLAWSON GA, 1985, MOL CELL BIOCHEM, V67, P87, DOI 10.1007/BF02370167; Daneholt B, 1976, Prog Nucleic Acid Res Mol Biol, V19, P319; DANEHOLT B, 1977, J CELL BIOL, V3, P149; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; FELDHERR CM, 1984, J CELL BIOL, V99, P2216, DOI 10.1083/jcb.99.6.2216; FETHERSTONE C, 1988, J CELL BIOL, V107, P1289; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P317, DOI 10.1016/S0022-5320(70)80065-X; FRANKE WW, 1981, J CELL BIOL, V91, P39; GALLER R, 1985, EMBO J, V4, P2977, DOI 10.1002/j.1460-2075.1985.tb04032.x; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; JONES RE, 1980, J CELL BIOL, V86, P235, DOI 10.1083/jcb.86.1.235; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; LONN U, 1977, NATURE, V270, P630, DOI 10.1038/270630a0; MAUL GR, 1977, INT REV CYTOL      S, V6, P75; MCDONALD JR, 1980, FEBS LETT, V116, P145, DOI 10.1016/0014-5793(80)80629-6; MEHLIN H, 1991, EXP CELL RES, V193, P72, DOI 10.1016/0014-4827(91)90539-7; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; OLINS AL, 1980, EUR J CELL BIOL, V22, P714; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; PETERS R, 1984, EMBO J, V3, P1831, DOI 10.1002/j.1460-2075.1984.tb02055.x; Preobrazhensky A A, 1978, Prog Nucleic Acid Res Mol Biol, V21, P1, DOI 10.1016/S0079-6603(08)60265-2; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIS H, 1989, Journal of Cell Biology, V109, p134A; ROWLAND SW, 1979, TOP APPL PHYS, V32, P9; SCHEER U, 1988, CELL BIOL INT REP, V12, P669, DOI 10.1016/0309-1651(88)90083-5; SCHRODER HC, 1987, PROG NUCLEIC ACID RE, V34, P89, DOI 10.1016/S0079-6603(08)60494-8; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SKOGLUND U, 1986, TRENDS BIOCHEM SCI, V11, P499, DOI 10.1016/0968-0004(86)90077-0; SKOGLUND U, 1986, NATURE, V319, P560, DOI 10.1038/319560a0; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEVENS BJ, 1966, J CELL BIOL, V31, P55, DOI 10.1083/jcb.31.1.55; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; WIESLANDER L, 1984, J MOL EVOL, V20, P304, DOI 10.1007/BF02104736; WURTZ T, 1990, P NATL ACAD SCI USA, V87, P831, DOI 10.1073/pnas.87.2.831; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436; [No title captured]	52	224	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					605	613		10.1016/0092-8674(92)90224-Z	http://dx.doi.org/10.1016/0092-8674(92)90224-Z			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586943				2022-12-24	WOS:A1992HV08900005
J	WIERTELAK, EP; MAIER, SF; WATKINS, LR				WIERTELAK, EP; MAIER, SF; WATKINS, LR			CHOLECYSTOKININ ANTIANALGESIA - SAFETY CUES ABOLISH MORPHINE ANALGESIA	SCIENCE			English	Article							SPINAL-CORD; OPIATE ANALGESIA; BINDING-SITES; ANTAGONIST; PAIN; CCK; NEUROPEPTIDE; NOCICEPTION; INHIBITION; L-365,260	Environmental stimuli that signal the occurrence of aversive or dangerous events activate endogenous opiate analgesia systems. Signals for safety (the nonoccurrence of aversive events) produce the opposite and inhibit environmentally produced analgesia. Stimuli that signal safety are now shown to abolish the analgesic effect of morphine, even when morphine is applied directly to spinal cord. Further, this antiopiate effect occurs because the environmental stimulus leads to release of the neuropeptide cholecystokinin in the spinal cord. This process may contribute to the regulation of pain and the development of opiate tolerance.			WIERTELAK, EP (corresponding author), UNIV COLORADO, DEPT PSYCHOL, BOULDER, CO 80309 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014617] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32MH14617-15] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLARD M, 1991, NEUROSCIENCE, V40, P81, DOI 10.1016/0306-4522(91)90176-O; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BELL JA, 1977, EUR J PHARMACOL, V42, P147, DOI 10.1016/0014-2999(77)90354-5; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; HARRO J, 1991, EUR J PHARMACOL, V193, P379, DOI 10.1016/0014-2999(91)90156-K; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HILL DR, 1988, NEUROSCI LETT, V89, P133, DOI 10.1016/0304-3940(88)90369-2; KELLY DD, 1986, ANN NY ACAD SCI, V467; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; MAIER SF, 1976, ANIM LEARN BEHAV, V4, P217, DOI 10.3758/BF03214039; MELZACK R, 1988, 5TH P WORLD C PAIN, P4; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; PASTERNAK GW, 1988, JAMA-J AM MED ASSOC, V259, P1362, DOI 10.1001/jama.259.9.1362; RATAUD J, 1991, BRAIN RES, V548, P315, DOI 10.1016/0006-8993(91)91139-R; SIEGEL S, 1979, PSYCHOPATHOLOGY ANIM, P143; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; TWYCROSS RG, 1984, TXB PAIN, P516; WATKINS LR, 1986, BRAIN RES, V362, P308, DOI 10.1016/0006-8993(86)90455-5; WATKINS LR, 1984, SCIENCE, V224, P395, DOI 10.1126/science.6546809; WESTBROOK RF, 1990, Q J EXP PSYCHOL-B, V42, P1; WIERTELAK E P, 1991, Society for Neuroscience Abstracts, V17, P109; WIERTELAK EP, UNPUB; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pa.25.040185.002245; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; ZADINA JE, 1987, BRAIN RES, V409, P10, DOI 10.1016/0006-8993(87)90736-0; ZINBERG NE, 1984, DRUG SET SETTING, P12	32	127	128	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					830	833		10.1126/science.1589765	http://dx.doi.org/10.1126/science.1589765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589765				2022-12-24	WOS:A1992HT23500043
J	HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M				HIRAI, Y; TAKEBE, K; TAKASHINA, M; KOBAYASHI, S; TAKEICHI, M			EPIMORPHIN - A MESENCHYMAL PROTEIN ESSENTIAL FOR EPITHELIAL MORPHOGENESIS	CELL			English	Article							CADHERIN ADHESION MOLECULES; CELL-SURFACE; EMBRYONIC HISTOGENESIS; GENE-EXPRESSION; MESSENGER-RNAS; INDUCTION; PHOSPHATIDYLINOSITOL; ORGANOGENESIS; KIDNEY; GLAND	A novel 150 kd protein expressed on the surface of mesenchymal cells of mouse embryonic tissues was identified. A monoclonal antibody to this molecule inhibited various processes of epithelial morphogenesis, such as hair follicle growth and lung epithelial tubular formation, in organ cultures of these tissues. Sequence analysis of cDNA encoding this protein revealed that it had 289 amino acids with a hydrophobic stretch at the C-terminus. NIH 3T3 cells transfected with the cDNA of this protein expressed the exogenous 150 kd protein on their surface. When lung epithelial cells were cocultured with these transfected cells, they showed normal tubular morphogenesis, but not with untransfected NIH 3T3 cells. These results indicate that this protein, termed epimorphin, plays a central role in epithelial-mesenchymal interactions.	KYOTO UNIV,FAC SCI,DEPT BIOPHYS,SAKYO KU,KYOTO 606,JAPAN	Kyoto University	HIRAI, Y (corresponding author), BIOMAT RES INST,1 TAYA CHO,SAKAE KU,YOKOHAMA 244,JAPAN.		Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER J, 1988, J BIOL CHEM, V263, P10016; BERGER J, 1989, P NATL ACAD SCI USA, V86, P1457, DOI 10.1073/pnas.86.5.1457; Bissell M. J., 1987, The mammary gland. Development, regulation, and function., P97; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BLAKESLEE D, 1976, J IMMUNOL METHODS, V13, P305, DOI 10.1016/0022-1759(76)90078-8; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CUTLER LS, 1973, DEV BIOL, V33, P229, DOI 10.1016/0012-1606(73)90133-4; DEMARCHEZ M, 1981, ARCH ANAT MICROSC MO, V70, P205; DEUCHAR E.M., 1975, CELLULAR INTERACTION; DHOUAILLY D, 1978, DEV BIOL, V65, P58, DOI 10.1016/0012-1606(78)90179-3; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FREGIEN N, 1986, GENE, V48, P1, DOI 10.1016/0378-1119(86)90346-X; GREEN JBA, 1991, TRENDS GENET, V7, P245, DOI 10.1016/0168-9525(91)90323-I; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GURDON JB, 1987, DEVELOPMENT, V99, P285; HARDY MH, 1983, J INVEST DERMATOL, V80, P27, DOI 10.1111/1523-1747.ep12530968; HARDY MH, 1954, ANN NY ACAD SCI, V53, P546; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1989, DEVELOPMENT, V105, P263; HIRAI Y, 1991, CYTOTECHNOLOGY, V6, P209, DOI 10.1007/BF00624759; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAHODA CAB, 1984, NATURE, V311, P560, DOI 10.1038/311560a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEHTONEN E, 1975, J EMBRYOL EXP MORPH, V33, P187; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASUI T, 1981, J EMBRYOL EXP MORPH, V62, P277; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MIZUNO T, 1990, CELL DIFFER DEV, V31, P151, DOI 10.1016/0922-3371(90)90117-F; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NOGAWA H, 1981, J EMBRYOL EXP MORPH, V66, P209; NOSE A, 1986, J CELL BIOL, V103, P2649, DOI 10.1083/jcb.103.6.2649; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SAWYER RH, 1983, EPITHELIAL MESENCHYM; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIRAYOSHI Y, 1986, CELL STRUCT FUNCT, V11, P245, DOI 10.1247/csf.11.245; SLAVKIN HC, 1976, DEV BIOL, V50, P428, DOI 10.1016/0012-1606(76)90163-9; TAKAMI N, 1988, J BIOL CHEM, V263, P12716; TAKIGUCHI K, 1988, DEV GROWTH DIFFER, V30, P241; TANABE Y, 1988, MOL CELL BIOL, V8, P466; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WARTIOVAARA J, 1974, J EMBRYOL EXP MORPH, V31, P667; WESSELS NK, 1977, TISSUE INTERACTION D; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X	52	214	227	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 1	1992	69	3					471	481		10.1016/0092-8674(92)90448-L	http://dx.doi.org/10.1016/0092-8674(92)90448-L			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581962				2022-12-24	WOS:A1992HT07800009
J	RIVIER, DH; RINE, J				RIVIER, DH; RINE, J			AN ORIGIN OF DNA-REPLICATION AND A TRANSCRIPTION SILENCER REQUIRE A COMMON ELEMENT	SCIENCE			English	Article							MATING-TYPE GENES; SACCHAROMYCES-CEREVISIAE; YEAST SILENCER; S-CEREVISIAE; REPRESSION; LOCI; SEGREGATION; HISTONE-H4; PURIFICATION; COMPONENTS	A eukaryotic chromosomal origin of replication was identified in the yeast Saccharomyces cerevisiae. By several criteria, including map position, deletion analysis, and a synthetic form of saturation mutagenesis, the origin co-localized with the HMR-E silencer, which is a DNA element that represses transcription of the adjacent genes. A specific site within the silencer was required for both initiation of chromosomal replication and for repression of transcription. This analysis directly demonstrates that initiation of eukaryotic chromosomal replication is dependent on specific sequence elements and that a particular element can act in both initiation of chromosomal replication and regulation of transcription.			RIVIER, DH (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV GENET,401 BARKER HALL,BERKELEY,CA 94720, USA.				NIEHS NIH HHS [ES07075] Funding Source: Medline; NIGMS NIH HHS [GM 31105] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXROD A, 1991, MOL CELL BIOL, V11, P1080; APARICIO OM, 1991, CELL, V66, P1; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER B, UNPUB; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; GIESMAN D, 1991, MOL CELL BIOL, V11, P1069, DOI 10.1128/MCB.11.2.1069; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIMMERLY WJ, 1987, MOL CELL BIOL, V7, P4225, DOI 10.1128/MCB.7.12.4225; KLAR AJS, 1981, CELL, V25, P517, DOI 10.1016/0092-8674(81)90070-2; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LINSKENS MHK, 1990, NUCLEIC ACIDS RES, V18, P647, DOI 10.1093/nar/18.3.647; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MILLS AD, 1989, J CELL SCI, V94, P471; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RINE J, 1987, GENETICS, V116, P9; RIVIER D, UNPUB; RIVIER DH, IN PRESS CURR OPIN C; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SPRADLING AC, 1990, GENETICS, V126, P779; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; TERLETH C, 1990, EMBO J, V9, P2899, DOI 10.1002/j.1460-2075.1990.tb07480.x; THOMAS GP, 1980, CELL, V22, P523; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L	48	130	132	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					659	663		10.1126/science.1585179	http://dx.doi.org/10.1126/science.1585179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585179				2022-12-24	WOS:A1992HR18500030
J	GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR				GLOOR, GB; NASSIF, NA; JOHNSONSCHLITZ, DM; PRESTON, CR; ENGELS, WR			TARGETED GENE REPLACEMENT IN DROSOPHILA VIA P-ELEMENT-INDUCED GAP REPAIR	SCIENCE			English	Article							HYBRID DYSGENESIS; TRANSPOSABLE ELEMENT; MOLECULAR ANALYSIS; GERM-LINE; RECOMBINATION; MELANOGASTER; DNA; MUTAGENESIS; LOCUS; CHROMOSOMES	Transposable elements of the P family in Drosophila are thought to transpose by a cut-and-paste process that leaves a double-strand gap. The repair of such gaps resulted in the transfer of up to several kilobase pairs of information from a homologous template sequence to the site of P element excision by a process similar to gene conversion. The template was an in vitro-modified sequence that was tested at various genomic positions. Characterization of 123 conversion tracts provided a detailed description of their length and distribution. Most events were continuous conversion tracts that overlapped the P insertion site without concomitant conversion of the template. The average conversion tract was 1379 base pairs, and the distribution of tract lengths fit a simple model of gap enlargement. The conversion events occurred at sufficiently high frequencies to form the basis of an efficient means of directed gene replacement.	UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	GLOOR, GB (corresponding author), MEM UNIV NEWFOUNDLAND,FAC MED,ST JOHNS A1C 5S7,NEWFOUNDLAND,CANADA.		Gloor, Greg B/D-1671-2013	Gloor, Gregory/0000-0001-5803-3380	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030948, R56GM030948] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30948] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA JW, 1989, MOBILE DNA, P939; BALLINGER DG, 1989, P NATL ACAD SCI USA, V86, P9402, DOI 10.1073/pnas.86.23.9402; BERG DE, 1989, MOBILE DNA, pCH6; BINGHAM PM, 1982, CELL, V29, P995, DOI 10.1016/0092-8674(82)90463-9; BORTS RH, 1989, GENETICS, V123, P69; BORTS RH, 1987, SCIENCE, V237, P1459, DOI 10.1126/science.2820060; COEN ES, 1989, MOBILE DNA, P413; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; CURTIS D, 1991, GENETICS, V127, P739; CURTIS D, 1989, GENETICS, V122, P653; DANIELS SB, 1990, GENETICS, V124, P339; Engels W.R, 1989, MOBILE DNA, P437; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; ENGELS WR, 1986, FOCUS, V8, P6; FELLER W, 1950, INTRO PROBABILITY TH, V1; GEYER PK, 1988, P NATL ACAD SCI USA, V85, P6455, DOI 10.1073/pnas.85.17.6455; GLOOR GB, IN PRESS DROS INFORM; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HASTINGS PJ, 1988, BIOESSAYS, V9, P61, DOI 10.1002/bies.950090206; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; KASSIS JA, COMMUNICATION; KIDWELL MG, 1983, P NATL ACAD SCI-BIOL, V80, P1655, DOI 10.1073/pnas.80.6.1655; KOSTRIKEN R, 1984, COLD SPRING HARB SYM, V49, P89, DOI 10.1101/SQB.1984.049.01.012; LEVERE G, 1976, GENETICS BIOL DROS A, V1, P32; LIM JK, 1988, P NATL ACAD SCI USA, V85, P9153, DOI 10.1073/pnas.85.23.9153; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MCGILL C, 1989, CELL, V57, P459, DOI 10.1016/0092-8674(89)90921-5; OHARE K, 1984, J MOL BIOL, V180, P437, DOI 10.1016/0022-2836(84)90021-4; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; ORRWEAVER TL, 1985, MICROBIOL REV, V49, P33, DOI 10.1128/MMBR.49.1.33-58.1985; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; ROBERTSON HM, 1988, GENETICS, V118, P461; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SALZ HK, 1987, GENETICS, V117, P221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SVED JA, 1990, GENETICS, V124, P331; SVED JA, 1991, MOL GEN GENET, V225, P443, DOI 10.1007/BF00261685; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; White T.J., 1990, PCR PROTOCOLS GUIDE, P315; WILLIAMS JA, 1988, MOL CELL BIOL, V8, P1489, DOI 10.1128/MCB.8.4.1489; [No title captured]	51	318	334	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 6	1991	253	5024					1110	1117		10.1126/science.1653452	http://dx.doi.org/10.1126/science.1653452			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653452				2022-12-24	WOS:A1991GD80800024
J	LI, R; MURRAY, AW				LI, R; MURRAY, AW			FEEDBACK-CONTROL OF MITOSIS IN BUDDING YEAST	CELL			English	Article							MITOTIC CHROMOSOME TRANSMISSION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DNA-REPLICATION; CHROMATIN CONDENSATION; MAMMALIAN-CELLS; TUBULIN GENES; PROTEIN; MUTANTS; CALCIUM	We have investigated the feedback control that prevents cells with incompletely assembled spindles from leaving mitosis. We isolated budding yeast mutants sensitive to the anti-microtubule drug benomyl. Mitotic arrest-deficient (mad) mutants are the subclass of benomyl-sensitive mutants in which the completion of mitosis is not delayed in the presence of benomyl and that die as a consequence of their premature exit from mitosis. A number of properties of the mad mutants indicate that they are defective in the feedback control over the exit from mitosis: their killing by benomyl requires passage through mitosis; their benomyl sensitivity can be suppressed by an independent method for delaying the exit from mitosis; they have normal microtubules; and they have increased frequencies of chromosome loss. We cloned MAD2, which encodes a putative calcium-binding protein whose disruption is lethal. We discuss the role of feedback controls in coordinating events in the cell cycle.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LI, R (corresponding author), UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143, USA.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ENGLE DB, 1990, J BIOL CHEM, V265, P16132; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDENIN DA, 1990, YEAST, V7, P37; HARA K, 1980, P NATL ACAD SCI-BIOL, V77, P462, DOI 10.1073/pnas.77.1.462; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HOYT MA, 1990, MOL CELL BIOL, V10, P223, DOI 10.1128/MCB.10.1.223; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JOHNSTON GC, 1983, EXP CELL RES, V149, P1, DOI 10.1016/0014-4827(83)90375-0; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIRAS P, 1978, GENETICS, V88, P651; MCCUSKER JH, 1981, GENETICS, V99, P383; MEIJER L, 1988, EXP CELL RES, V174, P116, DOI 10.1016/0014-4827(88)90147-4; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; PALMER RE, 1990, GENETICS, V125, P763; PICARD A, 1988, DEV BIOL, V128, P121, DOI 10.1016/0012-1606(88)90273-4; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCHLEGEL R, 1987, J CELL PHYSIOL, V131, P85, DOI 10.1002/jcp.1041310113; Sherman F., 1974, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1990, GENETICS, V124, P237; STEARNS T, 1988, GENETICS, V119, P249; STEARNS T, 1990, GENETICS, V124, P251; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	50	987	1012	0	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 9	1991	66	3					519	531		10.1016/0092-8674(81)90015-5	http://dx.doi.org/10.1016/0092-8674(81)90015-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GA941	1651172				2022-12-24	WOS:A1991GA94100013
J	KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M				KLEIN, R; NANDURI, V; JING, SQ; LAMBALLE, F; TAPLEY, P; BRYANT, S; CORDONCARDO, C; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRKB TYROSINE PROTEIN-KINASE IS A RECEPTOR FOR BRAIN-DERIVED NEUROTROPHIC FACTOR AND NEUROTROPHIN-3	CELL			English	Article							NERVE GROWTH-FACTOR; MOLECULAR-CLONING; FACTOR FAMILY; CHOLINERGIC NEURONS; MESSENGER-RNA; EXPRESSION; GENE; BDNF; IDENTIFICATION; SURVIVAL	trkB is a tyrosine protein kinase gene highly related to trk, a proto-oncogene that encodes a receptor for nerve growth factor (NGF) and neurotrophin-3 (NT-3). trkB expression is confined to structures of the central and peripheral nervous systems, suggesting it also encodes a receptor for neurotrophic factors. Here we show that brain-derived neurotrophic factor (BDNF) and NT-3, but not NGF, can induce rapid phosphorylation on tyrosine of gp145trkB, one of the receptors encoded by trkB. BDNF and NT-3 can induce DNA synthesis in quiescent NIH 3T3 cells that express gp145trkB. Cotransfection of plasmids encoding gp145trkB and BDNF or NT-3 leads to transformation of recipient NIH 3T3 cells. In these assays, BDNF elicits a response at least two orders of magnitude higher than NT-3. Finally, I-125-NT-3 binds to NIH 3T3 cells expressing gp145trkB; binding can be competed by NT-3 and BDNF but not by NGF. These findings indicate that gp145trkB may function as a neurotrophic receptor for BDNF and NT-3.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	KLEIN, R (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,POB 4000,PRINCETON,NJ 08543, USA.		Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017; Klein, Ruediger/C-6147-2008	Lamballe, Fabienne/0000-0001-7631-942X; Klein, Ruediger/0000-0002-3109-0163; JONES, KEVIN/0000-0002-3802-7562	NINDS NIH HHS [P01 NS016033, P01 NS016033-230014] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; BARBACID M, 1991, IN PRESS BIOCH BIOPH; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, P NATL ACAD SCI USA, V88, P961, DOI 10.1073/pnas.88.3.961; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LETWIN K, 1988, ONCOGENE, V3, P621; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; RODRIGEUZTEBAR A, 1988, J NEUROSCI, V8, P3337; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0	38	819	849	2	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					395	403		10.1016/0092-8674(91)90628-C	http://dx.doi.org/10.1016/0092-8674(91)90628-C			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649702	Green Accepted			2022-12-24	WOS:A1991FY71200019
J	MIZUUCHI, K; ADZUMA, K				MIZUUCHI, K; ADZUMA, K			INVERSION OF THE PHOSPHATE CHIRALITY AT THE TARGET SITE OF MU-DNA STRAND TRANSFER - EVIDENCE FOR A ONE-STEP TRANSESTERIFICATION MECHANISM	CELL			English	Article							DIASTEREOMERIC PHOSPHOROTHIOATE ANALOGS; BACTERIOPHAGE-MU; DEOXYADENOSINE TRIPHOSPHATE; POLYMERASE-I; TRANSPOSITION; PROTEIN; RECOMBINATION; CLEAVAGE; GENE; PURIFICATION	Central to transposition of phage Mu are two reactions mediated by the MuA protein. First, MuA introduces single-stranded cuts at the ends of the Mu DNA to generate 3'OH termini. In the subsequent strand-transfer step, the MuA-Mu DNA end complex cuts a target DNA and joins the Mu 3 'ends to the 5' ends of the target. DNA containing chiral phosphorothioates was used to demonstrate inversion of the chirality during the course of strand transfer. This result strongly supports a one-step transesterification mechanism in which the 3'OH of the cleaved donor DNA is the attacking nucleophile. Furthermore, this donor 3'OH group was essential for target DNA cleavage. In contrast, during lambda-integration the phosphate chirality was retained, as expected for a two-step transesterification involving a covalent protein-DNA intermediate.			MIZUUCHI, K (corresponding author), NIADDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA.							BAKER TA, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BUCHWALD SL, 1982, METHOD ENZYMOL, V87, P279; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; BURGERS PMJ, 1979, BIOCHEMISTRY-US, V18, P592, DOI 10.1021/bi00571a007; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIG NL, 1988, ANNU REV GENET, V22, P77; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HANIFORD DB, 1991, CELL, V64, P171; HERSCHLAG D, 1991, IN PRESS BIOCHEMISTR, V30; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KITTS PA, 1988, NUCLEIC ACIDS RES, V16, P6839, DOI 10.1093/nar/16.14.6839; KITTS PA, 1988, J MOL BIOL, V204, P95, DOI 10.1016/0022-2836(88)90602-X; KNOWLES JR, 1980, ANNU REV BIOCHEM, V49, P877, DOI 10.1146/annurev.bi.49.070180.004305; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; POTTER BVL, 1983, BIOCHEMISTRY-US, V22, P1369, DOI 10.1021/bi00275a008; ROMANIUK PJ, 1982, J BIOL CHEM, V257, P7684; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANMANSFELD ADM, 1986, NUCLEIC ACIDS RES, V14, P4229, DOI 10.1093/nar/14.10.4229	32	139	141	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 12	1991	66	1					129	140		10.1016/0092-8674(91)90145-O	http://dx.doi.org/10.1016/0092-8674(91)90145-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649006				2022-12-24	WOS:A1991FW91300015
J	UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM				UMESONO, K; MURAKAMI, KK; THOMPSON, CC; EVANS, RM			DIRECT REPEATS AS SELECTIVE RESPONSE ELEMENTS FOR THE THYROID-HORMONE, RETINOIC ACID, AND VITAMIN-D3 RECEPTORS	CELL			English	Article							DNA-BINDING DOMAIN; HUMAN OSTEOCALCIN GENE; GLUCOCORTICOID RECEPTOR; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; NEGATIVE REGULATION; PROMOTER ELEMENTS; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; NUCLEAR-PROTEIN; AMINO-ACIDS	We report here the identification of thyroid hormone response elements (TREs) that consist of a direct repeat, not a palindrome, of the half-sites. Unlike palindromic TREs, direct repeat TREs do not confer a retinoic acid response. The tandem TRE can be converted into a retinoic acid response element by increasing the spacing between the half-sites by 1 nucleotide, and the resulting retinoic acid response element is no longer a TRE. Decreasing the half-site spacing by 1 nucleotide converts the TRE to a vitamin D3 response element, while eliminating response to T3. These results correlate well with DNA-binding affinities of the thyroid hormone, retinoic acid, and vitamin D3 receptors. This study points to the general importance of tandem repeat hormone response elements and suggests a simple physiologic code exists in which half-site spacing plays a critical role in achieving selective hormonal response.			UMESONO, K (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,POB 85800,SAN DIEGO,CA 92186, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT GA, 1989, J BIOL CHEM, V264, P178; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CRONE DE, 1990, J BIOL CHEM, V265, P10851; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DEVERNEUIL H, 1990, NUCLEIC ACIDS RES, V18, P4489; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUESTER G, 1991, MOL CELL BIOL, V11, P1638, DOI 10.1128/MCB.11.3.1638; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GREEN S, 1988, TRENDS GENET, V249, P157; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HU MCT, 1986, MOL CELL BIOL, V6, P15, DOI 10.1128/MCB.6.1.15; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; MUNOZCANOVES P, 1990, J BIOL CHEM, V265, P20065; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OZONO K, 1991, IN PRESS J BIOL CHEM; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TRASK RV, 1988, J BIOL CHEM, V263, P17142; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WEINBERGER C, 1990, ANNU REV PHYSIOL, V52, P823; WONDISFORD FE, 1989, J BIOL CHEM, V264, P14601; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	72	1614	1655	0	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1255	1266		10.1016/0092-8674(91)90020-Y	http://dx.doi.org/10.1016/0092-8674(91)90020-Y			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648450	Green Accepted			2022-12-24	WOS:A1991FU89900017
J	MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J				MEIER, B; URBAN, P; DORSAZ, PA; FAVRE, J			SURGICAL STANDBY FOR CORONARY BALLOON ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC-SURGERY; TASK-FORCE; COMPLICATIONS; OCCLUSION; GUIDELINES; CARDIOLOGY; HEART	Objective.-To assess the predictability of need for emergency surgery after coronary balloon angioplasty. Design.-Nonrandomized intervention study. Setting.-Nonprofit university hospital. Patients.-Prior to balloon angioplasty, 1000 consecutive patients were assigned to either the "standby" group (189 patients [19%]) or the "no-standby" group (811 patients [81%]). Patients in the standby group (intervention coordinated with cardiac surgery) included all operable patients undergoing angioplasty of their largest coronary arteries that were not currently or previously totally occluded or collateralized; the no-standby group consisted of the remainder of patients. Intervention.-Allocation to coronary angioplasty with or without surgical standby. Main Outcome Measures.-Need for bypass surgery, occurrence of myocardial infarction, and mortality from complications of angioplasty. Results.-Bypass surgery immediately after angioplasty was done in one patient in each group (standby, 0.5%, vs no-standby, 0.1%). The frequency of infarction was 5% vs 4%, respectively. All eight deaths occurred in the no-standby group (1.0%), but none of them were consequences of a lack of surgical standby. They occurred in situations in which bypass surgery would not have changed the outcome (two cardiac failures late after technically successful angioplasty for postinfarct cardiogenic shock, one in-laboratory rupture of an unrecognized ventricular pseudoaneurysm, and one protamine reaction), secondary to acute problems late after successful angioplasty (two sudden deaths and one vessel occlusion in an inoperable patient), or despite surgery (one patient with left main stem dissection). Conclusions.-Performing roughly 80% of coronary angioplasties without surgical standby did not increase patient risk. Coronary angioplasty without surgical backup, albeit not an ideal setting, appears ethically feasible in selected patients if dictated by logistic considerations.			MEIER, B (corresponding author), UNIV GENEVA,HOP CANTONAL,CTR CARDIOL,CH-1211 GENEVA 4,SWITZERLAND.							BOURASSA M G, 1988, European Heart Journal, V9, P1034; CAMERON DE, 1990, ANN THORAC SURG, V50, P35, DOI 10.1016/0003-4975(90)90078-K; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DETRE KM, 1990, CIRCULATION, V82, P739, DOI 10.1161/01.CIR.82.3.739; Deutsche Gessellschaft fur Herz- und Kreislaufforschung, 1987, Z KARDIOL, V76, P382; GRUENTZIG AR, 1979, NEW ENGL J MED, V301, P61; MEIER B, 1991, J AM COLL CARDIOL, V17, pB50; MEIER B, 1987, CORONARY ANGIOPLASTY, P146; REIFART N, 1990, Z KARDIOL, V79, P446; RENNER U, 1991, HERZ KREISLAUF, V23, P409; RICHARDSON SG, 1990, BRIT MED J, V300, P355, DOI 10.1136/bmj.300.6721.355; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; RYAN TJ, 1990, J AM COLL CARDIOL, V15, P1469, DOI 10.1016/0735-1097(90)92812-G; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SIGWART U, 1988, CIRCULATION, V78, P1121, DOI 10.1161/01.CIR.78.5.1121; STEFFENINO G, 1988, BRIT HEART J, V59, P151; STEWART JT, 1990, BRIT HEART J, V63, P74; ULLYOT DJ, 1987, CIRCULATION, V76, P149; WEAVER WF, 1985, CATHETER CARDIO DIAG, V11, P109, DOI 10.1002/ccd.1810110117; 1988, CATHET CARDIOVASC DI, V15, P136	20	42	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					741	745		10.1001/jama.268.6.741	http://dx.doi.org/10.1001/jama.268.6.741			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640573				2022-12-24	WOS:A1992JG66600014
J	HILL, RJ; STERNBERG, PW				HILL, RJ; STERNBERG, PW			THE GENE LIN-3 ENCODES AN INDUCTIVE SIGNAL FOR VULVAR DEVELOPMENT IN C-ELEGANS	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; NEMATODE CAENORHABDITIS-ELEGANS; SPECIFIES CELL FATES; FACTOR-ALPHA; TYROSINE KINASE; MYXOMA VIRUS; SEQUENCE; EGF; EXPRESSION; LINEAGES	The lin-3 gene is necessary for induction of the Caenorhabditis elegans vulva by the anchor cell. It encodes a molecule similar to epidermal growth factor and to transforming growth factor-alpha and acts through the epidermal growth factor receptor homologue let-23. Expression of lin-3 in the anchor cell stimulates vulval induction; lin-3 may encode the vulval inducing signal.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology	HILL, RJ (corresponding author), CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125, USA.			Sternberg, Paul/0000-0002-7699-0173				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; AVERY L, 1987, CELL, V51, P1071, DOI 10.1016/0092-8674(87)90593-9; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRENNER S, 1974, GENETICS, V77, P71; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; CHANG W, 1987, MOL CELL BIOL, V7, P535, DOI 10.1128/MCB.7.1.535; CLARK DV, 1988, GENETICS, V119, P345; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DAVIS C G, 1990, New Biologist, V2, P410; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HAN M, 1990, GENETICS, V126, P899; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HORVITZ HR, 1980, GENETICS, V96, P435; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN YZ, 1991, BIOCHEMISTRY-US, V30, P3310, DOI 10.1021/bi00227a020; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; OCHMAN H, 1988, GENETICS, V120, P621; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENZWEIG B, 1983, NUCLEIC ACIDS RES, V11, P4201, DOI 10.1093/nar/11.12.4201; RUVKUN G, 1989, GENETICS, V121, P501; Sambrook J., 1989, MOL CLONING LAB MANU; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STROOBANT P, 1985, CELL, V42, P383, DOI 10.1016/S0092-8674(85)80133-1; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS JH, 1990, CELL, V62, P1041, DOI 10.1016/0092-8674(90)90382-O; UPTON C, 1987, J VIROL, V61, P1271, DOI 10.1128/JVI.61.4.1271-1275.1987; VENKATESAN S, 1982, J VIROL, V44, P637, DOI 10.1128/JVI.44.2.637-646.1982; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Wood WB, 1988, NEMATODE CAENORHABDI; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	58	321	339	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					470	476		10.1038/358470a0	http://dx.doi.org/10.1038/358470a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641037				2022-12-24	WOS:A1992JG73900039
J	AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL				AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL			ATROPINE POISONING IN CHILDREN DURING THE PERSIAN GULF CRISIS - A NATIONAL SURVEY IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHARMACOKINETICS	Objective.-To evaluate the effects of high doses of atropine in children accidentally injected with automatic atropine injectors. These were distributed in Israel during the Persian Gulf Crisis as an antidote for chemical warfare agents. Design and Setting.-A national survey in pediatric emergency departments in Israel, involving 22 medical centers, with prospective data collection in 14 centers. Patients.-Children (n=268) presenting to emergency departments following misuse of automatic atropine injectors. Main Outcome Measures.-Documentation of atropine dose and clinical manifestations; determination of a clinical severity score and its correlation with atropine dose; measurements of serum atropine levels in six patients. Results.-Over a period of 4 months, 268 cases were reported, of which 240 were clinically evaluated. The most common site of injection (75%) was the finger or palm. Doses were up to 17-fold higher than standard doses for age. In 116 children (48%), systemic effects of atropine were observed, and 20 (8%) had severe atropinization. Seizures and life-threatening arrhythmias were not reported, and there were no fatalities. The severity of atropinization was correlated with the dose following a classic nonlinear, dose-response relationship. Serum atropine levels (6.2 to 61.0 ng/mL) were much higher than those observed after administration of therapeutic doses. Conclusions.-The high incidence of injection in the hand implies accidental use of automatic atropine injectors among children. The lack of mortality or life-threatening complications from injection of large doses of atropine attests to its relative safety in children. The low risk from atropine injections weighed against expected benefit as a lifesaving antidote justifies the distribution of personal atropine injectors to children at risk of organophosphorus nerve agent attack.	CHAIM SHEBA MED CTR, INST CLIN PHARMACOL & TOXICOL, IL-52621 TEL HASHOMER, ISRAEL; SOROKA MED CTR, IL-84101 BEER SHEVA, ISRAEL; ISRAELS NATL POISON INFORMAT CTR, HAIFA, ISRAEL; CHILDRENS MED CTR ISRAEL, PETAH TIQWA, ISRAEL	Chaim Sheba Medical Center; Ben Gurion University; Soroka Medical Center	AMITAI, Y (corresponding author), HADASSAH UNIV HOSP, DEPT PEDIAT, MT SCOPUS, IL-91240 JERUSALEM, ISRAEL.							ADAMS RG, 1982, J CLIN PHARMACOL, V22, P477, DOI 10.1002/j.1552-4604.1982.tb02638.x; BERGHEM L, 1980, BRIT J ANAESTH, V52, P597, DOI 10.1093/bja/52.6.597; Brown JH, 1990, PHARM BASIS THERAPEU, V8th, P150; FASTH A, 1975, ACTA PHARM SUEC, V12, P311; HEATH WE, 1950, BRIT MED J, V2, P608, DOI 10.1136/bmj.2.4679.608; HINDERLING PH, 1985, J PHARM SCI-US, V74, P703, DOI 10.1002/jps.2600740702; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; KETCHUM JS, 1973, PSYCHOPHARMACOLOGIA, V28, P121, DOI 10.1007/BF00421398; Morton HG, 1939, J PEDIATR-US, V14, P755, DOI 10.1016/S0022-3476(39)80097-X; Munns GF, 1929, J AMER MED ASSOC, V96, P171; OLSSON GL, 1983, ANAESTHESIA, V38, P1179, DOI 10.1111/j.1365-2044.1983.tb12521.x; Owens SM, 1890, LANCET, Vii, P443; Pilcher JD, 1934, J PHARMACOL EXP THER, V52, P196; SECORD E, 1991, AM J DIS CHILD, V145, P724	14	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					630	632		10.1001/jama.268.5.630	http://dx.doi.org/10.1001/jama.268.5.630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629992				2022-12-24	WOS:A1992JF47300029
J	FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH				FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH			AN OUTBREAK OF TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT TUBERCLE-BACILLI AMONG PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HAITIAN PATIENTS; FLORIDA	Objective: To evaluate a nosocomial outbreak of tuberculosis caused by multiple-drug-resistant bacilli among patients with tuberculosis and HIV infection. Design: A case-control study. Patients: Patients with HIV infection and culture-proven tuberculosis. Measurements: Patient characteristics, date of diagnoses of HIV infection and disease, date of diagnosis of tuberculosis, Mycobacterium tuberculosis susceptibility results, and medical center contact. Results: Sixty-two patients who had tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients who had tuberculosis caused by susceptible or single-drug-resistant bacilli (controls) were identified. Controls were more likely to be black (odds ratio, 0.4; 95% Cl, 0.2 to 0.9) or Haitian (odds ratio, 0.2; Cl, 0.1 to 0.6) compared with cases, who were more likely to be homosexual men (odds ratio, 2.9; Cl, 1.3 to 6.4). Forty-four cases (71%) had previous contact with an HIV clinic compared with 15 controls (27%) (P < 0.0001). Cases were more likely to have had AIDS (odds ratio, 7.7; Cl, 1.5 to 53.7), to have been hospitalized on an HIV ward (odds ratio, 8.3; Cl, 2.3 to 29.7), to have been seen in an HIV clinic (odds ratio, 7.8; Cl, 3.4 to 18.1), to have received intravenous therapy in an HIV clinic (odds ratio, 13.0; Cl, 4.6 to 37.0), or to have received inhalation pentamidine in an HIV clinic before a diagnosis of tuberculosis was made. Multiple logistic regression analysis showed that a diagnosis of AIDS (odds ratio, 11.2; Cl, 3.1 to 40.6) and HIV clinic visits (odds ratio, 13.0; Cl, 2.7 to 63.7) before a diagnosis of tuberculosis were significantly associated with tuberculosis caused by multiple-drug-resistant bacilli. Using susceptibility patterns and appointment dates, we found that 22 cases had previous contact with a person who had tuberculosis caused by multiple-drug-resistant bacilli in the HIV clinic. Conclusions: Nosocomial transmission of M. tuberculosis from other HIV-infected patients with tuberculosis caused by multiple-drug-resistant bacilli can occur. These findings have serious public health implications and demand strict adherence to acid-fast bacilli isolation precautions.	F KEVIN MURPHY & ASSOCIATES, DALLAS, TX 75218 USA; CLEVELAND CLIN FLORIDA, FT LAUDERDALE, FL 33109 USA; UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	Cleveland Clinic Foundation; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1986, MMWR, V35, P587; 1991, MMWR, V40, P649; 1989, MMWR, V36, P795; 1989, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133; 1990, MMWR, V39, P1	19	342	354	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					177	183		10.7326/0003-4819-117-3-177	http://dx.doi.org/10.7326/0003-4819-117-3-177			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616211				2022-12-24	WOS:A1992JF30400001
J	CUNLIFFE, V; SMITH, JC				CUNLIFFE, V; SMITH, JC			ECTOPIC MESODERM FORMATION IN XENOPUS EMBRYOS CAUSED BY WIDESPREAD EXPRESSION OF A BRACHYURY HOMOLOG	NATURE			English	Article							EARLY AMPHIBIAN EMBRYO; PATTERN; LAEVIS; CELLS; TRANSCRIPTION; ORGANIZATION; ACTIVATION; PROTEIN; MUSCLE; GENES	THE Brachyury (T) gene is required cell-autonomously for mesoderm formation in the posterior of the mouse embryo1,2, and both its complementary DNA sequence and expression pattern3 closely resemble those of a Xenopus homologue (Xbra)4, suggesting that these genes have an evolutionarily conserved function in vertebrate development. Strong expression of Xbra messenger RNA is found in the ring of involuting mesoderm during Xenopus gastrulation 4, and the expression of Xbra is an immediate-early response of animal pole blastomeres to mesoderm-inducing factors4. To assess the role of Xbra in mesoderm formation, we increased its domain of expression in the embryo by microinjection of Xbra transcripts into the animal pole of Xenopus embryos at the one-cell stage. We show that expression of Xbra by cells of the early embryo is sufficient to direct their development into differentiated mesodermal tissues. At the molecular level this response shows a sharp threshold of sensitivity to the dose of Xbra RNA delivered, and we suggest that Xbra may act as a genetic switch initiating posterior mesodermal specification during embryogenesis.			CUNLIFFE, V (corresponding author), NATL INST MED RES, DEV BIOL LAB, RIDGEWAY, MILL HILL, LONDON NW7 1AA, ENGLAND.		Cunliffe, Vincent/E-6170-2010	Smith, Jim/0000-0003-2413-9392; Cunliffe, Vincent/0000-0001-7483-7610				ALTABA ARI, 1989, DEVELOPMENT, V106, P173; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; COOKE J, 1987, DEVELOPMENT, V101, P893; COOKE J, 1979, J EMBRYOL EXP MORPH, V51, P165; DALE L, 1992, DEVELOPMENT, V115, P573; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1990, DEVELOPMENT, V108, P173; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOPWOOD ND, 1990, NATURE, V347, P197, DOI 10.1038/347197a0; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; RASHBASS P, 1991, NATURE, V353, P348, DOI 10.1038/353348a0; RUIZ IA, 1989, CELL, V57, P317; SARGENT MG, 1990, DEVELOPMENT, V109, P967; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; [No title captured]	25	216	216	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 30	1992	358	6385					427	430		10.1038/358427a0	http://dx.doi.org/10.1038/358427a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641026				2022-12-24	WOS:A1992JF85300060
J	STONER, GR; ALBRIGHT, TD				STONER, GR; ALBRIGHT, TD			NEURAL CORRELATES OF PERCEPTUAL MOTION COHERENCE	NATURE			English	Article								THE motions of overlapping contours in a visual scene may arise from the physical motion(s) of either a single or multiple surface(s). A central problem facing the visual motion system is that of assigning the most likely interpretation. The rules underlying this perceptual decision can be explored using a visual stimulus formed by superimposing two moving gratings. The resultant percept is either that of a single coherently moving 'plaid pattern' (coherent motion) or of the two component gratings sliding noncoherently across one another (noncoherent motion)1,2. When plaid patterns are configured to mimic one transparent grating overlying another, the percept of noncoherent motion dominates3. We now report that neurons in the visual cortex of rhesus monkeys exhibit changes in direction tuning that parallel this perceptual phenomenon: sensitivity to the motions of the component gratings is enhanced under conditions that favour the perception of noncoherent motion. These results challenge models of cortical visual processing that fail to take into account the contribution of figural image segmentation cues to the analysis of visual motion.			STONER, GR (corresponding author), SALK INST BIOL STUDIES,VIS CTR LAB,LA JOLLA,CA 92037, USA.							ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ADELSON EH, 1984, J OPT SOC AM A, V1, P1266; BECK J, 1986, HUMAN MACHINE VISION, V2, P1; KOOI FL, IN PRESS PERCEPTION; KRAUSKOPF J, 1990, NATURE, V348, P328, DOI 10.1038/348328a0; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; MOVSHON JA, 1985, STUDY GROUP PATTERN; RODMAN HR, 1989, EXP BRAIN RES, V75, P53; STONER GR, 1990, NATURE, V344, P153, DOI 10.1038/344153a0; STONER GR, 1992, INVEST OPHTH VIS SCI, V33, P1050; VALLORTIGARA G, 1992, VISION RES, V31, P1967	11	147	147	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					412	414		10.1038/358412a0	http://dx.doi.org/10.1038/358412a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641024				2022-12-24	WOS:A1992JF85300055
J	KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK				KAELIN, WG; KREK, W; SELLERS, WR; DECAPRIO, JA; AJCHENBAUM, F; FUCHS, CS; CHITTENDEN, T; LI, Y; FARNHAM, PJ; BLANAR, MA; LIVINGSTON, DM; FLEMINGTON, EK			EXPRESSION CLONING OF A CDNA-ENCODING A RETINOBLASTOMA-BINDING PROTEIN WITH E2F-LIKE PROPERTIES	CELL			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; SV40 LARGE-T; DNA-BINDING; REGULATORY ELEMENT; IMMUNE INTERFERON; MESSENGER-RNA; RB GENE; CELLS	An expression vector was modified to permit the rapid synthesis of purified, P-32-labeled, glutathione S-transferase (GST)-retinoblastoma (RB) fusion proteins. The products were used to screen lambda-gt11 expression libraries, from which we cloned a cDNA encoding a polypeptide (RBAP-1) capable of binding directly to a putative functional domain (the pocket) of the retinoblastoma gene product (RB). The RB "pocket" is known to bind, directly or indirectly, to the cellular transcription factor, E2F, implicated in cell growth control. We have found that RBAP-1 copurifies with E2F, interacts specifically with the adenovirus E4 ORF 6/7 protein, binds specifically and directly to a known E2F DNA recognition sequence, and contains a functional transactivation domain. Therefore, RBAP-1 is a species of E2F and can bind specifically to the RB pocket.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706; UNIV CALIF SAN FRANCISCO,SCH MED,HORMONE RES INST,SAN FRANCISCO,CA 94143	Harvard University; Harvard Medical School; University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California San Francisco	KAELIN, WG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.			Farnham, Peggy/0000-0003-4469-7914				ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BIGGIN M, 1987, J VIROL, V61, P3120, DOI 10.1128/JVI.61.10.3120-3132.1987; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; FOSS K, 1987, GENE, V59, P285, DOI 10.1016/0378-1119(87)90336-2; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG MM, 1989, GENE DEV, V3, P1699, DOI 10.1101/gad.3.11.1699; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEILL SD, 1990, P NATL ACAD SCI USA, V87, P2008, DOI 10.1073/pnas.87.5.2008; NEILL SD, 1991, J VIROL, V65, P5364, DOI 10.1128/JVI.65.10.5364-5373.1991; PRIMIG M, 1992, IN PRESS NATURE; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; REICHEL R, 1988, P NATL ACAD SCI USA, V85, P387, DOI 10.1073/pnas.85.2.387; RICKSTEN A, 1988, NUCLEIC ACIDS RES, V16, P8391, DOI 10.1093/nar/16.17.8391; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	73	845	890	1	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					351	364		10.1016/0092-8674(92)90108-O	http://dx.doi.org/10.1016/0092-8674(92)90108-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638635				2022-12-24	WOS:A1992JE75700017
J	GOLDFRANK, LR				GOLDFRANK, LR			MEDICAL TOXICOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							2,3-DIMERCAPTOSUCCINIC ACID; BENZODIAZEPINES; FLUMAZENIL; ANTIBODIES; REVERSAL		NYU MED CTR,NEW YORK,NY 10016	New York University	GOLDFRANK, LR (corresponding author), BELLEVUE HOSP CTR,NEW YORK,NY 10016, USA.							BASILE AS, 1991, NEW ENGL J MED, V325, P473, DOI 10.1056/NEJM199108153250705; BOSMAN DK, 1991, GASTROENTEROLOGY, V101, P772, DOI 10.1016/0016-5085(91)90538-V; BOWYER K, 1980, CHEST, V77, P232, DOI 10.1378/chest.77.2.232; BRUNN GJ, 1991, INT J IMMUNOPHARMACO, V13, P841, DOI 10.1016/0192-0561(91)90035-6; BURR W, 1989, BRIT MED J, V298, P1713, DOI 10.1136/bmj.298.6689.1713-a; GRAZIANO JH, 1986, MED TOXICOL ADV DRUG, V1, P155, DOI 10.1007/BF03259834; GRAZIANO JH, 1988, J PEDIATR-US, V113, P751, DOI 10.1016/S0022-3476(88)80396-2; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LOPEZ A, 1990, CRIT CARE MED, V18, P1480, DOI 10.1097/00003246-199012000-00032; OBOYLE C, 1983, BRIT J ANAESTH, V55, P349, DOI 10.1093/bja/55.4.349; OSULLIVAN GF, 1987, CLIN PHARMACOL THER, V42, P254, DOI 10.1038/clpt.1987.143; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233; PRISCHL F, 1988, MED TOXICOL ADV DRUG, V3, P334, DOI 10.1007/BF03259944; SCANLON JW, 1991, REPROD TOXICOL, V5, P89, DOI 10.1016/0890-6238(91)90037-G; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; TERRIEN N, 1990, TOXICOL APPL PHARM, V104, P504, DOI 10.1016/0041-008X(90)90172-Q; WEISMAN RS, 1991, J TOXICOL-CLIN TOXIC, V29, P553, DOI 10.3109/15563659109025754; 1991, STRATEGIC PLAN ELIMI; 1988, ROLE PRIMARY CARE PH	21	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					375	376						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613924				2022-12-24	WOS:A1992JC35200036
J	STANLEY, FJ; WATSON, L				STANLEY, FJ; WATSON, L			TRENDS IN PERINATAL-MORTALITY AND CEREBRAL-PALSY IN WESTERN-AUSTRALIA, 1967 TO 1985	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; WHITE MATTER NECROSIS; CHANGING PANORAMA; INTRAPARTUM ASPHYXIA; GESTATIONAL-AGE; SWEDEN; PERIOD; DAMAGE	Objective-To analyse the trends in stillbirths, neonatal deaths, and cerebral palsy in all infants born in Western Australia from 1967 to 1985. To relate these trends to changes in perinatal care, particularly in relation to avoidance of intrapartum asphyxia in term infants and the increased survival of low birthweight infants. Design-Descriptive epidemiological study calculating population rates for perinatal deaths and cerebral palsy according to year of birth and birth weight. Setting-Western Australia. Subjects-All infants born after 20 weeks' gestation or weighing at least 400 g (live and stillborn). Main Outcome Measures-Stillbirths, neonatal deaths (from perinatal death certificates), and cerebral palsy (from a population based register). Results-Overall stillbirth rates fell from 12.1/1000 total births in 1967-70 to 8.1 in 1983-5. Early neonatal mortality fell from 13.0/1000 live births to 4-4 over the same period whereas total cerebral palsy rates remained at around 2-2.5/1000 live births. Death rates fell in all birth weight categories, particularly in low birthweight infants between 1975 and 1985, the period when birthweight data were available. In contrast, cerebral palsy rates in infants under 1500 g rose significantly over this period (from 12.1 in 1968 to 64.9 in 1985). The rise was seen in all spastic categories, including severely and multiply handicapped children. Conclusions-Large increases in the use of interventions aimed at reducing birth asphyxia and handicaps had not (by 1985) resulted in lower rates of cerebral palsy. This suggests that birth asphyxia is not a major cause. The increased survival of low birthweight infants has resulted in more cerebral palsy in this group, due either to postnatal complications of immaturity or prenatal damage to the fetal brain. These findings have implications for planning perinatal care and for litigation for putative obstetric malpractice in cerebral palsy cases.			STANLEY, FJ (corresponding author), PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.							ALBERMAN E, 1963, Dev Med Child Neurol, V5, P388; ARMSTRONG DL, 1987, AM J DIS CHILD, V141, P617, DOI 10.1001/archpedi.1987.04460060035027; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEJAR R, 1986, ANN NEUROL, V20, P436; BERNFIELD M, 1990, PEDIATR RES, V27, P21; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR E, 1985, DEV MED CHILD NEUROL, V27, P615; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COOKE RWI, 1987, ARCH DIS CHILD, V62, P931, DOI 10.1136/adc.62.9.931; DOWDING VM, 1988, IRISH MED J, V81, P25; FISHER CC, 1990, MED J AUSTRALIA, V153, P639, DOI 10.5694/j.1326-5377.1990.tb126307.x; FREEMAN JM, 1988, PEDIATRICS, V82, P240; GEE V, 1989, PERINATAL STATISTICS; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; HAGBERG B, 1989, BRAIN DEV-JPN, V11, P368, DOI 10.1016/S0387-7604(89)80018-X; HILL C, 1987, VALIDATION STUDY W A; KITCHEN WH, 1987, AM J PERINAT, V4, P29, DOI 10.1055/s-2007-999733; LARROCHE JC, 1986, BIOL NEONATE, V50, P61; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; MCDONALD AD, 1963, ARCH DIS CHILD, V38, P579, DOI 10.1136/adc.38.202.579; MOORE DJ, 1987, PERINATAL STATISTICS; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PANETH N, 1990, J PEDIATR-US, V116, P975, DOI 10.1016/S0022-3476(05)80664-X; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1971, LANCET, V1, P308; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SARNAT HB, 1987, AM J DIS CHILD, V141, P969, DOI 10.1001/archpedi.1987.04460090046022; SHEARER MH, 1986, BIRTHS, V12, P151; STANLEY F J, 1985, Neuroepidemiology, V4, P146, DOI 10.1159/000110226; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STANLEY FJ, 1986, AM J PUBLIC HEALTH, V76, P35, DOI 10.2105/AJPH.76.1.35; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, LANCET, V2, P1251	39	174	175	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1658	1663		10.1136/bmj.304.6843.1658	http://dx.doi.org/10.1136/bmj.304.6843.1658			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633518	Green Published, Bronze			2022-12-24	WOS:A1992JB93900020
J	CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P				CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P			NUCLEAR-LOCALIZATION OF AGROBACTERIUM VIRE2 PROTEIN IN PLANT-CELLS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; TOBACCO MOSAIC-VIRUS; BINDING-PROTEIN; T-DNA; VIRD2 PROTEIN; 5' END; TUMEFACIENS; PLASMID; COMPLEX; ASSOCIATION	The Agrobacterium single-stranded DNA (ssDNA) intermediate T-strand is likely transferred to the plant cell nucleus as a complex with a single VirD2 molecule at its 5' end and multiple VirE2 molecules along its length. VirD2 contains a nuclear localization signal (NLS); however, because the T-strand is principally coated with VirE2 molecules, VirE2 also might assist in nuclear uptake. Indeed, VirE2 fused to a reporter protein localizes to plant cell nuclei, a process mediated by two amino acid sequences with homology to the bipartite NLS of Xenopus nucleoplasmin. Moreover, tumorigenicity of an avirulent virE2 mutant is restored when inoculated on transgenic plants expressing VirE2, supporting in planta function of VirE2.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,GENET & PLANT BIOL BLDG,BERKELEY,CA 94720; SANDOZ CROP PROTECT CORP,PALO ALTO,CA 94304	University of California System; University of California Berkeley; Novartis; Sandoz				Citovsky, Vitaly/0000-0003-2024-6844	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM045244, R01GM045244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45244-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; DAS A, 1988, P NATL ACAD SCI USA, V85, P2909, DOI 10.1073/pnas.85.9.2909; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GERACE L, 1988, ANN REV CELL BIOL, V4, P355; GIETL C, 1987, P NATL ACAD SCI USA, V84, P9006, DOI 10.1073/pnas.84.24.9006; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HODGES LM, UNPUB; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HOWARD E, 1990, BIOESSAYS, V12, P103, DOI 10.1002/bies.950120302; HOWARD E, 1990, UCLA SYM BI, V129, P1; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; HOWARD EA, 1992, BIOESSAYS, V68, P109; KNORR DA, 1988, P NATL ACAD SCI USA, V85, P170, DOI 10.1073/pnas.85.1.170; LEHTO K, 1990, VIROLOGY, V174, P290, DOI 10.1016/0042-6822(90)90077-5; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCDONNELL RE, 1987, PLANT MOL BIOL REP, V5, P380; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; WINANS SC, 1987, NUCLEIC ACIDS RES, V15, P825, DOI 10.1093/nar/15.2.825; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	35	217	244	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1802	1805		10.1126/science.1615325	http://dx.doi.org/10.1126/science.1615325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615325				2022-12-24	WOS:A1992JA43400031
J	GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M				GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M			THE MOTOR CORTEX AND THE CODING OF FORCE	SCIENCE			English	Article							FREE ARM MOVEMENTS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; VISUAL TARGETS; CELL DISCHARGE; DIRECTION; MONKEY; DYNAMICS; PATTERN; MUSCLE	The relation of cellular activity in the motor cortex to the direction of two-dimensional isometric force was investigated under dynamic conditions in monkeys. A task was designed so that three force variables were dissociated: the force exerted by the subject, the net force, and the change in force. Recordings of neuronal activity in the motor cortex revealed that the activity of single cells was directionally tuned and that this tuning was invariant across different directions of a bias force. Cell activity was not related to the direction of force exerted by the subject, which changed drastically as the bias force changed. In contrast, the direction of net force, the direction of force change, and the visually instructed direction all remained quite invariant and congruent and could be the directional variables, alone or in combination, to which cell activity might relate.	UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	GEORGOPOULOS, AP (corresponding author), VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55455, USA.		SMYRNIS, NIKOLAOS/B-9822-2011; Smyrnis, Nikolaos/AAA-3783-2020		NINDS NIH HHS [NS17413, NS07226] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS007226, R01NS017413] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; Bernstein N.A., 1967, COORDINATION REGULAT; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; CONRAD B, 1977, EXP BRAIN RES, V29, P85; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; EVARTS EV, 1969, J NEUROPHYSIOL, V32, P375, DOI 10.1152/jn.1969.32.3.375; FLANDERS M, 1992, J NEUROPHYSIOL, V67, P931, DOI 10.1152/jn.1992.67.4.931; FROMM C, 1983, PFLUG ARCH EUR J PHY, V398, P318, DOI 10.1007/BF00657241; Georgopoulos A. P., 1984, DYNAMIC ASPECTS NEOC, P501; GEORGOPOULOS AP, 1985, BEHAV BRAIN RES, V18, P159, DOI 10.1016/0166-4328(85)90071-3; GEORGOPOULOS AP, 1991, ANNU REV NEUROSCI, V14, P361, DOI 10.1146/annurev.ne.14.030191.002045; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GHEZ C, 1979, INTEGRATION NERVOUS, P307; GIBSON AR, 1985, J PHYSIOL-LONDON, V358, P551, DOI 10.1113/jphysiol.1985.sp015566; GROBSTEIN P, 1988, BRAIN BEHAV EVOLUT, V31, P34, DOI 10.1159/000116574; HEPPREYMOND MC, 1978, J PHYSIOL-PARIS, V74, P287; HOCHERMAN S, 1991, EXP BRAIN RES, V83, P285; HOLLERBACH JM, 1982, BIOL CYBERN, V44, P67, DOI 10.1007/BF00353957; Humphrey D R, 1983, Adv Neurol, V39, P347; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KALASKA JF, 1991, MOTOR CONTROL CONCEP, P307; LURITO J T, 1991, Society for Neuroscience Abstracts, V17, P1226; LURITO J T, 1990, Society for Neuroscience Abstracts, V16, P1087; MARTIN JH, 1985, EXP BRAIN RES, V57, P427; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MASSEY JT, 1991, EXP BRAIN RES, V83, P439, DOI 10.1007/BF00231170; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SNEDECOR GW, 1980, STATISTICAL METHODS, P288; SOECHTING JF, 1987, NEUROSCIENCE, V23, P39, DOI 10.1016/0306-4522(87)90269-7; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; VIVIANI P, 1982, NEUROSCIENCE, V7, P431, DOI 10.1016/0306-4522(82)90277-9; [No title captured]	45	281	287	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1692	1695		10.1126/science.256.5064.1692	http://dx.doi.org/10.1126/science.256.5064.1692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609282				2022-12-24	WOS:A1992HZ17400049
J	MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF				MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF			GUSTDUCIN IS A TASTE-CELL-SPECIFIC G-PROTEIN CLOSELY RELATED TO THE TRANSDUCINS	NATURE			English	Article							AMINO-ACID SEQUENCE; CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; INHIBITORY SUBUNIT; ADENOSINE RECEPTOR; ELONGATION-FACTORS; PERTUSSIS TOXIN	A novel G protein alpha-subunit (alpha-gustducin) has been identified and cloned from taste tissue. Alpha-gustducin messenger RNA is expressed in taste buds of all taste papillae (circumvallate, foliate and fungiform); it is not expressed in non-sensory portions of the tongue, nor is it expressed in the other tissues examined. Alpha-gustducin most closely resembles the transducins (the rod and cone photoreceptor G proteins), suggesting that gustducin's role in taste transduction is analogous to that of transducin in light transduction.	ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				Margolskee, Robert/0000-0002-9572-2887				AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; Ausubel F, 1989, MOL REPROD DEV, V1, P146; AVENET P, 1987, J MEMBRANE BIOL, V97, P223, DOI 10.1007/BF01869225; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; BEIDLER LM, 1970, CIBA F S, P51; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIADEI PPC, 1970, 2ND S OR SENS PERC, P5; GROVERJOHNSON N, 1976, CELL TISSUE RES, V169, P395; GUTH L, 1963, EXP NEUROL, V8, P336, DOI 10.1016/0014-4886(63)90085-2; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KURIHARA K, 1972, BIOCHEM BIOPH RES CO, V48, P30, DOI 10.1016/0006-291X(72)90339-7; LAW JS, 1982, RES COMMUN CHEM PATH, V38, P439; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAVON SE, 1988, J BIOL CHEM, V263, P489; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; REUTTER K, 1971, Z ZELLFORSCH MIK ANA, V120, P280, DOI 10.1007/BF00335540; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; Sambrook J., 1989, MOL CLONING; SCHIFFMAN SS, 1983, P NATL ACAD SCI-BIOL, V80, P6136, DOI 10.1073/pnas.80.19.6136; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPICKOFSKY N, 1992, ASS CHEMORECEPTION S, V14, P192; SPIELMAN AI, 1989, CHEM SENSES, V14, P841, DOI 10.1093/chemse/14.6.841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRIEM BJ, 1990, CHEM SENSES, V15, P529, DOI 10.1093/chemse/15.5.529; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	60	538	565	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					563	569		10.1038/357563a0	http://dx.doi.org/10.1038/357563a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608467				2022-12-24	WOS:A1992HZ11200044
J	SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH				SALTZMAN, LE; MERCY, JA; OCARROLL, PW; ROSENBERG, ML; RHODES, PH			WEAPON INVOLVEMENT AND INJURY OUTCOMES IN FAMILY AND INTIMATE ASSAULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; HOMICIDE; WOMEN; GUNS	Objective. - To compare the risk of death and the risk of nonfatal injury during firearm-associated family and intimate assaults (FIAs) with the risks during non-firearm-associated FiAs. Design. - Records review of police incident reports of FIAs that occurred in 1984. Victim outcomes (death, nonfatal injury, no injury) and weapon involvement were examined for incidents involving only one perpetrator. Setting. - City of Atlanta, Ga, within Fulton County. Participants. - Stratified sample (n = 142) of victims of nonfatal FIAs, drawn from seven nonfatal crime categories, plus all fatal victims (n = 23) of FIAs. Main Outcome Measures.-Risk of death (vs nonfatal injury or no injury) during FIAs involving firearms, relative to other types of weapons; risk of nonfatal injury (vs all other outcomes, including death) during FIAs involving firearms, relative to other types of weapons. Results. - Firearm-associated FIAs were 3.O times (95% confidence interval, 0.9 to 10.0) more likely to result in death than FIAs involving knives or other cutting instruments and 23.4 times (95% confidence interval, 7.0 to 78.6) more likely to result in death than FIAs involving other weapons or bodily force. Overall, firearm-associated FIAs were 12.0 times (95% confidence interval, 4.6 to 31.5) more likely to result in death than non-firearm-associated FIAs. Conclusions. - Strategies for limiting the number of deaths and injuries resulting from FIAs include reducing the access of potential FIA assailants to firearms, modifying firearm lethality through redesign, and establishing programs for primary prevention of violence among intimates.			SALTZMAN, LE (corresponding author), CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,DIV INJURY CONTROL,ATLANTA,GA 30333, USA.				PHS HHS [U50/CCU400931-01-1] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMS D, 1982, ABUSIVE PARTNER ANAL, P170; [Anonymous], 1968, U CHICAGO LAW REV; BAKER SP, 1985, AM J PUBLIC HEALTH, V75, P587, DOI 10.2105/AJPH.75.6.587; BILLINGHAM RE, 1987, FAM RELAT, V36, P283, DOI 10.2307/583541; Campbell J, 1981, ANS Adv Nurs Sci, V3, P67; Conklin JE, 1972, ROBBERY CRIMINAL JUS; Cook P., 1991, CRIME JUSTICE REV RE, P1; COOK PJ, 1981, ANN AM ACAD POLIT SS, V455, P63, DOI 10.1177/000271628145500107; COOK PJ, 1987, J CRIM LAW CRIM, V78, P357, DOI 10.2307/1143453; Cox DR, 1974, THEORETICAL STATISTI; FOLLINGSTAD DR, 1988, CLIN PSYCHOL REV, V8, P373, DOI 10.1016/0272-7358(88)90065-7; Gelles R., 1990, INTIMATE VIOLENCE FA, V2nd ed.; Goetting A., 1989, J FAM VIOLENCE, V4, P285, DOI [10.1007/bf00980429Goetting, DOI 10.1007/BF00980429GOETTING]; HABER JD, 1985, AM J NURS, V85, P1010, DOI 10.2307/3425176; HEDEBOE J, 1985, AM J PUBLIC HEALTH, V75, P651, DOI 10.2105/AJPH.75.6.651; Hotaling G T, 1986, Violence Vict, V1, P101; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Levy B., 1984, SKILLS VIOLENCE FREE; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; Mercy J A, 1988, Violence Vict, V3, P285; PARROT A, 1986, ACQUAINTANCE RAPE SE; Rand M., 1986, USE WEAPONS COMMITTI; RAND MR, 1990, HANDGUN CRIME VICTIM; SALTZMAN L, 1977, IN PRESS AM J PUBLIC; Saltzman L E, 1990, Violence Vict, V5, P3; SAUNDERS DG, 1991, EMERG CARE Q, V7, P51; Schulman Mark, 1979, SURVEY SPOUSAL VIOLE; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; SPROULE CF, 1989, CAN J CRIMINOL, V31, P245; STARK E, 1981, OFFICE DOMESTIC VIOL, V7; Stets J.E., 1989, PHYSICAL VIOLENCE AM, P151; STRAUS MA, 1986, B NEW YORK ACAD MED, V62, P446; SWEETMAN S, 1987, REPORT ATTORNEY GENE; TESKE R, 1983, SPOUSE ABUSE TEXAS S; WEBSTER DE, 1991, ISSUES SCI TECHN SPR, P73; WIDOM CS, 1989, SCIENCE, V244, P160, DOI 10.1126/science.2704995; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; 1958, VITAL STATISTICS MOR; 1989, INJURY PREVENTION M; 1991, HLTH PEOPLE 2000 NAT; 1991, NATIONAL CRIME SURVE; 1989, MMWR, V38, P17; 1984, PREVENTING FAMILY VI; 1990, CRIMINAL VICTIMIZATI	45	88	88	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3043	3047		10.1001/jama.267.22.3043	http://dx.doi.org/10.1001/jama.267.22.3043			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588718				2022-12-24	WOS:A1992HW97000024
J	KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA				KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA			A NOVEL TRANSCRIPTION FACTOR REVEALS A FUNCTIONAL LINK BETWEEN THE RNA POLYMERASE-II CTD AND TFIID	CELL			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; REPEAT DOMAIN; SACCHAROMYCES-CEREVISIAE; HEPTAPEPTIDE REPEAT; INITIATION; YEAST; PHOSPHORYLATION; PROMOTER; PROTEIN	The RNA polymerase II large subunit carboxy-terminal domain (CTD) plays a role in transcription initiation, but its mechanism of action is not well understood. We have investigated the function of the SRB2 gene, which was isolated as a dominant suppressor of CTD truncation mutations. The allele specificity of this suppressor indicates that SRB2 and the CTD are involved in the same function. Indeed, cells lacking SRB2 and cells lacking a large portion of the CTD exhibit the same set of conditional growth phenotypes and exhibit very similar defects in gene expression in vivo. The SRB2 protein is a novel transcription factor that has an important role in basal and activated transcription in vitro and is essential for efficient establishment of the transcription initiation apparatus. Template commitment experiments suggest that SRB2 becomes physically associated with the transcription initiation complex. We f ind that SRB2 binds specifically to TFIID. As SRB2 and the RNA polymerase II CTD are involved in the same function, these results reveal a functional link between the CTD and the TATA-binding factor. This study implicates the CTD in recruitment of RNA polymerase II to the transcription initiation complex.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KOLESKE, AJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1992, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDLER RT, 1983, P NATL ACAD SCI USA, V80, P2432; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARLOW E, 1988, ANTIBODIES LABORATOR; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; Sambrook J., 1989, MOL CLONING LAB MANU; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, IN PRESS PROG NUCL A; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	65	153	155	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					883	894		10.1016/0092-8674(92)90298-Q	http://dx.doi.org/10.1016/0092-8674(92)90298-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591782				2022-12-24	WOS:A1992HW83800017
J	PELOSI, AJ; APPLEBY, L				PELOSI, AJ; APPLEBY, L			PSYCHOLOGICAL INFLUENCES ON CANCER AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTORS		UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	PELOSI, AJ (corresponding author), HAIRMYRES HOSP,E KILBRIDE G75 8RG,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				BINIK YM, 1991, BEHAV RES THER, V29, P33, DOI 10.1016/S0005-7967(09)80004-1; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1989, J SOC POLIT ECON ST, V14, P25; EYSENCK HJ, 1985, PERS INDIV DIFFER, V6, P535, DOI 10.1016/0191-8869(85)90003-0; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1986, SMOKING SOC MORE BAL; FOX BH, 1988, TOPICS HLTH PSYCHOL, P37; GROSSARTHMATICE.R, 1988, PRIMARY PREVENTION C, P199; GROSSARTHMATICE.R, 1980, PSYCHOTHER PSYCHOSOM, V33, P120; GROSSARTHMATICE.R, 1988, TOPICS HLTH PSYCHOL, P57; GROSSARTHMATICEK R, 1984, CANCER DETECT PREV, V7, P201; GROSSARTHMATICEK R, 1990, J BEHAV THER EXP PSY, V21, P91, DOI 10.1016/0005-7916(90)90014-C; GROSSARTHMATICEK R, 1983, PSYCHOTHER PSYCHOSOM, V40, P191, DOI 10.1159/000287767; GROSSARTHMATICEK R, 1985, J PSYCHOSOM RES, V29, P167, DOI 10.1016/0022-3999(85)90038-8; GROSSARTHMATICEK R, 1982, SOC SCI MED, V16, P493, DOI 10.1016/0277-9536(82)90058-2; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P1; GROSSARTHMATICEK R, 1980, PSYCHOTHER PSYCHOSOM, V33, P129, DOI 10.1159/000287423; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSARTHMATICEK R, 1990, PSYCHOL REP, V66, P355, DOI 10.2466/PR0.66.2.355-373; GROSSARTHMATICEK R, 1989, PSYCHOL REP, V65, P177, DOI 10.2466/pr0.1989.65.1.177; GROSSARTHMATICK R, 1985, PERS INDIV DIFFER, V6, P313, DOI 10.1016/0191-8869(85)90055-8	21	29	29	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1295	1298		10.1136/bmj.304.6837.1295	http://dx.doi.org/10.1136/bmj.304.6837.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606436	Bronze, Green Published			2022-12-24	WOS:A1992HV08600029
J	POGGIO, T; FAHLE, M; EDELMAN, S				POGGIO, T; FAHLE, M; EDELMAN, S			FAST PERCEPTUAL-LEARNING IN VISUAL HYPERACUITY	SCIENCE			English	Article							ORIENTATION; IMPROVEMENT	In many different spatial discrimination tasks, such as in determining the sign of the offset in a vernier stimulus, the human visual system exhibits hyperacuity by evaluating spatial relations with the precision of a fraction of a photoreceptor's diameter. It is proposed that this impressive performance depends in part on a fast learning process that uses relatively few examples and that occurs at an early processing stage in the visual pathway. This hypothesis is given support by the demonstration that it is possible to synthesize, from a small number of examples of a given task, a simple network that attains the required performance level. Psychophysical experiments agree with some of the key predictions of the model. In particular, fast stimulus-specific learning is found to take place in the human visual system, and this learning does not transfer between two slightly different hyperacuity tasks.	WEIZMANN INST SCI, DEPT APPL MATH & COMP SCI, IL-76100 REHOVOT, ISRAEL; UNIV TUBINGEN, EYE CLIN, DEPT NEUROOPHTHALMOL, W-7400 TUBINGEN 1, GERMANY	Weizmann Institute of Science; Eberhard Karls University of Tubingen	POGGIO, T (corresponding author), MIT, CTR BIOL INFORMAT PROC, ARTIFICIAL INTELLIGENCE LAB, CAMBRIDGE, MA 02139 USA.							BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968; BARLOW HB, 1979, NATURE, V279, P189, DOI 10.1038/279189a0; BENNETT RG, 1991, PERCEPT PSYCHOPHYS, V49, P541, DOI 10.3758/BF03212188; Black H. S., 1953, MODULATION THEORY; BRUNELLI R, 1991, IRST9111004 I RIC SC; BRUNELLI R, 1991, 12TH P INT JOINT C A; CRICK FHC, 1980, ORG CEREBRAL CORTEX, P505; Duda R. O., 1973, PATTERN CLASSIFICATI; EDELMAN S, 1991, BIOL CYBERN, V64, P209, DOI 10.1007/BF00201981; EDELMAN S, IN PRESS INT J PATTE; EDELMAN S, 1990, AI MEMO MIT ARTIFICI, V1181; EDELMAN S, IN PRESS IMAGE PRO B; EDELMAN S, 1991, CSTR9120 WEIZM I DEP; FAHLE M, UNPUB; FIORENTINI A, 1980, NATURE, V287, P43, DOI 10.1038/287043a0; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MARUYAMA M, 1992, AI MEMO MIT ARTIFICI, V1291; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097; Omohundro S. M., 1987, Complex Systems, V1, P273; POGGIO T, 1990, P IEEE, V78, P1481, DOI 10.1109/5.58326; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; POGGIO T, 1989, AI MEMO MIT ARTIFICI, V1140; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; WATT R J, 1985, Spatial Vision, V1, P31, DOI 10.1163/156856885X00053; WEISS Y, 1991, CSTR9121 WEIZM I DEP; WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4	29	438	444	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1018	1021		10.1126/science.1589770	http://dx.doi.org/10.1126/science.1589770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589770	Green Submitted			2022-12-24	WOS:A1992HU22400038
J	BHOPAL, RS; DIGGLE, P; ROWLINGSON, B				BHOPAL, RS; DIGGLE, P; ROWLINGSON, B			PINPOINTING CLUSTERS OF APPARENTLY SPORADIC CASES OF LEGIONNAIRES-DISEASE	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To test the hypothesis that many non-outbreak cases of legionnaires' disease are not sporadic and to attempt to pinpoint cases clustering in space and time. Design - Descriptive study of a case series, 1978-86. Setting - 15 health boards in Scotland. Patients - 203 probable cases of non-outbreak, non-travel, community acquired legionnaires' disease in patients resident in Scotland. Main measures - Date of onset of disease and postcode and health board of residence of cases. Results - Space-time clustering was present and numerous groups of cases were identified, all but two being newly recognised. Nine cases occurred during three months within two postcodes in Edinburgh, and an outbreak was probably missed. In several places cases occurred in one area over a prolonged period-for example, nine cases in postcode districts G11.5 and G12.8 in Glasgow during five years (estimated mean annual incidence of community acquired, non-outbreak, non-travel legionnaires' disease of 146 per million residents v 4.8 per million for Scotland). Statistical analysis showed that the space time clustering of cases in the Glasgow and Edinburgh areas was unusual (p = 0.036, p = 0.068 respectively). Conclusion - Future surveillance requires greater awareness that clusters can be overlooked; case searching whenever a case is identified; collection of complete information particularly of date of onset of the disease and address or postcode; ongoing analysis for space-time clustering; and an accurate yet workable definition of sporadic cases. Other researchers should re-examine their data on apparently sporadic infection.	UNIV LANCASTER,SCH ENGN COMP & MATH SCI,DEPT MATH,LANCASTER LA1 4YF,ENGLAND	Lancaster University	BHOPAL, RS (corresponding author), SCH HLTH CARE SCI,DIV EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,ENGLAND.		Diggle, Peter J/A-3025-2009	Rowlingson, Barry/0000-0002-8586-6625; Diggle, Peter/0000-0003-3521-5020				ADDISS DG, 1989, J INFECT DIS, V159, P572, DOI 10.1093/infdis/159.3.572; BARTLETT CLR, 1986, LEGIONELLA INFECTION; BHOPAL R S, 1990, Health Bulletin (Edinburgh), V48, P288; BHOPAL RS, 1991, J INFECTION, V22, P153, DOI 10.1016/0163-4453(91)91569-J; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P281; BHOPAL RS, 1991, EPIDEMIOL INFECT, V106, P45, DOI 10.1017/S0950268800056430; BHOPAL RS, 1991, BRIT MED J, V302, P378, DOI 10.1136/bmj.302.6773.378; BHOPAL RS, 1991, J INFECTION, V22, P97, DOI 10.1016/0163-4453(91)91178-Z; DIGGLE P., 1985, APPL STAT-J ROY ST C, V34, P138, DOI DOI 10.2307/2347366; DIGGLE PJ, 1983, STATISTICAL ANAL SPA; DIGGLE PJ, 1991, 2ND ORDER ANAL SPACE; ENGLAND AC, 1981, ANN INTERN MED, V94, P164, DOI 10.7326/0003-4819-94-2-164; FALLON RJ, 1982, J HYG-CAMBRIDGE, V89, P439, DOI 10.1017/S002217240007100X; GATRELL AC, 1991, ENVIRON PLANN A, V23, P1447, DOI 10.1068/a231447; HELMS CM, 1984, AM J MED SCI, V288, P2, DOI 10.1097/00000441-198407000-00001; KNOX G, 1963, BRIT J PREV SOC MED, V17, P121; MCFARLANE JT, 1990, RESPIRATORY MED, P906; Nimmo A W, 1984, Health Bull (Edinb), V42, P199; RASHED K, 1986, LANCET, V1, P197; Ripley B.D., 1981, SPAT STAT-NETH, DOI 10.1002/0471725218; ROTHMAN KJ, 1990, AM J EPIDEMIOL, V132, pS6, DOI 10.1093/oxfordjournals.aje.a115790; STOUT JE, 1987, JAMA-J AM MED ASSOC, V257, P1215, DOI 10.1001/jama.257.9.1215; TIMBURY MC, 1986, J HYG-CAMBRIDGE, V97, P393, DOI 10.1017/S0022172400063580; 1986, LANCET, V2, P380; 1987, 2ND COMM INQ REP	25	32	32	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1022	1027		10.1136/bmj.304.6833.1022	http://dx.doi.org/10.1136/bmj.304.6833.1022			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586784	Bronze, Green Published			2022-12-24	WOS:A1992HQ14200020
J	SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M				SADLER, DW; POUNDER, DJ; URQUHART, GED; PORTERBOVERI, M			PREVALENCE OF HIV ANTIBODY IN FORENSIC CASES	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,ROYAL INFIRM,DEPT FORENS MED,DUNDEE DD1 9ND,SCOTLAND; TAYSIDE HLTH BOARD,DEPT PUBL HLTH MED,DUNDEE,SCOTLAND; UNIV DUNDEE,ROYAL INFIRM,DEPT MED MICROBIOL,DUNDEE DD1 9ND,SCOTLAND	Royal Infirmary of Edinburgh; University of Dundee; Royal Infirmary of Edinburgh; University of Dundee								EVANS BG, 1991, BRIT MED J, V302, P1351, DOI 10.1136/bmj.302.6789.1351; MCCORMICK A, 1991, BRIT MED J, V302, P1365, DOI 10.1136/bmj.302.6789.1365; MOSS AR, 1973, AIDS, V3, P5589; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; 1991, LANCET, V337, P950	5	10	10	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1027	1028		10.1136/bmj.304.6833.1027	http://dx.doi.org/10.1136/bmj.304.6833.1027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586785	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200021
J	NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B				NISHISHO, I; NAKAMURA, Y; MIYOSHI, Y; MIKI, Y; ANDO, H; HORII, A; KOYAMA, K; UTSUNOMIYA, J; BABA, S; HEDGE, P; MARKHAM, A; KRUSH, AJ; PETERSEN, G; HAMILTON, SR; NILBERT, MC; LEVY, DB; BRYAN, TM; PREISINGER, AC; SMITH, KJ; SU, LK; KINZLER, KW; VOGELSTEIN, B			MUTATIONS OF CHROMOSOME-5Q21 GENES IN FAP AND COLORECTAL-CANCER PATIENTS	SCIENCE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; P53 GENE; CELL-LINES; CARCINOMAS; RATES; COLI; TUMORIGENESIS; ANTIONCOGENES; LOCALIZATION; ONCOGENES	Previous studies suggested that one or more genes on chromosome 5q2l are responsible for the inheritance of familial adenomatous polyposis (FAP) and Gardner's syndrome (GS), and contribute to tumor development in patients with noninherited forms of colorectal cancer. Two genes on 5q2l that are tightly linked to FAP (MCC and APC) were found to be somatically altered in tumors from sporadic colorectal cancer patients. One of the genes (APC) was also found to be altered by point mutation in the germ line of FAP and GS patients. These data suggest that more than one gene on chromosome 5q2l may contribute to colorectal neoplasia, and that mutations of the APC gene can cause both FAP and GS. The identification of these genes should aid in understanding the pathogenesis of colorectal neoplasia and in the diagnosis and counseling of patients with inherited predispositions to colorectal cancer.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOKYO 170,JAPAN; HYOGO MED UNIV,DEPT SURG 2,NISHINOMIYA,HYOGO 663,JAPAN; HAMAMATSU MED COLL,DEPT SURG 2,SHIZUOKA 43131,JAPAN; ICI PLC,PHARMACEUT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,DEPT MED,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,MOLEC GENET LAB,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH HYG,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH PUBL HLTH,BALTIMORE,MD 21218	Japanese Foundation for Cancer Research; Hyogo College of Medicine; University of Hyogo; Hamamatsu University School of Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Horii, Akira/AAW-2839-2021; Bryan, Tracy M/B-8468-2014	Horii, Akira/0000-0002-3967-3291; Nilbert, Mef/0000-0003-2717-1937; Bryan, Tracy/0000-0002-7990-5501	NCI NIH HHS [CA35494, CA44688, CA06973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044688, R01CA035494, R37CA035494, P30CA006973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1989, ONCOGENE, V4, P1169; ASHTONRICKARDT PG, IN PRESS ONCOGENE; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BELDJORD C, 1988, NUCLEIC ACIDS RES, V16, P4927, DOI 10.1093/nar/16.11.4927; BISHOPJM, 1990, CELL, V64, P235; BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BONADIO J, 1990, J BIOL CHEM, V265, P2262; CHIBA I, 1990, ONCOGENE, V5, P1603; DELATTRE O, 1989, LANCET, V2, P353; DUNLOP MG, 1989, GENOMICS, V5, P350, DOI 10.1016/0888-7543(89)90068-2; ELMORE E, 1983, CANCER RES, V43, P1650; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GROSS ME, 1991, CANCER RES, V51, P1452; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAO QL, 1989, MOL CELL BIOL, V9, P1587, DOI 10.1128/MCB.9.4.1587; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; JOSLYN G, IN PRESS CELL; KADEN D, 1989, CANCER RES, V49, P3374; KENDAL WS, 1986, CANCER RES, V46, P6131; KHAN PM, 1988, HUM GENET, V79, P183, DOI 10.1007/BF00280563; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1985, CANCER RES, V45, P1437; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LEPPERT M, 1990, NEW ENGL J MED, V322, P904, DOI 10.1056/NEJM199003293221306; LOEB LA, 1991, CANCER RES, V51, P3075; MIKI Y, IN PRESS JPN J CANCE; MORRIS C, 1990, CYTOGENET CELL GENET, V53, P4; MYERS RM, 1986, COLD SPRING HARB SYM, V51, P275, DOI 10.1101/SQB.1986.051.01.033; NAKAMURA Y, 1988, AM J HUM GENET, V43, P638; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, UNPUB; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; SASAKI M, 1989, CANCER RES, V49, P4402; SESHADRI R, 1987, CANCER RES, V47, P407; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; Suqarbaker J, 1985, CANCER PRINCIPLES PR, P800; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WADDELL WR, 1989, AM J SURG, V157, P174; WEINBERG RA, 1989, CANCER RES, V49, P3713	50	1600	1708	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 9	1991	253	5020					665	669		10.1126/science.1651563	http://dx.doi.org/10.1126/science.1651563			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA304	1651563				2022-12-24	WOS:A1991GA30400039
J	LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H				LASSAR, AB; DAVIS, RL; WRIGHT, WE; KADESCH, T; MURRE, C; VORONOVA, A; BALTIMORE, D; WEINTRAUB, H			FUNCTIONAL-ACTIVITY OF MYOGENIC HLH PROTEINS REQUIRES HETERO-OLIGOMERIZATION WITH E12/E47-LIKE PROTEINS INVIVO	CELL			English	Article							MUSCLE-SPECIFIC ENHANCER; LOOP-HELIX PROTEINS; DNA-BINDING; NEGATIVE REGULATOR; 10T1/2 FIBROBLASTS; DETERMINATION GENE; SEX DETERMINATION; MYC HOMOLOGY; MYOD; EXPRESSION	In this report we provide four lines of evidence indicating that E12/E47-like proteins interact in vivo with the myogenic HLH proteins MyoD and myogenin. First, cotransfection of MyoD and E47 in COS cells indicates that these factors synergistically enhance transcription of a reporter gene containing an oligomerized MyoD-binding site. Second, mobility-shift assays of muscle cell nuclear extracts, "double shifted" with specific antisera, have identified complexes binding to the MEF1 site that contain either MyoD or myogenin in association with E12/E47-like proteins. Third, association with E47 alters the phosphorylation state of MyoD. Fourth, C3H10T1/2 cells expressing antisense E2A transcripts contain low levels of E2A gene products and display less terminal muscle differentiation when infected with retroviral MyoD or when challenged to differentiate with 5-azacytidine treatment. In addition we demonstrate that MyoD, in conjunction with E12/E47-like proteins, is functioning as a regulatory nodal point for activation of several other downstream muscle regulators.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104; UNIV TEXAS,SW MED SCH,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235; UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104; MIT,WHITEHEAD INST,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Massachusetts Institute of Technology (MIT); Whitehead Institute					NIGMS NIH HHS [GM39458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CAMPOSORTEGA JA, 1990, EUR J BIOCHEM, V190, P1, DOI 10.1111/j.1432-1033.1990.tb15538.x; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2827; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DELABROUSSE FC, 1990, GENE DEV, V4, P567, DOI 10.1101/gad.4.4.567; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; HARVEY RP, 1990, DEVELOPMENT, V108, P669; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCALES JB, 1990, MOL CELL BIOL, V10, P1516, DOI 10.1128/MCB.10.4.1516; SCHAFER BW, 1990, NATURE, V344, P454, DOI 10.1038/344454a0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, IN PRESS GENES DEV; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	57	798	808	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					305	315		10.1016/0092-8674(91)90620-E	http://dx.doi.org/10.1016/0092-8674(91)90620-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649701				2022-12-24	WOS:A1991FY71200011
J	SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF				SUN, XJ; ROTHENBERG, P; KAHN, CR; BACKER, JM; ARAKI, E; WILDEN, PA; CAHILL, DA; GOLDSTEIN, BJ; WHITE, MF			STRUCTURE OF THE INSULIN-RECEPTOR SUBSTRATE IRS-1 DEFINES A UNIQUE SIGNAL TRANSDUCTION PROTEIN	NATURE			English	Article							GROWTH FACTOR-I; TYROSINE-PHOSPHORYLATION; PHOSPHATIDYLINOSITOL KINASE; CELLS; ADIPOCYTES; COMMON; PHOSPHOPROTEIN; PURIFICATION; 3-KINASE; BINDING	SINCE the discovery of insulin nearly 70 years ago, there has been no problem more fundamental to diabetes research than understanding how insulin works at the cellular level. Insulin binds to the alpha-subunit of the insulin receptor which activates the tyrosine kinase in the beta-subunit, but the molecular events linking the receptor kinase to insulin-sensitive enzymes and transport processes are unknown 1,2. Our discovery that insulin stimulates tyrosine phosphorylation of a protein of relative molecular mass between 165,000 and 185,000, collectively called pp185, showed that the insulin receptor kinase has specific cellular substrates 3. The pp185 is a minor cytoplasmic phosphoprotein found in most cells and tissues 4-10; its phosphorylation is decreased in cells expressing mutant receptors defective in signalling 6,11. We have now cloned IRS-1, which encodes a component of the pp185 band. IRS-1 contains over ten potential tyrosine phosphorylation sites, six of which are in Tyr-Met-X-Met motifs. During insulin stimulation, the IRS-1 protein undergoes tyrosine phosphorylation and binds phosphatidylinositol 3-kinase, suggesting that IRS-1 acts as a multisite 'docking' protein to bind signal-transducing molecules containing Src-homology 2 and Src-homology-3 domains 12-14. Thus IRS-1 may link the insulin receptor kinase and enzymes regulating cellular growth and metabolism.			SUN, XJ (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,DIV RES,1 JOSLIN PL,BOSTON,MA 02115, USA.		Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BACKER JM, IN PRESS BIOCHEMISTR; BRINDLE NPJ, 1990, BIOCHEM J, V268, P615, DOI 10.1042/bj2680615; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; ESCOBEDO JA, 1991, CELL, V65; GIBBS EM, 1986, J BIOL CHEM, V261, P6597; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HJOLLUND E, 1988, ACTA ENDOCRINOL-COP, V118, P59; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LATHE R, 1985, J MOL BIOL, V83, P1; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MOMOMURA K, 1988, BIOCHEM BIOPH RES CO, V155, P1181, DOI 10.1016/S0006-291X(88)81264-6; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; PERLMAN R, 1989, J BIOL CHEM, V264, P8946; PINES J, 1990, New Biologist, V2, P389; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHEMER J, 1987, J BIOL CHEM, V262, P15476; TOBE K, 1990, DIABETES, V39, P528, DOI 10.2337/diabetes.39.5.528; WHITE MF, 1987, J BIOL CHEM, V262, P9769; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILDEN PA, 1990, P NATL ACAD SCI USA, V87, P3358, DOI 10.1073/pnas.87.9.3358	31	1413	1448	1	59	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 4	1991	352	6330					73	77		10.1038/352073a0	http://dx.doi.org/10.1038/352073a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV178	1648180				2022-12-24	WOS:A1991FV17800074
J	TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD				TEDDER, RS; GILSON, RJC; BRIGGS, M; LOVEDAY, C; CAMERON, CH; GARSON, JA; KELLY, GE; WELLER, IVD			HEPATITIS-C VIRUS - EVIDENCE FOR SEXUAL TRANSMISSION	BRITISH MEDICAL JOURNAL			English	Article							NON-B-HEPATITIS; NON-A; ANTIBODIES	Objective-To determine the prevalence of hepatitis C virus infection and associated risk factors in patients attending a genitourinary medicine clinic, as evidence for sexual transmission. Design-Seroprevalence estimated by reactivity in an enzyme immunoassay for antibodies to C100 protein with supplementary testing with a recombinant immunoblot assay and an assay for hepatitis C virus RNA. Setting-Outpatient genitourinary medicine clinic in central London. Patients-The panel of 1046 serum samples was from 1074 consecutive patients attending the clinic during November and December 1987 and having blood taken for routine testing for syphilis. Before samples were anonymised demographic and risk factor information was extracted from the clinic notes. Samples had already been tested for antibody to HIV-1 and antibody to hepatitis B core antigen. Main results-Significantly more homosexual subjects than heterosexual subjects were positive for hepatitis C antibody determined by enzyme immunoassay alone (19/275 (6.9%) v 8/771 (1.0%), odds ratio 7.14, p < 0.0001) and also when reactive serum samples were also tested by recombinant immunoblot assay (6/270) (2.2%) v 3/770 (0.4%), odds ratio 5.88, p < 0.02). There were also significant associations in patients positive for hepatitis C antibody with positivity for antibodies to HIV and to hepatitis B core antigen, lifetime number of sexually transmitted diseases (homosexual men only), and age (all groups combined). Most patients whose serum samples contained specific antibodies to hepatitis C virus were viraemic. Conclusions-The study provides strong evidence for the sexual transmission of hepatitis C virus. Assays derived from other gene products are desirable to investigate the specificity and sensitivity of the enzyme immunoassay for C100 antibody as a marker of hepatitis C virus infection.	UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT GENITOURINARY MED,LONDON WC1E 6JJ,ENGLAND	University of London; University College London	TEDDER, RS (corresponding author), UNIV COLL & MIDDLESEX SCH MED,ACAD DEPT UROL,LONDON WC1E 6JJ,ENGLAND.		Garson, Jeremy A/C-5357-2008; Kelly, Gabrielle E./A-4147-2015; RIESTRA, SABINO/N-2897-2019	Kelly, Gabrielle E./0000-0003-2769-9555; Tedder, Richard/0000-0002-9672-5721; Garson, Jeremy/0000-0003-0553-0126				ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; ESTEBAN JI, 1989, LANCET, V2, P294; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; GARSON JA, 1990, LANCET, V336, P878, DOI 10.1016/0140-6736(90)92384-T; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MELBYE M, 1990, BRIT MED J, V301, P210, DOI 10.1136/bmj.301.6745.210; MORTIMER PP, 1989, LANCET, V2, P798	10	132	134	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1299	1302		10.1136/bmj.302.6788.1299	http://dx.doi.org/10.1136/bmj.302.6788.1299			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FQ444	1647826	Bronze, Green Published			2022-12-24	WOS:A1991FQ44400016
J	MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H				MCGOVERN, PG; BURKE, GL; SPRAFKA, JM; XUE, SL; FOLSOM, AR; BLACKBURN, H			TRENDS IN MORTALITY, MORBIDITY, AND RISK FACTOR LEVELS FOR STROKE FROM 1960 THROUGH 1990 - THE MINNESOTA HEART SURVEY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBROVASCULAR-DISEASE; SURVEY EXPERIENCE; DECLINE; POPULATION; SURVIVAL	Objective.-The Minnesota Heart Survey is a population-based study designed to monitor and explain trends in cardiovascular mortality, morbidity, and risk factors. Design.-Surveillance time-trends study. Methods.-The following trends were examined among men and women aged 25 to 74 years living in Minneapolis-St Paul, Minn: (1) stroke mortality from 1960 through 1990; (2) risk factors in population-based surveys conducted in 1973 through 1974, 1980 through 1982, and 1985 through 1987; and (3) morbidity in a 50% sample of hospitalized discharges for acute-stroke in 1970, 1980, and 1985. Results.-Stroke mortality in Minneapolis-St Paul declined slowly from 1960 through 1972 (average fall, 2.4% per year), dropped sharply from 1972 through 1984 (average fall, 6.5% per year), but exhibited little change thereafter (average fall, 1.5% per year). The average level of cardiovascular disease risk factors fell from 1973-1974 to 1985-1987, with the exception of body mass index. In particular, hypertension diagnosis, treatment, and control levels improved substantially between 1973-1974 and 1980-1982, although there was little improvement after 1980-1982. While discharge rates for hospital-coded acute stroke declined substantially between 1970 and 1985 in both sexes, no clear trend was observed in definite stroke rates as validated using standard clinical criteria. Twenty-eight-day case fatality rates of definite stroke improved significantly from 1970 to 1985. Conclusions.-The substantial decline in stroke mortality of more than 50% from 1960 through 1990 appears to have been attributable to both primary and secondary prevention. These data suggest that the long decline in stroke mortality and morbidity in Minneapolis-St Paul has plateaued, although improved detection of stroke with computed tomography prevents an unequivocal conclusion.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	Wake Forest University; Wake Forest Baptist Medical Center	MCGOVERN, PG (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST,SUITE 300,MINNEAPOLIS,MN 55454, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023727] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-23727] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILLER J, 1991, SEMIN NEUROL, V11, P353, DOI 10.1055/s-2008-1041240; Bonita R, 1989, HYPERTENSION S1, V3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; CAPLAN LR, 1991, JAMA-J AM MED ASSOC, V266, P2413, DOI 10.1001/jama.266.17.2413; DAWSON DA, 1987, VITAL HLTH STAT, V10, P164; EDLAVITCH SA, 1988, AM J EPIDEMIOL, V127, P1164, DOI 10.1093/oxfordjournals.aje.a114910; FOLSOM AR, 1983, JAMA-J AM MED ASSOC, V250, P916, DOI 10.1001/jama.250.7.916; GILLUM RF, 1986, STROKE, V17, P656, DOI 10.1161/01.STR.17.4.656; GILLUM RF, 1985, J CHRON DIS, V38, P8911; GRAVES EJ, 1984, PHS100 US DEP HLTH H; HOWARD G, 1989, STROKE, V20, P345, DOI 10.1161/01.STR.20.3.345; JACOBS DR, 1980, J CHRON DIS, V33, P395, DOI 10.1016/0021-9681(80)90037-5; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; KLAG MJ, 1989, STROKE, V20, P14, DOI 10.1161/01.STR.20.1.14; LUEPKER RV, 1988, J CLIN EPIDEMIOL, V41, P825, DOI 10.1016/0895-4356(88)90098-4; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; ROSE G, 1991, CIRCULATION, V84, P1405, DOI 10.1161/01.CIR.84.3.1405; ROTHROCK JF, 1991, ANN INTERN MED, V115, P885, DOI 10.7326/0003-4819-115-11-885; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; TILLINGHAST SJ, 1991, AM J EPIDEMIOL, V134, P851, DOI 10.1093/oxfordjournals.aje.a116160; WHISNANT JP, 1984, STROKE, V15, P160, DOI 10.1161/01.STR.15.1.160; 1976, PHS871232 US DEP HLT, P125; 1967, MANUAL INT STATISTIC; 1957, MANUAL INT STATISTIC; 1990, WORLD HLTH STATISTIC; 1975, INT CLASSIFICATION 2, V66; [No title captured]; 1987, JAMA-J AM MED ASSOC, V257, P937; 1980, MONTHLY VITAL STAT S, V28, P1; 1992, MONTHLY VITAL STA S2, V40, P1; 1989, SAS STAT GUIDE; 1989, MMWR, V38, P194; 1972, PHS861684 US DEP 11	33	128	131	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					753	759						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640576				2022-12-24	WOS:A1992JG66600017
J	HE, XM; CARTER, DC				HE, XM; CARTER, DC			ATOMIC-STRUCTURE AND CHEMISTRY OF HUMAN SERUM-ALBUMIN	NATURE			English	Article							AMINO-ACID SEQUENCE; DRUG-BINDING-SITES; ALPHA-FETOPROTEIN; MACROMOLECULAR CRYSTALLOGRAPHY; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; VARIANTS; GENE; POPULATIONS; EXPRESSION	The three-dimensional structure of human serum albumin has been determined crystallographically to a resolution of 2.8 angstrom. It comprises three homologous domains that assemble to form a heart-shaped molecule. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. The structure explains numerous physical phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.	NASA,GEORGE C MARSHALL SPACE FLIGHT CTR,SPACE SCI LAB,ES76 BIOPHYS,HUNTSVILLE,AL 35812	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center								AOKI K, 1973, BIOCHIM BIOPHYS ACTA, V328, P323, DOI 10.1016/0005-2795(73)90265-1; ARAI K, 1989, P NATL ACAD SCI USA, V86, P434, DOI 10.1073/pnas.86.2.434; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; BROWN JR, 1976, FED PROC, V35, P2141; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P25; BROWN WM, 1989, NUCLEIC ACIDS RES, V17, P10495, DOI 10.1093/nar/17.24.10495; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYRNES L, 1990, DNA CELL BIOL, V9, P647, DOI 10.1089/dna.1990.9.647; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CARTER DC, 1990, SCIENCE, V249, P302, DOI 10.1126/science.2374930; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DIXON JW, 1974, J BIOL CHEM, V249, P5872; Dugiaczyk A, 1982, P NATL ACAD SCI USA, V79, P71; FEHSKE KJ, 1981, BIOCHEM PHARMACOL, V30, P687, DOI 10.1016/0006-2952(81)90151-9; FELDHOFF RC, 1983, BIOCHEM BIOPH RES CO, V114, P20, DOI 10.1016/0006-291X(83)91588-7; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GALLIANO M, 1990, P NATL ACAD SCI USA, V87, P8721, DOI 10.1073/pnas.87.22.8721; GORIN MB, 1980, P NATL ACAD SCI-BIOL, V77, P1351, DOI 10.1073/pnas.77.3.1351; GRAY JE, 1992, PROTEIN SCI, V1, P289; HAGAG N, 1983, BIOCHEMISTRY-US, V22, P2420, DOI 10.1021/bi00279a018; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JAGDODZINSKI LL, 1981, P NATL ACAD SCI USA, V78, P3521; JONES TA, 1987, J APPL CRYSTALLOGR, V20, P383; KING TP, 1973, ARCH BIOCHEM BIOPHYS, V156, P509, DOI 10.1016/0003-9861(73)90300-7; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; KURONO Y, 1987, CHEM PHARM BULL, V35, P734; LUFT AJ, 1983, BIOCHEMISTRY-US, V22, P5978, DOI 10.1021/bi00294a043; MINGHETTI PP, 1985, MOL BIOL EVOL, V2, P347; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; OZEKI Y, 1980, CHEM PHARM BULL, V28, P535; PARDRIDGE WM, 1987, AM J PHYSIOL, V252, P157; PEDERSEN SM, 1987, BIOCHEM PHARMACOL, V35, P2661; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PUTNAM FW, 1984, PLSMA PROTEINS, V4; QUIRK AV, 1989, BIOTECHNOL APPL BIOC, V11, P273; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SOLLENE NP, 1979, MOL PHARMACOL, V14, P754; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; TAKAHASHI N, 1987, P NATL ACAD SCI USA, V84, P8001, DOI 10.1073/pnas.84.22.8001; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINSTOCK J, 1988, NUCLEIC ACIDS RES, V16, P9045, DOI 10.1093/nar/16.18.9045; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X	48	3277	3434	13	515	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					209	215		10.1038/358209a0	http://dx.doi.org/10.1038/358209a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630489	Green Published			2022-12-24	WOS:A1992JD58700045
J	BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC				BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC			CELL-DEATH AND CONTROL OF CELL-SURVIVAL IN THE OLIGODENDROCYTE LINEAGE	CELL			English	Article							GROWTH FACTOR-I; RAT OPTIC-NERVE; GLIAL PROGENITOR-CELL; TYPE-2 ASTROCYTE DEVELOPMENT; FREE SUPPLEMENTED MEDIUM; MONOCLONAL-ANTIBODY; NEURONAL DEATH; CHICK-EMBRYO; NEUROTROPHIC FACTOR; PROTEIN-SYNTHESIS	Dead cells are observed in many developing animal tissues, but the causes of these normal cell deaths are mostly unknown. We show that about 50% of oligodendrocytes normally die in the developing rat optic nerve, apparently as a result of a competition for limiting amounts of survival signals. Both platelet-derived growth factor and insulin-like growth factors are survival factors for newly formed oligodendrocytes and their precursors in culture. Increasing platelet-derived growth factor in the developing optic nerve decreases normal oligodendrocyte death by up to 90% and doubles the number of oligodendrocytes in 4 days. These results suggest that a requirement for survival signals is more general than previously thought and that some normal cell deaths in nonneural tissues may also reflect competition for survival factors.			BARRES, BA (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOL, MRC, DEV NEUROBIOL PROGRAMME, MEDAWAR BLDG, LONDON WC1E 6BT, ENGLAND.		Richardson, William/C-1762-2008	Richardson, William/0000-0001-7261-2485				AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALOISI F, 1990, J NEUROSCI RES, V27, P16, DOI 10.1002/jnr.490270104; [Anonymous], [No title captured]; ARONVANEVERCOOR.A, 1991, J NEUROSCI RES, V28, P244; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; BANNON MJ, 1984, BRAIN RES, V301, P184, DOI 10.1016/0006-8993(84)90421-9; BARDE YA, 1983, ANNU REV PHYSIOL, V45, P601, DOI 10.1146/annurev.ph.45.030183.003125; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARTLETT PF, 1981, BRAIN RES, V204, P339, DOI 10.1016/0006-8993(81)90593-X; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CARSON MJ, 1990, THESIS U PENNSYLVANI; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUTLY F, 1991, GLIA, V4, P559, DOI 10.1002/glia.440040603; ECCLESTON PA, 1985, DEV BRAIN RES, V21, P315, DOI 10.1016/0165-3806(85)90221-4; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; FULTON BP, 1992, IN PRESS J NEUROSCI; GARD AL, 1989, DEVELOPMENT, V106, P119; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HABU S, 1977, EUR J IMMUNOL, V7, P451, DOI 10.1002/eji.1830070710; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HANSSON HA, 1989, EXP EYE RES, V48, P411, DOI 10.1016/S0014-4835(89)80009-0; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HILDEBRAND C, 1971, ACTA PHYSL SCAND S, V354, P109; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; HYNES RO, 1978, CELL, V13, P151, DOI 10.1016/0092-8674(78)90146-0; JACKSON KF, 1988, J NEUROCYTOL, V17, P657, DOI 10.1007/BF01260993; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KNAPP PE, 1986, J NEUROSCI, V6, P2813; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYPIANOU N, 1988, ENDOCRINOLOGY, V122, P552; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIEVRE C, 1991, DEVELOPMENT, V111, P105; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V4, P525, DOI 10.1016/0896-6273(90)90110-2; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MCMORRIS FA, 1990, CELLULAR MOL BIOL MY, P281; MESSNER PW, 1991, ABST SOC NEUR, V17, P1124; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MORI S, 1970, J COMP NEUROL, V139, P1, DOI 10.1002/cne.901390102; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOBLE M, 1984, EMBO J, V3, P2243, DOI 10.1002/j.1460-2075.1984.tb02122.x; NOBLE M, 1991, IN PRESS ANN NY ACAD; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANNESE E, 1967, ACTA NEUROPATHOL, V8, P309, DOI 10.1007/BF00688831; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; PRINGLE N, 1992, IN PRESS DEVELOPMENT; PRUSS R, 1979, NATURE, V303, P390; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAFF MC, 1992, IN PRESS NATURE; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; Richardson WD, 1990, SEMIN NEUROSCI, V2, P445; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SARA VR, 1990, KAR INS NCS, P179; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWARTZ LM, 1991, ABSTR SOC NEUROSCI, V17, P228; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STURROCK RR, 1979, NEUROPATH APPL NEURO, V5, P433, DOI 10.1111/j.1365-2990.1979.tb00642.x; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0; VAUGHN JE, 1969, Z ZELLFORSCH MIK ANA, V94, P293, DOI 10.1007/BF00319179; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844	115	1173	1191	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					31	46		10.1016/0092-8674(92)90531-G	http://dx.doi.org/10.1016/0092-8674(92)90531-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623522				2022-12-24	WOS:A1992JC95700006
J	CAMERON, D; BISHOP, C				CAMERON, D; BISHOP, C			FARM ACCIDENTS IN ADULTS	BRITISH MEDICAL JOURNAL			English	Article											CAMERON, D (corresponding author), BRITISH COLUMBIA CHILDRENS HOSP,NEWBORN SERV,VANCOUVER V6H 3V4,BC,CANADA.							DOYLE Y, 1989, J R SOC HLTH, V4, P128; MAY JJ, 1990, AM J IND MED, V18, P121, DOI 10.1002/ajim.4700180205; 1989, CENSUS 1989; 1986, AGR BLACK SPOT; 1991, 1990 1991 HLTH SAF C	5	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					25	26		10.1136/bmj.305.6844.25	http://dx.doi.org/10.1136/bmj.305.6844.25			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638193	Green Published, Green Submitted, Bronze			2022-12-24	WOS:A1992JC79900024
J	PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR				PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR			CONFORMATION OF THE TAR RNA-ARGININE COMPLEX BY NMR-SPECTROSCOPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; SEQUENCE; BINDING; LOOP; TRANSACTIVATION; TRANSCRIPTION; INVITRO; BULGE	The messenger RNAs of human immunodeficiency virus-1 (HIV-1) have an RNA hairpin structure, TAR, at their 5' ends that contains a six-nucleotide loop and a three-nucleotide bulge. The conformations of TAR RNA and of TAR with an arginine analog specifically bound at the binding site for the viral protein, Tat, were characterized by nuclear magnetic resonance (NMR) spectroscopy. Upon arginine binding, the bulge changes conformation, and essential nucleotides for binding, U23 and A27.U38, form a base-triple interaction that stabilizes arginine hydrogen bonding to G26 and phosphates. Specificity in the arginine-TAR interaction appears to be derived largely from the structure of the RNA.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Williamson, James R/B-2891-2009; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAVIS PW, 1990, BIOPOLYMERS, V29, P109, DOI 10.1002/bip.360290116; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DELLING U, 1992, J VIROL, V66, P3018, DOI 10.1128/JVI.66.5.3018-3025.1992; Denoyelle S., SYNTHESIS SAR STUDY; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RIORDAN FA, IN PRESS J MOL BIOL; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1986, HNMR PROTEINS NUCLEI; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	37	560	584	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					76	80		10.1126/science.1621097	http://dx.doi.org/10.1126/science.1621097			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621097				2022-12-24	WOS:A1992JC16500033
J	JONES, DT; TAYLOR, WR; THORNTON, JM				JONES, DT; TAYLOR, WR; THORNTON, JM			A NEW APPROACH TO PROTEIN FOLD RECOGNITION	NATURE			English	Article							SECONDARY STRUCTURE; MEAN FORCE; PREDICTION; POTENTIALS; FEATURES; MODELS; ENERGY	THE prediction of protein tertiary structure from sequence using molecular energy calculations has not yet been successful; an alternative strategy of recognizing known motifs 1 or folds 2-4 in sequences looks more promising. We present here a new approach to fold recognition, whereby sequences are fitted directly onto the backbone coordinates of known protein structures. Our method for protein fold recognition involves automatic modelling of protein structures using a given sequence, and is based on the frameworks of known protein folds. The plausibility of each model, and hence the degree of compatibility between the sequence and the proposed structure, is evaluated by means of a set of empirical potentials derived from proteins of known structure. The novel aspect of our approach is that the matching of sequences to backbone coordinates is performed in full three-dimensional space, incorporating specific pair interactions explicitly.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	JONES, DT (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096				BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; ORENGO CA, 1990, J THEOR BIOL, V147, P517, DOI 10.1016/S0022-5193(05)80263-2; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PASTORE A, 1990, PROTEINS, V8, P133, DOI 10.1002/prot.340080204; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; TAYLOR WR, 1991, PROTEIN ENG, V4, P853, DOI 10.1093/protein/4.8.853; TAYLOR WR, 1984, J MOL BIOL, V173, P487, DOI 10.1016/0022-2836(84)90393-0; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0	19	985	1017	4	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					86	89		10.1038/358086a0	http://dx.doi.org/10.1038/358086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614539				2022-12-24	WOS:A1992JB34100061
J	HEALY, B				HEALY, B			RESEARCH OFFERS NEW HOPE FOR YOUNG PERSONS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					20	20						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608101				2022-12-24	WOS:A1992JA16500004
J	FORSCHER, P; LIN, CH; THOMPSON, C				FORSCHER, P; LIN, CH; THOMPSON, C			NOVEL FORM OF GROWTH CONE MOTILITY INVOLVING SITE-DIRECTED ACTIN FILAMENT ASSEMBLY	NATURE			English	Article							LATEX BEADS; LIPID FLOW; MOVEMENTS; NEURONS	REGULATION of cytoskeletal structure and motility by extracellular signals is essential for all directed forms of cell movement and underlies the developmental process of axonal guidance in neuronal growth cones. Interaction with polycationic microbeads can trigger morphogenic changes in neurons and muscle cells normally associated with formation of pre- and postsynaptic specializations 1,2. Furthermore, when various types of microscopic particles are applied to the lamellar surface of a neuronal growth cone or motile cell they often exhibit retrograde movement at rates of 1-6-mu-m min-1 (refs 3-6). There is strong evidence that this form of particle movement results from translocation of membrane proteins associated with cortical F-actin networks, not from bulk retrograde lipid flow 4,5,7 and may be a mechanism behind processes such as cell locomotion, growth cone migration and capping of cell-surface antigens 6,8,9. Here we report a new form of motility stimulated by polycationic bead interactions with the growth-cone membrane surface. Bead binding rapidly induces intracellular actin filament assembly, coincident with a production of force sufficient to drive bead movements. These extracellular bead movements resemble intracellular movements of bacterial parasites known to redirect host cell F-actin assembly for propulsion. Our results suggest that site-directed actin filament assembly may be a widespread cellular mechanism for generating force at membrane-cytoskeletal interfaces.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	FORSCHER, P (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.			Smith, Peter/0000-0003-4400-6853; Forscher, Paul/0000-0003-1988-5155				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P459; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; PENG HB, 1981, NATURE, V292, P831, DOI 10.1038/292831a0; PENG HB, 1987, SYNAPSE, V1, P10, DOI 10.1002/syn.890010104; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979	13	132	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					515	518		10.1038/357515a0	http://dx.doi.org/10.1038/357515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608453				2022-12-24	WOS:A1992HY05200069
J	PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J				PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J			ONCHOCERCIASIS IN MEMBERS OF AN EXPEDITION TO CAMEROON - ROLE OF ADVICE BEFORE TRAVEL AND LONG-TERM FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article											PRYCE, D (corresponding author), HOSP TROP DIS,1ST FLOOR,QUEENS HOUSE,LONDON W1P 9LE,ENGLAND.							GILLES HM, 1984, RECENT ADV TROPICAL; MANSONBAHR PEC, 1987, MANSONS TROPICAL DIS; 1987, WHO TECH REP SER, P752	3	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1286		10.1136/bmj.304.6837.1285-a	http://dx.doi.org/10.1136/bmj.304.6837.1285-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606433	Green Published, Bronze			2022-12-24	WOS:A1992HV08600025
J	MOORE, MJ; SHARP, PA				MOORE, MJ; SHARP, PA			SITE-SPECIFIC MODIFICATION OF PRE-MESSENGER-RNA - THE 2'-HYDROXYL GROUPS AT THE SPLICE SITES	SCIENCE			English	Article							POLYNUCLEOTIDE LIGASE; LARIAT FORMATION; GROUP-II; TETRAHYMENA; SEQUENCE; RIBOZYME; INTRONS; CLEAVAGE; INVITRO; DNA	A simple and efficient method for synthesizing long, site-specifically modified RNA molecules was developed whereby segments of RNA were joined with the use of bacteriophage T4 DNA ligase. A single hydrogen or O-methyl group was substituted for the 2'-hydroxyl group at either splice site of a nuclear pre-messenger RNA substrate. Splicing of the modified pre-messenger RNA's in vitro revealed that, although a 2'-hydroxyl is not absolutely required at either splice site, the 2'-hydroxyl at the 3' splice site is important for the second step of splicing. These results are compared to previous studies of analogous 2'-hydroxyl groups in the self-splicing Tetrahymena group I intron.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	MOORE, MJ (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA14051] Funding Source: Medline; NIGMS NIH HHS [R01 GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Blackburn P, 1982, ENZYMES, VXV, P317; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FAREED GC, 1971, J BIOL CHEM, V246, P925; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NOBLE JCS, 1986, NUCLEIC ACIDS RES, V14, P1219; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RICHARDS FM, 1971, ENZYMES, V4, P647; ROMANIUK E, 1982, EUR J BIOCHEM, V125, P639, DOI 10.1111/j.1432-1033.1982.tb06730.x; ROMANIUK PJ, 1983, METHOD ENZYMOL, V100, P52; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANO H, 1974, BIOCHEMISTRY-US, V13, P5110, DOI 10.1021/bi00722a009; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SUGINO A, 1977, J BIOL CHEM, V252, P3987; Takahashi K., 1982, ENZYMES, V15, p435 468; TSIAPALIS CM, 1970, BIOCHEM BIOPH RES CO, V39, P631, DOI 10.1016/0006-291X(70)90251-2; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; UHLENBECK OC, 1977, NUCLEIC ACIDS RES, V4, P85, DOI 10.1093/nar/4.1.85; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; VANDERVEEN R, 1987, EMBO J, V6, P3827, DOI 10.1002/j.1460-2075.1987.tb02719.x; WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795; WEISS B, 1968, J BIOL CHEM, V243, P4543; WEISS B, 1976, J MOL BIOL, V103, P669, DOI 10.1016/0022-2836(76)90226-6; WITTENBERG WL, 1985, BIOCHEMISTRY-US, V24, P2705, DOI 10.1021/bi00332a017; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	56	434	508	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					992	997		10.1126/science.1589782	http://dx.doi.org/10.1126/science.1589782			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589782				2022-12-24	WOS:A1992HU22400029
J	WANG, LY; SALTER, MW; MACDONALD, JF				WANG, LY; SALTER, MW; MACDONALD, JF			REGULATION OF KAINATE RECEPTORS BY CAMP-DEPENDENT PROTEIN-KINASE AND PHOSPHATASES	SCIENCE			English	Article							HIPPOCAMPAL-NEURONS; ACID; CHANNELS; QUISQUALATE; MODULATION; CALCIUM; FAMILY	In the mammalian central nervous system, receptors for excitatory amino acid neurotransmitters such as the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-kainate receptor mediate a large fraction of excitatory transmission. Currents induced by activation of the AMPA-kainate receptor were potentiated by agents that specifically stimulate adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase A (PKA) activity or were supported by intracellular application of the catalytic subunit of PKA by itself or in combination with cAMP. Furthermore, depression of these currents by a competitive inhibitor of PKA indicates that AMPA-kainate receptors are regulated by endogenous PKA. Endogenous protein phosphatases also regulate these receptors because an inhibitor of cellular phosphatases enhanced kainate currents. Modulation of PKA and phosphatases may regulate the function of these receptors and thus contribute to synaptic plasticity in hippocampal neurons.	HOSP SICK CHILDREN, DIV NEUROSCI, TORONTO M5G 1X8, ONTARIO, CANADA; UNIV TORONTO, DEPT PHARMACOL, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	WANG, LY (corresponding author), UNIV TORONTO, DEPT PHYSIOL, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA.							BARNARD EA, 1990, TRENDS PHARMACOL SCI, V11, P500, DOI 10.1016/0165-6147(90)90051-9; BLAKE JF, 1988, NEUROSCI LETT, V89, P182, DOI 10.1016/0304-3940(88)90378-3; BRAUMANN T, 1985, J CHROMATOGR, V350, P105, DOI 10.1016/S0021-9673(01)93510-1; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; FORSCHER P, 1985, J GEN PHYSIOL, V85, P743, DOI 10.1085/jgp.85.5.743; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; ISHIDA AT, 1985, P NATL ACAD SCI USA, V82, P1837, DOI 10.1073/pnas.82.6.1837; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALINOW R, 1991, NEURON, V6, P53; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SONG Y, 1990, NATURE, V348, P242, DOI 10.1038/348242a0; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; YUSTA B, 1988, J NEUROCHEM, V51, P1807, DOI 10.1111/j.1471-4159.1988.tb01162.x	23	387	389	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 6	1991	253	5024					1132	1135		10.1126/science.1653455	http://dx.doi.org/10.1126/science.1653455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GD808	1653455				2022-12-24	WOS:A1991GD80800030
J	BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I				BOTHE, K; AGUZZI, A; LASSMANN, H; RETHWILM, A; HORAK, I			PROGRESSIVE ENCEPHALOPATHY AND MYOPATHY IN TRANSGENIC MICE EXPRESSING HUMAN FOAMY VIRUS GENES	SCIENCE			English	Article							HUMAN SPUMARETROVIRUS; TAT GENE; DEGENERATION; NEURONS; CELLS; AIDS	Transgenic mice carrying the bel region of human foamy retrovirus (HFV) under transcriptional control of its own long terminal repeat expressed the transgene in their central nervous systems and in smooth and striated muscle tissues. The animals developed a progressive degenerative disease of the central nervous system and of the striated muscle. Because expression of the transgene was closely correlated with the appearance of structural damage and inflammatory reactions were scanty, the disease is likely to be caused directly by the HFV proteins. These unexpected findings call for a reevaluation of the pathogenic potential of HFV in humans.	UNIV WURZBURG,INST VIROL & IMMUNOBIOL,VERSBACHERSTR 7,W-8700 WURZBURG,GERMANY; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST NEUROL,A-1090 VIENNA,AUSTRIA	University of Wurzburg; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008; Lassmann, Hans/Z-2269-2019	Lassmann, Hans/0000-0001-8617-5052; Aguzzi, Adriano/0000-0002-0344-6708				ACHONG G, 1971, J NATL CANCER I, V42, P299; AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1990, New Biologist, V2, P533; AGUZZI A, UNPUB; BOTHE K, UNPUB; CAMERONKR, 1978, LANCET, V2, P796; FLUGEL RM, 1987, EMBO J, V6, P2077, DOI 10.1002/j.1460-2075.1987.tb02473.x; GIANGASPERO F, 1989, ACTA NEUROPATHOL, V78, P662, DOI 10.1007/BF00691293; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hogan B., 1986, MANIPULATING MOUSE E; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KLEIHUES P, 1985, ACTA NEUROPATHOL, V68, P333, DOI 10.1007/BF00690837; MULLER RH, 1980, J GEN VIROL, V47, P399; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; PICCARDO P, 1988, ANN NEUROL S, V23, P156; RETHWILM A, 1990, VIROLOGY, V175, P568, DOI 10.1016/0042-6822(90)90442-T; RETHWILM A, 1991, P NATL ACAD SCI USA, V88, P941, DOI 10.1073/pnas.88.3.941; RETHWILM A, 1990, NUCLEIC ACIDS RES, V18, P733, DOI 10.1093/nar/18.4.733; SHARPE AH, 1990, NATURE, V346, P181, DOI 10.1038/346181a0; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEISS RA, 1988, NATURE, V333, P497, DOI 10.1038/333497a0; YOUNG D, 1973, ARCH GES VIRUSFORSCH, V42, P228, DOI 10.1007/BF01265647; [No title captured]	27	98	102	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 2	1991	253	5019					555	557		10.1126/science.1650034	http://dx.doi.org/10.1126/science.1650034			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FZ347	1650034	Green Submitted			2022-12-24	WOS:A1991FZ34700036
J	MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J				MITRAKI, A; FANE, B; HAASEPETTINGELL, C; STURTEVANT, J; KING, J			GLOBAL SUPPRESSION OF PROTEIN FOLDING DEFECTS AND INCLUSION BODY FORMATION	SCIENCE			English	Article							TAIL-SPIKE PROTEIN; AMINO-ACID SUBSTITUTIONS; P22 TAILSPIKE PROTEIN; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; PHAGE-P22 TAILSPIKE; RAMAN-SPECTROSCOPY; POLYPEPTIDE-CHAIN; GENETIC-ANALYSIS; WILD-TYPE	Amino acid substitutions at a site in the center of the bacteriophage protein P22 tailspike polypeptide chain suppress temperature-sensitive folding mutations at many sites throughout the chain. Characterization of the intracellular folding and chain assembly process reveals that the suppressors act in the folding pathway, inhibiting the aggregation of an early folding intermediate into the kinetically trapped inclusion body state. The suppressors alone increase the folding efficiency of the otherwise wild-type polypeptide chain without altering the stability or activity of the native state. These amino acid substitutions identify an unexpected aspect of the protein folding grammar-sequences within the chain that carry information inhibiting unproductive off-pathway conformations. Such mutations may serve to increase the recovery of protein products of cloned genes.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511	Yale University	MITRAKI, A (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.		MITRAKI, Anna/A-6034-2014	MITRAKI, Anna/0000-0001-5072-1939	NIGMS NIH HHS [GMS17,980] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; BOWDEN GA, 1990, J BIOL CHEM, V265, P16760; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; FANE B, 1991, GENETICS, V127, P263; FANE B, IN PRESS J BIOL CHEM; FUCHS A, IN PRESS BIOCHEMISTR; GEORGIOU G, 1986, APPL ENVIRON MICROB, V52, P1152; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HARRINGT.WF, 1970, BIOCHEMISTRY-US, V9, P3714, DOI 10.1021/bi00821a010; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KING J, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P225; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; Lee S. J., COMMUNICATION; LONDON J, 1974, EUR J BIOCHEM, V47, P409, DOI 10.1111/j.1432-1033.1974.tb03707.x; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MAURIDES PA, 1990, GENETICS, V125, P673; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MITRAKI A, UNPUB; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RICHARDSON J, 1988, SCIENCE, V240, P4859; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SARGENT D, 1988, J MOL BIOL, V199, P491, DOI 10.1016/0022-2836(88)90620-1; SATHER S, UNPUB; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SECKLER R, 1989, J BIOL CHEM, V264, P11750; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; SMITH DH, 1980, GENETICS, V96, P331; STROUP AN, 1990, BIOCHEMISTRY-US, V29, P9765, DOI 10.1021/bi00494a002; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; THOMAS GJ, 1990, BIOCHEMISTRY-US, V29, P4181, DOI 10.1021/bi00469a022; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WETZEL R, IN PRESS BIOTECHNOLO; WETZEL R, 1990, PROTEIN DESIGN DEV N, P79; YU MH, 1988, J BIOL CHEM, V263, P1424; YU MH, 1984, P NATL ACAD SCI-BIOL, V81, P6584, DOI 10.1073/pnas.81.21.6584; ZETTLMEISSL G, 1979, BIOCHEMISTRY-US, V18, P5567, DOI 10.1021/bi00592a007	57	186	201	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					54	58		10.1126/science.1648264	http://dx.doi.org/10.1126/science.1648264			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648264				2022-12-24	WOS:A1991FV17700031
J	ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR				ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR			PRIMARY IMMUNODEFICIENCY CAUSED BY MUTATIONS IN THE GENE ENCODING THE CD3-GAMMA SUBUNIT OF THE LYMPHOCYTE-T RECEPTOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SURFACE EXPRESSION; FAMILIAL DEFECT; COMPLEX		UNIV VALLADOLID,SCH MED,DEPT PEDIAT,VALLADOLID,SPAIN	Universidad de Valladolid	ARNAIZVILLENA, A (corresponding author), UNIV COMPLUTENSE MADRID,HOSP 12 OCTUBRE,DEPT IMMUNOL,E-28041 MADRID,SPAIN.		Regueiro, José R./B-5499-2014; Martin-Villa, Jose M./K-2522-2019; Corell, Alfredo/E-1903-2011; Martin-Villa, Jose M. M/F-9234-2013; Corell, Alfredo/AAE-2133-2020	Regueiro, José R./0000-0001-8442-7762; Martin-Villa, Jose M./0000-0002-2436-8585; Martin-Villa, Jose M. M/0000-0002-2436-8585; Corell, Alfredo/0000-0001-5797-7814				ALARCON B, 1990, Immunodeficiency Reviews, V2, P1; ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ARNAIZVILLENA A, 1991, LAB INVEST, V64, P675; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CORELL A, 1990, MOL IMMUNOL, V27, P313, DOI 10.1016/0161-5890(90)90145-P; CORELL A, 1991, MOL IMMUNOL, V28, P533, DOI 10.1016/0161-5890(91)90168-J; CORELL J, 1990, MOL IMMUNOL, V27, P471; Davis R W, 1980, Methods Enzymol, V65, P404; GELFAND EW, 1990, NEW ENGL J MED, V322, P1741, DOI 10.1056/NEJM199006143222410; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; REGUEIRO JR, 1990, EUR J IMMUNOL, V20, P2411, DOI 10.1002/eji.1830201108; REGUEIRO JR, 1986, LANCET, V1, P1274; REGUEIRO JR, 1992, SCAND J IMMUNOL, V36, P363; REGUEIRO JR, 1987, SCAND J IMMUNOL, V26, P699, DOI 10.1111/j.1365-3083.1987.tb02306.x; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x	16	179	183	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					529	533		10.1056/NEJM199208203270805	http://dx.doi.org/10.1056/NEJM199208203270805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635567				2022-12-24	WOS:A1992JJ45700005
J	TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM				TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM			A SURVEY OF OCCUPATIONAL BLOOD CONTACT AND HIV-INFECTION AMONG ORTHOPEDIC SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; TRANSMISSION	Objective.-To study the seroprevalence of human immunodeficiency virus (HIV) among orthopedic surgeons, and correlate the results with occupational and nonoccupational risk factors. Orthopedic surgeons are one of several groups of health care workers at risk for occupationally acquired HIV infection; however, few HIV seroprevalence studies in health care workers, and none in surgeons, have been performed to assist in estimating the extent of occupational risk. Design.-A voluntary, anonymous HIV serosurvey at an annual meeting. To assess the representativeness of participants, a mail survey of orthopedic surgeons was conducted 5 months prior to the annual meeting. Setting.-The 1991 annual meeting of the American Academy of Orthopaedic Surgeons held in Anaheim, Calif. Participants.-United States or Canadian orthopedic surgeons in training, in practice, or retired from practice who attended the annual meeting. Main Outcome Measures.-Participants' HIV serostatus and reporting of occupational and nonoccupational risk factors for HIV infection. Results.-Of 7147 eligible orthopedists at the annual meeting, 3420 (47.9%) participated. Compared with the 10411 orthopedic surgeons responding to the mail survey, serosurvey participants had at least as many opportunities for occupational contact with blood and with HIV-infected patients. Among participants, 87.4% reported a blood-skin contact and 39.2% reported a percutaneous blood contact in the previous month. Among 3267 participants without reported nonoccupational risk factors for HIV infection, none was positive for HIV antibody (0%; upper limit of the 95% confidence interval [CI] = 0.09%); among 108 participants with reported nonoccupational HIV risk factors, two were positive for HIV antibody (1.9%; upper limit of the 95% CI = 5.7%). Conclusion.-Although these findings may not be generalizable to all orthopedic surgeons, we found no evidence of HIV infection among serosurvey participants without nonoccupational risk factors. The high rates of self-reported blood contact underscore the importance of compliance with infection control precautions and of development of new techniques and equipment to minimize the risk of exposures to blood during surgical procedures.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCQUILLAN GM, 1989, AM J MED, V87, pS5; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; 1988, MMWR, V37, P387; 1991, MMWR, V40, P309; 1991, REDUCING RISK BLOOD; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS1; 1991, ADVISORY STATEMENT H; 1988, MMWR, V37, P377; 1989, RECOMMENDATIONS PREV; 1990, HIV AIDS SURVEILLANC, P1; 1989, MMWR, V38, P95; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	26	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					489	494		10.1001/jama.268.4.489	http://dx.doi.org/10.1001/jama.268.4.489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619740				2022-12-24	WOS:A1992JD47200023
J	FISHLEDER, AJ				FISHLEDER, AJ			PRENATAL HEMOGLOBINOPATHY SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHLEDER, AJ (corresponding author), CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608146				2022-12-24	WOS:A1992JB27900035
J	WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA				WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA			AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROM STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS	SCIENCE			English	Article							HEXONATE DEHYDROGENASE; KIDNEY ALDOSE; INHIBITION; SORBINIL; ALDEHYDE; PROTEINS; NEUROPATHY; CRYSTALLIN; FEATURES; KINETICS	Aldose reductase, which catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds, is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney. A 1.65 angstrom refined structure of a recombinant human placenta aldose reductase reveals that the enzyme contains a parallel beta-8/alpha-8-barrel motif and establishes a new motif for NADP-binding oxidoreductases. The substrate-binding site is located in a large, deep elliptical pocket at the COOH-terminal end of the beta-barrel with a bound NADPH in an extended conformation. The highly hydrophobic nature of the active site pocket greatly favors aromatic and apolar substrates over highly polar monosaccharides. The structure should allow for the rational design of specific inhibitors that might provide molecular understanding of the catalytic mechanism, as well as possible therapeutic agents.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-39,044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; EINSPAHR HM, 1989, P S PROTEIN CARBOHYD, V25; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P18; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MARTYN CN, 1987, DIABETES, V36, P987, DOI 10.2337/diabetes.36.9.987; OBRIEN MM, 1982, J NEUROCHEM, V39, P810, DOI 10.1111/j.1471-4159.1982.tb07964.x; Pai EF, 1991, CURR OPIN STRUC BIOL, V1, P796, DOI 10.1016/0959-440X(91)90181-R; POULSOM R, 1986, BIOCHEM PHARMACOL, V35, P2955, DOI 10.1016/0006-2952(86)90492-2; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; ROSE IA, 1980, P NATL ACAD SCI-BIOL, V77, P2439, DOI 10.1073/pnas.77.5.2439; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; WERMUTH B, 1992, ENZYMOLOGY CARBONYL, P261; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	40	403	413	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					81	84		10.1126/science.1621098	http://dx.doi.org/10.1126/science.1621098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621098				2022-12-24	WOS:A1992JC16500034
J	MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C				MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C			TRIPLE HELIX SPECIFIC LIGANDS	SCIENCE			English	Article							COLI RNA-POLYMERASE; ANTINEOPLASTIC AGENTS; DNA; OLIGONUCLEOTIDES; SEQUENCES; PROMOTER; COMPLEX	A triple helix is formed upon binding of an oligodeoxynucleotide to the major groove of duplex DNA. A benzo[e]pyridoindole derivative (BePI) strongly stabilized this structure and showed preferential binding to a triplex rather than to a duplex. Energy transfer experiments suggest that BePI intercalates within the triple helix. Sequence-specific inhibition of transcription initiation of a specific gene by Escherichia coli RNA polymerase by a triplex-forming oligodeoxynucleotide is strongly enhanced when the triplex is stabilized by BePI. Upon irradiation with ultraviolet light, BePI induces covalent modifications of the target within the triple helix structure.	MUSEUM NATL HIST NAT, BIOPHYS LAB,CNRS,UA 481,INSERM,U201,43 RUE CUVIER, F-75005 PARIS, FRANCE; INST CURIE, SYNTH LAB, CNRS, URA 1387, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Mergny, Jean-Louis/E-2860-2013; Nguyen, Chi/GZG-5146-2022; Nguyen, Chi/GWR-1592-2022	Mergny, Jean-Louis/0000-0003-3043-8401; 				BISAGNI E, 1988, J MED CHEM, V31, P398, DOI 10.1021/jm00397a023; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; COLLIER DA, 1991, NUCLEIC ACIDS RES, V19, P4219, DOI 10.1093/nar/19.15.4219; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CROTHERS DM, 1971, BIOPOLYMERS, V10, P2147, DOI 10.1002/bip.360101110; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DUVALVALENTIN G, 1988, NUCLEIC ACIDS RES, V16, P2031, DOI 10.1093/nar/16.5.2031; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MERGNY JL, 1991, NUCLEIC ACIDS RES, V19, P1521, DOI 10.1093/nar/19.7.1521; MONTENAYGARESTIER T, 1990, JERUS SYM Q, V23, P275; MORGAN JP, 1980, PHOTOCHEM PHOTOBIOL, V31, P101, DOI 10.1111/j.1751-1097.1980.tb03692.x; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NGUYEN CH, 1990, J MED CHEM, V33, P1519, DOI 10.1021/jm00167a037; NGUYEN CH, 1987, J MED CHEM, V30, P1642, DOI 10.1021/jm00392a021; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; ROUGEE M, UNPUB; SARI MA, 1986, BIOCHEM BIOPH RES CO, V141, P643, DOI 10.1016/S0006-291X(86)80221-2; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198	27	309	312	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1681	1684		10.1126/science.256.5064.1681	http://dx.doi.org/10.1126/science.256.5064.1681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609278				2022-12-24	WOS:A1992HZ17400045
J	LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW				LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW			THE MECHANISM OF Z-ALPHA-1-ANTITRYPSIN ACCUMULATION IN THE LIVER	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; PURIFICATION; DEFICIENCY; DAMAGE; PLASMA	MOST northern Europeans have only the normal M form of the plasma protease inhibitor alpha-1-antitrypsin, but some 4% are heterozygotes for the Z deficiency variant 1. For reasons that have not been well-understood, the Z mutation results in a blockage in the final stage of processing of antitrypsin in the liver 2 such that in the Z homozygote only 15% of the protein is secreted into the plasma.The 85% of the alpha-1-antitrypsin that is not secreted accumulates in the endoplasmic reticulum of the hepatocyte; much of it is degraded but the remainder aggregates to form insoluble intracellular inclusions. These inclusions are associated with hepatocellular damage, and 10% of newborn Z homozygotes develop liver disease which often leads to a fatal childhood cirrhosis. Here we demonstrate the molecular pathology underlying this accumulation and describe how the Z mutation in antitrypsin results in a unique molecular interaction between the reactive centre loop of one molecule and the gap in the A-sheet of another. This loop-sheet polymerization of Z antitrypsin occurs spontaneously at 37-degrees-C and is completely blocked by the insertion of a specific peptide into the A-sheet of the antitrypsin molecule. Z antitrypsin polymerized in vitro has identical properties and ultrastructure to the inclusions isolated from hepatocytes of a Z homozygote. The concentration and temperature dependence of this loop-sheet polymerization has implications for the management of the liver disease of the newborn Z homozygote.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	LOMAS, DA (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,CAMBRIDGE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; CURIEL DT, 1989, J BIOL CHEM, V264, P13939; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; EVANS DLI, 1991, THESIS U CAMBRIDGE; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAURELL CB, 1975, EUR J BIOCHEM, V57, P107, DOI 10.1111/j.1432-1033.1975.tb02281.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LE AQ, 1992, J BIOL CHEM, V267, P1072; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7	15	840	883	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					605	607		10.1038/357605a0	http://dx.doi.org/10.1038/357605a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608473				2022-12-24	WOS:A1992HZ11200059
J	PETERSON, M; MILLER, J				PETERSON, M; MILLER, J			ANTIGEN PRESENTATION ENHANCED BY THE ALTERNATIVELY SPLICED INVARIANT CHAIN GENE-PRODUCT P41	NATURE			English	Article							H-2-RESTRICTED T-CELLS; II MHC MOLECULES; B-CELL; RECOGNITION; HYBRIDOMAS; TRANSPORT; PEPTIDE; BINDING; ENCODES; REGIONS	DURING biosynthesis, class II molecules of the major histocompatibility complex are associated with a nonpolymorphic protein called invariant chain, Ii, which facilitates folding of class II molecules and their exit from the endoplasmic reticulum 1-4, interferes with their association with peptide 5,6 and directs their post-Golgi transport (refs 7-9). If Ii blocks class II loading with endogenous antigens in the endoplasmic reticulum and/or directs class II molecules to the exogenous antigen-loading compartment, then the co-expression of Ii should enhance the ability of class II molecules to present exogenous antigens to T cells. But data supporting a role for Ii in class II-restricted antigen presentation are controversial 1,10-13. Here we show that Ii can facilitate exogenous antigen presentation for a subset of antigens. Although all known functions of li have been ascribed to the principal form of Ii, p31, we find that in most cases antigen presentation is facilitated only by the alternatively spliced, minor form of Ii, p41.			PETERSON, M (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; EKHOLM R, 1990, INT REV CYTOL, V120, P243; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; JENSEN PE, 1988, J IMMUNOL, V141, P2545; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; OZAKI S, 1988, J IMMUNOL, V141, P71; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROSIONIEC E, 1989, J IMMUNOL, V143, P50; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SETTE A, 1992, J IMMUNOL, V148, P844; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; YAMAMOTO K, 1985, J IMMUNOL, V134, P3461	35	124	125	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					596	598		10.1038/357596a0	http://dx.doi.org/10.1038/357596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608470				2022-12-24	WOS:A1992HZ11200056
J	SUTHERLAND, VJ; COOPER, CL				SUTHERLAND, VJ; COOPER, CL			JOB STRESS, SATISFACTION, AND MENTAL-HEALTH AMONG GENERAL-PRACTITIONERS BEFORE AND AFTER INTRODUCTION OF NEW CONTRACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORK; CONSULTATION; QUALITY; DOCTORS; TIME	Objective - To compare measures of job stress, job satisfaction, and mental health among general practitioners before and after the introduction of the new contract in April 1990. Design - Cross sectional postal questionnaire survey in July 1990. Comparison of results with those obtained in previous survey in November 1987. Setting - General practice in United Kingdom. Subjects - 1500 general practitioners randomly selected from general medical services lists, 917 of whom (61%) returned questionnaires usable for statistical analysis. Main outcome measures - Aspects of job causing stress, job satisfaction (Warr, Cook, and Wall scale), and mental health (Crown-Crisp experiential index). Results - Compared with 1987, in 1990 doctors experienced more stress from night calls (mean score 3.83 in 1990 v 3.45 in 1987), emergencies during surgery hours (3.72 v 3.48), and interruption of family life by telephone (3.58 v 2.73; p<0.001 for all three variables). Scores for somatic anxiety and depression were higher in both men and women in 1990 (men: somatic anxiety 3.12 v 2.36; depression 3.80 v 2.94; women: somatic anxiety 3.56 v 2.65; depression 4.02 v 3.37; p<0.001). Job satisfaction had also decreased in 1990 (5.23 v 4.26; p<0.001). Conclusions - Doctors experienced more stress, less job satisfaction, and poorer mental health in 1990 than in 1987. These changes may have resulted from the introduction of the new contract.			SUTHERLAND, VJ (corresponding author), UNIV MANCHESTER, INST SCI & TECHNOL, MANCHESTER SCH MANAGEMENT, DEPT ORG PSYCHOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ABROOK M, 1990, PRACTITIONER, V234, P992; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Crown S, 1979, MANUAL CROWN CRISP E; FRENCH JRP, 1973, FAILURE SUCCESS, P30; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; HOWIE JGR, 1989, BMJ-BRIT MED J, V298, P1008, DOI 10.1136/bmj.298.6679.1008; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; LLOYD G, 1990, BRIT MED J, V300, P728, DOI 10.1136/bmj.300.6726.728; MACPHERSON G, 1989, BRIT MED J, V298, P1406, DOI 10.1136/bmj.298.6685.1406; MARSH G, 1976, TEAM CARE GENERAL PR; MORRELL D, 1989, BRIT MED J, V298, P1005, DOI 10.1136/bmj.298.6679.1005; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; MYERSON S, 1990, PRACTITIONER, V234, P973; PORTER AMD, 1985, FAM PRACT, V2, P136, DOI 10.1093/fampra/2.3.136; PORTER AMD, 1987, STRESS HLTH PROFESSI, P45; SALES SM, 1971, J CHRON DIS, V23, P861, DOI 10.1016/0021-9681(71)90015-4; SCHEIBER SC, 1987, STRESS HLTH PROFESSI, P23; Selye H., 1979, STRESS DISTRESS; SMITH T, 1989, BRIT MED J, V298, P1405, DOI 10.1136/bmj.298.6685.1405; SUTHERLAND VJ, 1990, UNDERSTANDING STRESS, P165; VANSELL M, 1981, HUM RELAT, V34, P43, DOI 10.1177/001872678103400104; WARR P, 1979, J OCCUP PSYCHOL, V52, P129, DOI 10.1111/j.2044-8325.1979.tb00448.x	23	162	162	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1545	1548		10.1136/bmj.304.6841.1545	http://dx.doi.org/10.1136/bmj.304.6841.1545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628056	Green Published, Bronze			2022-12-24	WOS:A1992HZ17800027
J	ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J				ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J			GALACTOSE OXIDATION IN THE DESIGN OF IMMUNOGENIC VACCINES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL ACTIVATION; INFLUENZA-A VIRUS; IMMUNE-RESPONSE; ANTIGEN; RECOGNITION; VACCINATION; ANTIBODIES; RETROVIRUS; INDUCTION	Potent immunological adjuvants are urgently required to complement recombinant and synthetic vaccines. However, it has not been possible to derive new principles for the design of vaccine adjuvants from knowledge of the mechanism of immunogenicity. Carbonyl-amino condensations, which are essential to the inductive interaction between antigen-presenting cells and T helper cells, were tested as a target for the enhancement of immune responses. Enzymic oxidation of cell-surface galactose to increase amine-reactive carbonyl groups on murine lymphocytes and antigen-presenting cells provided a potent, noninflammatory method of enhancing the immunogenicity of viral, bacterial, and protozoal subunit vaccines in mice.	WELLCOME RES LABS,DEPT PHARMACOL,LANGLEY COURT,S EDEN PK RD,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT DRUG SAFETY EVALUAT,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories								ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHEDID L, 1976, P NATL ACAD SCI USA, V73, P2472, DOI 10.1073/pnas.73.7.2472; FURUKAWA KS, 1989, J EXP MED, V169, P583; GAO XM, 1990, J IMMUNOL, V144, P2883; GAO XM, 1991, J IMMUNOL, V147, P3268; GAO XM, 1989, J IMMUNOL, V143, P3007; GLENNY AT, 1926, CHEM IND         JUN, P415; GREGORIADIS G, 1989, IMMUNOLOGICAL ADJUVA; HART MK, 1990, J IMMUNOL, V145, P2677; KOFF WC, 1989, AIDS, V3, pS125, DOI 10.1097/00002030-198901001-00018; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LIFELY MR, 1991, VACCINE, V9, P60, DOI 10.1016/0264-410X(91)90318-Z; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MURPHY VF, 1990, PARASITOLOGY, V100, P177, DOI 10.1017/S0031182000061175; NOVOGRODSKY A, 1973, P NATL ACAD SCI USA, V70, P1824, DOI 10.1073/pnas.70.6.1824; PLAYFAIR JHL, 1990, LANCET, V335, P1263, DOI 10.1016/0140-6736(90)91316-3; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRINGER TA, 1990, NATURE, V345, P426; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZHENG B, UNPUB	28	54	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1560	1563		10.1126/science.1598588	http://dx.doi.org/10.1126/science.1598588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598588				2022-12-24	WOS:A1992HY07500030
J	MILTON, RCD; MILTON, SCF; KENT, SBH				MILTON, RCD; MILTON, SCF; KENT, SBH			TOTAL CHEMICAL SYNTHESIS OF A D-ENZYME - THE ENANTIOMERS OF HIV-1 PROTEASE SHOW DEMONSTRATION OF RECIPROCAL CHIRAL SUBSTRATE-SPECIFICITY	SCIENCE			English	Article							PROTEINASE; PEPTIDES	The D and L forms of the enzyme HIV-1 protease have been prepared by total chemical synthesis. The two proteins had identical covalent structures. However, the folded protein-enzyme enantiomers showed reciprocal chiral specificity on peptide substrates. That is, each enzyme enantiomer cut only the corresponding substrate enantiomer. Reciprocal chiral specificity was also evident in the effect of enantiomeric inhibitors. These data imply that the folded forms of the chemically synthesized D- and L-enzyme molecules are mirror images of one another in all elements of the three-dimensional structure. Enantiomeric proteins are expected to display reciprocal chiral specificity in all aspects of their biochemical interactions.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERGMAN DA, 1992, FEB LORN C VICT; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CHAIT BT, UNPUB; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; FERSHT A, 1977, ENZYME STRUCTURE MEC, P75; FRUTON JS, 1972, MOL LIFE, P53; HENKLEIN P, IN PRESS SOLID PHASE; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; MACKAY AL, 1989, NATURE, V342, P133, DOI 10.1038/342133a0; MASON SF, 1991, CHIRALITY, V3, P223, DOI 10.1002/chir.530030403; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MIRSKY AE, 1936, P NATL ACAD SCI USA, V22, P438; PASTEUR L, 1960, SOC CHIM PARIS, P1; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; RICHARDSON JS, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, IN PRESS INT J PEPT; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	25	320	357	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1445	1448		10.1126/science.1604320	http://dx.doi.org/10.1126/science.1604320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604320				2022-12-24	WOS:A1992HX33700036
J	GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D				GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D			HYPERCALCEMIA - CHANGING CAUSES OVER THE PAST 10 YEARS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								FISKEN R A, 1980, QJM, V196, P405; FISKEN RA, 1981, LANCET, V1, P202; HEATH D, 1991, CLIN ENDOCRINOL, V34, P155, DOI 10.1111/j.1365-2265.1991.tb00286.x; MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187	4	16	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1284	1284		10.1136/bmj.304.6837.1284	http://dx.doi.org/10.1136/bmj.304.6837.1284			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606431	Green Published, Bronze			2022-12-24	WOS:A1992HV08600023
J	KNOLL, AH				KNOLL, AH			THE EARLY EVOLUTION OF EUKARYOTES - A GEOLOGICAL PERSPECTIVE	SCIENCE			English	Article							RIBOSOMAL-RNA; PROTEROZOIC PLANKTON; ORIGIN; CHLOROPLASTS; AUSTRALIA; CANADA; BASIN	Molecular phylogenies of eukaryotic organisms imply patterns of biological and environmental history that can be tested against the geological record. As predicted by sequence comparisons, Precambrian rocks show evidence of episodic increases in biological diversity and atmospheric oxygen concentrations. Nonetheless, complete integration of the two records remains elusive and may require that the earliest macroscopic organisms be recognized as extinct experiments in eukaryotic multicellularity.			KNOLL, AH (corresponding author), HARVARD UNIV, BOT MUSEUM, CAMBRIDGE, MA 02138 USA.							ALLISON CW, 1986, J PALEONTOL, V60, P973, DOI 10.1017/S0022336000022538; [Anonymous], EARTHS EARLIEST BIOS; [Anonymous], 1985, PALEOALGOLOGY; BARGHOORN ES, 1965, SCIENCE, V147, P563, DOI 10.1126/science.147.3658.563; BHATTACHARYA D, 1990, J PHYCOL, V26, P181, DOI 10.1111/j.0022-3646.1990.00181.x; BUTTERFIELD NJ, 1990, SCIENCE, V250, P104, DOI 10.1126/science.11538072; BUTTERFIELD NJ, 1988, NATURE, V334, P424, DOI 10.1038/334424a0; BUTTERFIELD NJ, 1992, THESIS HARVARD U CAM; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CLOUD P, 1976, Paleobiology, V2, P351; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; DERRY LA, IN PRESS GEOCHIM COS; DOOLITTLE RF, 1989, INT CONGR SER, V824, P73; DOUGLAS SE, 1991, NATURE, V350, P148, DOI 10.1038/350148a0; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIOVANNONI SJ, 1988, J BACTERIOL, V170, P3584, DOI 10.1128/jb.170.8.3584-3592.1988; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRANT SWF, 1991, J PALEONTOL, V65, P1; GREY K, 1990, PRECAMBRIAN RES, V46, P307, DOI 10.1016/0301-9268(90)90018-L; Hermann T. N., 1990, ORGANIC WORLD BILLIO; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; HOLLAND HD, 1990, AM J SCI, V290A, P1; HORODYSKI RJ, 1980, J PALEONTOL, V54, P649; HORODYSKI RJ, 1990, AM J SCI, V290A, P149; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANKAUSKAS T, 1989, MIKROFOSSILLI DOKEMB; KASTING JF, 1987, PRECAMBRIAN RES, V34, P205, DOI 10.1016/0301-9268(87)90001-5; KAUFMAN AJ, 1992, GEOLOGY, V20, P181, DOI 10.1130/0091-7613(1992)020<0181:BACCON>2.3.CO;2; KNOLL AH, 1991, J PALEONTOL, V65, P531, DOI 10.1017/S0022336000030663; KNOLL AH, 1989, NATURE, V337, P602, DOI 10.1038/337602a0; KNOLL AH, 1991, SCI AM, V265, P64, DOI 10.1038/scientificamerican1091-64; KNOLL AH, IN PRESS PALYNOLOGY; KNOLL AH, 1978, J PALEONTOL, V52, P576; KNOLL AH, IN PRESS BIOTIC RESP; KNOLL AH, IN PRESS PALAEONTOLO; LAKE JA, 1989, CAN J MICROBIOL, V35, P109, DOI 10.1139/m89-017; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; Margulis L., 1993, SYMBIOSIS CELL EVOLU; Margulis L., 1989, HDB PROTOCTISTA; Moczydlowska M., 1991, FOSSILS STRATA, V29, P1; NURSALL JR, 1959, NATURE, V183, P1170, DOI 10.1038/1831170b0; OURISSON G, 1987, ANNU REV MICROBIOL, V41, P301, DOI 10.1146/annurev.mi.41.100187.001505; PEAT C J, 1978, BMR (Bureau of Mineral Resources) Journal of Australian Geology and Geophysics, V3, P1; PERASSO R, 1989, NATURE, V339, P142, DOI 10.1038/339142a0; Postgate J. R., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P31; RAFF RA, 1989, INT CONGR SER, V824, P247; RUNNEGAR B, 1982, J GEOL SOC AUST, V29, P395, DOI 10.1080/00167618208729222; Schopf JW, 1983, EARTHS EARLIEST BIOS; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SOKOLOV BS, 1990, VENDIAN SYSTEM, V1; SUMMONS RE, 1990, AM J SCI, V290A, P212; Tappan H, 1980, PALEOBIOLOGY PLANT P; TIBAYRENC M, 1991, P NATL ACAD SCI USA, V88, P5129, DOI 10.1073/pnas.88.12.5129; TOWE KM, 1990, NATURE, V348, P54, DOI 10.1038/348054a0; VIDAL G, 1983, GEOL SOC AM MEM, V161, P265; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; WALTER MR, 1990, AM J SCI, V290A, P133; WHATLEY JM, 1981, ANN NY ACAD SCI, V361, P154, DOI 10.1111/j.1749-6632.1981.tb46517.x; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Yin L., 1985, PALAEONTOLOGIA CATHA, V2, P229; ZANG WL, 1989, NATURE, V337, P642, DOI 10.1038/337642a0; ZECHMAN FW, 1990, J PHYCOL, V26, P700, DOI 10.1111/j.0022-3646.1990.00700.x; Zhang Zhongying, 1986, Journal of Micropalaeontology, V5, P9; ZUCKERKANDL E, 1965, J THEOR BIOL, V8, P357, DOI 10.1016/0022-5193(65)90083-4	68	517	545	3	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					622	627		10.1126/science.1585174	http://dx.doi.org/10.1126/science.1585174			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585174				2022-12-24	WOS:A1992HR18500022
J	WARNOCK, M				WARNOCK, M			GREEN-COLLEGE LECTURE - ETHICAL CHALLENGES IN EMBRYO MANIPULATION	BRITISH MEDICAL JOURNAL			English	Article											WARNOCK, M (corresponding author), GIRTON COLL,CAMBRIDGE CB3 0JG,ENGLAND.							1982, SPLICING LIFE	1	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1045	1049		10.1136/bmj.304.6833.1045	http://dx.doi.org/10.1136/bmj.304.6833.1045			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586793	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200029
J	WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR				WRIGHT, TL; HSU, H; DONEGAN, E; FEINSTONE, S; GREENBERG, H; READ, A; ASCHER, NL; ROBERTS, JP; LAKE, JR			HEPATITIS-C VIRUS NOT FOUND IN FULMINANT NON-A, NON-B HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Note							FAILURE		DEPT VET AFFAIRS MED CTR, PALO ALTO, CA 94304 USA; US FDA, HEPATITIS RES LAB, SAN FRANCISCO, CA 94102 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, STANFORD, CA 94305 USA	US Food & Drug Administration (FDA); University of California System; University of California San Francisco; Stanford University	WRIGHT, TL (corresponding author), VET AFFAIRS MED CTR, GASTROENTEROL UNIT, 111B, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.			greenberg, harry/0000-0002-2128-9080; Lake, John/0000-0002-4332-0528	NIDDK NIH HHS [DK-26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BERNUAU J, 1986, SEMIN LIVER DIS, V6, P97, DOI 10.1055/s-2008-1040593; CRISTIANO K, IN PRES HEPATOLOGY; DIENSTAG JL, 1983, GASTROENTEROLOGY, V85, P439; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; MUTO Y, 1990, Gastroenterologia Japonica, V25, P32; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4	7	131	132	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1991	115	2					111	112		10.7326/0003-4819-115-2-111	http://dx.doi.org/10.7326/0003-4819-115-2-111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FW091	1647717				2022-12-24	WOS:A1991FW09100006
J	GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH				GAO, F; YUE, L; WHITE, AT; PAPPAS, PG; BARCHUE, J; HANSON, AP; GREENE, BM; SHARP, PM; SHAW, GM; HAHN, BH			HUMAN INFECTION BY GENETICALLY DIVERSE SIVSM-RELATED HIV-2 IN WEST AFRICA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-2; GENOMIC DIVERGENCE; SOOTY MANGABEY; MONKEYS; AIDS; VARIABILITY; ISOLATE	OUR understanding of the biology and origins of human immunodeficiency virus type 2 (HIV-2) derives from studies of cultured isolates from urban populations experiencing epidemic infection and disease1-8. To test the hypothesis that such isolates might represent only a subset of a larger, genetically more diverse group of viruses, we used nested polymerase chain reactions to characterize HIV-2 sequences in uncultured mononuclear blood cells of two healthy Liberian agricultural workers, from whom virus isolation was repeatedly unsuccessful, and from a culture-positive symptomatic urban dweller. Analysis of pol, env and long terminal repeat regions revealed the presence of three highly divergent HIV-2 strains, one of which (from one of the healthy subjects) was significantly more closely related to simian immunodeficiency viruses infecting sooty mangabeys and rhesus macaques (SIV(SM)/SIV(MAC)) than to any virus of human derivation. This subject also harboured multiply defective viral genotypes that resulted from hypermutation of G to A bases. Our results indicate that HIV-2, SIV(SM) and SIV(MAC) comprise a single, highly diverse group of lentiviruses which cannot be separated into distinct phylogenetic lineages according to species of origin.	UNIV ALABAMA,DIV GEOG MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV INFECT DIS,BIRMINGHAM,AL 35294; LIBERIAN INST BIOMED RES,ROBERTSFIELD,LIBERIA; UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Trinity College Dublin	GAO, F (corresponding author), UNIV ALABAMA,DEPT MED,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.		Sharp, Paul/Y-3787-2019; Sharp, Paul M/GPX-1497-2022; Sharp, Paul M/F-5783-2010	Sharp, Paul M/0000-0001-9771-543X; Sharp, Paul M/0000-0001-9771-543X; Hahn, Beatrice/0000-0002-9400-9887				ALLAN JS, 1991, J VIROL, V65, P2816, DOI 10.1128/JVI.65.6.2816-2828.1991; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DIETRICH U, 1989, NATURE, V342, P948, DOI 10.1038/342948a0; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FIENNES TW, 1978, ZOONOSES ORIGINS ECO; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; FRANCHINI G, 1989, P NATL ACAD SCI USA, V86, P2433, DOI 10.1073/pnas.86.7.2433; FULTZ PN, 1990, AIDS, V4, P619, DOI 10.1097/00002030-199007000-00002; GILKS C, 1991, NATURE, V354, P262, DOI 10.1038/354262a0; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HASEGAWA A, 1989, AIDS RES HUM RETROV, V5, P593, DOI 10.1089/aid.1989.5.593; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; JOHNSON PR, 1991, VIROLOGY, V185, P217, DOI 10.1016/0042-6822(91)90769-8; KHAN AS, 1991, J VIROL, V65, P7061, DOI 10.1128/JVI.65.12.7061-7065.1991; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KIRCHHOFF F, 1990, AIDS, V4, P847, DOI 10.1097/00002030-199009000-00003; KUMAR P, 1990, J VIROL, V64, P890, DOI 10.1128/JVI.64.2.890-901.1990; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LI YX, 1991, J VIROL, V65, P3973, DOI 10.1128/JVI.65.8.3973-3985.1991; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MYERS G, 1991, HUMAN RETROVIRUSES A; NOVEMBRE FJ, 1992, VIROLOGY, V186, P783, DOI 10.1016/0042-6822(92)90047-S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULZ TF, 1990, J VIROL, V64, P5177, DOI 10.1128/JVI.64.10.5177-5182.1990; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941	30	356	363	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					495	499		10.1038/358495a0	http://dx.doi.org/10.1038/358495a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641038				2022-12-24	WOS:A1992JG73900047
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			REGULATION OF THE CDC25 PROTEIN DURING THE CELL-CYCLE IN XENOPUS EXTRACTS	CELL			English	Article							FISSION YEAST; MITOTIC CONTROL; STEP PURIFICATION; DNA-REPLICATION; MESSENGER-RNA; M-PHASE; MITOSIS; KINASE; INVITRO; ACTIVATION	The cdc25 protein is a highly specific tyrosine phosphatase that triggers mitosis by dephosphorylating the cdc2 protein kinase. Using Xenopus extracts, we have found that the cdc25 protein is active at a low level throughout interphase. Near the onset of mitosis, the cdc25 protein undergoes a marked elevation in phosphatase activity that coincides with an extensive phosphorylation of the protein in its N-terminal region. In vitro dephosphorylation of this hyperphosphorylated form of cdc25 reduces its phosphatase activity back to the interphase level. Moreover, treatment of interphase Xenopus extracts with okadaic acid, a phosphatase inhibitor that accelerates the entry into mitosis, elicits both the premature hyperphosphorylation of cdc25 and the stimulation of its cdc2-specific tyrosine phosphatase activity. These experiments demonstrate the existence of a cdc25 regulatory system consisting of both a stimulatory kinase that phosphorylates a putative regulatory domain of the cdc25 protein and an inhibitory serine/threonine phosphatase that counteracts this kinase activity.			KUMAGAI, A (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fleig U N, 1991, Semin Cell Biol, V2, P195; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; JESSUS C, 1991, DEVELOPMENT, V111, P813; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M	53	360	374	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					139	151		10.1016/0092-8674(92)90540-S	http://dx.doi.org/10.1016/0092-8674(92)90540-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623517				2022-12-24	WOS:A1992JC95700015
J	MILLER, LH				MILLER, LH			THE CHALLENGE OF MALARIA	SCIENCE			English	Editorial Material											MILLER, LH (corresponding author), NIAID,MALARIA RES LAB,BETHESDA,MD 20892, USA.							[Anonymous], 1991, MALARIA OBSTACLES OP; ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Harrison G, 1978, MOSQUITOES MALARIA M; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; 1992, LANCET, V339, P649	12	38	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					36	37		10.1126/science.1621092	http://dx.doi.org/10.1126/science.1621092			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621092				2022-12-24	WOS:A1992JC16500022
J	WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD				WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD			REVIEW OF COMPANY POSTMARKETING SURVEILLANCE STUDIES	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To review postmarketing surveillance studies sponsored by the pharmaceutical industry since the introduction of voluntary guidelines in 1987 and to evaluate their contribution to monitoring drug safety. Design - Retrospective analysis of the information submitted to the Medicines Control Agency on postmarketing surveillance studies. Setting - United Kingdom. Main outcome measures - Study designs, projected and actual sample sizes, provision of interim and final reports, number of suspected serious adverse reactions reported, identification of new drug safety hazards. Results - 31 studies had been conducted under the guidelines, of which 27 were prospective and four retrospective. Nine studies had at least one comparator group, the remainder were uncontrolled. The median projected sample size for the studies was 5600 patients. Only five studies had achieved at least 75% of the projected sample size. 11 studies had been abandoned, predominantly because of difficulties in recruitment, and 15 were ongoing. One study had identified an important new safety hazard. Conclusions - Company postmarketing surveillance studies have made only a limited contribution to the assessment of drug safety, principally because of weak study designs and difficulties in recruitment. The guidelines require modification to take this experience into account.	COMM SAFETY MED,ADVERSE REACT GRP,LONDON SW8 5BR,ENGLAND; COMM SAFETY MED,SUBCOMM SAFETY EFFICACY & ADVERSE REACT,LONDON SW8 5BR,ENGLAND		WALLER, PC (corresponding author), MED CONTROL AGCY,PHARMACOVIGILANCE UNIT,MARKET TOWERS,LONDON SW8 5NQ,ENGLAND.							RAWLINS MD, 1991, BRIT MED J, V302, P223, DOI 10.1136/bmj.302.6770.223; 1987, ADVERSE DRUG REACT, P62; 1988, BMJ, V296, P399	3	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1470	1472		10.1136/bmj.304.6840.1470	http://dx.doi.org/10.1136/bmj.304.6840.1470			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611368	Bronze, Green Published			2022-12-24	WOS:A1992HY55300020
J	COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT				COLEMAN, RA; WINTER, HS; WOLF, B; GILCHRIST, JM; CHEN, YT			GLYCOGEN-STORAGE-DISEASE TYPE-III (GLYCOGEN DEBRANCHING ENZYME DEFICIENCY) - CORRELATION OF BIOCHEMICAL DEFECTS WITH MYOPATHY AND CARDIOMYOPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						GLYCOGEN STORAGE DISEASE TYPE-III; GLYCOGEN DEBRANCHING ENZYME SYSTEM; MUSCULAR DISEASES; MYOCARDIAL DISEASES; LIVER DISEASES; GROWTH DISORDERS	IMMUNOBLOT ANALYSES; INVOLVEMENT; ADULTS	Objective: To determine whether a specific subtype of glycogen storage disease type III is associated with myopathy and cardiomyopathy. Design: Case series. Setting: Three referral medical centers. Patients: All patients with glycogen storage disease type III who were followed in 1990 and for whom both immunoblot analysis and clinical data were available. Main Outcome Measures: Evaluation for myopathy and cardiomyopathy included determinations of serum creatine kinase activity; muscle strength testing; ischemic exercise testing; nerve conduction studies; and electromyographic, electrocardiographic, and echocardiographic studies. Results: Three patients with deficient debranching enzyme activity and deficient immunoreactive material in liver but normal debranching enzyme activity in muscle (glycogen storage disease IIIb) had no clinical evidence of myopathy or cardiomyopathy. Serum creatine kinase activity, muscle strength, ischemic exercise testing, electrocardiograms, and echocardiograms were normal in these patients. These studies and electromyograms were abnormal in seven patients with total debranching enzyme deficiency and an absence of immunoreactive material in both liver and muscle (glycogen storage disease IIIa) and in three patients who had debranching enzyme transferase deficiency but normal glucosidase activity in both liver and muscle (glycogen storage disease IIId). All 10 of these patients had progressive myopathy, and 6 had progressive cardiomyopathy. Conclusion: Clinical features of glycogen storage disease type III correlate with the particular biochemical defect seen with the disorder. Assessments of debranching enzyme or debranching enzyme transferase activity in muscle can be used to predict whether patients with glycogen storage disease type III will develop myopathy and cardiomyopathy.	DUKE UNIV, MED CTR, DEPT PEDIAT, DURHAM, NC 27710 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT PEDIAT, BOSTON, MA 02115 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT HUMAN GENET, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PEDIAT, RICHMOND, VA 23298 USA; RHODE ISL HOSP, DEPT NEUROL, PROVIDENCE, RI 02902 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA	Duke University; Harvard University; Boston Children's Hospital; Harvard Medical School; Virginia Commonwealth University; Virginia Commonwealth University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039078] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR30] Funding Source: Medline; NIDDK NIH HHS [DK 39078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES EJ, 1975, FEBS LETT, V58, P181, DOI 10.1016/0014-5793(75)80254-7; BROWN BI, 1968, CARBOHYD METABOL, P123; Brown D.H., 1966, METHOD ENZYMOL, P515, DOI 10.1016/0076-6879(66)08093-5; BRUNBERG JA, 1971, ARCH NEUROL-CHICAGO, V25, P171, DOI 10.1001/archneur.1971.00490020089011; CHEN YT, 1987, AM J HUM GENET, V41, P1002; COLEMAN RA, 1986, MUSCLE NERVE, V9, P216, DOI 10.1002/mus.880090305; CORNELIO F, 1984, ARCH NEUROL-CHICAGO, V41, P1027, DOI 10.1001/archneur.1984.04050210025008; DAESCHEL IE, 1983, J AM DIET ASSOC, V83, P135; DIMAURO S, 1979, ANN NEUROL, V5, P422, DOI 10.1002/ana.410050504; DING JH, 1990, J PEDIATR-US, V116, P95, DOI 10.1016/S0022-3476(05)81652-X; FORBES GB, 1953, J PEDIATR-US, V42, P645, DOI 10.1016/S0022-3476(53)80420-8; HERS HG, 1967, EUR J BIOCHEM, V2, P257, DOI 10.1111/j.1432-1033.1967.tb00133.x; Hers HG, 1989, METABOLIC BASIS INHE, P425; ILLINGWORTH B, 1956, J BIOL CHEM, V218, P123; MOSES SW, 1986, ACTA PAEDIATR SCAND, V75, P289, DOI 10.1111/j.1651-2227.1986.tb10201.x; MURASE T, 1973, J NEUROL SCI, V20, P287, DOI 10.1016/0022-510X(73)90190-1; NELSON TE, 1970, ANAL BIOCHEM, V33, P87, DOI 10.1016/0003-2697(70)90442-2; PERNOT C, 1978, ARCH MAL COEUR VAISS, V71, P428; POWELL HC, 1985, MUSCLE NERVE, V8, P667, DOI 10.1002/mus.880080808; SLONIM AE, 1983, METABOLISM, V32, P70, DOI 10.1016/0026-0495(83)90159-2; SLONIM AE, 1982, ANN NEUROL, V11, P420, DOI 10.1002/ana.410110417; VANHOOF F, 1967, EUR J BIOCHEM, V2, P265; YANG BZ, 1990, AM J HUM GENET, V47, P735	23	64	68	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					896	900		10.7326/0003-4819-116-11-896	http://dx.doi.org/10.7326/0003-4819-116-11-896			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580445				2022-12-24	WOS:A1992HW13700003
J	HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C				HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C			FUNCTIONAL SPECIALIZATION OF OLFACTORY GLOMERULI IN A MOTH	SCIENCE			English	Article							PHEROMONE-SENSITIVE NEURONS; DROSOPHILA-MELANOGASTER; ANTENNAL LOBE; BULB; DEUTOCEREBRUM; PROJECTION; BRAIN	The specific function of the glomerular structures present in the antennal lobes or olfactory bulbs of organisms ranging from insects to humans has been obscure because of limitations in neuronal marking methods. By tracing individual neurons in the moth Agrotis segetum, it was determined that physiologically distinct types of pheromone receptor neurons project axons to different regions of the macroglomerular complex (MGC). Each glomerulus making up the MGC has a specific functional identity, initially processing information about one specific pheromone component. This indicates that, at least through the first stage of synapses, olfactory information moves through labeled lines.	UNIV LUND,DEPT ZOOL,S-22362 LUND,SWEDEN	Lund University	HANSSON, BS (corresponding author), UNIV LUND,DEPT ECOL,S-22362 LUND,SWEDEN.		Hansson, Bill S/G-2774-2013; Löfstedt, Christer/G-2016-2014	Hansson, Bill S/0000-0002-4811-1223; Löfstedt, Christer/0000-0002-3116-6922				ARNOLD G, 1987, CR ACAD SCI III-VIE, V305, P271; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BOECKH J, 1979, J COMP PHYSIOL, V132, P235, DOI 10.1007/BF00614495; BURROWS M, 1982, J COMP PHYSIOL A, V15, P447; Christensen T.A., 1987, P457; CHRISTENSEN TA, 1991, J COMP PHYSIOL A, V169, P259; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOSL M, 1990, J COMP PHYSIOL A, V167, P321, DOI 10.1007/BF00192567; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; Kaissling KE, 1974, BIOCH SENSORY FUNCTI, P243; LOFSTEDT C, 1982, J CHEM ECOL, V8, P1305, DOI 10.1007/BF00987764; MATSUMOTO SG, 1981, PROC R SOC SER B-BIO, V213, P249, DOI 10.1098/rspb.1981.0066; MELLON D, 1990, J COMP NEUROL, V296, P253, DOI 10.1002/cne.902960205; OBERMAYER M, 1980, NEUROANATOMICAL TECH, P406; PEDERSEN PE, 1986, J COMP NEUROL, V250, P93, DOI 10.1002/cne.902500109; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROWELL CHF, 1963, Q J MICROSC SCI, V104, P81; SCHNEIDERMAN AM, 1982, NATURE, V298, P844, DOI 10.1038/298844a0; SHANBHAG SR, 1992, CELL TISSUE RES, V267, P273, DOI 10.1007/BF00302965; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; VANDERPERS JNC, 1978, J INSECT PHYSIOL, V24, P337, DOI 10.1016/0022-1910(78)90033-1	21	188	198	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1313	1315		10.1126/science.1598574	http://dx.doi.org/10.1126/science.1598574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598574				2022-12-24	WOS:A1992HW13500031
J	THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA				THERIOT, JA; MITCHISON, TJ; TILNEY, LG; PORTNOY, DA			THE RATE OF ACTIN-BASED MOTILITY OF INTRACELLULAR LISTERIA-MONOCYTOGENES EQUALS THE RATE OF ACTIN POLYMERIZATION	NATURE			English	Article							FILAMENTS	THE Gram-positive bacterium Listeria monocytogenes is a facultative intracellular pathogen capable of rapid movement through the host cell cytoplasm 1. The biophysical basis of the motility of L. monocytogenes is an interesting question in its own right, the answer to which may shed light on the general processes of actin-based motility in cells. Moving intracellular bacteria display phase-dense 'comet tails' made of actin filaments, the formation of which is required for bacterial Motility 2,3. We have investigated the dynamics of the actin filaments in the comet tails using the technique of photoactivation of fluorescence, which allows monitoring of the movement and turnover of labelled actin filaments after activation by illumination with ultraviolet light. We find that the actin filaments remain stationary in the cytoplasm as the bacterium moves forward, and that length of the comet tails is linearly proportional to the rate of movement. Our results imply that the motile mechanism involves continuous polymerization and release of actin filaments at the bacterial surface and that the rate of filament generation is related to the rate of movement. We suggest that actin polymerization provides the driving force for bacterial propulsion.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	University of California System; University of California San Francisco; University of Pennsylvania; University of Pennsylvania	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Theriot, Julie/HHN-2034-2022	Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; HILL TL, 1982, P NATL ACAD SCI-BIOL, V79, P490, DOI 10.1073/pnas.79.2.490; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; OSTER GF, 1987, J CELL SCI, P35; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SANGER J M, 1990, Journal of Cell Biology, V111, p415A; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TILNEY LG, IN PRESS J CELL BIOL	13	431	437	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 21	1992	357	6375					257	260		10.1038/357257a0	http://dx.doi.org/10.1038/357257a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589024				2022-12-24	WOS:A1992HV19500060
J	WANG, L; HELMANN, JD; WINANS, SC				WANG, L; HELMANN, JD; WINANS, SC			THE A-TUMEFACIENS TRANSCRIPTIONAL ACTIVATOR OCCR CAUSES A BEND AT A TARGET PROMOTER, WHICH IS PARTIALLY RELAXED BY A PLANT TUMOR METABOLITE	CELL			English	Article							AGROBACTERIUM TI-PLASMID; ESCHERICHIA-COLI; RNA-POLYMERASE; REGULATORY PROTEINS; BINDING-SPECIFICITY; INDUCIBLE GENES; DNA; SEQUENCE; ORGANIZATION; FAMILY	Octopine is released from crown gall tumors as a nutrient source and a signal molecule for the plant pathogen Agrobacterium tumefaciens. Some or all octopine-inducible genes are regulated by a protein called OccR. Primer extension analysis showed that OccR protein represses the occR gene and both represses and activates the occQ operon, which is divergently transcribed from occR. These promoters initiate transcription 46 bp apart. This regulatory system was reconstituted in vitro using purified OccR protein and Escherichia coli RNA polymerase. OccR binds with high affinity to a single site overlapping these promoters. Octopine shortens the DNAase I footprint of OccR and increases the gel mobility of OccR-DNA complexes by relaxing an OccR-incited DNA bend.			WANG, L (corresponding author), CORNELL UNIV,MICROBIOL SECT,ITHACA,NY 14853, USA.			Helmann, John/0000-0002-3832-3249	NIGMS NIH HHS [1 R29 GM2893-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BINNS AN, 1988, ANNU REV MICROBIOL, V42, P575, DOI 10.1146/annurev.mi.42.100188.003043; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1989, J BIOL CHEM, V264, P903; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHANG M, 1991, J BACTERIOL, V173, P1590, DOI 10.1128/jb.173.5.1590-1597.1991; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CHUNG YT, 1990, MOL CELL BIOL, V10, P206, DOI 10.1128/MCB.10.1.206; DEGREVE H, 1981, PLASMID, V6, P235, DOI 10.1016/0147-619X(81)90069-X; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; DEVOS G, 1981, PLASMID, V6, P249, DOI 10.1016/0147-619X(81)90070-6; ECKERT RL, 1987, CURRENT PROTOCOLS MO; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P379, DOI 10.1094/MPMI-4-379; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HELMANN JD, 1989, J BACTERIOL, V171, P222, DOI 10.1128/jb.171.1.222-229.1989; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HO YS, 1983, NATURE, V304, P703, DOI 10.1038/304703a0; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; HRYNIEWICZ MM, 1991, J BACTERIOL, V173, P5876, DOI 10.1128/jb.173.18.5876-5886.1991; HUANG MW, 1990, J BACTERIOL, V172, P1814, DOI 10.1128/jb.172.4.1814-1822.1990; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; JIN SG, 1990, J BACTERIOL, V172, P531, DOI 10.1128/jb.172.2.531-537.1990; KADO CI, 1991, CRIT REV PLANT SCI, V10, P1, DOI 10.1080/07352680490273310; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KERPPOLA TK, 1991, NATURE, V254, P1210; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KLAPWIJK PM, 1979, J BACTERIOL, V141, P424; KNAUF VC, 1982, PLASMID, V8, P45, DOI 10.1016/0147-619X(82)90040-3; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX B, 1987, EMBO J, V6, P849, DOI 10.1002/j.1460-2075.1987.tb04830.x; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; REAM W, 1989, ANNU REV PHYTOPATHOL, V27, P583, DOI 10.1146/annurev.py.27.090189.003055; ROJO F, 1990, J MOL BIOL, V211, P713, DOI 10.1016/0022-2836(90)90072-T; ROTHMEL RK, 1991, J BACTERIOL, V173, P4717, DOI 10.1128/jb.173.15.4717-4724.1991; SCHELL MA, 1989, J BACTERIOL, V171, P1952, DOI 10.1128/jb.171.4.1952-1959.1989; SCHINDLER U, 1989, J BACTERIOL, V171, P847, DOI 10.1128/jb.171.2.847-854.1989; SCHRODER J, 1990, 5TH INT S MOL GEN PL, P52; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; STACHEL SE, 1985, EMBO J, V4, P891, DOI 10.1002/j.1460-2075.1985.tb03715.x; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STRAGIER P, 1983, J MOL BIOL, V168, P333, DOI 10.1016/S0022-2836(83)80022-9; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P459; TABATA S, 1989, J BACTERIOL, V171, P1665, DOI 10.1128/jb.171.3.1665-1672.1989; TEMPE J, 1982, MOL BIOL PLANT TUMOR, P00451, DOI DOI 10.1016/B978-0-12-394380-4.50022-0; Tempe J, 1982, MOL BIOL PLANT TUMOR, P427, DOI [10.1016/B978-0-12-394380-4.50021-9, DOI 10.1016/B978-0-12-394380-4.50021-9]; THOMASHOW MF, 1980, CELL, V19, P729, DOI 10.1016/S0092-8674(80)80049-3; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VALDIVIA RH, 1991, J BACTERIOL, V173, P6398, DOI 10.1128/jb.173.20.6398-6405.1991; VONBODMAN SB, 1992, P NATL ACAD SCI USA, V89, P643, DOI 10.1073/pnas.89.2.643; VONLINTIG J, 1991, MOL PLANT MICROBE IN, V4, P370, DOI 10.1094/MPMI-4-370; WINANS SC, 1986, P NATL ACAD SCI USA, V83, P8278, DOI 10.1073/pnas.83.21.8278; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAMBRYSKI P, 1989, CELL, V56, P193, DOI 10.1016/0092-8674(89)90892-1; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245; ZAMBRYSKI P, 1989, MOBILE DNA, P309; ZWEIB C, 1989, GENE DEV, V3, P606; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	69	118	122	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					659	667		10.1016/0092-8674(92)90229-6	http://dx.doi.org/10.1016/0092-8674(92)90229-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586946				2022-12-24	WOS:A1992HV08900010
J	IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA				IRVING, M; LOMBARDI, V; PIAZZESI, G; FERENCZI, MA			MYOSIN HEAD MOVEMENTS ARE SYNCHRONOUS WITH THE ELEMENTARY FORCE-GENERATING PROCESS IN MUSCLE	NATURE			English	Article							STRIATED-MUSCLE; MECHANISM; FIBERS; HYDROLYSIS; ACTOMYOSIN; LENGTH; ACTIN	MOTOR proteins such as myosin, dynein and kinesin use the free energy of ATP hydrolysis to produce force or motion, but despite recent progress 1-4 their molecular mechanism is unknown. The best characterized system is the myosin motor which moves actin filaments in muscle 5-12. When an active muscle fibre is rapidly shortened the force first decreases, then partially recovers over the next few milliseconds 5. This elementary force-generating process is thought to be due to a structural 'working stroke' in the myosin head domain 5-9, although structural studies have not provided definitive support for this 10-12. X-ray diffraction has shown that shortening steps produce a large decrease in the intensity of the 14.5 nm reflection arising from the axial repeat of the myosin heads along the filaments 13,14 . This was interpreted as a structural change at the end of the working stroke, but the techniques then available did not allow temporal resolution of the elementary force-generating process itself. Using improved measurement techniques, we show here that myosin heads move by about 10 nm with the same time course as the elementary force-generating process.	UNIV FLORENCE,DIPARTIMENTO SCI FISIOL,I-50134 FLORENCE,ITALY; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	University of Florence; MRC National Institute for Medical Research	IRVING, M (corresponding author), UNIV LONDON KINGS COLL,DEPT BIOPHYS CELL & MOLEC BIOL,26-29 DRURY LANE,LONDON WC2B 5RL,ENGLAND.		Ferenczi, Michael/F-9510-2015	Ferenczi, Michael/0000-0002-0349-331X				BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cecchi G, 1976, Boll Soc Ital Biol Sper, V52, P733; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; FORD LE, 1977, J PHYSIOL-LONDON, V269, P441, DOI 10.1113/jphysiol.1977.sp011911; FORD LE, 1981, J PHYSIOL-LONDON, V311, P219, DOI 10.1113/jphysiol.1981.sp013582; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; HUXLEY AF, 1981, J PHYSIOL-LONDON, V317, pP12; HUXLEY AF, 1980, J PHYSIOL-LONDON, V305, pP15; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1983, J MOL BIOL, V169, P469, DOI 10.1016/S0022-2836(83)80062-X; HUXLEY HE, 1982, J MOL BIOL, V158, P637, DOI 10.1016/0022-2836(82)90253-4; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1991, NATURE, V352, P284, DOI 10.1038/352284a0; IRVING M, 1987, FIBROUS PROTEIN STRU, P495; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; KUSHMERICK MJ, 1969, PROC R SOC SER B-BIO, V174, P315, DOI 10.1098/rspb.1969.0096; LOMBARDI V, 1990, J PHYSIOL-LONDON, V431, P141, DOI 10.1113/jphysiol.1990.sp018324; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MATSUBARA I, 1985, J PHYSIOL-LONDON, V361, P151, DOI 10.1113/jphysiol.1985.sp015638; PIAZZESI G, 1992, J PHYSIOL-LONDON, V445, P659, DOI 10.1113/jphysiol.1992.sp018945; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0	30	184	187	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					156	158		10.1038/357156a0	http://dx.doi.org/10.1038/357156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579164				2022-12-24	WOS:A1992HU12200057
J	KENDRICK, KM; LEVY, F; KEVERNE, EB				KENDRICK, KM; LEVY, F; KEVERNE, EB			CHANGES IN THE SENSORY PROCESSING OF OLFACTORY SIGNALS INDUCED BY BIRTH IN SHEEP	SCIENCE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; MATERNAL-BEHAVIOR; BULB; RAT; NOREPINEPHRINE; PARTURITION; STIMULATION; ASPARTATE; OXYTOCIN	After giving birth, sheep and many other species form a selective bond with their offspring based on the sense of smell. Processing of olfactory signals is altered to allow the animals to perform this selective recognition. Lamb odors have little effect on either neurotransmitter release or electrical activity of neurons in the olfactory bulb before birth. However, after birth there is an increase in the number of mitral cells, the principal cells of the olfactory bulb, that respond to lamb odors, which is associated with increased cholinergic and noradrenergic neurotransmitter release. Selective recognition of lambs is accompanied by increased activity of a subset of mitral cells and release of glutamate and gamma-aminobutyric acid (GABA) from the dendrodendritic synapses between the mitral and granule cells. The relation between the release of each transmitter after birth also suggests an increased efficacy of glutamate-evoked GABA release.	INRA,COMPORTEMENT ANIM LAB,F-37380 NOUZILLY,FRANCE; UNIV CAMBRIDGE,SUBDEPT ANIM BEHAV,CAMBRIDGE CB3 8AA,ENGLAND	INRAE; University of Cambridge	KENDRICK, KM (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.			Kendrick, Keith/0000-0002-0371-5904				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BALDWIN BA, 1974, ANIM BEHAV, V22, P220, DOI 10.1016/S0003-3472(74)80072-2; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; FREEMAN WJ, 1982, PSYCHOPHYSIOLOGY, V19, P44, DOI 10.1111/j.1469-8986.1982.tb02598.x; GERVAIS R, 1984, ELECTROEN CLIN NEURO, V57, P462, DOI 10.1016/0013-4694(84)90076-2; GODFREY DA, 1980, NEUROSCIENCE, V5, P273, DOI 10.1016/0306-4522(80)90103-7; GRAY CM, 1986, BEHAV NEUROSCI, V100, P585, DOI 10.1037/0735-7044.100.4.585; HIGASHIMA M, 1988, EXP BRAIN RES, V72, P37, DOI 10.1007/BF00248498; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KENDRICK KM, 1988, BRAIN RES, V442, P171, DOI 10.1016/0006-8993(88)91447-3; KENDRICK KM, 1991, PHYSIOL BEHAV, V50, P595, DOI 10.1016/0031-9384(91)90551-X; KENDRICK KM, 1991, CURR SEP, V10, P96; KENDRICK KM, 1991, METHODS NEUROSCI, V4, P3; KENDRICK KM, 1991, MICRODIALYSIS NEUROS, P327; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, SCIENCE, V219, P81, DOI 10.1126/science.6849123; LEVY F, 1983, PHYSIOL BEHAV, V31, P687, DOI 10.1016/S0031-9384(83)80004-3; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; POINDRON P, 1980, ADV STUD BEHAV, V11, P75; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Rozin P., 1976, NEURAL MECHANISMS LE, P3; SHEPHERD GM, 1972, PHYSIOL REV, V52, P864, DOI 10.1152/physrev.1972.52.4.864; SHIPLEY MT, 1985, BRAIN RES, V329, P294, DOI 10.1016/0006-8993(85)90537-2; SMITH FV, 1966, ANIM BEHAV, V14, P120, DOI 10.1016/S0003-3472(66)80019-2; STANTON PK, 1985, J NEUROSCI, V5, P2169; SULLIVAN RM, 1989, J NEUROSCI, V9, P3998; SULLIVAN RM, 1987, DEV BRAIN RES, V35, P301; TAYLOR JG, 1991, BIOL CYBERN, V64, P301, DOI 10.1007/BF00199593	30	206	207	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					833	836		10.1126/science.1589766	http://dx.doi.org/10.1126/science.1589766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589766				2022-12-24	WOS:A1992HT23500044
J	CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM				CULPEPPER, RC; WILLIAMS, RG; MEASE, PJ; KOEPSELL, TD; KOBAYASHI, JM			NATURAL-HISTORY OF THE EOSINOPHILIA-MYALGIA-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						EOSINOPHILIA; MUSCULAR DISEASES; TRYPTOPHAN; FATIGUE; PREDNISONE	TOXIC OIL SYNDROME; TRYPTOPHAN; SCLERODERMA; INGESTION; FASCIITIS; FEATURES	Objective: To describe the natural history and disease progression of the eosinophilia-myalgia syndrome and to assess the therapeutic effects of orally administered steroids on the disorder as of October 1990. Design: Case-series analysis. A cohort of 45 patients with the eosinophilia-myalgia syndrome was followed prospectively by periodic telephone interviews and medical examinations for an average of 14 months after onset of illness. Setting: Washington state. Patients: The cases of 47 patients were reported to the Washington State Department of Health from 1 July to 12 December 1989. Two patients were unavailable for follow-up, and the remaining 45 completed the study. Main Results: Patients were predominantly non-Hispanic white women (87%) with an average age of 49 years. Symptoms typically progressed from early onset of myalgia and fatigue to later development of neurologic and scleroderma-like skin changes. Six (13%) patients recovered completely within 2 to 5 months of symptom onset. After 14 months of illness, over half of the patients who initially presented with myalgia, fatigue, or scleroderma-like skin changes remained symptomatic. The average severity of each major symptom was measured using interviews and patient self-reports and has improved subjectively by at least 40%. Statistical analyses showed no significant difference in long-term symptom duration or severity between patients treated and those not treated with prednisone. Conclusions: The eosinophilia-myalgia syndrome is a long-term illness characterized by progressive improvement during the first 25 weeks after symptom onset, followed by a protracted phase of symptom resolution. We could not show a clear-cut benefit of prednisone in reducing the long-term severity or duration of the disease.	UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA; MADIGAN ARMY MED CTR, TACOMA, WA 98431 USA; MINOR & JAMES MED CLIN, SEATTLE, WA 98104 USA; WASHINGTON STATE DEPT HLTH, SEATTLE, WA 98155 USA	University of Washington; University of Washington Seattle; Madigan Army Medical Center								ALONSORUIZ A, 1986, SEMIN ARTHRITIS RHEU, V15, P200, DOI 10.1016/0049-0172(86)90017-X; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; CALLAHAN LF, 1987, ARTHRITIS RHEUM, V30, P630, DOI 10.1002/art.1780300605; CLAUW DJ, 1990, JAMA-J AM MED ASSOC, V263, P1502; FLANNERY MT, 1990, ANN INTERN MED, V112, P300, DOI 10.7326/0003-4819-112-4-300; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; KAUFMAN LD, 1991, LANCET, V337, P1071, DOI 10.1016/0140-6736(91)91717-9; KILBOURNE EM, 1990, ANN INTERN MED, V112, P85, DOI 10.7326/0003-4819-112-2-85; KILBOURNE EM, 1988, AM J EPIDEMIOL, V127, P1210, DOI 10.1093/oxfordjournals.aje.a114914; MARTIN RW, 1990, ANN INTERN MED, V113, P124, DOI 10.7326/0003-4819-113-2-124; MAYENO AN, 1990, SCIENCE, V250, P1707, DOI 10.1126/science.2270484; MEDSGER TA, 1990, NEW ENGL J MED, V322, P926, DOI 10.1056/NEJM199003293221309; MINDEL A, 1982, LANCET, V1, P697; PHILEN RM, 1991, ARCH INTERN MED, V151, P533, DOI 10.1001/archinte.151.3.533; SILVER RM, 1990, NEW ENGL J MED, V322, P874, DOI 10.1056/NEJM199003293221302; SLUTSKER L, 1990, JAMA-J AM MED ASSOC, V264, P213, DOI 10.1001/jama.264.2.213; STERNBERG EM, 1980, NEW ENGL J MED, V303, P782, DOI 10.1056/NEJM198010023031403; SWYGERT LA, 1990, JAMA-J AM MED ASSOC, V264, P1698, DOI 10.1001/jama.264.13.1698; VARGA J, 1990, ANN INTERN MED, V112, P344, DOI 10.7326/0003-4819-112-5-344; 1990, SPSS REFERENCE GUIDE, P687; 1990, MMWR, V39, P89; 1990, MMWR, V39, P14; 1990, MMWR, V38, P327; 1989, MMWR, V38, P785; 1989, MMWR, V38, P765	25	43	43	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1991	115	6					437	442		10.7326/0003-4819-115-6-437	http://dx.doi.org/10.7326/0003-4819-115-6-437			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GE810	1651673				2022-12-24	WOS:A1991GE81000004
J	BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y				BAUSKIN, AR; ALKALAY, I; BEN-NERIAH, Y			REDOX REGULATION OF A PROTEIN TYROSINE KINASE IN THE ENDOPLASMIC-RETICULUM	CELL			English	Article							REDUCTION SENSITIVE INTERACTION; BETA-N-ACETYLGLUCOSAMINIDASE; CELLULAR 50-KDA PROTEIN; 5' NONCODING REGION; OXIDATION-REDUCTION; DISULFIDE ISOMERASE; INSULIN-RECEPTOR; TRANSMEMBRANE PROTEINS; SECRETORY PROTEINS; DNA FRAGMENTATION	The subcellular localization of the mouse Ltk transmembrane protein tyrosine kinase was studied in transfected COS cells, a mature B lymphocyte line, and a low expressing transfected lymphocyte clone. Indirect immunofluorescence and immunogold staining of COS transfectants and endoglycosidase analysis of both COS transfectants and lymphocytes indicate the unusual localization of Ltk to the endoplasmic reticulum (ER). Ltk resembles a receptor tyrosine kinase; it has a short, glycosylated, and cysteine-rich N-terminal domain. Yet, it appears to function in a ligand-independent mechanism: its in vivo catalytic activity is markedly enhanced by alkylating and thiol-oxidizing agents, and the active fraction of the protein occurs as disulfide-linked multimers. The catalytic activity of Ltk in the ER may be regulated via changes in the cellular redox potential, a novel mechanism for regulating protein tyrosine kinases. The ability to respond to redox changes in the cell may, however, be shared with certain receptor kinases during their passage through the ER.			BAUSKIN, AR (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BUMP EA, 1990, PHARMACOL THERAPEUT, V47, P117, DOI 10.1016/0163-7258(90)90048-7; CLANCEY CJ, 1987, J BIOL CHEM, V262, P13545; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERNST V, 1978, P NATL ACAD SCI USA, V75, P4110, DOI 10.1073/pnas.75.9.4110; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1984, TRENDS BIOCHEM SCI, V9, P438, DOI 10.1016/0968-0004(84)90152-X; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GERONIMO J, 1983, P NATL ACAD SCI USA, V80, P6848; GIUGNI TD, 1985, J BIOL CHEM, V260, P5081; GRIPPO JF, 1985, J BIOL CHEM, V260, P93; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P363; HEDO JA, 1983, J BIOL CHEM, V258, P20; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUYE S, 1988, SYNTHESIS APPLICATIO; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KAMPS MP, 1988, ONCOGENE, V2, P305; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P264; KROLEWSKI JJ, 1990, ONCOGENE, V5, P277; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARU Y, 1990, ONCOGENE RES, V5, P199; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NAJITA L, 1990, P NATL ACAD SCI USA, V87, P5846, DOI 10.1073/pnas.87.15.5846; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OLSON TS, 1987, J BIOL CHEM, V262, P6816; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER S, 1986, ONCOGENES GROWTH CON, P70; PORUCHYNSKY MS, 1985, J CELL BIOL, V101, P2199, DOI 10.1083/jcb.101.6.2199; RICE GC, 1986, CANCER RES, V46, P6105; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; ROWE GT, 1984, J MOL CELL CARDIOL, V16, P1075, DOI 10.1016/S0022-2828(84)80020-6; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SISK WP, 1986, GENE, V48, P183, DOI 10.1016/0378-1119(86)90076-4; SITIA R, 1987, EMBO J, V6, P3939; SOMPAYRAC LM, 1981, P NATL ACAD SCI-BIOL, V78, P7575, DOI 10.1073/pnas.78.12.7575; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAKAHASHI S, 1989, EUR J IMMUNOL, V19, P1911, DOI 10.1002/eji.1830191023; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WORD CJ, 1981, MOL IMMUNOL, V18, P311, DOI 10.1016/0161-5890(81)90055-9; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	77	249	251	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	AUG 23	1991	66	4					685	696		10.1016/0092-8674(91)90114-E	http://dx.doi.org/10.1016/0092-8674(91)90114-E			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652370				2022-12-24	WOS:A1991GC74500009
J	KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG				KAPILOFF, MS; FARKASH, Y; WEGNER, M; ROSENFELD, MG			VARIABLE EFFECTS OF PHOSPHORYLATION OF PIT-1 DICTATED BY THE DNA RESPONSE ELEMENTS	SCIENCE			English	Article							POU-SPECIFIC DOMAIN; GROWTH-HORMONE; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; BINDING; ACTIVATION; PROTEIN; OCT-1; PROMOTERS; SEQUENCE	Pit-1, a tissue-specific POU domain transcription factor, is required for the activation of the prolactin, growth hormone, and Pit-1 promoters that confer regulation by epidermal growth factor, adenosine 3',5'-monophosphate (cAMP), and phorbol esters. Pit-1 is phosphorylated in pituitary cells at two distinct sites in response to phorbol esters and cAMP. Phosphorylation of Pit-1 modifies its conformation on DNA recognition elements and results in increased binding at certain sites and decreased binding at other sites, dependent on DNA sequences adjacent to the core Pit-1 binding motif. One residue (Thr220), located in the POU homeodomain within a sequence conserved throughout the POU-domain family, confers these responses.	UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego	KAPILOFF, MS (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, EUKARYOT REGULATORY BIOL PROGRAM, LA JOLLA, CA 92093 USA.			Kapiloff, Michael/0000-0002-7005-6953; Wegner, Michael/0000-0002-4586-3294	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018477] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; CAPPS GG, 1989, J CELL BIOL, V108, P1317, DOI 10.1083/jcb.108.4.1317; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; COPP RP, 1989, MOL ENDOCRINOL, V3, P790, DOI 10.1210/mend-3-5-790; DANA S, 1989, MOL ENDOCRINOL, V3, P815, DOI 10.1210/mend-3-5-815; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KAPILOFF MS, UNPUB; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANGALAM HJ, 1989, GENE DEV, V3, P946, DOI 10.1101/gad.3.7.946; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MOHR IJ, 1989, P NATL ACAD SCI USA, V86, P6479, DOI 10.1073/pnas.86.17.6479; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; SIMMONS DM, 1990, GENE DEV, V4, P695, DOI 10.1101/gad.4.5.695; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VERRIJZER CP, 1990, GENE DEV, V4, P1964, DOI 10.1101/gad.4.11.1964; VOSS J, IN PRESS GNEES DEV; VOSS J, IN PRESS J BIOL CHEM	33	196	199	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 16	1991	253	5021					786	789		10.1126/science.1652153	http://dx.doi.org/10.1126/science.1652153			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB295	1652153				2022-12-24	WOS:A1991GB29500037
J	AMAYA, E; MUSCI, TJ; KIRSCHNER, MW				AMAYA, E; MUSCI, TJ; KIRSCHNER, MW			EXPRESSION OF A DOMINANT NEGATIVE MUTANT OF THE FGF RECEPTOR DISRUPTS MESODERM FORMATION IN XENOPUS EMBRYOS	CELL			English	Article							FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA; SIGNAL TRANSDUCTION; CELL-LINE; TGF-BETA; INDUCTION; GENES; INVITRO; LAEVIS; IDENTIFICATION	Peptide growth factors may play a role in patterning of the early embryo, particularly in the induction of mesoderm. We have explored the role of fibroblast growth factor (FGF) in early Xenopus development by expressing a dominant negative mutant form of the FGF receptor. Using a functional assay in frog oocytes, we found that a truncated form of the receptor effectively abolished wild-type receptor function. Explants from embryos expressing this dominant negative mutant failed to induce mesoderm in response to FGF. In whole embryos the mutant receptor caused specific defects in gastrulation and in posterior development, and overexpression of a wild-type receptor could rescue these developmental defects. These results demonstrate that the FGF signaling pathway plays an important role in early embryogenesis, particularly in the formation of the posterior and lateral mesoderm.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	AMAYA, E (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1989, DEVELOPMENT, V106, P173; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COOKE J, 1989, DEV BIOL, V131, P383, DOI 10.1016/S0012-1606(89)80012-0; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; GILLESPIE LL, 1989, DEVELOPMENT, V106, P203; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Holtfreter J., 1955, ANAL DEV, P230; HOLWILL S, 1987, DEVELOPMENT, V100, P735; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Nieuwkoop P D, 1973, Adv Morphog, V10, P1; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1985, EPIGENETIC NATURE EA; PATERNO GD, 1989, DEVELOPMENT, V106, P79; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SASAVAGE NL, 1982, J BIOL CHEM, V257, P678; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOKOL S, 1990, SCIENCE, V249, P561, DOI 10.1126/science.2382134; SYMES K, 1987, DEVELOPMENT, V101, P339; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WHITTAKER J, 1990, DIABETES CARE, V13, P576, DOI 10.2337/diacare.13.6.576; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939; WOODLAND HR, 1989, CELL, V59, P767, DOI 10.1016/0092-8674(89)90596-5	52	1026	1043	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 26	1991	66	2					257	270		10.1016/0092-8674(91)90616-7	http://dx.doi.org/10.1016/0092-8674(91)90616-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FY712	1649700				2022-12-24	WOS:A1991FY71200007
J	DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD				DAVIS, S; ALDRICH, TH; VALENZUELA, DM; WONG, V; FURTH, ME; SQUINTO, SP; YANCOPOULOS, GD			THE RECEPTOR FOR CILIARY NEUROTROPHIC FACTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CELL EXPRESSION SYSTEM; MOLECULAR-CLONING; CHOLINERGIC DIFFERENTIATION; NEURONAL DIFFERENTIATION; SYMPATHETIC NEURONS; BETA-CHAIN; INTERLEUKIN-6; PURIFICATION; FAMILY	Although neurotrophic factors were originally isolated on the basis of their ability to support the survival of neurons, these molecules are now thought to influence many aspects of the development and maintenance of the nervous system. Identifying the receptors for these neurotrophic factors should aid in identifying the cells on which these factors act and in understanding their precise mechanisms of action. A "tagged-ligand panning" procedure was used to clone a receptor for ciliary neurotrophic factor (CNTF). This receptor is expressed exclusively within the nervous system and skeletal muscle. The CNTF receptor has a structure unrelated to the receptors utilized by the nerve growth factor family of neurotrophic molecules, but instead is most homologous to the receptor for a cytokine, interleukin-6. This similarity suggests that the CNTF receptor, like the interleukin-6 receptor, requires a second, signal-transducing component. In contrast to all known receptors, the CNTF receptor is anchored to cell membranes by a glycosyl-phosphatidylinositol linkage.			DAVIS, S (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							ADLER JE, 1989, P NATL ACAD SCI USA, V86, P1080, DOI 10.1073/pnas.86.3.1080; ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARUFFO A, 1987, EMBO J, V6, P3313, DOI 10.1002/j.1460-2075.1987.tb02651.x; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BAZAN JF, IN PRESS NEURON; BOULTON TG, IN PRESS CELL; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; Davis S.M, UNPUB; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANDL J, UNPUB; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FUKUDA K, 1985, P NATL ACAD SCI USA, V82, P8795; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD D, 1991, NATURE, V350, P678; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; LOW MG, 1987, BIOCHEM J, V244, P1; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MANTHORPE M, 1989, NERVE GROWTH FACTORS, P31; MANTHORPE M, 1984, GROWTH MATURATION FA; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; MEAKIN SO, IN PRESS P NATL ACAD; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RAO MS, 1990, DEV BIOL, V139, P654; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SENDTNER M, 1989, NATURE, V345, P920; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; SQUINTO SP, IN PRESS CELL; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; WEBER MJ, 1985, J NEUROCHEM, V45, P1541, DOI 10.1111/j.1471-4159.1985.tb07225.x; WONG V, 1987, P NATL ACAD SCI USA, V84, P8726, DOI 10.1073/pnas.84.23.8726; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	56	603	628	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 5	1991	253	5015					59	63		10.1126/science.1648265	http://dx.doi.org/10.1126/science.1648265			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FV177	1648265				2022-12-24	WOS:A1991FV17700032
J	IGARASHI, K; ISHIHAMA, A				IGARASHI, K; ISHIHAMA, A			BIPARTITE FUNCTIONAL MAP OF THE ESCHERICHIA-COLI RNA POLYMERASE-ALPHA SUBUNIT - INVOLVEMENT OF THE C-TERMINAL REGION IN TRANSCRIPTION ACTIVATION BY CAMP-CRP	CELL			English	Article							AMP RECEPTOR PROTEIN; TEMPERATURE-SENSITIVE MUTATIONS; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES; PROMOTER STRENGTH; SIGMA-FACTOR; GENE; EXPRESSION; OPERON; LACTOSE	The alpha-subunit of Escherichia coli RNA polymerase plays a major role in the subunit assembly. Carboxy-terminal deletion derivatives lacking 73 or 94 amino acid residues were assembled in vitro into enzyme molecules. Core enzymes consisting of these C-terminal-truncated alpha-subunits were as active in RNA synthesis as native core enzyme. By the addition of sigma-70 subunit, these mutant enzymes initiated transcription from certain promoters. The mutant RNA polymerases, however, did not show cAMP-CRP activated transcription. These results demonstrate that the N-terminal region of the alpha-subunit is involved in the formation of active enzyme molecule, while the C-terminal region plays an essential role in response to transcription activation by cAMP-CRP.			IGARASHI, K (corresponding author), NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN.			Igarashi, Kazuhiko/0000-0002-2470-2475				ADHYA S, 1990, J BIOL CHEM, V265, P10797; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BLANCO C, 1986, MOL GEN GENET, V202, P112, DOI 10.1007/BF00330526; DALE EC, 1986, J MOL BIOL, V192, P793, DOI 10.1016/0022-2836(86)90029-X; DONNELLY CE, 1987, J BACTERIOL, V169, P1812, DOI 10.1128/jb.169.5.1812-1817.1987; FUJIKI H, 1976, MOL GEN GENET, V145, P19, DOI 10.1007/BF00331552; FUKUDA R, 1974, J MOL BIOL, V83, P353, DOI 10.1016/0022-2836(74)90284-8; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GEIDUSCHEK EP, 1988, BACTERIOPHAGES, V2, P93; GIFFARD PM, 1988, MOL GEN GENET, V214, P148, DOI 10.1007/BF00340193; HALLING C, 1990, J BACTERIOL, V172, P3541, DOI 10.1128/jb.172.7.3541-3548.1990; HERBERT M, 1986, P NATL ACAD SCI USA, V83, P2807, DOI 10.1073/pnas.83.9.2807; HUGOUVIEUXCOTTEPATTAT N, 1983, J GEN MICROBIOL, V129, P3345; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; ISHIHAMA A, 1980, J MOL BIOL, V137, P137, DOI 10.1016/0022-2836(80)90321-6; Ishihama A, 1981, Adv Biophys, V14, P1; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KAJITANI M, 1980, MOL GEN GENET, V179, P489, DOI 10.1007/BF00271738; KAWAKAMI K, 1980, BIOCHEMISTRY-US, V19, P3491, DOI 10.1021/bi00556a013; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; MALAN TP, 1984, CELL, V39, P173, DOI 10.1016/0092-8674(84)90203-4; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MARTINDALE DW, 1990, NUCLEIC ACIDS RES, V18, P2953, DOI 10.1093/nar/18.10.2953; NAKAMURA Y, 1980, MOL GEN GENET, V178, P487, DOI 10.1007/BF00337853; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; REN YL, 1988, P NATL ACAD SCI USA, V85, P4138, DOI 10.1073/pnas.85.12.4138; RIFTINA F, 1990, BIOCHEMISTRY-US, V29, P4440, DOI 10.1021/bi00470a026; RIFTINA F, 1989, BIOCHEMISTRY-US, V28, P3299, DOI 10.1021/bi00434a027; ROWLAND GC, 1985, J BACTERIOL, V164, P972, DOI 10.1128/JB.164.2.972-975.1985; SAITOH T, 1976, J MOL BIOL, V206, P591; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUNSHINE MG, 1975, P NATL ACAD SCI USA, V72, P2770, DOI 10.1073/pnas.72.7.2770; VENEZIA ND, 1990, J BIOL CHEM, V265, P8122; ZALENSKAYA K, 1990, GENE, V89, P7, DOI 10.1016/0378-1119(90)90199-2	40	304	314	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1015	1022		10.1016/0092-8674(91)90553-B	http://dx.doi.org/10.1016/0092-8674(91)90553-B			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646077				2022-12-24	WOS:A1991FR04700012
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY		UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605, USA.							BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COOK SL, 1991, CIRCULATION, V84, P632, DOI 10.1161/01.CIR.84.2.632; DALEN JE, 1991, ARCH INTERN MED, V151, P1066, DOI 10.1001/archinte.151.6.1066; GROVER SA, 1982, JAMA-J AM MED ASSOC, V267, P816; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; OLSON RE, 1989, ARCH INTERN MED, V149, P1501, DOI 10.1001/archinte.149.7.1501; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; SERRUYS PW, 1991, J AM COLL CARDIOL, V17, pB143; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; TOPOL EJ, 1991, CIRCULATION, V84, P632; 1992, LANCET, V339, P753; 1990, LANCET, V366, P71	15	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					338	340						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613912				2022-12-24	WOS:A1992JC35200022
J	LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS				LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS			SPECTRUM BIAS IN THE EVALUATION OF DIAGNOSTIC-TESTS - LESSONS FROM THE RAPID DIPSTICK TEST FOR URINARY-TRACT INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						URINARY TRACT INFECTIONS; DIPSTICK TEST; DIAGNOSTIC TESTS, ROUTINE; URINALYSIS; SPECTRUM BIAS	FACTORS AFFECTING SENSITIVITY; SPECIFICITY; BACTERIURIA; SCREENS	Objective: To determine if the leukocyte esterase and bacterial nitrite rapid dipstick test for urinary tract infection (UTI) is susceptible to spectrum bias (when a diagnostic test has different sensitivities or specificities in patients with different clinical manifestations of the disease for which the test is intended). Design: Cross-sectional study. Patients: A total of 366 consecutive adult patients in whom clinicians performed urinalysis to diagnose or exclude UTI. Setting: An urban emergency department and walk-in clinic. Measurements: After the patient encounter, but before dipstick test or culture was done, clinicians recorded the signs and symptoms that were the basis for suspecting UTI and for performing a urinalysis and an estimate of the probability of UTI based on the clinical evaluation. For all patients who received urinalysis, dipstick tests and culture were done in the clinical microbiology laboratory by medical technologists blinded to clinical evaluation. Sensitivity for the dipstick was calculated using a positive result in either leukocyte esterase or bacterial nitrite, or both, as the criterion for a positive dipstick, and greater than 10(5) CFU/mL for a positive culture. Results: In the 107 patients with a high (>50%) prior probability of UTI, who had many characteristic UTI symptoms, the sensitivity of the test was excellent (0.92; 95% CI, 0.82 to 0.98). In the 259 patients with a low (less-than-or-equal-to 50%) prior probability of UTI, the sensitivity of the test was poor (0.56; CI, 0.03 to 0.79). Conclusions: The leukocyte esterase and bacterial nitrite dipstick test for UTI is susceptible to spectrum bias, which may be responsible for differences in the test's sensitivity reported in previous studies. As a more general principle, diagnostic tests may have different sensitivities or specificities in different parts of the clinical spectrum of the disease they purport to identify or exclude, but studies evaluating such tests rarely report sensitivity and specificity in subgroups defined by clinical symptoms. When diagnostic tests are evaluated, information about symptoms in the patients recruited for study should be included, and analyses should be done within appropriate clinical subgroups so that clinicians may decide if reported sensitivities and specificities are applicable to their patients.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	LACHS, MS (corresponding author), YALE UNIV, SCH MED, 333 CEDAR ST, TMP B15, NEW HAVEN, CT 06510 USA.		Nachamkin, Irving/Q-3673-2019; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279; Nachamkin, Irving/0000-0003-4811-9716				CHERNOW B, 1984, ANN EMERG MED, V13, P150, DOI 10.1016/S0196-0644(84)80603-4; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; GARDNER S, 1989, CONFIDENCE INTERVAL; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HLATKY MA, 1987, AM J CARDIOL, V59, P1195, DOI 10.1016/0002-9149(87)90875-7; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; KELLOGG JA, 1987, AM J MED, V83, P739, DOI 10.1016/0002-9343(87)90907-7; KOMAROFF AL, 1984, NEW ENGL J MED, V310, P368, DOI 10.1056/NEJM198402093100607; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MALES BM, 1985, J CLIN MICROBIOL, V22, P531, DOI 10.1128/JCM.22.4.531-534.1985; PELS RJ, 1989, JAMA-J AM MED ASSOC, V262, P1220, DOI 10.1001/jama.1989.03430090082038; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705	15	211	211	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					135	140		10.7326/0003-4819-117-2-135	http://dx.doi.org/10.7326/0003-4819-117-2-135			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605428				2022-12-24	WOS:A1992JD12300008
J	RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L				RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L			DETECTION AND SIGNIFICANCE OF INTRAOPERATIVE AND POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PERIPHERAL VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC RISK; MORTALITY; DISEASE	Objective.-To determine the incidence and significance of intraoperative and postoperative myocardial ischemia and their relationship to preoperative ischemia and postoperative cardiac events in patients undergoing peripheral arterial surgery. Design.-Prospective cohort trial. Patients.-One hundred fifteen patients undergoing elective vascular surgery who met predefined eligibility criteria and were thought to have acceptable cardiac risk as assessed by independent cardiologists. Interventions.-Ambulatory electrocardiographic monitoring preoperatively, intraoperatively, and up to 72 hours postoperatively. Measurements.-Preoperative clinical characteristics and laboratory data were collected. Predefined adverse cardiac events were identified by an investigator who was "blinded" to monitoring results. Monitor recordings were interpreted for ST-segment depression by investigators blinded to patient information. Main Results.-Intraoperative ischemia was present in 21 patients (18%), and postoperative ischemia was present in 35 (30%). There were 16 postoperative cardiac events. The relative risk of suffering a cardiac event was 2.7 in patients with intraoperative ischemia and was 16 in patients with postoperative ischemia. Preoperative ischemia closely correlated with intraoperative and postoperative ischemia. Preoperative and postoperative ischemia preceded cardiac events in 14 of 16 patients. Conclusions.-Preoperative ischemia appears to identify high-risk patients, and subsequent perioperative monitoring detects silent ischemia that commonly precedes clinical events and that may be treatable with anti-ischemia therapy.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV VASC MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RABY, KE (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002553, R01HL035295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02553-01, R01 HL35295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY J, 1987, AM J CARDIOL, V60, P483, DOI 10.1016/0002-9149(87)90290-6; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; DEANFIELD JE, 1983, LANCET, V2, P753; DODDS TM, 1990, 12TH ANN SOC CARD AN; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KENNEDY HL, 1987, AM J CARDIOL, V59, P1190, DOI 10.1016/0002-9149(87)90874-5; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LEVIN RI, 1988, AM J CARDIOL, V61, pB13; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MCCANN RL, 1989, J VASC SURG, V9, P583; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; PASTERNACK PF, 1989, J VASC SURG, V10, P617; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; SILICIANO D, 1990, ANESTH ANALG, V70, pS1; TISCHLER M D, 1991, Journal of the American College of Cardiology, V17, p264A; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P	22	166	174	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					222	227		10.1001/jama.268.2.222	http://dx.doi.org/10.1001/jama.268.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608141				2022-12-24	WOS:A1992JB27900029
J	FISHER, JC				FISHER, JC			THE SILICONE CONTROVERSY - WHEN WILL SCIENCE PREVAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONNECTIVE-TISSUE DISEASE; BREAST IMPLANTS; AUGMENTATION; MAMMOPLASTY; CANCER				FISHER, JC (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,SAN DIEGO,CA 92103, USA.							ANDERSON N, 1988, 1988 M FDA ADV PAN G; BALCH CM, 1991, 1991 FDA ADV PAN GEN; BERKEL H, 1992, NEW ENGL J MED, V326, P1649, DOI 10.1056/NEJM199206183262501; CALNAN KC, 1992, SILICONE GELE BREAST; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GAYOU RM, 1979, PLAST RECONSTR SURG, V63, P700, DOI 10.1097/00006534-197905000-00015; HAUSNER RJ, 1978, PLAST RECONSTR SURG, V62, P381, DOI 10.1097/00006534-197809000-00007; HEGGERS JP, 1992, FEB TOX FOR  WASH; IVERSON R, 1990, PATIENT SURVEY COMMI; JENNINGS DA, 1991, ANN PLAS SURG, V27, P553, DOI 10.1097/00000637-199112000-00007; OPPENHEIMER BS, 1955, CANCER RES, V15, P333; RUDOLPH R, 1978, PLAST RECONSTR SURG, V62, P185, DOI 10.1097/00006534-197808000-00006; SERGENT JS, 1992, SILICONE GEL BREAST; SILVERSTEIN MJ, 1988, ARCH SURG-CHICAGO, V123, P681; STAHL DL, 1992, 1992 FDA ADV PAN GEN; VANNUNEN SA, 1982, ARTHRITIS RHEUM, V25, P694, DOI 10.1002/art.1780250613; WEISMAN MH, 1988, PLAST RECONSTR SURG, V82, P626, DOI 10.1097/00006534-198810000-00011; 1991, REPORT BREAST IMPLAN	18	67	67	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1696	1698		10.1056/NEJM199206183262511	http://dx.doi.org/10.1056/NEJM199206183262511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588986				2022-12-24	WOS:A1992HY62800011
J	GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD				GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD			EPIDEMIC CHOLERA IN THE AMERICA	SCIENCE			English	Editorial Material									PAN AMER HLTH ORG,HLTH SITUAT & TREND ASSESSMENT PROGRAM,WASHINGTON,DC	Pan American Health Organization	GLASS, RI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30333, USA.							[Anonymous], 1991, Epidemiol Bull, V12, P1; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; KAMAL AM, 1974, CHOLERA, P1; KOBLAVI S, 1990, RES MICROBIOL, V141, P645, DOI 10.1016/0923-2508(90)90059-Y; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAKUKUTU CA, 1986, APPL ENVIRON MICROB, V52, P824, DOI 10.1128/AEM.52.4.824-831.1986; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Pollitzer R., 1959, WHO MONOGRAPH SERIES, V43; WACHSMUTH IK, 1991, LANCET, V337, P1097	11	42	44	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1524	1525		10.1126/science.1598586	http://dx.doi.org/10.1126/science.1598586			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598586				2022-12-24	WOS:A1992HY07500019
J	BORN, RT; TOOTELL, RBH				BORN, RT; TOOTELL, RBH			SEGREGATION OF GLOBAL AND LOCAL MOTION PROCESSING IN PRIMATE MIDDLE TEMPORAL VISUAL AREA	NATURE			English	Article							MACAQUE MONKEY; CORTEX; NEURONS; DIRECTION; ANATOMY; FIELD; MT	THE early stages Of primate visual processing appear to be divided up into several component parts so that, for example, colour, form and motion are analysed by anatomically distinct streams 1-3. We have found that further subspecialization occurs within the motion processing stream. Neurons representing two different kinds of information about visual motion are segregated in columnar fashion within the middle temporal area of the owl monkey. These columns can be distinguished by labelling with 2-deoxyglucose in response to large-field random-dot patterns. Neurons in lightly labelled interbands have receptive fields with antagonistic surrounds: the response to a centrally placed moving stimulus is suppressed by motion in the surround. Neurons in more densely labelled bands have surrounds that reinforce the centre response so that they integrate motion cues over large areas of the visual field. Interband cells carry information about local motion contrast that may be used to detect motion boundaries or to indicate retinal slip during visual tracking. Band cells encode information about global motion that might be useful for orienting the animal in its environment.			BORN, RT (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Born, Richard/M-6454-2019	Born, Richard/0000-0003-4360-427X				ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FROST BJ, 1981, EXP BRAIN RES, V43, P173; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KAAS JH, 1992, INVEST OPHTH VIS SCI, V33, P1219; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; ROCKLAND KS, 1989, VISUAL NEUROSCI, V3, P155, DOI 10.1017/S0952523800004466; STERLING P, 1969, J NEUROPHYSIOL, V32, P1, DOI 10.1152/jn.1969.32.1.1; TANAKA K, 1986, J NEUROSCI, V6, P134; TOOTELL R B H, 1990, Investigative Ophthalmology and Visual Science, V31, P238; TOOTELL RBH, 1988, J NEUROSCI, V8, P1500; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; Treisman A, 1986, SCI AM, V255, P106; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WURTZ RH, 1990, COLD SPRING HARB SYM, V55, P45	22	288	288	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					497	499		10.1038/357497a0	http://dx.doi.org/10.1038/357497a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608448				2022-12-24	WOS:A1992HY05200063
J	HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A				HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A			EXPECTATIONS OF ASSISTED CONCEPTION FOR INFERTILITY	BRITISH MEDICAL JOURNAL			English	Article							INVITRO FERTILIZATION; PREGNANCY; RATES	Objective - To provide reliable prognostic information for couples seeking assisted conception. Design - Analysis of four years' practice (1988-91). Setting - Private university service finked with NHS reproductive medicine services. Patients - 804 couples with various causes of subfertility, median duration five years, median age of women 34 years. Interventions - 1280 completed cycles: 950 in vitro fertilisation, 144 gamete intrafallopian transfer, and 186 intrauterine insemination and superovulation. Main outcome measures - Pregnancy and birth rates per cycle and cumulative pregnancy and take home baby rates per couple. Results - In women under 40 years and men with normal sperm, whatever the cause of infertility, results with in vitro fertilisation improved steadily reaching a pregnancy rate per cycle of 30% (95% confidence interval 26% to 35%) during 1990-1 and birth rate per cycle of 29% (23% to 35%) in 1990. Pregnancy and birth rates for gamete intrafallopian transfer were 36% (28% to 44%) and 26% (17% to 37%) and for intrauterine insemination 18% (12% to 24%) and 16% (10% to 22%). After six cycles cumulative probability of pregnancy was 82% and cumulative take home baby rate 70%. Considering only in vitro fertilisation and gamete intrafallopian transfer after four cycles the pregnancy rate was 78% (66% to 91%). Conclusions - Conception is less likely in women over 40 and men with sperm dysfunction. For other couples the prognosis for a live birth is at least as good as for fertile couples if they persist with treatment.	UNIV BRISTOL,BUPA HOSP,IVF UNIT,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol			Cahilll, David/AAQ-6724-2020; Cahill, David/AAE-9893-2019					CHAFFKIN LM, 1991, FERTIL STERIL, V55, P252; CROSIGNANI PG, 1991, HUM REPROD, V6, P953, DOI 10.1093/oxfordjournals.humrep.a137468; DEMOUZON J, 1990, CONTRACEPT FERTIL S, V18, P589; DODSON WC, 1991, FERTIL STERIL, V55, P457; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HAAN G, 1991, HUM REPROD, V6, P939, DOI 10.1093/oxfordjournals.humrep.a137465; HULL MGR, 1990, BRIT MED BULL, V46, P580, DOI 10.1093/oxfordjournals.bmb.a072418; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; MATTHEWS DE, 1988, USING UNDERSTANDING, P75; MILLS MS, IN PRESS HUM REPROD; NICE L, 1991, J REPR FERT ABSTR SE, V7, P48; TAN SL, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90126-P; TIETZE C, 1956, FERTIL STERIL, V7, P88; TIETZE C, 1986, FERTIL STERIL, V13, P385; VESSEY MP, 1978, BRIT MED J, V1, P265, DOI 10.1136/bmj.1.6108.265; WARDLE PG, 1985, LANCET, V2, P236; 1990, WHO EURICPMCH122S RE	17	91	91	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1465	1469		10.1136/bmj.304.6840.1465	http://dx.doi.org/10.1136/bmj.304.6840.1465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611367	Green Published, Bronze			2022-12-24	WOS:A1992HY55300019
J	LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA				LEVINE, RL; PEPE, PE; FROMM, RE; CURKA, PA; CLARK, PA			PROSPECTIVE EVIDENCE OF A CIRCADIAN-RHYTHM FOR OUT-OF-HOSPITAL CARDIAC ARRESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; FREQUENCY; DEATH	Objectives. --Published studies have indicated a circadian rhythm in the occurrence of sudden cardiac death. However, these studies have involved either retrospective analyses of death certificates or analyses of data collected during studies of pharmacologic agents in selected populations. Purpose. --To determine whether a circadian pattern could be clearly demonstrated in a prospective study of out-of-hospital sudden cardiac death in a large, unselected population. Design. --All adult cases of sudden death of presumed primary cardiac cause from a large urban population were prospectively evaluated over a 12-month period. The incidence of sudden cardiac death was analyzed using harmonic regression of the data tabulated by hour of the day. Results. --During the year of study, 1019 consecutive primary cardiac arrests were analyzed. A significant circadian pattern was found (P < .0001) with the frequency of cardiac arrests increasing dramatically from 6 AM until noon. Conclusions. --This prospective study of out-of-hospital cardiac arrest confirms the existence of a circadian rhythm. These data have important implications for future investigations concerning the pathophysiology of sudden cardiac deaths.	CITY HOUSTON CTR RESUSCITAT & EMERGENCY MED SERV,410 BAGBY,SUITE 300,HOUSTON,TX 77002; BAYLOR COLL MED,PULM & CRIT CARE SECT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,CARDIOL SECT,HOUSTON,TX 77030; METHODIST HOSP,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston								ARGENTINO C, 1990, STROKE, V21, P387, DOI 10.1161/01.STR.21.3.387; COUCH RD, 1990, AM J FOREN MED PATH, V11, P106, DOI 10.1097/00000433-199006000-00003; LAMBERT CR, 1989, AM J CARDIOL, V64, P835, DOI 10.1016/0002-9149(89)90827-8; LUCENTE M, 1988, AM J CARDIOL, V62, P670, DOI 10.1016/0002-9149(88)91200-3; MANCIA G, 1988, J CARDIOVASC PHARM, V12, pS11, DOI 10.1097/00005344-198812007-00003; MILLARCRAIG MW, 1978, LANCET, V1, P795; MULCAHY D, 1988, LANCET, V2, P755; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; Nademanee K, 1988, CIRCULATION S2, V78, P610; NESTO RW, 1991, AM J CARDIOL, V67, P128, DOI 10.1016/0002-9149(91)90433-L; PEPINE CJ, 1991, JAMA-J AM MED ASSOC, V265, P386, DOI 10.1001/jama.265.3.386; TOFLER GH, 1987, NEW ENGL J MED, V316, P1514, DOI 10.1056/NEJM198706113162405; 1987, TXB ADV CARDIAC LIFE, P1	13	109	110	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2935	2937		10.1001/jama.267.21.2935	http://dx.doi.org/10.1001/jama.267.21.2935			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW133	1583765				2022-12-24	WOS:A1992HW13300033
J	MISHRA, M; CHAMBERS, JB; JACKSON, G				MISHRA, M; CHAMBERS, JB; JACKSON, G			MURMURS IN PREGNANCY - AN AUDIT OF ECHOCARDIOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article									LEWISHAM HOSP,CARDIOL,LONDON SE13 6LH,ENGLAND									ELKAYAM U, 1985, PRINCIPLES MED TREAT; MCFAUL PB, 1988, BRIT J OBSTET GYNAEC, V95, P861, DOI 10.1111/j.1471-0528.1988.tb06570.x; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; 1990, LANCET, V335, P88; 1990, DRUG THER B, V28, P90	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1413	1414		10.1136/bmj.304.6839.1413	http://dx.doi.org/10.1136/bmj.304.6839.1413			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628016	Green Published, Bronze			2022-12-24	WOS:A1992HX08200019
J	LEUTHER, KK; JOHNSTON, SA				LEUTHER, KK; JOHNSTON, SA			NONDISSOCIATION OF GAL4 AND GAL80 INVIVO AFTER GALACTOSE INDUCTION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; YEAST; GENE; ACTIVATOR; TRANSCRIPTION; INVITRO; PROTEIN; VP16	Transcription of galactose-inducible genes in yeast is regulated by interaction between the activator protein GAL4 and the negative regulatory protein GAL80. It has been suggested that GAL80 binds to and represses GAL4 under uninduced conditions and dissociates from GAL4 on induction. However, the possibility that GAL80 remains associated with GAL4 after induction has not been ruled out. Experiments to discriminate between these two models were performed and revealed that GAL80 stays bound after induction.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; LANGDON SD, UNPUB; LEUTHER KK, UNPUB; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MATSUMOTO K, 1980, J BACTERIOL, V141, P509; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOCUM RR, 1984, GENE, V32, P75, DOI 10.1016/0378-1119(84)90034-9	14	128	132	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1333	1335		10.1126/science.1598579	http://dx.doi.org/10.1126/science.1598579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598579				2022-12-24	WOS:A1992HW13500038
J	DUNPHY, WG; KUMAGAI, A				DUNPHY, WG; KUMAGAI, A			THE CDC25 PROTEIN CONTAINS AN INTRINSIC PHOSPHATASE-ACTIVITY	CELL			English	Article							FISSION YEAST CDC25; CELL-CYCLE; TYROSINE-PHOSPHATASES; M-PHASE; MITOTIC INDUCER; HUMAN-PLACENTA; KINASE; ACTIVATION; MITOSIS; DIVISION	Genetic and biochemical studies have indicated that the cdc25 protein controls the entry into mitosis by triggering tyrosine dephosphorylation of the cdc2 protein kinase. We show that the isolated cdc25 protein can catalyze dephosphorylation of several model phosphatase substrates, including p-nitrophenyl phosphate and two distinct tyrosine-phosphorylated peptides. The cdc25-dependent cleavage reaction closely resembles dephosphorylation by known tyrosine phosphatases: the reaction requires a reducing agent, shows high sensitivity to sodium vanadate, and proceeds efficiently in the presence of metal chelators. Moreover, the phosphatase activity of the cdc25 protein is eliminated by treatment with N-ethylmaleimide or by alteration of a single conserved cysteine residue by site-directed mutagenesis. These observations indicate that the cdc25 protein can function as a tyrosine phosphatase in the absence of any other protein.			DUNPHY, WG (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; Doree M, 1990, CURR OPIN CELL BIOL, V2, P269, DOI 10.1016/0955-0674(90)90018-A; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JESSUS C, 1990, FEBS LETT, V266, P4, DOI 10.1016/0014-5793(90)90002-C; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORGAN DO, 1991, METHOD ENZYMOL, V200, P645; MORIA AO, 1989, CELL, V58, P193; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OFARRELL PH, 1989, SCIENCE, V246, P635, DOI 10.1126/science.2683080; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1990, New Biologist, V2, P389; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722	43	539	553	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					189	196		10.1016/0092-8674(91)90582-J	http://dx.doi.org/10.1016/0092-8674(91)90582-J			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655274				2022-12-24	WOS:A1991GJ32000017
J	GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R				GOLDSTEIN, DJ; FINBOW, ME; ANDRESSON, T; MCLEAN, P; SMITH, K; BUBB, V; SCHLEGEL, R			BOVINE PAPILLOMAVIRUS-E5 ONCOPROTEIN BINDS TO THE 16K COMPONENT OF VACUOLAR H+-ATPASES	NATURE			English	Article							OPEN READING FRAME; TRANSFORMING ACTIVITY; GAP-JUNCTIONS; E5; PROTEIN; GENE; LOCALIZATION; POLYPEPTIDE; MEMBRANES; ENCODES	THE major transforming protein of bovine papillomavirus type 1, E5 (refs 1-4), is mainly associated with endomembranes 5,6, specifically binding to a cellular protein of relative molecular mass 16,000 (16K) (ref. 7). At the same time as transformation, E5 causes the phosphorylation of tyrosine residues in epidermal and platelet-derived growth factor receptors 8,9. We show here that the 16K protein associated with E5 is the 16K component of vacuolar ATPases. This protein is known to be an integral membrane protein in endosomes, bovine chromaffin granules, synaptic vesicles, fungal and plant vacuoles and clathrin-coated vesicles 10-16, as well as a component of gap-junction-like membrane complexes 17. Because proton pumps are critical for the function of cellular compartments that process growth-factor receptors, the interaction of E5 with the 16K protein could explain the pleiomorphic features of cells transformed by E5.	BEATSON INST CANC RES,GLASGOW G61 1BD,SCOTLAND	Beatson Institute	GOLDSTEIN, DJ (corresponding author), GEORGETOWN UNIV,DEPT PATHOL,WASHINGTON,DC 20007, USA.							ARAI H, 1987, J BIOL CHEM, V262, P11006; BIRMAN S, 1990, FEBS LETT, V261, P303, DOI 10.1016/0014-5793(90)80577-6; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BUULTJENS TEJ, 1988, CELL TISSUE RES, V251, P571, DOI 10.1007/BF00214005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEITCH B, 1990, EXP CELL RES, V190, P218, DOI 10.1016/0014-4827(90)90189-H; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MEAGHER L, 1990, NUCLEIC ACIDS RES, V18, P22; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SETTLEMAN J, 1988, P NATL ACAD SCI USA, V85, P9007, DOI 10.1073/pnas.85.23.9007; SUN SZ, 1987, J BIOL CHEM, V262, P14790; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030	26	172	177	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUL 25	1991	352	6333					347	349		10.1038/352347a0	http://dx.doi.org/10.1038/352347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FY289	1649407				2022-12-24	WOS:A1991FY28900075
J	CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P				CHAILLET, JR; VOGT, TF; BEIER, DR; LEDER, P			PARENTAL-SPECIFIC METHYLATION OF AN IMPRINTED TRANSGENE IS ESTABLISHED DURING GAMETOGENESIS AND PROGRESSIVELY CHANGES DURING EMBRYOGENESIS	CELL			English	Article							DNA METHYLATION; DETERMINES METHYLATION; PATERNAL GENOMES; MOUSE; EXPRESSION; MICE; REGION; CELLS	Genomic imprinting is a regulatory process that requires a cell to recognize the parental origin of alleles. To understand how these alleles are distinguished, we have assessed changes in the DNA methylation of an imprinted transgene as it switches from one inheritance pattern to another while moving through gametogenesis and embryogenesis. We find that both maternally and paternally inherited methylation patterns are erased in primordial germ cells and that distinctive patterns emerge during germ cell maturation. In the case of the maternal allele, the methylation pattern is fully acquired during oogenesis. In the case of the paternal allele, the methylation pattern found in sperm undergoes further modification during embryogenesis. Thus, the distinction between "erased" maternal and paternal alleles is first established during their residence in different germ cells and then may be maintained by the recognition of the distinctive patterns that each allele displays in the zygote.			CHAILLET, JR (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA.							ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HEATH JK, 1978, DEV MAMMALS, V3; Hogan B., 1986, MANIPULATING MOUSE E; KIRSCH IR, 1981, NATURE, V293, P585, DOI 10.1038/293585a0; MCGOWAN R, 1989, GENE DEV, V3, P1669, DOI 10.1101/gad.3.11.1669; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MONK M, 1987, DEVELOPMENT, V99, P371; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; PEDERSEN RA, 1988, PHYSL REPRODUCTION; QUINN P, 1982, J REPROD FERTIL, V66, P161; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REIK W, 1990, DEVELOPMENT, P99; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SEARLE AG, 1978, CYTOGENET CELL GENET, V20, P282, DOI 10.1159/000130859; SOLTER D, 1988, ANNU REV GENET, V22, P127; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SURANI MA, 1990, PHILOS T ROY SOC B, V326, P313, DOI 10.1098/rstb.1990.0014; SURANI MA, 1988, TRENDS GENET, V4, P59, DOI 10.1016/0168-9525(88)90040-6; SURANI MAH, 1986, CELL, V45, P127, DOI 10.1016/0092-8674(86)90544-1; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WASSERMAN PM, 1988, PHYSL REPRODUCTION; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176	34	214	221	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					77	83		10.1016/0092-8674(91)90140-T	http://dx.doi.org/10.1016/0092-8674(91)90140-T			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649008				2022-12-24	WOS:A1991FW91300010
J	BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW				BIRD, GS; ROSSIER, MF; HUGHES, AR; SHEARS, SB; ARMSTRONG, DL; PUTNEY, JW			ACTIVATION OF CA2+ ENTRY INTO ACINAR-CELLS BY A NON-PHOSPHORYLATABLE INOSITOL TRISPHOSPHATE	NATURE			English	Article							RAT-LIVER CELLS; 1,4,5-TRISPHOSPHATE 3-KINASE; INTRACELLULAR CA-2+; CALCIUM RELEASE; 1,3,4,5-TETRAKISPHOSPHATE; PHOSPHATES; RECEPTOR; MEMBRANE; THAPSIGARGIN; PURIFICATION	IN many cell types, receptor activation of phosphoinositidase C results in an initial release of intracellular Ca2+ stores followed by sustained Ca2+ entry across the plasma membrane. Inositol 1,4,5-trisphosphate is the mediator of the initial Ca2+ release 1, although its role in the mechanism underlying Ca2+ entry remains controversial 2-6. We have now used two techniques to introduce inositol phosphates into mouse lacrimal acinar cells and measure their effects on Ca2+ entry: microinjection into cells loaded with Fura-2, a fluorescent dye which allows the measurement of intracellular free calcium concentration by microspectrofluorimetry, and perfusion of patch clamp pipettes in the whole-cell configuration while monitoring the activity of Ca2+-activated K+ channels as an indicator of intracellular Ca2+. We report here that inositol 1,4,5-trisphosphate serves as a signal that is both necessary and sufficient for receptor activation of Ca2+ entry across the plasma membrane in these cells.			BIRD, GS (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, RES TRIANGLE PK, NC 27709 USA.		Shears, Stephen B/C-6335-2019; Rossier, Michel/AAW-2895-2021; Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Shears, Stephen B/0000-0001-7309-8916; Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS GM, IN PRESS J BIOL CHEM; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; IRVINE RF, 1984, BIOCHEM J, V222, P269, DOI 10.1042/bj2220269; IRVINE RF, 1989, BIOCHEM SOC T, V17, P6, DOI 10.1042/bst0170006; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; KENNEDY ED, 1989, J NEUROCHEM, V53, P1652, DOI 10.1111/j.1471-4159.1989.tb08566.x; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LLANO I, 1987, PFLUG ARCH EUR J PHY, V409, P499, DOI 10.1007/BF00583807; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAROD RJ, 1978, J PHYSIOL-LONDON, V281, P371, DOI 10.1113/jphysiol.1978.sp012428; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RYU SH, 1987, FASEB J, V1, P388, DOI 10.1096/fasebj.1.5.2824270; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; STEPHENS LR, 1989, BIOCHEM J, V262, P727, DOI 10.1042/bj2620727; TANG JM, 1990, PFLUG ARCH EUR J PHY, V416, P347, DOI 10.1007/BF00392072; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; YAMAGUCHI K, 1988, BIOCHEM J, V251, P129, DOI 10.1042/bj2510129	32	175	177	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 11	1991	352	6331					162	165		10.1038/352162a0	http://dx.doi.org/10.1038/352162a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FW097	1648669				2022-12-24	WOS:A1991FW09700059
J	BAKER, TA; MIZUUCHI, M; MIZUUCHI, K				BAKER, TA; MIZUUCHI, M; MIZUUCHI, K			MUB PROTEIN ALLOSTERICALLY ACTIVATES STRAND TRANSFER BY THE TRANSPOSASE OF PHAGE-MU	CELL			English	Article							BACTERIOPHAGE-MU; B-PROTEIN; TARGET IMMUNITY; DNA; MECHANISM; ENDS; PURIFICATION; INTEGRATION; INVITRO; TN10	The MuA and MuB proteins collaborate to mediate efficient transposition of the phage Mu genome into many DNA target sites. MuA (the transposase) carries out all the DNA cleavage and joining steps. MuB stimulates strand transfer by activating the MuA-donor DNA complex through direct protein-protein contact. The C-terminal domain of MuA is required for this MuA-MuB interaction. Activation of strand transfer occurs irrespective of whether MuB is bound to target DNA. When high levels of MuA generate a pool of free MuB (not bound to DNA) or when chemical modification of MuB impairs its ability to bind DNA, MuB still stimulates strand transfer. However, under these conditions, intramolecular target sites are used exclusively because of their close proximity to the MuA-MuB-donor DNA complex.			BAKER, TA (corresponding author), NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ADZUMA K, 1991, J BIOL CHEM, V266, P6159; BAINTON R, 1991, IN PRESS CELL, V65; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHACONAS G, 1985, CELL, V41, P857, DOI 10.1016/S0092-8674(85)80066-0; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, J BIOL CHEM, V260, P1832; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1985, P NATL ACAD SCI USA, V82, P7570, DOI 10.1073/pnas.82.22.7570; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DARZINS A, 1988, P NATL ACAD SCI USA, V85, P6826, DOI 10.1073/pnas.85.18.6826; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; GRINDLEY NDF, 1985, ANNU REV BIOCHEM, V54, P863, DOI 10.1146/annurev.biochem.54.1.863; GROENEN MAM, 1985, P NATL ACAD SCI USA, V82, P2087, DOI 10.1073/pnas.82.7.2087; HARSHEY RM, 1986, J GENET, V65, P159, DOI 10.1007/BF02931149; MAXWELL A, 1987, P NATL ACAD SCI USA, V84, P699, DOI 10.1073/pnas.84.3.699; MIZUUCHI K, 1986, ANNU REV GENET, V20, P385; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; SHERRATT D, 1989, MOBILE DNA, P163; SURETTE MG, 1989, J BIOL CHEM, V264, P3028; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; Symonds N., 1987, PHAGE MU; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; [No title captured]	30	99	101	1	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1003	1013		10.1016/0092-8674(91)90552-A	http://dx.doi.org/10.1016/0092-8674(91)90552-A			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646076				2022-12-24	WOS:A1991FR04700011
J	ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ				ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ			POPULATION-BASED MONITORING OF AN URBAN HIV AIDS EPIDEMIC - MAGNITUDE AND TRENDS IN THE DISTRICT-OF-COLUMBIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-TERM PROJECTIONS; UNITED-STATES; SENTINEL HOSPITALS; INFECTION; PREVALENCE; SPREAD; SIZE	Objective.-To assess the extent of the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic in the District of Columbia and demonstrate an approach to monitoring HIV infection and projecting AIDS incidence at a community level. Design.-Backcalculation methods to reconstruct HIV incidence from AIDS incidence in subgroups. Results were compared with directly measured HIV seroprevalence in selected sentinel populations: childbearing women, civilian applicants for military service, and hospital patients admitted for conditions unrelated to HIV infection. Results.-Between the start of the epidemic in 1980 and January 1, 1991, one in 57 District of Columbia men aged 20 to 64 years was diagnosed with AIDS. Unlike the plateau projected for the nation, AIDS incidence for the District of Columbia was projected to increase by 34% between 1990 and 1994. Models of HIV infection incidence suggested two broad epidemic waves of approximately equal size. The first occurred in men who have sex with men and peaked during the period from 1982 through 1983. The second began in the mid-1980s in injecting drug users and heterosexuals. We estimated that among District of Columbia residents aged 20 to 64 years, 0.3% of white women, 2.9% of white men, 1.6% of black women, and 4.9% of black men were living with HIV infection as of January 1, 1991. These estimates are broadly consistent with survey data: among black childbearing women in their 20s, HIV prevalence doubled to 2% between the fall of 1989 and the spring of 1991; from military applicant data, we estimated that over 5% of black men born from 1951 through 1967 were HIV-positive; in the sentinel hospital, HIV prevalence rates among male patients aged 25 to 34 years were 11.3% in white men and 16.9% in black men. Conclusion.-Backcalculation and surveys yielded quantitatively consistent estimates of HIV prevalence. Many injecting drug users and heterosexuals in the District of Columbia were infected after January 1, 1986. Similar monitoring of the epidemic in other localities is needed to focus efforts to reduce the incidence of HIV transmission.	NCI, ENVIRONM EPIDEMIOL BRANCH, VIRAL EPIDEMIOL SECT, ROCKVILLE, MD 20892 USA; WALTER REED ARMY MED CTR, DIV PREVENT MED, WASHINGTON, DC 20307 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, POPULAT STUDIES SECT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, STAT & DATA MANAGEMENT BRANCH, ATLANTA, GA 30333 USA; DIST COLUMBIA COMMISS PUBL HLTH, AGCY HIV AIDS, WASHINGTON, DC USA; NIAID, DIV AIDS, VACCINE TRIALS EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; DIST COLUMBIA COMMISS PUBL HLTH, PREVENT HLTH SERV ADM, WASHINGTON, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	ROSENBERG, PS (corresponding author), NCI, BIOSTAT BRANCH, EPIDEMIOL METHODS SECT, 6130 EXECUT BLVD, EPN 403, ROCKVILLE, MD 20892 USA.		Vermund, Sten/AAD-3592-2020; Brundage, John/Q-9244-2019	Vermund, Sten/0000-0001-7289-8698; 				BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BROOKMEYER R, 1989, BIOMETRICS, V45, P325, DOI 10.2307/2532057; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BROOKMEYER R, 1986, LANCET, V2, P1320; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; CHU SY, 1992, AM J PUBLIC HEALTH, V82, P220, DOI 10.2105/AJPH.82.2.220; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DANGELO LJ, 1991, PEDIATRICS, V88, P982; DANGELO LJ, 1991, OCT INT C ANT AG CH; DAY NE, 1989, SHORT TERM PREDICTIO; DEGRUTTOLA V, 1989, STAT MED, V8, P35, DOI 10.1002/sim.4780080106; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GARDNER LI, 1989, J ACQ IMMUN DEF SYND, V2, P521; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GREEN TA, 1992, J ACQ IMMUN DEF SYND, V5, P547; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; ISHAM V, 1989, SHORT TERM PREDICTIO; JACK N, 1992, 8TH INT C AIDS 3 STD; KARON JM, 1988, J ACQ IMMUN DEF SYND, V1, P542; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1991, AM J EPIDEMIOL, V133, P276, DOI 10.1093/oxfordjournals.aje.a115872; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBERG PS, IN PRESS STAT MED; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; TAYLOR JMG, 1989, STAT MED, V8, P45, DOI 10.1002/sim.4780080107; 1991, DIMENSION HIV AIDS E; 1991, HIV AIDS SURVEILLANC, P1; 1991, SAN FRANCISCO EPIDEM, V7, P31; 1992, COMPREHENSIVE HIV AI; 1987, MMWR S15, V36, P1; 1991, INDICES STATISTICAL, P80; 1990, MMWR, V39, P110; 1989, DISTRICT COLUMBIA CO	45	25	25	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					495	503						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619741				2022-12-24	WOS:A1992JD47200024
J	SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D				SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D			RESIDENTS EXPERIENCES IN, AND ATTITUDES TOWARD, THE CARE OF PERSONS WITH AIDS IN CANADA, FRANCE, AND THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; RISK	Objective.-To evaluate resident physicians' experiences in, and attitudes toward, the care of persons with the acquired immunodeficiency syndrome (AIDS) in Canada, France, and the United States. Design.-Cross-sectional survey, using a self-administered, mailed questionnaire to residents in 1 0 American states, three French regions, and all 10 Canadian provinces, with follow-up surveys of nonresponders in France and the United States. Subjects.-Systematic samples of residents in the last year of internal medicine or family medicine residencies prior to subspecialization or entry into medical practice. Results.-While the majority of residents had provided inpatient and outpatient care to persons with AIDS, most believed that their training in ambulatory care of persons with AIDS had been deficient. The rate of blood-contaminated needle-sticks from human immunodeficiency virus-infected patients ranged from 4% for internal medicine residents in Canada to 14% in the United States (P<.05). The majority recognized an ethical obligation to treat AIDS, but 4% in France, 14% in Canada, and 23% in the United States indicated that they would not care for persons with AIDS if they had a choice (P<.001). A substantial minority of US physicians reported that a patient of theirs had been refused care by a medical specialist (19%) or a surgeon (39%), but less than 10% of French physicians reported such refusals (P<.001). Conclusion.-Concerns about caring for AIDS patients were common and many physicians reported that patients were refused care. While most residents acknowledged an obligation to treat human immunodeficiency virus infection, many did not, and viewpoints varied considerably across the countries studied. The lower level of reluctance to treat AIDS patients in France and Canada makes it clear that the higher rate in the United States is far from optimal and needs to be addressed.	UNIV MICHIGAN,DEPT MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; ASSOC PREVENT SIDA,PARIS,FRANCE; CTR REG INFORMAT & PREVENT SIDA,PARIS,FRANCE	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	SHAPIRO, MF (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,CTR GEN MED,8-552 LOUIS FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Guillemot, Didier/AAN-3051-2020	Guillemot, Didier/0000-0002-8497-1765				[Anonymous], 1989, PRIVATE ACTS SOCIAL; CONNER G, 1990, PSYCHOL REP, V67, P1147; DOUGLAS CJ, 1985, HOSP COMMUNITY PSYCH, V36, P1309; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P861, DOI 10.1093/infdis/156.6.861; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; HAYWARD RA, 1991, J GEN INTERN MED, V6, P18, DOI 10.1007/BF02599384; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; MORGAN DR, 1988, J HOSP INFECT, V12, P301, DOI 10.1016/0195-6701(88)90072-2; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; POLLAK M, 1989, SCI SOC SANTE, V7, P111; Prual A, 1991, Int J STD AIDS, V2, P1; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1989, HIV AIDS SURVEILLANC, P1; 1991, B EPIDEMIOL HEBDOMAD, V44, P187; 1991, MMWR SRR8, V40, P1	21	50	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					510	515		10.1001/jama.268.4.510	http://dx.doi.org/10.1001/jama.268.4.510			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JD472	1619743				2022-12-24	WOS:A1992JD47200026
J	STOECKLE, MY; DOUGLAS, RG				STOECKLE, MY; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,RAHWAY,NJ 07065	Merck & Company	STOECKLE, MY (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.		Stoeckle, Mark/D-3729-2011	Stoeckle, Mark/0000-0002-8280-4795				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1125, DOI 10.1001/jama.266.8.1125; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, MMWR, V40, P1; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	17	0	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					366	368						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613922				2022-12-24	WOS:A1992JC35200034
J	CAMERON, D; BISHOP, C; SIBERT, JR				CAMERON, D; BISHOP, C; SIBERT, JR			FARM ACCIDENTS IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							INJURIES	Objective-To examine the problem of accidental injury to children on farms. Design-Prospective county based study of children presenting to accident and emergency departments over 12 months with injuries sustained in a farm setting and nationwide review of fatal childhood farm accidents over the four years April 1986 to March 1990. Setting-Accident and emergency departments in Aberystwyth, Carmarthen, Haverfordwest, and Llanelli and fatal accidents in England, Scotland, and Wales notified to the Health and Safety Executive register. Subjects-Children aged under 16. Main outcome measure-Death or injury after farm related accidents. Results-65 accidents were recorded, including 18 fractures. Nine accidents necessitated admission to hospital for a mean of two (range one to four) days. 13 incidents were related to tractors and other machinery; 24 were due to falls. None of these incidents were reported under the statutory notification scheme. 33 deaths were notified, eight related to tractors and allied machinery and 10 related to falling objects. Conclusions-Although safety is improving, the farm remains a dangerous environment for children. Enforcement of existing safety legislation with significant penalties and targeting of safety education will help reduce accident rates further.	UNIV WALES COLL CARDIFF,LANDSDOWNE HOSP,COLL MED,DEPT CHILD HLTH,COMMUNITY HLTH UNIT,CARDIFF CF1 8UL,WALES; UNIV WALES COLL MED,DEPT CHILD HLTH,CARDIFF CF4 4XN,S GLAM,WALES; HLTH & SAFETY EXECUT,EMPLOYMENT MED ADVISORY SERV,CARDIFF,WALES	Cardiff University; Cardiff University								COGBILL TH, 1985, PEDIATRICS, V76, P562; DOYLE Y, 1989, J SOC OCCUP MED, V39, P35; HALLER JA, 1983, JAMA-J AM MED ASSOC, V249, P47, DOI 10.1001/jama.249.1.47; RIVARA FP, 1985, PEDIATRICS, V76, P567; SALMI LR, 1989, PEDIATRICS, V83, P267; SWANSON JA, 1987, AM J DIS CHILD, V141, P1276, DOI 10.1001/archpedi.1987.04460120038029; 1986, LABOUR FORCE REPORT; 1986, AGR BLACK SPOT; 1988, PREVENTING ACCIDENTS; 1988, AGR SAFETY LISTINGS	10	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 4	1992	305	6844					23	25		10.1136/bmj.305.6844.23	http://dx.doi.org/10.1136/bmj.305.6844.23			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638192	Bronze, Green Published, Green Submitted			2022-12-24	WOS:A1992JC79900023
J	WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV				WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV			HARPIN, ELICITOR OF THE HYPERSENSITIVE RESPONSE PRODUCED BY THE PLANT PATHOGEN ERWINIA-AMYLOVORA	SCIENCE			English	Article							SYRINGAE PV SYRINGAE; K+/H+ EXCHANGE; TOBACCO; TN5	A proteinaceous elicitor of the plant defense reaction known as the hypersensitive response was isolated from Erwinia amylovora, the bacterium that causes fire blight of pear, apple, and other rosaceous plants. The elicitor, named harpin, is an acidic, heat-stable, cell-envelope-associated protein with an apparent molecular weight of 44 kilodaltons. Harpin caused tobacco leaf lamina to collapse and caused an increase in the pH of bathing solutions of suspension-cultured tobacco cells. The gene encoding harpin (hrpN) was located in the 40-kilobase hrp gene cluster of E. amylovora, sequenced, and mutated with Tn5tac1. The hrpN mutants were not pathogenic to pear, did not elicit the hypersensitive response, and did not produce harpin.	CORNELL UNIV, DEPT PLANT PATHOL, ITHACA, NY 14853 USA	Cornell University				He, Sheng Yang/0000-0003-1308-498X				Aldwinkle H. S., 1979, Horticultural Reviews, V1, P423; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; BAKER CJ, 1987, PHYTOPATHOLOGY, V77, P1268, DOI 10.1094/Phyto-77-1268; BAUER DW, 1991, MOL PLANT MICROBE IN, V4, P493, DOI 10.1094/MPMI-4-493; Beer S. V., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P53; BEER SV, 1989, PLANT PATHOGENIC B B, P675; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; DANIELS MJ, 1988, ANNU REV PHYTOPATHOL, V26, P285, DOI 10.1146/annurev.py.26.090188.001441; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; KLEMENT Z, 1964, PHYTOPATHOLOGY, V54, P474; LABY RJ, UNPUB; LABY RJ, 1991, THESIS CORNELL U; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J., 1989, MOL CLONING LAB MANU; Steinberger E. M., 1988, Molecular Plant-Microbe Interactions, V1, P135, DOI 10.1094/MPMI-1-135; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WEI ZM, 1992, J BACTERIOL, V174, P1875, DOI 10.1128/jb.174.6.1875-1882.1992; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132	25	653	803	4	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					85	88		10.1126/science.1621099	http://dx.doi.org/10.1126/science.1621099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621099				2022-12-24	WOS:A1992JC16500035
J	REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ				REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ			VALVE DISEASE ASSOCIATED WITH ERGOT ALKALOID USE - ECHOCARDIOGRAPHIC AND PATHOLOGICAL CORRELATIONS	ANNALS OF INTERNAL MEDICINE			English	Note						ERGOT ALKALOIDS; HEART VALVE DISEASES; ECHOCARDIOGRAPHY; MIGRAINE; METHYSERGIDE		Five patients had valve disease that was associated with long-term ingestion (6 to 20 years) of ergotamine (n = 3) or methysergide (n = 2). Only one patient had vascular disease suggestive of ergotism. Two patients had involvement of three or four valves, and three had mitral valve disease. Valvular lesions in the patients were both stenotic and regurgitant. Echocardiographic findings suggestive of ergot valve disease included fixed tricuspid lesions in the absence of the carcinoid syndrome. When left-sided lesions predominated, echocardiographic findings were indistinguishable from those seen in chronic rheumatic disease. All patients underwent valve replacement. Gross pathologic findings included excised valves and chordae tendineae that were thickened and retracted but not calcified; these findings were often initially reported as consistent with rheumatic disease. Microscopic findings differed from those seen in rheumatic disease and resembled those associated with carcinoid lesions. Leaflets and chordae were coated by myofibroblasts in an avascular myxoid or collagenous matrix, but underlying valve architecture was intact. The pathologic process was similar for methysergide and ergotamine.	CARDIAC DIAGNOST ASSOCIATES, YORK, PA USA		REDFIELD, MM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BANA DS, 1974, AM HEART J, V88, P640, DOI 10.1016/0002-8703(74)90251-8; GRAHAM JR, 1967, AM J MED SCI, V254, P1; HAUCK AJ, 1990, ARCH PATHOL LAB MED, V114, P62; MASON JW, 1977, CIRCULATION, V56, P889, DOI 10.1161/01.CIR.56.5.889; MISCH KA, 1974, BRIT MED J, V2, P365, DOI 10.1136/bmj.2.5915.365; MUNROE DS, 1969, CAN MED ASSOC J, V101, P536; Seiler K, 1973, Vasa, V2, P366; SPIERINGS ELH, 1988, HEADACHE, V28, P278, DOI 10.1111/j.1526-4610.1988.hed2804278.x	8	116	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					50	52		10.7326/0003-4819-117-1-50	http://dx.doi.org/10.7326/0003-4819-117-1-50			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596047				2022-12-24	WOS:A1992JA43500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ACCELERATED APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13234	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-24	WOS:A1992HY94400006
J	MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R				MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R			CA2+ RELEASE INDUCED BY INOSITOL 1,4,5-TRISPHOSPHATE IS A STEADY-STATE PHENOMENON CONTROLLED BY LUMINAL CA2+ IN PERMEABILIZED CELLS	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; CA-2+ RELEASE; RAT; STORES; TRISPHOSPHATE; PHOSPHATES; KINETICS; ENTRY	Low concentrations of inositol 1,4,5-trisphosphate (InsP3) evoke a very rapid mobilization of intracellular Ca2+ stores in many cell types, which can be followed by a further, much slower efflux 1-8. Two explanations have been suggested for this biphasic release. The first proposes that the Ca2+ stores vary in their sensitivity to InsP3, and each store releases either its entire contents or nothing 2,5,7 (all-or-none release); the second proposes instead that the stores are uniformly sensitive to the effects of InsP3, but that they can release only a fraction of their Ca2+ before their sensitivity is somehow attenuated 6,8-11 (steady-state release). Experiments using purified InsP3 receptor molecules reconstituted into lipid vesicles have shown heterogeneity of the receptors in their response to InsP3 under conditions in which the total Ca2+ level at both sides of the receptor is held constant 7. We now report that in permeabilized A7r5 smooth-muscle cells incubated in Ca2+-free medium, the amount of Ca-45(2+) remaining in the stores after the rapid transient phase of release is independent of their initial Ca2+ levels, indicating that partially depleted stores are less sensitive to InsP3. Moreover, if the stores are reloaded with Ca-40(2+) after the first stimulus, reapplication of the same low concentration of InsP3 will release further Ca-45(2+). This recovery of InsP3 sensitivity is almost complete. Under these conditions, Ca2+ release must thus occur by a steady-state mechanism, in which the decreasing Ca2+ content of the stores slows down further release.			MISSIAEN, L (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040	32	250	252	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					599	602		10.1038/357599a0	http://dx.doi.org/10.1038/357599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608471				2022-12-24	WOS:A1992HZ11200057
J	MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD				MASCARI, MJ; GOTTLIEB, W; ROGAN, PK; BUTLER, MG; WALLER, DA; ARMOUR, JAL; JEFFREYS, AJ; LADDA, RL; NICHOLIS, RD			THE FREQUENCY OF UNIPARENTAL DISOMY IN PRADER-WILLI SYNDROME - IMPLICATIONS FOR MOLECULAR DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARENTAL ORIGIN; ANGELMAN SYNDROME; CHROMOSOME-ABNORMALITIES; 15Q DELETIONS; X-CHROMOSOME; HUMAN DNA; LOCUS; POLYMORPHISMS; TRISOMY; PROBES	Background. Prader-Willi syndrome is a genetic disorder characterized by infantile hypotonia, obesity, hypogonadism, and mental retardation, but it is difficult to diagnose clinically in infants and young children. In about two thirds of patients, a cytogenetically visible deletion can be detected in the paternally derived chromosome 15(15q11q13). Recently, patients with Prader-Willi syndrome have been described who do not have the cytogenetic deletion but instead have two copies of the 15q11q13 region that are inherited from the mother (with none inherited from the father). This unusual form of inheritance is known as maternal uniparental disomy. Using molecular genetic techniques, we sought to determine the frequency of uniparental disomy in Prader-Willi syndrome. Methods. We performed molecular analyses using DNA markers within 15q11ql3 and elsewhere on chromosome 15 in 30 patients with Prader-Willi syndrome who had no cytogenetically visible deletion. We also studied their parents. Three patients with Prader-Willi syndrome who had a cytogenetic deletion served as controls. Results. In 18 of the 30 patients without a cytogenetic deletion (60 percent), we demonstrated the presence of maternal uniparental disomy for chromosome 15 and its association with advanced maternal age. In another eight patients (27 percent), we identified large molecular deletions. The remaining four patients (13 percent) had evidence of normal biparental inheritance for chromosome 15; three of these patients were the only ones in the study who had some atypical clinical features. Conclusions. In about 20 percent of all cases, Prader-Willi syndrome results from the inheritance of both copies of chromosome 15 from the mother (maternal uniparental disomy). With the combined use of cytogenetic and molecular techniques, the genetic basis of Prader-Willi syndrome can be identified in up to 95 percent of patients.	UNIV FLORIDA, INST BRAIN, DEPT NEUROSCI, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, CTR MAMMALIAN GENET, GAINESVILLE, FL 32611 USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, DIV GENET, GAINESVILLE, FL 32611 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PEDIAT, DIV GENET, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT PSYCHIAT, DIV CHILD & ADOLESCENT PSYCHIAT, DALLAS, TX 75230 USA; UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, ENGLAND	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Leicester	MASCARI, MJ (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT PEDIAT, DIV GENET, 500 UNIV DR, HERSHEY, PA 17033 USA.		Rogan, Peter/B-9845-2017	Rogan, Peter/0000-0003-2070-5254; Armour, John/0000-0002-8558-8506	NICHD NIH HHS [P01 HD030329] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALDRIDGE J, 1984, AM J HUM GENET, V36, P546; ANGELMAN H, 1965, DEV MED CHILD NEUROL, V7, P681; ANTONARAKIS SE, 1991, NEW ENGL J MED, V324, P872, DOI 10.1056/NEJM199103283241302; ARMOUR JAL, 1990, GENOMICS, V8, P501, DOI 10.1016/0888-7543(90)90037-U; AUGHTON DJ, 1990, AM J DIS CHILD, V144, P1251, DOI 10.1001/archpedi.1990.02150350083032; BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BRISSENDEN JE, 1986, GENET EPIDEMIOL, V3, P231, DOI 10.1002/gepi.1370030404; BUTLER MG, 1983, LANCET, V1, P1285; BUTLER MG, 1986, AM J MED GENET, V23, P793, DOI 10.1002/ajmg.1320230307; BUTLER MG, 1989, AM J HUM GENET, V45, P140; BUTLER MG, 1990, AM J MED GENET, V35, P319, DOI 10.1002/ajmg.1320350306; Cassidy S B, 1984, Curr Probl Pediatr, V14, P1; CASSIDY SB, IN PRESS AM J HUM GE; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P6964; DONLON TA, 1988, HUM GENET, V80, P322, DOI 10.1007/BF00273644; DONLON TA, 1986, P NATL ACAD SCI USA, V83, P4408, DOI 10.1073/pnas.83.12.4408; DRISCOLL DJ, IN PRESS GENOMICS; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; FRYBURG JS, 1991, AM J MED GENET, V38, P58, DOI 10.1002/ajmg.1320380114; GREENBERG F, 1987, AM J MED GENET, V28, P845, DOI 10.1002/ajmg.1320280409; HALL JG, 1990, AM J HUM GENET, V46, P857; HALL JG, 1992, NEW ENGL J MED, V326, P827, DOI 10.1056/NEJM199203193261210; HAMABE J, 1990, NUCLEIC ACIDS RES, V18, P5579, DOI 10.1093/nar/18.18.5579; HASSOLD T, 1985, HUM GENET, V70, P11, DOI 10.1007/BF00389450; HASSOLD TJ, 1984, ANNU REV GENET, V18, P69, DOI 10.1146/annurev.genet.18.1.69; HAWKEY CJ, 1976, J MED GENET, V13, P152, DOI 10.1136/jmg.13.2.152; HIGGS DR, 1986, P NATL ACAD SCI USA, V83, P5165, DOI 10.1073/pnas.83.14.5165; Holm V. A., 1981, PRADERWILLI SYNDROME, P27; KAPLAN LC, 1987, AM J MED GENET, V28, P45, DOI 10.1002/ajmg.1320280107; KNOLL JHM, 1991, AM J HUM GENET, V48, P16; KNOLL JHM, 1990, AM J HUM GENET, V47, P149; KNOLL JHM, 1989, AM J MED GENET, V32, P285, DOI 10.1002/ajmg.1320320235; KUPKE KG, 1989, AM J HUM GENET, V45, P599; LEDBETTER DH, 1987, AM J MED GENET, V28, P779, DOI 10.1002/ajmg.1320280402; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; MAGENIS RE, 1990, AM J MED GENET, V35, P333, DOI 10.1002/ajmg.1320350307; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MASCARI MJW, 1991, THESIS PENNSYLVANIA; MAY KM, 1990, AM J HUM GENET, V46, P754; NICHOLLS RD, 1989, AM J MED GENET, V33, P66, DOI 10.1002/ajmg.1320330109; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; NICHOLLS RD, 1991, AM J HUM GENET, V49, P334; NICHOLLS RD, IN PRESS SEMINARS DE; NICHOLLS RD, IN PRESS ANN NEUROL; NICHOLLS RD, IN PRESS AM J MED GE; RICH DC, 1988, NUCLEIC ACIDS RES, V16, P8740, DOI 10.1093/nar/16.17.8740; ROBINSON WP, 1991, AM J HUM GENET, V49, P1219; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; SAPIENZA C, 1990, SCI AM, V263, P52, DOI 10.1038/scientificamerican1090-52; SEABRIGH.M, 1971, LANCET, V2, P971; SMEETS DFCM, 1992, NEW ENGL J MED, V326, P807, DOI 10.1056/NEJM199203193261206; SOLTER D, 1988, ANNU REV GENET, V22, P127; SPENCE JE, 1988, AM J HUM GENET, V42, P217; TANTRAVAHI U, 1989, AM J MED GENET, V33, P78, DOI 10.1002/ajmg.1320330110; WARBURTON D, 1988, AM J HUM GENET, V42, P215; WEBER JL, 1989, AM J HUM GENET, V44, P388; WILLIAMS CA, 1990, AM J MED GENET, V35, P350, DOI 10.1002/ajmg.1320350308; WILLIAMS CA, 1989, AM J MED GENET, V32, P339, DOI 10.1002/ajmg.1320320313; YU RL, 1981, CYTOGENET CELL GENET, V31, P111, DOI 10.1159/000131634; ZACKOWSKI JL, IN PRESS AM J MED GE	60	227	229	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	1992	326	24					1599	1607		10.1056/NEJM199206113262404	http://dx.doi.org/10.1056/NEJM199206113262404			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX633	1584261	Green Accepted			2022-12-24	WOS:A1992HX63300005
J	TERET, SP; WINTEMUTE, GJ; BEILENSON, PL				TERET, SP; WINTEMUTE, GJ; BEILENSON, PL			THE FIREARM FATALITY REPORTING SYSTEM - A PROPOSAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHILD RESTRAINT LAWS; COVERAGE; DEATHS; STATES; GAPS		UNIV CALIF DAVIS,SACRAMENTO MED CTR,SCH MED,SACRAMENTO,CA 95817	University of California System; University of California Davis	TERET, SP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS INJURY PREVENT CTR,624 N BROADWAY,BALTIMORE,MD 21205, USA.				PHS HHS [R49CCR302484-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKER S, 1991, INJURY FACT BOOK; BAUM HM, 1990, J SAFETY RES, V21, P1, DOI 10.1016/0022-4375(90)90042-A; BOYD JH, 1986, AM J PUBLIC HEALTH, V76, P1240, DOI 10.2105/AJPH.76.10.1240; FELL JC, 860038 SOC AUT ENG I; FINGERHUT LA, 1991, MONTHLY VITAL STAT R, V39, P1; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Rice DP, 1989, COST INJURY US REPOR; ROBERTSON LS, 1989, AM J PUBLIC HEALTH, V79, P300, DOI 10.2105/AJPH.79.3.300; ROBERTSON LS, 1981, AM J PUBLIC HEALTH, V71, P818, DOI 10.2105/AJPH.71.8.818; ROKAW WM, 1990, PUBLIC HEALTH REP, V105, P447; TERET SP, 1986, AM J PUBLIC HEALTH, V76, P31, DOI 10.2105/AJPH.76.1.31; WAGENAAR AC, 1987, J TRAUMA, V27, P726, DOI 10.1097/00005373-198707000-00006; WELLS JK, 1989, AM J PUBLIC HEALTH, V79, P332, DOI 10.2105/AJPH.79.3.332; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT J, 1989, INJURY PREVENTION M; 1977, INT STATISTICAL CLAS; 1988, CRIME US 1987	18	45	45	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 10	1992	267	22					3073	3074		10.1001/jama.267.22.3073	http://dx.doi.org/10.1001/jama.267.22.3073			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW970	1588724				2022-12-24	WOS:A1992HW97000031
J	DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y				DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y			C-ABL HAS A SEQUENCE-SPECIFIC ENHANCER BINDING-ACTIVITY	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; B VIRUS ENHANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; MOLECULAR-CLONING; GENE-PRODUCT; PROTEIN; KINASE; REGION; BCR	The enhancers of several distinct viruses contain a common functional element, termed EP. This element binds ubiquitous cellular proteins and generates specific complexes in gel retardation analysis. Ultraviolet cross-linking and Southwestern analysis showed that a 140 kd polypeptide is the major EP DNA-binding protein. Using a combination of DNA binding and immunological techniques, we have identified the c-abl protein in a nuclear complex that binds to the EP element. abl was found to have both a specific and high affinity DNA binding activity. The ability to bind DNA is abolished in the mutant abl protein, p210bcr-abl, consistent with its cytoplasmic localization in chronic myelogenous leukemia.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	DIKSTEIN, R (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ANAFI M, 1992, IN PRESS J BIOL CHEM, V267; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1986, CURR TOP MICROBIOL, V132, P81; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1984, CELL, V36, P349; WESTBROOK CA, 1988, BLOOD, V71, P697	29	70	71	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					751	757		10.1016/0092-8674(92)90287-M	http://dx.doi.org/10.1016/0092-8674(92)90287-M			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591775				2022-12-24	WOS:A1992HW83800006
J	REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P				REED, A; RAMSDEN, S; MARSHALL, J; BALL, J; OBRIEN, J; FLYNN, A; ELTON, N; ELKABIR, D; JOSEPH, P			PSYCHIATRIC MORBIDITY AND SUBSTANCE-ABUSE AMONG RESIDENTS OF A COLD WEATHER SHELTER	BRITISH MEDICAL JOURNAL			English	Article							LONDON		GREAT CHAPEL ST MED CTR,LONDON W1V 7AL,ENGLAND; INST PSYCHIAT,LONDON SE5 8AF,ENGLAND	University of London; King's College London				O'Brien, John/0000-0002-0837-5080				KOEGEL P, 1988, ARCH GEN PSYCHIAT, V45, P1011; LODGEPATCH IC, 1971, BRIT J PSYCHIAT, V118, P313; PRIEST RG, 1971, AM J PSYCHOTHER, V25, P194, DOI 10.1176/appi.psychotherapy.1971.25.2.194; RAMSDEN SS, 1989, BRIT MED J, V298, P372, DOI 10.1136/bmj.298.6670.372; WELLER BGA, 1907, LANCET, V1, P553	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1028	1029		10.1136/bmj.304.6833.1028	http://dx.doi.org/10.1136/bmj.304.6833.1028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HQ142	1586786	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200022
J	SADEGHNASSERI, S; GERMAIN, RN				SADEGHNASSERI, S; GERMAIN, RN			A ROLE FOR PEPTIDE IN DETERMINING MHC CLASS-II STRUCTURE	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; SEPARATE ALPHA-CHAINS; IMMUNOGENIC PEPTIDES; ANTIGENIC PEPTIDES; LYMPHOCYTE-T; BETA-CHAINS; MOLECULES; BINDING; IA; RECOGNITION	T LYMPHOCYTES recognize antigen-derived peptides associated with major histocompatibility complex (MHC) class I or class II proteins 1,2. Peptide is critical in class I heavy folding and/or stable association with beta-2-Microglobulin 3-6. Although data exist suggesting a relationship between class II structure and peptide association 7-9, no equivalent positive contribution of peptide to the folding state or stability of class II dimers has yet been demonstrated. We report here that most purified E-alpha(k)E-beta-k molecules leaving low pH in the absence of specific peptide lack a compact, stable dimeric structure. Brief exposure to the appropriate peptide just before and during neutralization promotes this specific conformation in proportion to stably bound peptide, indicating that peptide is important in determining class II MHC structure. Our results also indicate that efficient generation of long-lived peptide-class II complexes involves two stages: initial peptide binding in an acidic environment, which enhances the ability of class II to enter a conformation, from which stabilization upon neutralization results in high-affinity binding of previously associated peptide.			SADEGHNASSERI, S (corresponding author), NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892, USA.		Germain, Ronald N./Z-1945-2019; Germain, Ronald/ABE-7090-2020	Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BEVAN MJ, 1989, NATURE, V342, P478, DOI 10.1038/342478a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; BUUS S, 1988, SCIENCE, V242, P1045, DOI 10.1126/science.3194755; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; DORNMAIR K, 1990, P NATL ACAD SCI USA, V87, P4134, DOI 10.1073/pnas.87.11.4134; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, CELL REGUL, V1, P499, DOI 10.1091/mbc.1.7.499; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P7170; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; MELLINS E, 1990, NATURE, V343, P71, DOI 10.1038/343071a0; OZATO K, 1980, J IMMUNOL, V124, P533; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; VIGUIER M, 1990, P NATL ACAD SCI USA, V87, P7170, DOI 10.1073/pnas.87.18.7170; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	26	290	297	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					167	170		10.1038/353167a0	http://dx.doi.org/10.1038/353167a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653903				2022-12-24	WOS:A1991GE73100054
J	FANG, F; NEWPORT, JW				FANG, F; NEWPORT, JW			EVIDENCE THAT THE G1-S AND G2-M TRANSITIONS ARE CONTROLLED BY DIFFERENT CDC2 PROTEINS IN HIGHER EUKARYOTES	CELL			English	Article							CELL-CYCLE CONTROL; MATURATION-PROMOTING FACTOR; YEAST SCHIZOSACCHAROMYCES-POMBE; HISTONE H-1 KINASE; CONTROL GENE CDC2+; FISSION YEAST; DNA-REPLICATION; M-PHASE; TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE	Xenopus eggs contain two distinct cdc2 homologs of 34 and 32 kd. We show that the 32 kd cdc2 protein, like the 34 kd protein, is a kinase. However, unlike the 34 kd homolog, the 32 kd cdc2 kinase activity does not decrease dramatically at the end of mitosis. The 32 kd protein does not associate with mitotic cyclins B1 and B2 but does associate with cyclin A and a novel doublet of proteins of 54 kd that may regulate its activity. We also show that depletion of the 32 kd cdc2 homolog from a Xenopus extract blocks DNA replication, but does not inhibit entry into mitosis. By contrast, depletion of the 34 kd cdc2 homolog or absence of mitotic cyclins from an extract does not inhibit replication, but does block entry into mitosis. Our results indicate that in higher eukaryotes, DNA replication (G1-S) and mitosis (G2-M) may be controlled by distinctly different cdc2 proteins.			FANG, F (corresponding author), UNIV CALIF SAN DIEGO, DEPT BIOL 0322, LA JOLLA, CA 92093 USA.				NIGMS NIH HHS [GM33523-07] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033523, R37GM033523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRILL SJS, 1990, GENE DEV, V4, P968; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MIAKELYE R, 1983, J CELL BIOL, V97, P81, DOI 10.1083/jcb.97.1.81; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	52	501	518	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 23	1991	66	4					731	742		10.1016/0092-8674(91)90117-H	http://dx.doi.org/10.1016/0092-8674(91)90117-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652371				2022-12-24	WOS:A1991GC74500012
J	FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH				FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH			CLINICAL PRESENTATION AND OUTCOME OF PATIENTS WITH HIV-INFECTION AND TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT BACILLI	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); DRUG RESISTANCE, MICROBIAL; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NON-HAITIAN PATIENTS; VIRUS-INFECTION; SYNDROME AIDS; FLORIDA	Objective: To determine the clinical manifestations of patients with human immunodeficiency virus (HIV) infection and tuberculosis caused by multiple-drug-resistant bacilli compared with those with single-drug-resistant or susceptible bacilli. Design: Descriptive, case-control, and cohort studies. Setting: A large urban teaching hospital. Patients: Sixty-two patients with tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients with tuberculosis caused by single-drug-resistant or susceptible bacilli (controls). Measurements: Characteristics of clinical presentation, radiographs, pathologic abnormalities, antituberculosis treatment, and clinical course. Results: Twenty cases (32%) had concomitant pulmonary and extrapulmonary disease at presentation compared with 9 controls (16%; odds ratio, 2.4; 95% Cl, 1.0 to 5.9). More cases had alveolar infiltrates (76%; odds ratio, 3.6; Cl, 1.2 to 11.4), interstitial infiltrates with a reticular pattern (67%; odds ratio, 7.8; Cl, 1.0 to 83.5), and cavitations (18%; odds ratio, 6.6; Cl, 0.8 to 315.3) on initial chest radiographs compared with controls (49%, 19%, and 3%, respectively). Pathologic specimens from cases showed extensive necrosis, poor granuloma formation, marked inflammatory changes with a predominance of neutrophils, and abundant acid-fast bacilli. Twenty-five cases received two or more effective antituberculosis drugs for more than 2 months. Only 2 cases had three consecutive negative cultures for Mycobacterium tuberculosis, one patient died within 1 day of the last negative culture, and the other had positive cultures 496 days later. The remaining 23 cases had persistently or intermittently positive cultures despite therapy. The clinical course of these cases suggested overwhelming miliary tuberculosis with involvement of the lungs (77%), pleura (15%), stool (34%), meninges (13%), bone marrow (16%), blood (10%), lymph nodes (10%), and skin (8%). The median survival time was 2.1 months for cases compared with 14.6 months for controls (P = 0.001, log-rank test). Conclusions: Tuberculosis caused by multiple-drug resistant bacilli in patients with HIV infection is associated with widely disseminated disease, poor treatment response with an inability to eradicate the organism, and substantial mortality.	UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT RADIOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	University of Miami; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HILL AR, 1991, AM REV RESPIR DIS, V144, P1164, DOI 10.1164/ajrccm/144.5.1164; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; MEHTA CR, 1991, STATXART USER MANUEL; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133	25	221	225	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					184	190		10.7326/0003-4819-117-3-184	http://dx.doi.org/10.7326/0003-4819-117-3-184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616212				2022-12-24	WOS:A1992JF30400002
J	HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA				HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA			ARCHITECTURE AND DESIGN OF THE NUCLEAR-PORE COMPLEX	CELL			English	Article							LINKED N-ACETYLGLUCOSAMINE; ELECTRON-MICROSCOPE; RIBOSOMAL-SUBUNITS; TRANSPORT SIGNALS; SINGLE PARTICLES; SOFTWARE SYSTEM; PROTEIN IMPORT; ENVELOPE; IDENTIFICATION; BINDING	A three-dimensional analysis of the nuclear pore complex reveals the underlying, highly symmetric framework of this supramolecular assembly, how it is anchored in the nuclear membrane, and how it is built from many distinct, interconnected subunits. The arrangement of the subunits within the membrane pore creates a large central channel, through which active nucleocytoplasmic transport is known to occur, and eight smaller peripheral channels that are probable routes for passive diffusion of ions and small molecules.	UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	HINSHAW, JE (corresponding author), Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Carragher, Bridget/0000-0002-0624-5020	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044932] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39155] Funding Source: Medline; NIGMS NIH HHS [GM44932] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI U, 1990, EMSA B, V20, P69; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; FINCH JT, 1965, J MOL BIOL, V13, P1, DOI 10.1016/S0022-2836(65)80075-4; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P288, DOI 10.1016/S0022-5320(70)80064-8; FRANKE WW, 1981, J CELL BIOL S, V91, pS39; FRANKE WW, 1974, CELL NUCLEUS, V1, P219; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; KESSEL RG, 1973, PROGR SURFACE MEMBRA, V6, P243; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MILLIGAN RA, 1986, NUCLEOCYTOPLASMIC TR, P113; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Ris H., 1989, I PHYS C SER, V98, P657; RIS H, 1991, EMSA B, V21, P54; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEWART M, 1988, J CELL SCI, V90, P409; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V7, P113, DOI 10.1016/0304-3991(81)90001-2; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	51	373	379	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1133	1141		10.1016/0092-8674(92)90635-P	http://dx.doi.org/10.1016/0092-8674(92)90635-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617726				2022-12-24	WOS:A1992JA43100008
J	MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO				MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO			PROCESSING PATHWAYS FOR PRESENTATION OF CYTOSOLIC ANTIGEN TO MHC CLASS-II-RESTRICTED T-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; LYMPHOBLASTOID-CELLS; EXPRESSION; REGION; HEMAGGLUTININ; TRANSPORTERS; RECOGNITION; SEQUENCES	ANTIGENS presented to CD4+ T cells derive primarily from exogenous proteins that are processed into peptides capable of binding to class II major histocompatibility complex (MHC) molecules in an endocytic compartment 1-4. In contrast, antigens presented to CD8+ T cells derive mostly from proteins processed in the cytosol, and peptide loading onto class I MHC molecules in an early exocytic compartment is dependent on a transporter for antigen presentation encoded in the class II MHC region 5-11. Endogenous cytosolic antigen can also be presented by class II molecules 12,13. Here we show that, unlike class I-restricted recognition of antigen, HLA-DR1-restricted recognition of cytosolic antigen occurs in mutant cells without a transporter for antigen presentation. In contrast, DR1-restricted recognition of a short cytosolic peptide is dependent on such a transporter. Thus helper T-cell epitopes can be generated from cytosolic antigens by several mechanisms, one of which is distinct from the classical class I pathway.	NIAID,IMMUNOGENET LAB,12441 PARKLAWN DR,ROCKVILLE,MD 20852; HOSP GERMANS TRIAS & PUJOL,IMMUNOL UNIT,E-08916 BADALONA,SPAIN; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Hospital Germans Trias i Pujol; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison			Long, Eric O/G-5475-2011; Malnati, Mauro/AAN-4207-2020; Martí, Mercè/I-2164-2015	Long, Eric O/0000-0002-7793-3728; Martí, Mercè/0000-0002-1846-0043; Malnati, mauro/0000-0001-5355-1680				CEMANBOGNER S, IN PRESS J IMMUN; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; GOULD KG, 1987, J EXP MED, V166, P693, DOI 10.1084/jem.166.3.693; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LONG EO, 1992, NEW BIOL, V4, P274; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033	28	182	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					702	704		10.1038/357702a0	http://dx.doi.org/10.1038/357702a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614517				2022-12-24	WOS:A1992JA43000076
J	JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG				JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG			ORAL AND DENTAL DISEASE IN TERMINALLY ILL CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									S GLAMORGAN HLTH AUTHOR,CARDIFF CF1 3NW,S GLAM,WALES; UNIV WALES COLL MED,ORAL MED & ORAL PATHOL,CARDIFF CF4 4XN,S GLAM,WALES; HOLME TOWER MARIE CURIE CTR,PENARTH,S GLAM,WALES; UNIV WALES COLL MED,PERIODONTOL,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,MED STAT,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University; Cardiff University			Newcombe, Robert G/B-4897-2009					Aldred M J, 1991, Spec Care Dentist, V11, P59; FINLAY IG, 1986, BRIT MED J, V292, P592, DOI 10.1136/bmj.292.6520.592; JANMOHAMED R, 1990, BRIT J CANCER, V61, P469, DOI 10.1038/bjc.1990.103; WALLACE TW, 1984, MICROBIOS, V41, P99; WRAY D, 1975, BRIT MED J, V2, P490, DOI 10.1136/bmj.2.5969.490	5	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1612	1612		10.1136/bmj.304.6842.1612	http://dx.doi.org/10.1136/bmj.304.6842.1612			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628090	Bronze, Green Published			2022-12-24	WOS:A1992JA43600025
J	GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J				GURWITZ, JH; AVORN, J; ROSSDEGNAN, D; CHOODNOVSKIY, I; ANSELL, J			AGING AND THE ANTICOAGULANT RESPONSE TO WARFARIN THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						AGING; ANTICOAGULANTS; WARFARIN; PROTHROMBIN TIME; DRUG MONITORING	PROTHROMBIN TIME; DRUG-THERAPY; VITAMIN-K; AGE; REQUIREMENTS; DETERMINANTS; WEIGHT	Objective: To assess the effect of aging on the anticoagulant response to warfarin. Design: Retrospective cohort study. Setting: A university hospital outpatient anticoagulation clinic. Patients: All patients (n = 530) monitored in the anticoagulation clinic over a 10-year period (1980 to 1990). The 530 study patients had a mean age of 61.5 (+/- 14.7) years (age range, 12 to 90 years). The patients were stratified into four age groups: younger than 50 years (n = 97); 50 to 59 years (n = 107); 60 to 69 years (n = 149); and 70 years or older (n = 177). Measurements: For each patient, a dose-adjusted mean prothrombin time ratio was calculated by dividing the mean prothrombin time ratio by the mean daily warfarin dose. Results: Older patients were more likely to be female (P < 0.001), to have more medical problems (P < 0.001), to be taking more medications (P < 0.001), and to weigh less than younger patients (P < 0.001). Across age groups, there were no significant differences in the use of medications that potentiated or inhibited the anticoagulant effects of warfarin. The prothrombin time ratio, when adjusted for dose, was significantly increased in older patients (P < 0.001). The increased anticoagulant response to warfarin seen with increasing patient age persisted even after simultaneously controlling for relevant demographic and clinical variables in a multivariate model. Other factors significantly associated with an increased sensitivity to warfarin included use of a medication with a potentiating interactive effect with warfarin, female gender, and overall medication use. Increased body weight and duration of warfarin use exceeding 6 months were found to be inversely related to anticoagulant response. Conclusion: The anticoagulant response to warfarin is exaggerated with advancing age. This finding emphasizes the need for close monitoring of older patients treated with warfarin therapy.	BETH ISRAEL HOSP, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HEBREW REHABIL CTR AGED, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01655 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester					NIA NIH HHS [K08 AG00510-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL RG, 1978, FED PROC, V37, P2599; CAMPION EW, 1988, J GERONTOL, V43, pM18, DOI 10.1093/geronj/43.1.M18; COON WW, 1977, ANN SURG, V186, P149, DOI 10.1097/00000658-197708000-00006; DOBRZANSKI S, 1983, J CLIN HOSP PHARM, V8, P75, DOI 10.1111/j.1365-2710.1983.tb00899.x; ECCLES J T, 1975, Age and Ageing, V4, P161, DOI 10.1093/ageing/4.3.161; GILMAN AG, 1990, GOODMAN GILMANS PHAR, P1317; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1985, PHARMACOKINETICS CLI, P84; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; HALLAK HO, 1991, DRUG METAB DISPOS, V19, P278; HAYES MJ, 1975, BRIT J CLIN PHARMACO, V2, P69, DOI 10.1111/j.1365-2125.1975.tb00474.x; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; HIRSH J, 1986, CHEST, V89, pS11, DOI 10.1378/chest.89.2_Supplement.11S; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HOTRAPHINYO K, 1978, CLIN EXP PHARMACOL P, V5, P143, DOI 10.1111/j.1440-1681.1978.tb00664.x; HUSTED S, 1977, BRIT J CLIN PHARMACO, V4, P559, DOI 10.1111/j.1365-2125.1977.tb00786.x; JONES BR, 1980, J AM GERIATR SOC, V28, P10, DOI 10.1111/j.1532-5415.1980.tb00116.x; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KIRKING DM, 1985, J CLIN HOSP PHARM, V10, P101; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1989, AM J MED, V87, P153; LIPPINCOTT JB, 1990, DRUG INTERACTION FAC; LOELIGER EA, 1964, THROMB DIATH HAEMOST, V10, P267; MACLENNAN WJ, 1977, GERONTOLOGY, V23, P360, DOI 10.1159/000212209; MANSON A, 1991, AM J PUBLIC HEALTH, V81, P1195, DOI 10.2105/AJPH.81.9.1195; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; OMALLEY K, 1977, BRIT J CLIN PHARMACO, V4, P309, DOI 10.1111/j.1365-2125.1977.tb00718.x; OREILLY RA, 1980, NEW ENGL J MED, V303, P160; PETITTI DB, 1989, J CLIN EPIDEMIOL, V42, P759, DOI 10.1016/0895-4356(89)90073-5; ROUTLEDGE PA, 1979, EUR J CLIN PHARMACOL, V15, P319, DOI 10.1007/BF00558434; Sackett DL, 1979, COMPLIANCE HLTH CARE; SHEPHERD AMM, 1977, BRIT J CLIN PHARMACO, V4, P315, DOI 10.1111/j.1365-2125.1977.tb00719.x; SHEPHERD AMM, 1978, POSTGRAD MED J, V54, P784, DOI 10.1136/pgmj.54.638.784; TOOHEY M, 1953, BRIT MED J, V1, P650, DOI 10.1136/bmj.1.4811.650; 1987, SADSTAT GUIDE PERSON	35	199	203	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					901	904		10.7326/0003-4819-116-11-901	http://dx.doi.org/10.7326/0003-4819-116-11-901			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580446				2022-12-24	WOS:A1992HW13700004
J	VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW				VEGETO, E; ALLAN, GF; SCHRADER, WT; TSAI, MJ; MCDONNELL, DP; OMALLEY, BW			THE MECHANISM OF RU486 ANTAGONISM IS DEPENDENT ON THE CONFORMATION OF THE CARBOXY-TERMINAL TAIL OF THE HUMAN PROGESTERONE-RECEPTOR	CELL			English	Article							HUMAN GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION FUNCTIONS; CELL-FREE TRANSCRIPTION; HUMAN ESTROGEN-RECEPTOR; STEROID BINDING DOMAIN; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; RESPONSIVE ELEMENT; HORMONE RECEPTORS	The human progesterone receptor form B (hPR-B) was expressed in Saccharomyces cerevisiae together with a specific reporter plasmid. To understand the mechanism underlying antagonist ligand activity, libraries of hormone binding domain (HBD)-mutated hPR-B molecules were prepared. A mutant receptor was identified that had lost the ability to bind either progesterone or R5020; it could still bind RU486 and, surprisingly, fully activated transcription in the presence of this "antagonist" and other antiprogestins. When this receptor mutant was assayed in mammalian cells, RU486 again demonstrated agonistic activity. Sequence analysis indicated that the mutant phenotype was due to truncation of the carboxy (C)-terminal 42 aa. We conclude that amino acids in the extreme C-terminal region are required for the receptor to bind progesterone, while antagonists bind to a site located more N-terminal of the HBD. Our results suggest that the extreme C-terminal region of the receptor contains an inhibitory function that silences receptor transactivation in the absence of agonist and in the presence of antagonist.			VEGETO, E (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BAGCHI MK, 1991, MOL CELL BIOL, V11, P4998, DOI 10.1128/MCB.11.10.4998; BAGCHI MK, 1992, IN PRESS P NATL ACAD; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKER PB, 1986, NATURE, V324, P686, DOI 10.1038/324686a0; BENHAMOU B, 1992, SCIENCE, V255, P206, DOI 10.1126/science.1372753; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHAO CC, 1991, CANCER RES, V51, P3938; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DENIS M, 1988, NATURE, V333, P686, DOI 10.1038/333686a0; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LERNER CG, 1990, J BIOL CHEM, V265, P20085; MAK P, 1989, J BIOL CHEM, V264, P21613; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MCDONNELL DP, 1991, J STEROID BIOCHEM, V39, P291, DOI 10.1016/0960-0760(91)90038-7; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MCDONNELL DP, 1989, MOL CELL BIOL, V9, P3517, DOI 10.1128/MCB.9.8.3517; MCDONNELL DP, 1991, MOL CELL BIOL, V11, P4350, DOI 10.1128/MCB.11.9.4350; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; Miller JH, 1972, EXPT MOL GENETICS; MISRAHI M, 1987, BIOCHEM BIOPH RES CO, V143, P740, DOI 10.1016/0006-291X(87)91416-1; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PRATT WB, 1988, J BIOL CHEM, V263, P267; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SCHNEIDER MR, 1990, J STEROID BIOCHEM, V37, P783, DOI 10.1016/0960-0760(90)90420-P; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILLMANN T, 1986, NATURE, V324, P688, DOI 10.1038/324688a0	68	352	371	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					703	713		10.1016/0092-8674(92)90234-4	http://dx.doi.org/10.1016/0092-8674(92)90234-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586949				2022-12-24	WOS:A1992HV08900015
J	HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE				HEDNER, T; SAMUELSSON, O; LUNDE, H; LINDHOLM, L; ANDREN, L; WIHOLM, BE			ANGIO-EDEMA IN RELATION TO TREATMENT WITH ANGIOTENSIN CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; SWEDEN	Objective-To evaluate and describe the clinical course of angio-oedema reactions induced by angiotensin converting enzyme inhibitors. Design and methods-All reports of angio-oedema reactions associated with angiotensin converting enzyme inhibitors submitted to Swedish Adverse Reactions Advisory Committee were reviewed and the clinical courses summarised. Numbers of cases judged to be induced by angiotensin converting enzyme inhibitors were related to their annual usage, estimated from total sales of defined daily doses, as well as to the estimated number of new patients. All cases of angio-oedema associated with angiotensin converting enzyme inhibitors reported to the World Health Organisation's international drug information system were also summarised. Results-36 of the 38 reported cases in Sweden between 1981 and 1990 were judged to be related to angiotensin converting enzyme inhibitors. During 1981 through 1990, altogether 1309 cases of angio-oedema associated with angiotensin converting enzyme inhibitors were registered with the international drug information system. The incidence of reported cases of angio-oedema increased largely in parallel with the increased sales (usage) of angiotensin converting enzyme inhibitors. Of the 36 Swedish patients, 77% experienced the reaction within the first three weeks after starting treatment. 10 patients needed hospitalisation, two of whom had life threatening laryngeal obstruction. With one exception all 36 patients were free of symptoms within one week after discontinuing the drug. Conclusions-Angio-oedema induced by angiotensin converting enzyme inhibitors is a rare but potentially life threatening reaction, which in most instances occurs shortly after the start of treatment. Any patient in whom the reaction is suspected should have the treatment interrupted and, if necessary, be admitted for observation.	GOTHENBURG UNIV,SAHLGRENS HOSP,NEPHROL,S-41345 GOTHENBURG,SWEDEN; SWEDISH MED PROD AGCY,UPPSALA,SWEDEN; UNIV LUND,HLTH SCI CTR,DALBY,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Medical Products Agency; Lund University	HEDNER, T (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN.							CHIN HL, 1990, ANN INTERN MED, V112, P312, DOI 10.7326/0003-4819-112-4-312_2; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; ERDOS EG, 1990, J CARDIOVASC PHARM, V15, pS20; FROHLICH ED, 1989, HYPERTENSION S1, V13, P125; KAPLAN AP, 1984, J ALLERGY CLIN IMMUN, V73, P573; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; OLSSON S, 1989, SEMIN DERMATOL, V8, P72; ORFAN N, 1990, JAMA-J AM MED ASSOC, V264, P1287, DOI 10.1001/jama.264.10.1287; Osler W, 1888, AM J MED SCI, V95, P362; Quincke H, 1882, MONATSH PRAKT DERMAT, V1, P129; RASTAM L, 1986, ACTA MED SCAND, V219, P243; RUCINSKA EJ, 1989, MED TOXICOL ADV DRUG, V4, P144, DOI 10.1007/BF03259909; RUSH JE, 1987, J CARDIOVASC PHAR S3, V9, P99; SAMUELSSON O, 1985, J HYPERTENS, V3, P167, DOI 10.1097/00004872-198504000-00010; SCHROR K, 1990, J CARDIOVASC PHARM, V15, pS60, DOI 10.1097/00005344-199015061-00012; SEARS M, 1991, ASTHMA ITS PATHOLOGY, V1; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SOTER NA, 1977, FED PROC, V36, P1736; WARNER NJ, 1988, DRUGS, V35, P89, DOI 10.2165/00003495-198800355-00016; WERNZE H, 1988, Z KARDIOL, V77, P61; WESSLING A, 1990, EUR J CLIN PHARMACOL, V38, P329, DOI 10.1007/BF00315570; WIHOLM BE, 1984, 1983 SKAND INT S DET, P152; WOOD SM, 1987, BRIT MED J, V294, P91, DOI 10.1136/bmj.294.6564.91; 1990, J HYPERTENS, V8, P985; 1985, BMJ, V291, P97; 1988, ARCH INTERN MED, V148, P1023; ADVERSE REACTION REG; 1990, LAKARTIDNINGEN, V87, P2255; 1989, J HYPERTENS, V7, P689	29	111	113	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					941	946		10.1136/bmj.304.6832.941	http://dx.doi.org/10.1136/bmj.304.6832.941			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581715	Bronze, Green Published			2022-12-24	WOS:A1992HP06400018
J	MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ				MADDEN, SL; COOK, DM; MORRIS, JF; GASHLER, A; SUKHATME, VP; RAUSCHER, FJ			TRANSCRIPTIONAL REPRESSION MEDIATED BY THE WT1 WILMS-TUMOR GENE-PRODUCT	SCIENCE			English	Article							FINGER POLYPEPTIDE GENE; MAMMALIAN-CELLS; SEQUENCE; ACTIVATION; BINDING; LOCUS; EXPRESSION; PROTEIN; SITE; FOS	The wt1 gene, a putative tumor suppressor gene located at the Wilms tumor (WT) locus on chromosome 11p13, encodes a zinc finger-containing protein that binds to the same DNA sequence as EGR-1, a mitogen-inducible immediate-early gene product that activates transcription. The transcriptional regulatory potential of WT1 has not been demonstrated. In transient transfection assays, the WT1 protein functioned as a repressor of transcription when bound to the EGR-1 site. The repression function was mapped to the glutamine- and proline-rich NH2-terminus of WT1; fusion of this domain to the zinc finger region of EGR-1 converted EGR-1 into a transcriptional repressor.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	The Wistar Institute; Howard Hughes Medical Institute			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [P01CA052009, R01CA023413] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52009, CA-23413, CA-0917-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COOK DM, UNPUB; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COWELL JK, 1991, ONCOGENE, V6, P595; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUFF V, 1991, AM J HUM GENET, V48, P997; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MADDEN SL, UNPUB; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MORRIS JDH, IN PRESS ONCOGENE; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; ROYERPOKORA B, 1991, GENE CHROMOSOME CANC, V3, P89, DOI 10.1002/gcc.2870030203; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; TON CCT, 1991, GENOMICS, V10, P293, DOI 10.1016/0888-7543(91)90516-H	31	497	515	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	1991	253	5027					1550	1553		10.1126/science.1654597	http://dx.doi.org/10.1126/science.1654597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GG651	1654597				2022-12-24	WOS:A1991GG65100044
J	SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B				SANDVIG, K; GARRED, O; PRYDZ, K; KOZLOV, JV; HANSEN, SH; VANDEURS, B			RETROGRADE TRANSPORT OF ENDOCYTOSED SHIGA TOXIN TO THE ENDOPLASMIC-RETICULUM	NATURE			English	Article							INTERNALIZED RICIN; PSEUDOMONAS EXOTOXIN; SHIGELLA TOXIN; GOLGI NETWORK; CELLS; SEQUENCE; PROTEIN	SHIGA toxin and some other protein toxins that act on targets in the cytosol have previously been shown to enter the trans-Golgi network1-9. Transport by this route may be necessary for translocation of the toxin to the cytosol and for intoxication5-9, but it is not known whether the enzymatically active part of the toxins actually enters the cytosol from the trans-Golgi network. It has been suggested that such toxins are transported in a retrograde manner to the endoplasmic reticulum and that translocation occurs in this organelle10, but retrograde transport of endocytosed material beyond the trans-Golgi network has never been demonstrated. Here we show that in butyric acid-treated A431 cells endocytosed Shiga toxin is not only transported to the trans-Golgi network, but also to all Golgi stacks, to the endoplasmic reticulum and to the nuclear envelope. Furthermore, butyric acid sensitizes the cells to Shiga toxin, which is consistent with the possibility that retrograde transport is required for translocation of the toxin to the cytosol.	WA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, USSR; UNIV COPENHAGEN, PANUM INST, DEPT ANAT, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN, DENMARK	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; University of Copenhagen	SANDVIG, K (corresponding author), NORWEGIAN RADIUM HOSP, INST CANC RES, N-0310 OSLO 3, NORWAY.			Hansen, Steen/0000-0002-9408-4676				CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; HANSEN SH, 1989, EXP CELL RES, V185, P373, DOI 10.1016/0014-4827(89)90307-8; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; KOZLOV YV, 1988, GENE, V67, P213, DOI 10.1016/0378-1119(88)90398-8; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; OLSNES S, 1988, IMMUNOTOXINS, V1, P39; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1991, J CELL BIOL, V113, P553, DOI 10.1083/jcb.113.3.553; SANDVIG K, 1989, J CELL BIOL, V108, P1331, DOI 10.1083/jcb.108.4.1331; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SEIDAH NG, 1986, J BIOL CHEM, V261, P13928; STROCKBINE NA, 1988, J BACTERIOL, V170, P1116, DOI 10.1128/jb.170.3.1116-1122.1988; VAN PN, 1989, J BIOL CHEM, V264, P17494; VANDEURS B, 1988, J CELL BIOL, V106, P253, DOI 10.1083/jcb.106.2.253; VANDEURS B, 1989, INT REV CYTOL, V117, P131; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; YOULE RJ, 1987, J BIOL CHEM, V262, P4676	18	381	394	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 6	1992	358	6386					510	512		10.1038/358510a0	http://dx.doi.org/10.1038/358510a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641040				2022-12-24	WOS:A1992JG73900052
J	JUVELA, S				JUVELA, S			ALCOHOL-CONSUMPTION AS A RISK FACTOR FOR POOR OUTCOME AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GAMMA-GLUTAMYL-TRANSFERASE; CEREBRAL-ISCHEMIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; LIVER-DISEASE; HEMORRHAGE; STROKE; POPULATION; QUESTIONNAIRE; HEART	Objective-To evaluate the effect of factors existing before aneurysmal subarachnoid haemorrhage on outcome of haemorrhage. Design-Prospective follow up study. Setting-Helsinki University Hospital. Patients-291 consecutive patients (149 men) aged 15 to 65 years admitted within 96 hours after the bleeding. Main outcome measures-Potential risk factors (baseline characteristics, health habits, and clinical variables) for poor outcome after haemorrhage (dependent state in the activities of daily living, or death) were studied using multiple logistic regression. Results-One year after haemorrhage, 179 (62%) patients were independent in the activities of daily living and 28 (10%) dependent; 84 (29%) had died. Risk of poor outcome was predicted, after adjustment for sex and age, by clinical condition at admission according to the Glasgow coma scale (p<0.0001); occurrence of rebleeding (relative risk 7.1, 95% confidence interval 2.8 to 18.0, p<0.0001) or delayed cerebral ischaemia (10.3, 4.2 to 25.4, p<0.0001); surgery on an aneurysm (0.13, 0.05 to 0.35, p<0.0001); and heavy consumption of alcohol (4-5, 1.8 to 11.0, p=0.0014). Heavy drinking remained a significant risk factor after additional adjustment for hypertension, body mass index, and presence of intracerebral haematoma. Heavy drinkers had a more unfavourable outcome after rebleeding and delayed ischaemia than did others with rebleeding or ischaemia. Those who had salicylates in urine on admission had delayed ischaemia with fixed neurological deficits less commonly than others. Conclusions-Heavy drinking impairs outcome mainly through severe rebleeding and delayed ischaemia and to a lesser extent through a poor initial condition and presence of intracerebral haematoma.			JUVELA, S (corresponding author), HELSINKI UNIV HOSP, DEPT NEUROSURG, TOPELIUKSENKATU 5, SF-00260 HELSINKI, FINLAND.			Juvela, Seppo/0000-0003-4944-4983				ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; BELL BA, 1979, BRIT MED J, V1, P577, DOI 10.1136/bmj.1.6163.577; BERGLUND M, 1981, ARCH GEN PSYCHIAT, V38, P351; BERNADT MW, 1982, LANCET, V1, P325; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; ELLIOTT P, 1988, BRIT MED J, V297, P319; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; HASELAGER EM, 1977, LANCET, V1, P774; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HILLBOM M, 1988, HAEMOSTASIS, V18, P170; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1990, NEUROSURGERY, V27, P929, DOI 10.1227/00006123-199012000-00011; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386; Juvela S, 1991, THESIS U HELSINKI HE; KASSELL NF, 1982, NEUROSURGERY, V10, P514, DOI 10.1227/00006123-198204000-00019; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; KRISTENSON H, 1980, PREV MED, V9, P108, DOI 10.1016/0091-7435(80)90062-6; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MONTEIRO MG, 1985, DRUG ALCOHOL DEPEN, V16, P31, DOI 10.1016/0376-8716(85)90079-1; MORGAN MY, 1981, CLIN LAB HAEMATOL, V3, P35; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; RAGNI MV, 1982, ALCOHOL CLIN EXP RES, V6, P267, DOI 10.1111/j.1530-0277.1982.tb04973.x; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TEASDALE G, 1974, LANCET, V2, P81	37	49	50	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1992	304	6843					1663	1667		10.1136/bmj.304.6843.1663	http://dx.doi.org/10.1136/bmj.304.6843.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633519	Green Published, Bronze			2022-12-24	WOS:A1992JB93900021
J	ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA				ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA			THE ROLE OF SOLVENT VISCOSITY IN THE DYNAMICS OF PROTEIN CONFORMATIONAL-CHANGES	SCIENCE			English	Article							GEMINATE RECOMBINATION; GLASS-TRANSITION; CARBON-MONOXIDE; LIGAND-BINDING; HEME-PROTEINS; MYOGLOBIN; PHOTODISSOCIATION; SPECTROSCOPY; DIFFUSION; KINETICS	Nanosecond lasers were used to measure the rate of conformational changes ir myoglobin after ligand dissociation at ambient temperatures. At low solvent viscosities the rate is independent of viscosity, but at high viscosities it depends on approximately the inverse first power of the viscosity. Kramers theory for unimolecular rate processes can be used to explain this result if the friction term is modified to include protein as well as solvent friction. The theory and experiment suggest that the dominant factor in markedly reducing the rate of conformational changes in myoglobin at low temperatures (<200 K) is the very high viscosity (>10(7) centipoise) of the glycerol-water solvent. That is, at low temperatures conformational substates may not be "frozen" so much as "stuck."	NIDDKD,CHEM PHYS LAB,BLDG 2,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Henry, Eric R/J-3414-2013	Henry, Eric R/0000-0002-5648-8696				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANGELL CA, 1976, ANN NY ACAD SCI, V279, P53, DOI 10.1111/j.1749-6632.1976.tb39693.x; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; DEMCHENKO AP, 1989, BIOCHIM BIOPHYS ACTA, V998, P196, DOI 10.1016/0167-4838(89)90273-2; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASINOFF BB, 1977, ARCH BIOCHEM BIOPHYS, V183, P176, DOI 10.1016/0003-9861(77)90432-5; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, BRUSSELS HEMOGLOBIN, P193; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6538; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; MASTRO AM, 1984, J CELL BIOL, V99, pS180, DOI 10.1083/jcb.99.1.180s; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NEWMAN AA, 1968, GLYCEROL; RASMUSSEN DH, 1971, J PHYS CHEM-US, V75, P967, DOI 10.1021/j100677a022; Rice SA., 1985, DIFFUSION LTD REACTI; Smoluchowski M. v, 1918, Z PHYS CHEM, V92, P129, DOI [10.1515/zpch-1918-9209, DOI 10.1515/ZPCH-1918-9209]; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886, DOI 10.1021/bi00234a008; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; WESTRICK JA, 1987, BIOCHEMISTRY-US, V26, P8313, DOI 10.1021/bi00399a043; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013	34	489	496	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1796	1798		10.1126/science.1615323	http://dx.doi.org/10.1126/science.1615323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615323				2022-12-24	WOS:A1992JA43400029
J	MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG				MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG			PROBING PROTEIN STABILITY WITH UNNATURAL AMINO-ACIDS	SCIENCE			English	Article							LYSOZYME; PACKING; HYDROPHOBICITY	Unnatural amino acid mutagenesis, in combination with molecular modeling and simulation techniques, was used to probe the effect of side chain structure on protein stability. Specific replacements at position 133 in T4 lysozyme included (i) leucine (wt), norvaline, ethyl-glycine, and alanine to measure the cost of stepwise removal of methyl groups from the hydrophobic core, (ii) norvaline and O-methyl serine to evaluate the effects of side chain solvation, and (iii) leucine, S,S-2-amino-4-methylhexanoic acid, and S-2-amino-3-cyclopentylpropanoic acid to measure the influence of packing density and side chain conformational entropy on protein stability. All of these factors (hydrophobicity, packing, conformational entropy, and cavity formation) significantly influence protein stability and must be considered when analyzing any structural change to proteins.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, CTR ADV MAT, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco			Ellman, Jonathan A/C-7732-2013		NCRR NIH HHS [NIH-RR-1081] Funding Source: Medline; NIGMS NIH HHS [GM-29072, GM-08388-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM029072] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P619, DOI 10.1002/bip.360260505; BEHE MJ, 1991, P NATL ACAD SCI USA, V88, P4195, DOI 10.1073/pnas.88.10.4195; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DAOPIN S, 1991, ANNU REV BIOPHYS BIO, V30, P11521; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS DA, 1990, J AM CHEM SOC, V112, P4011, DOI 10.1021/ja00166a045; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HEUCKROTH RO, 1986, P NATL ACAD SCI USA, V85, P8795; HUANG C, 1991, MIDAS PLUS; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; NAEF R, 1985, HELV CHIM ACTA, V68, P135, DOI 10.1002/hlca.19850680117; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SCHAFMEISTER C, 1991, LEAP; SEIBEL G, 1991, AMBER 30 REV A; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	33	136	137	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1798	1802		10.1126/science.1615324	http://dx.doi.org/10.1126/science.1615324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615324				2022-12-24	WOS:A1992JA43400030
J	MOORE, MS; BLOBEL, G				MOORE, MS; BLOBEL, G			THE 2 STEPS OF NUCLEAR IMPORT, TARGETING TO THE NUCLEAR-ENVELOPE AND TRANSLOCATION THROUGH THE NUCLEAR-PORE, REQUIRE DIFFERENT CYTOSOLIC FACTORS	CELL			English	Article							SIGNAL-BINDING PROTEINS; COMPLEX GLYCOPROTEINS; LOCALIZATION SIGNALS; TRANSPORT SIGNAL; LOCATION SIGNAL; T-ANTIGEN; IDENTIFICATION; SEQUENCE; INHIBITION; MIGRATION	We have isolated two cytosolic fractions from Xenopus oocytes that contain all of the activity necessary to support both steps of nuclear import in digitonin-permeabilized mammalian cells: binding at the nuclear envelope and translocation through the nuclear pore. The first cytosolic fraction (fraction A) interacts with an import-competent, but not a mutant, nuclear localization sequence-bearing conjugate and stimulates its accumulation at the nuclear envelope in an ATP-independent fashion. The second cytosolic fraction (fraction B) gives no discernible effect when added alone; but when added either together with fraction A, or after fraction A, stimulates the passage of the conjugate from the outer nuclear envelope to the interior of the nucleus in an ATP-dependent fashion.			MOORE, MS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.				PHS HHS [1F326M137585-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	46	259	259	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					939	950		10.1016/0092-8674(92)90613-H	http://dx.doi.org/10.1016/0092-8674(92)90613-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606616				2022-12-24	WOS:A1992HY79200006
J	MUSIERFORSYTH, K; SCHIMMEL, P				MUSIERFORSYTH, K; SCHIMMEL, P			FUNCTIONAL CONTACTS OF A TRANSFER-RNA SYNTHETASE WITH 2'-HYDROXYL GROUPS IN THE RNA MINOR GROOVE	NATURE			English	Article							IDENTITY	THE functional analysis of determinants on RNA has been largely limited to molecules that contain naturally occurring ribonucleotides, so little is known about the role of 2'-hydroxyl groups in protein-RNA recognition. A single base pair (G3.U70) in the acceptor stem of tRNA(Ala) is the principal element for specific recognition by Escherichia coli alanine-tRNA synthetase 1,2. This tRNA synthetase aminoacylates small RNA helices that contain the G3.U70 base pair. Furthermore, removal of the G3 exocyclic 2-amino group that projects into the minor groove eliminates aminoacylation 3. This 2-amino group is flanked on either side by ribose 2'-hydroxyl groups that line the minor groove. Here we use chemical synthesis to construct 32 helices that make deoxy and O-methyl substitutions of individual and multiple 2'-hydroxyl groups near and beyond the G3.U70 base pair and find that functional 2'-hydroxyl contacts are clustered within a few angstroms of the critical 2-amino group. These contacts are highly specific and make a thermodynamically significant contribution to RNA recognition.			MUSIERFORSYTH, K (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JASIN M, 1985, J BIOL CHEM, V260, P2226; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0	15	113	113	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					513	515		10.1038/357513a0	http://dx.doi.org/10.1038/357513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608452				2022-12-24	WOS:A1992HY05200068
J	LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T				LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T			NERVE GROWTH-FACTOR STIMULATION OF THE RAS-GUANINE NUCLEOTIDE EXCHANGE FACTOR AND GAP ACTIVITIES	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN; PC12 CELLS; TYROSINE PHOSPHORYLATION; BOVINE BRAIN; DIFFERENTIATION; MICROINJECTION; PURIFICATION; P21RAS; ONCOGENES; INDUCTION	The biological activity of Ras proteins is thought to be controlled by the guanine nucleotide exchange factor and the guanosine triphosphatase activating protein (GAP). Treatment of rat pheochromocytoma PC-12 cells with nerve growth factor (NGF) increased the amount of active Ras guanosine triphosphate complex and stimulated the activities of both the guanine nucleotide exchange factor and GAP. In PC-12 cells that overexpressed the tyrosine kinase encoded by the trk proto-oncogene (a component of the high-affinity NGF receptor), the NGF-induced activation of the regulatory proteins was potentiated. These results suggest that the NGF receptor system enhances the activities of both the guanine nucleotide exchange factor and GAP and that the activation of Ras might be controlled by the balance in activity between these two regulatory proteins.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74102, N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102, N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, UNPUB; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAMATA T, 1987, BIOCHEM BIOPH RES CO, V144, P19, DOI 10.1016/S0006-291X(87)80469-2; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Kamata T., UNPUB; KAPLAN DE, UNPUB; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Li B. A., UNPUB; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SUBULESKI MJ, UNPUB; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	37	121	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1456	1459		10.1126/science.1604323	http://dx.doi.org/10.1126/science.1604323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604323				2022-12-24	WOS:A1992HX33700039
J	BLACK, DL				BLACK, DL			ACTIVATION OF C-SRC NEURON-SPECIFIC SPLICING BY AN UNUSUAL RNA ELEMENT INVIVO AND INVITRO	CELL			English	Article							PRE-MESSENGER-RNA; GENE-EXPRESSION; RIBONUCLEOPROTEIN-PARTICLES; BINDING PROTEINS; POLYMERASE-II; SEX-LETHAL; INTRON; SITE; INITIATION; CONTAINS	A conserved positive-acting RNA sequence was found to be required for the neuron-specific splicing of the mouse c-src N1 exon. The sequence lies in the intron between exons N1 and 4, close to the N1 donor site. Normally, only the neural-specific splicing of exon N1 required this sequence. When the intron downstream of N1 was shortened, splicing at the constitutive exon 4 acceptor also became dependent on the activating sequence. The neuronal and nonneuronal patterns of src splicing were reconstituted in vitro. HeLa cell extracts spliced exon 4 to exon 3, skipping exon N1. Weri-1 retinoblastoma cell extracts spliced exon 4 to exon N1 as well as to exon 3. Both patterns of splicing were dependent on the activating sequence. A 123 nt RNA containing just the activating sequence specifically inhibited both patterns of src splicing, indicating that factors bound to the activator were required for its effects.			BLACK, DL (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NICHD NIH HHS [HD28063-1] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; COTE GJ, 1991, NUCLEIC ACIDS RES, V19, P3601, DOI 10.1093/nar/19.13.3601; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; Erlich H.A., 1989, PCR TECHNOLOGY; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; PAWSON T, 1988, ONCOGENE, V3, P491; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TSENG JC, 1991, MECH DEVELOP, V35, P65, DOI 10.1016/0925-4773(91)90042-5	51	150	152	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					795	807		10.1016/0092-8674(92)90291-J	http://dx.doi.org/10.1016/0092-8674(92)90291-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591778				2022-12-24	WOS:A1992HW83800010
J	KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW				KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW			LESS MORTALITY BUT MORE RELAPSES IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN CD8-/- MICE	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SUPPRESSOR CELLS; T-CELLS; INVIVO; DEPLETION; ANTIBODY; INVITRO; EAE	Mice lacking in CD8 were generated from homologous recombination in embryonal stem cells at the CD8 locus and bred with the experimental allergic encephalomyelitis (EAE)-susceptible PL/J H-2u through four backcross generations to investigate the role of CD8+ T cells in this model of multiple sclerosis. The disease onset and susceptibility were similar to those of wild-type mice. However, the mutant mice had a milder acute EAE, reflected by fewer deaths, but more chronic EAE, reflected by a higher frequency of relapse. This suggests that CD8+ T lymphocytes may participate as both effectors and regulators in this animal model.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Ludwig Institute for Cancer Research	KOH, DR (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA.			Fung-Leung, Wai-Ping/0000-0001-7013-8855				ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ARNASON BG, 1962, J EXP MED, V116, P177, DOI 10.1084/jem.116.2.177; ARNON R, 1981, IMMUNOL REV, V55, P5, DOI 10.1111/j.1600-065X.1981.tb00337.x; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; BROWN A, 1982, LAB INVEST, V46, P171; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUNGLEUNG WP, UNPUB; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KARPUS WJ, 1989, J IMMUNOL, V143, P3492; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; LEMIRE JM, 1986, J IMMUNOL, V137, P3169; LIDER O, 1989, J IMMUNOL, V142, P748; MASON D, 1991, IMMUNOL TODAY, V12, P57, DOI 10.1016/0167-5699(91)90158-P; MATHIESON PW, 1991, EUR J IMMUNOL, V21, P2105, DOI 10.1002/eji.1830210919; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOSSMANN TR, 1989, ADV IMMUNOL, V46, P111; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1991, J IMMUNOL, V146, P3012; SAKAI K, 1986, J IMMUNOL, V137, P1527; SAMBHARA SR, 1991, SCIENCE, V252, P1424; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SEDGWICK JD, 1990, J IMMUNOL, V145, P2474; SRIRAM S, 1988, J NEUROIMMUNOL, V17, P147, DOI 10.1016/0165-5728(88)90022-7; SRIRAM S, 1988, J IMMUNOL, V141, P464; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	33	319	332	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1210	1213		10.1126/science.256.5060.1210	http://dx.doi.org/10.1126/science.256.5060.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589800				2022-12-24	WOS:A1992HV19200038
J	HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J				HAMBLETON, P; COHEN, HE; PALMER, BJ; MELLING, J			ANTITOXINS AND BOTULINUM TOXIN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									PORTON DEV LTD,MED & REGULATORY ADM,MAIDENHEAD SL6 4UB,BERKS,ENGLAND		HAMBLETON, P (corresponding author), PUBL HLTH LAB SERV,CTR APPL MICROBIOL & RES,DIV BIOL,SALISBURY SP4 0JG,WILTS,ENGLAND.							ELSTON JS, 1988, EYE, V2, P12, DOI 10.1038/eye.1988.4; ELSTON JS, 1990, J PHYSIOLOGY PARIS, V84, P285; GARLAND PE, 1987, OPHTHALMOLOGY, V94, P288; STELL R, 1988, BRIT MED J, V297, P616, DOI 10.1136/bmj.297.6648.616; [No title captured]	5	43	45	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					959	960		10.1136/bmj.304.6832.959-a	http://dx.doi.org/10.1136/bmj.304.6832.959-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581719	Green Published, Bronze			2022-12-24	WOS:A1992HP06400023
J	TSAI, LH; HARLOW, E; MEYERSON, M				TSAI, LH; HARLOW, E; MEYERSON, M			ISOLATION OF THE HUMAN CDK2 GENE THAT ENCODES THE CYCLIN-A-ASSOCIATED AND ADENOVIRUS-E1A-ASSOCIATED P-33 KINASE	NATURE			English	Article							ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; CELL-CYCLE; FISSION YEAST; M-PHASE; CDC2; HOMOLOG; MITOSIS; DNA; PHOSPHORYLATION	CYCLINS are regulatory subunits which associate with kinases to form complexes that control many of the important steps in cell-cycle progression. The best characterized of the cyclin-containing complexes is the association of cyclin B with the p34cdc2 kinase. The p34cdc2/cyclin B complex is required for the G2 to M transition (see refs 1-4 for review), but the physiological role of other cyclin complexes is unclear. Human cyclin A binds independently to two kinases, associating with either p34cdc2 or a related protein, p33 (refs 5-7). In adenovirus-transformed cells, the viral E1A oncoprotein seems to associate with p33/cyclin A but not with p34cdc2/cyclin A (B. Faha, M.M., L-H.T. and E.H., manuscript submitted). To isolate the gene for p33, we have cloned several novel human cdc2-related genes. The protein product of one of these genes, cdk2 (cyclin-dependent kinase 2), shares 65% sequence identity with p34cdc2 (ref. 8) and 89% identity with the Xenopus Eg-1 gene product 9. Immunochemical characterization and partial proteolytic mapping show that the cdk2 gene product is the cyclin A-associated p33. Immunoprecipitations of the p33cdk2 protein suggest that it can act as a protein kinase in vitro. As p33cdk2 is bound to cyclin A and is targeted by the viral E1A protein, we suggest that the p33cdk2/cyclin A complex has a unique role in cell-cycle regulation of vertebrate cells.			TSAI, LH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BLDG 149,13TH ST,BOSTON,MA 02129, USA.		Meyerson, Matthew L/E-7123-2012					ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BELLETT AJD, 1985, MOL CELL BIOL, V5, P1933, DOI 10.1128/MCB.5.8.1933; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, IN PRESS SCIENCE; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HERMANN CH, IN PRESS J VIROL; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LANE DP, 1978, VIROLOGY, V87, P182, DOI 10.1016/0042-6822(78)90170-8; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NINOMIYATSUJI J, IN PRESS P NATN ACAD; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1990, New Biologist, V2, P389; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	35	490	520	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	SEP 12	1991	353	6340					174	177		10.1038/353174a0	http://dx.doi.org/10.1038/353174a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GE731	1653904				2022-12-24	WOS:A1991GE73100056
J	COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N				COLOMBO, M; DEFRANCHIS, R; DELNINNO, E; SANGIOVANNI, A; DEFAZIO, C; TOMMASINI, M; DONATO, MF; PIVA, A; DICARLO, V; DIOGUARDI, N			HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background and Methods. Patients with cirhosis of the liver are recognized as being at risk for hepatocellular carcinoma. The magnitude of the risk, the natural history of this disease, and the possibilities for detecting potentially curable tumors in patients in the Western world are unknown. To address these questions, we examined 447 Italian patients with well-compensated cirrhosis (which was of viral origin in 62 percent of them) from 1985 through 1990, performing serum alpha-fetoprotein assays and real-time ultrasonography every 3 to 12 months. Results. Hepatocellular carcinoma was found in 30 patients (7 percent) at base line and in another 29 patients (7 percent of 417 patients free of tumor at base line) during follow-up periods averaging 33 months (range, 1 to 48). The cumulative hazard of the development of hepatocellular carcinoma during follow-up was higher among patients with persistently elevated serum alpha-fetaprotein levels (12 with tumors among 42 with such levels) than among those with fluctuating levels (11 among 82) or those with consistently normal levels (6 among 255). Only 17 patients had potentially operable tumors. The proportion of potentially operable tumors among those detected during follow-up was significantly lower than the proportion at enrollment (4 of 29 vs. 13 of 30, P = 0.027). The survival at one year of the 12 patients who underwent surgery was 67 percent, and the tumor-recurrence rate was 60 percent. Outcome was not appreciably different for the five patients who refused surgery. Conclusions. In the West, as in Asia, patients with cirrhosis of the liver are at substantial risk for hepatocellular carcinoma, with a yearly incidence rate of 3 percent. Our screening program did not appreciably increase the rate of detection of potentially curable tumors.	UNIV MILAN, SAN RAFFAELE HOSP, DEPT SURG, I-20122 MILAN, ITALY	University of Milan; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	COLOMBO, M (corresponding author), POLICLIN HOSP MILAN, CTR A MIGLIAVACCA, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.		Piemonti, Lorenzo/P-7605-2017; Donato, Maria francesca/AAC-2372-2019	Piemonti, Lorenzo/0000-0002-2172-2198; sangiovanni, angelo/0000-0002-9996-9385				ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; [Anonymous], 1990, ANN SURG, V211, P277; BENEDETTI J, 1983, BMDP STATISTICAL SOF, P557; COLOMBO M, 1985, LIVER, V5, P336; COTTONE M, 1988, HEPATO-GASTROENTEROL, V35, P101; CUTLER SJ, 1958, J CHRON DIS, V8, P699; EBARA M, 1986, GASTROENTEROLOGY, V90, P289, DOI 10.1016/0016-5085(86)90923-6; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GIBSON JB, 1978, INT HISTOLOGICAL CLA, V20, P12; HSU HC, 1988, CANCER, V61, P2095, DOI 10.1002/1097-0142(19880515)61:10<2095::AID-CNCR2820611027>3.0.CO;2-H; JOHNSON PJ, 1987, J HEPATOL, V4, P140, DOI 10.1016/S0168-8278(87)80021-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEW MC, 1984, SEMIN LIVER DIS, V4, P136, DOI 10.1055/s-2008-1040653; KOBAYASHI K, 1985, HEPATOLOGY, V5, P1100, DOI 10.1002/hep.1840050607; KONDO F, 1990, HEPATOLOGY, V12, P592, DOI 10.1002/hep.1840120324; KUBO Y, 1978, GASTROENTEROLOGY, V74, P578; LIAW YF, 1986, GASTROENTEROLOGY, V90, P263, DOI 10.1016/0016-5085(86)90919-4; MARINGHINI A, 1988, DIGEST DIS SCI, V33, P47, DOI 10.1007/BF01536630; MUNOZ N, 1987, NEOPLASMS LIVER, P3, DOI DOI 10.1007/978-4-431-68349-0_1; NELSON W, 1972, TECHNOMETRICS, V14, P945, DOI 10.2307/1267144; OKA H, 1990, HEPATOLOGY, V12, P680, DOI 10.1002/hep.1840120411; OKAZAKI N, 1989, CANCER, V63, P2207, DOI 10.1002/1097-0142(19890601)63:11<2207::AID-CNCR2820631124>3.0.CO;2-C; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SHELL JC, 1985, CANCER, V56, P660, DOI 10.1002/1097-0142(19850801)56:3<660::AID-CNCR2820560338>3.0.CO;2-F; TANAKA R, 1987, LIVER, V7, P316; TANG Z-Y, 1986, Seminars in Surgical Oncology, V2, P103, DOI 10.1002/ssu.2980020207; ZAMAN SN, 1985, LANCET, V1, P1357; [No title captured]	28	751	770	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 5	1991	325	10					675	680		10.1056/NEJM199109053251002	http://dx.doi.org/10.1056/NEJM199109053251002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GD497	1651452				2022-12-24	WOS:A1991GD49700002
J	ARNOLD, FH; HAYMORE, BL				ARNOLD, FH; HAYMORE, BL			ENGINEERED METAL-BINDING PROTEINS - PURIFICATION TO PROTEIN FOLDING	SCIENCE			English	Editorial Material							RECOMBINANT PROTEINS; DENOVO DESIGN; PEPTIDES		MONSANTO CO,DEPT CHEM SCI,CENT RES LABS,ST LOUIS,MO 63167	Monsanto	ARNOLD, FH (corresponding author), CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125, USA.			Arnold, Frances H./0000-0002-4027-364X				ARNOLD FH, 1991, BIO-TECHNOL, V9, P151, DOI 10.1038/nbt0291-151; BREWER SJ, 1991, PURIFICATION ANAL RE, P239; GHADIRI MR, 1990, J AM CHEM SOC, V112, P1630, DOI 10.1021/ja00160a054; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HAYMORE BL, UNPUB; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; IVERSON BL, 1990, SCIENCE, V249, P659, DOI 10.1126/science.2116666; KELLIS JT, UNPUB; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; SMITH MC, 1988, J BIOL CHEM, V263, P7211; SUH SS, 1991, PROTEIN ENG, V4, P301, DOI 10.1093/protein/4.3.301; TODD RJ, 1991, PROTEINS, V10, P156, DOI 10.1002/prot.340100209	13	204	215	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 28	1991	252	5014					1796	1797		10.1126/science.1648261	http://dx.doi.org/10.1126/science.1648261			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU061	1648261				2022-12-24	WOS:A1991FU06100027
J	JOHNSON, E				JOHNSON, E			ALCOHOLS IMPACT ON FETAL CNS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											JOHNSON, E (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PUBL AFFAIRS,PARKLAWN BLDG,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							1992, ALCOHOLISM CLIN EXPT, V16, P295	1	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					854	854						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640596				2022-12-24	WOS:A1992JH58800010
J	MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA				MCCLELLAN, WM; FLANDERS, WD; GUTMAN, RA			VARIABLE MORTALITY-RATES AMONG DIALYSIS TREATMENT CENTERS	ANNALS OF INTERNAL MEDICINE			English	Article						KIDNEY FAILURE, CHRONIC; DIALYSIS; AGE FACTORS; DIABETIC NEPHROPATHY	STAGE RENAL-DISEASE; LONG-TERM DIALYSIS; SURVIVAL; HEMODIALYSIS; PATIENT; RISK	Objective: To examine the variation in the risk for mortality among patients treated at renal dialysis facilities within a defined geographic area. Setting: All free-standing and hospital-based dialysis facilities in a single southeastern state reported to the registry. Design: Cohort of dialysis patients followed for 1 year by an end-stage renal disease registry. Patients: Patients (n = 3612) aged 20 years and older receiving treatment at the dialysis facilities reporting to the registry during 1987. Measurements: Demographic, comorbid, and severity of illness indicators were abstracted from patient records. Facility-specific risk estimates were derived from a Cox proportional hazards model. Results: Facility-specific mortality rates ranged between 2.0 and 10.5 deaths per 10 000 patient days. Mortality rates were higher among older persons; whites; those with a history of diabetic nephropathy, angina, or congestive heart failure; and patients with either nutritional or functional status impairment. Facility-specific prevalence of each mortality risk factor varied widely. The unadjusted risk for death in a facility at the 75th percentile of risk was 1.3 times that of a facility at the median, whereas at the 25th percentile, it was 0.68 times as likely-a twofold range of risk. Controlling for differences in the prevalence of patient characteristics did not change the interquartile range in risks, and a facility's adjusted risk estimate showed a strong correlation with its unadjusted estimate (R2, 0.566; P < 0.0001). Conclusions: Patient attributes associated with increased risk for mortality vary widely among dialysis facilities. Adjustment for these differences did not, however, substantially change either the degree of variation in mortality risks or the relative ranking of a facility's mortality.	EMORY UNIV, SCH MED, ATLANTA, GA 30322 USA; EMORY UNIV, SCH PUBL HLTH, DIV EPIDEMIOL, ATLANTA, GA 30322 USA; DURHAM REG HOSP, DURHAM, NC USA; DUKE UNIV, SCH MED, DURHAM, NC 27706 USA	Emory University; Emory University; Duke University	MCCLELLAN, WM (corresponding author), CLARK HOLDER CLIN, 303 SMITH ST, LA GRANGE, GA 30240 USA.							Acchiardo S R, 1983, Kidney Int Suppl, V16, pS199; BURTON BT, 1971, J AMER MED ASSOC, V218, P718, DOI 10.1001/jama.218.5.718; Degoulet P, 1980, Proc Eur Dial Transplant Assoc, V17, P149; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; GROSS JB, 1973, ANN INTERN MED, V78, P341, DOI 10.7326/0003-4819-78-3-341; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HELLERSTEDT WL, 1984, MAYO CLIN PROC, V59, P776, DOI 10.1016/S0025-6196(12)65589-X; HUSEBYE DG, 1987, ARCH INTERN MED, V147, P1921, DOI 10.1001/archinte.147.11.1921; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; HUTCHINSON TA, 1984, KIDNEY INT, V26, P44, DOI 10.1038/ki.1984.132; LEWIS EJ, 1969, ANN INTERN MED, V70, P311, DOI 10.7326/0003-4819-70-2-311; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MAIORCA R, 1988, KIDNEY INT, V34, P518, DOI 10.1038/ki.1988.212; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; RADECKI SE, 1988, AM J KIDNEY DIS, V11, P7, DOI 10.1016/S0272-6386(88)80167-7; ROBERTS JL, 1976, KIDNEY INT, V9, P363, DOI 10.1038/ki.1976.43; UMEN AJ, 1986, STAT MED, V5, P637, DOI 10.1002/sim.4780050611; WALKER JV, 1988, AM J NEPHROL, V8, P40, DOI 10.1159/000167551; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; 1991, USRDS1991  NAT I DIA; 1985, EGRET MANUAL STATIST; 1991, USRDS1991 NAT I DIAB	25	73	73	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					332	336		10.7326/0003-4819-117-4-332	http://dx.doi.org/10.7326/0003-4819-117-4-332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637029				2022-12-24	WOS:A1992JH46400011
J	SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H				SENDTNER, M; SCHMALBRUCH, H; STOCKLI, KA; CARROLL, P; KREUTZBERG, GW; THOENEN, H			CILIARY NEUROTROPHIC FACTOR PREVENTS DEGENERATION OF MOTOR NEURONS IN MOUSE MUTANT PROGRESSIVE MOTOR NEURONOPATHY	NATURE			English	Article							NERVE GROWTH-FACTOR; SPINAL-CORD; FACTOR CNTF; EXPRESSION; SURVIVAL; RAT; SEQUENCE; CULTURE; CLONING	CILIARY neurotrophic factor (CNTF) supports the survival of embryonic motor neurons in vitro1,2 and in vivo3, and prevents lesion-mediated degeneration of rat motor neurons during early post-natal stages4. Here we report that CNTF greatly reduces all the functional and morphological changes in pmn/pmn mice5, an autosomal recessive mutant leading to progressive caudo-cranial motor neuron degeneration. The first manifestations of progressive motor neuronopathy in homozygous pmn/pmn mice become apparent in the hind limbs at the end of the third post-natal week, and all the mice die up to 6 or 7 weeks after birth from respiratory paralysis. Treatment with CNTF prolongs survival and greatly improves motor function of these mice. Moreover, morphological manifestations, such as loss of motor axons in the phrenic nerve and degeneration of facial motor neurons, were greatly reduced by CNTF, although the treatment did not start until the first symptoms of the disease had already become apparent and substantial degenerative changes were already present. The protective and restorative effects of CNTF in this mouse mutant give new perspectives for the treatment of human degenerative motor neuron diseases with CNTF.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,W-8033 MARTINSRIED,GERMANY; UNIV COPENHAGEN,PANUM INST,INST NEUROPHYSIOL,DK-2200 COPENHAGEN,DENMARK	Max Planck Society; University of Copenhagen	SENDTNER, M (corresponding author), MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY.		Sendtner, Michael/J-1542-2012; Carroll, Patrick/AAL-7773-2021; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; DUCHEN LW, 1968, J NEUROL NEUROSUR PS, V31, P535, DOI 10.1136/jnnp.31.6.535; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; KAUPMANN K, 1992, GENOMICS, V13, P39, DOI 10.1016/0888-7543(92)90199-3; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MESSER A, 1987, J NEUROGENET, V4, P201, DOI 10.3109/01677068709102341; MESSER A, 1986, J NEUROGENET, V3, P345, DOI 10.3109/01677068609106858; OPPENHEIM RW, 1986, J COMP NEUROL, V246, P281, DOI 10.1002/cne.902460211; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; POLLIN MM, 1990, J NEUROCYTOL, V19, P29, DOI 10.1007/BF01188437; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENDTNER M, IN PRESS J CELL BIOL; SENDTNER M, 1991, J CELL SCI S, V15, P103; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; ULLRICH A, 1983, NATURE, V303, P821, DOI 10.1038/303821a0	21	541	553	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					502	504		10.1038/358502a0	http://dx.doi.org/10.1038/358502a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641039	Green Submitted			2022-12-24	WOS:A1992JG73900049
J	GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM				GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM			3-DIMENSIONAL STRUCTURE OF AN ANGIOTENSIN-II FAB COMPLEX AT 3 ANGSTROM - HORMONE RECOGNITION BY AN ANTIIDIOTYPIC ANTIBODY	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; INTERNAL IMAGE; NETWORK; PEPTIDE	The elucidation of bioactive conformations of small peptide hormones remains an elusive goal to structural chemists because of the inherent flexibility of these molecules. Angiotensin II (AII), the major effector of the renin-angiotensin system, is an octapeptide hormone for which no clear structural models exist. Peptide hormones such as AII share the property that they bind to their receptors with high affinities, in spite of the fact that they must overcome an extremely large conformational entropy barrier to bind in one conformation. A "surrogate system" that consists of a high-affinity monoclonal antibody (MAb) and AII has been used to study a bound conformation of AII. The crystallographic structure of the complex reveals a structure of AII that is compatible with predicted bioactive conformations of AII derived from structure-activity studies and theoretical calculations. In the complex, the deeply bound hormone is folded into a compact structure in which two turns bring the amino and carboxyl termini close together. The antibody of this complex (MAb 131) has the unusual property that it was not generated against AII, but rather against an anti-idiotypic antibody reactive with a MAb to AII, which renders this antibody an anti-anti-idiotypic antibody. The high affinity for AII of the original MAb to AII was passed on to MAb 131 through a structural determinant on the anti-idiotypic antibody. Strikingly, the conformation of AII in this complex is highly similar to complementarity determining region loops of antibodies, possibly indicating that a true molecular mimic of bound AII was present on the anti-idiotypic antibody against which MAb 131 was elicited.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yale University; Yale University			Ronco, Pierre/AAC-8390-2022	Brunger, Axel/0000-0001-5121-2036; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMELAS A, 1985, P NATL ACAD SCI USA, V82, P1881, DOI 10.1073/pnas.82.7.1881; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL VERSION; BUDISAVLJEVIC M, 1990, J IMMUNOL, V145, P1440; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CARSON MJ, COMMUNICATION; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P463; COURAUD PO, 1986, J IMMUNOL, V136, P3365; COURAUD PO, 1987, J IMMUNOL, V138, P1164; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EPP D, 1979, EUR J BIOCHEM, V45, P513; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; LARAGAH JH, 1973, HDB PHYSL, V8, P831; LENKINSKI RE, 1981, J INORG BIOCHEM, V15, P95, DOI 10.1016/S0162-0134(00)80295-0; LENKINSKI RE, 1985, PEPTIDES ANAL SYNTHE, V7, P301; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; PHILLIPS MI, 1978, NEUROENDOCRINOLOGY, V25, P354, DOI 10.1159/000122756; REICHMAN L, 1988, NATURE, V332, P327; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VALLOTTON MB, 1974, HDB EXPT PHARM, V37, P185; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WEINSTOCK J, 1991, J MED CHEM, V34, P1514, DOI 10.1021/jm00108a043; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082	42	168	174	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					502	507		10.1126/science.1636085	http://dx.doi.org/10.1126/science.1636085			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636085				2022-12-24	WOS:A1992JE75500019
J	OROURKE, AM; MESCHER, MF				OROURKE, AM; MESCHER, MF			CYTOTOXIC LYMPHOCYTE-T ACTIVATION INVOLVES A CASCADE OF SIGNALING AND ADHESION EVENTS	NATURE			English	Article							RECEPTOR-MEDIATED ACTIVATION; TYROSINE PHOSPHORYLATION; CLASS-I; CELLS; CD8; BINDING; RECOGNITION; LFA-1	IN addition to the antigen-specific T-cell receptor (TCR), T cells bear an array of 'accessory' molecules that can contribute to stable adhesion to the antigen-bearing cell1 and provide costimulatory signals1-7. For several of these2-7, T-cell adhesion to the ligand can be activated by TCR-dependent signalling (a signal from the TCR primes the coreceptor to bind to its ligand). It is unclear whether the individual coreceptors share common mechanisms of priming and cosignalling, and perhaps act in a redundant manner, or whether they act in a distinct way and contribute uniquely to the activation process. We report here the use of isolated alloantigen, class I proteins and fibronectin ligands to show that coreceptors on cytotoxic T lymphocytes are activated sequentially and deliver distinct biochemical signals on binding to their ligands. TCR engagement activates CD8 by a protein tyrosine kinase-dependent pathway, and CD8 then acts as a signal for initiation of polyphosphoinositide hydrolysis on binding to class I. In contrast, activated adhesion to fibronectin does not initiate polyphosphoinositide hydrolysis, but amplifies hydrolysis once it has been initiated. Thus, cytotoxic T-lymphocyte activation involves a TCR-initiated cascade of adhesion and signalling events leading to response.			OROURKE, AM (corresponding author), MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Mescher, Matthew/B-8068-2009					BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANE KP, 1989, J IMMUNOL, V142, P4153; KANE KP, 1990, J IMMUNOL, V144, P824; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OROURKE AM, 1988, J BIOL CHEM, V263, P18594; PANACCIO M, 1987, P NATL ACAD SCI USA, V84, P6874, DOI 10.1073/pnas.84.19.6874; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIU G, 1989, J IMMUNOL, V143, P3813; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	23	103	104	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					253	255		10.1038/358253a0	http://dx.doi.org/10.1038/358253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630493				2022-12-24	WOS:A1992JD58700059
J	PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG				PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG			A NOVEL TRANSFORMING PROTEIN (SHC) WITH AN SH2 DOMAIN IS IMPLICATED IN MITOGENIC SIGNAL TRANSDUCTION	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; I PHOSPHATIDYLINOSITOL KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; VIRAL ONCOGENE; GROWTH; COLLAGEN; SRC; GAP	A new SH2-containing sequence, SHC, was isolated by screening cDNA libraries with SH2 representative DNA probes. The SHC cDNA is predicted to encode overlapping proteins of 46.8 and 51.7 kd that contain a single C-terminal SH2 domain, and an adjacent glycine/proline-rich motif with regions of homology with the alpha-1 chain of collagen, but no identifiable catalytic domain. Anti-SHC antibodies recognized three proteins of 46, 52, and 66 kd in a wide range of mammalian cell lines. These SHC proteins complexed with and were phosphorylated by activated epidermal growth factor receptor. The physical association of SHC proteins with activated receptors was recreated in vitro by using a bacterially expressed SHC SH2 domain. NIH 3T3 mouse fibroblasts that constitutively overexpressed SHC acquired a transformed phenotype in culture and formed tumors in nude mice. These results suggest that the SHC gene products couple activated growth factor receptors to a signaling pathway that regulates the proliferation of mammalian cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TURIN, IST MICROBIOL, I-10126 TURIN, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Turin	PELICCI, G (corresponding author), UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY.		Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Pawson, Tony J/E-4578-2013; Lanfrancone, Luisa/AAC-8671-2019; Grignani, Francesco/AAC-2565-2022; Cavallo, Federica/C-5666-2011	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; Cavallo, Federica/0000-0003-4571-1060				ALCALAY M, 1990, ONCOGENE, V5, P267; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAY ED, 1981, J CELL BIOL, V91, P205; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOCH CA, 1991, SCIENCE, V252, P669; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; REEDIJK M, 1992, IN PRESS EMBO J, V11; Sambrook J., 1989, MOL CLONING LAB MANU; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	57	1255	1293	0	20	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					93	104		10.1016/0092-8674(92)90536-L	http://dx.doi.org/10.1016/0092-8674(92)90536-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623525				2022-12-24	WOS:A1992JC95700011
J	REEVE, HK				REEVE, HK			QUEEN ACTIVATION OF LAZY WORKERS IN COLONIES OF THE EUSOCIAL NAKED MOLE-RAT	NATURE			English	Article							POLISTES-FUSCATUS; HYMENOPTERA; VESPIDAE; WASPS	EVOLUTIONARY ConfliCtS of interest are expected to arise in genetically diverse social groups 1. In eusocial insect societies, a potential conflict exists between the queen and her workers over how active the workers should be 2-5, and evidence exists that queen aggression increases activity levels of her lazier workers 2,3. Here I provide evidence that queen aggression (shoving) in laboratory colonies of the eusocial mammal, the naked mole-rat (Heterocephalus glaber), is a convergently evolved manifestation of queen-worker conflict over worker activity. Queen-initiated shoves activate inherently lazy workers, which tend to be larger and/or less related to the queen than are infrequently shoved, industrious workers. In addition, queen removal selectively depresses the activity of workers that are larger and less related to her. Finally, queen shoving and worker inactivity are pronounced when colonies are satiated but not when colonies are hungry, indicating that the underlying 'work-conflict' is highly context specific.	CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853	Cornell University								Braude S.H., 1991, P185; Brett R.A., 1991, P97; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Jarvis J.U.M., 1991, P384; Jarvis J.U.M., 1991, P66; JARVIS JUM, 1981, SCIENCE, V212, P571, DOI 10.1126/science.7209555; Lacey E.A., 1991, P209; Lacey E.A., 1991, P275; Reeve H., 1991, BIOL NAKED MOLE RAT, P337; REEVE HK, 1987, BEHAVIOUR, V102, P147, DOI 10.1163/156853986X00090; REEVE HK, 1983, BEHAV ECOL SOCIOBIOL, V13, P63, DOI 10.1007/BF00295077; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; REEVE HK, 1991, THESIS CORNELL U; SCHMIDHEMPEL P, 1990, AM NAT, V135, P501, DOI 10.1086/285059; West-Eberhard M.J., 1981, P3	15	136	142	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					147	149		10.1038/358147a0	http://dx.doi.org/10.1038/358147a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614546				2022-12-24	WOS:A1992JC58300050
J	MANN, GV				MANN, GV			LIPID-LEVELS AND AFFLUENT DIETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter																		MANN GV, 1955, NEW ENGL J MED, V253, P349, DOI 10.1056/NEJM195509012530901; MCMURRY MP, 1991, NEW ENGL J MED, V325, P1704, DOI 10.1056/NEJM199112123252405; WALKER WJ, 1953, AM J MED, V14, P654, DOI 10.1016/0002-9343(53)90383-0	3	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					52	52						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598109				2022-12-24	WOS:A1992JA76100020
J	MEADOR, CK				MEADOR, CK			THE PERSON WITH THE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					35	35						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608104				2022-12-24	WOS:A1992JA16500007
J	TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS				TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS			OUTCOME OF PATIENTS SUSTAINING ACUTE ISCHEMIC MITRAL REGURGITATION DURING MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; MITRAL VALVE INSUFFICIENCY; HEART CATHETERIZATION; CORONARY ARTERY BYPASS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY	CORONARY-ARTERY DISEASE; VALVE REPAIR; WALL MOTION; ANGIOPLASTY; REPLACEMENT; TRIAL; RECONSTRUCTION; STREPTOKINASE; THROMBOLYSIS; THERAPY	Objective: To describe outcomes of patients sustaining an acute myocardial infarction complicated by mitral regurgitation managed with contemporary reperfusion therapies. Design: Inception cohort case study. Long-term follow-up was obtained in 99% of all patients. Setting: University referral center. Patients: A series of 1480 consecutive patients presenting between April 1986 and March 1989 who had emergency cardiac catheterization within 6 hours of infarction. Fifty patients were found to have moderately severe or severe mitral regurgitation. Outcome Measures: Mortality; follow-up cardiac catheterization in patients with regurgitation. Results: Acute ischemic moderately severe to severe (3 + or 4 +) mitral regurgitation was associated with a mortality of 24% at 30 days (95% Cl, 12% to 36%), 42% at 6 months (Cl, 28% to 56%), and 52% at 1 year (Cl, 38% to 66%); multivariable analysis identified 3 + or 4 + mitral regurgitation as a possible independent predictor of mortality (P = 0.06). Patients with mitral regurgitation tended to be female, older, and to have cerebrovascular disease, diabetes, and pre-existing symptomatic coronary artery disease. A physical examination did not identify 50% of patients with moderately severe to severe regurgitation. Acute reperfusion with thrombolysis or angioplasty did not reliably reverse valvular incompetence. In this observational study, the greatest in-hospital and 1-year mortalities were seen in patients reperfused with emergency balloon angioplasty, whereas patients managed medically or with coronary bypass surgery had lower mortalities. Conclusions: Moderately severe to severe (3 + or 4 +) mitral regurgitation complicating acute myocardial infarction portends a grave prognosis. Acute reperfusion does not reduce mortality to levels experienced by patients with lesser degrees of mitral regurgitation nor does it reliably restore valvular competence.			TCHENG, JE (corresponding author), DUKE UNIV, MED CTR, BOX 3275, DURHAM, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045702, P50HL017670, P01HL036587] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45702, HL-36587, HL-17670] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELL WW, 1987, J THORAC CARDIOV SUR, V93, P665; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BONCHEK LI, 1984, J THORAC CARDIOV SUR, V88, P122; BURCH GE, 1963, ARCH INTERN MED, V112, P112, DOI 10.1001/archinte.1963.03860010138015; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COHN LH, 1988, ANN THORAC SURG, V45, P284, DOI 10.1016/S0003-4975(10)62463-0; CONNOLLY MW, 1986, J THORAC CARDIOV SUR, V91, P379; DAVID TE, 1986, CIRCULATION, V74, P116; DESERVI S, 1988, EUR HEART J, V9, P5, DOI 10.1093/eurheartj/9.suppl_F.5; ESTES EH, 1966, AM HEART J, V71, P356, DOI 10.1016/0002-8703(66)90475-3; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HEUSER RR, 1987, ANN INTERN MED, V107, P852, DOI 10.7326/0003-4819-107-6-852; HICKEY MS, 1988, CIRCULATION, V78, P51; Kay G L, 1987, Cardiovasc Clin, V17, P41; KAY GL, 1986, CIRCULATION, V74, P88; LOPERFIDO F, 1986, AM J CARDIOL, V58, P692, DOI 10.1016/0002-9149(86)90339-5; MAGOVERN JA, 1985, ANN THORAC SURG, V39, P346, DOI 10.1016/S0003-4975(10)62628-8; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; Rankin J S, 1989, Semin Thorac Cardiovasc Surg, V1, P149; RANKIN JS, 1989, CIRCULATION, V79, P116; RANKIN JS, 1988, J THORAC CARDIOV SUR, V95, P165; RANKIN JS, 1986, TXB SURGERY, P2344; REINFELD HB, 1985, CATHETER CARDIO DIAG, V11, P273, DOI 10.1002/ccd.1810110307; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SAND ME, 1987, J THORAC CARDIOV SUR, V94, P208; SHAWL FA, 1989, J AM COLL CARDIOL, V14, P986, DOI 10.1016/0735-1097(89)90477-4; SHEEHAN FH, 1983, CIRCULATION, V68, P756, DOI 10.1161/01.CIR.68.4.756; SHEEHAN FH, 1983, CIRCULATION, V68, P550, DOI 10.1161/01.CIR.68.3.550; SMITH LR, 1991, CIRCULATION, V84, P245; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, pB65, DOI 10.1016/S0735-1097(87)80430-8	37	170	177	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					18	24		10.7326/0003-4819-117-1-18	http://dx.doi.org/10.7326/0003-4819-117-1-18			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596043				2022-12-24	WOS:A1992JA43500003
J	PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL				PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL			STAGE-SPECIFIC ADHESION OF LEISHMANIA PROMASTIGOTES TO THE SANDFLY MIDGUT	SCIENCE			English	Article							MAJOR PROMASTIGOTES; TRYPANOSOMA-CRUZI; LIPOPHOSPHOGLYCAN; METACYCLOGENESIS; IDENTIFICATION; GLYCOCONJUGATE; ATTACHMENT; GUT	Although leishmaniasis is transmitted to humans almost exclusively by the bite of infected phlebotomine sandflies, little is known about the molecules controlling the survival and development of Leishmania parasites in their insect vectors. Adhesion of Leishmania promastigotes to the midgut epithelial cells of the sandfly was found to be an inherent property of noninfective-stage promastigotes, which was lost during their transformation to metacyclic forms, thus permitting the selective release of infective-stage parasites for subsequent transmission by bite. Midgut attachment and release was found to be controlled by specific developmental modifications in terminally exposed saccharides on lipophosphoglycan, the major surface molecule on Leishmania promastigotes.	NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892; WALTER REED ARMY MED CTR,DEPT ENTOMOL,WASHINGTON,DC 20307; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Kentucky; University of Dundee			Pimenta, Paulo/AAH-1502-2020					BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; COOMBS G, 1991, BIOCH PARASITIC PROT; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HENDRY KAK, 1988, PARASITOL RES, V74, P403, DOI 10.1007/BF00535138; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; IBRAHIM EAR, 1984, TROPENMED PARASITOL, V35, P151; KARP CL, 1991, J IMMUNOL, V147, P680; KILLICKKENDRICK R, 1979, BIOL KINETOPLASTIDA, V2, pCH8; LAWYER PG, 1990, AM J TROP MED HYG, V43, P31, DOI 10.4269/ajtmh.1990.43.31; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, UNPUB; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; ORLANDI P, 1987, J BIOL CHEM, V262, P10382; PEREIRA MEA, 1981, SCIENCE, V211, P597, DOI 10.1126/science.7006082; PIMENTA PFP, 1985, J SUBMICR CYTOL PATH, V17, P413; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, UNPUB; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SACKS DL, UNPUB; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; WALLBANKS KR, 1986, TROP MED PARASITOL, V37, P409; WARBURG A, 1989, J PROTOZOOL, V36, P613, DOI 10.1111/j.1550-7408.1989.tb01104.x	26	204	207	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1812	1815		10.1126/science.1615326	http://dx.doi.org/10.1126/science.1615326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615326				2022-12-24	WOS:A1992JA43400034
J	DIFFLEY, JFX; COCKER, JH				DIFFLEY, JFX; COCKER, JH			PROTEIN DNA INTERACTIONS AT A YEAST REPLICATION ORIGIN	NATURE			English	Article							NUCLEASE-SENSITIVE REGIONS; SACCHAROMYCES-CEREVISIAE; CHROMATIN; ARS1; PURIFICATION; INITIATION; SEQUENCES; SILENCER	AN understanding of the protein-DNA interactions in vivo at origins of DNA replication in eukaryotes is essential to delineate the mechanism of initiation of DNA synthesis and its control in the cell cycle 1,2. In the yeast Saccharomyces cerevisiae, a family of sequences known as autonomously replicating sequences (ARSs) function as origins of bidirectional DNA replication on plasmids and, in several instances, also in their normal chromosomal location 3. Here we use nucleotide resolution genomic footprinting to investigate the association of proteins with ARS1. Nuclease protection patterns indicate that at least two different cellular factors interact with functional elements in ARS1. The first seems to be ARS-binding factor 1. The second seems to be a novel protein that generates extensive protection over the essential ARS consensus sequence and phased DNaseI-sensitive sites across a functionally important flanking sequence. Hypersensitivity of this region to cleavage by copper phenanthroline indicates that it is under torsional strain, analogous to that produced at transcriptional start sites by assembly of an initiation complex. The protection in situ is similar to that generated by the origin recognition complex (ORC) protein.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, BLANCHE LANE, POTTERS BAR EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CAMPBELL JL, IN PRESS MOL BIOL YE; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1990, TRENDS GENET, V6, P426; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Sambrook J., 1989, MOL CLONING LAB MANU; SAWODOGO M, 1985, R G CELL, V43, P165; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9097, DOI 10.1021/bi00491a001; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; van Holde KE., 1989, SPRINGER SERIES MOL; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; [No title captured]	33	321	324	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					169	172		10.1038/357169a0	http://dx.doi.org/10.1038/357169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579168				2022-12-24	WOS:A1992HU12200062
J	KRISHNA, S; BENAROCH, P; PILLAI, S				KRISHNA, S; BENAROCH, P; PILLAI, S			TETRAMERIC CELL-SURFACE MHC CLASS-I MOLECULES	NATURE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN; COMPLEX; MOUSE	PURIFIED major histocompatibility complex (MHC) class I molecules have been studied at high resolution by X-ray crystallography 1; the structure is a complex of a single heavy chain, a beta-2-microglobulin light chain and a tightly bound peptide moiety. We show here that complete MHC class I molecules are post-translationally assembled into tetramers (made up of four heavy chains and four beta-2-microglobulin units) and that this tetrameric species is expressed on the cell surface. The multivalent tetrameric structure of class I molecules can be reconciled with models of T-cell activation that invoke antigen-receptor crosslinking, as opposed to models that depend on an allosteric change.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KRISHNA, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET GRP,MOLEC IMMUNOL LAB,BLDG 149,13TH ST,BOSTON,MA 02129, USA.			Benaroch, Philippe/0000-0002-2655-0129				BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BRAUN J, 1983, J IMMUNOL, V130, P2113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANIER LL, 1981, J IMMUNOL, V127, P1691; MICHAELSON J, 1983, IMMUNOGENETICS, V17, P219, DOI 10.1007/BF00364409; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; OZATO K, 1980, J IMMUNOL, V125, P2473; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125	15	33	34	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 14	1992	357	6374					164	167		10.1038/357164a0	http://dx.doi.org/10.1038/357164a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579167				2022-12-24	WOS:A1992HU12200060
J	BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R				BODANSKY, HJ; STAINES, A; STEPHENSON, C; HAIGH, D; CARTWRIGHT, R			EVIDENCE FOR AN ENVIRONMENTAL-EFFECT IN THE ETIOLOGY OF INSULIN-DEPENDENT DIABETES IN A TRANSMIGRATORY POPULATION	BRITISH MEDICAL JOURNAL			English	Article							ASIAN CHILDREN; PREVALENCE; MELLITUS	Objective - To examine whether children of families moving from an area of low incidence of childhood diabetes to one which is higher show a corresponding rise in disease incidence. Design - Disease incidence study over 12 years. Setting - Bradford District Metropolitan Council area. Subjects - All subjects aged 0-16 years resident within the study area. Main outcome measures - The incidences of childhood diabetes in Asian and non-Asian families. Results - The incidence of diabetes in Asian children increased from 3.1/100000 per year in 1978-81 to 11.7/100000 per year in 1988-90 (chi-2 for trend = 4.95, df = 1, p = 0.026) whereas that for other children remained constant at 10.5/100000 per year. Over the entire study period rates were lower in Asian females (4.9/100000 per year) than in Asian males (8.8/100000 per year) whereas the reverse was true for other children (males 9.2/100000 per year; females 12.0/100000 per year) (test for common odds ratio: chi-2 = 3.81, df = 1, p = 0.052). Conclusions - Offspring of this transmigratory population had a rising incidence of childhood diabetes which was approaching that of the indigenous population. The data provide strong evidence for an environmental effect in the aetiology of insulin dependent diabetes.	UNIV LEEDS,LEUKAEMIA RES FUND,CTR CLIN EPIDEMIOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND; ST LUKES HOSP,DEPT PAEDIAT,BRADFORD,ENGLAND	University of Leeds	BODANSKY, HJ (corresponding author), GEN INFIRM,PROFESSORIAL MED UNIT,LEEDS LS1 3EX,W YORKSHIRE,ENGLAND.		Staines, Anthony/AFQ-7565-2022	Staines, Anthony/0000-0001-9161-1357				BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BINGLEY PJ, 1989, DIABETES CARE, V12, P289, DOI 10.2337/diacare.12.4.289; BODANSKY HJ, 1987, ARCH DIS CHILD, V62, P227, DOI 10.1136/adc.62.3.227; BURDEN AC, 1990, INT J DIABETES DEV C, V10, P8; GAMBLE DR, 1988, CLIN DIABETES; HELGASON T, 1981, LANCET, V2, P716; MARMOT G, 1989, ETHNIC FACTORS HLTH, P12; Menon PSN., 1990, INT J DIABETES DEV C, V10, P11; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; Payne R. W., 1987, GENSTAT 5 REFERENCE; REIJONEN H, 1990, DIABETOLOGIA, V33, P357, DOI 10.1007/BF00404640; SAMANTA A, 1987, DIABETIC MED, V4, P65, DOI 10.1111/j.1464-5491.1987.tb00832.x; SAMANTA A, 1990, LANCET, V335, P1341, DOI 10.1016/0140-6736(90)91219-Z; SIMMONS D, 1990, DIABETIC MED, V7, P238, DOI 10.1111/j.1464-5491.1990.tb01377.x; TONIOLO A, 1988, CLIN DIABETES; WALKER A, 1980, DIABETES, V29, P1036, DOI 10.2337/diabetes.29.12.1036; 1987, BMJ, V295, P479	17	140	144	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1020	1022		10.1136/bmj.304.6833.1020	http://dx.doi.org/10.1136/bmj.304.6833.1020			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586783	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200019
J	DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H				DARBY, SC; OLSEN, JH; DOLL, R; THAKRAR, B; BROWN, PD; STORM, HH; BARLOW, L; LANGMARK, F; TEPPO, L; TULINIUS, H			TRENDS IN CHILDHOOD LEUKEMIA IN THE NORDIC COUNTRIES IN RELATION TO FALLOUT FROM ATMOSPHERIC NUCLEAR-WEAPONS TESTING	BRITISH MEDICAL JOURNAL			English	Article							YOUNG-PEOPLE; MORTALITY; LEUKEMIA; CANCER	Objective - To obtain further information about the risks of childhood leukaemia after exposure to ionising radiation at low doses and low dose rates before or after birth or to the father's testes shortly before conception. Design - Observational study of trends in incidence of childhood leukaemia in relation to estimated radiation exposures due to fallout from atmospheric nuclear weapons testing during the 1950s and 1960s. Setting - Nordic countries. Subjects - Children aged under 15 years. Main outcome measures - Incidence rates of leukaemia by age at diagnosis, sex, country, and calendar year of diagnosis or year of birth; exposure category; relation between leukaemia and exposure for children aged 0-14 and 0-4 separately. Results - During the high fallout period the average estimated dose equivalent to the fetal red bone marrow was around 140-mu-Sv and the average annual testicular dose 140-mu-Sv. There was little evidence of increased incidence of leukaemia among children born in these years. Doses to the red bone marrow of a child after birth were higher, and during the high exposure period children would have been subjected to an additional dose equivalent of around 1500-mu-Sv, similar to doses received by children in several parts of central and eastern Europe owing to the Chernobyl accident and about 50% greater than the annual dose equivalent to the red bone marrow of a child from natural radiation. Leukaemia incidence and red marrow dose was not related overall, but rates of leukaemia in the high exposure period were slightly higher than in the surrounding medium exposure period (relative risk for ages 0-14: 1.07, 95% confidence interval 1.00 to 1.14; for ages 0-4: 1.11, 1.00 to 1.24). Conclusions - Current predicted risks of childhood leukaemia after exposure to radiation are not greatly underestimated for low dose rate exposures.	CANC REGISTRY NORWAY,INST EPIDEMIOL CANC RES,OSLO 3,NORWAY; DANISH CANC REGISTRY,DANISH CANC SOC,DK-2100 COPENHAGEN 0,DENMARK; NATL BOARD HLTH & WELF,SWEDISH CANC REGISTRY,S-10630 STOCKHOLM,SWEDEN; FINNISH CANC REGISTRY,INST STAT & EPIDEMIOL CANC RES,SF-00170 HELSINKI,FINLAND; ICELAND CANC REGISTRY,IS-125 REYKJAVIK,ICELAND	University of Oslo; Danish Cancer Society; National Board of Health & Welfare; Finnish Cancer Registry	DARBY, SC (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND.			Olsen, Jorgen Helge/0000-0001-9633-5662; Storm, Hans/0000-0001-7223-8198				[Anonymous], 1990, HLTH EFFECTS EXPOSUR; DARBY SC, 1987, BRIT J CANCER, V55, P179, DOI 10.1038/bjc.1987.35; DARBY SC, 1987, BMJ-BRIT MED J, V294, P603, DOI 10.1136/bmj.294.6572.603; DIONIAN J, 1987, NRPBR202; ETHERINGTON G, 1990, ENV CONTAMINATION FO, V2, P327; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; HARVEY EB, 1985, NEW ENGL J MED, V312, P541, DOI 10.1056/NEJM198502283120903; HEASMAN MA, 1986, LANCET, V1, P266; HEASMAN MA, 1986, LANCET, V1, P385; MORREY M, 1988, EUR11523EN COMM EUR; Muirhead CR., 1989, J RADIOL PROTECT, V9, P209; PAYNE CD, 1986, GLIM SYSTEM RELEASE; PIFER JW, 1963, J NATL CANCER I, V31, P1333; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; STEVENS W, 1990, JAMA-J AM MED ASSOC, V264, P585, DOI 10.1001/jama.264.5.585; 1987, NRPBGS8 NAT RAD PROT; 1987, NRBPGS7 NAT RAD PROT; 1962 UN SCI COMM EFF; 1972 UN SCI COMM EFF; 1964 UN SCI COMM EFF; 1966 UN SCI COMM EFF; 1969 UN SCI COMM EFF; 1990, EUR12551EN COMM EUR	25	43	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 18	1992	304	6833					1005	1009		10.1136/bmj.304.6833.1005	http://dx.doi.org/10.1136/bmj.304.6833.1005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ142	1586779	Green Published, Bronze			2022-12-24	WOS:A1992HQ14200015
J	HANN, BC; WALTER, P				HANN, BC; WALTER, P			THE SIGNAL RECOGNITION PARTICLE IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							YEAST ENDOPLASMIC-RETICULUM; PREPRO-ALPHA-FACTOR; SECRETORY PROTEIN TRANSLOCATION; COLI 4.5S RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; HEAT-SHOCK; MICROSOMAL MEMBRANE; PLASMA-MEMBRANE	We have identified the Saccharomyces cerevisiae homolog of the signal recognition particle (SRP) and characterized its function in vivo. S. cerevisiae SRP is a 16S particle that includes a homolog of the signal sequence-binding protein subunit of SRP (SRP54p) and a small cytoplasmic RNA (scR1). Surprisingly, the genes encoding scR1 and SRP54p are not essential for growth, though SRP-deficient cells grow poorly, suggesting that SRP function can be partially bypassed in vivo. Protein translocation across the ER membrane is impaired in SRP-deficient cells, indicating that yeast SRP, like its mammalian counterpart, functions in this process. Unexpectedly, the degree of the translocation defect varies for different proteins. The ability of some proteins to be efficiently targeted in SRP-deficient cells may explain why previous genetic and biochemical analyses in yeast and bacteria did not reveal components of the SRP-dependent protein targeting pathway.			HANN, BC (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							AMAYA Y, 1990, J BIOCHEM-TOKYO, V107, P457, DOI 10.1093/oxfordjournals.jbchem.a123067; AMAYA Y, 1991, FEBS LETT, V283, P325, DOI 10.1016/0014-5793(91)80619-E; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BIEKER KL, 1990, J BIOENERG BIOMEMBR, V22, P291, DOI 10.1007/BF00763169; BIEKER KL, 1990, CELL, V61, P833, DOI 10.1016/0092-8674(90)90193-I; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; Davis R W, 1980, Methods Enzymol, V65, P404; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DIDOMENICO BJ, 1982, P NATL ACAD SCI-BIOL, V79, P6181, DOI 10.1073/pnas.79.20.6181; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; GARCIA PD, 1988, J CELL BIOL, V106, P1043, DOI 10.1083/jcb.106.4.1043; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HANSEN W, 1988, J CELL BIOL, V106, P1075, DOI 10.1083/jcb.106.4.1075; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HE F, 1989, CURR GENET, V16, P347, DOI 10.1007/BF00340713; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOSHLAND D, 1982, CELL, V30, P893, DOI 10.1016/0092-8674(82)90294-X; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Maniatis T., 1982, MOL CLONING; MEYER DI, 1982, NATURE, V297, P647, DOI 10.1038/297647a0; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARKER R, 1988, MOL CELL BIOL, V8, P3150, DOI 10.1128/MCB.8.8.3150; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; RIBES V, 1988, EMBO J, V7, P231, DOI 10.1002/j.1460-2075.1988.tb02804.x; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHBLATT JA, 1986, EMBO J, V5, P1031; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHLOSS P, 1988, EMBO J, V7, P2889, DOI 10.1002/j.1460-2075.1988.tb03146.x; Sherman F., 1986, METHODS YEAST GENETI; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRUB K, 1991, IN PRESS MOL CELL BI; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P7740, DOI 10.1093/nar/16.15.7740; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x	60	264	265	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					131	144		10.1016/0092-8674(91)90577-L	http://dx.doi.org/10.1016/0092-8674(91)90577-L			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655273				2022-12-24	WOS:A1991GJ32000012
J	TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG				TANABE, T; ADAMS, BA; NUMA, S; BEAM, KG			REPEAT-I OF THE DIHYDROPYRIDINE RECEPTOR IS CRITICAL IN DETERMINING CALCIUM-CHANNEL ACTIVATION KINETICS	NATURE			English	Article							SODIUM-CHANNEL; SKELETAL-MUSCLE; POTASSIUM CHANNELS; EXPRESSION; MEMBRANE; CDNA	MEMBRANE depolarization causes many kinds of ion channels to open, a process termed activation 1. For both Na+ channels 2-4 and Ca2+ channels 5,6, kinetic analysis of current has suggested that during activation the channel undergoes several conformational changes before reaching the open state. Structurally, these channels share a common motif 7: the central element is a large polypeptide with four repeating units of homology (repeats I-IV), each containing a voltage-sensing region, the S4 segment 8-11. This suggests that the distinct conformational transitions inferred from kinetic analysis may be equated with conformational changes of the individual structural repeats 8. To investigate the molecular basis of channel activation, we constructed complementary DNAs encoding chimaeric Ca2+ channels in which one or more of the four repeats of the skeletal muscle dihydropyridine receptor are replaced by the corresponding repeats derived from the cardiac dihydropyridine receptor. We report here that repeat I determines whether the chimaeric Ca2+ channel shows slow (skeletal muscle-like) 12 or rapid (cardiac-like) 13 activation.	KYOTO UNIV, FAC MED, DEPT MED CHEM, KYOTO 606, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC GENET, KYOTO 606, JAPAN; COLORADO STATE UNIV, COLL VET MED & BIOMED SCI, DEPT PHYSIOL, FT COLLINS, CO 80523 USA	Kyoto University; Kyoto University; Colorado State University			Tuluc, Petronel/C-2527-2011					ADAMS BA, 1990, NATURE, V346, P569, DOI 10.1038/346569a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; GUY HR, 1990, TRENDS NEUROSCI, V13, P201; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B, 1984, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; KEYNES RD, 1990, PROC R SOC SER B-BIO, V240, P411, DOI 10.1098/rspb.1990.0045; KOSTYUK PG, 1981, J PHYSIOL-LONDON, V310, P403, DOI 10.1113/jphysiol.1981.sp013557; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NODA M, 1984, NATURE, V312, P121, DOI 10.1038/312121a0; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; NUMA S, 1989, HARVEY LECT, V83, P121; SANCHEZ JA, 1983, J PHYSIOL-LONDON, V337, P1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1990, NATURE, V344, P451, DOI 10.1038/344451a0; TANABE T, 1990, NATURE, V346, P567, DOI 10.1038/346567a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, J GEN PHYSIOL, V95, P29, DOI 10.1085/jgp.95.1.29	27	121	123	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 29	1991	352	6338					800	803		10.1038/352800a0	http://dx.doi.org/10.1038/352800a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC964	1652692				2022-12-24	WOS:A1991GC96400059
J	NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG				NAAR, AM; BOUTIN, JM; LIPKIN, SM; YU, VC; HOLLOWAY, JM; GLASS, CK; ROSENFELD, MG			THE ORIENTATION AND SPACING OF CORE DNA-BINDING MOTIFS DICTATE SELECTIVE TRANSCRIPTIONAL RESPONSES TO 3 NUCLEAR RECEPTORS	CELL			English	Article							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RETINOIC ACID RECEPTORS; SUBUNIT GENE PROMOTER; 5' FLANKING REGION; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; NEGATIVE REGULATION; PITUITARY-CELLS; AMINO-ACIDS	Characterization of several thyroid hormone (T3), retinoic acid, and estrogen response elements has led to the identification of conserved DNA half-sites (core binding motifs). We present evidence that differences in both the relative orientation and spacing of these motifs within hormone response elements determine the distinct transcriptional responses of three members of the nuclear receptor superfamily. When separated by 3 bp, direct repeat, palindromic, and inverted palindromic arrangements of these motifs impart selective transcriptional responses to retinoic acid, estrogen, and T3 receptors, respectively. Varying the spacing between core motifs alters the specificity. Without spacing, a direct repeat of the core motif paradoxically configures the T3 receptor to confer transactivation in the absence of T3 and repression in its presence. Such an element occurs naturally in the mouse beta-thyrotropin promoter, physiologically under negative regulation by T3. The orientation and spacing of core binding motifs may thus function in concert as a code that accounts for the selective patterns of transcriptional responses of hormonally regulated promoters.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,MOLEC PATHOL GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,NEUROSCI GRP,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	NAAR, AM (corresponding author), UNIV CALIF SAN DIEGO,SCH MED,EUKARYOT REGULATORY BIOL PROGRAM,LA JOLLA,CA 92093, USA.		Yu, Victor/A-7899-2015; Glass, Christopher/AAI-3933-2021	Yu, Victor/0000-0003-3270-4734; Glass, Christopher/0000-0003-4344-3592				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1987, J BIOL CHEM, V262, P981; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; JONAT G, 1990, CELL, V62, P1189; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MORITA S, 1990, J ENDOCRINOL, V125, P251, DOI 10.1677/joe.0.1250251; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHUPNIK MA, 1987, ENDOCRINOLOGY, V121, P619, DOI 10.1210/endo-121-2-619; SLATER EP, 1991, MOL ENDOCRINOL, V5, P386, DOI 10.1210/mend-5-3-386; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	53	573	578	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1267	1279		10.1016/0092-8674(91)90021-P	http://dx.doi.org/10.1016/0092-8674(91)90021-P			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648451				2022-12-24	WOS:A1991FU89900018
J	SHENG, M; THOMPSON, MA; GREENBERG, ME				SHENG, M; THOMPSON, MA; GREENBERG, ME			CREB - A CA2+-REGULATED TRANSCRIPTION FACTOR PHOSPHORYLATED BY CALMODULIN-DEPENDENT KINASES	SCIENCE			English	Article							AMP RESPONSE ELEMENT; NUCLEAR FACTOR CREB; PROTEIN-KINASE; CYCLIC-AMP; LEUCINE ZIPPER; C-FOS; SOMATOSTATIN GENE; BINDING-PROTEIN; PYRUVATE-KINASE; NERVOUS-SYSTEM	The mechanism by which Ca2+ mediates gene induction in response to membrane depolarization was investigated. The adenosine 3',5'-monophosphate (cAMP) response element-binding protein (CREB) was shown to function as a Ca2+-regulated transcription factor and as a substrate for depolarization-activated Ca2+-calmodulin-dependent protein kinases (CaM kinases) I and II. CREB residue Ser133 was the major site of phosphorylation by the CaM kinases in vitro and of phosphorylation after membrane depolarization in vivo. Mutation of Ser133 impaired the ability of CREB to respond to Ca2+. These results suggest that CaM kinases may transduce electrical signals to the nucleus and that CREB functions to integrate Ca2+ and cAMP signals.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School				Sheng, Morgan/0000-0002-8703-5366	NCI NIH HHS [R01 CA 43855] Funding Source: Medline; NINDS NIH HHS [R01 NS 28829] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028829] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DASH PK, IN PRESS P NATL ACAD; DOSKELAND AP, 1984, EUR J BIOCHEM, V145, P31, DOI 10.1111/j.1432-1033.1984.tb08518.x; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODMAN RH, 1990, ANNU REV NEUROSCI, V13, P111, DOI 10.1146/annurev.neuro.13.1.111; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NGUYEN TV, 1990, J NEUROSCI, V10, P2825; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1988, NATURE, V335, P559; SCHWORER CM, 1985, J BIOL CHEM, V260, P3018; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SODERLING TR, 1986, BIOCHEM BIOPH RES CO, V139, P1017, DOI 10.1016/S0006-291X(86)80279-0; THOMPSON M, UNPUB; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZHU Z, 1989, J BIOL CHEM, V264, P6550	30	1364	1387	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 7	1991	252	5011					1427	1430		10.1126/science.1646483	http://dx.doi.org/10.1126/science.1646483			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FP868	1646483				2022-12-24	WOS:A1991FP86800035
J	BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M				BORZIO, M; BRUNO, S; RONCALLI, M; MELS, GC; RAMELLA, G; BORZIO, F; LEANDRO, G; PODDA, M			LIVER-CELL DYSPLASIA AND RISK OF HEPATOCELLULAR-CARCINOMA IN CIRRHOSIS - A PRELIMINARY-REPORT	BRITISH MEDICAL JOURNAL			English	Article							INFECTION; ALCOHOL		FATEBENEFRATELLI HOSP,DEPT PATHOL,I-20129 MILAN,ITALY; PREDABISSI HOSP,DEPT MED 1,MELEGNANO,ITALY; CASTELLANA GROTTE HOSP,DEPT MED,BARI,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT MED 1,I-20122 MILAN,ITALY; UNIV MILAN,SCH MED S PAOLO,DEPT PATHOL 2,I-20122 MILAN,ITALY; BOLOGNINI HOSP,DEPT MED,SERIATE,ITALY	University of Milan; University of Milan	BORZIO, M (corresponding author), FATEBENEFRATELLI HOSP,DEPT MED 1,I-20129 MILAN,ITALY.			Roncalli, Massimo/0000-0002-7901-8910; Leandro, Gioacchino/0000-0001-6624-4532; Bruno, Savino/0000-0002-3887-864X				ANTHONY PP, 1973, J CLIN PATHOL, V26, P217, DOI 10.1136/jcp.26.3.217; FARBER E, 1976, CANCER RES, V36, P2532; PAGLIARO L, 1983, HEPATO-GASTROENTEROL, V30, P48; RONCALLI M, 1986, CANCER, V57, P1515, DOI 10.1002/1097-0142(19860415)57:8<1515::AID-CNCR2820570813>3.0.CO;2-J; VILLA E, 1988, CANCER-AM CANCER SOC, V62, P611, DOI 10.1002/1097-0142(19880801)62:3<611::AID-CNCR2820620328>3.0.CO;2-0	5	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 1	1991	302	6788					1312	1312		10.1136/bmj.302.6788.1312	http://dx.doi.org/10.1136/bmj.302.6788.1312			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FQ444	1647827	Green Published, Bronze			2022-12-24	WOS:A1991FQ44400020
J	HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD				HESSOL, NA; KATZ, MH; LIU, JY; BUCHBINDER, SP; RUBINO, CJ; HOLMBERG, SD			INCREASED INCIDENCE OF HODGKIN DISEASE IN HOMOSEXUAL MEN WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; HODGKINS DISEASE; HOMOSEXUALITY; ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HODGKIN LYMPHOMA	HUMAN-IMMUNODEFICIENCY-VIRUS; BISEXUAL MEN; COHORT; AIDS	Objective: To evaluate the incidence of Hodgkin disease and non-Hodgkin lymphoma among homosexual men infected with human immunodeficiency virus (HIV). Design: Cohort study with computer-matched identification of participants with the Northern California Cancer Center registry. Population rate comparisons were made with data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry. Participants: The 6704 homosexual men in the San Francisco City Clinic Cohort study. Measurements: Incidence of Hodgkin disease, non-Hodgkin lymphoma, HIV infection, and the acquired immunodeficiency syndrome (AIDS); calculation of sex and age-adjusted standardized morbidity ratios and attributable risk. Results: Eight cases of Hodgkin disease and 90 cases of non-Hodgkin lymphoma were identified through computer matching among cohort members residing in the San Francisco Bay area from 1978 through 1989. Among the HIV-infected men, the age-adjusted standardized morbidity ratio was 5.0 (95% Cl, 2.0 to 10.3) for Hodgkin disease and 37.7 (Cl, 30.3 to 46.7) for non-Hodgkin lymphoma. The excess risk attributable to HIV infection was 19.3 cases of Hodgkin disease per 100 000 person-years and 224.9 cases of non-Hodgkin lymphoma per 100 000 person-years. Conclusion: An excess incidence of Hodgkin disease was found in HIV-infected homosexual men. Additional well-designed epidemiologic studies are needed to determine whether Hodgkin disease should be considered an HIV-related malignancy.	SAN FRANCISCO DEPT PUBL HLTH, SAN FRANCISCO, CA USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, ATLANTA, GA 30333 USA	San Francisco Department of Public Health; Centers for Disease Control & Prevention - USA					PHS HHS [U64/CCU900523-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUCHBINDER S, 1991, 7 INT C AIDS FLOR, P33; BYERS RH, 1988, AIDS, V2, P207; GARNIER G, 1991, ANN INTERN MED, V115, P233, DOI 10.7326/0003-4819-115-3-233_1; HESSOL NA, 1989, AM J EPIDEMIOL, V130, P1167, DOI 10.1093/oxfordjournals.aje.a115445; MONFARDINI S, 1988, JNCI-J NATL CANCER I, V80, P855, DOI 10.1093/jnci/80.11.855; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; RABKIN CS, 1991, INT J CANCER, V47, P692, DOI 10.1002/ijc.2910470511; RABKIN CS, 1992, JAMA-J AM MED ASSOC, V267, P1090, DOI 10.1001/jama.267.8.1090; ROITHMANN S, 1990, NEW ENGL J MED, V323, P275; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SERRANO M, 1990, CANCER-AM CANCER SOC, V65, P2248, DOI 10.1002/1097-0142(19900515)65:10<2248::AID-CNCR2820651015>3.0.CO;2-W; TIRELLI U, 1988, ANN INTERN MED, V108, P309, DOI 10.7326/0003-4819-108-2-309_2; 1987, MMWR, V36, pS1; 1990, SEER CANCER REGISTRY	14	138	138	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					309	311		10.7326/0003-4819-117-4-309	http://dx.doi.org/10.7326/0003-4819-117-4-309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637026				2022-12-24	WOS:A1992JH46400007
J	GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB				GLUCKSMANN, MA; MARKIEWICZ, P; MALONE, C; ROTHMANDENES, LB			SPECIFIC SEQUENCES AND A HAIRPIN STRUCTURE IN THE TEMPLATE STRAND ARE REQUIRED FOR N4-VIRION RNA-POLYMERASE PROMOTER RECOGNITION	CELL			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION INITIATION; OPEN COMPLEX; IDENTIFICATION; PURIFICATION; MECHANISM; KINETICS; INTERACT; ELEMENTS; LOOP	Coliphage N4 virion-encapsidated, DNA-dependent RNA polymerase (vRNAP) is inactive on double-stranded N4 DNA; however, denatured promoter-containing templates are accurately transcribed. We report that all determinants of vRNAP promoter recognition exist in the template strand, indicating that this enzyme is a site-specific, single-stranded DNA-binding protein. We show that conserved sequences and the integrity of inverted repeats present at the promoters are essential for activity, suggesting the necessity for specific secondary structure. Evidence for such a structure is presented. We propose a model for in vivo utilization of vRNAP promoters in which template negative supercoiling yields single-strandedness at the promoter to reveal the determinants of vRNAP binding. This structure is stabilized by the binding of E. coli single-stranded DNA-binding protein to yield an "activated promoter."	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NIAID NIH HHS [AI 07099, AI 12575] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07183] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007183] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEN MD, 1983, METHOD ENZYMOL, V101, P90; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Chamberlin M., 1982, ENZYMES, V15, P87; COWING DW, 1989, J MOL BIOL, V210, P521, DOI 10.1016/0022-2836(89)90128-9; CRICK F, 1971, NATURE, V234, P25, DOI 10.1038/234025a0; DEMASSY B, 1987, J MOL BIOL, V193, P359, DOI 10.1016/0022-2836(87)90224-5; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; FALCO SC, 1978, P NATL ACAD SCI USA, V75, P3220, DOI 10.1073/pnas.75.7.3220; FALCO SC, 1980, J BIOL CHEM, V255, P4339; FALCO SC, 1977, P NATL ACAD SCI USA, V74, P520, DOI 10.1073/pnas.74.2.520; FEAVERS IM, 1989, J BIOL CHEM, V264, P9114; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GEIDER K, 1974, J BIOL CHEM, V249, P3999; GERMANN MW, 1990, NUCLEIC ACIDS RES, V18, P1489, DOI 10.1093/nar/18.6.1489; GRACHEV MA, 1986, FEBS LETT, V200, P287, DOI 10.1016/0014-5793(86)81154-1; GUALBERTO A, 1992, GENE DEV, V6, P815, DOI 10.1101/gad.6.5.815; GUINTA D, 1986, VIROLOGY, V150, P33, DOI 10.1016/0042-6822(86)90263-1; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HAYNES LL, 1985, CELL, V41, P597, DOI 10.1016/S0092-8674(85)80032-5; HIASA H, 1990, NUCLEIC ACIDS RES, V18, P4825, DOI 10.1093/nar/18.16.4825; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; KIINO DR, 1988, BACTERIOPHAGES, V2, P457; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; Maniatis T., 1982, MOL CLONING; MARKIEWICZ P, 1988, NUCLEIC ACIDS RES, V16, P1011, DOI 10.1093/nar/16.3.1011; MARKIEWICZ P, 1992, IN PRESS GENES DEV; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242; STEFANO JE, 1982, P NATL ACAD SCI-BIOL, V79, P1069, DOI 10.1073/pnas.79.4.1069; TAKASE H, 1991, BIOCHEM BIOPH RES CO, V176, P1593, DOI 10.1016/0006-291X(91)90470-R; VANDERLAAN K, 1977, VIROLOGY, V76, P596, DOI 10.1016/0042-6822(77)90241-0; VOS JC, 1991, CELL, V65, P105, DOI 10.1016/0092-8674(91)90412-R; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YEE HA, 1991, NUCLEIC ACIDS RES, V19, P949, DOI 10.1093/nar/19.4.949; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZEHRING WA, 1983, J BIOL CHEM, V258, P8074; ZIVIN R, 1981, J MOL BIOL, V152, P335, DOI 10.1016/0022-2836(81)90246-1	49	74	76	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					491	500		10.1016/0092-8674(92)90173-A	http://dx.doi.org/10.1016/0092-8674(92)90173-A			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643660				2022-12-24	WOS:A1992JH12400014
J	SAUNDERS, WS; HOYT, MA				SAUNDERS, WS; HOYT, MA			KINESIN-RELATED PROTEINS REQUIRED FOR STRUCTURAL INTEGRITY OF THE MITOTIC SPINDLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; MICROBEAM IRRADIATIONS; GENE; DROSOPHILA; MOTOR; MICROTUBULES; SEGREGATION	For S. cerevisiae cells, the assembly of a bipolar mitotic spindle requires the action of either Cin8p or Kip1p, gene products related to the mechanochemical enzyme kinesin. In this paper we demonstrate that the activity of either one of these proteins is also required following spindle assembly. When their function was eliminated, preanaphase bipolar spindles rapidly collapsed, with previously separated poles being drawn together. In contrast, anaphase spindles were apparently resistant to collapse. Deletion of kinesin-related KAR3 partially suppressed the phenotypes associated with loss of Cin8p/Kip1p function. Our findings suggest that the structure of the preanaphase bipolar spindle is maintained by counteracting forces produced by kinesin-related proteins.			SAUNDERS, WS (corresponding author), JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218, USA.				NIGMS NIH HHS [GM40714] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040714] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HOGAN CJ, 1990, CELL MOTIL CYTOSKEL, V16, P99, DOI 10.1002/cm.970160203; HOYT MA, 1992, IN PRESS J CELL BIOL; HYAMS JS, 1989, MITOSIS MOL MECHANIS; INOUE S, 1981, J CELL BIOL, V91, pS131, DOI 10.1083/jcb.91.3.131s; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; LAFOUNTAIN JR, 1972, J CELL SCI, V10, P79; LESLIE RJ, 1983, J CELL BIOL, V96, P548, DOI 10.1083/jcb.96.2.548; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; McDonald K., 1989, MITOSIS MOL MECHANIS, P1; MCDONALD KL, 1979, J CELL BIOL, V83, P443, DOI 10.1083/jcb.83.2.443; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCNEILL PA, 1981, J CELL BIOL, V88, P543, DOI 10.1083/jcb.88.3.543; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROOF DM, 1992, IN PRESS J CELL BIOL; ROSE MD, 1992, IN PRESS GUIDEBOOK C; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; Salmon ED, 1989, MITOSIS MOL MECHANIS, P119; Sherman F., 1983, METHODS YEAST GENETI; SNYDER J A, 1985, European Journal of Cell Biology, V39, P373; SPURCK TP, 1990, J CELL BIOL, V111, P1505, DOI 10.1083/jcb.111.4.1505; STEARNS T, 1990, GENETICS, V124, P251; TAYLOR EW, 1960, ANN NY ACAD SCI, V90, P430, DOI 10.1111/j.1749-6632.1960.tb23261.x; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WICKNER RB, 1987, YEAST, V3, P51, DOI 10.1002/yea.320030108	31	330	335	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					451	458		10.1016/0092-8674(92)90169-D	http://dx.doi.org/10.1016/0092-8674(92)90169-D			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643659				2022-12-24	WOS:A1992JH12400010
J	SCHNEEWIND, O; MODEL, P; FISCHETTI, VA				SCHNEEWIND, O; MODEL, P; FISCHETTI, VA			SORTING OF PROTEIN-A TO THE STAPHYLOCOCCAL CELL-WALL	CELL			English	Article							ESCHERICHIA-COLI K-12; MEMBRANE-PROTEIN; OUTER-MEMBRANE; ENDOPLASMIC-RETICULUM; BACILLUS-SUBTILIS; TRANSMEMBRANE PROTEINS; ALKALINE-PHOSPHATASE; CYTOPLASMIC DOMAIN; LEADER PEPTIDASE; BINDING PROTEIN	The cell wall of gram-positive bacteria can be thought of as representing a unique cell compartment, which contains anchored surface proteins that require specific sorting signals. Some biologically important products are anchored in this way, including protein A and fibronectin binding protein of Staphylococcus aureus and streptococcal M protein. Studies of staphylococcal protein A and Escherichia coli alkaline phosphatase show that the signal both necessary and sufficient for cell wall anchoring consists of an LPXTGX motif, a C-terminal hydrophobic domain, and a charged tail. These sequence elements are conserved in many surface proteins from different gram-positive bacteria. We propose the existence of a hitherto undescribed sorting mechanism that positions proteins on the surface of gram-positive bacteria.			SCHNEEWIND, O (corresponding author), ROCKEFELLER UNIV,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011822, R01AI011822] Funding Source: NIH RePORTER; NIAID NIH HHS [AI11822] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; ANDERSSON H, 1991, P NATL ACAD SCI USA, V88, P9751, DOI 10.1073/pnas.88.21.9751; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; BRAUN V, 1970, BIOCHEMISTRY-US, V9, P5041, DOI 10.1021/bi00828a001; BRAUN V, 1970, EUR J BIOCHEM, V13, P336, DOI 10.1111/j.1432-1033.1970.tb00936.x; BRISSETTE JL, 1990, J MOL BIOL, V211, P565, DOI 10.1016/0022-2836(90)90266-O; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG S, 1979, MOL GEN GENET, V168, P111, DOI 10.1007/BF00267940; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GAREN A, 1955, VIROLOGY, V1, P347, DOI 10.1016/0042-6822(55)90030-1; GENNITY JM, 1991, J BIOL CHEM, V266, P16458; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GOBER JW, 1991, CELL, V64, P381, DOI 10.1016/0092-8674(91)90646-G; GOMI H, 1990, J IMMUNOL, V144, P4046; GUSS B, 1984, EUR J BIOCHEM, V138, P413, DOI 10.1111/j.1432-1033.1984.tb07931.x; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOSEFSSON LG, 1981, J BIOL CHEM, V256, P2504; KAUFMAN MR, 1991, GENE DEV, V5, P1834, DOI 10.1101/gad.5.10.1834; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KORONAKIS V, 1991, EMBO J, V10, P3263, DOI 10.1002/j.1460-2075.1991.tb04890.x; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUROKI K, 1989, MOL CELL BIOL, V9, P4459, DOI 10.1128/MCB.9.10.4459; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOEWY ZG, 1987, GENE DEV, V1, P626, DOI 10.1101/gad.1.6.626; LOFDAHL S, 1983, P NATL ACAD SCI-BIOL, V80, P697, DOI 10.1073/pnas.80.3.697; MACALISTER TJ, 1983, P NATL ACAD SCI-BIOL, V80, P1372, DOI 10.1073/pnas.80.5.1372; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCGOVERN K, 1991, J BIOL CHEM, V266, P20870; MODEL P, 1990, CELL, V61, P739, DOI 10.1016/0092-8674(90)90180-M; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; MURPHY E, 1981, PLASMID, V5, P292, DOI 10.1016/0147-619X(81)90006-8; NILSSON B, 1990, METHOD ENZYMOL, V185, P144; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NOVICK R, 1967, VIROLOGY, V33, P155, DOI 10.1016/0042-6822(67)90105-5; Novick R.P., 1990, MOL BIOL STAPHYLOCOC; NOVICK RP, 1979, PLASMID, V2, P109, DOI 10.1016/0147-619X(79)90010-6; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PATEE PA, 1961, CAN J MICROBIOL, V82, P875; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PROJAN SJ, 1987, J BACTERIOL, V169, P5131, DOI 10.1128/jb.169.11.5131-5139.1987; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P365, DOI 10.1111/j.1365-2958.1990.tb00604.x; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1986, METHOD ENZYMOL, V125, P129; RANDALL LL, 1983, CELL, V33, P231, DOI 10.1016/0092-8674(83)90352-5; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1990, J BACTERIOL, V172, P3310, DOI 10.1128/jb.172.6.3310-3317.1990; SHOCKMAN GD, 1983, ANNU REV MICROBIOL, V37, P501, DOI 10.1146/annurev.mi.37.100183.002441; SHORTLE D, 1983, GENE, V22, P181, DOI 10.1016/0378-1119(83)90102-6; SHUTTLEWORTH H, 1986, NUCLEIC ACIDS RES, V14, P8689, DOI 10.1093/nar/14.21.8689; SJODAHL J, 1977, EUR J BIOCHEM, V78, P471, DOI 10.1111/j.1432-1033.1977.tb11760.x; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; SJOQUIST J, 1972, EUR J BIOCHEM, V29, P572, DOI 10.1111/j.1432-1033.1972.tb02023.x; SJOQUIST J, 1972, EUR J BIOCHEM, V30, P190, DOI 10.1111/j.1432-1033.1972.tb02086.x; STANLEY P, 1991, MOL MICROBIOL, V5, P2391, DOI 10.1111/j.1365-2958.1991.tb02085.x; STIRZAKER SC, 1989, CELL, V56, P741, DOI 10.1016/0092-8674(89)90677-6; STROM MS, 1987, J BACTERIOL, V169, P3181, DOI 10.1128/jb.169.7.3181-3188.1987; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TWETEN RK, 1983, J BACTERIOL, V153, P297, DOI 10.1128/JB.153.1.297-303.1983; UHLEN M, 1984, J BACTERIOL, V159, P713; UHLEN M, 1984, J BIOL CHEM, V259, P1695; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VONHEIJNE G, 1988, P NATL ACAD SCI USA, V85, P3363; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WU CH, 1971, INFECT IMMUN, V3, P784, DOI 10.1128/IAI.3.6.784-792.1971; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1984, J BIOL CHEM, V259, P6013	93	446	468	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 24	1992	70	2					267	281		10.1016/0092-8674(92)90101-H	http://dx.doi.org/10.1016/0092-8674(92)90101-H			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638631				2022-12-24	WOS:A1992JE75700010
J	DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR				DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR			CRYSTAL-STRUCTURE OF TRANSFORMING GROWTH-FACTOR-BETA-2 - AN UNUSUAL FOLD FOR THE SUPERFAMILY	SCIENCE			English	Article							DEOXYRIBONUCLEIC-ACID CLONING; MESSENGER RIBONUCLEIC-ACID; X-RAY-DIFFRACTION; FACTOR-BETA; EMBRYO CHONDROCYTES; IDENTIFICATION; PURIFICATION	The transforming growth factors-beta (TGF-beta-1 through -beta-5) are a family of homodimeric cytokines that regulate proliferation and function in many cell types. Family members have 66 to 80% sequence identity and nine strictly conserved cysteines. A crystal structure of a member of this family, TGF-beta-2, has been determined at 2.1 angstrom (angstrom) resolution and refined to an R factor of 0.172. The monomer lacks a well-defined hydrophobic core and displays an unusual elongated nonglobular fold with dimensions of approximately 60 angstrom by 20 angstrom by 15 angstrom. Eight cysteines form four intrachain disulfide bonds, which are clustered in a core region forming a network complementary to the network of hydrogen bonds. The dimer is stabilized by the ninth cysteine, which forms an interchain disulfide bond, and by two identical hydrophobic interfaces. Sequence profile analysis of other members of the TGF-beta superfamily, including the activins, inhibins, and several developmental factors, imply that they also adopt the TGF-beta fold.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIH,FOGARTY INT CTR,BETHESDA,MD 20892; CELTRIX PHARMACEUT INC,SANTA CLARA,CA 95052	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)								ARCHER S, COMMUNICATION; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BHAT TN, BROOKHAVEN PROTEIN D; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P1186, DOI 10.1210/mend-2-12-1186; JOHNSON CK, 1970, ORTEP FORTRAN THERMA; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OGAWA Y, COMMUNICATION; PIEZ KA, 1990, TRANSFORMING GROWTH, P593; QIAN SW, IN PRESS P NATL ACAD; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	40	394	436	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					369	373		10.1126/science.1631557	http://dx.doi.org/10.1126/science.1631557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631557	Green Submitted			2022-12-24	WOS:A1992JD67400028
J	MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR				MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR			THE PIE-1 AND MEX-1 GENES AND MATERNAL CONTROL OF BLASTOMERE IDENTITY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GERM-LINE; CELLULAR INTERACTIONS; GLP-1; SEGREGATION; GRANULES; LIN-12; MUSCLE; NOTCH; LOCUS	During C. elegans embryogenesis an 8-cell stage blastomere, called MS, undergoes a reproducible cleavage pattern, producing pharyngeal cells, body wall muscles, and cell deaths. We show here that maternal-effect mutations in the pie-1 and mex-1 genes cause additional 8-cell stage blastomeres to adopt a fate very similar to that of the wild-type MS blastomere. In pie-1 mutants one additional posterior blastomere adopts an MS-like fate, and in mex-1 mutants four additional anterior blastomeres adopt an MS-like fate. We propose that maternally provided pie-1(+) and mex-1(+) gene products may function in the early embryo to localize or regulate factors that determine the fate of the MS blastomere.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	MELLO, CC (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Krause, Michael/0000-0001-6127-3940; Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOSSETT LA, 1982, CELL, V30, P193, DOI 10.1016/0092-8674(82)90025-3; GREENWALD IS, 1985, CELL, V45, P583; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1984, DEV BIOL, V101, P240, DOI 10.1016/0012-1606(84)90136-2; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YAMAGUCHI Y, 1983, DEV GROWTH DIFFER, V25, P121; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	36	207	217	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					163	176		10.1016/0092-8674(92)90542-K	http://dx.doi.org/10.1016/0092-8674(92)90542-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623520				2022-12-24	WOS:A1992JC95700017
J	NAKAYAMA, K; LOH, DY				NAKAYAMA, K; LOH, DY			NO REQUIREMENT FOR P56(LCK) IN THE ANTIGEN-STIMULATED CLONAL DELETION OF THYMOCYTES	SCIENCE			English	Article							T-CELL-RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; HERBIMYCIN-A; INHIBITION; ACTIVATION; CD4; IA	Activation of protein-tyrosine kinases (PTKs) is required for signal transduction during T cell activation, although the pathway used during thymic selection is unknown. An in vitro system was established in which T cell receptor transgenic thymocytes underwent clonal deletion in response to peptide antigen. The effects of two PTK-specific inhibitors, herbimycin A and genistein, on the clonal deletion of immature thymocytes and the activation of mature thymocytes were examined. Clonal deletion occurred while T cell activation was inhibited and when no p56lck activity was evident. Thus, p56lck is not required for the antigen-stimulated step of clonal deletion of immature thymocytes, and negative selection proceeds via a distinct pathway.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; IWABUCHI K, IN PRESS P NATL ACAD; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH DY, 1991, NEW BIOL, V3, P924; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA K, UNPUB; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARK DJ, 1991, J BIOL CHEM, V266, P16277; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TANTI JF, 1991, J BIOL CHEM, V266, P2099; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	27	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					94	96		10.1126/science.1621101	http://dx.doi.org/10.1126/science.1621101			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621101				2022-12-24	WOS:A1992JC16500038
J	FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A				FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A			QUANTIFICATION OF THE DISORDER IN NETWORK-MODIFIED SILICATE-GLASSES	NATURE			English	Article							BOND-ANGLE DISTRIBUTION; VITREOUS SILICA; O-17 NMR; TEMPERATURE; DYNAMICS; SOLIDS; NUCLEI; TIME	Local order in silicate glasses has been observed by many experimental techniques to be similar to that in crystalline materials. Details of the intermediate-range order are more elusive, but essential for understanding the lack of long-range symmetry in glasses and the effect of composition on glass structure. Two-dimensional O-17 dynamic-angle-spinning nuclear magnetic resonance experiments reveal intermediate-range order in the distribution of inter-tetrahedral (Si-O-Si) bond angles and a high degree of order in the disposition of oxygen atoms around the network-modifying cations.	LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	FARNAN, I (corresponding author), STANFORD UNIV,DEPT GEOL,STANFORD,CA 94305, USA.		Baltisberger, Jay/C-8340-2019; Farnan, Ian/M-3881-2014; Grandinetti, Philip J/F-1084-2010	Baltisberger, Jay/0000-0003-2305-0046; Farnan, Ian/0000-0001-7844-5112; Grandinetti, Philip J/0000-0003-0102-316X; Stebbins, Jonathan/0000-0002-2384-6637				CHMELKA BF, 1989, NATURE, V339, P42, DOI 10.1038/339042a0; COHEN MH, 1957, SOLID STATE PHYS, V5, P321, DOI 10.1016/S0081-1947(08)60105-8; Dupree R, 1984, NATURE, V308, P523, DOI 10.1038/308523a0; DUPREE R, 1984, J NON-CRYST SOLIDS, V68, P399, DOI 10.1016/0022-3093(84)90020-6; EASTMAN MA, IN PRESS J MAGN RESO; ECKERSLEY MC, 1988, NATURE, V335, P525, DOI 10.1038/335525a0; ENGELHARDT G, 1984, CHEM PHYS LETT, V108, P271, DOI 10.1016/0009-2614(84)87063-3; FARNAN I, 1990, J AM CHEM SOC, V112, P32, DOI 10.1021/ja00157a008; GASKELL PH, 1991, NATURE, V350, P675, DOI 10.1038/350675a0; GEISSBERGER AE, 1983, J NON-CRYST SOLIDS, V54, P121, DOI 10.1016/0022-3093(83)90087-X; GLADDEN LF, 1986, PHILOS MAG B, V53, pL81, DOI 10.1080/01418638608244284; GREAVES GN, 1981, NATURE, V293, P611, DOI 10.1038/293611a0; GREAVES GN, 1990, GLASS SCI TECHNOLO B, V4, P1; HUANG CD, 1991, J CHEM PHYS, V95, P3634, DOI 10.1063/1.460814; Kirkpatrick R. J., 1986, STRUCTURE BONDING NO; LLOR A, 1988, CHEM PHYS LETT, V152, P248, DOI 10.1016/0009-2614(88)87362-7; MELMAN H, 1991, J NON-CRYST SOLIDS, V134, P107, DOI 10.1016/0022-3093(91)90017-Z; MOZZI RL, 1969, J APPL CRYSTALLOGR, V2, P164, DOI 10.1107/S0021889869006868; MUELLER KT, 1990, J MAGN RESON, V86, P470, DOI 10.1016/0022-2364(90)90025-5; MUELLER KT, IN PRESS J PHYS CHEM; NEWTON MD, 1980, PHYS CHEM MINER, V6, P221, DOI 10.1007/BF00309858; PETTIFER RF, 1988, J NON-CRYST SOLIDS, V106, P408, DOI 10.1016/0022-3093(88)90299-2; SAMOSON A, 1988, MOL PHYS, V65, P1013, DOI 10.1080/00268978800101571; SCHWEINSBERG H, 1974, ACTA CRYSTALLOGR B, V30, P2206, DOI 10.1107/S0567740874006753; SOULES TF, 1979, J CHEM PHYS, V71, P4570, DOI 10.1063/1.438210; SPEARING DR, IN PRESS PHYS CHEM M; STEBBINS JF, 1991, NATURE, V351, P638, DOI 10.1038/351638a0; STEBBINS JF, 1988, J NON-CRYST SOLIDS, V106, P359, DOI 10.1016/0022-3093(88)90289-X; TESAR AA, 1987, J CHEM PHYS, V87, P2986, DOI 10.1063/1.453034; TOSSELL JA, 1988, PHYS CHEM MINER, V15, P564, DOI 10.1007/BF00311027; VESSAL B, 1992, NATURE, V356, P504, DOI 10.1038/356504a0; XUE X, 1991, T AM GEOPHYS UN, V72, P572	32	231	231	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					31	35		10.1038/358031a0	http://dx.doi.org/10.1038/358031a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614527				2022-12-24	WOS:A1992JB34100043
J	TSANEVA, IR; MULLER, B; WEST, SC				TSANEVA, IR; MULLER, B; WEST, SC			ATP-DEPENDENT BRANCH MIGRATION OF HOLLIDAY JUNCTIONS PROMOTED BY THE RUVA AND RUVB PROTEINS OF ESCHERICHIA-COLI	CELL			English	Article							STRAND EXCHANGE-REACTIONS; ESCHERICHIA-COLI; RECA PROTEIN; DNA-REPAIR; ENZYMATIC FORMATION; K-12 REVEALS; RECOMBINATION; PURIFICATION; RESOLUTION; MOLECULES	The RuvA and RuvB proteins of E. coli, which are induced as part of the cellular response to DNA damage, act together to promote the branch migration of Holliday junctions. Addition of purified RuvA and RuvB to a RecA-mediated recombination reaction stimulates the rate of strand exchange and the formation of heteroduplex DNA. Stimulation does not occur via interaction with RecA; instead, RuvA and RuvB act directly upon recombination intermediates (Holliday junctions) made by RecA. We show that RuvAB-mediated branch migration requires ATP and can bypass UV-induced DNA lesions. At high RuvB concentrations, the requirement for RuvA is overcome, indicating that the RuvB ATPase provides the motor force for branch migration. RuvA protein provides specificity by binding to the Holliday junction, thereby reducing the requirement for RuvB by 50-fold. The newly discovered biochemical properties of RuvA, RuvB, and RuvC are incorporated into a model for the postreplicational repair of DNA following UV irradiation.			TSANEVA, IR (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418; Muller, Berndt/0000-0003-1279-5421				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CLARK AJ, 1988, RECOMBINATION GENETI, P155; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; HAHN TR, 1988, J BIOL CHEM, V263, P7431; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.biophys.20.1.539; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1991, J BIOL CHEM, V266, P19028; MULLER B, 1992, IN PRESS EMBO J; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1992, IN PRESS P NATL ACAD; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TSANEVA IR, 1992, IN PRESS MOL GEN GEN; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	44	240	240	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1171	1180		10.1016/0092-8674(92)90638-S	http://dx.doi.org/10.1016/0092-8674(92)90638-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617728				2022-12-24	WOS:A1992JA43100011
J	ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S				ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S			EFFECT OF SEROTESTING WITH COUNSELING ON CONDOM USE AND SEROCONVERSION AMONG HIV DISCORDANT COUPLES IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HETEROSEXUAL TRANSMISSION; SEXUAL PARTNERS; UNITED-STATES; RISK; INFECTION; AIDS; MEN; ALCOHOL; FEMALE	Objective-To determine whether HIV testing and counselling increased condom use and decreased heterosexual transmission of HIV in discordant couples. Design-Prospective study. Setting-Kigali, the capital of Rwanda. Subjects-Cohabiting couples with discordant HIV serology results. Main outcome measures-Condom use in the couple and HIV seroconversion in the negative partners. Results-60 HIV discordant couples were identified, of whom 53 were followed for an average of 2.2 years. The proportion of discordant couples using condoms increased from 4% to 57% after one year of follow up. During follow up two of the 23 HIV negative men and six of the 30 HIV negative women seroconverted (seroconversion rates of 4 and 9 per 100 person years). The rate among women was less than half that estimated for similar women in discordant couples whose partners had not been serotested. Condom use was less common among those who seroconverted (100% v 5%, p=0.01 in men; 67% v 25%, p=0.14 in women). Conclusions-Roughly one in seven cohabiting couples in Kigali have discordant HIV serological results. Confidential HIV serotesting with counselling caused a large increase in condom use and was associated with a lower rate of new HIV infections. HIV testing is a promising intervention for preventing the spread of HIV in African cities.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; PROJET SAN FRANCISCO,KIGALI,RWANDA; MINISTRY HLTH,KIGALI,RWANDA; NATL AIDS CONTROL PROGRAM,KIGALI,RWANDA; CTR HOSP KIGALI,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427; Tice, Jeffrey/0000-0002-9857-2028	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; CAMERON DW, 1989, LANCET, V2, P403; CARAEL M, 1988, AIDS, V2, P201; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; Cochran W.G, 1957, STAT METHODS, V6th ed; FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P83; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; Johnson NL, 1969, DISTRIBUTIONS STAT D; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAMENGA M, 1989, 5 INT C AIDS MONTR; KING R, 1991, LANCET, V338, P1278, DOI 10.1016/0140-6736(91)92149-V; KREISS J, 1985, ANN INTERN MED, V102, P632; LAGA M, 1989, AIDS, V3, P361, DOI 10.1097/00002030-198906000-00004; LARSON A, 1989, REV INFECT DIS, V11, P716; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; Laurian Y., 1989, New England Journal of Medicine, V321, P268; LAWRENCE DN, 1989, AM J HEMATOL, V30, P68, DOI 10.1002/ajh.2830300204; MANN J, 1987, NEW ENGL J MED, V316, P345; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PERRONI L, 1989, 5 INT C AIDS MONTR; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; ROBERTSON JA, 1988, DRUG ALCOHOL DEPEN, V22, P75, DOI 10.1016/0376-8716(88)90039-7; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Sheehan A, 1990, Nursing (Lond), V4, P13; SILVESTRE AJ, 1989, AIDS, V3, P647, DOI 10.1097/00002030-198910000-00005; SMILEY ML, 1988, AM J HEMATOL, V28, P27, DOI 10.1002/ajh.2830280106; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; 1989, BMJ, V298, P411	38	369	375	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1605	1609		10.1136/bmj.304.6842.1605	http://dx.doi.org/10.1136/bmj.304.6842.1605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628088	Green Published, Bronze			2022-12-24	WOS:A1992JA43600021
J	PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F				PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F			TOXICITY OF NORPETHIDINE IN SICKLE-CELL CRISIS	BRITISH MEDICAL JOURNAL			English	Article							MEPERIDINE; CANCER		ST THOMAS HOSP,DEPT ANAESTHESIA,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; MITCHELL A, 1991, BRIT MED J, V303, P249, DOI 10.1136/bmj.303.6796.249-a; REYNOLDS F, 1968, BRIT J PHARMACOL, V20, P704; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; Tang R, 1980, HOSP FORMUL, V15, P764	5	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1478	1479		10.1136/bmj.304.6840.1478	http://dx.doi.org/10.1136/bmj.304.6840.1478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611370	Green Published, Bronze			2022-12-24	WOS:A1992HY55300023
J	KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ				KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ			NF-KAPPA-B SUBUNIT REGULATION IN NONTRANSFORMED CD4+ LYMPHOCYTES-T	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; HUMAN INTERLEUKIN-2 GENE; DNA-BINDING SUBUNIT; PROTEIN-BINDING; REL ONCOGENE; EXPRESSION; ENHANCER; ACTIVATION; IDENTIFICATION; TRANSCRIPTION	Regulation of interleukin-2 (IL-2) gene expression by the p50 and p65 subunits of the DNA binding protein NF-kappa-B was studied in nontransformed CD4+ T lymphocyte clones. A homodimeric complex of the NF-kappa-B p50 subunit was found in resting T cells. The amount of p50-p50 complex decreased after full antigenic stimulation, whereas the amount of the NF-kappa-B p50-p65 heterodimer was increased. Increased expression of the IL-2 gene and activity of the IL-2 kappa-B DNA binding site correlated with a decrease in the p50-p50 complex. Overexpression of p50 repressed IL-2 promoter expression. The switch from p50-p50 to p50-p65 complexes depended on a protein that caused sequestration of the p50-p50 complex in the nucleus.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			grilli, mariagrazia/ABF-1542-2020	grilli, mariagrazia/0000-0001-9165-5827				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOURS V, 1992, MOL CELL BIOL, V12, P682; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHIU JJS, UNPUB; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; EMMEL EA, 1989, SCIENCE, V246, P617; FATHMAN CG, 1989, FUNDAMENTAL IMMUNOLO, P803; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; GRILLI MG, 1991, CYTOKINE, V3, P372; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HECHT TT, 1983, J IMMUNOL, V131, P1049; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; JAMIESON C, 1991, J IMMUNOL, V147, P416; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Kang S.-G., UNPUB; KANG SM, IN PRESS MOL CELL BI; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO M, UNPUB; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUELLER DL, 1990, J IMMUNOL, V144, P3701; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; RADLER-POHL A, 1990, New Biologist, V2, P566; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P675; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THOMPSON CC, 1991, SCIENCE, V253, P672; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	66	313	330	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1452	1456		10.1126/science.1604322	http://dx.doi.org/10.1126/science.1604322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604322				2022-12-24	WOS:A1992HX33700038
J	WECHSLER, H; ISAAC, N				WECHSLER, H; ISAAC, N			BINGE DRINKERS AT MASSACHUSETTS COLLEGES - PREVALENCE, DRINKING STYLE, TIME TRENDS, AND ASSOCIATED PROBLEMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							CONSUMPTION	Objective. --To compare drinking patterns among college freshmen with those found among students at similar schools 12 years ago, and to describe in detail the differences between "binge" drinkers and "nonbinge" drinkers. Design. --Mailed survey. Setting. --Fourteen 4-year colleges in Massachusetts. Participants. --A total of 1669 first-year college students. Main Outcome Measures. --The survey instrument contains a variety of self-report measures of drinking behaviors, attitudes, and consequences. "Binge" drinking is defined as the consumption of five or more drinks on one or more occasions in the past 2 weeks. Main Results. --The proportion of "frequent-heavy" drinkers remained constant between the 1977 and 1989 surveys (30% vs 31% of men; 13% vs 14% of women), but today's students get intoxicated more often and are more motivated to drink to get drunk. The proportion of students who said "to get drunk" was a "somewhat" or "very important" reason for drinking was two to three times as high in 1989 as in 1977. Among students surveyed in 1989, binge drinkers drank greater quantities, with greater regularity, and experienced more intoxication and alcohol-associated problems than did nonbinge drinkers. Close to half of the binge drinkers (46.5% of men, 48.3% of women) were drunk twice or more in the past month, compared with 5% or fewer of the nonbinge drinkers. Conclusions. --The stability over time of the prevalence of frequent heavy drinking among college students indicates an apparent failure of both social and institutional policies to alter this behavior. Binge drinkers in particular appear to be a population whose drinking patterns and attitudes place them and those around them at increased risk for adverse consequences.	HARVARD UNIV,SCH PUBL HLTH,CTR INJURY CONTROL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	WECHSLER, H (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.							ENGS RC, 1988, PUBLIC HEALTH REP, V103, P667; JOHNSTON LD, 1991, DRUG USE AM HIGH SCH, V2; MEILMAN PW, 1990, J STUD ALCOHOL, V51, P389, DOI 10.15288/jsa.1990.51.389; OHARE TM, 1990, J STUD ALCOHOL, V51, P536, DOI 10.15288/jsa.1990.51.536; REINISCH OJ, 1991, N3189CHF RAND CORP P; ROOM R, 1971, DRINKING DRUG PRACTI, V3, P15; Straus R, 1953, DRINKING IN COLLEGE; WECHSLER H, 1979, J STUD ALCOHOL, V40, P969, DOI 10.15288/jsa.1979.40.969; WECHSLER H, 1991, ALCOHOL COLLEGE FRES; 1990, ALCOHOL HLTH; 1990, CAMPUS LIFE SEARCH C	11	213	213	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	1992	267	21					2929	2931						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HW133	1583763				2022-12-24	WOS:A1992HW13300031
J	SCHULTZ, MC; REEDER, RH; HAHN, S				SCHULTZ, MC; REEDER, RH; HAHN, S			VARIANTS OF THE TATA-BINDING PROTEIN CAN DISTINGUISH SUBSETS OF RNA POLYMERASE-I, POLYMERASE-II, AND POLYMERASE-III PROMOTERS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENES	Transcription extracts prepared from yeast that are deficient in the TATA-binding protein (TBP or TFIID) are also impaired in specific promoter recognition by all three nuclear RNA polymerases (pol I, II, and III). Specific initiation can be rescued by the addition of purified recombinant TBP, demonstrating that pol I, II, and III all require this factor, A mutation of TBP has been identified that will function with pol I but not with pol II or III. Conversely, another mutation, which inactivates TATA element binding in vitro, will function with pol I and III promoters but is inactive for a pol II promoter. Thus, it is possible to identify TBP variants that will only function on different subsets of all nuclear promoters.			SCHULTZ, MC (corresponding author), HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BELL GI, 1977, J BIOL CHEM, V252, P8118; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; CHOE SY, 1992, NUCLEIC ACIDS RES, V20, P279, DOI 10.1093/nar/20.2.279; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEIDUSCHEK P, 1992, IN PRESS TRANSCRIPTI; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HOEY T, 1990, CELL, V61, P1179, DOI 10.1016/0092-8674(90)90682-5; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; KLEKAMP MS, 1982, J BIOL CHEM, V257, P8432; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; POON D, 1991, MOL CELL BIOL, V11, P4809, DOI 10.1128/MCB.11.10.4809; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REDDY P, 1991, CELL, V65, P349, DOI 10.1016/0092-8674(91)90168-X; REEDER RH, 1992, IN PRESS TRANSCRIPTI; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STRUBIN M, 1992, CELL, V68, P721, DOI 10.1016/0092-8674(92)90147-5; ZAWEL L, 1992, IN PRESS PROGR NUCLE; ZHOU Q, 1991, EMBO J, V10, P1843, DOI 10.1002/j.1460-2075.1991.tb07710.x	30	198	199	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					697	702		10.1016/0092-8674(92)90233-3	http://dx.doi.org/10.1016/0092-8674(92)90233-3			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586948				2022-12-24	WOS:A1992HV08900014
J	VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD				VALLEN, EA; SCHERSON, TY; ROBERTS, T; VANZEE, K; ROSE, MD			ASYMMETRIC MITOTIC SEGREGATION OF THE YEAST SPINDLE POLE BODY	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CA-2+-BINDING PROTEIN; CELL-CYCLE; GENE; DUPLICATION; TUBULIN; FUSIONS; CLONING; MUTANT; ACTIN	The yeast KAR1 gene is required for spindle pole body (SPB) duplication and nuclear fusion. We determine here that KAR1-beta-galactosidase hybrid proteins localize to the outer face of the SPB. Remarkably, after SPB duplication, the hybrid protein was found associated with only one of the two SPBs, usually the one that enters the bud. Using an ndc1 mutant, which forms a defective SPB at the nonpermissive temperature, we found that the hybrid was exclusively associated with the "new" SPB. Two regions of KAR1 contribute to its localization; an internal 70 residue region was necessary and sufficient to localize hybrids to the SPB, and the hydrophobic carboxyl terminus localized proteins to the nuclear envelope. The localization domains correspond to two functional domains required for SPB duplication. We suggest that KAR1 is anchored to the nuclear envelope and interacts with at least one other SPB component during the cell cycle.			VALLEN, EA (corresponding author), LEWIS THOMAS LAB, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA.			Rose, Mark/0000-0003-1112-4765	NIGMS NIH HHS [GM37739, R01 GM037739] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037739] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; BYERS B, 1973, COLD SPRING HARB SYM, V38, P123, DOI 10.1101/SQB.1974.038.01.016; BYERS B, 1981, MOL GENETICS YEAST, P119; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FINK GR, 1976, INT CELL BIOL 1976 1, P414; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KOCHANSKI RS, 1990, J CELL BIOL, V110, P1599, DOI 10.1083/jcb.110.5.1599; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; SHIM J, 1991, J CELL BIOL, V113, P55, DOI 10.1083/jcb.113.1.55; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; THOMAS JH, 1986, CELL, V44, P65, DOI 10.1016/0092-8674(86)90485-X; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; WINEY M, 1992, CENTROSOME, P201; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	36	89	90	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 1	1992	69	3					505	515		10.1016/0092-8674(92)90451-H	http://dx.doi.org/10.1016/0092-8674(92)90451-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HT078	1581964				2022-12-24	WOS:A1992HT07800012
J	HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE				HOSTETTER, MK; IVERSON, S; THOMAS, W; MCKENZIE, D; DOLE, K; JOHNSON, DE			MEDICAL EVALUATION OF INTERNATIONALLY ADOPTED-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYTOMEGALO-VIRUS INFECTION; HEPATITIS-B VIRUS; DAY-CARE; TRANSMISSION; TUBERCULOSIS; EPIDEMIOLOGY; PHYSICIANS; PREVALENCE; COUNTRIES; RISKS	Background. Despite many reports of medical illness in children adopted from abroad, there are currently no accepted guidelines for medical evaluation of this population. Methods. Two hundred ninety-three children adopted from 15 countries (mean age, 14.0 months; 55 percent girls) were evaluated by history taking, physical examination, and screening tests for hepatitis B virus (HBV), human immunodeficiency virus type 1, tuberculin reactivity, intestinal parasites, syphilis, excretion of cytomegalovirus, renal disease, and anemia. All but four were seen within one month of their arrival in the United States. Results. Fifty-seven percent of the children (168 of 293) were found to have at least one important medical condition. Eighty-one percent of the diagnoses were established by screening test, rather than by history taking or physical examination. Infectious diseases made up the majority of the medical conditions (73 percent). Serologic testing for hepatitis B surface antigen was positive in 5 percent of the children. Characteristics associated with the acquisition of HBV infection included arrival within the first three years of the study (P = 0.017), Asian origin (P = 0.011), and receipt of a blood transfusion abroad (P = 0.008). Ten children (3 percent) had positive Mantoux skin tests, and four of these had active pulmonary tuberculosis. Tuberculin reactivity was significantly associated with older age (P < 0.001) and lower weight (P = 0.037). Intestinal parasites were isolated from 14 percent of the international adoptees. Non-Korean adoptees were 16 times more likely to be harboring at least one intestinal parasite than were Korean adoptees (P = 0.005). Conclusions. Directed screening tests should be a routine component of the medical evaluation of all children adopted from abroad, regardless of age, sex, or country of origin.	UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	HOSTETTER, MK (corresponding author), UNIV MINNESOTA, DEPT PEDIAT, INT ADOPT CLIN, UMHC BOX 296, 420 DELAWARE ST SE, MINNEAPOLIS, MN 55455 USA.							AACH RD, 1987, TXB PEDIATRIC INFECT, V1, P718; ADLER SP, 1988, J PEDIATR-US, V112, P366, DOI 10.1016/S0022-3476(88)80314-7; BASS JL, IN PRESS PEDIATRICS; BLACK RE, 1977, PEDIATRICS, V60, P486; BLACKMAN JA, 1987, PEDIATR INFECT DIS J, V6, P1011, DOI 10.1097/00006454-198706110-00001; CHRISTENSON B, 1986, SCAND J INFECT DIS, V18, P105, DOI 10.3109/00365548609032315; FRIEDE A, 1988, AM J PUBLIC HEALTH, V78, P26, DOI 10.2105/AJPH.78.1.26; GREENBLATT M, 1985, NEW ENGL J MED, V312, P1639; HERSHOW RC, 1987, PEDIATR INFECT DIS J, V6, P431, DOI 10.1097/00006454-198705000-00002; HOSTETTER M, 1989, AM J DIS CHILD, V143, P325, DOI 10.1001/archpedi.1989.02150150079022; HOSTETTER MK, 1989, PEDIATRICS, V83, P559; HOSTETTER MK, 1989, PEDIATRICS, V84, P936; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JENISTA JA, 1987, AM J DIS CHILD, V141, P298, DOI 10.1001/archpedi.1987.04460030076029; KAUNITZ AM, 1987, JAMA-J AM MED ASSOC, V258, P3537, DOI 10.1001/jama.258.24.3537; LANGE WR, 1989, PEDIATR INFECT DIS J, V8, P625, DOI 10.1097/00006454-198909000-00012; LANGE WR, 1987, PEDIATR INFECT DIS J, V6, P447, DOI 10.1097/00006454-198705000-00006; MURPH JR, 1988, AM J DIS CHILD, V142, P843, DOI 10.1001/archpedi.1988.02150080049020; NORDENFELT E, 1978, SCAND J INFECT DIS, V10, P161, DOI 10.3109/inf.1978.10.issue-3.01; PASS RF, 1987, NEW ENGL J MED, V316, P1366, DOI 10.1056/NEJM198705283162203; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SCHULZER M, 1987, INT J EPIDEMIOL, V16, P584, DOI 10.1093/ije/16.4.584; Smith-Garcia T, 1989, J Community Health, V14, P227, DOI 10.1007/BF01338874; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; VERNON TM, 1976, JAMA-J AM MED ASSOC, V235, P2829, DOI 10.1001/jama.235.26.2829; WALPOLE RE, 1982, INTRO STATISTICS, P40; WESSEL MA, 1960, NEW ENGL J MED, V262, P446, DOI 10.1056/NEJM196003032620906; WHITE NH, 1989, J INFECT DIS, V159, P1013, DOI 10.1093/infdis/159.6.1013; 1985, MMWR, V34, P313; 1985, ADOPTION FACTBOOK, P126; 1990, STATISTICAL ABSTRACT, P835; 1985, MMWR, V34, P329; 1988, PEDIATRICS, V82, P941; 1983, MEASURING CHANGE NUT, P75; 1990, MMWR, V39, P1	35	119	120	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 15	1991	325	7					479	485		10.1056/NEJM199108153250706	http://dx.doi.org/10.1056/NEJM199108153250706			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GA763	1649404				2022-12-24	WOS:A1991GA76300006
J	VORTKAMP, A; GESSLER, M; GRZESCHIK, KH				VORTKAMP, A; GESSLER, M; GRZESCHIK, KH			GLI3 ZINC-FINGER GENE INTERRUPTED BY TRANSLOCATIONS IN GREIG SYNDROME FAMILIES	NATURE			English	Article							CEPHALOPOLYSYNDACTYLY SYNDROME; LOCALIZATION; CHROMOSOME-7	THE Greig cephalopolysyndactyly syndrome (GCPS) is an autosomal dominant disorder affecting limb and craniofacial development in humans 1,2. GCPS-affected individuals are characterized by postaxial polysyndactyly of hands, preaxial polysyndactyly of feet, macroephaly, a broad base of the nose with mild hypertelorism and a prominent forehead. The genetic locus has been pinpointed to chromosome 7p13 by three balanced translocations associated with GCPS in different families 3,4,19. This assignment is corroborated by the detection of two sporadic GCPS cases carrying overlapping deletions in 7p13 (ref. 7), as well as by tight linkage of GCPS to the epidermal growth factor receptor gene in 7p12-13 (ref. 8). Of the genes that map to this region, those encoding T cell receptor-gamma, interferon-beta-2, epidermal growth factor receptor, and Hox1.4, a potential candidate gene for GCPS, have been excluded from the region in which the deletions overlap 7,9. Here we show that two of the three translocations interrupt the GLI3 gene, a zinc-finger gene of the GLI-Kruppel family already localized to 7p13 (refs 5, 6). The breakpoints are within the first third of the coding sequence. In the third translocation, chromosome 7 is broken at about 10 kilobases downstream of the 3' end of GLI3. Our results indicate that mutations disturbing normal GLI3 expression may have a causative role in GCPS.			VORTKAMP, A (corresponding author), UNIV MARBURG,INST HUMANGENET,BAHNHOFSTR 7A,W-3550 MARBURG,GERMANY.			Gessler, Manfred/0000-0002-7915-6045				BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BRUETON L, 1988, AM J MED GENET, V31, P799, DOI 10.1002/ajmg.1320310412; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRABKIN H, 1989, GENOMICS, V4, P518, DOI 10.1016/0888-7543(89)90275-9; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOLLOP TR, 1985, AM J MED GENET, V22, P59, DOI 10.1002/ajmg.1320220106; GREIG DAVID M., 1926, EDINBURGH MED JOUR, V33, P189; JOBS A, 1990, HUM GENET, V84, P147; KRUGER G, 1989, AM J MED GENET, V32, P411, DOI 10.1002/ajmg.1320320329; Maniatis T., 1982, MOL CLONING; POHL TM, 1990, DEVELOPMENT, V110, P1153; ROMMENS JM, 1988, AM J HUM GENET, V43, P645; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; TOMMERUP N, 1983, AM J MED GENET, V16, P313, DOI 10.1002/ajmg.1320160304; VORTKAMP A, IN PRESS GENOMICS; WAGNER K, 1990, GENOMICS, V8, P487, DOI 10.1016/0888-7543(90)90035-S; WINTER RM, 1988, AM J MED GENET, V31, P793, DOI 10.1002/ajmg.1320310411	19	473	487	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					539	540		10.1038/352539a0	http://dx.doi.org/10.1038/352539a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650914	Green Submitted			2022-12-24	WOS:A1991GA22600066
J	GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z				GRIFO, JA; TANG, YX; COHEN, J; GILBERT, F; SANYAL, MK; ROSENWAKS, Z			PREGNANCY AFTER EMBRYO BIOPSY AND COAMPLIFICATION OF DNA FROM X-CHROMOSOME AND Y-CHROMOSOME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN PREIMPLANTATION EMBRYOS; AMPLIFICATION; FERTILIZATION		YALE UNIV,SCH MED,DEPT OBSTET & GYNECOL,NEW HAVEN,CT 06510	Yale University	GRIFO, JA (corresponding author), CORNELL UNIV,MED CTR,COLL MED,CTR REPROD MED & INFERTIL,DEPT OBSTET & GYNECOL,505 E 70TH ST,NEW YORK,NY 10021, USA.			Grifo, James/0000-0003-0439-2374				COHEN J, 1992, MICROMANIPULATION HU; GORDON JW, 1986, J EXP ZOOL, V239, P347, DOI 10.1002/jez.1402390306; GRIFO JA, 1991, 30TH ANN M SOC GYN I; GRIFO JA, 1990, J IN VITRO FERTIL EM, V1, P92; HANDYSIDE AH, 1989, LANCET, V1, P347; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; PIETERS MHEC, 1992, J ASSIST REPROD GEN, V9, P68, DOI 10.1007/BF01204118; PLACHOT M, 1988, HUM REPROD, V3, P125, DOI 10.1093/oxfordjournals.humrep.a136644; STROM CM, 1991, J IN VITRO FERTIL EM, V8, P225, DOI 10.1007/BF01130810; WAYE JS, 1985, NUCLEIC ACIDS RES, V13, P2731, DOI 10.1093/nar/13.8.2731	10	92	93	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1992	268	6					727	729		10.1001/jama.268.6.727	http://dx.doi.org/10.1001/jama.268.6.727			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG666	1640572				2022-12-24	WOS:A1992JG66600012
J	DONIACH, T; PHILLIPS, CR; GERHART, JC				DONIACH, T; PHILLIPS, CR; GERHART, JC			PLANAR INDUCTION OF ANTEROPOSTERIOR PATTERN IN THE DEVELOPING CENTRAL-NERVOUS-SYSTEM OF XENOPUS-LAEVIS	SCIENCE			English	Article							NEURAL INDUCTION; POSITIONAL INFORMATION; PROSPECTIVE AREAS; HOMEOBOX GENE; EXPRESSION; EMBRYOS; ANTERIOR; ECTODERM; MARKER; MOUSE	It has long been thought that anteroposterior (A-P) pattern in the vertebrate central nervous system is induced in the embryo's dorsal ectoderm exclusively by signals passing vertically from underlying, patterned dorsal mesoderm. Explants from early gastrulae of the frog Xenopus laevis were prepared in which vertical contact between dorsal ectoderm and mesoderm was prevented but planar contact was maintained. In these, four position-specific neural markers (engrailed-2, Krox-20, XIHbox 1, and XIHbox 6) were expressed in the ectoderm in the same A-P order as in the embryo. Thus, planar signals alone, following a path available in the normal embryo, can induce A-P neural pattern.	BOWDOIN COLL,DEPT BIOL,BRUNSWICK,ME 04011	Bowdoin College	DONIACH, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,301 LSA,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019363, R37GM019363] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19363] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA ARI, 1990, DEVELOPMENT, V108, P595; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BOLCE ME, IN PRESS DEVELOPMENT; DEROBERTIS EM, 1989, CELL, V57, P189, DOI 10.1016/0092-8674(89)90954-9; DIXON JE, 1989, DEVELOPMENT, V106, P749; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; Holtfreter J., 1955, ANAL DEV, P230; HOLTFRETER J, 1933, ARCH ENTWICKLUNGSMEC, V129, P669; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; KELLER R, 1992, DEV DYNAM, V193, P218, DOI 10.1002/aja.1001930303; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; ROBERTS SA, UNPUB; SATER AK, UNPUB; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1988, EMBRYONIC DEV INDUCT; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	41	155	158	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					542	545		10.1126/science.1636091	http://dx.doi.org/10.1126/science.1636091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636091				2022-12-24	WOS:A1992JE75500033
J	FLORIG, HK				FLORIG, HK			CONTAINING THE COSTS OF THE EMF PROBLEM	SCIENCE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; BRAIN-TISSUE INVITRO; ELF 1-120 HZ; ELECTROMAGNETIC-FIELDS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; CALCIUM-IONS; RF FIELDS; EXPOSURE; CELLS				FLORIG, HK (corresponding author), RESOURCES FUTURE INC,1616 P ST NW,WASHINGTON,DC 20036, USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BALCERKUBICZEK EK, 1991, RADIAT RES, V126, P65, DOI 10.2307/3578172; BARRY RE, 1991, SEP COMP C ROCK MOUN; BERNHARDT J, 1979, RADIAT ENVIRON BIOPH, V16, P309, DOI 10.1007/BF01340569; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; BLANK M, 1988, BIOELECTROCH BIOENER, V19, P569, DOI 10.1016/0302-4598(88)80035-7; BOSTROM A, 1991, 13TH ANN M BIOEL SOC; COLE P, 1991, COMMUNICATION   0114; COOPER MS, 1984, J THEOR BIOL, V111, P123, DOI 10.1016/S0022-5193(84)80200-3; DAVIS MK, 1988, LANCET, V2, P365; FISHER A, 1989, J POLICY ANAL MANAG, V8, P88, DOI 10.2307/3324426; FITZSIMMONS R, 1991, 13TH ANN M BIOEL SOC; FLORIG HK, 1991, DEC ANN M SOC RISK A; FRANCESCHI C, 1991, 1991 ANN REV RES BIO; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; FURBY L, 1988, J ENVIRON MANAGE, V27, P69; FURBY L, 1988, J ENVIRON PSYCHOL, V8, P19, DOI 10.1016/S0272-4944(88)80021-5; GIBNEY KB, 1991, JUN RIGHT WAY ASS C; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GORDON I, 1990, 242 U MELB STAT CONS; GRAHAM C, 1990, DE90006671 NAT TECHN; GROTA LJ, 1991, 13TH ANN M BIOEL SOC; JOHN EM, 1991, AM J EPIDEMIOL, V133, P123, DOI 10.1093/oxfordjournals.aje.a115851; KUNREUTHER H, 1987, J ENVIRON ECON MANAG, V14, P371, DOI 10.1016/0095-0696(87)90027-1; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LOVELY RH, 1988, ELECTROMAGNETIC FIEL, P327; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; LYLE DB, 1991, BIOELECTROMAGNETICS, V12, P145, DOI 10.1002/bem.2250120303; MALTIN L, COMMUNICATION; MATANOSKI G, 1991, 13TH ANN M BIOEL SOC; MCLEAN JRN, 1991, BIOELECTROMAGNETICS, V12, P273, DOI 10.1002/bem.2250120503; MIZUSHIMA Y, 1975, EXPERIENTIA, V21, P1411; MORGAN MG, 1985, RISK ANAL, V5, P139, DOI 10.1111/j.1539-6924.1985.tb00161.x; MORGAN MG, 1986, SCIENCE, V232, P917, DOI 10.1126/science.3704631; MORGAN MG, 1988, PUBLIC UTILITIES FOR, V121, P49; MURTHY KK, 1991, 1991 ANN REV RES BIO; PILLA AA, 1992, CHARGE FIELD EFFECTS, V3, P231; POOL R, 1990, SCIENCE, V249, P1096, DOI 10.1126/science.2204111; POOLE C, 1991, CANCER CAUSES CONTRO, V2; Portney KE, 1991, HAZARDOUS WASTE TREA; RAYNER S, 1988, NONIONIZING RAD, P39; REESE JA, 1988, BIOELECTROMAGNETICS, V9, P237, DOI 10.1002/bem.2250090305; SANGHVI AP, 1990, EL6791 EL POW RES I; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; SULZMAN FM, 1987, EFFECTS ELECTROMAGNE; Susskind L., 1987, BREAKING IMPASSE; TENFORDE TS, 1991, BIOELECTROCH BIOENER, V25, P1, DOI 10.1016/0302-4598(91)87015-9; THERIAULT GP, 1991, NIOSH91111 PUBL, P91; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; TRAVIS CC, 1987, ENVIRON SCI TECHNOL, V21, P415, DOI 10.1021/es00159a001; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; WALBORG EF, 1991, EXTREMELY LOW FREQUE; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1980, AM J EPIDEMIOL, V111, P461, DOI 10.1093/oxfordjournals.aje.a112924; WILSON BW, 1981, BIOELECTROMAGNETICS, V2, P371, DOI 10.1002/bem.2250020408; Wilson R., 1982, RISK BENEFIT ANAL; ZAFFANELLA LE, 1985, ENV HLTH PERSPECT, V62, P297; 1991, 1991 P AM LAW FILM A; 1990, MICROW NEWS, V10, P5; 1991, MICROW NEWS, V11, P6; 1987, MAGNETIC FIELDS; 1987, MICROW NEWS, V7, P1; 1991, STATISTICAL YB ELECT; 1991, MICROW NEWS, V11, P7; 1987, BIOL EFFECTS POWERLI; 1991, ELECTRIC SUPPLY DEMA; 1991, NIOSH91111 NAT I OCC; 1989, OTABPE53 US C OFF TE	78	30	30	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					468	&		10.1126/science.1636078	http://dx.doi.org/10.1126/science.1636078			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636078				2022-12-24	WOS:A1992JE75500005
J	LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC				LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC			CUMULATIVE METAANALYSIS OF THERAPEUTIC TRIALS FOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; CORONARY HEART-DISEASE; SCIENTIFIC DISCIPLINE; THROMBOLYTIC THERAPY; PUBLICATION BIAS; MORTALITY; STREPTOKINASE; INTRACORONARY; LONG; REHABILITATION	Background. The large volume of published randomized, controlled trials has led to a need for meta-analyses to track therapeutic advances. Performing a new meta-analysis whenever the results of a new trial of a particular therapy are published permits the study of trends in efficacy and makes it possible to determine when a new treatment appears to be significantly effective or deleterious. We describe the use of such a procedure, cumulative meta-analysis, to assess therapeutic trials among patients with myocardial infarction. Methods. We performed cumulative meta-analyses of clinical trials that evaluated 15 treatments and preventive measures for acute myocardial infarction. Results. An example of this method is its application to the use of intravenous streptokinase as thrombolytic therapy for acute infarction. Thirty-three trials evaluating this therapy were performed between 1959 and 1988. We found that a consistent, statistically significant reduction in total mortality (odds ratio, 0.74; 95 percent confidence interval, 0.59 to 0.92) was achieved in 1973, after only eight trials involving 2432 patients had been completed. The results of the 25 subsequent trials, which enrolled an additional 34,542 patients through 1988, had little or no effect on the odds ratio establishing efficacy, but simply narrowed the 95 percent confidence interval. In particular, two very large trials, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico trial in 1986 (11,712 patients) and the Second International Study of Infarct Survival trial in 1988 (17,187 patients) did not modify the already established evidence of efficacy. We used a similar approach to study the accumulating evidence of efficacy (or lack of efficacy) of 14 other therapies and preventive measures for myocardial infarction. Conclusions. Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and making clinical recommendations for therapy.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; NEW ENGLAND MED CTR, CTR CARDIOVASC HLTH SERV RES, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School					AHRQ HHS [P0RT-1-PO1-HS 06341-02, R01 HS-05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ARMITAGE P, 1989, J CLIN EPIDEMIOL, V42, P293, DOI 10.1016/0895-4356(89)90033-4; BABER NJ, 1982, PRIM CARDIOL S, V1, P31; BABER NS, 1983, CIRCULATION, V67, P71; BABER NS, 1982, BRIT MED J, V284, P1749, DOI 10.1136/bmj.284.6331.1749; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CANNER PL, 1987, STAT MED, V6, P255, DOI 10.1002/sim.4780060310; CANNER PL, 1983, ISRAEL J MED SCI, V19, P413; CHALMERS I, 1991, OXFORD DATABASE PERI; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ERKELENS DW, 1990, CARDIOLOGY, V77, P33; FURBERG CD, 1983, CIRCULATION, V67, P83; FURBERG CD, 1984, AM J CARDIOL, V53, P626, DOI 10.1016/0002-9149(84)90042-0; HELD PH, 1990, CIRCULATION, V82, P1668, DOI 10.1161/01.CIR.82.5.1668; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; KAPLAN K, 1986, ARCH INTERN MED, V146, P593, DOI 10.1001/archinte.146.3.593; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAU J, IN PRESS CONTROLLED; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LOELIGER EA, 1981, ACTA MED SCAND, P305; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MACMAHON S, 1987, ACUTE CORONARY CARE, P51; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARDER VJ, 1984, AM J MED, V77, P921, DOI 10.1016/0002-9343(84)90543-6; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PATEL B, 1987, AM J CARDIOL, V59, P501, DOI 10.1016/0002-9149(87)91156-8; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; Topol E J, 1989, Cardiol Clin, V7, P827; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1988, LANCET, V1, P1088; YUSUF S, 1985, ACUTE CORONARY CARE, P73; 1982, LANCET, V1, P1159	62	897	911	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					248	254		10.1056/NEJM199207233270406	http://dx.doi.org/10.1056/NEJM199207233270406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614465				2022-12-24	WOS:A1992JE38100006
J	KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM				KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM			MHC CLASS-I ALLOANTIGEN SPECIFICITY OF LY-49+ IL-2-ACTIVATED NATURAL-KILLER-CELLS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGEN; IDENTIFICATION; RECEPTOR; GENE; MOLECULES; SUSCEPTIBILITY; RECOGNITION; RESISTANCE	THE molecular basis of target cell recognition by CD3- natural killer (NK) cells is poorly understood, despite the ability of NK cells to lyse specific tumour cells 1,2. In general, target cell major histocompatibility complex (MHC) class I antigen expression correlates with resistance to NK cell-mediated lysis 3-9, possibly because NK cell-surface molecules engage MHC class I antigens and consequently deliver inhibitory signals 3,4. Natural killer cell allospecificity involves the MHC class I peptide-binding cleft 10, and further understanding of this allospecificity should provide insight into the molecular mechanisms of NK cell recognition. The Ly-49 cell surface molecule is expressed by 20% of CD3- NK cells 11 in C57BL/6 mice (H-2b). Here we show that C57BL/6-derived, interleukin-2-activated NK cells expressing Ly-49 do not lyse target cells displaying H-2d or H-2k despite efficient spontaneous lysis by Ly-49- effector cells. This preferential resistance correlates with expression of target cell MHC class I antigens. Transfection and expression of H-2D(d), but not H-2K(d) or H-2L(d), renders a susceptible target (H-2b) resistant to Ly-49+ effector cells. The transfected resistance is abrogated by monoclonal antibodies directed against Ly-49 or the alpha-1/alpha-2 domains of H-2D(d), suggesting that Ly-49 specifically interacts with the peptide-binding domains of the MHC class I alloantigen, H-2D(d) Inas-much as Ly49+ effector cells cannot be stimulated to lyse H-2D(d) targets, our results indicate that NK cells may possess inhibitory receptors that specifically recognize MHC class I antigens.	SAN FRANCISCO GEN HOSP, MED SERV, SAN FRANCISCO, CA 94110 USA; NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	San Francisco General Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KARLHOFER, FM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, ROSALIND RUSSELL ARTHRITIS RES LAB, SAN FRANCISCO, CA 94143 USA.		Ribaudo, Randall/AAH-7094-2021					BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; COCHET M, 1986, IMMUNOGENETICS, V24, P267, DOI 10.1007/BF00364531; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERBERMAN RB, 1982, NK CELLS OTHER NATUR; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1986, J IMMUNOL, V137, P3874; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; NAGASAWA R, 1987, J IMMUNOL, V138, P815; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QUILLET A, 1988, J IMMUNOL, V141, P17; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; SUZUKI N, 1990, J EXP MED, V172, P457, DOI 10.1084/jem.172.2.457; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229	34	738	748	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1992	358	6381					66	70		10.1038/358066a0	http://dx.doi.org/10.1038/358066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614533				2022-12-24	WOS:A1992JB34100055
J	ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ				ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ			THE LEVEL OF CD8 EXPRESSION CAN DETERMINE THE OUTCOME OF THYMIC SELECTION	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; NEGATIVE SELECTION; POSITIVE SELECTION; ANTIGEN RECEPTOR; LYMPHOCYTES-T; KINASE P56LCK; TOLERANCE; DELETION; SELF	During thymic development, thymocytes that can recognize major histocompatability complex (MHC) molecules on thymic epithelial cells are selected to survive and mature (positive selection), whereas thymocytes that recognize MHC on hematopoietic cells are destroyed (negative selection). It is not known how MHC recognition can mediate both death and survival. One model to explain this paradox proposes that thymocytes whose T cell antigen receptors (TCRs) recognize MHC with high affinity are eliminated by negative selection, whereas low affinity TCR-MHC interactions are sufficient to mediate positive selection. Here we report that, while the expression of a 2C TCR transgene leads to positive selection of thymocytes in H-2b mice, expression of both a CD8 transgene and a 2C TCR transgene causes negative selection. This observation indicates that quantitative differences in TCR-MHC recognition are a critical determinant of T cell fate, a finding predicted by the affinity model for thymic selection.	WASHINGTON UNIV, DEPT IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); MRC National Institute for Medical Research; Columbia University; Columbia University; Howard Hughes Medical Institute				Axel, Richard/0000-0002-3141-4076				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEE NA, 1992, IN PRESS J EXP MED; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	38	146	147	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1089	1096		10.1016/0092-8674(92)90631-L	http://dx.doi.org/10.1016/0092-8674(92)90631-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617724				2022-12-24	WOS:A1992JA43100004
J	MILLER, DJ; MACEK, MB; SHUR, BD				MILLER, DJ; MACEK, MB; SHUR, BD			COMPLEMENTARITY BETWEEN SPERM SURFACE BETA-1,4-GALACTOSYL-TRANSFERASE AND EGG-COAT ZP3 MEDIATES SPERM EGG BINDING	NATURE			English	Article							O-LINKED OLIGOSACCHARIDES; ZONA PELLUCIDA; MOUSE SPERM; ACROSOME REACTION; RECEPTOR ACTIVITY; GALACTOSYLTRANSFERASE; IDENTIFICATION; PROTEIN; FERTILIZATION; GLYCOPROTEINS	DESPITE its importance, the molecular basis of mammalian gamete recognition has remained unclear. The enzyme beta-1,4-galactosyltransferase (Gal-transferase) has been viewed traditionally as a biosynthetic component of the Golgi complex, but is also found on the surface of many cells where it can bind its specific glycoside substrate on adjacent cell surfaces or in the extracellular matrix 1-3. In mouse it has been suggested that Gal-transferase on the sperm head mediates fertilization by binding oligosaccharide residues in the egg coat, or zona pellucida 4-9, and that the ability of the zona pellucida to bind sperm is conferred by oligosaccharides of the ZP3 glycoprotein 10,13. However, it has not been confirmed that Gal-transferase and ZP3 are in fact complementary gamete receptors whose interaction mediates sperm-eg binding. Here we show that mouse sperm Gal-transferase specifically recognizes those oligosaccharides on ZP3 that have sperm-binding activity, but does not interact with other zona pellucida glycoproteins. In contrast, all zona pellucida glycoproteins are recognized by non-sperm Gal-transferase, demonstrating a more stringent substrate specificity for the sperm enzyme. This interaction is required for sperm-egg binding because blocking or removing the binding site for Gal-transferase on ZP3 inhibits its ability to bind sperm. After the release of the sperm acrosome, the transferase relocalizes to a new membrane domain where it can no longer bind to ZP3, which is consistent with the inability of acrosome-reacted sperm to bind ZP3 or to initiate binding to the zona pellucida. Following fertilization, ZP3 is modified by egg cortical granule secretions so that it loses sperm receptor activity, which can be accounted for by a selective loss of its binding site for sperm Gal-transferase. These results show that sperm surface beta-1,4-galactosyltransferase and the egg-coat glycoprotein ZP3 are complementary adhesion molecules that mediate primary gamete binding in the mouse.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Miller, David J/ABC-2156-2020	Miller, David J/0000-0001-7147-5546				BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BEER D, 1985, HELV CHIM ACTA, V68, P2254, DOI 10.1002/hlca.19850680821; BEGOVAC PC, 1991, J CELL BIOL, V113, P637, DOI 10.1083/jcb.113.3.637; BENAU DA, 1988, BIOL REPROD, V39, P235, DOI 10.1095/biolreprod39.2.235; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; FAYRER-HOSKEN R A, 1987, Biology of Reproduction, V36, P53; FAYRERHOSKEN RA, 1991, MOL REPROD DEV, V28, P74, DOI 10.1002/mrd.1080280112; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; HUMPHREYSBEHER MG, 1990, FERTIL STERIL, V54, P133; JONES R, 1988, DEVELOPMENT, V102, P781; LAMBERT CC, 1989, DEVELOPMENT, V105, P415; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; LOPEZ LC, 1987, J CELL BIOL, V105, P1663, DOI 10.1083/jcb.105.4.1663; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MILLER DJ, 1992, COMP SPERMATOLOGY 20, P569; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; NEILL JM, 1988, GAMETE RES, V20, P459, DOI 10.1002/mrd.1120200407; NETER J, 1974, APPLIED LINEAR STATI; PASSANITI A, 1990, CANCER RES, V50, P7261; PRODY GA, 1985, J EXP ZOOL, V235, P335, DOI 10.1002/jez.1402350304; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1973, Q REV BIOL, V48, P541, DOI 10.1086/407816; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SULLIVAN R, 1989, BIOCHEM BIOPH RES CO, V162, P184, DOI 10.1016/0006-291X(89)91979-7; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215	39	417	429	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					589	593		10.1038/357589a0	http://dx.doi.org/10.1038/357589a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608469	Bronze			2022-12-24	WOS:A1992HZ11200054
J	KEMP, IW; CLARKE, K; KINLEN, LJ				KEMP, IW; CLARKE, K; KINLEN, LJ			ESOPHAGEAL CANCER AND DISTILLERIES IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN EPIDEMIOL GRP,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	KEMP, IW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AJ,SCOTLAND.							BRESLOW NE, 1987, IARC SCI PUBL, V82, P96; KEMP JW, 1985, ATLAS CANCER SCOTLAN; MUIR CS, 1987, IARC SCI PUBLICATION, V88; PATHAN AH, 1985, ABERDEEN POSTGRADUAT, V19, P8	4	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1543	1544		10.1136/bmj.304.6841.1543	http://dx.doi.org/10.1136/bmj.304.6841.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628054	Green Published, Bronze			2022-12-24	WOS:A1992HZ17800025
J	PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ				PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ			LYMPHOID DEVELOPMENT IN MICE CONGENITALLY LACKING T-CELL RECEPTOR-ALPHA-BETA EXPRESSING CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; GAMMA-CHAIN; ANTIGEN; COMPLEX; DIFFERENTIATION; RECOGNITION; SPECIFICITY; COMMITMENT	Vertebrate T cells express either an alpha-beta or gamma-delta T cell receptor (TCR). The developmental relatedness of the two cell types is unresolved. Alpha-beta+ T cells respond to specific pathogens by collaborating with immunoglobulin-producing B cells in distinct lymphoid organs such as the spleen and Peyer's patches. The precise influence of alpha-beta+ T cells on B cell development is poorly understood. To investigate the developmental effects of alpha-beta+ T cells on B cells and gamma-delta+ T cells, mice homozygous for a disrupted TCR-alpha gene were generated. The homozygotes showed elimination of alpha-beta+ T cells and the loss of thymic medullae. Despite this, gamma-delta+ T cells developed in normal numbers, and there was an increase in splenic B cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Cancer Research UK; Medical Research Council Clinical Trials Unit; Yale University			Kay, Graham F/A-4130-2011		NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BONNEVILLE M, 1989, NATURE, V342, P931, DOI 10.1038/342931a0; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BUTCHER EC, 1989, FUNDAMENTAL IMMUNOLO, P117; CARBONE A, 1991, IMMUNOL REV, V120, P35; CARDING SR, 1990, GENE DEV, V4, P1304, DOI 10.1101/gad.4.8.1304; CEBRA JJ, 1983, ANN NY ACAD SCI, V409, P25, DOI 10.1111/j.1749-6632.1983.tb26857.x; CEBRA JJ, 1982, RECENT ADV MUCOSAL I, P155; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Cobbold S P, 1983, Mol Biol Med, V1, P285; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; GLICK B, 1956, POULTRY SCI, V35, P224, DOI 10.3382/ps.0350224; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HAYDAY AC, UNPUB; HAYDAY AC, IN PRESS ENCY IMMUNO; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; IKEDA RM, 1978, ANIMAL MODELS COMP D, P201; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KAWANISHI H, 1983, J EXP MED, V157, P433, DOI 10.1084/jem.157.2.433; Kay G., UNPUB; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MACKAY CR, 1990, RES IMMUNOL, V141, P611, DOI 10.1016/0923-2494(90)90067-9; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; MILLER JF, 1961, LANCET, V2, P748; MIXTER PF, 1991, J IMMUNOL, V147, P4109; MONGINI PKA, 1983, J EXP MED, V157, P69, DOI 10.1084/jem.157.1.69; PHILPOTT KL, UNPUB; PORTOLES P, 1989, J IMMUNOL, V142, P4169; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; STINGL G, 1987, P NATL ACAD SCI USA, V84, P4586, DOI 10.1073/pnas.84.13.4586; STROBER W, 1985, ADV HOST DEFENSE MEC, V4, P1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0	46	344	353	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1448	1452		10.1126/science.1604321	http://dx.doi.org/10.1126/science.1604321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604321				2022-12-24	WOS:A1992HX33700037
J	SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB				SESSO, R; SANTOS, AP; NISHIDA, SK; KLAG, MJ; CARVALHAES, JT; AJZEN, H; RAMOS, OL; PEREIRA, AB			PREDICTION OF STEROID RESPONSIVENESS IN THE IDIOPATHIC NEPHROTIC SYNDROME USING URINARY RETINOL-BINDING PROTEIN AND BETA-2-MICROGLOBULIN	ANNALS OF INTERNAL MEDICINE			English	Article						RETINOL-BINDING PROTEINS; BETA 2 MICROGLOBULIN; NEPHROTIC SYNDROME; NEPHROSIS, LIPOID	RENAL-FUNCTION	Objectives: To determine the prevalence of early proximal tubular dysfunction, measured by urinary excretion of retinol-binding protein (RBP) and beta-2-microglobulin (B2M), in patients with the idiopathic nephrotic syndrome and to investigate the value of these tests in predicting steroid responsiveness. Design: Before-after trial with 8-week treatment period. Setting: Tertiary referral center. Patients: Sequential sample of 37 patients with the idiopathic nephrotic syndrome caused by minimal change disease, focal segmental glomerulosclerosis, or mesangial proliferative glomerulonephritis. Intervention: All patients were treated with prednisone as one dose of 1 to 1.5 mg/kg body weight per day for 8 weeks. Measurements: Urinary RBP was measured by an immunoenzymometric assay and B2M, by an enzyme-linked immunosorbent assay. Remission of the nephrotic syndrome after steroid treatment was the main outcome variable. Results: Elevated levels of urinary RBP and B2M before treatment were detected in 65% and 75% of the patients, respectively. Median urinary RBP and B2M, before treatment, were significantly higher in the steroid-unresponsive group than in the responsive group (P < 0.01). In the steroid-responsive group, urinary RBP and B2M levels decreased significantly after remission (P < 0.01). In the steroid-unresponsive group, the likelihood ratios for urinary RBP greater than 4000-mu-g/g creatinine and for B2M greater than 3000-mu-g/g creatinine were 3.8 and 3.0, respectively. The probability was 100% that values of RBP of less than 1300-mu-g/g creatinine and B2M of less than 130-mu-g/g creatinine were from steroid-responsive patients. Multivariate analysis confirmed that higher urinary levels of RBP and B2M were associated with a lower likelihood of steroid responsiveness, independent of age and histologic diagnosis. Conclusions: Proximal tubular dysfunction is frequent in patients with the idiopathic nephrotic syndrome. Pretreatment urinary RBP and B2M levels may be helpful in identifying nephrotic patients who are more likely to be responsive to steroids.	ESCOLA PAULISTA MED SCH, DIV NEPHROL, BR-04023 SAO PAULO, BRAZIL; ESCOLA PAULISTA MED SCH, DEPT PEDIAT, BR-04023 SAO PAULO, BRAZIL	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP)	SESSO, R (corresponding author), JOHNS HOPKINS MED INST, WELCH CTR PREVENT EPIDEMIOL & CLIN RES, 600 N WOLFE ST, CARNEGIE 292, BALTIMORE, MD 21205 USA.		Sesso, Ricardo C C/B-4767-2013	Tavares, Alze/0000-0003-0783-0106; Sesso, Ricardo/0000-0002-1062-0073				BERNARD AM, 1987, CLIN CHEM, V33, P775; BOHLE A, 1990, PATHOL RES PRACT, V186, P135, DOI 10.1016/S0344-0338(11)81021-6; BOUISSOU F, 1980, CLIN NEPHROL, V14, P135; CAMERON JS, 1990, AM J NEPHROL, V10, P81; EDDY AA, 1989, AM J PATHOL, V135, P719; ERDREICH LS, 1981, AM J EPIDEMIOL, V114, P649, DOI 10.1093/oxfordjournals.aje.a113236; FERRUA B, 1980, J IMMUNOL METHODS, V36, P149, DOI 10.1016/0022-1759(80)90039-3; MCVICAR M, 1980, J PEDIATR-US, V97, P918, DOI 10.1016/S0022-3476(80)80420-3; PEREIRA A B, 1991, Clinical Chemistry, V37, P1062; PORTMAN RJ, 1986, KIDNEY INT, V30, P91, DOI 10.1038/ki.1986.156; Sackett D.L., 1985, CLIN EPIDEMIOLOGY BA; SCHARDIJN GHC, 1987, KIDNEY INT, V32, P635, DOI 10.1038/ki.1987.255; SHIOJI R, 1974, CLIN NEPHROL, V2, P76; STICKLER GB, 1960, PEDIATRICS, V26, P75; TEGLAERS WH, 1955, HELV PAEDIATR ACTA, V10, P269	15	30	30	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					905	909		10.7326/0003-4819-116-11-905	http://dx.doi.org/10.7326/0003-4819-116-11-905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580447				2022-12-24	WOS:A1992HW13700005
J	USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y				USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y			SPECIFIC INTERACTION BETWEEN THE NONPHOSPHORYLATED FORM OF RNA POLYMERASE-II AND THE TATA-BINDING PROTEIN	CELL			English	Article							MAJOR LATE PROMOTER; C-TERMINAL DOMAIN; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; ACCURATE TRANSCRIPTION; INVITRO TRANSCRIPTION; COMPLEXES; INVIVO; GENE; ADENOVIRUS-2	Fractionation of a transcription-competent HeLa cell extract on a column containing one copy of the heptamer repeat (YSPTSPS) present in the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II resulted in the loss of transcriptional activity. Fractionation of the extracts on columns containing mutations of the heptamer repeat was without effect. Such transcriptionally inactive extracts regained their ability to specifically transcribe different class II promoters upon the addition of human TFIID, recombinant yeast TATA-binding protein (TBP), or proteins bound to the column. Fractionation of RNA polymerase II on columns containing human or yeast TBP resulted in the specific retention of the nonphosphorylated form of RNA polymerase II. The phosphorylated form of the enzyme was unable to interact with TBP. The specific interaction of RNA polymerase II with TBP was mediated by the CTD of RNA polymerase II.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Weizmann Institute of Science; Rutgers State University New Brunswick; Rutgers State University Medical Center				Reinberg, Danny/0000-0003-4288-2016	NCI NIH HHS [CA 14995] Funding Source: Medline; NIGMS NIH HHS [GM 37120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHEARN JM, 1987, J BIOL CHEM, V265, P425; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1992, J BIOL CHEM, V267, P2786; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE A, 1992, IN PRESS CELL, V69; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Roeder R.G., 1976, RNA POLYMERASE, P285; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHWARTZ LB, 1975, J BIOL CHEM, V250, P3221; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	49	215	217	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					871	881		10.1016/0092-8674(92)90297-P	http://dx.doi.org/10.1016/0092-8674(92)90297-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591781				2022-12-24	WOS:A1992HW83800016
J	VETTER, NJ; LEWIS, PA; LLEWELLYN, L				VETTER, NJ; LEWIS, PA; LLEWELLYN, L			SUPPORTING ELDERLY DEPENDENT PEOPLE AT HOME	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To clarify the relation between the dependency of elderly people and the assistance they receive from others by using a detailed but simple measure of dependency. Design - Secondary analysis of data from a survey of people aged 70 and over. Setting-Two general practices in south Wales. Subjects - 1280 people aged 70 and over. Main outcome measures-Dependency on others to perform essential functions; detailed data on who assists with those functions. Results-Increasing dependency was associated with increased use of more than one member of the family or friends and an increase in the provision of statutory services. Conclusion-The complexity of the relation between dependency and those who care for dependent people has previously been underestimated. The presence of providers of statutory services at the household of elderly dependent people suggests that these services can be developed further to help those caring for elderly people at home.	UNIV WALES COLL MED,DEPT PUBL HLTH MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	VETTER, NJ (corresponding author), UNIV WALES COLL MED,DEPT EPIDEMIOL & COMMUNITY MED,CARDIFF CF4 4XN,S GLAM,WALES.							BOYDEN PGK, 1979, NZ MED J, V89, P265; BRODY EM, 1981, GERONTOLOGIST, V21, P471, DOI 10.1093/geront/21.5.471; ISAACS B, 1971, BRIT MED J, V4, P282, DOI 10.1136/bmj.4.5782.282; JONES DA, 1984, SOC SCI MED, V19, P511, DOI 10.1016/0277-9536(84)90046-7; NISSEL M, 1984, AGEING SOC, V4, P185; SALVAGE AV, 1988, AGE AGEING, V17, P270, DOI 10.1093/ageing/17.4.270; Vetter N J, 1990, Int Disabil Stud, V12, P22; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; 1980, EXPERIENCE CARING EL	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1290	1292		10.1136/bmj.304.6837.1290	http://dx.doi.org/10.1136/bmj.304.6837.1290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606435	Green Published, Bronze			2022-12-24	WOS:A1992HV08600027
J	BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K				BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K			HIGH-FREQUENCY NETWORK OSCILLATION IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PATTERNED STIMULATION; THETA-RHYTHM; CA1 REGION; NEURONS; INTERNEURONS; INDUCTION; ORIGIN	Pyramidal cells in the CA1 hippocampal region displayed transient network oscillations (200 hertz) during behavioral immobility, consummatory behaviors, and slow-wave sleep. Simultaneous, multisite recordings revealed temporal and spatial coherence of neuronal activity during population oscillations. Participating pyramidal cells discharged at a rate lower than the frequency of the population oscillation, and their action potentials were phase locked to the negative phase of the simultaneously recorded oscillatory field potentials. In contrast, interneurons discharged at population frequency during the field oscillations. Thus, synchronous output of cooperating CA1 pyramidal cells may serve to induce synaptic enhancement in target structures of the hippocampus.	UNIV MICHIGAN,CTR INTEGRATED SENSORS & CIRCUITS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	BUZSAKI, G (corresponding author), RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,197 UNIV AVE,NEWARK,NJ 07102, USA.			Buzsaki, Gyorgy/0000-0002-3100-4800	NINDS NIH HHS [NS27058, NS02383] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027058] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUDRY M, 1991, LONG TERM POTENTIATI; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, J NEUROSCI METH, V28, P209, DOI 10.1016/0165-0270(89)90038-1; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1982, J NEUROPHYSIOL, V48, P597, DOI 10.1152/jn.1982.48.3.597; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHRISTIAN EP, 1988, J NEUROPHYSIOL, V59, P110, DOI 10.1152/jn.1988.59.1.110; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; FINCH DM, 1983, BRAIN RES, V271, P201, DOI 10.1016/0006-8993(83)90283-4; FOX SE, 1981, EXP BRAIN RES, V41, P299; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; KRUGER GJ, 1991, TRENDS NEUROSCI, V7, P1001; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LACAILLE JC, 1990, NEUROSCIENCE, V36, P349, DOI 10.1016/0306-4522(90)90431-3; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; PERKEL DH, 1967, BIOPHYS J, V7, P327; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SEJNOWSKI TJ, 1988, SCIENCE, V241, P1299, DOI 10.1126/science.3045969; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V67, P438; TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; TRAUB RD, 1985, NEUROSCIENCE, V15, P947, DOI 10.1016/0306-4522(85)90245-3; WISE KD, 1991, SCIENCE, V254, P1335, DOI 10.1126/science.1962192	34	843	858	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1025	1027		10.1126/science.1589772	http://dx.doi.org/10.1126/science.1589772			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589772				2022-12-24	WOS:A1992HU22400040
J	MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER				MAYFORD, M; BARZILAI, A; KELLER, F; SCHACHER, S; KANDEL, ER			MODULATION OF AN NCAM-RELATED ADHESION MOLECULE WITH LONG-TERM SYNAPTIC PLASTICITY IN APLYSIA	SCIENCE			English	Article							IMMUNOGLOBULIN SUPERFAMILY; NEURITE OUTGROWTH; SENSORY NEURONS; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; PROTEIN-SYNTHESIS; SENSITIZATION; DOMAINS; MEMBER; STIMULATION	A form of learning in the marine mollusk Aplysia, long-term sensitization of the gill- and siphon-withdrawal reflex, results in the formation of new synaptic connections between the presynaptic siphon sensory neurons and their target cells. These structural changes can be mimicked, when the cells are maintained in culture, by application of serotonin, an endogenous facilitating neurotransmitter in Aplysia. A group of cell surface proteins, designated Aplysia cell adhesion molecules (apCAM's) was down-regulated in the sensory neurons in response to serotonin. The deduced amino acid sequence obtained from complementary DNA clones indicated that the apCAM's are a family of proteins that seem to arise from a single gene. The apCAM's are members of the immunoglobulin class of cell adhesion molecules and resemble two neural cell adhesion molecules, NCAM and fasciclin II. In addition to regulating newly synthesized apCAM, serotonin also altered the amount of preexisting apCAM on the cell surface of the presynaptic sensory neurons. By contrast, the apCAM on the surface of the postsynaptic motor neuron was not modulated by serotonin. This rapid, transmitter-mediated down-regulation of a cell adhesion molecule in the sensory neurons may be one of the early molecular changes in long-term synaptic facilitation.	COLUMBIA UNIV COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	MAYFORD, M (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168 ST, NEW YORK, NY 10032 USA.			Mayford, Mark/0000-0002-9001-5024; Keller, Flavio/0000-0002-6449-6960				BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P9356, DOI 10.1073/pnas.85.23.9356; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAILEY CH, 1989, J NEUROSCI, V9, P1774; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARZILAI A, 1989, NEURON, V2, P1577, DOI 10.1016/0896-6273(89)90046-9; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; CHANG FLF, 1984, BRAIN RES, V309, P35, DOI 10.1016/0006-8993(84)91008-4; CHANGE FL, 1984, BRAIN RES, V309, P476; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DOHERTY P, 1990, NATURE, V343, P464, DOI 10.1038/343464a0; DOHERTY P, 1990, NEURON, V5, P209, DOI 10.1016/0896-6273(90)90310-C; DOHERTY P, 1991, NEURON, V6, P247, DOI 10.1016/0896-6273(91)90360-C; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FIFKOVA E, 1977, J NEUROCYTOL, V6, P211, DOI 10.1007/BF01261506; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; HUFFNER WB, 1991, CURR OPIN NEUROBIOL, V1, P388; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KELLER F, 1990, J CELL BIOL, V111, P2637, DOI 10.1083/jcb.111.6.2637; KELLER F, UNPUB; LANDMESSER L, 1990, NEURON, V4, P655, DOI 10.1016/0896-6273(90)90193-J; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LEMMON V, 1992, J NEUROSCI, V12, P818; MEYFORD M, UNPUB; MONTAROLO P G, 1991, Society for Neuroscience Abstracts, V17, P1591; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; RAYPORT SG, 1986, J NEUROSCI, V6, P759; RECHSTEINER M, 1988, ADV ENZYME REGUL, V27, P135; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; Sambrook J., 1989, MOL CLONING LAB MANU; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHACHER S, 1990, COLD SPRING HARB SYM, V55, P187; THIERY JP, 1982, P NATL ACAD SCI-BIOL, V79, P6737, DOI 10.1073/pnas.79.21.6737; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	46	362	366	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					638	644		10.1126/science.1585176	http://dx.doi.org/10.1126/science.1585176			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585176				2022-12-24	WOS:A1992HR18500025
J	GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D				GOLDBERG, DJ; MACKINNON, H; SMITH, R; PATEL, NB; SCRIMGEOUR, JB; INGLIS, JM; PEUTHERER, JF; URQUHART, GE; EMSLIE, JAN; COVELL, RG; REID, D			PREVALENCE OF HIV AMONG CHILDBEARING WOMEN AND WOMEN HAVING TERMINATION OF PREGNANCY - MULTIDISCIPLINARY STEERING GROUP-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION	Objective - To determine the prevalence of HIV among pregnant women, in particular those whose behaviour or that of their partners put them at "low risk" of infection. Design - Voluntary named or anonymous HIV testing of pregnant women during 21 months (November 1988 to July 1990). Subjects and setting - All women who planned to continue their pregnancy and attended clinics serving the antenatal populations of Edinburgh and Dundee. All women admitted for termination of pregnancy to gynaecology wards serving the pregnant populations of Dundee and outlying rural areas. Main outcome measures-Period prevalence of HIV antibody positivity. Results - 91% of antenatal clinic attenders and 97% of women having termination of pregnancy agreed to HIV testing on a named or anonymous basis. HIV period prevalences for antenatal clinic attenders and women having termination of pregnancy tested in Dundee were 0.13% and 0.85% respectively, and for antenatal clinic attenders tested in Edinburgh 0.26%. For those at "low risk" rates for antenatal clinic attenders and women having termination of pregnancy in Dundee were 0.11% and 0.13%, and for antenatal clinic attenders in Edinburgh 0.02%. In Dundee HIV prevalence among women having a termination of pregnancy (0.85%) was significantly greater than that among antenatal clinic attenders (0.13%). Conclusions - HIV infection is undoubtedly occurring among women at "low risk," and it is clear that a policy of selective testing of those at only "high risk" is inadequate for pregnant women living in areas of high prevalence such as Edinburgh and Dundee. Moreover, when studying pregnant populations in such areas there is the need to include those having a termination of pregnancy.	RUCHILL HOSP, COMMUN DIS SCOTLAND UNIT, GLASGOW G20 9NB, SCOTLAND; EASTERN GEN HOSP, DEPT OBSTET, EDINBURGH, SCOTLAND; NINEWELLS HOSP, DEPT REPROD MED, DUNDEE, SCOTLAND; CITY HOSP EDINBURGH, REG VIRUS LAB, EDINBURGH EH10 5SB, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT MED MICROBIOL, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND; NINEWELLS HOSP, DEPT MED MICROBIOL, DUNDEE, SCOTLAND	University of Dundee; University of Edinburgh; University of Dundee								ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BIRD AG, 1988, LANCET, V1, P713; EMANUELLI F, 1991, 7 P INT C AIDS, V2, P364; GILL ON, 1989, BRIT MED J, V299, P1295, DOI 10.1136/bmj.299.6711.1295; HADLINGTON S, 1988, NATURE, V333, P486, DOI 10.1038/333486a0; HEATH RB, 1988, LANCET, V1, P1394; KRASINSKI K, 1988, NEW ENGL J MED, V318, P185; MEADOWS J, 1991, 7 P INT C AIDS, V1, P380; ROBERTSON JR, 1986, BRIT MED J, V292, P527, DOI 10.1136/bmj.292.6519.527; SAAH AJ, 1991, TANSCRIPT, V19, P7; SMITH R, 1990, BRIT MED J, V301, P518, DOI 10.1136/bmj.301.6751.518; TAPPIN DM, 1991, LANCET, V337, P1565; Urquhart G. E. D., 1987, Communicable Diseases in Scotland, V21, P5; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, LANCET, V335, P575; 1991, COMMUNICABLE DISEA S, V25, pA208; 1991, COMMUNICABLE DISEASE, V1, pR69	18	42	42	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1082	1085		10.1136/bmj.304.6834.1082	http://dx.doi.org/10.1136/bmj.304.6834.1082			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586820	Green Published, Bronze			2022-12-24	WOS:A1992HR13600015
J	LAW, NW; TRAPNELL, JE				LAW, NW; TRAPNELL, JE			DOES A TRUSS BENEFIT A PATIENT WITH INGUINAL-HERNIA	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BOURNEMOUTH HOSP,GEN SURG,BOURNEMOUTH BH7 7DW,DORSET,ENGLAND									CONDON RE, 1971, SURG CLIN N AM, V51, P1325; GOLDMAN M, 1991, BRIT MED J, V302, P238, DOI 10.1136/bmj.302.6770.238-d; Ljungdahl I, 1973, ACTA CHIR SCAND    S, V439, P7	3	12	12	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1092	1092		10.1136/bmj.304.6834.1092	http://dx.doi.org/10.1136/bmj.304.6834.1092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586824	Green Published, Bronze			2022-12-24	WOS:A1992HR13600019
J	LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM				LACERDA, AE; KIM, HS; RUTH, P; PEREZREYES, E; FLOCKERZI, V; HOFMANN, F; BIRNBAUMER, L; BROWN, AM			NORMALIZATION OF CURRENT KINETICS BY INTERACTION BETWEEN THE ALPHA-1-SUBUNIT AND BETA-SUBUNIT OF THE SKELETAL-MUSCLE DIHYDROPYRIDINE-SENSITIVE CA2+ CHANNEL	NATURE			English	Article							CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GAMMA-SUBUNIT; CA-2+ CHANNEL; RECEPTOR; SEQUENCE; PROTEIN; CELLS; CDNA	PURIFICATION of skeletal muscle dihydropyridine binding sites has enabled protein complexes to be isolated from which Ca2+ currents have been reconstituted. Complementary DNAs encoding the five subunits of the dihydropyridine receptor, alpha-1, beta, gamma, alpha-2 and delta (ref. 1), have been cloned 2-6 and it is now recognized that alpha-2 and delta are derived from a common precursor 7,8. The alpha-1 subunit can itself produce Ca2+ currents, as was demonstrated using mouse L cells lacking alpha-2-delta (refs 9, 10), beta (ref. 10) and gamma (our unpublished results). In L cells, stable expression of skeletal muscle-alpha-1 alone was sufficient to generate voltage-sensitive, high-threshold L-type Ca2+ channel currents which were dihydropyridine-sensitive and blocked by Cd2+, but the activation kinetics were about 100 times slower than expected for skeletal muscle Ca2+ channel currents. This could have been due to the cell type in which alpha-1 was being expressed or to the lack of a regulatory component particularly one of the subunits that copurifies with alpha-1. We show here that coexpression of skeletal muscle-beta with skeletal muscle-alpha-1 generates cell lines expressing Ca2+ channel currents with normal activation kinetics as evidence for the participation of the dihydropyridine-receptor beta-subunits in the generation of skeletal muscle Ca2+ channel currents.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DIV NEUROSCI,HOUSTON,TX 77030; UNIV SAARLAND,FAC MED,INST PHYSIOL CHEM,W-6650 HOMBURG,GERMANY	Baylor University; Baylor University; Saarland University	LACERDA, AE (corresponding author), BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.							BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; BROWN AM, 1983, J PHYSIOL-LONDON, V344, P549, DOI 10.1113/jphysiol.1983.sp014956; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; COGNARD C, 1986, PFLUG ARCH EUR J PHY, V407, P677, DOI 10.1007/BF00582651; COGNARD C, 1986, P NATL ACAD SCI USA, V83, P1518, DOI 10.1073/pnas.83.5.1518; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JAY SD, 1991, J BIOL CHEM, V266, P3287; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; LACERDA AE, 1989, J GEN PHYSIOL, V93, P1243, DOI 10.1085/jgp.93.6.1243; LIAO CF, 1989, J BIOL CHEM, V264, P7328; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SCHWARTZ LM, 1985, NATURE, V314, P747, DOI 10.1038/314747a0; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	21	268	273	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 8	1991	352	6335					527	530		10.1038/352527a0	http://dx.doi.org/10.1038/352527a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GA226	1650913				2022-12-24	WOS:A1991GA22600062
J	GOODWIN, FK				GOODWIN, FK			COCAINE ANALOGS AND BRAIN IMAGING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							KUHAR MJ, 1991, EUR J PHARMACOL, V194, P133; 1991, MOL PHARMACOL, V39, P339; IN PRESS PHARM EXP T	3	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-24	WOS:A1991FR83500006
J	WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G				WIGLEY, DB; DAVIES, GJ; DODSON, EJ; MAXWELL, A; DODSON, G			CRYSTAL-STRUCTURE OF AN N-TERMINAL FRAGMENT OF THE DNA GYRASE B-PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; A-PROTEIN; GYRB GENE; RESOLUTION; TOPOISOMERASES; REFINEMENT; COMPLEX; SITE	The crystal structure of an N-terminal fragment of the Escherichia coli DNA gyrase B protein, complexed with a nonhydrolysable ATP analogue, has been solved at 2.5 angstrom resolution. It consists of two domains, both containing novel protein folds. The protein fragment forms a dimer, whose N-terminal domains are responsible for ATP binding and hydrolysis. The C-terminal domains form the sides of a 20 angstrom hole through the protein dimer which may play a role in DNA strand passage during the supercoiling reaction.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,ENGLAND	University of Leicester	WIGLEY, DB (corresponding author), YORK UNIV,DEPT CHEM,YORK YO1 5DD,ENGLAND.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Maxwell, Anthony/0000-0002-5756-6430	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADACHI T, 1987, NUCLEIC ACIDS RES, V15, P771, DOI 10.1093/nar/15.2.771; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P6289, DOI 10.1073/pnas.76.12.6289; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JACKSON AP, 1991, J MOL BIOL, V217, P15, DOI 10.1016/0022-2836(91)90606-7; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; MORRISON A, 1980, J BIOL CHEM, V255, P2211; RAU DC, 1987, J MOL BIOL, V193, P555, DOI 10.1016/0022-2836(87)90266-X; REECE RJ, 1990, J MOL BIOL, V215, P493, DOI 10.1016/S0022-2836(05)80162-7; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, NUCLEIC ACIDS RES, V19, P1399, DOI 10.1093/nar/19.7.1399; REECE RJ, 1991, J BIOL CHEM, V266, P3540; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; RICE DW, 1981, ACTA CRYSTALLOGR A, V37, P491, DOI 10.1107/S0567739481001186; SUBRAMANIAN E, 1977, P NATL ACAD SCI USA, V74, P556, DOI 10.1073/pnas.74.2.556; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; TAMURA JK, 1990, J BIOL CHEM, V265, P21342; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; YAMAGISHI J, 1986, MOL GEN GENET, V204, P367, DOI 10.1007/BF00331012	26	491	495	0	28	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					624	629		10.1038/351624a0	http://dx.doi.org/10.1038/351624a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646964				2022-12-24	WOS:A1991FT11200055
J	SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC				SLEMENDA, CW; CHRISTIAN, JC; REED, T; REISTER, TK; WILLIAMS, CJ; JOHNSTON, CC			LONG-TERM BONE LOSS IN MEN - EFFECTS OF GENETIC AND ENVIRONMENTAL-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						OSTEOPOROSIS; TWINS; ALCOHOL DRINKING; SMOKING	NHLBI TWIN; CIGARETTE-SMOKING; RISK-FACTORS; MASS; FRACTURES; OSTEOPOROSIS; WOMEN; HIP; AGE; HERITABILITY	Objective: To identity environmental factors associated with bone loss in adult male twins and to determine the extent to which shared environmental characteristics affect estimates of the genetic influence on bone loss. Design: A 16-year cohort study. Setting: A midwestern university hospital. Participants:One hundred and eleven male veterans of World War II or the Korean conflict, born between 1916 and 1927. All were twins, with the sample comprising 48 pairs and 15 persons whose twin brothers were deceased or seriously ill. Measurements: Bone mass and environmental characteristics (cigarette smoking, alcohol consumption, physical activity, dietary calcium intake, use of thiazide diuretics) measured at baseline and 16 years later. Results: Rates of radial bone loss averaged 0.45% per year. Those who both smoked and used alcohol at levels greater than the median for the population had a rate of bone loss (10% in 16 years) twice the rate of those who were below the median level for both variables (5% bone loss, P = 0.003). Rates of bone loss were correlated within twin pairs, and these correlations were diminished 25% to 35% by adjustments for environmental influences on bone loss. However, statistically significant within-pair correlations remained (r congruent-to 0.4), which did not differ between monozygotic and dizygotic twin pairs after adjustments for smoking, alcohol use, dietary calcium intake, and exercise. Conclusions: Bone loss in men during mid-life is determined, at least in part, by environmental factors, including smoking, alcohol intake, and, possibly, physical activity. Rates of bone loss were similar within twin pairs, apparently because of a shared environment.			SLEMENDA, CW (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, DIV BIOSTAT, 702 BARNHILL DR, INDIANAPOLIS, IN 46202 USA.			Williams, Christopher/0000-0001-6346-8100	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055027] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR750] Funding Source: Medline; NHLBI NIH HHS [HC 55027] Funding Source: Medline; NIA NIH HHS [AG 05793] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BACON WE, 1989, AM J PUBLIC HEALTH, V79, P1556, DOI 10.2105/AJPH.79.11.1556; CHRISTIAN JC, 1989, AM J HUM GENET, V44, P429; CHRISTIAN JC, 1974, AM J HUM GENET, V26, P154; CHRISTIANSEN C, 1987, LANCET, V1, P1106; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DEVERNEJOUL MC, 1983, CLIN ORTHOP RELAT R, V179, P107; FABSITZ R, 1985, J CHRON DIS, V38, P165, DOI 10.1016/0021-9681(85)90089-X; FABSITZ RR, 1988, ACTA GENET MED GEMEL, V37, P217, DOI 10.1017/S0001566000003822; FEINLEIB M, 1977, AM J EPIDEMIOL, V106, P284, DOI 10.1093/oxfordjournals.aje.a112464; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; HUTCHINSON TA, 1979, LANCET, V2, P705; KLATSKY AL, 1981, ANN INTERN MED, V95, P139, DOI 10.7326/0003-4819-95-2-139; KRALL EA, 1991, J BONE MINER RES, V6, P331; MEIER DE, 1984, ANN INTERN MED, V101, P605, DOI 10.7326/0003-4819-101-5-605; NILSSON BE, 1970, ACTA CHIR SCAND, V136, P383; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PEDERSEN N, 1981, TWIN RES G, V3, P37; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SUZUKI DT, 1981, INTRO GENETIC ANAL; Swan G E, 1990, J Subst Abuse, V2, P39; TYLAVSKY FA, 1989, CALCIFIED TISSUE INT, V45, P265, DOI 10.1007/BF02556017; VASSART G, 1987, SCIENCE, V235, P683, DOI 10.1126/science.2880398; WASNICH RD, 1985, AM J OBSTET GYNECOL, V153, P745, DOI 10.1016/0002-9378(85)90338-2; 1989, REDUCING HLTH CONSEQ	32	181	188	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1992	117	4					286	291		10.7326/0003-4819-117-4-286	http://dx.doi.org/10.7326/0003-4819-117-4-286			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH464	1637023				2022-12-24	WOS:A1992JH46400003
J	PERKINS, LA; LARSEN, I; PERRIMON, N				PERKINS, LA; LARSEN, I; PERRIMON, N			CORKSCREW ENCODES A PUTATIVE PROTEIN TYROSINE PHOSPHATASE THAT FUNCTIONS TO TRANSDUCE THE TERMINAL SIGNAL FROM THE RECEPTOR TYROSINE KINASE TORSO	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYO; POSTERIOR PATTERN; BICOID PROTEIN; X-CHROMOSOME; BODY PATTERN; MELANOGASTER; MUTATIONS; REQUIREMENT; SYSTEM	We describe the characterization of the Drosophila gene, corkscrew (csw), which is maternally required for normal determination of cell fates at the termini of the embryo. Determination of terminal cell fates is mediated by a signal transduction pathway that involves a receptor tyrosine kinase, torso, a serine/threonine kinase, D-raf, and the transcription factors, tailless and huckebein. Double mutant and cellular analyses between csw, torso, D-raf, and tailless indicate that csw acts downstream of torso and in concert with D-raf to positively transduce the torso signal via tailless, to downstream terminal genes. The csw gene encodes a putative nonreceptor protein tyrosine phosphatase covalently linked to two N-terminal SH2 domains, which is similar to the mammalian PTP1C protein.	HARVARD UNIV, SCH MED, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	PERKINS, LA (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSSON D, 1983, GENETICS, V105, P309; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, IN PRESS GENETICS; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; HARIHARAN IK, 1991, P NATL ACAD SCI USA, V89, P1123; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; Klingler M, 1990, Semin Cell Biol, V1, P151; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LINDSLEY D, 1987, DROS INF SERV, V65; LINDSLEY D, 1990, DROS INF SERV, V68; LINDSLEY D, 1986, DROS INF SERV, V64; LINDSLEY DL, 1985, DROS INF SERV, V62; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; Maniatis T., 1982, MOL CLONING; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MLODZIK M, 1987, GENE DEV, V1, P603, DOI 10.1101/gad.1.6.603; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Perkins L A, 1991, In Vivo, V5, P521; PERRIMON N, 1985, GENETICS, V111, P23; PERRIMON N, 1986, GENETICS, V113, P695; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; ROBERTSON HM, 1988, GENETICS, V118, P461; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SMOUSE D, 1988, GENE DEV, V2, P830, DOI 10.1101/gad.2.7.830; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1988, DEVELOPMENT, V102, P721; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van der Meer JM., 1977, DROS INFORM SERV, V52, P160; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836	83	374	379	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					225	236		10.1016/0092-8674(92)90098-W	http://dx.doi.org/10.1016/0092-8674(92)90098-W			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638629				2022-12-24	WOS:A1992JE75700007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SILICONE BREAST IMPLANT DECISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-24	WOS:A1992HY94400005
J	POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D				POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D			MYOGLOBIN IN A CYANOBACTERIUM	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; NITROGEN-FIXATION; PROTEINS	Myoglobin was found in the nitrogen-fixing cyanobacterium Nostoc commune. This cyanobacterial myoglobin, referred to as cyanoglobin, was shown to be a soluble hemoprotein of 12.5 kilodaltons with an amino acid sequence that is related to that of myoglobins from two lower eukaryotes, the ciliated protozoa Paramecium caudatum and Tetrahymena pyriformis. Cyanoglobin is encoded by the glbNgene, which is positioned between nifU and nifH-two genes essential for nitrogen fixation-in the genome of Nostoc. Cyanoglobin was detected in Nostoc cells only when they were starved for nitrogen and incubated microaerobically.			POTTS, M (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061, USA.							Bothe H., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P87; CARPENTER EJ, 1976, SCIENCE, V191, P1278, DOI 10.1126/science.1257749; DEFRANCESCO N, 1988, J BACTERIOL, V170, P3297, DOI 10.1128/jb.170.7.3297-3300.1988; GALLON JR, 1974, CAN J MICROBIOL, V20, P1633, DOI 10.1139/m74-254; Haselkorn R, 1992, BIOL NITROGEN FIXATI, P166; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2441; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schopf JW, 1982, BIOL CYANOBACTERIA, P543; STEWART WDP, 1978, ENDEAVOUR, V2, P170, DOI 10.1016/0160-9327(78)90097-2; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wolk C. P., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P359	18	98	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1690	1692		10.1126/science.256.5064.1690	http://dx.doi.org/10.1126/science.256.5064.1690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609281				2022-12-24	WOS:A1992HZ17400048
J	CALVERLEY, DC; JONES, GW; KELTON, JG				CALVERLEY, DC; JONES, GW; KELTON, JG			SPLENIC RADIATION FOR CORTICOSTEROID-RESISTANT IMMUNE THROMBOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						SPLEEN; RADIOTHERAPY; THROMBOCYTOPENIA; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PREDNISONE	CHRONIC LYMPHOCYTIC-LEUKEMIA; PURPURA; SPLENECTOMY; IRRADIATION	Objective: To determine the role of splenic radiation as a treatment for immune thrombocytopenia. Design: Retrospective analysis of an open, nonrandomized investigation. Setting: A regional cancer center, referred care, and primary care settings. Patients: Eleven older patients with idiopathic thrombocytopenic purpura (ITP) and 8 patients with secondary immune thrombocytopenia refractory to corticosteroid treatment for whom surgery would have posed a high risk. Intervention: A short course (1 to 6 weeks) of radiation therapy to the spleen (total dose, 75 to 1370 cGy) with or without concurrent and postradiation corticosteroid administration. Measurements: Efficacy was assessed by measuring any increase in the platelet count and by monitoring the duration of response and side effects. Results: Of 11 patients with ITP, 8 patients responded. Three patients had a sustained (> 52 weeks) increase in the platelet count to safe levels after therapy was discontinued. An additional patient had a sustained response but required intermittent, low-dose corticosteroids. Four other patients had increases in their platelet counts that lasted from 8 to 25 weeks. Two of the eight patients without ITP had a positive response, whereas four did not respond, and two were not evaluable. Patients had no adverse reactions to the radiation treatment. Conclusion: Splenic radiation can be a safe and effective method to raise the platelet count in older patients with ITP that is refractory to corticosteroids and in whom the risks associated with splenectomy are high.	MCMASTER UNIV, MED CTR, DEPT MED, ROOM 2N34, 1200 MAIN ST W, HAMILTON L8N 3Z5, ONTARIO, CANADA; MCMASTER UNIV, MED CTR, DEPT PATHOL, HAMILTON L8N 3Z5, ONTARIO, CANADA; HAMILTON REG CANC CTR, DEPT RADIAT ONCOL, HAMILTON L8V 1C3, ONTARIO, CANADA; CANADIAN RED CROSS, BLOOD TRANSFUS SERV, HAMILTON, ONTARIO, CANADA	McMaster University; McMaster University; McMaster University								AKWARI OE, 1987, ANN SURG, V206, P529, DOI 10.1097/00000658-198710000-00014; BRENNAN MF, 1975, AM J SURG, V129, P490, DOI 10.1016/0002-9610(75)90197-X; BYHARDT RW, 1975, CANCER, V35, P1621, DOI 10.1002/1097-0142(197506)35:6<1621::AID-CNCR2820350622>3.0.CO;2-U; COLA B, 1986, INT SURG, V71, P195; COMAS FV, 1968, AMER J ROENTGENOL RA, V104, P668, DOI 10.2214/ajr.104.3.668; COON WW, 1987, SURG GYNECOL OBSTET, V164, P225; DAILEY MO, 1980, NEW ENGL J MED, V302, P215, DOI 10.1056/NEJM198001243020406; GUINEY MJ, 1989, INT J RADIAT ONCOL, V16, P225, DOI 10.1016/0360-3016(89)90035-7; JACOBS P, 1986, Q J MED, V58, P153; PIZZUTO J, 1984, BLOOD, V64, P1179; RUSSO D, 1987, HAEMATOLOGICA, V72, P445; SCHWARTZ SI, 1980, SURGERY, V88, P497; STRATTON JR, 1989, J NUCL MED, V30, P629; TERSTAPPEN LWMM, 1988, EUR J HAEMATOL, V41, P496; WARKENTIN TE, 1990, DRUGS, V40, P531, DOI 10.2165/00003495-199040040-00004; WILLIAMS WJ, 1990, HEMATOLOGY, P1381	16	32	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1992	116	12	1				977	981		10.7326/0003-4819-116-12-977	http://dx.doi.org/10.7326/0003-4819-116-12-977			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY793	1586107				2022-12-24	WOS:A1992HY79300004
J	HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ				HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ			TARGETING OF CELL-SURFACE BETA-AMYLOID PRECURSOR PROTEIN TO LYSOSOMES - ALTERNATIVE PROCESSING INTO AMYLOID-BEARING FRAGMENTS	NATURE			English	Article							ALZHEIMERS-DISEASE; IDENTIFICATION; RECEPTOR	PROGRESSIVE cerebral deposition of the amyloid beta-peptide is an early and invariant feature of Alzheimer's disease. The beta-peptide is released by proteolytic cleavages from the beta-amyloid precursor protein (beta-APP) 1, a membrane-spanning glycoprotein expressed in most mammalian cells. Normal secretion of beta-APP involves a cleavage in the beta-peptide region 2,3, releasing the soluble extramembranous portion 4,5 and retaining a 10K C-terminal fragment in the membrane 6. Because this secretory pathway precludes beta-amyloid formation, we searched for an alternative proteolytic processing pathway that can generate beta-peptide-bearing fragments from full-length beta-APP. Incubation of living human endothelial cells with a beta-APP antibody revealed reinternalization of mature PAPP from the cell surface and its targeting to endosomes/lysosomes. After cell-surface biotinylation, full-length biotinylated beta-APP was recovered inside the cells. Purification of lysosomes directly demonstrated the presence of mature beta-APP and an extensive array of beta-peptide-containing proteolytic products. Our results define a second processing pathway for beta-APP and suggest that it may be responsible for generating amyloid-bearing fragments in Alzheimer's disease.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, NEUROSCI PROGRAM, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA.							BASKIN F, 1991, J NEUROSCI RES, V29, P127, DOI 10.1002/jnr.490290115; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DICE JF, 1990, CRIT REV THER DRUG, V7, P211; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	26	825	843	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					500	503		10.1038/357500a0	http://dx.doi.org/10.1038/357500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608449				2022-12-24	WOS:A1992HY05200064
J	GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L				GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L			THE ROLE OF CRYSTAL POLARITY IN ALPHA-AMINO-ACID CRYSTALS FOR INDUCED NUCLEATION OF ICE	SCIENCE			English	Article							CONSISTENT FORCE-FIELD; WATER; CRYSTALLIZATION; DENSITIES; PEPTIDES	The hydrophobic faces of single crystals of a series of pairs of racemic and chiral-resolved hydrophobic alpha-amino acids were used as a substrate, onto which water vapor has been cooled to freezing. The morphologies and molecular packing arrangements within each crystal pair are similar but only one of each pair exhibits a polar axis, parallel to the hydrophobic face exposed to water. Those crystals that have a polar axis induce a freezing point higher by 4-degrees to 5-degrees-C than the corresponding crystals that do not have a polar axis. The results are interpreted in terms of an electric field mechanism that helps align the water molecules into ice-like clusters en route to crystallization.	WEIZMANN INST SCI, DEPT MAT & INTERFACES, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BARTHAKUR N, 1963, NATURE, V200, P866, DOI 10.1038/200866a0; BENEDETTI E, 1973, ACTA CRYSTALLOGR B, V29, P730, DOI 10.1107/S0567740873003250; Blair D. N., 1973, Journal of Applied Meteorology, V12, P1012, DOI 10.1175/1520-0450(1973)012<1012:CCTOGU>2.0.CO;2; COLL M, 1986, ACTA CRYSTALLOGR C, V42, P599, DOI 10.1107/S0108270186095240; CORRIN ML, 1968, J PHYS CHEM-US, V72, P643, DOI 10.1021/j100848a043; DAVIS BL, 1975, J APPL METEOROL, V14, P891, DOI 10.1175/1520-0450(1975)014<0891:AEFTUN>2.0.CO;2; DESTRO R, 1988, J PHYS CHEM-US, V92, P966, DOI 10.1021/j100315a022; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; DIBLASIO B, 1975, ACTA CRYSTALLOGR B, V31, P601, DOI 10.1107/S0567740875003342; DONOHUE J, 1950, J AM CHEM SOC, V72, P949, DOI 10.1021/ja01158a079; EISENSTEIN M, 1988, ACTA CRYSTALLOGR B, V44, P412, DOI 10.1107/S0108768188002356; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; GAVISH M, 1990, SCIENCE, V250, P973, DOI 10.1126/science.250.4983.973; GRAYER S, 1990, THESIS WEIZMANN I SC; GRAYER S, 1986, THESIS WEIZMANN I SC; GREEN RL, 1985, NATURE, V317, P645, DOI 10.1038/317645a0; HAGLER AT, 1974, J AM CHEM SOC, V96, P5319, DOI 10.1021/ja00824a004; HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096; HIRSHFELD FL, 1977, ISRAEL J CHEM, V16, P226; HIRSHFELD FL, 1971, ACTA CRYSTALL B-STRU, VB 27, P769, DOI 10.1107/S0567740871002905; JACQUEMAIN D, 1991, J AM CHEM SOC, V113, P7684, DOI 10.1021/ja00020a034; LIFSON S, 1979, J AM CHEM SOC, V101, P5111, DOI 10.1021/ja00512a001; LINDOW SE, 1983, ANNU REV PHYTOPATHOL, V21, P363, DOI 10.1146/annurev.py.21.090183.002051; MALLIKARJUNAN M, 1969, ACTA CRYSTALL B-STRU, VB 25, P296, DOI 10.1107/S0567740869002147; MATHIESON AM, 1952, ACTA CRYSTALLOGR, V5, P332; MATHIESON AM, 1953, ACTA CRYSTALLOGR, V6, P399; MIZUNO H, 1989, PROTEINS, V5, P47, DOI 10.1002/prot.340050107; MOSTAD A, 1972, ACTA CHEM SCAND, V26, P3819, DOI 10.3891/acta.chem.scand.26-3819; MOSTAD A, 1973, ACTA CHEM SCAND, V27, P401, DOI 10.3891/acta.chem.scand.27-0401; PARUNGO FP, 1965, J ATMOS SCI, V22, P309, DOI 10.1175/1520-0469(1965)022<0309:MSAINO>2.0.CO;2; PARUNGO FP, 1967, J ATMOS SCI, V24, P274, DOI 10.1175/1520-0469(1967)024<0274:AAAIN>2.0.CO;2; POWER BA, 1962, NATURE, V194, P1170, DOI 10.1038/1941170a0; SIMPSON HJ, 1966, ACTA CRYSTALLOGR, V20, P550, DOI 10.1107/S0365110X66001221; STOREY KB, 1990, SCI AM, V263, P92, DOI 10.1038/scientificamerican1290-92; TORII K, 1970, ACTA CRYSTALL B-STRU, VB 26, P1317, DOI 10.1107/S0567740870004065; TORII K, 1971, ACTA CRYSTALL B-STRU, VB 27, P2237, DOI 10.1107/S0567740871005612; TORII K, 1973, ACTA CRYSTALLOGR B, V29, P2799, DOI 10.1107/S0567740873007569; VONNEGUT B, 1947, J APPL PHYS, V18, P593, DOI 10.1063/1.1697813; WANG JC, UNPUB; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; ZHU SB, 1991, J CHEM PHYS, V94, P1403, DOI 10.1063/1.459998	41	138	144	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					815	818		10.1126/science.1589763	http://dx.doi.org/10.1126/science.1589763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589763				2022-12-24	WOS:A1992HT23500037
J	GOODWIN, FK				GOODWIN, FK			TRICYCLICS AND HEART-TRANSPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), US ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							SHAPIRO PA, 1991, AM J PSYCHIAT, V148, P371; DIAGNOSTIC STATISTIC	2	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	1991	265	24					3221	3221						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	FR835	1646339				2022-12-24	WOS:A1991FR83500005
J	DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA				DOMBROSKI, AJ; WALTER, WA; RECORD, MT; SIEGELE, DA; GROSS, CA			POLYPEPTIDES CONTAINING HIGHLY CONSERVED REGIONS OF TRANSCRIPTION INITIATION-FACTOR SIGMA-70 EXHIBIT SPECIFICITY OF BINDING TO PROMOTER DNA	CELL			English	Article								The sigma-70 subunit of E. coli RNA polymerase is required for sequence-specific recognition of promoter DNA. Genetic studies and sequence analysis have indicated that sigma-70 contains two specific DNA-binding domains that recognize the two conserved portions of the prokaryotic promoter. However, intact sigma-70 does not bind to DNA. Using C-terminal and internal polypeptides of sigma-70, carrying one or both putative DNA-binding domains, we demonstrate that sigma-70 does contain two DNA-binding domains, but that N-terminal sequences inhibit the ability of intact sigma-70 to bind to DNA. Thus, we propose that sigma-70 is a sequence-specific DNA-binding protein that normally functions through an allosteric interaction with the core subunits of RNA polymerase.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	DOMBROSKI, AJ (corresponding author), UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA.				NIAID NIH HHS [AI19635] Funding Source: Medline; NIGMS NIH HHS [GM23467] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023467, R01GM023467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1990, ANNU REV BIOCHEM, V53, P293; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; BURGESS RR, 1970, FED PROC, V29, P1164; Chamberlin M.J., 1976, RNA POLYMERASE, P159; CHENCHICK A, 1981, FEBS LETT, V128, P46, DOI 10.1016/0014-5793(81)81076-9; CHENCHIK AA, 1982, MOL BIOL+, V16, P26; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DEHASETH P L, 1978, Biochemistry, V17, P1612, DOI 10.1021/bi00602a006; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; GROSS CA, 1992, IN PRESS TRANSCRIPTI; GUNSALUS RP, 1980, P NATL ACAD SCI-BIOL, V77, P7117, DOI 10.1073/pnas.77.12.7117; HARLEY CB, 1987, NUCLEIC ACIDS RES, V15, P2343, DOI 10.1093/nar/15.5.2343; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HILTON MD, 1985, J BIOL CHEM, V260, P8121; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HU JC, 1988, J MOL BIOL, V203, P15, DOI 10.1016/0022-2836(88)90087-3; KILLEEN MT, 1992, MOL CELL BIOL, V12, P30, DOI 10.1128/MCB.12.1.30; KOBAYASHI M, 1990, NUCLEIC ACIDS RES, V18, P7367, DOI 10.1093/nar/18.24.7367; KROOS L, 1989, SCIENCE, V243, P526, DOI 10.1126/science.2492118; KUDO T, 1981, MOL GEN GENET, V181, P63, DOI 10.1007/BF00339006; KUDO T, 1981, J BIOL CHEM, V256, P9778; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; LEDERER H, 1991, J MOL BIOL, V219, P747, DOI 10.1016/0022-2836(91)90669-W; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3516, DOI 10.1021/bi00556a016; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; LU SJ, 1990, P NATL ACAD SCI USA, V87, P9722, DOI 10.1073/pnas.87.24.9722; Maniatis T., 1982, MOL CLONING; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; MOYLE H, 1991, J BACTERIOL, V173, P1944, DOI 10.1128/jb.173.6.1944-1950.1991; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; RAMESH U, 1989, BIOCHEM BIOPH RES CO, V160, P121, DOI 10.1016/0006-291X(89)91629-X; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SHANER SL, 1982, COLD SPRING HARB SYM, V47, P463; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIMPSON RB, 1979, CELL, V18, P277, DOI 10.1016/0092-8674(79)90047-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOPTA M, 1989, NATURE, V341, P410, DOI 10.1038/341410a0; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; STRAGIER P, 1989, SCIENCE, V243, P507, DOI 10.1126/science.2536191; STRAUSS HS, 1980, BIOCHEMISTRY-US, V19, P3504, DOI 10.1021/bi00556a015; STRICKLAND MS, 1988, BIOCHEMISTRY-US, V27, P5755, DOI 10.1021/bi00415a054; TREMPY JE, 1985, MOL BIOL MICROBIAL D, P162; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6; WELLMAN A, 1991, BIOCHEM BIOPH RES CO, V177, P140, DOI 10.1016/0006-291X(91)91959-G; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU CW, 1975, P NATL ACAD SCI USA, V72, P3019, DOI 10.1073/pnas.72.8.3019; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUDERIAN P, 1982, CELL, V30, P843, DOI 10.1016/0092-8674(82)90289-6; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010; ZUBER P, 1989, J MOL BIOL, V206, P605, DOI 10.1016/0022-2836(89)90569-X	65	296	302	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 7	1992	70	3					501	512		10.1016/0092-8674(92)90174-B	http://dx.doi.org/10.1016/0092-8674(92)90174-B			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643661	Bronze			2022-12-24	WOS:A1992JH12400015
J	GALAN, JE; PACE, J; HAYMAN, MJ				GALAN, JE; PACE, J; HAYMAN, MJ			INVOLVEMENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN THE INVASION OF CULTURED-MAMMALIAN-CELLS BY SALMONELLA-TYPHIMURIUM	NATURE			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; INFECTION; CLONING	SALMONELLA infection continues to be a major world-wide health problem 1. One essential pathogenic feature common to all Salmonella is their ability to penetrate the cells of the intestinal epithelium which are normally non-phagocytic 2. The internalization of Salmonella into mammalian cells is thought to be a receptor-mediated phenomenon and the invasion of cultured epithelial cells depends on several Salmonella genes, but nothing is known about the host determinants participating in this interaction 3-6. Protein tyrosine phosphorylation follows stimulation of many cell-surface receptors to initiate signal transduction pathways that stimulate cellular responses 7. We report here that invasion of cultured Henle-407 cells by Salmonella typhimurium induces the tyrosine phosphorylation of the epidermal growth factor (EGF) receptor. In contrast, an isogenic strain of S. typhimurium that is defective in invasion owing to a mutation in the invA gene is unable to induce such phosphorylation. Addition of EGF to cultured Henle-407 cells allowed the internalization of the invasion-defective S. typhimurium invA mutant although it did not cause the internalization of an adherent, but non-invasive, strain of Escherichia coli. This result indicates that stimulation of the EGF receptor is involved in the invasion of cultured Henle-407 cells by S. typhimurium.			GALAN, JE (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							CHALKER RB, 1988, REV INFECT DIS, V10, P111; CHENEY CP, 1980, INFECT IMMUN, V28, P1019; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GALAN JE, IN PRESS J BACT; GINOCCHIO C, IN PRESS P NATN ACAD; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAMPS MP, 1988, ONCOGENE, V2, P305; LEE EB, 1990, ONCOGENE, V5, P1165; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; RIJKEN PJ, 1991, J CELL SCI, V100, P491; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Todaro G J, 1990, Semin Cancer Biol, V1, P257; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	182	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					588	589		10.1038/357588a0	http://dx.doi.org/10.1038/357588a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608468				2022-12-24	WOS:A1992HZ11200053
J	UDAKA, K; TSOMIDES, TJ; EISEN, HN				UDAKA, K; TSOMIDES, TJ; EISEN, HN			A NATURALLY-OCCURRING PEPTIDE RECOGNIZED BY ALLOREACTIVE CD8+ CYTOTOXIC LYMPHOCYTES-T IN ASSOCIATION WITH A CLASS-I MHC PROTEIN	CELL			English	Article							CELL RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; HISTOCOMPATIBILITY ANTIGENS; TRANSGENIC MICE; VIRAL PEPTIDES; CLONE; GENE; DETERMINANT; EXPRESSION	The antigenic structures that initiate T cell responses to foreign (allogeneic) cells have long attracted considerable interest. We have purified and sequenced a peptide from mouse spleen that is recognized in association with the class I MHC protein H-2L(d) by 2C, an alloreactive CD8+ T cell clone. The peptide (LSP-FPFDL) greatly enhances the susceptibility of L(d+) cells to lysis by 2C, and this activity is completely blocked by a clonotypic antibody against the 2C T cell receptor. Thus, this study characterizes the naturally occurring peptide moiety of an MHC-I/peptide complex recognized by alloreactive CD8+ T cells. The peptide, which occurs in the thymus of MHC-disparate mice, can be used to study T cell development in mice expressing transgenes for the 2C T cell receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [R35-CA42504, CA14051, CA09255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042504, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; ERARD F, 1985, EUR J IMMUNOL, V15, P798, DOI 10.1002/eji.1830150811; EVANS GA, 1982, P NATL ACAD SCI-BIOL, V79, P1994, DOI 10.1073/pnas.79.6.1994; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1982, EUR J IMMUNOL, V12, P401, DOI 10.1002/eji.1830120508; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MESCHER MF, 1983, METHOD ENZYMOL, V92, P86; MOORE KW, 1982, SCIENCE, V215, P679, DOI 10.1126/science.7058332; MULLBACHER A, 1991, J IMMUNOL, V147, P1765; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SCHULZ M, 1991, EUR J IMMUNOL, V21, P1181, DOI 10.1002/eji.1830210513; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; VANBLEEK GM, 1990, NATURE, V348, P213; VANMEERWIJK JPM, 1991, J EXP MED, V174, P815, DOI 10.1084/jem.174.4.815	51	287	296	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					989	998		10.1016/0092-8674(92)90617-L	http://dx.doi.org/10.1016/0092-8674(92)90617-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606619				2022-12-24	WOS:A1992HY79200010
J	MITSUHASHI, M; KELLER, C; AKITAYA, T				MITSUHASHI, M; KELLER, C; AKITAYA, T			GENE MANIPULATION ON PLASTIC PLATES	NATURE			English	Article							HYBRIDIZATION	Oligonucleotide-immobilized plastic plates provide a rapid and easy-to-use tool for use in mRNA research, including the long-term storage, amplification and detection of the specific message, in vitro synthesis of both strands of sense and antisense mRNA, and ligation of cDNA to other DNA molecules.			MITSUHASHI, M (corresponding author), HITACHI CHEM RES CTR,DIV MED SCI,1003 HLTH SCI RD W,IRVINE,CA 92715, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Melton D. A., 1984, NUCLEIC ACIDS RES, V7, P1175; Sambrook J., 1989, MOL CLONING LAB MANU; WHITE BA, 1982, J BIOL CHEM, V257, P8569	6	27	60	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					519	520		10.1038/357519a0	http://dx.doi.org/10.1038/357519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608454				2022-12-24	WOS:A1992HY05200070
J	SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM				SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM			PRESENCE OF THE EARLIEST VERTEBRATE HARD TISSUES IN CONODONTS	SCIENCE			English	Article								From histological investigations into the microstructure of conodont elements, a number of tissue types characteristic of the phosphatic skeleton of vertebrates have been identified. These include cellular bone, two forms of hypermineralized enamel homologs, and globular calcified cartilage. The presence of cellular bone in conodont elements provides unequivocal evidence for their vertebrate affinities. Furthermore, the identification of vertebrate hard tissues in the oral elements of conodonts extends the earliest occurrence of vertebrate hard tissues back by around 40 million years, from the Middle Ordovician (475 million years ago) to the Late Cambrian (515 million years ago).	UNIV BIRMINGHAM,SCH EARTH SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	University of Birmingham; University of London; King's College London	SANSOM, IJ (corresponding author), UNIV DURHAM,DEPT GEOL SCI,SOUTH RD,DURHAM DH1 3LE,ENGLAND.		Sansom, Ivan/B-4078-2009	Smith, Paul/0000-0002-5141-1577				ALDRIDGE RJ, 1986, LETHAIA, V19, P279, DOI 10.1111/j.1502-3931.1986.tb00741.x; ANDRES D, 1988, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V200, P105; Barnes C.R., 1973, Life Sci Contr R Ont Mus, VNo. 90, P1; BARSKOV IS, 1982, PALEONTOL J, P82; BENGTSON S, 1976, Lethaia, V9, P185, DOI 10.1111/j.1502-3931.1976.tb00966.x; BRIGGS DEG, 1987, LETHAIA, V20, P381, DOI 10.1111/j.1502-3931.1987.tb00799.x; BRIGGS DEG, 1983, LETHAIA, V16, P1, DOI 10.1111/j.1502-3931.1983.tb01139.x; Denison R H, 1963, Clin Orthop Relat Res, V31, P141; Dzik J., 1986, PROBLEMATIC FOSSIL T, P240; Fahraeus L.E., 1987, P105; Gross W., 1954, Senckenbergiana Lethaea, V35, P73; HALSTEAD LB, 1982, PROBLEMS PHYLOGENETI, P159; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JEPPSSON L, 1979, LETHAIA, V12, P153, DOI 10.1111/j.1502-3931.1979.tb00994.x; KREJSA RJ, 1990, LETHAIA, V23, P359, DOI 10.1111/j.1502-3931.1990.tb01369.x; Lindstrom M, 1964, CONODONTS; MULLER KJ, 1981, TREATISE INVERTE W S, V2, pW78; ORVIG T, 1989, ZOOL SCR, V18, P427, DOI 10.1111/j.1463-6409.1989.tb00138.x; ORVIG T, 1968, CURRENT PROBLEMS LOW, P374; Pander C. H., 1856, AKAD WISS, V10, P1; Pietzner H., 1968, Palaeontographica A, V128, P115; Schmidt H., 1964, Palaeontologische Zeitschrift, V38, P105; Smith M.M., 1989, Historical Biology, V3, P97; SMITH MM, 1990, BIOL REV, V65, P277, DOI 10.1111/j.1469-185X.1990.tb01427.x; SMITH MM, 1991, SCIENCE, V251, P301, DOI 10.1126/science.251.4991.301; STEWART GA, 1956, J PALEONTOL, V30, P261; Sweet WC, 1988, CONODONTA MORPHOLOGY; Szaniawski H., 1987, P35; TILLIER S, 1986, RECHERCHE, V17, P1574; TILLIER S, 1986, CR ACAD SCI II, V303, P627; 1968, ODONT REVY S13, V19, P1	31	135	145	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1308	1311		10.1126/science.1598573	http://dx.doi.org/10.1126/science.1598573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598573				2022-12-24	WOS:A1992HW13500029
J	CHEN, JW; LEE, J; JAYARAM, M				CHEN, JW; LEE, J; JAYARAM, M			DNA CLEAVAGE IN TRANS BY THE ACTIVE-SITE TYROSINE DURING FLP RECOMBINATION - SWITCHING PROTEIN PARTNERS BEFORE EXCHANGING STRANDS	CELL			English	Article							CEREVISIAE 2-MU-M PLASMID; CIRCLE PLASMID; MECHANISM; MUTANTS; TARGET; IDENTIFICATION; RECOGNITION; RESOLVASE; SUBSTRATE; BENDS	Each recombination event mediated by the Flp recombinase is the sum of four strand breakage and reunion reactions executed in two steps of two-strand exchanges. The reaction requires four Flp monomers. The key catalytic residue in Flp is Tyr-343. Arg-191, His-305, and Arg-308 appear to facilitate the cleavage and exchange steps of recombination. These four residues constitute the invariant tetrad of the Int family site-specific recombinases. Complementation tests between "step-arrest" mutants of Flp suggest that each Flp protomer harbors a "fractional active site." Hybrid "half site-recombinase" complexes reveal that efficient catalysis occurs when the Arg-His-Arg triad is present on one Flp monomer and the active site Tyr on a second monomer. Strand cleavage by an Flp monomer occurs virtually exclusively on the half site to which its partner protein is bound (cleavage in trans), and almost never on the half site to which it is bound (cleavage in cis). Trans-cleavage by Flp can provide a means for functionally exchanging Flp monomers between two DNA partners. Such a mechanism would be germane to recombination, since cleavage and rejoining in cis can only restore the parental substrate configuration and cannot yield recombinants.			CHEN, JW (corresponding author), UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712, USA.		Lee, Jehee/AAS-3229-2021	Lee, Jehee/0000-0001-9144-3648				AMIN A, 1991, MOL CELL BIOL, V11, P4497, DOI 10.1128/MCB.11.9.4497; ANDREWS BJ, 1986, MOL CELL BIOL, V6, P2482, DOI 10.1128/MCB.6.7.2482; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; CHEN JW, 1991, J MOL BIOL, V218, P107, DOI 10.1016/0022-2836(91)90877-9; CHEN JW, 1991, P NATL ACAD SCI USA, V88, P5944, DOI 10.1073/pnas.88.14.5944; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; EVANS BR, 1990, J BIOL CHEM, V265, P18504; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; KIM SH, 1990, CELL, V63, P773, DOI 10.1016/0092-8674(90)90143-3; Maniatis T., 1982, MOL CLONING; PAN H, 1991, J BIOL CHEM, V266, P11347; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; PRASAD PV, 1986, MOL CELL BIOL, V6, P4329, DOI 10.1128/MCB.6.12.4329; QIAN XH, 1990, J BIOL CHEM, V265, P21779; QIAN XH, 1992, IN PRESS J BIOL CHEM; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SCHWARTZ CJE, 1990, J MOL BIOL, V216, P289, DOI 10.1016/S0022-2836(05)80320-1; SERRE MC, 1992, IN PRESS J MOL BIOL; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; WENTE SR, 1987, P NATL ACAD SCI USA, V84, P31, DOI 10.1073/pnas.84.1.31	24	152	156	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 15	1992	69	4					647	658		10.1016/0092-8674(92)90228-5	http://dx.doi.org/10.1016/0092-8674(92)90228-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HV089	1586945				2022-12-24	WOS:A1992HV08900009
J	MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW				MOLINA, TJ; KISHIHARA, K; SIDEROVSKI, DP; VANEWIJK, W; NARENDRAN, A; TIMMS, E; WAKEHAM, A; PAIGE, CJ; HARTMANN, KU; VEILLETTE, A; DAVIDSON, D; MAK, TW			PROFOUND BLOCK IN THYMOCYTE DEVELOPMENT IN MICE LACKING P56(LCK)	NATURE			English	Article							TYROSINE-PROTEIN-KINASE; T-CELL DEVELOPMENT; SIGNAL TRANSDUCTION; CD4; RECEPTOR; TRANSCRIPTS; EXPRESSION; ACTIVATION; P56LCK; GENE	THE protein Lck (p56lck) has a relative molecular mass of 56,000 and belongs to the Src family of tyrosine kinases 1-3. It is expressed exclusively in lymphoid cells, predominantly in thymocytes and peripheral T cells 4-5. Lck associates specifically with the cytoplasmic domains of both CD4 and CD8 T-cell surface glycoproteins 6,7 and interacts with the beta-chain of the interleukin-2 receptor 8, which implicates Lck activity in signal transduction during thymocyte ontogeny 9-13 and activation of mature T cells 14-19. Here we generate an lck null mutation by homologous recombination in embryonic stem cells to evaluate the role of p56lck in T-cell development and activation. Lck-deficient mice show a pronounced thymic atrophy, with a dramatic reduction in the double-positive (CD4+CD8+) thymocyte population. Mature, single-positive thymocytes are not detectable in these mice and there are only very few peripheral T cells. These results illustrate the crucial role of this T-cell-specific tyrosine kinase in the thymocyte development.	UNIV TORONTO, ONTARIO CANC INST, 500 SHERBOURNE ST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED BIOPHYS, TORONTO M4X 1K9, ONTARIO, CANADA; ERASMUS UNIV, DEPT CELL BIOL & IMMUNOL 2, 3000 DR ROTTERDAM, NETHERLANDS; UNIV MARBURG, INST EXPTL IMMUNOL, W-3550 MARBURG, GERMANY; MCGILL UNIV, CTR CANC, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Erasmus University Rotterdam; Philipps University Marburg; McGill University			Siderovski, David Peter/AAA-9603-2019; Molina, Thierry/ABA-5214-2020	Siderovski, David Peter/0000-0002-0688-8210; Molina, Thierry/0000-0002-3929-9754				ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FERRICK DA, 1989, IMMUNOL TODAY, V10, P403, DOI 10.1016/0167-5699(89)90035-2; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; PAIGE CJ, 1982, J IMMUNOL METHODS, V52, P51, DOI 10.1016/0022-1759(82)90349-0; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Veillette A, 1991, Semin Immunol, V3, P143; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0	29	945	982	0	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					161	164		10.1038/357161a0	http://dx.doi.org/10.1038/357161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579166				2022-12-24	WOS:A1992HU12200059
J	BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M				BARRACLOUGH, J; PINDER, P; CRUDDAS, M; OSMOND, C; TAYLOR, I; PERRY, M			LIFE EVENTS AND BREAST-CANCER PROGNOSIS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether psychosocial stress, in the form of adverse life events and social difficulties, depressive illness, or lack of confiding relationships, shortens the postoperative disease free interval in breast cancer patients. Design - Prospective follow up of a cohort of newly diagnosed breast cancer patients for 42 months after primary surgical treatment, using a life events and social difficulties schedule (LEDS) and assessment of depressive symptomatology (DSM-III). Setting - Patients recruited from breast clinics in Southampton and Portsmouth were interviewed in their homes. Patients - 204 women (83% of 246 consecutive cases) treated either by mastectomy or wide excision followed by radiotherapy interviewed four, 24, and 42 months after operation. Main outcome measures - Hazard ratios for relapse of breast cancer in relation to various measures of psychosocial stress. Relapse was defined as local recurrence or distant metastasis, or both, with histological or radiological confirmation and timed from the month when clinical symptoms began. Results - After adjustment for age and axillary lymph node involvement, the hazard ratio associated with severe life events or social difficulties (excluding "own health" ones), or both, during the year before breast cancer surgery was 0.43 (95% confidence interval 0.20 to 0.93); for those during the follow up period it was 0.88 (0.48 to 1.64). For prolonged major depression before surgery and during the follow up period, hazard ratios were 1.26 (0.49 to 3.26) and 0.85 (0.41 to 1.79) respectively. For absence of a full confidant the figures were 0.93 (0.42 to 2.09) and 0.86 (0.38 to 1.93). Conclusion - These results give no support to the theory that psychosocial stress contributes to relapse of breast cancer.	UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PSYCHIAT,SOUTHAMPTON SO9 4PE,ENGLAND; SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,SURG UNIT,SOUTHAMPTON SO9 4PE,ENGLAND; QUEEN ALEXANDRA HOSP,PORTSMOUTH PO6 3LY,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital				Osmond, Clive/0000-0002-9054-4655				Brown G., 1978, SOCIAL ORIGINS DEPRE; COX DR, 1984, ANAL SURVIVAL DATA, P112; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; HOLLAND JC, 1989, HDB PSYCHOONCOLOGY, P705; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; 1980, DIAGNOSTIC STATISTIC	7	96	96	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 25	1992	304	6834					1078	1081		10.1136/bmj.304.6834.1078	http://dx.doi.org/10.1136/bmj.304.6834.1078			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586819	Green Published, Bronze			2022-12-24	WOS:A1992HR13600014
J	HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A				HENDERSON, S; ROWE, M; GREGORY, C; CROOMCARTER, D; WANG, F; LONGNECKER, R; KIEFF, E; RICKINSON, A			INDUCTION OF BCL-2 EXPRESSION BY EPSTEIN-BARR-VIRUS LATENT MEMBRANE PROTEIN-1 PROTECTS INFECTED B-CELLS FROM PROGRAMMED CELL-DEATH	CELL			English	Article							POSITIVE BURKITTS-LYMPHOMA; ANTIGEN-DRIVEN SELECTION; ENDONUCLEASE ACTIVATION; FOLLICULAR LYMPHOMA; DEREGULATED BCL2; TRANSGENIC MICE; GENE-EXPRESSION; GROWTH; TRANSLOCATION; APOPTOSIS	Epstein-Barr virus (EBV) not only induces growth transformation in human B lymphocytes, but has more recently been shown to enhance B cell survival under suboptimal conditions where growth is inhibited; both effects are mediated through the coordinate action of eight virus-coded latent proteins. The effect upon cell survival is best recognized in EBV-positive Burkitt's lymphoma cell lines where activation of full virus latent gene expression protects the cells from programmed cell death (apoptosis). Here we show by DNA transfection into human B cells that protection from apoptosis is conferred through expression of a single EBV latent protein, the latent membrane protein LMP 1. Furthermore, we demonstrate that LMP 1 mediates this effect by up-regulating expression of the cellular oncogene bcl-2. The interplay between EBV infection and expression of this cellular oncogene has important implications for virus persistence and for the pathogenesis of virus-associated malignant disease.	BRIGHAM & WOMENS HOSP,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	HENDERSON, S (corresponding author), UNIV BIRMINGHAM,DEPT CANC STUDIES,CANC RES CAMPAIGN LABS,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND.		Rowe, Martin/B-2880-2009	Rowe, Martin/0000-0003-4139-7326; Hope, Sheila/0000-0002-3608-4379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], EPSTEIN BARR VIRUS; BAKHSHI A, 1985, CELL, V41, P889; CHEAH MSC, 1986, NATURE, V319, P239; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFF E, 1990, VIROLOGY, P1889; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; PEZZELLA F, 1990, AM J PATHOL, V137, P225; REED JC, 1989, ONCOGENE, V4, P1123; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROONEY CM, 1986, J NATL CANCER I, V77, P681, DOI 10.1093/jnci/77.3.681; ROWE M, 1985, INT J CANCER, V35, P435, DOI 10.1002/ijc.2910350404; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; ROWE M, 1986, INT J CANCER, V37, P363; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THORLEYLAWSON DA, 1985, J EXP MED, V162, P45, DOI 10.1084/jem.162.1.45; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANG F, 1987, P NATL ACAD SCI USA, V84, P3452, DOI 10.1073/pnas.84.10.3452; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	50	1129	1155	0	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 28	1991	65	7					1107	1115		10.1016/0092-8674(91)90007-L	http://dx.doi.org/10.1016/0092-8674(91)90007-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FU899	1648447				2022-12-24	WOS:A1991FU89900004
J	BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE				BEZPROZVANNY, I; WATRAS, J; EHRLICH, BE			BELL-SHAPED CALCIUM-RESPONSE CURVES OF INS(1,4,5)P3-GATED AND CALCIUM-GATED CHANNELS FROM ENDOPLASMIC-RETICULUM OF CEREBELLUM	NATURE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; MUSCLE SARCOPLASMIC-RETICULUM; PANCREATIC ACINAR-CELLS; SMOOTH-MUSCLE; TRISPHOSPHATE RECEPTOR; SINGLE CHANNEL; ADENINE-NUCLEOTIDES; RELEASE CHANNEL; SKELETAL-MUSCLE; CA-2+ RELEASE	RELEASE of calcium from intracellular stores occurs by two pathways, an inositol 1,4,5-trisphosphate (InsP3)-gated channel 1-3 and a calcium-gated channel (ryanodine receptor) 4-6. Using specific antibodies, both receptors were found in Purkinje cells of cerebellum 7,8. We have now Compared the functional properties of the channels corresponding to the two receptors by incorporating endoplasmic reticulum vesicles from canine cerebellum into planar bilayers. InsP3-gated channels were observed most frequently. Another channel type was activated by adenine nucleotides or caffeine, inhibited by ruthenium red, and modified by ryanodine, characteristics of the ryanodine receptor/channel 6. The open probability of both channel types displayed a bell-shaped curve for dependence on calcium. For the InsP3-gated channel, the maximum probability of opening occurred at 0.2-mu-M free calcium, with sharp decreases on either side of the maximum. Maximum activity for the ryanodine receptor/channel was maintained between 1 and 100-mu-M calcium. Thus, within the physiological range of cytoplasmic calcium, the InsP3-gated channel itself allows positive feedback and then negative feedback for calcium release, whereas the ryanodine receptor/channel behaves solely as a calcium-activated channel. The existence in the same cell of two channels with different responses to calcium and different ligand sensitivities provides a basis for complex patterns of intracellular calcium regulation.	UNIV CONNECTICUT, CTR HLTH, DEPT MED, FARMINGTON, CT 06032 USA; UNIV CONNECTICUT, CTR HLTH, DEPT PHYSIOL, FARMINGTON, CT 06032 USA; ACAD SCI USSR, INST CYTOL, LENINGRAD 194064, USSR	University of Connecticut; University of Connecticut; Russian Academy of Sciences			/AAX-8408-2021; Oka, Yoshitaka/C-9670-2010	/0000-0001-9657-9704; Oka, Yoshitaka/0000-0002-3482-3051				AIREY JA, 1990, J BIOL CHEM, V265, P14187; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORGATTA L, 1991, P NATL ACAD SCI USA, V88, P2486, DOI 10.1073/pnas.88.6.2486; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; ELLISMAN MH, 1990, NEURON, V5, P135, DOI 10.1016/0896-6273(90)90304-X; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HARTOONIAN AT, 1991, SCIENCE, V251, P75; HERRMANNFRANK A, 1990, BIOPHYS J, V57, pA156; HINGORANI S R, 1990, Society for Neuroscience Abstracts, V16, P1018; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; OSIPCHUK YV, 1990, EMBO J, V9, P697, DOI 10.1002/j.1460-2075.1990.tb08162.x; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1986, BIOPHYS J, V50, P1009, DOI 10.1016/S0006-3495(86)83543-3; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; VARNEY MA, 1990, BIOCHEM J, V269, P211, DOI 10.1042/bj2690211; VOLPE P, 1990, AM J PHYSIOL, V258, pC1077, DOI 10.1152/ajpcell.1990.258.6.C1077; WATRAS J, 1987, BIOCHIM BIOPHYS ACTA, V931, P354, DOI 10.1016/0167-4889(87)90227-8; WATRAS J, IN PRESS J NEUROSCI; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	35	1538	1561	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	1991	351	6329					751	754		10.1038/351751a0	http://dx.doi.org/10.1038/351751a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FU201	1648178				2022-12-24	WOS:A1991FU20100066
J	SCHLUNEGGER, MP; GRUTTER, MG				SCHLUNEGGER, MP; GRUTTER, MG			AN UNUSUAL FEATURE REVEALED BY THE CRYSTAL-STRUCTURE AT 2.2-ANGSTROM RESOLUTION OF HUMAN TRANSFORMING GROWTH-FACTOR-BETA-2	NATURE			English	Article							FACTOR-BETA; MACROMOLECULAR CRYSTALLOGRAPHY; PROTEINS; REFINEMENT; COMPLEX; PATTERN; PROGRAM; MEMBER	TRANSFORMING growth factor type-beta-2 (TGF-beta-2)1 is a member of an expanding family of growth factors that regulate proliferation and differentiation of many different cell types2,3. TGF-beta-2 binds to various receptors4, one of which was shown to be a serine/threonine kinase5. TGF-beta-2 is involved in wound healing6, bone formation7 and modulation of immune functions8. We report here the crystal structure of TGF-beta-2 at 2.2 angstrom resolution, which reveals a novel monomer fold and dimer association. The monomer consists of two antiparallel pairs of beta-strands forming a flat curved surface and a separate, long alpha-helix. The disulphide-rich core has one disulphide bond pointing through a ring formed by the sequence motifs Cys-Ala-Gly-Ala-Cys and Cys-Lys-Cys, which are themselves connected through the cysteines. Two monomers are connected through a single disulphide bridge and associate such that the helix of one subunit interacts with the concave beta-sheet surface of the other. Four exposed loop regions might determine receptor specificity. The structure provides a suitable model for the TGF-beta-s and other members of the super-family9-11 and is the basis for the analysis of the TGF-beta-2 interactions with the receptor.			SCHLUNEGGER, MP (corresponding author), CIBA GEIGY AG,DIV PHARMACEUT,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND.							BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; COX DA, 1992, ANGIOGENESIS KEY PRI, P287; IKEDA T, 1987, BIOCHEMISTRY-US, V26, P2406, DOI 10.1021/bi00383a002; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; LEE SJ, 1990, MOL ENDOCRINOL, V4, P1034, DOI 10.1210/mend-4-7-1034; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; Massague J., 1990, REV CELL BIOL, V6, P597; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; REES DC, 1980, P NATL ACAD SCI-BIOL, V77, P4633, DOI 10.1073/pnas.77.8.4633; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; SCHLUNEGGER MP, 1992, FEBS LETT, V303, P91, DOI 10.1016/0014-5793(92)80484-X; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	25	306	338	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					430	434		10.1038/358430a0	http://dx.doi.org/10.1038/358430a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641027				2022-12-24	WOS:A1992JF85300061
J	YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H				YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H			TCP1 COMPLEX IS A MOLECULAR CHAPERONE IN TUBULIN BIOGENESIS	NATURE			English	Article							HEAT-SHOCK PROTEIN; HUMAN ALPHA-TUBULIN; BETA-TUBULIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELLS; MICROTUBULES; EXPRESSION; COLOCALIZATION; OVEREXPRESSION	A ROLE in folding of newly translated proteins in the cytosol of eukaryotes has been proposed for t-complex polypeptide-1 (TCP1), although its molecular targets have not yet been identified1-3. Tubulin is a major cytosolic protein whose assembly into microtubules is critical to many cellular processes4-8. Although numerous studies have focused on the expression of tubulin9-20, little is known about the processes where by newly translated tubulin subunits acquire conformations that enable them to form alpha-beta-heterodimers. We examined the biogenesis of alpha- and beta-tubulin in rabbit reticulocyte lysate, and report here that newly translated tubulin subunits entered a 900K complex in a protease-sensitive conformation. Addition of Mg-ATP, but not nonhydrolysable analogues, released the tubulin subunits as assembly-competent protein with a conformation that was relatively protease-resistant. The 900K complex purified from reticulocyte lysate contained as its major constituent a 58K protein that cross-reacted with a monoclonal antiserum against mouse TCP1. We conclude that TCP1 functions as a cytosolic chaperone in the biogenesis of tubulin.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02146; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Case Western Reserve University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University; Yale University								AHMAD S, 1990, MOL CELL BIOL, V10, P5160, DOI 10.1128/MCB.10.10.5160; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLLAG DM, 1990, EUR J CELL BIOL, V51, P295; BROWN HR, 1983, ARCH BIOCHEM BIOPHYS, V220, P46, DOI 10.1016/0003-9861(83)90385-5; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; CLEVELAND DW, 1978, CELL, V15, P1021, DOI 10.1016/0092-8674(78)90286-6; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dustin P., 1984, MICROTUBULES; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRASSO JA, 1986, ANAT REC, V156, P397; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; ISAACS WB, 1989, CELLULAR MOL BIOL MU, P137; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SKOUFIAS DA, 1990, J CELL BIOL, V111, P1929, DOI 10.1083/jcb.111.5.1929; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VALLEE R, 1991, NATURE, V352, P187; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WU J, 1987, GENE, V61, P51, DOI 10.1016/0378-1119(87)90364-7; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1988, BIOCHEMISTRY-US, V27, P1869, DOI 10.1021/bi00406a012; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	33	397	405	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					245	248		10.1038/358245a0	http://dx.doi.org/10.1038/358245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630491				2022-12-24	WOS:A1992JD58700057
J	CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE				CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE			AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIRCULATION; SCLERODERMA; REGRESSION; SEROTONIN; THERAPY; DISEASE; HUMANS	Background. Constriction of small pulmonary arteries and arterioles and focal vascular injury are features of pulmonary hypertension. Because thromboxane A2 is both a vasoconstrictor and a potent stimulus for platelet aggregation, it may be an important mediator of pulmonary hypertension. Its effects are antagonized by prostacyclin, which is released by vascular endothelial cells. We tested the hypothesis that there may be an imbalance between the release of thromboxane A2 and prostacyclin in pulmonary hypertension, reflecting platelet activation and an abnormal response of the pulmonary vascular endothelium. Methods. We used radioimmunoassays to measure the 24-hour urinary excretion of two stable metabolites of thromboxane A2 and a metabolite of prostacyclin in 20 patients with primary pulmonary hypertension, 14 with secondary pulmonary hypertension, 9 with severe chronic obstructive pulmonary disease (COPD) but no clinical evidence of pulmonary hypertension, and 23 normal controls. Results. The 24-hour excretion of 11-dehydro-thromboxane B2 (a stable metabolite of thromboxane A2) was increased in patients with primary pulmonary hypertension and patients with secondary pulmonary hypertension, as compared with normal controls (3224+/-482, 5392+/-1640, and 1145+/-221 pg per milligram of creatinine, respectively; P<0.05), whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin F1-alpha (a stable metabolite of prostacyclin) was decreased (369+/-106, 304+/-76, and 644+/-124 pg per milligram of creatinine, respectively; P<0.05). The rate of excretion of all metabolites in the patients with COPD but no clinical evidence of pulmonary hypertension was similar to that in the normal controls. Conclusions. An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension. By contrast, the release of prostacyclin is depressed in these patients. Whether the imbalance in the release of these mediators is a cause or a result of pulmonary hypertension is unknown, but it may play a part in the development and maintenance of both forms of the disorder.	UNIV COLORADO, HLTH SCI CTR, DIV CARDIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHRISTMAN, BW (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, CTR LUNG RES, DIV PULM & CRIT CARE MED, NASHVILLE, TN 37232 USA.				NHLBI NIH HHS [HL 41952, HL 43167, HL 39952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043167, R01HL039952, R01HL041952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADESCH DB, 1989, AM J RESP CELL MOL, V1, P489, DOI 10.1165/ajrcmb/1.6.489; BARST RJ, 1985, AM REV RESPIR DIS, V131, P171; CATELLA F, 1987, THROMB RES, V47, P647, DOI 10.1016/0049-3848(87)90103-4; CHRISTMAN BW, 1989, BIOMED ENVIRON MASS, V18, P258, DOI 10.1002/bms.1200180409; Ciabattoni G, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P598; COHEN M, 1986, J AM COLL CARDIOL, V7, P172, DOI 10.1016/S0735-1097(86)80277-7; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; EDWARDS BS, 1987, J AM COLL CARDIOL, V10, P1233, DOI 10.1016/S0735-1097(87)80123-7; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Groves BM, 1990, PULMONARY CIRCULATIO, P359; HART CM, 1989, CLIN CHEST MED, V10, P59; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HENRIKSSON P, 1986, BRIT HEART J, V55, P543; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; KAHALEH MB, 1982, ANN INTERN MED, V96, P610, DOI 10.7326/0003-4819-96-5-610; NAIR SS, 1980, ARCH INTERN MED, V140, P109, DOI 10.1001/archinte.140.1.109; PATRONO C, 1986, J CLIN INVEST, V77, P590, DOI 10.1172/JCI112341; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, CHEST, V91, P356, DOI 10.1378/chest.91.3.356; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; Siegel S., 2009, NONPARAMETRIC STAT B, V2nd; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TURNERSTOKES L, 1982, CLIN RHEUM DIS, V8, P229; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; VESTERQVIST O, 1987, THROMB RES, V45, P393, DOI 10.1016/0049-3848(87)90228-3; VOELKEL NF, 1989, PULMONARY VASCULAR P, V38, P513; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2	33	892	929	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					70	75		10.1056/NEJM199207093270202	http://dx.doi.org/10.1056/NEJM199207093270202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603138				2022-12-24	WOS:A1992JC21400002
J	KARLIN, S; BRENDEL, V				KARLIN, S; BRENDEL, V			CHANCE AND STATISTICAL SIGNIFICANCE IN PROTEIN AND DNA-SEQUENCE ANALYSIS	SCIENCE			English	Article							MARKOV-CHAIN ANALYSIS; EPSTEIN-BARR VIRUS; ESCHERICHIA-COLI; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE-SEQUENCES; GROWTH-FACTOR; LYTIC ORIGIN; GENOME; IDENTIFICATION; METHYLATION	Statistical approaches help in the determination of significant configurations in protein and nucleic acid sequence data. Three recent statistical methods are discussed: (i) score-based sequence analysis that provides a means for characterizing anomalies in local sequence text and for evaluating sequence comparisons; (ii) quantile distributions of amino acid usage that reveal general compositional biases in proteins and evolutionary relations; and (iii) r-scan statistics that can be applied to the analysis of spacings of sequence markers.			KARLIN, S (corresponding author), STANFORD UNIV, DEPT MATH, STANFORD, CA 94305 USA.				NHGRI NIH HHS [HG00335-04] Funding Source: Medline; NIGMS NIH HHS [GM10452-29] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERS DG, 1991, J VIROL, V65, P931, DOI 10.1128/JVI.65.2.931-937.1991; [Anonymous], 1968, INTRO PROBABILITY TH; ARRATIA R, 1989, ANN PROBAB, V17, P9, DOI 10.1214/aop/1176991491; ARRATIA R, 1985, ADV MATH, V55, P13, DOI 10.1016/0001-8708(85)90003-9; ARRATIA R, 1991, ANNU REV BIOPHYS BIO, V11, P806; Arratia R., 1990, STAT SCI, P403, DOI [10.1214/ss/1177012015, DOI 10.1214/SS/1177012015]; ASMUSSEN S, 1982, ADV APPL PROBAB, V14, P143, DOI 10.2307/1426737; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BELL G, 1989, COMPUTERS DNA, V7; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BEUTLER E, 1989, P NATL ACAD SCI USA, V86, P192, DOI 10.1073/pnas.86.1.192; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP YM, 1975, MULTIVARIATE ANAL TH; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLAISDELL BE, 1985, J MOL EVOL, V21, P278, DOI 10.1007/BF02102360; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENDEL V, 1992, MATH COMPUT MODEL, V16, P37, DOI 10.1016/0895-7177(92)90150-J; BRENDEL V, 1991, P NATL ACAD SCI USA, V88, P1536, DOI 10.1073/pnas.88.4.1536; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHURCHILL GA, 1990, NUCLEIC ACIDS RES, V18, P589, DOI 10.1093/nar/18.3.589; CRESSIE N, 1977, AUSTR J STATIST, V19, P132; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEMBO A, 1991, ANN PROBAB, V19, P1737, DOI 10.1214/aop/1176990232; DEMBO A, 1991, ANN PROBAB, V19, P1756, DOI 10.1214/aop/1176990233; DEMBO A, 1992, ANN APPL PROBAB, V2, P304; DONOFRIO G, 1991, J MOL EVOL, V32, P504, DOI 10.1007/BF02102652; Doolittle R.F., 1990, MOL EVOLUTION COMPUT, V183; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DOOLITTLE RF, 1986, URFS ORFS, P55; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; Feller W., 1968, INTRO PROBABILITY TH, V2; GALAMBOS J, 1992, ASYMPTOTIC THEORY EX, V24, P113; GLAZ J, 1989, J AM STAT ASSOC, V84, P560; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; HAMZEH FM, 1990, J VIROL, V64, P6184, DOI 10.1128/JVI.64.12.6184-6195.1990; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HOLST L, 1980, J APPL PROBAB, V17, P284, DOI 10.2307/3212948; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOWARD B H, 1990, New Biologist, V2, P759; IGLEHART DL, 1972, ANN MATH STAT, V43, P627, DOI 10.1214/aoms/1177692642; IKEMURA T, 1990, GENOMICS, V8, P207, DOI 10.1016/0888-7543(90)90273-W; INMAN RB, 1966, J MOL BIOL, V18, P464, DOI 10.1016/S0022-2836(66)80037-2; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JOSSE J, 1961, J BIOL CHEM, V236, P864; JUKES TH, 1986, J MOL EVOL, V24, P39, DOI 10.1007/BF02099949; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KARLIN S, 1991, NUCLEIC ACIDS RES, V19, P4241, DOI 10.1093/nar/19.15.4241; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KARLIN S, 1990, ANN STAT, V18, P571, DOI 10.1214/aos/1176347616; KARLIN S, 1991, ANNU REV BIOPHYS BIO, V20, P175, DOI 10.1146/annurev.bb.20.060191.001135; KARLIN S, 1981, 2ND COURSE STOCHASTI, pCH13; KARLIN S, UNPUB; KARLIN S, 1989, MATH METHODS DNA SEQ, P133; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOZHUKHIN CG, 1991, COMPUT APPL BIOSCI, V7, P39; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P861; LEUNG MY, 1991, J MOL BIOL, V221, P1367, DOI 10.1016/0022-2836(91)90938-3; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MASSE MJO, 1992, P NATL ACAD SCI USA, V89, P5246, DOI 10.1073/pnas.89.12.5246; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; MIKOLAS GLG, 1985, MOL EVOLUTIONARY GEN, P241; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUCHIROND D, 1988, J MOL EVOL, V28, P7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NAUS JI, 1979, INT STAT REV, V47, P47; NEY P, 1987, ANN PROBAB, V15, P561, DOI 10.1214/aop/1176992159; NUSSINOV R, 1987, J THEOR BIOL, V125, P219, DOI 10.1016/S0022-5193(87)80043-7; NUSSINOV R, 1981, J BIOL CHEM, V256, P8458; OHNO S, 1988, P NATL ACAD SCI USA, V85, P9630, DOI 10.1073/pnas.85.24.9630; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; REICH JG, 1984, NUCLEIC ACIDS RES, V12, P5529, DOI 10.1093/nar/12.13.5529; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; Sankoff D., 1983, TIME WARPS STRING ED; SCHACHTEL GA, 1991, J MOL EVOL, V33, P483, DOI 10.1007/BF02102801; SCHILDKRAUT CL, 1962, J MOL BIOL, V4, P430; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAPIRO HS, 1976, CRC HDB BIOCH MOL BI, V3, P241; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STERNBERG N, 1985, J BACTERIOL, V164, P490, DOI 10.1128/JB.164.1.490-493.1985; STORMO GD, 1988, ANNU REV BIOPHYS BIO, V17, P241; STUCKLE EE, 1990, NUCLEIC ACIDS RES, V18, P6641, DOI 10.1093/nar/18.22.6641; SUEOKA N, 1961, COLD SPRING HARB SYM, V26, P35, DOI 10.1101/SQB.1961.026.01.009; VANHEEL M, 1991, J MOL BIOL, V220, P877, DOI 10.1016/0022-2836(91)90360-I; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; VONHEIJNE G, 1987, SEQUENCE AMA; WALLENSTEIN S, 1987, STAT MED, V6, P197, DOI 10.1002/sim.4780060212; Waterman M.S, 1989, MATH METHODS DNA SEQ; WATERMAN MS, 1987, P NATL ACAD SCI USA, V84, P1239, DOI 10.1073/pnas.84.5.1239; WATERMAN MS, 1984, B MATH BIOL, V46, P515; WILLIAMS ML, 1990, J ACQ IMMUN DEF SYND, V3, P192; ZUKER M, 1991, J MOL BIOL, V221, P403, DOI 10.1016/0022-2836(91)80062-Y; ZYSKIND JW, 1990, BACTERIAL CHROMOSOME, P269; [No title captured]	116	148	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					39	49		10.1126/science.1621093	http://dx.doi.org/10.1126/science.1621093			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621093				2022-12-24	WOS:A1992JC16500024
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PARALLEL TRACK POLICY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13250	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-24	WOS:A1992HY94400007
J	GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM				GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM			IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN	SCIENCE			English	Article							GENOME REPLICATION; MOLECULAR-CLONING; HEPATITIS; RNA; PROTEINS; AGENT; SERUM; LIVER; CELLS; HETEROGENEITY	During replication, hepatitis delta virus (HDV) switches from production of small to large delta antigen. Both antigen isoforms have an HDV genome binding domain and are packaged into hepatitis B virus (HBV)-derived envelopes but differ at their carboxyl termini. The large antigen was shown to contain a terminal CXXX box and undergo prenylation. The large, but not the small, antigen formed secreted particles when expressed singly with HBV surface antigen. Mutation of Cys211 in the CXXX box of the large antigen abolished both prenylation and particle formation, suggesting that this site is important for virion morphogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GLENN, JS (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.							BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERGMANN KF, 1986, J INFECT DIS, V154, P702, DOI 10.1093/infdis/154.4.702; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BONINO F, 1984, INFECT IMMUN, V43, P1000, DOI 10.1128/IAI.43.3.1000-1005.1984; BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1016/0270-9139(91)92451-D; DENY P, 1991, J GEN VIROL, V72, P735, DOI 10.1099/0022-1317-72-3-735; ELLENS H, 1989, METHOD CELL BIOL, V31, P155; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLENN J, UNPUB; GLENN JS, 1991, J VIROL, V65, P2357, DOI 10.1128/JVI.65.5.2357-2361.1991; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; GLENN JS, 1992, THESIS U CALIFORNIA; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; RAMIG RF, 1990, VIROLOGY, P112; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RIZZETTO M, 1980, J INFECT DIS, V141, P590, DOI 10.1093/infdis/141.5.590; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; RYU WS, IN PRESS J VIROL; RYU WS, UNPUB; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SUREAU C, COMMUNICATION; WANG CJ, 1991, J VIROL, V65, P6630, DOI 10.1128/JVI.65.12.6630-6636.1991; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N	39	230	245	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1992	256	5061					1331	1333		10.1126/science.1598578	http://dx.doi.org/10.1126/science.1598578			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598578				2022-12-24	WOS:A1992HW13500037
J	COLOMBO, MF; RAU, DC; PARSEGIAN, VA				COLOMBO, MF; RAU, DC; PARSEGIAN, VA			PROTEIN SOLVATION IN ALLOSTERIC REGULATION - A WATER EFFECT ON HEMOGLOBIN	SCIENCE			English	Article							HYDRATION FORCES; VOLUME CHANGES; ENERGETICS; BINDING; CHANNEL; SOLVENT; LINKAGE	The oxygen affinity of hemoglobin varies linearly with the chemical potential of water in the bathing medium, as seen from the osmotic effect of several neutral solutes, namely sucrose, stachyose, and two polyethyleneglycols (molecular weights of 150 and 400). The data, analyzed either by Wyman linkage equations or by Gibbs-Duhem relations, show that approximately 60 extra water molecules bind to hemoglobin during the transition from the fully deoxygenated tense (T) state to the fully oxygenated relaxed (R) state. This number, independent of the nature of the solute, agrees with the difference in water-accessible surface areas previously computed for the two conformations. The work of solvation in allosteric regulation can no longer go unrecognized.	NIDDKD,DIV COMP RES & TECHNOL,PHYS SCI LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	COLOMBO, MF (corresponding author), NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892, USA.		Colombo, Marcio F/K-5229-2013	Colombo, Marcio F/0000-0003-3035-3926				ACKERS GK, 1990, BIOPHYS CHEM, V37, P371, DOI 10.1016/0301-4622(90)88036-R; ANUSIEM ACI, 1976, ARCH BIOCHEM BIOPHYS, V175, P138, DOI 10.1016/0003-9861(76)90492-6; ARAKAWA T, 1982, BIOCHEMISTRY-US, V21, P6536, DOI 10.1021/bi00268a033; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BLANK M, 1980, COLLOID SURFACE, V1, P139, DOI 10.1016/0166-6622(80)80001-1; BRANCACCIO A, COMMUNICATION; CHOTHIA C, 1976, P NATL ACAD SCI USA, V73, P3793, DOI 10.1073/pnas.73.11.3793; COLOMBO MF, 1990, BIOPHYS CHEM, V36, P33, DOI 10.1016/0301-4622(90)85004-P; COLOMBO MG, UNPUB; CORDONE L, 1983, BIOPOLYMERS, V22, P1677, DOI 10.1002/bip.360220706; DICERA E, 1990, BIOPHYS CHEM, V37, P147, DOI 10.1016/0301-4622(90)88015-K; HAIRE RN, 1983, BIOCHEMISTRY-US, V22, P327, DOI 10.1021/bi00271a015; HOPFIELD JJ, 1973, J MOL BIOL, V77, P207, DOI 10.1016/0022-2836(73)90332-X; JANIN J, 1985, BIOPOLYMERS, V24, P509, DOI 10.1002/bip.360240307; KORNBLATT JA, 1990, BIOCHEMISTRY-US, V29, P9370, DOI 10.1021/bi00492a010; LESK AM, 1985, J MOL BIOL, V183, P267, DOI 10.1016/0022-2836(85)90219-0; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; PERUTZ M, 1990, MECHANISM COOPERATIV; PODGORNIK R, 1989, MACROMOLECULES, V22, P1780, DOI 10.1021/ma00194a048; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663; Riggs A., 1981, Methods in Enzymology, V76, P5; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0	28	336	341	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 1	1992	256	5057					655	659		10.1126/science.1585178	http://dx.doi.org/10.1126/science.1585178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585178				2022-12-24	WOS:A1992HR18500029
J	BENJAMIN, CM; CHEW, GC; SILMAN, AJ				BENJAMIN, CM; CHEW, GC; SILMAN, AJ			JOINT AND LIMB SYMPTOMS IN CHILDREN AFTER IMMUNIZATION WITH MEASLES, MUMPS, AND RUBELLA VACCINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VIRUS VACCINE	Objective - To assess whether the combined measles, mumps, and rubella vaccine increases the incidence of joint and limb symptoms in young children. Design - Comparison of six week recalled incidence of symptoms in two groups of children: children who had been immunised at the start of the six weeks, and children eligible for immunisation but who had not received it. Setting - South Manchester Health Authority. Subjects - 2658 children immunised during July 1989-February 1990 and 2359 not yet immunised. Questionnaires were returned for 1846 immunised children and 1075 not immunised. Main outcome measure - Recalled rate of joint and limb episodes determined by postal questionnaire and later by clinical follow up. Results - Compared with non-immunised children the immunised group had an increased incidence of new episodes (relative risk 1.6 (95% confidence interval (1.2 to 2.1)) and first ever episodes, though this was not significant (1.7 (0.3 to 3.5)). The risk of first episodes was increased in girls (3.5 (1.1 to 12.2)) but not in boys (1.0 (0.4 to 2.6)). Similarly, an increased risk was seen in children aged under 5 (12.0 (1.6 to 92.3)) but not in older children (0.7 (0.3 to 1.5)). Most episodes were mild and self limiting, but three immunised children required hospital referral. Conclusion - Measles, mumps, and rubella vaccine is associated with an increased risk of episodes of joint and limb symptoms, especially in girls and children under 5. The risk of frank arthritis is substantially less than after wild rubella infection.	UNIV MANCHESTER, ARTHRIT & RHEUMATISM COUNCIL, EPIDEMIOL RES UNIT, STOPFORD BLDG, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								[Anonymous], 1969, AM J DIS CHILD, V118, P1; BALFOUR HH, 1976, AM J DIS CHILD, V130, P1089, DOI 10.1001/archpedi.1976.02120110051006; FRY J, 1962, BMJ-BRIT MED J, P833, DOI 10.1136/bmj.2.5308.833; HILDEBRANDT HM, 1966, NEW ENGL J MED, V274, P1428, DOI 10.1056/NEJM196606232742507; LASS R, 1961, BMJ-BRIT MED J, V2, P1613, DOI 10.1136/bmj.2.5267.1613; LOUDON ISL, 1953, BRIT MED J, V1, P1388, DOI 10.1136/bmj.1.4824.1388; MILLER C, 1989, PRACTITIONER, V233, P69; PELTOLA H, 1986, LANCET, V1, P939; PREBLUD SR, 1985, JAMA-J AM MED ASSOC, V254, P253, DOI 10.1001/jama.254.2.253; SPRUANCE SL, 1971, AM J DIS CHILD, V122, P105, DOI 10.1001/archpedi.1971.02110020039002; TINGLE AJ, 1986, ANN RHEUM DIS, V45, P110, DOI 10.1136/ard.45.2.110; 1990, IMMUNISATION INFECTI	12	48	48	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	1992	304	6834					1075	1078		10.1136/bmj.304.6834.1075	http://dx.doi.org/10.1136/bmj.304.6834.1075			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HR136	1586818	Bronze, Green Published			2022-12-24	WOS:A1992HR13600013
J	HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM				HAWKINS, MM; WILSON, LMK; STOVALL, MA; MARSDEN, HB; POTOK, MHN; KINGSTON, JE; CHESSELLS, JM			EPIPODOPHYLLOTOXINS, ALKYLATING-AGENTS, AND RADIATION AND RISK OF SECONDARY LEUKEMIA AFTER CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NON-HODGKINS LYMPHOMA; LOW-DOSE RADIATION; T-CELL LEUKEMIA; MYELODYSPLASTIC SYNDROME; 2ND MALIGNANCIES; OVARIAN-CANCER; NEURO-BLASTOMA; CHEMOTHERAPY	Objective-To investigate the incidence and aetiology of secondary leukaemia after childhood cancer in Britain. Design-Cohort study and a case-control study. Setting-Britain and population based National Register of Childhood Tumours. Subjects-Cohort of 16 422 one year survivors of childhood cancer diagnosed in Britain between 1962 and 1983, among whom 22 secondary leukaemias were observed. A case-control study of 26 secondary leukaemias observed among survivors of childhood cancer diagnosed in Britain between 1940 and 1983; % controls were selected matched for sex, type of first cancer, age at first cancer, and interval to diagnosis of secondary leukaemia. Main outcome measures-Dose of radiation averaged over patients' active bone marrow and total accumulated dose of epipodophyllotoxins, alkylating agents, vinca alkaloids, antimetabolites, and antibiotics (mg/m2) given for the original cancer. Results-Cumulative risk of secondary leukaemia within the cohort did not exceed 0.5% over the initial five years beyond one year survival, except that after non-Hodgkin's lymphomas 1.4% of patients developed secondary leukaemia. Corresponding figure for patients treated for non-Hodgkin's lymphomas in the early 1980s was 4%. The relative risk of secondary leukaemia increased significantly with exposure to epipodophyllotoxins and dose of radiation averaged over patients' active bone marrow. Ten patients developed leukaemia after having an epipodophyllotoxin-teniposide in nine cases, etoposide in one. Chromosomal translocations involving 11q23 were observed relating to two secondary leukaemias from a total of six for which there were successful cytogenetic studies after administration of an epipodophyllotoxin. Conclusions-Epipodophyllotoxins acting alone or together with alkylating agents or radiation seem to be involved in secondary leukaemia after childhood cancer.	ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT PATHOL,MANCHESTER M27 1HA,LANCS,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND; HOSP SICK CHILDREN,HAEMATOL & ONCOL,LONDON WC1N 3JH,ENGLAND; UNIV TEXAS,MD ANDERSON CANC CTR,HOUSTON,TX 77025	Royal Manchester Children's Hospital; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Texas System; UTMD Anderson Cancer Center	HAWKINS, MM (corresponding author), UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND.							BOICE JD, 1983, NEW ENGL J MED, V309, P1079, DOI 10.1056/NEJM198311033091802; BOICE JD, 1987, J NATL CANCER I, V79, P1295; Boice Jr J., 1984, RAD CARCINOGENESIS E; BOIVIN JF, 1986, AM J EPIDEMIOL, V123, P993, DOI 10.1093/oxfordjournals.aje.a114351; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CURTIS RE, 1984, J NATL CANCER I, V72, P531; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; DERBYSHIRE PJ, 1986, CLIN LAB HAEMATOL, V8, P71; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P792, DOI 10.1038/bjc.1989.165; DEVEREUX S, 1990, BRIT MED J, V301, P1077, DOI 10.1136/bmj.301.6760.1077; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; HAAS JF, 1987, BRIT J CANCER, V55, P213, DOI 10.1038/bjc.1987.40; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; INGRAM L, 1987, BRIT J CANCER, V55, P463, DOI 10.1038/bjc.1987.91; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KANTARJIAN HM, 1986, J CLIN ONCOL, V4, P1748, DOI 10.1200/JCO.1986.4.12.1748; KREISSMAN SG, 1990, P AN M AM SOC CLIN, V9, P219; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LONG BH, 1985, CANCER RES, V45, P3106; MOTT MG, 1984, BRIT J CANCER, V50, P463, DOI 10.1038/bjc.1984.202; MOTT MG, 1984, BRIT J CANCER, V50, P457, DOI 10.1038/bjc.1984.201; PEDERSENBJERGAARD J, 1991, LANCET, V338, P359, DOI 10.1016/0140-6736(91)90490-G; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PRIETO F, 1990, CANCER GENET CYTOGEN, V45, P1, DOI 10.1016/0165-4608(90)90061-E; PUI CH, 1990, LANCET, V336, P1130, DOI 10.1016/0140-6736(90)92607-J; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1990, LANCET, V336, P417, DOI 10.1016/0140-6736(90)91956-B; RATAIN MJ, 1987, BLOOD, V70, P1412; ROSS W, 1984, CANCER RES, V44, P5857; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; THIRD MIC, 1988, CANCER GENET CYTOGEN, V32, P1; TRAVIS LB, 1991, CANCER-AM CANCER SOC, V67, P2002, DOI 10.1002/1097-0142(19910401)67:7<2002::AID-CNCR2820670729>3.0.CO;2-E; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; TUCKER MA, 1987, J NATL CANCER I, V78, P459, DOI 10.1093/jnci/78.3.459; TUCKER MA, 1984, RAD CARCINOGENESIS E, P211; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; WHANGPENG J, 1988, BLOOD, V71, P403; WHITLOCK JA, 1991, CANCER, V68, P600, DOI 10.1002/1097-0142(19910801)68:3<600::AID-CNCR2820680326>3.0.CO;2-F; 1980, ORNL NUREGCRE1159 RE; 1990, EGRET REFERENCE MANU	46	186	188	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 11	1992	304	6832					951	958		10.1136/bmj.304.6832.951	http://dx.doi.org/10.1136/bmj.304.6832.951			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HP064	1581717	Green Published, Bronze			2022-12-24	WOS:A1992HP06400021
J	MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K				MOLL, T; TEBB, G; SURANA, U; ROBITSCH, H; NASMYTH, K			THE ROLE OF PHOSPHORYLATION AND THE CDC28 PROTEIN-KINASE IN CELL-CYCLE REGULATED NUCLEAR IMPORT OF THE SACCHAROMYCES-CEREVISIAE TRANSCRIPTION FACTOR-SWI5	CELL			English	Article							HO GENE; C-MYB; B-MYB; YEAST; DNA; SACCHAROMYCES; BINDING; IDENTIFICATION; NUCLEOPLASMIN; TRANSLOCATION	The intracellular localization of the S. cerevisiae transcription factor SWI5 is cell cycle dependent. The protein is nuclear in G1 cells but cytoplasmic in S, G2, and M phase cells. We have identified SWI5's nuclear localization signal (NLS) and show that it can confer cell cycle-dependent nuclear entry to a heterologous protein. Located within or close to the NLS are three serine residues, mutation of which results in constitutive nuclear entry. These residues are phosphorylated in a cell cycle-dependent manner in vivo, being phosphorylated when SWI5 is in the cytoplasm and dephosphorylated when it is in the nucleus. As all three serines are phosphorylated by purified CDC28-dependent H1 kinase activity in vitro, we propose a model in which the CDC28 kinase acts directly to control nuclear entry of SWI5.			MOLL, T (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Surana, Uttam/H-1142-2011	Tebb, Graham/0000-0002-1294-2025; Surana, Uttam/0000-0002-4785-6514; Nasmyth, Kim/0000-0001-7030-4403				BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BUCKINGTHROM E, 1973, EXP CELL RES, V76, P99, DOI 10.1016/0014-4827(73)90424-2; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HICKS JB, 1976, GENETICS, V83, P245; HUNT T, 1989, CELL, V59, P949, DOI 10.1016/0092-8674(89)90747-2; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NASMYTH K, 1987, SCIENCE, V237, P1162, DOI 10.1126/science.3306917; NASMYTH K, 1985, CELL, V42, P213, DOI 10.1016/S0092-8674(85)80117-3; NEWMEYER DD, 1986, EMBO J, V5, P501, DOI 10.1002/j.1460-2075.1986.tb04239.x; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; REED SI, 1980, GENETICS, V95, P561; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Rubin G M, 1975, Methods Cell Biol, V12, P45; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; SUISSA M, 1983, ANAL BIOCHEM, V133, P511, DOI 10.1016/0003-2697(83)90117-3; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V	47	459	463	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					743	758		10.1016/0092-8674(91)90118-I	http://dx.doi.org/10.1016/0092-8674(91)90118-I			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652372				2022-12-24	WOS:A1991GC74500013
J	KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM				KIM, JW; CLOSS, EI; ALBRITTON, LM; CUNNINGHAM, JM			TRANSPORT OF CATIONIC AMINO-ACIDS BY THE MOUSE ECOTROPIC RETROVIRUS RECEPTOR	NATURE			English	Article							CULTURED ANIMAL-CELLS; GLUCOSE TRANSPORTER; MAMMALIAN-CELLS; RAT-LIVER; GENE; MEMBRANE; PROTEIN; SYSTEM; HISTIDINE; PROMOTER	SUSCEPTIBILITY of rodent cells to infection by ecotropic murine leukaemia viruses (MuLV) is determined by binding of the virus envelope to a membrane receptor that has multiple membrane-spanning domains 1. Cells infected by ecotropic MuLV synthesize envelope protein, gp70, which binds to this receptor, thereby preventing additional infections. The consequences of envelope-MuLV receptor binding for the infected host cell have not been directly determined, partly because the cellular function of the MuLV receptor protein is unknown. Here we report a coincidence in the positions of the first eight putative membrane-spanning domains found in the virus receptor 1 and in two related proteins 2, the arginine 2-4 and histidine 2,3,5 permeases of Saccharomyces cerevisiae (Fig. 1), but not in any other proteins identified by computer-based sequence comparison of the GenBank data base 1. Xenopus oocytes injected with receptor-encoding messenger RNA show increased uptake of L-arginine, L-lysine and L-ornithine. The transport properties and the expression pattern of the virus receptor behave in ways previously attributed to y+ (refs 6, 7), the principal transporter of cationic L-amino acids in mammalian cells.	BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,75 FRANCIS ST,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ARONSON DL, 1981, BIOCHEMISTRY-US, V20, P7064, DOI 10.1021/bi00528a002; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CHRISTENSEN HN, 1967, J BIOL CHEM, V238, P3686; Cooper T., 1982, MOL BIOL YEAST SACCH, P399; DESJEUX JF, 1987, PEDIATR RES, V21, P477, DOI 10.1203/00006450-198705000-00011; HATZOGLOU M, 1990, J BIOL CHEM, V265, P17285; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HOFFMANN W, 1985, J BIOL CHEM, V260, P1831; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PARDRIDGE WM, 1975, AM J PHYSIOL, V228, P1155; ROSENBERG LE, 1962, J BIOL CHEM, V237, P2265; SAMARZIJA I, 1982, PFLUG ARCH EUR J PHY, V393, P199, DOI 10.1007/BF00584070; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; TANAKA J, 1985, GENE, V38, P205, DOI 10.1016/0378-1119(85)90219-7; VADGAMA JV, 1987, J BIOL CHEM, V262, P13273; VANWINKLE LJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P173, DOI 10.1016/0304-4157(88)90024-X; WEBER E, 1988, J MOL EVOL, V27, P342; WHITE MF, 1982, J BIOL CHEM, V257, P4450; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443; WHITE MF, 1983, J BIOL CHEM, V258, P8028	29	492	507	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 22	1991	352	6337					725	728		10.1038/352725a0	http://dx.doi.org/10.1038/352725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC064	1652100				2022-12-24	WOS:A1991GC06400062
J	NATSOULIS, G; BOEKE, JD				NATSOULIS, G; BOEKE, JD			NEW ANTIVIRAL STRATEGY USING CAPSID NUCLEASE FUSION PROTEINS	NATURE			English	Article							VIRUS-LIKE PARTICLES; SACCHAROMYCES-CEREVISIAE; STAPHYLOCOCCAL NUCLEASE; ELEMENT TRANSPOSITION; REVERSE-TRANSCRIPTASE; TY1 TRANSPOSITION; YEAST; GENE; RIBONUCLEASE; EXPRESSION	OVEREXPRESSION of dominant-negative mutants of various viral proteins can result in 'intracellular immunization' (refs 1, 2). Here we describe a new approach to interfering with viral replication in which a nuclease is fused to a capsid component so that the nuclease is encapsidated inside the virion where it can inactivate viral nucleic acid. We used Ty1, a yeast retrotransposon whose transposition closely parallels retroviral replication mechanisms and serves as an easily manipulated model for the retroviral infection process 3. We constructed fusion genes consisting of the region encoding the N-terminal portion of the TYA/TYB open reading frames of retrotransposon Ty1 and either of two different nuclease genes. Ty1-nuclease fusion proteins are targeted to Ty1 virus-like particles, and are active in degrading nucleic acids. A Ty1-barnase fusion protein causes 98-99% reduction in the efficiency of Ty1 transposition in vivo, presumably by degrading encapsidated Ty1 RNA. This strategy, referred to as capsid-targeted viral inactivation, may be useful for interfering with the replication of retroviruses and other viruses.			NATSOULIS, G (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ADAMS SE, 1987, CELL, V49, P111, DOI 10.1016/0092-8674(87)90761-6; ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BOEKE JD, 1988, SCIENCE, V239, P280, DOI 10.1126/science.2827308; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; BOEKE JD, 1988, MOL CELL BIOL, V8, P1432, DOI 10.1128/MCB.8.4.1432; BOEKE JD, 1989, MOBILE DNA, P335; BRIERLEY C, 1990, NUCLEIC ACIDS RES, V18, P2947, DOI 10.1093/nar/18.10.2947; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; GARFINKEL DJ, 1985, CELL, V42, P507, DOI 10.1016/0092-8674(85)90108-4; HARTLEY RW, 1989, TRENDS BIOCHEM SCI, V14, P450, DOI 10.1016/0968-0004(89)90104-7; HARTLEY RW, 1988, J MOL BIOL, V202, P913, DOI 10.1016/0022-2836(88)90568-2; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; JONES TA, 1990, J VIROL, V64, P2265, DOI 10.1128/JVI.64.5.2265-2279.1990; MARIANI C, 1990, NATURE, V347, P737, DOI 10.1038/347737a0; MELLOR J, 1985, NATURE, V318, P583, DOI 10.1038/318583a0; MOSSAKOWSKA DE, 1989, BIOCHEMISTRY-US, V28, P3843, DOI 10.1021/bi00435a033; MULLER F, 1987, MOL GEN GENET, V207, P421, DOI 10.1007/BF00331610; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; SIKORSKI RS, 1989, GENETICS, V122, P19; TUCKER PW, 1978, MOL CELL BIOCHEM, V22, P67, DOI 10.1007/BF00496235; WEBER DJ, 1990, BIOCHEMISTRY-US, V29, P8632, DOI 10.1021/bi00489a020; WELDON RA, 1990, J VIROL, V64, P4169, DOI 10.1128/JVI.64.9.4169-4179.1990; YOSHINAKA Y, 1985, P NATL ACAD SCI USA, V82, P1618, DOI 10.1073/pnas.82.6.1618; YOSHIOKA K, 1990, EMBO J, V9, P535, DOI 10.1002/j.1460-2075.1990.tb08140.x; YOUNGREN SD, 1988, J MOL CELL BIOL, V8, P1421	29	62	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 15	1991	352	6336					632	635		10.1038/352632a0	http://dx.doi.org/10.1038/352632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GB211	1650915				2022-12-24	WOS:A1991GB21100059
J	SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW				SHENTON, ME; KIKINIS, R; JOLESZ, FA; POLLAK, SD; LEMAY, M; WIBLE, CG; HOKAMA, H; MARTIN, J; METCALF, D; COLEMAN, M; MCCARLEY, RW			ABNORMALITIES OF THE LEFT TEMPORAL-LOBE AND THOUGHT-DISORDER IN SCHIZOPHRENIA - A QUANTITATIVE MAGNETIC-RESONANCE-IMAGING STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENTORHINAL CORTEX; PARAHIPPOCAMPAL GYRUS; CEREBRAL ASYMMETRY; VENTRICULAR VOLUME; PLANUM TEMPORALE; MR IMAGES; BRAIN; MONKEY; SYMPTOMS; SYSTEM	Background. Data from postmortem, CT, and magnetic resonance imaging (MRI) studies indicate that patients with schizophrenia may have anatomical abnormalities of the left temporal lobe, but it is unclear whether these abnormalities are related to the thought disorder characteristic of schizophrenia. Methods. We used new MRI neuroimaging techniques to derive (without knowledge of the diagnosis) volume measurements and three-dimensional reconstructions of temporal-lobe structures in vivo in 15 right-handed men with chronic schizophrenia and 15 matched controls. Results. As compared with the controls, the patients had significant reductions in the volume of gray matter in the left anterior hippocampus-amygdala (by 19 percent [95 percent confidence interval, 3 to 36 percent]), the left parahippocampal gyrus (by 13 percent [95 percent confidence interval, 3 to 23 percent], vs. 8 percent on the right), and the left superior temporal gyrus (by 15 percent [95 percent confidence interval, 5 to 25 percent]). The volume of the left posterior superior temporal gyrus correlated with the score on the thought-disorder index in the 13 patients evaluated (r = -0.81, P = 0.001). None of these regional volume decreases were accompanied by a decrease in the volume of the overall brain or temporal lobe. The volume of gray matter in a control region (the superior frontal gyrus) was essentially the same in the patients and controls. Conclusions. Schizophrenia involves localized reductions in the gray matter of the left temporal lobe. The degree of thought disorder is related to the size of the reduction in volume of the left posterior superior temporal gyrus.	HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; BROCKTON VET AFFAIRS MED CTR,BROCKTON,MA; BRIGHAM & WOMENS HOSP,MAGNET RESONANCE IMAGING CTR,BOSTON,MA 02115; MASSACHUSETTS MENTAL HLTH CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Shenton, Martha/V-8780-2019; Pollak, Seth D/G-2345-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040799, K01MH000746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001083] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH040799, K01-MH-00746-04] Funding Source: Medline; NINDS NIH HHS [K04-NS-01083] Funding Source: Medline; PHS HHS [40,799] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARAL DG, 1983, BRAIN RES, V275, P263, DOI 10.1016/0006-8993(83)90987-3; Andreasen N., 1984, SCALE ASSESSMENT POS; Andreasen N.C, 1981, SCALE ASSESSMENT NEG; ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625; BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; BLEULER E, 1950, MONOGRAPH SERIES SCH, V1; BOGERTS B, 1990, PSYCHIAT RES-NEUROIM, V35, P1; BOGERTS B, 1985, ARCH GEN PSYCHIAT, V42, P784; BOGERTS B, 1984, FORTSCHR NEUROL PSYC, V52, P428, DOI 10.1055/s-2007-1002212; Boyd E, 1962, BIOL HDB, P346; BROWN R, 1986, ARCH GEN PSYCHIAT, V43, P36; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CLINE HE, 1987, MAGN RESON IMAGING, V5, P345, DOI 10.1016/0730-725X(87)90124-X; CLINE HE, 1991, J COMPUT ASSIST TOMO, V15, P344, DOI 10.1097/00004728-199103000-00035; CLINE HE, 1988, MED PHYS, V15, P320, DOI 10.1118/1.596225; CLINE HE, 1990, J COMPUT ASSIST TOMO, V14, P1037, DOI 10.1097/00004728-199011000-00041; COLTER N, 1987, ARCH GEN PSYCHIAT, V44, P1023; CROW TJ, 1990, BRIT J PSYCHIAT, V156, P788, DOI 10.1192/bjp.156.6.788; CROW TJ, 1990, SCHIZOPHRENIA BULL, V16, P433, DOI 10.1093/schbul/16.3.433; CROW TJ, 1989, ARCH GEN PSYCHIAT, V46, P1145; Daniels DL, 1987, CRANIAL SPINAL MAGNE; DEGREEF G, 1991, INT C SCHIZOPHRENIA; DELISI LE, 1988, SCHIZOPHRENIA BULL, V14, P185, DOI 10.1093/schbul/14.2.185; DELISI LE, 1991, BIOL PSYCHIAT, V29, P159, DOI 10.1016/0006-3223(91)90044-M; DELISI LE, 1989, BIOL PSYCHIAT, V25, P835, DOI 10.1016/0006-3223(89)90263-1; DELISI LE, 1991, BIOL PSYCHIAT, V29, P519; Duvernoy HM, 1988, HUMAN HIPPOCAMPUS; FALKAI P, 1986, EUR ARCH PSY CLIN N, V236, P154, DOI 10.1007/BF00380943; FALKAI P, 1988, BIOL PSYCHIAT, V24, P515, DOI 10.1016/0006-3223(88)90162-X; FAUX SF, 1990, ELECTROEN CLIN NEURO, V75, P378, DOI 10.1016/0013-4694(90)90083-V; FILIPEK PA, 1989, ANN NEUROL, V25, P61, DOI 10.1002/ana.410250110; GALABURDA AM, 1987, NEUROPSYCHOLOGIA, V25, P853, DOI 10.1016/0028-3932(87)90091-1; GALABURDA AM, 1984, CEREBRAL DOMINANCE B, P11; GERIG G, 1990, BIWIITR124 ETH EIDG; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; GRANT R, 1987, MAGN RESON IMAGING, V5, P465, DOI 10.1016/0730-725X(87)90380-8; GUR RE, 1991, ARCH GEN PSYCHIAT, V48, P407; Hollingshead AB, 1965, 2 FACTOR INDEX SOCIA; Holzman, 1979, ASSESSING SCHIZOPHRE; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; JAKOB H, 1989, J ROY SOC MED, V82, P466, DOI 10.1177/014107688908200808; JESTE DV, 1989, ARCH GEN PSYCHIAT, V46, P1019; JOHNSTONE EC, 1989, J NEUROL NEUROSUR PS, V52, P736, DOI 10.1136/jnnp.52.6.736; KELSOE JR, 1988, ARCH GEN PSYCHIAT, V45, P533; KIKINIS R, 1990, NATO ADV SCI I F-COM, V60, P441; KOVELMAN JA, 1984, BIOL PSYCHIAT, V19, P1601; MCCARLEY RW, 1991, SCHIZOPHR RES, V4, P209, DOI 10.1016/0920-9964(91)90034-O; MCCARLEY RW, 1989, ARCH GEN PSYCHIAT, V46, P698; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; OJEMANN GA, 1988, BRAIN, V111, P1383, DOI 10.1093/brain/111.6.1383; PENFIELD W, 1963, BRAIN, V86, P595, DOI 10.1093/brain/86.4.595; PERONA P, 1987, 1987 P IEEE WORKSH C, P16; PFEFFERBAUM A, 1990, SCHIZOPHRENIA BULL, V16, P453, DOI 10.1093/schbul/16.3.453; POSNER MI, 1988, ARCH GEN PSYCHIAT, V45, P814; Rosene D. L., 1987, CEREB CORTEX, V6, P345, DOI DOI 10.1007/978-1-4615-6616-8_9; ROSSI A, 1990, BIOL PSYCHIAT, V27, P61, DOI 10.1016/0006-3223(90)90020-3; SANGHERA MK, 1979, EXP NEUROL, V63, P610, DOI 10.1016/0014-4886(79)90175-4; SAUNDERS RC, 1988, J COMP NEUROL, V271, P185, DOI 10.1002/cne.902710203; SCHWARZKOPF SB, 1991, SCHIZOPHR RES, V4, P412, DOI 10.1016/0920-9964(91)90367-Z; SHELTON RC, 1986, HDB SCHIZOPHRENIA, V1, P207; SHENTON ME, 1989, BIOL PSYCHIAT, V25, P710, DOI 10.1016/0006-3223(89)90242-4; SHENTON ME, 1991, SCHIZOPHR RES, V5, P103, DOI 10.1016/0920-9964(91)90037-R; SHENTON ME, 1987, ARCH GEN PSYCHIAT, V44, P21; SHENTON ME, 1990, 145TH AM PSYCH ASS A; SOLOVAY MR, 1986, SCHIZOPHRENIA BULL, V12, P483; Spitzer R.L., 1978, SCHEDULE AFFECTIVE D; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Wechsler D., 1997, WAIS 3 WECHSLER ADUL, V3rd, DOI 10.1111/j.1749-6632.1989.tb21005.x; WEINBERGER DR, 1986, HDB SCHIZOPHRENIA, V1, P397; Wernicke C., 1874, APHASISCHE SYMPTOMEN; WIESEL FA, 1987, ACTA PSYCHIAT SCAND, V76, P628, DOI 10.1111/j.1600-0447.1987.tb02933.x; WITTER MP, 1991, J COMP NEUROL, V307, P437, DOI 10.1002/cne.903070308; WYPER DJ, 1979, J NEUROL NEUROSUR PS, V42, P345, DOI 10.1136/jnnp.42.4.345; YOUNG AH, 1991, BRIT J PSYCHIAT, V158, P158, DOI 10.1192/bjp.158.2.158; ZIPURSKY RB, 1992, ARCH GEN PSYCHIAT, V49, P195; 1987, DIAGNOSTIC STATISTIC	78	1002	1010	1	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1992	327	9					604	612		10.1056/NEJM199208273270905	http://dx.doi.org/10.1056/NEJM199208273270905			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JK204	1640954	Green Published			2022-12-24	WOS:A1992JK20400005
J	NICHOLAS, R; OMEARA, PD; CALONGE, N				NICHOLAS, R; OMEARA, PD; CALONGE, N			IS SYNCOPE RELATED TO MODERATE ALTITUDE EXPOSURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							BLOOD-PRESSURE; CIRCULATORY ADJUSTMENTS; DIAGNOSTIC EVALUATION; FOLLOW-UP; HYPOXIA	Study Objective.-To investigate factors related to syncope occurring on recent ascent to moderate altitude. Design.-A 1-year retrospective case-control study, using local acclimatized residents as a control group. Setting.-The two main ambulance destinations for Summit County, Colorado (elevation, 2770 m). Patients.-All patients with a diagnosis of syncope, near-syncope, or fainting whose medical records were available for review. Results.-There was a significant relationship (P<.05) between syncope of unknown origin and recent arrival at altitude (<24 hours), and a significant inverse relationship (P<.05) between syncope of unknown origin and arterial oxygen saturation as measured by pulse oximetry. Conclusions.-Short-term exposure to moderate altitude may be related to otherwise unexplained syncope in healthy young adults. We suggest the name high-altitude syncope for this entity and encourage further research in this area.	UNIV COLORADO,HLTH SCI CTR,DEPT FAMILY MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,AF WILLIAMS FAMILY MED RESIDENCY,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	NICHOLAS, R (corresponding author), SNAKE RIVER HLTH SERV,COLORADO ALTITUDE RES INST,POB 38,KEYSTONE,CO 80435, USA.							ABBOUD FM, 1989, NEW ENGL J MED, V320, P390, DOI 10.1056/NEJM198902093200609; APPLETON F, 1967, CIRCULATION S, V36, P55; BRINCHMANNHANSEN O, 1989, AVIAT SPACE ENVIR MD, V60, P970; CLEGG EJ, 1970, P R SOC LOND, V194, P83; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DOHERTY JU, 1985, AM J CARDIOL, V55, P703, DOI 10.1016/0002-9149(85)90140-7; HEISTAD DD, 1980, CIRCULATION, V61, P463, DOI 10.1161/01.CIR.61.3.463; HOUSTON CS, 1980, GOING HIGHER; KAPOOR W, 1984, ANN INTERN MED, V100, P755, DOI 10.7326/0003-4819-100-5-755; KAPOOR W, 1986, AM J MED, V80, P419, DOI 10.1016/0002-9343(86)90716-3; KAPOOR WN, 1983, NEW ENGL J MED, V309, P197, DOI 10.1056/NEJM198307283090401; MANOLIS AS, 1990, ANN INTERN MED, V112, P850, DOI 10.7326/0003-4819-112-11-850; MARTICOR.E, 1969, AM J CARDIOL, V23, P364, DOI 10.1016/0002-9149(69)90516-5; MARTIN GJ, 1984, ANN EMERG MED, V13, P499, DOI 10.1016/S0196-0644(84)80511-9; PALATINI P, 1989, AM J CARDIOL, V64, P1379, DOI 10.1016/0002-9149(89)90587-0; PIERCE EC, 1962, J APPL PHYSIOL, V17, P899, DOI 10.1152/jappl.1962.17.6.899; STULTS BM, 1986, WESTERN J MED, V144, P234; Thoren P, 1979, Rev Physiol Biochem Pharmacol, V86, P1, DOI 10.1007/BFb0031531; WEITZ CA, 1982, SOC SCI MED, V16, P223, DOI 10.1016/0277-9536(82)90026-0; 1988, SUMMIT COUNTY STATIS	20	34	35	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1992	268	7					904	906		10.1001/jama.268.7.904	http://dx.doi.org/10.1001/jama.268.7.904			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH588	1640621				2022-12-24	WOS:A1992JH58800043
J	JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ				JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ			HIV-INFECTION AMONG PATIENTS IN UNITED-STATES ACUTE CARE HOSPITALS - STRATEGIES FOR THE COUNSELING AND TESTING OF HOSPITAL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SENTINEL HOSPITALS; RISK; SURVEILLANCE; EPIDEMIOLOGY; EMERGENCY; WORKERS	Background. Routine, voluntary testing of hospital patients for the human immunodeficiency virus (HIV) has been proposed in order to identify those with early HIV infection in a setting where there is ready access to counseling, appropriate clinical referral, evaluation, and therapy. We studied the pattern of HIV infection among patients in 20 U.S. hospitals, in order to evaluate possible national strategies for the routine, voluntary HIV counseling and testing of hospital patients. Methods. Blood specimens remaining after clinical use from a systematically selected sample of patients at 20 hospitals in 15 U.S. cities were tested anonymously for antibody to HIV type 1 (HIV-1). Multivariate regression was used to determine which variables best predicted HIV seroprevalence in individual hospitals. Using these data, we estimated the number of HIV-positive patients in all U.S. hospitals and considered the efficiency of routine counseling and testing in different subgroups of patients and hospitals. Results. From September 1989 through October 1991, 9286 of 195,829 specimens (4.7 percent) were positive for HIV-1 in the 20 hospitals. The seroprevalence of HIV at these institutions ranged from 0.2 percent to 14.2 percent. Among HIV-positive patients, 32 percent had symptomatic HIV infection or the acquired immunodeficiency syndrome (AIDS) at the time of admission or evaluation. In the 20 hospitals, HIV seroprevalence was 10.4 times (95 percent confidence interval, 8.8 to 12.0) the AIDS-diagnosis rate (the annual number of patients with new diagnoses of AIDS per 1000 discharges in 1990). In a multivariate model that included 13 hospital-specific variables, only the AIDS-diagnosis rate was associated with the hospital-specific HIV-seroprevalence rate (P<0.001). Using these data and the AIDS-diagnosis rates for all U.S. acute care hospitals, we estimated that 225,000 HIV-positive persons were hospitalized (95 percent confidence interval, 190,000 to 260,000) in all 5558 such hospitals in 1990, including 163,000 persons presenting with conditions other than HIV or AIDS (95 percent confidence interval, 130,000 to 196,000). In 1990, in 593 U.S. hospitals with AIDS-diagnosis rates of 1.0 or more per 1000 discharges, HIV testing of patients 15 to 54 years old (3 million patients, or 12.0 percent of all patients in U.S. acute care hospitals) would have identified an estimated 68 percent of all HIV-positive patients (110,000 patients) who were admitted with conditions other than symptomatic HIV infection or AIDS. Conclusions. We estimate that about 225,000 HIV-positive persons were hospitalized in 1990, of whom only one third were admitted for symptomatic HIV infection or AIDS. Routine, voluntary HIV testing of patients 15 to 54 years old in hospitals with 1 or more patients with newly diagnosed AIDS per 1000 discharges per year could potentially have identified as many as 110,000 patients with HIV infection that was previously unrecognized.	CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AID,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,AIDS SURVEILLANCE BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271; Satten, Glen/0000-0001-7275-5371				ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LOMBARDO JM, 1991, ARCH INTERN MED, V151, P965, DOI 10.1001/archinte.151.5.965; MARCUS R, 1990, 6TH INT C AIDS SAN F, V1, P276; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RISI GF, 1989, SOUTHERN MED J, V82, P1079, DOI 10.1097/00007611-198909000-00005; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR MORB MORT SRR8, V39; 1991, MMWR MORB MOTAL WKLY, V40, P1; 1992, HIV AIDS SURVEIL JAN; 1987, MMWR MORB MORTAL S1S, V36, pS1; 1989, MMWR MORB MORTAL SS7, V38; 1991, AHA ANN SURVEY HOSPI; 1990, NATIONAL HLTH INTERV; 1990, MMWR MORB MORT SRR16, V39, P1; 1989, MMWR MORB MORTAL SS5, V38; 1990, SAS STAT USERS GUIDE, V2; 1986, MMWR MORB MOTAL WKLY, V35, P152	31	109	109	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					445	452		10.1056/NEJM199208133270701	http://dx.doi.org/10.1056/NEJM199208133270701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625734				2022-12-24	WOS:A1992JH34000001
J	BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB				BURKHOLDER, JM; NOGA, EJ; HOBBS, CH; GLASGOW, HB			NEW PHANTOM DINOFLAGELLATE IS THE CAUSATIVE AGENT OF MAJOR ESTUARINE FISH KILLS	NATURE			English	Article							TOXINS	A WORLDWIDE increase in toxic phytoplankton blooms over the past 20 years1,2 has coincided with increasing reports of fish diseases and deaths of unknown cause3. Among estuaries that have been repeatedly associated with unexplained fish kills on the western Atlantic Coast are the Pamlico and Neuse Estuaries of the southeastern United States4. Here we describe a new toxic dinoflagellate with 'phantom-like' behaviour that has been identified as the causative agent of a significant portion of the fish kills in these estuaries, and which may also be active in other geographic regions. The alga requires live finfish or their fresh excreta for excystment and release of a potent toxin. Low cell densities cause neurotoxic signs and fish death, followed by rapid algal encystment and dormancy unless live fish are added. This dinoflagellate was abundant in the water during major fish kills in local estuaries, but only while fish were dying; within several hours of death where carcasses were still present, the flagellated vegetative algal population had encysted and settled back to the sediments. Isolates from each event were highly lethal to finfish and shellfish in laboratory bioassays. Given its broad temperature and salinity tolerance, and its stimulation by phosphate enrichment, this toxic phytoplankter may be a widespread but undetected source of fish mortality in nutrient-enriched estuaries.	N CAROLINA STATE UNIV,DEPT COMPAN ANIM & SPECIAL SPECIES MED,RALEIGH,NC 27606	University of North Carolina; North Carolina State University	BURKHOLDER, JM (corresponding author), N CAROLINA STATE UNIV,DEPT BOT,BOX 7612,RALEIGH,NC 27695, USA.							Gaines G, 1987, BIOL DINOFLAGELLATES; HALLEGRAEFF GM, 1988, J PLANKTON RES, V10, P533, DOI 10.1093/plankt/10.3.533; LAGLER KF, 1962, ICHTHYOLOGY, P268; MILLER KH, 1990, PAMLICO ENV RESPONSE; PALENIK B, 1988, Biological Oceanography, V6, P347; ROBERTS RJ, 1983, J MAR BIOL ASSOC UK, V63, P741, DOI 10.1017/S0025315400071186; ROBINEAU B, 1991, MAR BIOL, V108, P293, DOI 10.1007/BF01344344; RUDEK J, 1991, MAR ECOL PROG SER, V75, P133, DOI 10.3354/meps075133; RYTHER JH, 1954, ECOLOGY, V35, P522, DOI 10.2307/1931041; SHUMWAY S E, 1990, Journal of the World Aquaculture Society, V21, P65, DOI 10.1111/j.1749-7345.1990.tb00529.x; SMAYDA TJ, 1989, NOVEL PHYTOPLANKTON, P449; SMITH SA, 1988, 3RD P INT C PATH MAR, P167; Sokal R. R, 1981, BIOMETRY; SPERO HJ, 1982, J PHYCOL, V18, P357; STANLEY DH, 1988, S COASTAL WATER RESO, P155; Taylor FJR, 1987, BIOL DINOFLAGELLATES, P24; THORP JH, 1991, ECOLOGY CLASSIFICATI, P77; WHITE AW, 1981, MAR BIOL, V65, P255, DOI 10.1007/BF00397119; WHITE AW, 1988, 1987 P INT C IMP TOX, P9; 1987, 1986 N CAR DEP ENV H; 1990, 1990 N CAR DEP ENV H; 1988, 1987 N CAR DEP ENV H; 1989, 1988 N CAR DEP ENV H	23	290	300	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					407	410		10.1038/358407a0	http://dx.doi.org/10.1038/358407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641022				2022-12-24	WOS:A1992JF85300053
J	KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR				KIM, SJ; WAGNER, S; LIU, F; OREILLY, MA; ROBBINS, PD; GREEN, MR			RETINOBLASTOMA GENE-PRODUCT ACTIVATES EXPRESSION OF THE HUMAN TGF-BETA-2 GENE THROUGH TRANSCRIPTION FACTOR ATF-2	NATURE			English	Article							PROTEIN; BINDING; GROWTH; FAMILY; BETA	THE retinoblastoma susceptibility gene product (pRb) plays an important role in constraining cellular proliferation and in regulating the cell cycle1,2. The pRb inhibits transcription of genes involved in growth control (reviewed in ref. 3) and can regulate transforming growth factor beta-1 (TGF-beta-1) gene expression4,5. TGF-beta isoforms also down-regulate cellular proliferation6,7. To determine whether pRb also regulates expression of other TGF-beta isoforms, we examined the effect of pRb on the expression of the human TGF-beta-2 gene. The human TGF-beta-2 promoter contains multiple elements including an ATF site, which is essential for basal promoter activity8. Here we report that pRb activates transcription of the human TGF-beta-2 gene. The promoter element responsible for pRb-mediated transcriptional regulation is a binding site for ATF proteins, an extensive transcription factor family9. We provide evidence that implicates ATF-2 in pRb-responsiveness. First, the ATF promoter element in the TGF-beta-2 gene is a high-affinity ATF-2-binding site. Second, a GAL4-ATF2 fusion protein can support pRb-mediated transcriptional activation of a promoter containing GAL4-binding sites. Third, ATF-2 in nuclear extracts can interact with pRb. Our results reveal a new mechanism by which pRb constrains cellular proliferation: by activating ex ression of the inhibitory growth factor, TGF-beta-2.	UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV PITTSBURGH,SCH MED,DEPT MOLEC GENET & BIOCHEM,PITTSBURGH,PA 15261	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	KIM, SJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Noma T, 1991, GROWTH FACTORS, V4, P247, DOI 10.3109/08977199109043910; RIO DC, 1986, CELL, V44, P21, DOI 10.1016/0092-8674(86)90481-2; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0	22	253	257	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					331	334		10.1038/358331a0	http://dx.doi.org/10.1038/358331a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641004				2022-12-24	WOS:A1992JE68400064
J	RADFORD, SE; DOBSON, CM; EVANS, PA				RADFORD, SE; DOBSON, CM; EVANS, PA			THE FOLDING OF HEN LYSOZYME INVOLVES PARTIALLY STRUCTURED INTERMEDIATES AND MULTIPLE PATHWAYS	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; EGG-WHITE LYSOZYME; RIBONUCLEASE-A; ALPHA-LACTALBUMIN; CIRCULAR-DICHROISM; PROTEIN; NMR; EXCHANGE; KINETICS	Analysis of the folding of hen lysozyme shows that the protein does not become organized in a single cooperative event but that different parts of the structure become stabilized with very different kinetics. In particular, in most molecules the alpha-helical domain folds faster than the beta-sheet domain. Furthermore, different populations of molecules fold by kinetically distinct pathways. Thus, folding is not a simple sequential assembly process but involves parallel alternative pathways, some of which may involve substantial reorganization steps.	UNIV OXFORD,INORGAN CHEM LAB,OXFORD OX1 3QR,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	University of Oxford; University of Cambridge; University of Cambridge	RADFORD, SE (corresponding author), UNIV OXFORD,OXFORD CTR MOLEC SCI,S PARKS RD,OXFORD OX1 3QR,ENGLAND.			Radford, Sheena/0000-0002-3079-8039				BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DOBSON CM, 1984, BIOCHEMISTRY-US, V23, P4267, DOI 10.1021/bi00314a001; ELOVE GA, 1991, ACS SYM SER, V470, P50; ELOVE GA, IN PRESS BIOCHEMISTR; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GOUX WJ, 1980, BIOPOLYMERS, V19, P2191, DOI 10.1002/bip.1980.360191205; HARDING MM, 1991, BIOCHEMISTRY-US, V30, P3120, DOI 10.1021/bi00226a020; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JACKSON SE, 1991, BIOCHEMISTRY-US, V30, P10436, DOI 10.1021/bi00107a011; JENG MF, 1991, J MOL BIOL, V221, P1045, DOI 10.1016/0022-2836(91)80191-V; JONG MF, 1990, BIOCHEMISTRY-US, V29, P10433; KATO S, 1982, BIOCHEMISTRY-US, V21, P38, DOI 10.1021/bi00530a007; KATO S, 1981, BIOCHEMISTRY-US, V20, P1080, DOI 10.1021/bi00508a006; KLEMM JD, 1991, BIOCHEMISTRY-US, V30, P589, DOI 10.1021/bi00216a038; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUWAJIMA K, 1991, BIOCHEMISTRY-US, V30, P7693, DOI 10.1021/bi00245a005; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MATOUSCHEK A, 1990, NATURE, V346, P440, DOI 10.1038/346440a0; MIRANKER A, 1991, NATURE, V349, P633, DOI 10.1038/349633a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; PEDERSEN TG, 1991, J MOL BIOL, V218, P413, DOI 10.1016/0022-2836(91)90722-I; RADFORD SE, IN PRESS PROTEINS ST; ROBERTSON AD, 1991, BIOCHEMISTRY-US, V30, P9907, DOI 10.1021/bi00105a014; RODER H, 1986, Proteins Structure Function and Genetics, V1, P34, DOI 10.1002/prot.340010107; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; ROPSON IJ, 1990, BIOCHEMISTRY-US, V29, P9591, DOI 10.1021/bi00493a013; SCHMID FX, 1983, BIOCHEMISTRY-US, V22, P4690, DOI 10.1021/bi00289a013; SCHMID FX, 1979, J MOL BIOL, V135, P199, DOI 10.1016/0022-2836(79)90347-4; STALEY JP, 1990, NATURE, V344, P685, DOI 10.1038/344685a0; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; UDGAONKAR JB, 1990, P NATL ACAD SCI USA, V87, P8197, DOI 10.1073/pnas.87.21.8197; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEDIN RE, 1982, BIOCHEMISTRY-US, V21, P1098, DOI 10.1021/bi00534a042; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; [No title captured]	45	747	751	0	88	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 23	1992	358	6384					302	307		10.1038/358302a0	http://dx.doi.org/10.1038/358302a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE684	1641003				2022-12-24	WOS:A1992JE68400055
J	FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL				FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL			NEGATIVE INOTROPIC EFFECTS OF CYTOKINES ON THE HEART MEDIATED BY NITRIC-OXIDE	SCIENCE			English	Article							MYOCARDIAL INJURY; REPERFUSION; DYSFUNCTION; NEUTROPHIL; ISCHEMIA; CELLS	The direct effects of pro-inflammatory cytokines on the contractility of mammalian heart were studied. Tumor necrosis factor-alpha, interleukin-6, and interleukin-2 inhibited contractility of isolated hamster papillary muscles in a concentration-dependent, reversible manner. The nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) blocked these negative inotropic effectS. L-Arginine reversed the inhibition by L-NMMA. Removal of the endocardial endothelium did not alter these responses. These findings demonstrate that the direct negative inotropic effect of cytokines is mediated through a myocardial nitric oxide synthase. The regulation of pro-inflammatory cytokines and myocardial nitric oxide synthase may provide new therapeutic strategies for the treatment of cardiac disease.	UNIV PITTSBURGH, SCH MED, DEPT NEUROBIOL ANAT & CELL SCI, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	FINKEL, MS (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HATTIER BG, 1991, 20TH ANN M KEYST S M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; LI LM, 1991, CANCER RES, V51, P2531; LUCCHESI BR, 1989, J MOL CELL CARDIOL, V21, P1241, DOI 10.1016/0022-2828(89)90670-6; MONCADA S, 1991, J CARDIOVASC PHARM, V17, pS1, DOI 10.1097/00005344-199117003-00002; MULLANE KM, 1988, ANN NY ACAD SCI, V524, P103; NALDINI A, 1987, J IMMUNOL, V139, P1880; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; SHAH AM, 1991, J CARDIOVASC PHARM, V17, pS251, DOI 10.1097/00005344-199117003-00046; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828	20	1423	1519	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1992	257	5068					387	389		10.1126/science.1631560	http://dx.doi.org/10.1126/science.1631560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631560				2022-12-24	WOS:A1992JD67400034
J	REIBER, GE; PECORARO, RE; KOEPSELL, TD				REIBER, GE; PECORARO, RE; KOEPSELL, TD			RISK-FACTORS FOR AMPUTATION IN PATIENTS WITH DIABETES-MELLITUS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; AMPUTATION; PATIENT EDUCATION; DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES	PERIPHERAL VASCULAR-DISEASE; LOWER-EXTREMITY AMPUTATIONS; FOLLOW-UP; LIMB AMPUTATION; MORTALITY; PREVENTION; FRAMINGHAM; SMOKING; HEALTH	Objective: To identify and quantify risk factors for lower extremity amputation in persons with diabetes mellitus. Design: Case-control study. Setting: A Veterans Affairs medical center. Patients: Eighty patients having amputation associated with diabetes and 236 diabetic controls without limb lesions were enrolled before surgery from the 21 167 inpatient care and outpatient surgical patients seen at the Seattle Veterans Affairs Medical Center during a 30-month period. Measurements: Selected vascular, neuropathic, environmental, health care, self care, nutritional, metabolic, lifestyle, and psychosocial risk factors were measured in all patients before surgery. Results: Statistically significant risk factors identified from analysis included insufficient mean below-knee and foot cutaneous circulation (odds ratio, 161; 95% CI, 55.1 to 469); ankle-arm blood pressure index < 0.45 (odds ratio, 55.8; CI, 14.9 to 209); absence of lower leg vibratory perception (odds ratio, 15.5; CI, 8.3 to 28.7); low levels of high-density lipoprotein (HDL) subfraction 3 less-than-or-equal-to 0.7-mu-mol/L (odds ratio, 4.9; CI, 2.9 to 8.3); and no previous outpatient diabetes education (odds ratio, 3.2; CI, 1.6 to 6.6). A logistic regression analysis done to control for the potentially confounding effects of age; race; socioeconomic status; diabetes duration, type, and severity confirmed these findings and added a statistically significant interaction between foot transcutaneous oxygen tension and peripheral vascular disease history. Clinical interventions to alter these risk factors were identified, including aggressive treatment of infection, diabetes education, protective footwear, and preventive footcare. Conclusions: Multiple risk factors exist along the continuum of conditions and events leading to lower extremity amputation in diabetes. Modification of certain risk factors by patients and health professionals may reduce the risk for amputation and thus decrease the human and dollar costs that accompany limb loss in this prevalent chronic disease.			REIBER, GE (corresponding author), VET ADM MED CTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; Bachorik P S, 1986, Methods Enzymol, V129, P78; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; Davis W, 1980, IARC SCI PUBL, V32, P192; DAVIS WK, 1988, DIABETES CARE, V11, P538, DOI 10.2337/diacare.11.7.538; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELGAL DW, 1989, RISK FACTORS AMPUTAT; FRONEK A, 1985, NONINVASIVE DIAGNOSI, P697; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOODSON WH, 1979, SURG GYNECOL OBSTET, V149, P600; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; HAUSER CJ, 1987, ARCH SURG-CHICAGO, V122, P1128; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOWARD BV, 1987, J LIPID RES, V28, P613; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658-198609000-00011; KREINES K, 1985, DIABETES CARE, V8, P235, DOI 10.2337/diacare.8.3.235; LABBE RF, 1989, SEMIN HEMATOL, V26, P40; LEVIN ME, 1988, DIABETIC FOOT, P1; LIEDBERG E, 1983, ACTA ORTHOP SCAND, V54, P383, DOI 10.3109/17453678308996589; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MATTOCK MB, 1982, ATHEROSCLEROSIS, V45, P67, DOI 10.1016/0021-9150(82)90172-1; Miller A D, 1985, J Med Soc N J, V82, P723; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8; OGBUAWA O, 1982, SOUTHERN MED J, V75, P285, DOI 10.1097/00007611-198203000-00010; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PECORARO R, 1990, WOUNDS, V2, P65; PECORARO R E, 1988, Diabetes Research and Clinical Practice, V5, pS398; PECORARO RE, 1991, PROG CLIN BIOL RES, V365, P27; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; PECORARO RE, 1979, DIABETES, V28, P1120, DOI 10.2337/diabetes.28.12.1120; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; REIBER GE, 1990, DIABETES, V39, pA18; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; RUTKOW IM, 1986, J BONE JOINT SURG AM, V68A, P716, DOI 10.2106/00004623-198668050-00011; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SHOPLAND DR, 1987, PUBLIC HEALTH REP, V102, P68; SKYLER JS, 1980, DIABETES CARE, V3, P369, DOI 10.2337/diacare.3.2.369; STEWART AL, 1980, R23742HEW RAND, P20; Warnick G R, 1986, Methods Enzymol, V129, P101; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P391; WHEELOCK FC, 1984, MANAGEMENT DIABETIC, P188; WYSS CR, 1984, SURGERY, V95, P339; 1990, 1990 CTR DIS CONTR D, P24; 1980, DHEW NIH801527 PUBL, P52; 1987, DHHS NIH871587 PUBL; 1963, 15 US BUR CENS WORK, P1; 1982, DHHS PHS825017 DEP H; 1980, DHHS PHS801260 DEP H, P235	54	332	341	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					97	105		10.7326/0003-4819-117-2-97	http://dx.doi.org/10.7326/0003-4819-117-2-97			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605439				2022-12-24	WOS:A1992JD12300001
J	ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI				ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI			RAPID SWITCHING TO MULTIPLE ANTIGENIC AND ADHESIVE PHENOTYPES IN MALARIA	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; PARASITIZED ERYTHROCYTES; MEMBRANE GLYCOPROTEIN; CONTINUOUS CULTURE; CYTOADHERENCE; EXPRESSION; SEQUESTRATION; RECEPTOR	ADHESION of parasitized erythrocytes to post-capillary venular endothelium 1 or uninfected red cells 2-4 is strongly implicated in the pathogenesis of severe Plasmodium falciparum malaria. Neoantigens at the infected red-cell surface adhere to a variety of host receptors 5-9, demonstrate serological diversity in field isolates 10,11 and may also be a target of the host-protective immune response 12. Here we use sequential cloning of P. falciparum by micromanipulation to investigate the ability of a parasite to switch antigenic and cytoadherence phenotypes. Our data show that antigens at the parasitized cell surface undergo clonal variation in vitro in the absence of immune pressure at the rate of 2% per generation with concomitant modulations of the adhesive phenotype. A clone has the potential to switch at high frequency to a variety of antigenic and adhesive phenotypes, including a new type of cytoadherence behaviour, 'auto-agglutination' of infected erythrocytes. This rapid appearance of antigenic and functional heterogeneity has important implications for pathogenesis and acquired immunity.	UNIV BIRMINGHAM,DEPT HAEMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	ROBERTS, DJ (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC PARASITOL GRP,OXFORD OX3 9DU,ENGLAND.		Nash, Gerard B/E-4182-2010	Nash, Gerard B/0000-0002-5935-2831; Newbold, Chris/0000-0002-9274-3789; Craig, Alister/0000-0003-0914-6164	Wellcome Trust [061524] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERENDT AR, 1992, CELL, V8, P71; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, IN PRESS J IMMUN; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MCLEAN SA, 1982, EXP PARASITOL, V54, P296, DOI 10.1016/0014-4894(82)90038-8; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835	30	524	530	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					689	692		10.1038/357689a0	http://dx.doi.org/10.1038/357689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614515	Green Accepted			2022-12-24	WOS:A1992JA43000071
J	LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH				LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH			OXYTOCIN GENE-EXPRESSION IN RAT UTERUS	SCIENCE			English	Article							HUMAN PARTURITION; LOCALIZATION; INITIATION; LACTATION; RECEPTORS; ELEMENT; LABOR	The neurohypophyseal hormone oxytocin (OT) is the most potent uterotonic agent known and is used to induce labor. Yet, endogenous circulating OT appears not to participate in the induction of labor. As shown here, the finding of OT messenger RNA and peptide in the uterus suggests a solution for this paradox. During gestation, rat uterus OT messenger RNA increased more than 150-fold and, at term, exceeded hypothalamic OT messenger RNA by 70-fold. Thus, during parturition, OT may act primarily as a local mediator and not as a circulating hormone.	MCGILL UNIV,ROYAL VICTORIA HOSP,MOLEC ENDOCRINOL LAB,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,MONTREAL GEN HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,ENDOCRINE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; Royal Victoria Hospital			Zingg, Hans/GPS-9984-2022					AKERLUND M, 1987, BRIT J OBSTET GYNAEC, V94, P1040, DOI 10.1111/j.1471-0528.1987.tb02287.x; ALE CC, 1961, J ENDOCRINOL, V22, P107; AYAD VJ, 1991, J ENDOCRINOL, V128, P187, DOI 10.1677/joe.0.1280187; BARASH I, 1988, ENDOCRINOLOGY, V122, P1151, DOI 10.1210/endo-122-3-1151; CHARD T, 1989, AM J PERINAT, V6, P145, DOI 10.1055/s-2007-999566; CIAROCHI FF, 1985, PEPTIDES, V6, P903, DOI 10.1016/0196-9781(85)90321-3; COLLINS S, 1990, J BIOL CHEM, V265, P19330; DEGEEST K, 1985, J PERINAT MED, V13, P3, DOI 10.1515/jpme.1985.13.1.3; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; FUCHS AR, 1984, BRIT J OBSTET GYNAEC, V91, P948, DOI 10.1111/j.1471-0528.1984.tb03671.x; GIRALDI A, 1990, DAN MED BULL, V37, P377; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOREWIT RC, 1979, P SOC EXP BIOL MED, V160, P80, DOI 10.3181/00379727-160-40394; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; HCIBBAR R, 1992, 39TH P ANN M SOC GYN, P251; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KUMARESAN P, 1979, J ENDOCRINOL INVEST, V2, P65, DOI 10.1007/BF03349277; LEFEBVRE D, UNPUB; LEFEBVRE DL, 1991, MOL ENDOCRINOL, V5, P645, DOI 10.1210/mend-5-5-645; LEFEBVRE DL, 1992, ENDOCRINOLOGY, V130, P1185, DOI 10.1210/en.130.3.1185; MARTINI L, 1977, CLIN NEUROENDOCRINOL, P569; PHELAN JP, 1978, AM J OBSTET GYNECOL, V130, P365; SELLERS SM, 1981, BRIT J OBSTET GYNAEC, V88, P725, DOI 10.1111/j.1471-0528.1981.tb01273.x; SHUKOVSKI L, 1991, J ENDOCRINOL, V128, P305, DOI 10.1677/joe.0.1280305; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; WALLACE JM, 1991, J ENDOCRINOL, V128, P253, DOI 10.1677/joe.0.1280253; WILSON L, 1990, AM J OBSTET GYNECOL, V163, P1875, DOI 10.1016/0002-9378(90)90767-2; ZINGG HH, 1988, MOL BRAIN RES, V4, P1, DOI 10.1016/0169-328X(88)90011-3; ZINGG HH, 1984, ENDOCRINOLOGY, V115, P90, DOI 10.1210/endo-115-1-90; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	33	181	182	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1553	1555		10.1126/science.1598587	http://dx.doi.org/10.1126/science.1598587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598587				2022-12-24	WOS:A1992HY07500028
J	COHN, M; STEWART, P				COHN, M; STEWART, P			PREVALENCE OF POTENTIAL PATHOGENS IN CERVICAL CANAL BEFORE TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC-ABORTION; INFECTION		NO GEN HOSP,DEPT OBSTET & GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital								AGRESTI A, 1990, CATEGORICAL DATA ANA, P332; FRANK PI, 1985, J ROY COLL GEN PRACT, V35, P175; HEISTERBERG L, 1988, DAN MED BULL, V35, P64; QVIGSTAD E, 1983, BRIT J VENER DIS, V59, P189; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a	5	14	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1479	1479		10.1136/bmj.304.6840.1479	http://dx.doi.org/10.1136/bmj.304.6840.1479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611371	Green Published, Bronze			2022-12-24	WOS:A1992HY55300024
J	JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES				JACOB, HJ; LINDPAINTNER, K; LINCOLN, SE; KUSUMI, K; BUNKER, RK; MAO, YP; GANTEN, D; DZAU, VJ; LANDER, ES			GENETIC-MAPPING OF A GENE CAUSING HYPERTENSION IN THE STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RAT	CELL			English	Article							ANGIOTENSIN-CONVERTING ENZYME; FRAGMENT LENGTH POLYMORPHISMS; QUANTITATIVE-TRAIT LOCI; BLOOD-PRESSURE; GROWTH-HORMONE; MENDELIAN FACTORS; LINKAGE MAP; DNA; IDENTIFICATION; CHROMOSOME-17	The stroke-prone spontaneously hypertensive rat (SHRSP) is a well-characterized model for primary hypertension in humans. High blood pressure in SHRSP shows polygenic inheritance, but none of the loci responsible have previously been identified. To locate genes controlling this quantitative trait, we mapped a large collection of DNA polymorphisms in a cross between SHRSP and the normotensive WKY strain. Here we report strong genetic evidence that a gene, Bp1, having a major effect on blood pressure maps to rat chromosome 10 with a LOD score of 5.10 and is closely linked to the rat gene encoding angiotensin-converting enzyme (ACE), an enzyme that plays a major role in blood pressure homeostasis and is an important target of anti-hypertensive drugs. We also find significant, albeit weaker, linkage to a locus, Bp2, on chromosome 18. We discuss the implications of genetic dissection of quantitative disease-related phenotypes in mammals.	UNIV HEIDELBERG, GERMAN INST HIGH BLOOD PRESSURE RES, W-6900 HEIDELBERG, GERMANY; CTR MOLEC MED, BERLIN, GERMANY; STANFORD UNIV, MED CTR, DIV CARDIOL, STANFORD, CA 94305 USA; UNIV HEIDELBERG, DEPT PHARMACOL, W-6900 HEIDELBERG, GERMANY; HARVARD UNIV, CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, DIV CARDIOL, BOSTON, MA 02115 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Ruprecht Karls University Heidelberg; Stanford University; Ruprecht Karls University Heidelberg; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Massachusetts Institute of Technology (MIT)	JACOB, HJ (corresponding author), WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012	Kusumi, Kenro/0000-0002-1458-4540	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, R01HL042663] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R37HG000198, R01HG000198] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00198] Funding Source: Medline; NHLBI NIH HHS [HL42663, HL35610] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNSTEIN KE, 1989, J BIOL CHEM, V264, P11945; BIANCH G, 1990, HYPERTENSION PATHOPH, pCH78; BOTSTEIN D, 1980, AM J HUM GENET, V32, P314; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOKE NE, 1986, ENDOCRINOLOGY, V119, P2451, DOI 10.1210/endo-119-6-2451; Dollery CT., 1985, CECIL TXB MED, V17th, P266; DZAU VJ, 1988, CIRCULATION, V77, P4; East EM, 1916, GENETICS, V1, P164; EDWARDS MD, 1987, GENETICS, V116, P113; ELY DL, 1990, HYPERTENSION, V16, P277, DOI 10.1161/01.HYP.16.3.277; HABER E, 1986, SCI AM MED CARDIOLOG; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HARPER ME, 1982, AM J HUM GENET, V34, P227; HAVLIK RJ, 1979, AM J EPIDEMIOL, V110, P304, DOI 10.1093/oxfordjournals.aje.a112815; HIGGINS M, 1980, AM J EPIDEMIOL, V111, P142, DOI 10.1093/oxfordjournals.aje.a112882; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; KURTZ TW, 1990, J CLIN INVEST, V85, P1328, DOI 10.1172/JCI114572; LANDER E S, 1987, Genomics, V1, P174, DOI 10.1016/0888-7543(87)90010-3; LANDER ES, 1989, GENETICS, V121, P185; LANDER ES, 1986, COLD SPRING HARB SYM, V51, P49, DOI 10.1101/SQB.1986.051.01.007; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; LEVAN G, 1990, GENETIC MAPS LOCUS M; LEVINE RS, 1982, AM J EPIDEMIOL, V116, P759, DOI 10.1093/oxfordjournals.aje.a113465; LINDPAINTNER K, 1990, J HYPERTENS, V8, P763, DOI 10.1097/00004872-199008000-00011; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; MUELLER SM, 1985, ARTERY, V12, P337; NAKATA K, 1987, J CARDIOVASC PHARM, V9, P305, DOI 10.1097/00005344-198703000-00007; NEUMANN PE, 1991, P NATL ACAD SCI USA, V88, P5408, DOI 10.1073/pnas.88.12.5408; Nilsson-Ehle H, 1909, LUNDS U AARSKR, V5, P1; OKAMOTO KOZO, 1963, JAPAN CIRCULATION JOUR, V27, P282; PAGE RCL, 1995, DIABETIC MED, V12, P209, DOI 10.1111/j.1464-5491.1995.tb00460.x; PATERSON AH, 1991, GENETICS, V127, P181; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PATERSON AH, 1990, GENETICS, V124, P735; PRATT RE, 1989, AM J PHYSIOL, V256, pF469, DOI 10.1152/ajprenal.1989.256.3.F469; PRAVENEC M, 1991, HYPERTENSION, V17, P242, DOI 10.1161/01.HYP.17.2.242; RAPP JP, 1982, HYPERTENSION, P582; RIORDAN JR, 1989, SCIENCE, V245, P1066; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; ROBINSON R, 1972, GENE MAPPING LABOR B; ROBINSON R, 1979, LABORATORY RAT, V1, P38; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLAGER G, 1967, GENETICS, V55, P497; STALLINGS RL, 1991, GENOMICS, V10, P807, DOI 10.1016/0888-7543(91)90467-S; TANASE H, 1970, JPN CIRCULATION J, V34, P1197; THODAY JM, 1961, NATURE, V191, P368, DOI 10.1038/191368a0; THOMAS MJ, 1990, MOL CELL BIOL, V10, P5378, DOI 10.1128/MCB.10.10.5378; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEBER JL, 1989, AM J HUM GENET, V44, P388; Wright S., 1968, EVOLUTION GENETICS P, P373; YAMORI Y, 1982, HYPERTENSION, P556	54	685	699	1	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	1991	67	1					213	224		10.1016/0092-8674(91)90584-L	http://dx.doi.org/10.1016/0092-8674(91)90584-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GJ320	1655275				2022-12-24	WOS:A1991GJ32000019
J	PARKER, CN; HALFORD, SE				PARKER, CN; HALFORD, SE			DYNAMICS OF LONG-RANGE INTERACTIONS ON DNA - THE SPEED OF SYNAPSIS DURING SITE-SPECIFIC RECOMBINATION BY RESOLVASE	CELL			English	Article							LAMBDA INTEGRATIVE RECOMBINATION; TN3 RESOLVASE; TN21 RESOLVASE; RECOGNITION FUNCTIONS; BACTERIOPHAGE-LAMBDA; LAC REPRESSOR; BINDING-SITES; RES SITES; PROTEIN; PRODUCTS	A noninvasive method for monitoring communications on DNA was developed from the specificity of resolvase for the arrangement of its recombinational sites. Constraints in DNA structure, caused by interactions between distant sites, can be detected by resolvase as they arise. The method was used to follow the formation and decay of synaptic intermediates during site-specific recombination by resolvase. Synaptic complexes were formed very rapidly, at a rate limited by the initial association of the protein with DNA rather than the physical motion of DNA segments. The recombinational sites seem to encounter each other by an ordered motion, perhaps dictated by DNA super-coiling instead of random collisions, so that the first encounter produces the active complex.	UNIV BRISTOL,CTR MOLEC RECOGNIT,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Bristol					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; ACKROYD AJ, 1990, J MOL BIOL, V216, P633, DOI 10.1016/0022-2836(90)90388-3; AVILA P, 1990, J MOL BIOL, V216, P645, DOI 10.1016/0022-2836(90)90389-4; BEDNARZ AL, 1990, GENE DEV, V4, P2366, DOI 10.1101/gad.4.12b.2366; BELLOMY GR, 1990, PROG NUCL ACIDS RES, V30, P81; BENJAMIN HA, 1989, J BIOL CHEM, V265, P6441; BENJAMIN HW, 1988, EMBO J, V7, P1897, DOI 10.1002/j.1460-2075.1988.tb03023.x; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; Berg O, 1981, BIOCHEMISTRY-US, V20, P6926; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BOOCOCK MR, 1986, BIOCHEM SOC T, V14, P214; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; CASTELL SE, 1989, NUCLEIC ACIDS RES, V17, P7045, DOI 10.1093/nar/17.17.7045; CASTELL SE, 1986, NUCLEIC ACIDS RES, V14, P7213, DOI 10.1093/nar/14.18.7213; CASTELL SE, 1988, THESIS U BRISTOL BRI; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; DIVER WP, 1983, MOL GEN GENET, V191, P189, DOI 10.1007/BF00334812; GELLERT M, 1987, NATURE, V325, P401, DOI 10.1038/325401a0; HAGERMAN P, 1908, ANNU REV BIOPHYS BIO, V17, P165; HALFORD SE, 1985, MOL GEN GENET, V200, P169, DOI 10.1007/BF00383331; HALFORD SE, 1983, BIOCHEM J, V211, P405, DOI 10.1042/bj2110405; HATFULL GF, 1988, GENETIC RECOMBINATIO, P3257; KLEIN J, 1990, SCIENCE, V250, P640, DOI 10.1126/science.250.4981.640; KRAMER H, 1988, EMBO J, V7, P547, DOI 10.1002/j.1460-2075.1988.tb02844.x; KRASNOW MA, 1983, CELL, V32, P1313, DOI 10.1016/0092-8674(83)90312-4; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Luke P A, 1987, Gene Amplif Anal, V5, P185; Maniatis T., 1982, MOL CLONING; MIZUUCHI K, 1980, J MOL BIOL, V141, P485, DOI 10.1016/0022-2836(80)90256-9; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; ROGOWSKY P, 1985, EMBO J, V4, P2135, DOI 10.1002/j.1460-2075.1985.tb03904.x; SALDANHA R, 1987, J MOL BIOL, V196, P505, DOI 10.1016/0022-2836(87)90028-3; SALVO JJ, 1988, STRUCTURE EXPRESSION, V3, P105; SHERRATT D, 1989, MOBILE DNA, P163; SPENGLER SJ, 1985, CELL, V42, P325, DOI 10.1016/S0092-8674(85)80128-8; STARK WM, 1989, TRENDS GENET, V5, P304, DOI 10.1016/0168-9525(89)90113-3; STARK WM, 1989, CELL, V58, P779, DOI 10.1016/0092-8674(89)90111-6; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WASSERMAN SA, 1985, P NATL ACAD SCI USA, V82, P1079, DOI 10.1073/pnas.82.4.1079	47	58	58	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					781	791		10.1016/0092-8674(91)90121-E	http://dx.doi.org/10.1016/0092-8674(91)90121-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652373				2022-12-24	WOS:A1991GC74500016
J	HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR				HERRMANN, JE; TAYLOR, DN; ECHEVERRIA, P; BLACKLOW, NR			ASTROVIRUSES AS A CAUSE OF GASTROENTERITIS IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODIES; ANTIGEN-DETECTION; SEROTYPES; DIAGNOSIS; VIRUSES	Background. Infection with astroviruses has been associated with gastroenteritis in children, and serologic surveys indicate that this infection may be frequent. The importance of astroviruses as agents of gastroenteritis has not been shown in a controlled study, however. Methods. We used monoclonal antibody-based enzyme immunoassays to detect astroviruses, enteric adenoviruses, and rotaviruses in stool samples obtained from age-matched children with and children without gastroenteritis. The samples were obtained in two studies, three years apart, among patients attending an outpatient clinic in Bangkok, Thailand. Results. In the first study, astroviruses were detected in 8.6 percent (96 of 1111) of the children with gastroenteritis and in 2.0 percent (19 of 947) of the children without gastroenteritis. In the second study the rates were 8.6 percent (50 of 580) and 2.1 percent (11 of 512), respectively. For both studies combined, enteric adenoviruses were detected in 2.6 percent of those with gastroenteritis and in 0.5 percent of the controls, whereas rotaviruses were detected in 19 percent of those with gastroenteritis and in 1.0 percent of the controls. The clinical findings associated with astrovirus infection were similar to those associated with rotavirus infection, except for a trend toward greater dehydration in the children infected with rotaviruses. Conclusions. These two controlled studies involving a total of 3150 Thai children provide evidence that astroviruses are a common cause of viral gastroenteritis. Astroviruses were found in association with gastroenteritis more frequently than were enteric adenoviruses, and with nearly half the frequency of rotaviruses.	ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	HERRMANN, JE (corresponding author), UNIV MASSACHUSETTS,SCH MED,DIV INFECT DIS & IMMUNOL,WORCESTER,MA 01655, USA.							ASHLEY CR, 1978, J CLIN PATHOL, V31, P939, DOI 10.1136/jcp.31.10.939; CEPKO CL, 1983, J CLIN MICROBIOL, V17, P360, DOI 10.1128/JCM.17.2.360-364.1983; CUKOR G, 1984, J CLIN MICROBIOL, V19, P888, DOI 10.1128/JCM.19.6.888-892.1984; ECHEVERRIA P, 1989, J INFECT DIS, V159, P543, DOI 10.1093/infdis/159.3.543; ELLIS ME, 1984, ARCH DIS CHILD, V59, P848, DOI 10.1136/adc.59.9.848; GRAY JJ, 1987, J MED VIROL, V23, P377, DOI 10.1002/jmv.1890230410; HERRMANN JE, 1990, ARCH VIROL, V110, P213, DOI 10.1007/BF01311289; HERRMANN JE, 1987, LANCET, V2, P743; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HERRMANN JE, 1988, J INFECT DIS, V158, P182, DOI 10.1093/infdis/158.1.182; KONNO T, 1982, J MED VIROL, V9, P11, DOI 10.1002/jmv.1890090103; KOTLOFF KL, 1975, LANCET, V2, P451; KURTZ J, 1978, MED MICROBIOL IMMUN, V166, P227, DOI 10.1007/BF02121154; KURTZ JB, 1987, CIBA F SYMP, V128, P92; KURTZ JB, 1984, LANCET, V2, P1405; KURTZ JB, 1977, J CLIN PATHOL, V30, P948, DOI 10.1136/jcp.30.10.948; KURTZ JB, 1979, J MED VIROL, V3, P221, DOI 10.1002/jmv.1890030308; LEE TW, 1981, J GEN VIROL, V57, P421, DOI 10.1099/0022-1317-57-2-421; MADELEY CR, 1977, J HYG-CAMBRIDGE, V78, P261, DOI 10.1017/S0022172400056151; MADELEY CR, 1975, LANCET, V2, P124; MADELEY CR, 1978, J HYG LOND, V82, P285; MIDDLETON PJ, 1982, VIRUS INFECTIONS GAS, P211; NAZER H, 1982, J PEDIATR GASTR NUTR, V1, P555, DOI 10.1097/00005176-198212000-00018; RIEPENHOFFTALTY M, 1983, J CLIN MICROBIOL, V17, P352, DOI 10.1128/JCM.17.2.352-356.1983; TAYLOR DN, 1986, J INFECT DIS, V153, P1132, DOI 10.1093/infdis/153.6.1132	26	159	164	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 20	1991	324	25					1757	1760		10.1056/NEJM199106203242501	http://dx.doi.org/10.1056/NEJM199106203242501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	FR681	1645459				2022-12-24	WOS:A1991FR68100001
J	BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C				BARGONETTI, J; FRIEDMAN, PN; KERN, SE; VOGELSTEIN, B; PRIVES, C			WILD-TYPE BUT NOT MUTANT P53 IMMUNOPURIFIED PROTEINS BIND TO SEQUENCES ADJACENT TO THE SV40 ORIGIN OF REPLICATION	CELL			English	Article							LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; MONKEY CELLS; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; TRANSFORMED-CELLS; DNA-REPLICATION; MOUSE P53; GENE; TRANSCRIPTION	The DNA from a wide variety of human tumors has sustained mutations within the conserved p53 coding regions. We have purified wild-type and tumor-derived mutant p53 proteins expressed from baculovirus vectors and examined their interactions with SV40 DNA. Using DNAase I footprinting assays, we observed that both human and murine wild-type p53 proteins bind specifically to sequences adjacent to the late border of the viral replication origin. By contrast, mutant p53 proteins failed to bind specifically to these sequences. SV40 T antigen prevented wild-type p53 from interacting with this region. These data show that normal but not oncogenic forms of p53 are capable of sequence-specific interactions with viral DNA. Furthermore, they provide insights into the mechanisms by which viral proteins might regulate the control of viral growth and cell division.	JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine	BARGONETTI, J (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991	NATIONAL CANCER INSTITUTE [R37CA043460, R01CA043460, P01CA033620] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460, CA33620] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DILLER L, 1990, MOL CELL BIOL, V10, P5775; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FROMM M, 1982, Journal of Molecular and Applied Genetics, V1, P457; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HOLLSTEIN M, 1991, IN PRESS SCIENCE; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, IN PRESS SCIENCE; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Maxam A M, 1980, Methods Enzymol, V65, P499; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; OROURKE RW, 1986, NATURE, V320, P182; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; STURZBECHER HW, 1988, ONCOGENE, V3, P405; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	65	395	407	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 14	1991	65	6					1083	1091		10.1016/0092-8674(91)90560-L	http://dx.doi.org/10.1016/0092-8674(91)90560-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FR047	1646078				2022-12-24	WOS:A1991FR04700019
J	RIDLEY, AJ; HALL, A				RIDLEY, AJ; HALL, A			THE SMALL GTP-BINDING PROTEIN RHO REGULATES THE ASSEMBLY OF FOCAL ADHESIONS AND ACTIN STRESS FIBERS IN RESPONSE TO GROWTH-FACTORS	CELL			English	Article							LYSOPHOSPHATIDIC ACID; CLOSTRIDIUM-BOTULINUM; ACTIVATING PROTEIN; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; ESCHERICHIA-COLI; GENE-PRODUCT; R-RAS; CELLS; IDENTIFICATION	Actin stress fibers are one of the major cytoskeletal structures in fibroblasts and are linked to the plasma membrane at focal adhesions. rho, a ras-related GTP-binding protein, rapidly stimulated stress fiber and focal adhesion formation when microinjected into serum-starved Swiss 3T3 cells. Readdition of serum produced a similar response, detectable within 2 min. This activity was due to a lysophospholipid, most likely lysophosphatidic acid, bound to serum albumin. Other growth factors including PDGF induced actin reorganization initially to form membrane ruff les, and later, after 5 to 10 min, stress fibers. For all growth factors tested the stimulation of focal adhesion and stress fiber assembly was inhibited when endogenous rho function was blocked, whereas membrane ruffling was unaffected. These data imply that rho is essential specifically for the coordinated assembly of focal adhesions and stress fibers induced by growth factors.			RIDLEY, AJ (corresponding author), CHESTER BEATTY RES INST,INST CANC RES,FULHAM RD,LONDON SW3 6JB,ENGLAND.			Ridley, Anne/0000-0001-8186-5708				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BENTON AM, 1982, BLOOD, V60, P642; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRETSCHER A, 1991, ANNU REV CELL BIOL, V7, P337, DOI 10.1146/annurev.cb.07.110191.002005; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; DEPASQUALE JA, 1991, J CELL BIOL, V113, P1352; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1991, BIOCHEM J, V276, P833, DOI 10.1042/bj2760833; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GERRARD JM, 1984, BIOCHIM BIOPHYS ACTA, V795, P487, DOI 10.1016/0005-2760(84)90177-2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HALL AL, 1989, J CELL BIOL, V109, P2207, DOI 10.1083/jcb.109.5.2207; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HIRAOKA K, 1992, BIOCHEM BIOPH RES CO, V182, P921, DOI 10.1016/0006-291X(92)91820-G; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JALINK K, 1990, J BIOL CHEM, V265, P12232; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAHN RA, 1991, J BIOL CHEM, V266, P2606; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1981, NATURE, V292, P373; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MELLSTROM K, 1983, J MUSCLE RES CELL M, V4, P589, DOI 10.1007/BF00712117; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1992, IN PRESS CELL, V70; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Salmon ED, 1989, CURR OPIN CELL BIOL, V1, P541, DOI 10.1016/0955-0674(89)90018-5; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHAAFI RI, 1986, J CELL BIOL, V102, P1459, DOI 10.1083/jcb.102.4.1459; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; Small J V, 1988, Electron Microsc Rev, V1, P155; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; SWITZER S, 1965, J LIPID RES, V6, P506; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WANG YL, 1984, J CELL BIOL, V99, P1478, DOI 10.1083/jcb.99.4.1478	53	3920	3997	6	169	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 7	1992	70	3					389	399		10.1016/0092-8674(92)90163-7	http://dx.doi.org/10.1016/0092-8674(92)90163-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JH124	1643657				2022-12-24	WOS:A1992JH12400004
J	BUCK, M; CANNON, W				BUCK, M; CANNON, W			SPECIFIC BINDING OF THE TRANSCRIPTION FACTOR SIGMA-54 TO PROMOTER DNA	NATURE			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN NTRC; ACTIVATION; INITIATION; MECHANISM; ENHANCERS; INVIVO; GENES	A CENTRAL event in transcription is the assembly on DNA of specific complexes near the initiation sites for RNA synthesis. Activation of transcription by one class of enhancer-binding proteins requires an RNA polymerase holoenzyme1 containing the specialized transcription factor, sigma-54 (sigma-54). We report here that sigma-54 alone specifically binds to promoter DNA and is responsible for many of the close contacts between RNA polymerase holoenzyme and promoter DNA, a property proposed for the major sigma-70 protein family. Binding of simga-54 to promoter DNA is not equivalent to that of holoenzyme suggesting that there is a constraint on sigma-54 conformation when bound with core RNA polymerase. Footprints indicate sigma-54 is at the leading edge of DNA-bound holoenzyme. Like the holoenzyme1-4, sigma-54-binding to promoter DNA does not result in DNA strand separation. Instead the specific DNA-binding activity of sigma-54 assists assembly of a closed promoter complex. This complex can be isomerized to the open (DNA melted) complex by activator protein5,6, but promoter-bound sigma-54 alone cannot be induced to melt DNA. The pathway leading to productive transcription is similar to that proposed for eukaryotic RNA polymerase II systems.			BUCK, M (corresponding author), UNIV SUSSEX,AFRC,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND.							AUSTIN S, 1991, NUCLEIC ACIDS RES, V19, P2281, DOI 10.1093/nar/19.9.2281; AUSTIN S, 1992, EMBO J, V6, P2219; BMORETT E, 1988, P NATL ACAD SCI USA, V8, P9401; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; BUCK M, IN PRESS MOL MICROBI; CANNON W, 1992, J MOL BIOL, V225, P271, DOI 10.1016/0022-2836(92)90921-6; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COPPARD JR, 1991, MOL MICROBIOL, V5, P1309, DOI 10.1111/j.1365-2958.1991.tb00777.x; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1986, REGULATION GENE EXPR, P139; LESLEY SA, 1991, J BIOL CHEM, V266, P2632; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SASSEDWIGHT S, 1990, CELL, V62, P945, DOI 10.1016/0092-8674(90)90269-K; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	22	133	133	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 30	1992	358	6385					422	424		10.1038/358422a0	http://dx.doi.org/10.1038/358422a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JF853	1641025	Bronze			2022-12-24	WOS:A1992JF85300058
J	MEIER, UT; BLOBEL, G				MEIER, UT; BLOBEL, G			NOPP140 SHUTTLES ON TRACKS BETWEEN NUCLEOLUS AND CYTOPLASM	CELL			English	Article							NUCLEAR LOCATION SIGNAL; CASEIN KINASE-II; GEL-ELECTROPHORESIS; SEQUENCE REQUIREMENTS; BINDING-PROTEINS; T-ANTIGEN; SPECIFICITY DETERMINANTS; PRECURSOR PARTICLES; SYNTHETIC PEPTIDES; TRANSPORT SIGNALS	Nopp140 is a nucleolar phosphoprotein of 140 kd that we originally identified and purified as a nuclear localization signal (NLS)-binding protein. Molecular characterization revealed a 10-fold repeated motif of highly conserved acidic serine clusters that contain an abundance of phosphorylation consensus sites for casein kinase II (CK II). Indeed, Nopp140 is one of the most phosphorylated proteins in the cell, and NLS binding was dependent on phosphorylation. Nopp140 was shown to shuttle between the nucleolus and the cytoplasm. Shuttling is likely to proceed on tracks that were revealed by immunoelectron microscopy. These tracks extend from the dense fibrillar component of the nucleolus across the nucleoplasm to some nuclear pore complexes. We suggest that Nopp140 functions as a chaperone for import into and/or export from the nucleolus.			MEIER, UT (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AHN YS, 1985, BIOCHEMISTRY-US, V24, P7296, DOI 10.1021/bi00346a041; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; BANVILLE D, 1982, EXP CELL RES, V137, P437, DOI 10.1016/0014-4827(82)90046-5; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; DANG CV, 1989, J BIOL CHEM, V264, P18019; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI Y, 1978, J CELL BIOL, V76, P146, DOI 10.1083/jcb.76.1.146; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1981, J CELL BIOL, V88, P516, DOI 10.1083/jcb.88.3.516; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUGLE B, 1985, CELL, V41, P615, DOI 10.1016/S0092-8674(85)80034-9; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; JOCKUSCH BM, 1974, EXP CELL RES, V89, P241, DOI 10.1016/0014-4827(74)90787-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Le Stourgeon WM, 1978, CELL NUCLEUS, V6, P305; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MADSEN P, 1986, J CELL BIOL, V103, P2083, DOI 10.1083/jcb.103.6.2083; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Maniatis T, 1989, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIKKODEM V, 1979, ANAL BIOCHEM, V97, P382; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PFEIFLE J, 1981, BIOCHIM BIOPHYS ACTA, V670, P274, DOI 10.1016/0005-2795(81)90020-9; PFEIFLE J, 1984, EUR J BIOCHEM, V39, P417; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RECHSTEINER M, 1979, CELL, V16, P901, DOI 10.1016/0092-8674(79)90105-3; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; WANG TC, 1981, EXP CELL RES, V134, P409, DOI 10.1016/0014-4827(81)90440-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEHNER JM, 1977, NATURE, V266, P842, DOI 10.1038/266842a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	78	350	354	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					127	138						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623516				2022-12-24	WOS:A1992JC95700014
J	RAVNSKOV, U				RAVNSKOV, U			CHOLESTEROL LOWERING TRIALS IN CORONARY HEART-DISEASE - FREQUENCY OF CITATION AND OUTCOME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; MYOCARDIAL-INFARCTION; PRIMARY-PREVENTION; RANDOMIZED TRIALS; MORTALITY; DIET; RISK; REDUCTION	Objective-To see if the claim that lowering cholesterol values prevents coronary heart disease is true or if it is based on citation of supportive trials only. Design-Comparison of frequency of citation with outcome of all controlled cholesterol lowering trials using coronary heart disease or death, or both, as end point. Subjects-22 controlled cholesterol lowering trials. Results-Trials considered by their directors as supportive of the contention were cited almost six times more often than others, according to Science Citation Index. Apart from trials discontinued because of alleged side effects of treatment, unsupportive trials were not cited after 1970, although their number almost equalled the number considered supportive. In three supportive reviews the outcome of the selected trials was more favourable than the outcome of the excluded and ignored trials. In the 22 controlled cholesterol lowering trials studied total and coronary heart disease mortality was not changed significantly either overall or in any subgroup. A statistically significant 0-32% reduction in non-fatal coronary heart disease seemed to be due to bias as event frequencies were unrelated to trial length and to mean net reduction in cholesterol value; individual changes in cholesterol values were unsystematically or not related to outcome; and after correction for a small but significant increase in non-medical deaths in the intervention groups total mortality remained unchanged (odds ratio 1.02). Conclusion-Lowering serum cholesterol concentrations does not reduce mortality and is unlikely to prevent coronary heart disease. Claims of the opposite are based on preferential citation of supportive trials.										[Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; HEADY JA, 1980, LANCET, V2, P379; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEREN P, 1966, ACTA MED SCAND, V446, P1; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCORMICK J, 1988, LANCET, V2, P839; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1992, BMJ-BRIT MED J, V304, P393, DOI 10.1136/bmj.304.6824.393; OLIVER MF, 1961, LANCET, V2, P499; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE G, 1986, LANCET, V1, P869; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; Smith RL, 1989, AM CLIN LAB, P26; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; STEHBENS WE, 1989, NUTR REV, V47, P1, DOI 10.1111/j.1753-4887.1989.tb02743.x; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZARLING EJ, 1983, JAMA-J AM MED ASSOC, V250, P1177; 1971, BMJ, V4, P775; 1971, BMJ, V4, P767; 1972, JAMA-J AM MED ASSOC, V220, P996; 1970, JAMA-J AM MED ASSOC, V214, P1303	40	253	252	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 4	1992	305	6844					15	19		10.1136/bmj.305.6844.15	http://dx.doi.org/10.1136/bmj.305.6844.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC799	1638188	Green Published, Bronze, Green Submitted			2022-12-24	WOS:A1992JC79900021
J	LEHMANN, KG; FRANCIS, CK; DODGE, HT				LEHMANN, KG; FRANCIS, CK; DODGE, HT			MITRAL REGURGITATION IN EARLY MYOCARDIAL-INFARCTION - INCIDENCE, CLINICAL DETECTION, AND PROGNOSTIC IMPLICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article						MITRAL VALVE INSUFFICIENCY; MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT RADIONUCLEOTIDE; VENTRICULOGRAPHY	PAPILLARY-MUSCLE DYSFUNCTION; PLASMINOGEN-ACTIVATOR; VENTRICULAR-FUNCTION; LEAFLET CLOSURE; RUPTURE; ECHOCARDIOGRAPHY; THROMBOLYSIS; ADVANTAGES; MECHANISM; TRIAL	Objective: To investigate mitral regurgitation occurring early in the course of acute myocardial infarction with respect to its incidence, the impact of infarct size and location, the accuracy of clinical detection, the contribution of global and regional left ventricular performance, and its influence on prognosis. Design: Prospective observational study derived from patients entering Phase I of the Thrombolysis in Myocardial Infarction (TIMI) trial. Setting: Multicenter trial involving 13 university-affiliated medical centers. Patients: A total of 206 patients studied within 7 hours of symptom onset during their first myocardial infarction. Measurements: Contrast left ventriculography was used to document mitral regurgitation. Results: Mitral regurgitation was present in 27 patients (13%). Although the presence of regurgitation correlated with the site of infarction (20 of 27 had anterior infarctions) and the number of akinetic chords, it was not statistically related to the peak creatine kinase value or to left ventricular chamber size or filling pressure. A murmur of mitral regurgitation was heard in only 2 patients (1 incorrectly). The presence of early mitral regurgitation predicted cardiovascular mortality at 1 year by univariate (relative risk, 12.2; 95% Cl, 3.5 to 42; P < 0.0001) and multivariate (relative risk, 7.5; Cl, 2.0 to 28.6; P = 0.0008) analyses. Conclusions: Mitral regurgitation in early myocardial infarction is generally clinically "silent," is more common in anterior infarction, is associated with regional dysfunction but not early ventricular dilation or peak enzyme release, and is an important predictor of cardiovascular mortality.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	Yale University; University of Washington; University of Washington Seattle								AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; BARBOUR DJ, 1986, J AM COLL CARDIOL, V8, P558, DOI 10.1016/S0735-1097(86)80182-6; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BARZILAI B, 1990, AM J CARDIOL, V65, P1169, DOI 10.1016/0002-9149(90)90968-7; BERGER P B, 1991, Journal of the American College of Cardiology, V17, p247A; BLUMLEIN S, 1986, CIRCULATION, V74, P306, DOI 10.1161/01.CIR.74.2.306; BRAND FR, 1967, CIRCULATION, V36, pII75; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1042; BURCH GE, 1968, AM HEART J, V75, P399, DOI 10.1016/0002-8703(68)90097-5; BURCH GE, 1985, ARCH INTERN MED, V312, P932; CHENG TO, 1969, AM J MED, V47, P924, DOI 10.1016/0002-9343(69)90206-X; FORRESTER JS, 1971, CIRCULATION, V44, P877, DOI 10.1161/01.CIR.44.5.877; GAHL K, 1977, BRIT HEART J, V39, P13; GODLEY RW, 1981, CIRCULATION, V63, P565, DOI 10.1161/01.CIR.63.3.565; Gross L., 1921, BLOOD SUPPLY HEART I; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HICKEY MS, 1988, CIRCULATION, V78, P51; HIRAKAWA S, 1977, AM J PHYSIOL, V233, pH384, DOI 10.1152/ajpheart.1977.233.3.H384; IZUMI S, 1987, CIRCULATION, V76, P777, DOI 10.1161/01.CIR.76.4.777; KINNEY EL, 1985, AM HEART J, V109, P87, DOI 10.1016/0002-8703(85)90420-X; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; MILLER GE, 1968, J THORAC CARDIOV SUR, V56, P611, DOI 10.1016/S0022-5223(19)42786-4; MITTAL AK, 1971, CIRCULATION, V44, P174, DOI 10.1161/01.CIR.44.2.174; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; NAJAFI H, 1975, ANN THORAC SURG, V20, P529, DOI 10.1016/S0003-4975(10)64252-X; NISHIMURA RA, 1983, AM J CARDIOL, V51, P373, DOI 10.1016/S0002-9149(83)80067-8; OGAWA S, 1979, AM HEART J, V97, P312, DOI 10.1016/0002-8703(79)90430-7; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PERLOFF JK, 1972, CIRCULATION, V46, P227, DOI 10.1161/01.CIR.46.2.227; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; PINSON CW, 1984, J THORAC CARDIOV SUR, V88, P663; RADFORD MJ, 1979, CIRCULATION, V60, pI39; REPLOGLE RL, 1989, CIRCULATION, V79, P122; ROBERTS WC, 1972, CIRCULATION, V46, P138, DOI 10.1161/01.CIR.46.1.138; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; SHEEHAN FH, 1986, CIRCULATION, V74, P293, DOI 10.1161/01.CIR.74.2.293; SPALTEHOLZ W, 1924, ARTERIENDIE HERZWAND; TEI C, 1983, CIRCULATION, V68, P183, DOI 10.1161/01.CIR.68.1.183; TSAKIRIS AG, 1970, MAYO CLIN PROC, V45, P275; WEI JY, 1979, ANN INTERN MED, V90, P149, DOI 10.7326/0003-4819-90-2-149; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; ZELDIS SM, 1980, CATHETER CARDIO DIAG, V6, P225, DOI 10.1002/ccd.1810060303	44	149	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					10	17		10.7326/0003-4819-117-1-10	http://dx.doi.org/10.7326/0003-4819-117-1-10			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596042				2022-12-24	WOS:A1992JA43500002
J	DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ				DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ			X-RAY ANALYSES OF PEPTIDE-INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS	NATURE			English	Article							HUMAN RENAL RENIN; 3-DIMENSIONAL STRUCTURE; SEQUENCE-ANALYSIS; GLAND RENIN; RESOLUTION	X-ray analyses have defined the three-dimensional structures of crystals of mouse and human renins complexed with peptide inhibitors at resolutions of 1.9 and 2.8 angstrom, respectively. The exquisite specificity of renin arises partly from ordered loop regions at the periphery of the binding cleft. Although the pattern of main-chain hydrogen bonding in other aspartic proteinase inhibitor complexes is conserved in renins, differences in the positions of secondary structure elements (particularly helices) also lead to improved specificity in renins for angiotensinogen substrates.	UNIV LONDON BIRKBECK COLL,MOLEC BIOL LAB,LONDON WC1E 7HX,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND; PFIZER INC,DEPT MOLEC GENET & PROT CHEM,GROTON,CT 06340; PFIZER INC,DEPT MED CHEM,DIV CENT RES,GROTON,CT 06340	University of London; Birkbeck University London; Cancer Research UK; University of London; Birkbeck University London; Pfizer; Pfizer			Wood, Stephen P/B-1438-2009; Frazao, Carlos/C-1965-2008	Tickle, Ian/0000-0003-2977-0650; Frazao, Carlos/0000-0002-7725-1671				AKAHANE K, 1985, HYPERTENSION, V7, P3, DOI 10.1161/01.HYP.7.1.3; BADASSO M, 1992, J MOL BIOL, V223, P447, DOI 10.1016/0022-2836(92)90663-5; BLUNDELL T, 1983, NATURE, V304, P273, DOI 10.1038/304273a0; CARLSON W, 1985, HYPERTENSION, V7, P13, DOI 10.1161/01.HYP.7.1.13; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DODSON EJ, 1985, MOL REPLACEMENT, P33; DRIESSEN H, 1989, J APPL CRYSTALLOGR, V22, P510, DOI 10.1107/S0021889889004097; DRIESSEN HPC, 1992, ACTA CRYSTALLOGR B, V47, P987; GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032; GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; HOLZMAN TF, 1991, J PROTEIN CHEM, V10, P553, DOI 10.1007/BF01025483; HUTCHINS C, 1991, CRIT REV BIOCHEM MOL, V26, P77, DOI 10.3109/10409239109081721; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LIM LW, 1989, J MOL BIOL, V210, P239, DOI 10.1016/0022-2836(89)90305-7; MORNON JP, 1982, J MOL BIOL, V155, P539, DOI 10.1016/0022-2836(82)90487-9; NAVIA MA, 1984, J BIOL CHEM, V259, P2714; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; POE M, 1984, ANAL BIOCHEM, V140, P459, DOI 10.1016/0003-2697(84)90194-5; RAHUEL J, 1991, J STRUCT BIOL, V107, P227, DOI 10.1016/1047-8477(91)90048-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALI A, 1989, EMBO J, V8, P2179, DOI 10.1002/j.1460-2075.1989.tb08340.x; SALI A, 1992, PROTEINS, V12, P158, DOI 10.1002/prot.340120209; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIBANDA BL, 1984, FEBS LETT, V174, P102, DOI 10.1016/0014-5793(84)81086-8; SIBANDA BL, 1986, THESIS U LONDON; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SKEGGS LT, 1968, J EXP MED, V120, P13; Tigerstedt R, 1898, SKAND ARCH PHYSL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x, DOI 10.1111/J.1748-1716.1898.TB00272.X]; VEERAPANDIAN B, 1990, J MOL BIOL, V216, P1017, DOI 10.1016/S0022-2836(99)80017-5; VEERAPANDIAN B, 1992, PROTEIN SCI, V1, P322	36	131	134	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					466	472		10.1038/357466a0	http://dx.doi.org/10.1038/357466a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608447				2022-12-24	WOS:A1992HY05200052
J	LUCK, CA				LUCK, CA			VALUE OF ROUTINE ULTRASOUND SCANNING AT 19 WEEKS - A 4 YEAR STUDY OF 8849 DELIVERIES	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Objective - To evaluate the effectiveness of routine ultrasound scanning at 19 weeks' gestation in an unselected population in terms of accuracy of detection of fetal structural abnormality and the effect on obstetric and neonatal care. Design - Prospective study over four years. Scans performed by radiographers with overall supervision by a radiologist. Setting - Ultrasound department of district general hospital. Subjects - All pregnant women were offered scans; 8523 of 8849 (96%) accepted. Main outcome measures - Information obtained from hospital records, genetic analysis, and post-mortem findings. Results - 166 fetal anomalies occurred; 140 were detected at 19 weeks (sensitivity 85%; specificity 99.9%). In 27 cases fetuses were shown to have severely crippling or lethal abnormalities; termination of pregnancy was requested in 25. Early diagnosis influenced timing and place of delivery in babies with severe cardiac or gastrointestinal anomalies. Conclusion - Scanning at 19 weeks with availability of termination can reduce perinatal morbidity and mortality. Scanning can be performed in a general ultrasound department with adequate counselling facilities and close cooperation between radiographers, midwives, obstetricians, paediatricians, and the radiologist.			LUCK, CA (corresponding author), HEATHERWOOD HOSP,ASCOT SL5 8AA,BERKS,ENGLAND.							BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; CAMPBELL S, 1983, CLIN OBSTET GYNAECOL, V10, P475; CAMPBELL S, 1984, PRENATAL DIAGNOSIS, P325; CHERVENAK FA, 1991, ULTRASOUND OBST GYN, V1, P18, DOI 10.1046/j.1469-0705.1991.01010018.x; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CRAWFORD DC, 1988, AM J OBSTET GYNECOL, V159, P352, DOI 10.1016/S0002-9378(88)80083-8; HANSMANN M, 1991, ULTRASOUND OBST GYN, V1, P305, DOI 10.1046/j.1469-0705.1991.01050305.x; HECHER K, 1991, ULTRASOUND OBST GYN, V1, P426, DOI 10.1046/j.1469-0705.1991.01060426.x; MCNAY M, 1991, BRIT MED SOC ULTRASO, V63, P23; THOMSON P, 1991, TIMES           1202, P15; 1984, WORKING PARTY REPORT, P10; 1989, REPORT PRENATAL DIAG, P14	12	157	160	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1474	1478		10.1136/bmj.304.6840.1474	http://dx.doi.org/10.1136/bmj.304.6840.1474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611369	Green Published			2022-12-24	WOS:A1992HY55300022
J	KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K				KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K			A CRITICAL ROLE OF LAMBDA-5 PROTEIN IN B-CELL DEVELOPMENT	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; LIGHT CHAIN GENES; LYMPHOCYTES-PRE-B; HEAVY-CHAINS; TRANSGENIC MICE; STEM-CELLS; MU; ANTIBODIES; MOUSE; VPREB	The lambda-5 gene is a homolog of immunoglobulin J(lambda)-C(lambda) genes, expressed specifically in immature B-lineage cells. Lambda-5-encoded molecules form membrane complexes with mu or D(mu) proteins in association with an additional protein specifically expressed in immature B cells that is encoded by the V(pre-B) gene. We have generated mice in which the lambda-5 gene is inactivated by targeted gene disruption in embryonic stem cells. In these mice, B cell development in the bone marrow is blocked at the pre-B cell stage. However, the blockade is leaky, allowing B cells to populate the peripheral immune system at a low rate. These cells are allelically excluded and able to respond to antigen.	UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY; BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND	University of Cologne			Muller, Werner/B-9044-2008; Kudo, Akira/C-7340-2015	Muller, Werner/0000-0002-1297-9725; Kudo, Akira/0000-0001-6289-3391				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; ISCOVE NN, 1978, J EXP MED, V147, P923, DOI 10.1084/jem.147.3.923; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MULLER CE, 1983, THESIS U COLOGNE COL; MULLER W, 1989, EUR J IMMUNOL, V19, P923, DOI 10.1002/eji.1830190520; MULLER W, 1991, EUR J IMMUNOL, V21, P921, DOI 10.1002/eji.1830210410; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SEEMANN G, 1981, THESIS U COLOGNE COL; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	54	543	547	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					823	831		10.1016/0092-8674(92)90293-L	http://dx.doi.org/10.1016/0092-8674(92)90293-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591779				2022-12-24	WOS:A1992HW83800012
J	KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B				KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B			ONCOGENIC FORMS OF P53 INHIBIT P53-REGULATED GENE-EXPRESSION	SCIENCE			English	Article							WILD-TYPE P53; BREAST-CANCER; LUNG-CANCER; CELL-LINE; MUTATIONS; TRANSFORMATION; SARCOMAS; PROTEIN; IDENTIFICATION; ABNORMALITIES	Mutant forms of the gene encoding the tumor suppressor p53 are found in numerous human malignancies, but the physiologic function of p53 and the effects of mutations on this function are unknown. The p53 protein binds DNA in a sequence-specific manner and thus may regulate gene transcription. Cotransfection experiments showed that wild-type p53 activated the expression of genes adjacent to a p53 DNA binding site. The level of activation correlated with DNA binding in vitro. Oncogenic forms of p53 lost this activity. Moreover, all mutants inhibited the activity of coexpressed wild-type p53, providing a basis for the selection of such mutants during tumorigenesis.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Thiagalingam, Sam/0000-0001-5211-266X	NATIONAL CANCER INSTITUTE [T32CA009243, R37CA035494, R01CA035494, P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA06973, CA09243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KERN S, UNPUB; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller J.H., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	49	1033	1064	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					827	830		10.1126/science.1589764	http://dx.doi.org/10.1126/science.1589764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589764				2022-12-24	WOS:A1992HT23500042
J	KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM				KAKIZUKA, A; MILLER, WH; UMESONO, K; WARRELL, RP; FRANKEL, SR; MURTY, VVVS; DMITROVSKY, E; EVANS, RM			CHROMOSOMAL TRANSLOCATION T(15-17) IN HUMAN ACUTE PROMYELOCYTIC LEUKEMIA FUSES RAR-ALPHA WITH A NOVEL PUTATIVE TRANSCRIPTION FACTOR, PML	CELL			English	Article							RETINOIC ACID RECEPTOR; DNA-BINDING DOMAIN; ZINC FINGER; GLUCOCORTICOID RECEPTOR; INSITU HYBRIDIZATION; RESPONSIVE ELEMENT; GENE-EXPRESSION; VIRUS TYPE-1; BETA-GENE; PROTEIN	A unique mRNA produced in leukemic cells from a t(15; 17) acute promyelocytic leukemia (APL) patient encodes a fusion protein between the retinoic acid receptor-alpha (RAR-alpha) and a myeloid gene product called PML. PML contains a cysteine-rich region present in a new family of apparent DNA-binding proteins that includes a regulator of the interleukin-2 receptor gene (Rpt-1) and the recombination-activating gene product (RAG-1). Accordingly, PML may represent a novel transcription factor or recombinase. The aberrant PML-RAR fusion product, while typically retinoic acid responsive, displays both cell type- and promoter-specific differences from the wild-type RAR-alpha. Because patients with APL can be induced into remission with high dose RA therapy, we propose that the nonliganded PML-RAR protein is a new class of dominant negative oncogene product. Treatment with RA would not only relieve this inhibition, but the activated PML-RAR protein may actually promote myelocyte differentiation.	HOWARD HUGHES MED INST,LA JOLLA,CA 92037; MEM SLOAN KETTERING CANC CTR,LEUKEMIA & DEV CHEMOTHERAPY SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	KAKIZUKA, A (corresponding author), SALK INST BIOL STUDIES,LA JOLLA,CA 92037, USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA-09207-14] Funding Source: Medline; FDA HHS [FD-R-000674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, CELL, V66; DOOLITTLE RF, 1987, URFS ORFS PRIMER HOW; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JHANWAR SC, 1983, P NATL ACAD SCI-BIOL, V80, P4794, DOI 10.1073/pnas.80.15.4794; JONES JS, 1988, NUCLEIC ACIDS RES, V16, P7119, DOI 10.1093/nar/16.14.7119; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURIBAYASHI K, 1988, NUCLEIC ACIDS RES S, V19, P61; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLER WH, 1990, J NATL CANCER I, V82, P1932, DOI 10.1093/jnci/82.24.1932; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1988, CATALOG CHROMOSOME A; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PERRY LJ, 1986, J GEN VIROL, V67, P2365, DOI 10.1099/0022-1317-67-11-2365; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; ROWLEY JD, 1977, LANCET, V1, P549; ROWLEY JD, 1977, INT J CANCER, V20, P860; SALVATO MS, 1989, VIROLOGY, V173, P1, DOI 10.1016/0042-6822(89)90216-X; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TAGAWA M, 1990, J BIOL CHEM, V265, P20021; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; THIEM SM, 1989, J VIROL, V63, P4489, DOI 10.1128/JVI.63.11.4489-4497.1989; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UMEX RM, 1991, SCIENCE, V251, P288; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZABEL BU, 1983, P NATL ACAD SCI-BIOL, V80, P6932, DOI 10.1073/pnas.80.22.6932; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	65	1353	1378	1	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 23	1991	66	4					663	674		10.1016/0092-8674(91)90112-C	http://dx.doi.org/10.1016/0092-8674(91)90112-C			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	GC745	1652368	Green Published			2022-12-24	WOS:A1991GC74500007
J	PARRILLO, JE				PARRILLO, JE			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; ENDOTOXIN; IMPACT; UNIT				PARRILLO, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612, USA.							COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HOLLENBERG SM, 1991, CHEST, V100, P1133, DOI 10.1378/chest.100.4.1133; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MUNDTH ED, 1976, CIRCULATION, V53, P176; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PARRILLO JE, 1985, JAMA-J AM MED ASSOC, V254, P2288, DOI 10.1001/jama.1985.03360160120029; PARRILLO JE, 1990, ANN INTERN MED, V113, P27; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; VANDEVENTER SJH, 1988, LANCET, V1, P605; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					340	342						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613913				2022-12-24	WOS:A1992JC35200023
J	FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C				FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C			WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							PROTEIN; REPLICATION; ONCOGENE; ANTIGEN; MUTANT	THE p53 protein is an important determinant in human cancer and regulates the growth of cells in culture 1-3. It is known to be a sequence-specific DNA-binding protein 4,5 with a powerful activation domain 6-8, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.			FARMER, G (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991				BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MURAKAMI Y, 1990, ONCOGENE, V5, P5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4750; ZAMBETTI GP, IN PRESS GENES DEV; ZHU H, 1991, NEW BIOL, V3, P455	31	647	662	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					83	86		10.1038/358083a0	http://dx.doi.org/10.1038/358083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614538				2022-12-24	WOS:A1992JB34100060
J	BERKEL, H; BIRDSELL, DC; JENKINS, H				BERKEL, H; BIRDSELL, DC; JENKINS, H			BREAST AUGMENTATION - A RISK FACTOR FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARCINOGENICITY; 2,4-TOLUENEDIAMINE; RATS	Background. A relation between breast augmentation and the subsequent risk of breast cancer has been postulated. Since an estimated 2 million women in the United States alone have received breast implants, even a small increase in the risk of breast cancer could have considerable public health consequences. Methods. We performed a population-based nonconcurrent cohort-linkage study. All women in Alberta, Canada, who underwent cosmetic breast augmentation from 1973 through 1986 were included in the implant cohort (n = 11,676). This cohort was compared with the cohort of all women in Alberta in whom a first primary breast cancer was diagnosed (n = 13,557). The expected number of breast-cancer cases in the implant cohort was estimated by applying age-specific and calendar year-specific incidence rates of breast cancer (obtained from the Alberta Cancer Registry) to the implant cohort, Standardized incidence ratios were calculated by dividing the observed by the expected number of breast-cancer cases in the implant cohort. Results. Forty-one patients with implants were subsequently found to have breast cancer. The expected number was 86.2. The standardized incidence ratio was thus 47.6 percent, significantly lower than expected (P<0.01). The average length of follow-up in the implant cohort was 10.2 years, and the average length of time from breast augmentation to the diagnosis of breast cancer was 7.5 years. Conclusions. Women who undergo breast augmentation with silicone implants have a lower risk of breast cancer than the general population. This finding suggests that these women are drawn from a population already at low risk and that the implants do not substantially increase the risk.	UNIV CALGARY, FOOTHILLS HOSP,SCH MED,DEPT SURG, DIV PLAST & RECONSTRUCT SURG, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary	BERKEL, H (corresponding author), ALBERTA CANC BOARD, DIV EPIDEMIOL & PREVENT ONCOL, 9707 110 ST, 6TH FL, EDMONTON T5K 2L9, ALBERTA, CANADA.							BAILAR JC, 1964, BIOMETRICS, V20, P639; BENAVENT WJ, 1973, PLAST RECONSTR SURG, V51, P588, DOI 10.1097/00006534-197305000-00026; BERKEL J, 1990, INCIDENCE SURVIVAL D; BINGHAM HG, 1988, ANN PLAS SURG, V20, P236, DOI 10.1097/00000637-198803000-00007; BLAKESLEE S, 1991, GLAMOUR          AUG; BOWERS DG, 1969, PLAST RECONSTR SURG, V44, P541, DOI 10.1097/00006534-196912000-00003; BOYES DC, 1991, CAN MED ASSOC J, V145, P1125; CARDY RH, 1979, J NATL CANCER I, V62, P1107; CHAN SC, 1991, CLIN CHEM, V37, P756; CHOLNOKY TD, 1970, PLAST RECONSTR SURG, V45, P573, DOI 10.1097/00006534-197006000-00007; DEAPEN DM, 1986, PLAST RECONSTR SURG, V77, P361, DOI 10.1097/00006534-198603000-00001; GILES AL, 1976, J TOXICOL ENV HEALTH, V1, P433, DOI 10.1080/15287397609529342; HARRIS HI, 1961, PLAST RECONSTR SURG, V28, P81, DOI 10.1097/00006534-196107000-00007; HIROHATA T, 1977, BRIT MED J, V2, P641, DOI 10.1136/bmj.2.6087.641-c; HOOPES JE, 1967, PLAST RECONSTR SURG, V39, P263, DOI 10.1097/00006534-196703000-00005; HSIEH CC, 1991, EUR J CANCER, V27, P131, DOI 10.1016/0277-5379(91)90469-T; ITO N, 1969, CANCER RES, V29, P1137; KOCH M, 1985, CHRONIC DIS CAN, V5, P74; LILIENFELD AM, 1976, F EIDEMIOLOGY; ROHLFING C, 1991, LONGEVITY        JUL; SNYDERMAN R K, 1960, Plast Reconstr Surg Transplant Bull, V25, P253, DOI 10.1097/00006534-196003000-00006; SONTAG JM, 1981, JNCI-J NATL CANCER I, V66, P591; UMEDA M, 1955, Gan, V46, P597; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; WYNDER EL, 1969, CANCER, V24, P1235, DOI 10.1002/1097-0142(196912)24:6<1235::AID-CNCR2820240629>3.0.CO;2-G	25	163	165	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1649	1653		10.1056/NEJM199206183262501	http://dx.doi.org/10.1056/NEJM199206183262501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588977	Bronze			2022-12-24	WOS:A1992HY62800001
J	FEUTREN, G; MIHATSCH, MJ				FEUTREN, G; MIHATSCH, MJ			RISK-FACTORS FOR CYCLOSPORINE-INDUCED NEPHROPATHY IN PATIENTS WITH AUTOIMMUNE-DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEPHROTOXICITY; TRANSPLANTS; CREATININE; CHILDREN; THERAPY; RATS	Background. Cyclosporine is an immunosuppressive drug that is used to treat patients with autoimmune disease as well a's patients who have received allografts. The drug can cause renal damage, but the incidence of and risk factors for nephropathy in patients treated with cyclosporine for autoimmune or inflammatory diseases are not known. Methods. We analyzed data from renal biopsies performed in 192 patients (129 adults and 63 children) who had been treated with cyclosporine for insulin-dependent diabetes mellitus of recent onset, uveitis, psoriasis, Sjogren's syndrome, or polychondritis. The mean (+/-SD) initial dose of cyclosporine was 8.2+/-2.8 mg per kilogram of body weight per day, and the duration of treatment was 4 to 39 months (median, 13). Results. Forty-one patients (37 adults and 4 children) had cyclosporine-induced nephropathy, defined as at least moderate focal interstitial fibrosis with tubular atrophy, arteriolar alterations, or both. As compared with patients in whom nephropathy did not develop, these patients received a larger initial dose of cyclosporine (9.3+/-2.8 vs. 8.0+/-2.8 mg per kilogram per day), had a larger maximal increase in the serum creatinine concentration above base-line values (101+/-77 percent vs. 50+/-33 percent), and were older (31+/-13 vs. 23+/-12 years). These three variables were shown by multivariate logistic-regression analysis to be significant risk factors. The duration of the elevation in the serum creatinine concentration and the occurrence of elevated blood pressure were not additional risk factors. Conclusions. Nephropathy is an important potential effect of cyclosporine therapy. The risk of its development in patients with autoimmune diseases who are treated with cyclosporine can be minimized by allowing a dose no higher than 5 mg per kilogram per day and avoiding increases in serum creatinine of more than 30 percent above the patient's base-line value.	UNIV BASEL,INST PATHOL,CH-4051 BASEL,SWITZERLAND	University of Basel	FEUTREN, G (corresponding author), SANDOZ PHARMA LTD,DEPT CLIN RES IMMUNOL,CH-4002 BASEL,SWITZERLAND.							[Anonymous], 1988, DIABETES, V37, P1574, DOI 10.2337/diabetes.37.11.15742903105; ANTIGNAC C, 1989, KIDNEY INT, V35, P1336, DOI 10.1038/ki.1989.132; ASSAN R, 1990, DIABETES, V39, P768, DOI 10.2337/diabetes.39.7.768; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BOUGNERES PF, 1988, NEW ENGL J MED, V318, P663, DOI 10.1056/NEJM198803173181103; DIETERLE A, 1990, TRANSPLANTATION, V49, P1093, DOI 10.1097/00007890-199006000-00013; Donatsch P, 1981, J Immunoassay, V2, P19, DOI 10.1080/01971528108062989; EKNOYAN G, 1988, DISEASES KIDNEY, P2191; FEUTREN G, 1988, TRANSPLANT P, V20, P356; FEUTREN G, 1991, LANCET, V38, P1017; GILBERT SC, 1989, J AM ACAD DERMATOL, V21, P470, DOI 10.1016/S0190-9622(89)70209-7; HOYER PF, 1984, CLIN NEPHROL, V22, P68; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; MIESCHER PA, 1987, KLIN WOCHENSCHR, V65, P727, DOI 10.1007/BF01736809; MIHATSCH MJ, 1986, PROG ALLERGY, V38, P447; MIHATSCH MJ, 1983, TRANSPLANT P, V15, P2821; MIHATSCH MJ, 1988, KLIN WOCHENSCHR, V66, P43, DOI 10.1007/BF01713009; MOSS NG, 1985, P NATL ACAD SCI USA, V82, P8222, DOI 10.1073/pnas.82.23.8222; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; PALESTINE AG, 1986, NEW ENGL J MED, V314, P1293, DOI 10.1056/NEJM198605153142005; SVENSON K, 1986, ARCH INTERN MED, V146, P2007, DOI 10.1001/archinte.146.10.2007; THOMSON SC, 1989, J CLIN INVEST, V83, P960, DOI 10.1172/JCI113982; TOMLANOVICH S, 1986, AM J KIDNEY DIS, V8, P332, DOI 10.1016/S0272-6386(86)80107-X; 1988, SAS USERS GUIDE STAT; 1990, BR J DERMATOL S36, V122, P95	26	417	426	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 18	1992	326	25					1654	1660		10.1056/NEJM199206183262502	http://dx.doi.org/10.1056/NEJM199206183262502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY628	1588978	Bronze			2022-12-24	WOS:A1992HY62800002
J	MARSH, RL; OLSON, JM; GUZIK, SK				MARSH, RL; OLSON, JM; GUZIK, SK			MECHANICAL PERFORMANCE OF SCALLOP ADDUCTOR MUSCLE DURING SWIMMING	NATURE			English	Article								MECHANICAL performance of skeletal muscle has long been the subject of intense interest 1, but the details of in vivo performance of individual skeletal muscles during normal locomotion remain largely unknown. Performance in vitro has been described with considerable precision under simplified loading conditions 2. The force production and shortening velocity of most muscles, however, probably change continuously during natural movements. Therefore, modelling in vivo performance on the basis of in vitro contractile properties 3 is subject to large degrees of uncertainty. Designing in vitro experiments that effectively examine the limits of mechanical performance requires increasing knowledge of precisely how muscles are used during normal movements. We report here measurements of the mechanical performance of the adductor muscle in scallops during jet-propulsion swimming. Swimming in scallops is powered solely by the striated portion of the single adductor muscle. Exploiting this simple locomotor morphology with simultaneous high-resolution measurements of pressure and flow rate, we have recorded nearly instantaneous measurements of the performance of a single skeletal muscle during normal locomotion.			MARSH, RL (corresponding author), NORTHEASTERN UNIV,DEPT BIOL,360 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Marsh, Richard/0000-0002-4264-9890				BENNETCLARK HC, 1975, J EXP BIOL, V63, P53; DANIEL TL, 1984, AM ZOOL, V24, P121; DAVIES CTM, 1989, EUR J APPL PHYSIOL O, V58, P838, DOI 10.1007/BF02332216; GADE G, 1978, J COMP PHYSIOL, V124, P121; HILL AV, 1920, J PHYSIOL-LONDON, V53, pR88; LOWY J, 1954, J PHYSIOL-LONDON, V124, P100, DOI 10.1113/jphysiol.1954.sp005088; MELLON D, 1969, Z VERGL PHYSIOL, V62, P318; MOORE J D, 1971, Journal of Experimental Marine Biology and Ecology, V6, P179, DOI 10.1016/0022-0981(71)90017-7; TRUEMAN ER, 1953, J EXP BIOL, V30, P453; VANLEEUWEN JL, 1991, J THEOR BIOL, V149, P229, DOI 10.1016/S0022-5193(05)80279-6; WANG CY, 1979, J BIOMECH, V12, P9, DOI 10.1016/0021-9290(79)90003-4; WILKENS LA, 1981, PROC R SOC SER B-BIO, V211, P341, DOI 10.1098/rspb.1981.0011; Woledge RC., 1985, ENERGETIC ASPECTS MU; Yonge C. M., 1936, Mem Mus Hist Nat Belg (2), V3, P77; [No title captured]	15	81	81	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					411	413		10.1038/357411a0	http://dx.doi.org/10.1038/357411a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594046				2022-12-24	WOS:A1992HX17200065
J	WILKES, MS; DOBLIN, BH; SHAPIRO, MF				WILKES, MS; DOBLIN, BH; SHAPIRO, MF			PHARMACEUTICAL ADVERTISEMENTS IN LEADING MEDICAL JOURNALS - EXPERTS ASSESSMENTS	ANNALS OF INTERNAL MEDICINE			English	Article						ADVERTISING; DRUG INFORMATION SERVICES; DRUG INDUSTRY; UNITED-STATES-FOOD-AND-DRUG-ADMINISTRATION	DRUG COMPANIES; PHYSICIANS; INFORMATION; DOCTORS; GIFTS	Objective: To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards. Design: Cross-sectional survey. Measurements: Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication. Results: In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication. Conclusion: In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.			WILKES, MS (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV GEN INTERNAL MED, LOS ANGELES, CA 90024 USA.				PHS HHS [R01-90-1088] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD SR, 1991, LANCET, V338, P1384; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; CHREN MM, 1989, JAMA-J AM MED ASSOC, V262, P3448, DOI 10.1001/jama.262.24.3448; CHRISTENSEN DB, 1979, SOC SCI MED-MED SOC, V13, P313, DOI 10.1016/0160-7979(79)90066-3; FASSOLD RW, 1968, CAN MED ASSOC J, V98, P701; GARFUNKEL JM, 1990, JAMA-J AM MED ASSOC, V263, P1369, DOI 10.1001/jama.263.10.1369; GORSKI TN, 1990, JAMA-J AM MED ASSOC, V263, P2177, DOI 10.1001/jama.1990.03440160039016; JACOBY J, 1975, J MARKETING, V39, P65, DOI 10.2307/1250601; LINN LS, 1972, SOC SCI MED, V6, P199, DOI 10.1016/0037-7856(72)90025-X; LIPTON HL, 1988, DRUGS ELDERLY CLIN S; LOCK S, 1986, DIFFICULT BALANCE, P24; MILLSTEIN LG, 1983, AM PHARM, V23, P54, DOI 10.1016/S0160-3450(16)32075-X; MOSER M, 1991, JAMA-J AM MED ASSOC, V265, P498, DOI 10.1001/jama.265.4.498; MOSER RH, 1977, ANN INTERN MED, V87, P114, DOI 10.7326/0003-4819-87-1-114; RELMAN AS, 1979, NEW ENGL J MED, V301, P999, DOI 10.1056/NEJM197911013011811; SCHIFF G, 1990, JAMA-J AM MED ASSOC, V263, P658, DOI 10.1001/jama.1990.03440050052019; ZELLMER WA, 1987, AM J HOSP PHARM, V44, P1651, DOI 10.1093/ajhp/44.7.1651; ZUCKERMAN H, 1971, MINERVA, V9, P66, DOI 10.1007/BF01553188; 1991, OEI01900000000482 DE; 1989, HLTH CARE COMMUNICAT	20	206	212	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	1992	116	11					912	919		10.7326/0003-4819-116-11-912	http://dx.doi.org/10.7326/0003-4819-116-11-912			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW137	1580449				2022-12-24	WOS:A1992HW13700007
J	KENNY, N; HILL, J				KENNY, N; HILL, J			GONAD PROTECTION IN YOUNG ORTHOPEDIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether gonad shields are correctly positioned on the pelvic radiographs of children with slipped capital femoral epiphysis. Design - Retrospective study of radiographs taken of children treated by in situ pinning of slipped capital femoral epiphysis between 1 january 1983 and 31 December 1988. Setting - Three teaching hospitals in north west England. Patients - 32 patients with complete set of radiographs. Results - An average of 10.8 anteroposterior pelvic radiographs plus 8.9 lateral hip radiographs had been performed per patient. Gonad shields had been completely omitted in 137 (40%) anteroposterior pelvic radiographs performed on the 32 patients at the time of completion of the study. In 100 (29%) the gonad shields were adequately protecting the gonads, but in 109(31%) the gonad shields were not protecting the gonads due to incorrect positioning of the shield. The incorrect positioning of the gonad shields was more commonly found in girls than boys (64 v 45; p < 0.012), presumably because of the difficulty in determining gonadal position in relation to surface landmarks. Absence of gonad shields was also more commonly seen in girls (82 v 55; p < 0.005), but this is not easily explained. Conclusions - Gonad shields are not protecting the gonads in a large percentage of anteroposterior pelvic radiographs (71%) because they have been omitted or inadequately placed. This avoidable excess radiation exposure to the gonads, combined with the inability to shield the gonads in lateral hip radiographs and the large number of radiographs performed, results in the gonads receiving a higher dose of radiation than may otherwise be the case, and may increase the potential for disease in the future offspring of these patients.	ROYAL PRESTON HOSP,RADIOL & NUCL MED,PRESTON PR2 4HT,LANCS,ENGLAND	Royal Preston Hospital	KENNY, N (corresponding author), ANCOATS HOSP,MANCHESTER M4 6EB,ENGLAND.							[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1977, ANN ICRP, V1, P228; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KENDALL GM, 1980, NRPBR104; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; RICHARDSON RB, 1990, BRIT J RADIOL, V63, P235, DOI 10.1259/0007-1285-63-748-235; RUSSELL JGB, 1986, BRIT J RADIOL, V59, P630, DOI 10.1259/0007-1285-59-702-630; WALL BF, 1980, NRPBR105; 1990, PATIENT DOSE REDUCTI; 1989, WORKING PATIENTS; 1991, BRIT J RADIOL, V64, P53; 1991, WHICH            JAN, P40; 1991, ANN ICRP, V21, P1	13	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1411	1413		10.1136/bmj.304.6839.1411	http://dx.doi.org/10.1136/bmj.304.6839.1411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628015	Green Published, Bronze			2022-12-24	WOS:A1992HX08200018
J	GOLDSTEIN, B				GOLDSTEIN, B			INDUCTION OF GUT IN CAENORHABDITIS-ELEGANS EMBRYOS	NATURE			English	Article								Two types of developmental events can cause an embryonic cell to adopt a fate different from that of its neighbours: during a cell division particular contents may be segregated to only one daughter cell and cells may experience different external cues, commonly in the form of inductive cell interactions. Work on development in the nematode Caenorhabditis elegans suggests that most cell fates are specified without a need for cell interactions. In particular, the gut cell lineage of C. elegans has been used as a primary example of specification by differential segregation of determinants 1. Here I re-examine the role of induction in gut specification by isolating early blastomeres. In C. elegans, the gut derives from all the progeny of a single blastomere (E) of the eight-cell stage 2. When a gut precursor cell (EMS) is isolated during the first half of the four-cell stage, gut does not differentiate. Gut differentiation is rescued by recombining EMS with its posterior neighbour (P2), but not by recombining EMS with one or both of the other two cells of the four-cell stage. These results demonstrate that P2 induces EMS to form gut in C. elegans.			GOLDSTEIN, B (corresponding author), UNIV TEXAS,DEPT ZOOL,CTR DEV BIOL,AUSTIN,TX 78712, USA.			Goldstein, Bob/0000-0001-6961-675X				Chitwood, 1974, INTRO NEMATOLOGY; Davidson E. H., 1986, GENE ACTIVITY EARLY; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; LAUFER JS, 1981, SCIENCE, V211, P402, DOI 10.1126/science.7194506; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MAINE EM, 1990, BIOESSAYS, V12, P265, DOI 10.1002/bies.950120604; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	12	184	184	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					255	257		10.1038/357255a0	http://dx.doi.org/10.1038/357255a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589023				2022-12-24	WOS:A1992HV19500059
J	MOLLER, AP				MOLLER, AP			FEMALE SWALLOW PREFERENCE FOR SYMMETRICAL MALE SEXUAL ORNAMENTS	NATURE			English	Article							FLUCTUATING ASYMMETRY; TAIL LENGTH; CHOICE	MANY secondary sexual characters are supposed to have evolved as a response to female choice of the most extravagantly ornamented males 1, a hypothesis supported by studies demonstrating female preferences for the most ornamented males 2-5. Comparative studies of elaborate feather ornaments in birds have shown that (1) ornaments have larger degrees of fluctuating asymmetry 6 (small, random deviations from bilateral symmetry caused by an inability of individuals to cope with environmental and genetic stress during development of a character 7) than other morphological traits, and (2) the degree of fluctuating asymmetry is often negatively related to the size of the ornament 6. The negative relationship between ornament asymmetry and size suggests that ornament size reliably reflects male quality because the largest secondary sex traits demonstrate the least degree of fluctuating asymmetry. I manipulated tail length and tail asymmetry independently in male swallows (Hirundo rustica) to determine whether ornament size or asymmetry were used as cues in mate choice. Male swallows with elongated, symmetric tails mated earlier, and enjoyed larger annual reproductive success than did males with shortened tails and increased asymmetry. Females therefore prefer large as well as symmetric ornaments, which suggests that females in their mate choice use ornament asymmetry and size as reliable indicators of male quality.	UNIV UPPSALA,DEPT ZOOL,S-75122 UPPSALA,SWEDEN	Uppsala University			Moller, Anders/O-6665-2016	Moller, Anders/0000-0003-3739-4675				ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Darwin C., 1871, P423; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LUDWIG W, 1932, RECHTS LINK PROBLEM; MOLLER AP, 1990, ANIM BEHAV, V39, P458, DOI 10.1016/S0003-3472(05)80409-9; MOLLER AP, 1988, NATURE, V332, P640, DOI 10.1038/332640a0; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V245, P1, DOI 10.1098/rspb.1991.0080; MOLLER AP, 1991, P ROY SOC B-BIOL SCI, V243, P59, DOI 10.1098/rspb.1991.0010; MOLLER AP, 1990, ANIM BEHAV, V40, P1185, DOI 10.1016/S0003-3472(05)80187-3; PALMER AR, 1986, ANNU REV ECOL SYST, V17, P391, DOI 10.1146/annurev.es.17.110186.002135; PARSONS PA, 1990, BIOL REV, V65, P131, DOI 10.1111/j.1469-185X.1990.tb01186.x; PETRIE M, 1991, ANIM BEHAV, V41, P323, DOI 10.1016/S0003-3472(05)80484-1; SMITH HG, 1990, BEHAV ECOL SOCIOBIOL, V28, P195; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	15	397	400	0	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 21	1992	357	6375					238	240		10.1038/357238a0	http://dx.doi.org/10.1038/357238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV195	1589021				2022-12-24	WOS:A1992HV19500053
J	CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C				CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C			OSTEOARTHRITIS OF THE HIP - AN OCCUPATIONAL-DISEASE IN FARMERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To test the hypothesis that farmers are at high risk of hip osteoarthritis and to investigate possible causes for such a hazard. Design-Cross sectional survey. Setting-Five rural general practices. Subjects-167 male farmers aged 60-76 and 83 controls from mainly sedentary jobs. All those without previous hip replacement underwent radiography of the hip. Main outcome measures-Hip replacement for osteoarthritis or radiological evidence of hip osteoarthritis. Results-Prevalence of hip osteoarthritis was higher in farmers than controls and especially in those who had farmed for over 10 years (odds ratio 9.3, 95% confidence interval 1.9 to 44.5). The excess could not be attributed to any one type of farming, and heavy lifting seems the likely explanation. Conclusions-Manual handling in agriculture should be limited where possible. Consideration should be given to making hip osteoarthritis a prescribed industrial disease in farmers. There may be wider implications for the prevention of hip osteoarthritis in the general population.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND; UNIV MANCHESTER,AFRC,EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	University of Southampton; University of Manchester; Bristol Royal Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXMACHER B, 1988, PROGR OCCUPATIONAL E, P203; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; CROFT P, IN PRESS BR J RHEUMA; FRANK O, 1968, Z RHEUMAFORSCH, V27, P371; FRANKEL S, 1990, EPIDEMIOLOGICALLY BA; HAGGLUND G, 1984, CLIN ORTHOPAEDICS, V191, P81; JACOBSSON B, 1987, INT ORTHOP, V11, P311, DOI 10.1007/BF00271306; LINDBERG H, 1984, CLIN ORTHOP RELAT R, V191, P159; LOUYOT P, 1966, REV RHUM, V33, P625; ORDEBERG G, 1984, CLIN ORTHOPAEDICS, V191, P95; THELIN A, 1990, AM J IND MED, V18, P339, DOI 10.1002/ajim.4700180316; Typpti T., 1985, ANN CHIR GYNAEC S201, V74, P1; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271; VINGARD E, 1991, SCAND J WORK ENV HEA, V17, P104, DOI 10.5271/sjweh.1727; VINGARD E, 1991, WORK SPORTS OVERWEIG; WALSH K, 1991, SCAND J WORK ENV HEA, V17, P420, DOI 10.5271/sjweh.1680; WILCOCK GK, 1979, INT J EPIDEMIOL, V8, P247, DOI 10.1093/ije/8.3.247; 1986, OCCUPATIONAL MORTALI; 1979, DHEW PHS791161 PUBL	20	157	158	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1269	1272		10.1136/bmj.304.6837.1269	http://dx.doi.org/10.1136/bmj.304.6837.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606427	Green Published, Bronze			2022-12-24	WOS:A1992HV08600017
J	BELL, SP; STILLMAN, B				BELL, SP; STILLMAN, B			ATP-DEPENDENT RECOGNITION OF EUKARYOTIC ORIGINS OF DNA-REPLICATION BY A MULTIPROTEIN COMPLEX	NATURE			English	Article							ESCHERICHIA-COLI CHROMOSOME; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEINS; T-ANTIGEN; YEAST; INVITRO; PURIFICATION; INITIATION; SEQUENCE; PLASMIDS	A multiprotein complex that specifically recognizes cellular origins of DNA replication has been identified and purified from the yeast Saccharomyces cerevisiae. We observe a strong correlation between origin function and origin recognition by this activity. Interestingly, specific DNA binding by the origin recognition complex is dependent upon the addition of ATP. We propose that the origin recognition complex acts as the initiator protein for S. cerevisiae origins of DNA replication.			BELL, SP (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Bell, Stephen/0000-0002-2876-610X; Stillman, Bruce/0000-0002-9453-4091				BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DODSON M, 1985, P NATL ACAD SCI USA, V82, P4678, DOI 10.1073/pnas.82.14.4678; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JAZWINSKI SM, 1982, P NATL ACAD SCI-BIOL, V79, P3428, DOI 10.1073/pnas.79.11.3428; JAZWINSKI SM, 1984, J BIOL CHEM, V259, P6852; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KORNBERG A, 1992, DNA REPLICATION, P1; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; LINSKENS MHK, 1990, CELL, V62, P845, DOI 10.1016/0092-8674(90)90258-G; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; PALZKILL TG, 1988, CELL, V37, P299; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TRAVERS AA, 1987, PHILOS T ROY SOC B, V317, P537, DOI 10.1098/rstb.1987.0080; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0	46	1020	1038	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 14	1992	357	6374					128	134		10.1038/357128a0	http://dx.doi.org/10.1038/357128a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU122	1579162				2022-12-24	WOS:A1992HU12200048
J	KIM, JJ; FANSELOW, MS				KIM, JJ; FANSELOW, MS			MODALITY-SPECIFIC RETROGRADE-AMNESIA OF FEAR	SCIENCE			English	Article							LESIONS; RATS; HIPPOCAMPAL; MEMORY; MECHANISMS	Emotional responses such as fear are rapidly acquired through classical conditioning. This report examines the neural substrate underlying memory of acquired fear. Rats were classically conditioned to fear both tone and context through the use of aversive foot shocks. Lesions were made in the hippocampus either 1, 7, 14, or 28 days after training. Contextual fear was abolished in the rats that received lesions 1 day after fear conditioning. However, rats for which the interval between learning and hippocampal lesions was longer retained significant contextual fear memory. In the same animals, lesions did not affect fear response to the tone at any time. These results indicate that fear memory is not a single process and that the hippocampus may have a time-limited role in associative fear memories evoked by polymodal (contextual) but not unimodal (tone) sensory stimuli.			KIM, JJ (corresponding author), UNIV CALIF LOS ANGELES, DEPT PSYCHOL, LOS ANGELES, CA 90024 USA.			Kim, Jeansok/0000-0001-7964-106X				BANDLER R, 1991, PROGR BRAIN RES, V87, P269; BLANCHARD DC, 1972, J COMP PHYSIOL PSYCH, V81, P281, DOI 10.1037/h0033521; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; FANSELOW MS, 1991, NATO ADV SCI I A-LIF, V213, P151; FANSELOW MS, 1986, LEARN MOTIV, V17, P16, DOI 10.1016/0023-9690(86)90018-4; HITCHCOCK JM, 1986, BEHAV NEUROSCI, V110, P11; IWATA J, 1986, BRAIN RES, V368, P161, DOI 10.1016/0006-8993(86)91055-3; KAPP BS, 1979, PHYSIOL BEHAV, V23, P1109, DOI 10.1016/0031-9384(79)90304-4; Milner B, 1972, Clin Neurosurg, V19, P421; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; PENFIELD W, 1958, ARCH NEURO PSYCHIATR, V79, P475, DOI 10.1001/archneurpsyc.1958.02340050003001; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SCHMALTZ LW, 1972, J COMP PHYSIOL PSYCH, V79, P328, DOI 10.1037/h0032531; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SOLOMON PR, 1977, J COMP PHYSIOL PSYCH, V91, P407, DOI 10.1037/h0077330; SQUIRE LR, 1986, SCIENCE, V232, P1612, DOI 10.1126/science.3086978; SQUIRE LR, 1990, NEURAL MODELS PLASTI, P208; THOMPSON RF, 1990, PHILOS T ROY SOC B, V329, P161, DOI 10.1098/rstb.1990.0161; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; WINOCUR G, 1987, BEHAV NEUROSCI, V101, P617, DOI 10.1037/0735-7044.101.5.617; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	23	1905	1924	2	119	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 1	1992	256	5057					675	677		10.1126/science.1585183	http://dx.doi.org/10.1126/science.1585183			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HR185	1585183				2022-12-24	WOS:A1992HR18500036
J	TENG, DHF; ENGELE, CM; VENKATESH, TR				TENG, DHF; ENGELE, CM; VENKATESH, TR			A PRODUCT OF THE PRUNE LOCUS OF DROSOPHILA IS SIMILAR TO MAMMALIAN GTPASE-ACTIVATING PROTEIN	NATURE			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; AWD PROTEINS; RAS P21; GAP; GENE; DNA; MELANOGASTER; ELEMENTS; CLONING	THE X-linked prune (pn) eye-colour mutation of Drosophila melanogaster has a highly specific, complementary lethal interaction with the conditional dominant Killer of prune (awd(K-pn)) mutation 1,2. Although awd(K-pn) flies have no apparent phenotype on their own, pn awd(K-pn) double mutants die as second or third larval instars. The awd locus encodes a nucleoside diphosphate kinase 3, an enzyme that catalyses the transfer of high-energy phosphate bonds between nucleoside diphosphates and nucleoside triphosphates 4, which is essential for the normal development of Drosophila. Analysis of the pn locus has suggested that the complementary DNA, TcD37, encodes a putative pn+ product 5. Here we report the nucleotide sequence of TcD37 and the similarity of its deduced protein product to the catalytic domain of mammalian GTPase-activating proteins (GAPs); GAPs stimulate the GTPase activity of Ras (ref. 6), which are plasma membrane-bound proteins involved in the regulation of cell proliferation and differentiation 7. These results suggest that the Drosophila TcD37 protein participates in a biochemical pathway similar to that of Ras and GAPs in mammals and yeast. We propose that the interaction between pn and awd is due to a neomorphic mutation that enhances the ability of Awd(K-pn) nucleoside diphosphate kinase to induce a regulatory GTPase into a GTP-bound 'on' state, whereas Pn modulates the activity of this GTPase either by switching it to a GDP-bound 'off' state or by interfering with its effector function.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403; UNIV OREGON,DEPT CHEM,EUGENE,OR 97403	University of Oregon; University of Oregon; University of Oregon								BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWN GM, 1985, CHEM BIOCH PTERINS, P115; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; DEAROLF CR, 1988, DEV BIOL, V129, P159, DOI 10.1016/0012-1606(88)90170-4; EMKEY R, 1991, J BIOL CHEM, V266, P9703; EVANS BA, 1978, BIOCHEM GENET, V16, P13, DOI 10.1007/BF00484381; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1990, J NATL CANCER I, V82, P1170, DOI 10.1093/jnci/82.14.1170; MACKAY WJ, 1983, GENETICS, V105, P35; MACLEAN JR, 1990, GENETICS, V126, P1007; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PARKS RW, 1973, ENZYMES, P307; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STURTEVANT AH, 1956, GENETICS, V41, P118; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TENG DHF, 1991, GENETICS, V128, P373; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLET V, 1990, J NATL CANCER I, V82, P1199, DOI 10.1093/jnci/82.14.1199; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	35	69	69	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	OCT 3	1991	353	6343					437	440		10.1038/353437a0	http://dx.doi.org/10.1038/353437a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GH606	1654526				2022-12-24	WOS:A1991GH60600059
J	SCHULTZ, SC; SHIELDS, GC; STEITZ, TA				SCHULTZ, SC; SHIELDS, GC; STEITZ, TA			CRYSTAL-STRUCTURE OF A CAP-DNA COMPLEX - THE DNA IS BENT BY 90-DEGREES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; AMP RECEPTOR PROTEIN; NUCLEIC-ACID INTERACTION; REPRESSOR OPERATOR COMPLEX; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; CYCLIC-AMP; RNA-POLYMERASE; B-DNA; BINDING DOMAIN	The 3 angstrom resolution crystal structure of the Escherichia coli catabolite gene activator protein (CAP) complexed with a 30-base pair DNA sequence shows that the DNA is bent by 90-degrees. This bend results almost entirely from two 40-degrees kinks that occur between TG/CA base pairs at positions 5 and 6 on each side of the dyad axis of the complex. DNA sequence discrimination by CAP derives both from sequence-dependent distortion of the DNA helix and from direct hydrogen-bonding interactions between three protein side chains and the exposed edges of three base pairs in the major groove of the DNA. The structure of this transcription factor-DNA complex provides insights into possible mechanisms of transcription activation.	YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06511; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511	Yale University; Howard Hughes Medical Institute; Yale University	SCHULTZ, SC (corresponding author), YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511, USA.		Shields, George C/C-6454-2012; Steitz, Thomas A./C-6559-2009	Shields, George C/0000-0003-1287-8585; 	NIGMS NIH HHS [GM-22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ANDERSON J, 1984, P NATL ACAD SCI-BIOL, V81, P1307, DOI 10.1073/pnas.81.5.1307; ANDERSON JE, 1987, NATURE, V326, P846, DOI 10.1038/326846a0; BANTZ DA, 1974, ACTA CRYSTALLOGR A, VA 30, P257, DOI 10.1107/S0567739474000520; BECKWITH J, 1972, J MOL BIOL, V69, P155, DOI 10.1016/0022-2836(72)90031-9; BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; BETTER M, 1982, P NATL ACAD SCI-BIOL, V79, P5837, DOI 10.1073/pnas.79.19.5837; BIENKOWSKA J, 1989, PROGRAM LOLIPLOT; BLAZY B, 1980, MOL BIOL REP, V6, P39, DOI 10.1007/BF00775753; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1989, PROGRAM XPLOR; BRUNGER AT, COMMUNICATION; BUSBY S, 1987, MICROBIOL SCI, V4, P371; CRICK FHC, 1975, NATURE, V255, P530, DOI 10.1038/255530a0; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DICKERSON RE, 1987, J BIOMOL STRUCT DYN, V5, P557, DOI 10.1080/07391102.1987.10506413; DICKERSON RE, COMMUNICATION; DICKSON RC, 1977, J MOL BIOL, V111, P65, DOI 10.1016/S0022-2836(77)80132-0; DIGABRIELE AD, 1989, P NATL ACAD SCI USA, V86, P1816, DOI 10.1073/pnas.86.6.1816; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; DRIPPS D, 1987, J BIOMOL STRUCT DYN, V5, P1; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1984, NATURE, V311, P232, DOI 10.1038/311232a0; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; ESCHENLAUER AC, IN PRESS J BACTERIOL; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRATINI AV, 1982, J BIOL CHEM, V257, P4686; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; FURNISH G, 1989, PROGRAM PLOT; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GENT ME, 1987, BIOCHEM J, V242, P645, DOI 10.1042/bj2420645; GILADI H, 1990, J MOL BIOL, V213, P109, DOI 10.1016/S0022-2836(05)80124-X; GOTOH O, 1981, BIOPOLYMERS, V20, P1033, DOI 10.1002/bip.1981.360200513; IRWIN N, 1987, P NATL ACAD SCI USA, V84, P8315, DOI 10.1073/pnas.84.23.8315; JANSEN C, 1987, BIOCHEM J, V246, P227, DOI 10.1042/bj2460227; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; JORDAN SR, 1985, SCIENCE, V230, P1383; KATTI S, COMMUNICATION; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; KOSTURKO LD, 1989, NUCLEIC ACIDS RES, V17, P317, DOI 10.1093/nar/17.1.317; KOTLARZ D, 1986, EMBO J, V5, P799, DOI 10.1002/j.1460-2075.1986.tb04284.x; KOUDELKA GB, 1987, NATURE, V326, P886, DOI 10.1038/326886a0; KOUDELKA GB, 1988, P NATL ACAD SCI USA, V85, P4633, DOI 10.1073/pnas.85.13.4633; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; Lu P, 1985, Adv Biophys, V20, P153, DOI 10.1016/0065-227X(85)90035-8; MAJORS J, 1977, THESIS HARVARD U CAM; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCGHEE JD, 1980, ANNU REV BIOCHEM, V49, P1115, DOI 10.1146/annurev.bi.49.070180.005343; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; PASSNER J, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PERLO A, PROGRAM SZAZAM VERSI; PINKNEY M, 1988, BIOCHEM J, V250, P897, DOI 10.1042/bj2500897; PORSCHKE D, 1984, EMBO J, V3, P2873, DOI 10.1002/j.1460-2075.1984.tb02223.x; RAVISHANKER G, 1989, J BIOMOL STRUCT DYN, V6, P669, DOI 10.1080/07391102.1989.10507729; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROULD MR, 1990, PROGRAM MAXIMAGE; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SAYRE D, 1982, COMPUTATIONAL CRYSTA, P303; SCHULTZ SC, 1990, J MOL BIOL, V213, P159, DOI 10.1016/S0022-2836(05)80128-7; SHIELDS GC, UNPUB; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SOBELL HM, 1976, P NATL ACAD SCI USA, V73, P3068, DOI 10.1073/pnas.73.9.3068; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; STEITZ TA, 1983, J BIOMOL STRUCT DYN, V1, P1023, DOI 10.1080/07391102.1983.10507500; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; SUSSMAN JL, 1978, P NATL ACAD SCI USA, V75, P103, DOI 10.1073/pnas.75.1.103; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WOLBERGER C, 1988, NATURE, V335, P789, DOI 10.1038/335789a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YOON C, 1988, P NATL ACAD SCI USA, V85, P6332, DOI 10.1073/pnas.85.17.6332; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHURKIN VB, 1979, NUCLEIC ACIDS RES, V6, P1081, DOI 10.1093/nar/6.3.1081; ZINKEL SS, 1990, BIOPOLYMERS, V29, P29, DOI 10.1002/bip.360290106	91	1038	1050	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 30	1991	253	5023					1001	1007		10.1126/science.1653449	http://dx.doi.org/10.1126/science.1653449			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653449	Green Submitted			2022-12-24	WOS:A1991GC98200037
J	WALTERS, ET; ALIZADEH, H; CASTRO, GA				WALTERS, ET; ALIZADEH, H; CASTRO, GA			SIMILAR NEURONAL ALTERATIONS INDUCED BY AXONAL INJURY AND LEARNING IN APLYSIA	SCIENCE			English	Article							SENSORY NEURONS; TRANSMITTER RELEASE; PRESYNAPTIC FACILITATION; BEHAVIORAL SENSITIZATION; SYNAPTIC CONNECTIONS; CELLULAR MECHANISM; INNERVATING TAIL; GILL-WITHDRAWAL; MODULATION; SUGGESTS	Learning in the marine mollusk Aplysia has been associated with enhanced sensory function, expressed in mechanosensory neurons as (i) decreases in action potential threshold, accommodation, and afterhyperpolarization, and (ii) increases in action potential duration, afterdischarge, and synaptic transmission. These alterations also occur, with a delay, after sensory axons are injured under conditions in which synaptic transmission is severely reduced. The latency and specificity of injury-induced alterations indicate that induction signals are generated at the site of injury and conveyed centrally by axonal transport. Similarities in neuronal modifications support the hypothesis that some memory mechanisms evolved from mechanisms of injury-induced sensory compensation and repair.			WALTERS, ET (corresponding author), UNIV TEXAS,SCH MED,DEPT PHYSIOL & CELL BIOL,HOUSTON,TX 77225, USA.			Walters, Edgar/0000-0003-0718-102X	NIAID NIH HHS [AI11361] Funding Source: Medline; NIMH NIH HHS [MH38726] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI011361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038726] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABRAMS TW, 1988, TRENDS NEUROSCI, V11, P128, DOI 10.1016/0166-2236(88)90137-3; ALIZADEH H, 1990, Society for Neuroscience Abstracts, V16, P597; BILLY AJ, 1989, J NEUROSCI, V9, P1254; BRONS JF, 1980, J NEUROPHYSIOL, V44, P605, DOI 10.1152/jn.1980.44.3.605; CROW TJ, 1980, SCIENCE, V209, P412, DOI 10.1126/science.209.4454.412; DISTERHOFT JF, 1986, P NATL ACAD SCI USA, V83, P2733, DOI 10.1073/pnas.83.8.2733; FROST WN, 1985, P NATL ACAD SCI USA, V82, P8266, DOI 10.1073/pnas.82.23.8266; GLANZMAN DL, 1989, J NEUROSCI, V9, P4200; HAWKINS RD, 1983, SCIENCE, V219, P400, DOI 10.1126/science.6294833; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; KANDEL ER, 1982, SCIENCE, V218, P433, DOI 10.1126/science.6289442; KLEIN M, 1978, P NATL ACAD SCI USA, V75, P3512, DOI 10.1073/pnas.75.7.3512; KLEIN M, 1986, P NATL ACAD SCI USA, V83, P7994, DOI 10.1073/pnas.83.20.7994; MACKEY SL, 1989, J NEUROSCI, V9, P4227; SCHOLZ KP, 1987, SCIENCE, V235, P685, DOI 10.1126/science.2433766; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; WALTERS E, UNPUB; WALTERS ET, 1987, J NEUROSCI, V7, P408; WALTERS ET, 1991, BIOL BULL, V180, P241, DOI 10.2307/1542394; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1522, DOI 10.1152/jn.1983.50.6.1522; WALTERS ET, 1983, J NEUROPHYSIOL, V50, P1543, DOI 10.1152/jn.1983.50.6.1543; WALTERS ET, 1983, SCIENCE, V219, P405, DOI 10.1126/science.6294834	22	89	92	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 16	1991	253	5021					797	799		10.1126/science.1652154	http://dx.doi.org/10.1126/science.1652154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	GB295	1652154				2022-12-24	WOS:A1991GB29500041
J	PLUMMER, MR; HESS, P				PLUMMER, MR; HESS, P			REVERSIBLE UNCOUPLING OF INACTIVATION IN N-TYPE CALCIUM CHANNELS	NATURE			English	Article							SINGLE SODIUM-CHANNELS; CHICK SENSORY NEURONS; SYMPATHETIC NEURONS; CA-2+ CHANNELS; CA-CHANNEL; CURRENTS; RELEASE; SENSITIVITY; MODULATION; MEMBRANE	N-TYPE calcium channels are thought to be expressed specifically in neuronal cells 1-3 and to have a dominant role in the control of neurotransmitter release from sympathetic neurons 4, 5. But their unitary properties are poorly understood and the separation of neuronal Ca2+ current into components carried by N-type or L-type Ca2+ channels is controversial 6. Here we show that individual N-type Ca2+ channels in sympathetic neurons can carry two kinetically distinct components of current, one that is rapidly transient and one that is long lasting. The mechanism that gives rise to these two components is unexpected for Ca2+ channels: a test depolarization elicits either a rapidly inactivating, single short burst with an average duration of 40 ms, or sustained, noninactivating channel activity lasting for over 1 s. The switching between inactivating and noninactivating activity is a slow process, the occurrence of each type of unitary kinetic behaviour remaining statistically correlated over several seconds. Variable coupling of inactivation in N-type Ca2+ channels could be an effective mechanism for the modulation of neuronal excitability and synaptic plasticity.	HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; BOLAND LM, 1990, J PHYSIOL-LONDON, V420, P223, DOI 10.1113/jphysiol.1990.sp017909; COOPER E, 1989, J GEN PHYSIOL, V94, P881, DOI 10.1085/jgp.94.5.881; FISHER RE, 1990, J NEUROPHYSIOL, V64, P91, DOI 10.1152/jn.1990.64.1.91; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; HESS P, 1990, ANNU REV NEUROSCI, V13, P337, DOI 10.1146/annurev.ne.13.030190.002005; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORN R, 1984, BIOPHYS J, V45, P323, DOI 10.1016/S0006-3495(84)84158-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; JONES SW, 1989, J GEN PHYSIOL, V94, P169, DOI 10.1085/jgp.94.1.169; KONGSAMUT S, 1989, ANN NY ACAD SCI, V560, P312, DOI 10.1111/j.1749-6632.1989.tb24112.x; KOSTYUK PG, 1988, PFLUG ARCH EUR J PHY, V411, P661, DOI 10.1007/BF00580863; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MCMANUS OB, 1987, PFLUG ARCH EUR J PHY, V410, P530, DOI 10.1007/BF00586537; MOORMAN JR, 1990, NEURON, V4, P243, DOI 10.1016/0896-6273(90)90099-2; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PATLAK JB, 1989, J GEN PHYSIOL, V94, P279, DOI 10.1085/jgp.94.2.279; PATLAK JB, 1985, J GEN PHYSIOL, V86, P89, DOI 10.1085/jgp.86.1.89; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; REGAN LJ, 1991, NEURON, V6, P1; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SWANDULLA D, 1991, TRENDS NEUROSCI, V14, P46, DOI 10.1016/0166-2236(91)90018-P; USOWICZ MM, 1990, J PHYSIOL-LONDON, V426, P95, DOI 10.1113/jphysiol.1990.sp018128; Zar JH., 1999, BIOSTAT ANAL	27	116	118	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	JUN 20	1991	351	6328					657	659		10.1038/351657a0	http://dx.doi.org/10.1038/351657a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	FT112	1646965				2022-12-24	WOS:A1991FT11200068
J	BAINTON, R; GAMAS, P; CRAIG, NL				BAINTON, R; GAMAS, P; CRAIG, NL			TN7 TRANSPOSITION INVITRO PROCEEDS THROUGH AN EXCISED TRANSPOSON INTERMEDIATE GENERATED BY STAGGERED BREAKS IN DNA	CELL			English	Article							ESCHERICHIA-COLI CHROMOSOME; BACTERIOPHAGE-MU; RETROVIRAL DNA; TN10 TRANSPOSITION; TY1 TRANSPOSITION; INTEGRATION; SEQUENCE; IDENTIFICATION; REPLICATION; MECHANISM	We have developed a cell-free system in which the bacterial transposon Tn7 inserts at high frequency into its preferred target site in the Escherichia coli chromosome, attTn7; Tn7 transposition in vitro requires ATP and Tn7-encoded proteins. Tn7 transposes via a cut and paste mechanism in which the element is excised from the donor DNA by staggered double-strand breaks and then inserted into attTn7 by the joining of 3' transposon ends to 5' target ends. Neither recombination intermediates nor products are observed in the absence of any protein component or DNA substrate. Thus, we suggest that Tn7 transposition occurs in a nucleoprotein complex containing several proteins and the substrate DNAs and that recognition of attTn7 within this complex provokes strand cleavages at the Tn7 ends.	UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BAINTON, R (corresponding author), UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.			Gamas, Pascal/0000-0002-6253-4249	NIGMS NIH HHS [GMO 7618] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BARTH PT, 1976, J BACTERIOL, V125, P800, DOI 10.1128/JB.125.3.800-810.1976; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHOLS H, 1990, J BIOL CHEM, V265, P14697; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; EICHINGER DJ, 1988, CELL, V54, P955, DOI 10.1016/0092-8674(88)90110-9; EICHINGER DJ, 1990, GENE DEV, V4, P324, DOI 10.1101/gad.4.3.324; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GRINDLEY NDF, 1978, COLD SPRING HARB SYM, V43, P1257; GRINGAUZ E, 1988, J BACTERIOL, V170, P2832, DOI 10.1128/jb.170.6.2832-2840.1988; HANIFORD DB, 1991, CELL, V64, P171; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; KLECKNER N, 1990, ANNU REV CELL BIOL, V6, P297, DOI 10.1146/annurev.cb.06.110190.001501; KUBO K, 1990, J BACTERIOL, V182, P2774; LEE CH, 1983, P NATL ACAD SCI-BIOL, V80, P6765, DOI 10.1073/pnas.80.22.6765; LICHTENSTEIN C, 1982, NATURE, V297, P601, DOI 10.1038/297601a0; MCKOWN RL, 1988, J BACTERIOL, V170, P352, DOI 10.1128/jb.170.1.352-358.1988; MCKOWN RL, 1987, P NATL ACAD SCI USA, V84, P7807, DOI 10.1073/pnas.84.22.7807; MIZUUCHI K, 1984, CELL, V39, P395, DOI 10.1016/0092-8674(84)90018-7; MIZUUCHI K, 1983, CELL, V35, P785, DOI 10.1016/0092-8674(83)90111-3; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NKLECKNER N, 1989, MOBILE DNA, P227; ORLE KA, 1990, GENE, V96, P1, DOI 10.1016/0378-1119(90)90333-M; Pato ML, 1989, MOBILE DNA, P23; QADRI MI, 1989, J MOL BIOL, V207, P85, DOI 10.1016/0022-2836(89)90442-7; ROBERTS D, 1988, P NATL ACAD SCI USA, V85, P6037, DOI 10.1073/pnas.85.16.6037; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; THOMPSON JF, 1989, MOBILE DNA, P1; VARMUS H, 1989, MOBILE DNA, P53; WADDELL CS, 1989, P NATL ACAD SCI USA, V86, P3958, DOI 10.1073/pnas.86.11.3958; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137	49	127	132	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 31	1991	65	5					805	816		10.1016/0092-8674(91)90388-F	http://dx.doi.org/10.1016/0092-8674(91)90388-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FP516	1645619				2022-12-24	WOS:A1991FP51600011
J	DAVIES, K				DAVIES, K			MOVING STRAIGHT TO THE TARGET	NATURE			English	Article							GENE											ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MILLER AD, 1992, NATURE, V357, P455, DOI 10.1038/357455a0; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TRAVIS GH, 1992, NEURON, V9, P113, DOI 10.1016/0896-6273(92)90226-4; VERMA IM, 1990, SCI AM, V263, P68, DOI 10.1038/scientificamerican1190-68; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	9	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 6	1992	358	6386					519	519		10.1038/358519a0	http://dx.doi.org/10.1038/358519a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JG739	1641042	Bronze			2022-12-24	WOS:A1992JG73900055
J	FU, XY				FU, XY			A TRANSCRIPTION FACTOR WITH SH2 AND SH3 DOMAINS IS DIRECTLY ACTIVATED BY AN INTERFERON-ALPHA-INDUCED CYTOPLASMIC PROTEIN TYROSINE KINASE(S)	CELL			English	Article							GENE REGULATORY ELEMENTS; INDUCED NUCLEAR FACTORS; PHOSPHOLIPASE-C-GAMMA; CLASS-I GENES; SIGNAL TRANSDUCTION; STIMULATED TRANSCRIPTION; BINDING PROTEIN; PDGF RECEPTOR; CONSENSUS SEQUENCE; ENHANCER ELEMENT	Interferon-stimulated gene factor 3 (ISGF3), the primary transcription factor induced by interferon-alpha, is a complex of four (113, 91, 84, and 48 kd) proteins. This paper reports that the 113, 91, and 84 kd (ISGF3-alpha) proteins of ISGF3 contain conserved SH2 and SH3 domains. A specific interferon alpha-induced cytoplasmic protein tyrosine kinase(s) can form a transient complex with ISGF3-alpha proteins. These ISGF3-alpha proteins can be immunoprecipitated by anti-phosphotyrosine antibodies only after interferon-alpha treatment. Phosphoamino acid analyses of P-32-labeled ISGF3-alpha proteins confirm that ISGF3-alpha proteins are directly tyrosine phosphorylated both in vitro and in vivo in response to interferon-alpha, and this tyrosine phosphorylation can be inhibited by staurosporine and genistein. Phosphatase treatment of these ISGF3-alpha proteins results in inhibition of ISGF3 complex formation in vitro. These observations indicate that interferon alpha-induced direct tyrosine phosphorylation of ISGF3-alpha proteins is necessary for activation of the transcription factor ISGF3.			FU, XY (corresponding author), CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA.							AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDYOPADHYAY SK, 1990, MOL CELL BIOL, V10, P5055, DOI 10.1128/MCB.10.10.5055; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALE TC, 1989, EMBO J, V8, P831, DOI 10.1002/j.1460-2075.1989.tb03444.x; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEMAEYER E, 1989, INTERFERONS OTHER RE; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EISEMAN E, 1992, NATURE, V355, P78; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1992, IN PRESS P NATL ACAD; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GRIBAUDO G, 1987, J BIOL CHEM, V262, P11878; HANNIGAN GE, 1991, J BIOL CHEM, V266, P8765; HARLOW E, 1988, ANTIBODIES LABORATOR; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1989, MOL CELL BIOL, V9, P4131, DOI 10.1128/MCB.9.10.4131; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LARNER AC, 1984, P NATL ACAD SCI-BIOL, V81, P6733, DOI 10.1073/pnas.81.21.6733; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVY D, 1990, New Biologist, V2, P923; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panayotou G, 1989, CURR OPIN CELL BIOL, V1, P167, DOI 10.1016/0955-0674(89)90082-3; PAWSON T, 1988, ONCOGENE, V3, P491; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PFEFFER LM, 1991, P NATL ACAD SCI USA, V88, P7988, DOI 10.1073/pnas.88.18.7988; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; RODAWAY ARF, 1990, MOL CELL BIOL, V10, P5388, DOI 10.1128/MCB.10.10.5388; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SALTZMAN EM, 1989, J BIOL CHEM, V264, P19979; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHINDLER C, 1992, IN PRESS SCIENCE; SCHINDLER C, 1992, IN PRESS P NATL ACAD; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TIWARI RK, 1987, EMBO J, V6, P3373, DOI 10.1002/j.1460-2075.1987.tb02659.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P427; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1992, IN PRESS MOL CELL BI; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VOGEL J, 1986, MOL CELL BIOL, V6, P3550, DOI 10.1128/MCB.6.10.3550; WATERFIELD MD, 1991, METHOD ENZYMOL, V200, P627; WATHELET MG, 1987, EUR J BIOCHEM, V169, P313, DOI 10.1111/j.1432-1033.1987.tb13614.x; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; [No title captured]; [No title captured]	125	379	400	2	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					323	335		10.1016/0092-8674(92)90106-M	http://dx.doi.org/10.1016/0092-8674(92)90106-M			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638633				2022-12-24	WOS:A1992JE75700015
J	HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A				HELIN, K; LEES, JA; VIDAL, M; DYSON, N; HARLOW, E; FATTAEY, A			A CDNA-ENCODING A PRB-BINDING PROTEIN WITH PROPERTIES OF THE TRANSCRIPTION FACTOR E2F	CELL			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE T-ANTIGEN; ADENOVIRUS E1A PROTEINS; REGION 1A PROTEINS; SV40 LARGE-T; CELL-CYCLE; DNA-BINDING; RB GENE; REGULATORY SEQUENCES; TRANS-ACTIVATION	The retinoblastoma protein (PRB) plays an important role in the control of cell proliferation, apparently by binding to and regulating cellular transcription factors such as E2F. Here we describe the characterization of a cDNA clone that encodes a protein with properties of E2F. This clone, RBP3, was identified by the ability of its gene product to interact with pRB. RBP3 bound to pRB both in vitro and in vivo, and this binding was competed by viral proteins known to disrupt pRB-E2F association. RBP3 bound to E2F recognition sequences in a sequence-specific manner. Furthermore, transient expression of RBP3 caused a 10-fold transactivation of the adenovirus E2 promoter, and this transactivation was dependent on the E2F recognition sequences. These properties suggest that RBP3 encodes E2F, or an E2F-like protein.			HELIN, K (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02129 USA.		Helin, Kristian/K-2526-2019; Helin, Kristian/HDM-8306-2022	Helin, Kristian/0000-0003-1975-6097				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EDWARDS GM, 1992, J BIOL CHEM, V267, P7971; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIVJI MKK, 1991, MOL CELL BIOL, V11, P1686, DOI 10.1128/MCB.11.3.1686; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YEE AS, 1987, EMBO J, V6, P2061, DOI 10.1002/j.1460-2075.1987.tb02471.x; YEE AS, 1989, MOL CELL BIOL, V9, P578, DOI 10.1128/MCB.9.2.578	79	651	685	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 24	1992	70	2					337	350		10.1016/0092-8674(92)90107-N	http://dx.doi.org/10.1016/0092-8674(92)90107-N			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JE757	1638634				2022-12-24	WOS:A1992JE75700016
J	LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC				LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC			HOSPITAL-ACQUIRED INFECTION WITH VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM TRANSMITTED BY ELECTRONIC THERMOMETERS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECIUM; GROSS INFECTION; DRUG RESISTANCE, MICROBIAL; VANCOMYCIN; THERMOMETERS	TRANSFERABLE RESISTANCE; ENDOCARDITIS; FAECALIS; INVITRO	Objectives: To describe an epidemic of vancomycin-resistant Enterococcus faecium causing bacteremia and bacteriuria, to identify the source of infection, to delineate risk factors associated with acquisition of the organism, and to determine antibiotic sensitivities for the organism. Design: Investigation of an epidemic, including a case-control study. Setting: Medical-surgical intensive care unit and ward in a university medical center. Patients: Nine patients infected or colonized with vancomycin-resistant Enterococcus faecium and 20 noninfected controls. Measurements: Clinical data, environmental surveillance cultures, and in-vitro microbiologic studies. Results: Colonization or infection by vancomycin-resistant E. faecium was associated with an increased duration of treatment with ceftazidime, 13.2 compared with 4.6 days, and a greater number of nonisolated days of hospitalization in the intensive care unit, 19.9 compared with 6.4 days for infected and noninfected patients, respectively (P < 0.05). Environmental surveillance cultures recovered the organism repeatedly from the rectal probe handles of three electronic thermometers used exclusively on nonisolated patients in the intensive care unit. Restriction endonuclease analysis of plasmid DNA showed that all clinical and environmental isolates were identical. Infection control measures, including isolation of colonized or infected patients and removal of the rectal thermometer probes suspected to be responsible for transmission, resulted in termination of the outbreak. In-vitro, time-kill studies showed that the combination of ciprofloxacin, rifampin, and gentamicin resulted in bactericidal activity against the organism. Conclusions: This nosocomial outbreak of infection due to a highly vancomycin-resistant strain of Enterococcus is the first epidemic in which an electronic thermometer has been implicated as the vehicle of transmission for an infectious agent.	DEPT VET AFFAIRS, PHILADELPHIA, PA USA; MED COLL PENN, PHILADELPHIA, PA 19129 USA	Drexel University								BENNETT PM, 1986, J ANTIMICROB CHEMOTH, V18, P421, DOI 10.1093/jac/18.3.421; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKS S, 1990, INFECT CONT HOSP EP, V11, P574; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P2291, DOI 10.1128/AAC.34.12.2291; ELIOPOULOS GM, 1989, REV INFECT DIS, V11, pS1210; FERNANDEZGUERRERO M, 1987, ANTIMICROB AGENTS CH, V31, P430, DOI 10.1128/AAC.31.3.430; French G L, 1981, J Hosp Infect, V2, P389, DOI 10.1016/0195-6701(81)90074-8; HERMAN DJ, 1991, ANTIMICROB AGENTS CH, V35, P215, DOI 10.1128/AAC.35.2.215; Im S W, 1981, J Hosp Infect, V2, P171, DOI 10.1016/0195-6701(81)90026-8; KAPLAN AH, 1988, J CLIN MICROBIOL, V26, P1216, DOI 10.1128/JCM.26.6.1216-1218.1988; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KREISWIRTH BN, 1991, 31ST INT C ANT AG CH, P131; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; MANDELL GL, 1970, ARCH INTERN MED, V125, P258, DOI 10.1001/archinte.125.2.258; MCALLISTER TA, 1986, LANCET, V1, P1262; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1121, DOI 10.1128/AAC.33.7.1121; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P71, DOI 10.1128/AAC.33.1.71; SCHOENKNECHT FD, 1985, MANUAL CLIN MICROBIO, P1000; SHLAES DM, 1989, J ANTIMICROB CHEMOTH, V23, P503, DOI 10.1093/jac/23.4.503; SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198; SMITH L, 1981, INFECT CONT HOSP EP, V2, P315, DOI 10.1017/S0195941700055363; SMITH SM, 1988, DIAGN MICR INFEC DIS, V9, P239, DOI 10.1016/0732-8893(88)90115-0; UTTLEY AHC, 1988, LANCET, V1, P57; WASHINGTON JA, 1985, MANUAL CLIN MICROBIO, P972; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687	27	379	387	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					112	116		10.7326/0003-4819-117-2-112	http://dx.doi.org/10.7326/0003-4819-117-2-112			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605425				2022-12-24	WOS:A1992JD12300003
J	TAYLOR, TC; KAHN, RA; MELANCON, P				TAYLOR, TC; KAHN, RA; MELANCON, P			2 DISTINCT MEMBERS OF THE ADP-RIBOSYLATION FACTOR FAMILY OF GTP-BINDING PROTEINS REGULATE CELL-FREE INTRA-GOLGI TRANSPORT	CELL			English	Article							ADENYLATE-CYCLASE; VESICULAR TRANSPORT; MOLECULAR-WEIGHT; BOVINE BRAIN; YEAST; PURIFICATION; SECRETION; COMPARTMENTS; LOCALIZATION; EXPRESSION	We have used an intra-Golgi transport assay to identify GTP-binding proteins involved in regulation of protein traffic. Two soluble proteins of 20 kd were purified by their ability to mediate GTP-gamma-S-dependent inhibition of transport. These GTP-dependent Golgi binding factors, or GGBFs, exhibit a 3-fold difference in activity and are differentiated by their hydrophobicity, isoelectric points, and apparent size. Removal of 80% of GGBFs from cytosol abolishes GTP-gamma-S sensitivity but does not affect inhibition by aluminum fluoride. We demonstrate that GGBFs are members of the ADP-ribosylation factor (ARF) family. Recombinant ARF1 exhibits GGBF activity and myristoylation is required. The distinct biochemical properties of GGBFs indicate that members of the ARF family may have related but distinct functions in intracellular transport.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAYLOR, TC (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Kahn, Richard/ABD-2666-2020; Melancon, Paul/P-1304-2018	Kahn, Richard/0000-0002-0259-0601; Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, IN PRESS J BIOL CHEM; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, IN PRESS NATURE; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1992, IN PRESS J BIOL CHEM; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LENHARD JM, 1992, IN PRESS J BIOL CHEM; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MELANCON P, 1989, SECRETION ITS CONTRO, P175; MELMAN I, 1992, CELL, V68, P829; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, CELL, V64, P1183; Penefsky H S, 1979, Methods Enzymol, V56, P527; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WEISS O, 1989, J BIOL CHEM, V264, P21066	54	124	124	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					69	79		10.1016/0092-8674(92)90534-J	http://dx.doi.org/10.1016/0092-8674(92)90534-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623523				2022-12-24	WOS:A1992JC95700009
J	EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT				EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT			MONITORING FOR MYOCARDIAL-ISCHEMIA DURING NONCARDIAC SURGERY - A TECHNOLOGY-ASSESSMENT OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY AND 12-LEAD ELECTROCARDIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; PERIPHERAL VASCULAR-SURGERY; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; WALL-MOTION ABNORMALITIES; CARDIAC SURGICAL PROCEDURES; CORONARY-ARTERY DISEASE; INTRAOPERATIVE DETECTION; RISK; INFARCTION; ANGIOPLASTY	Objective.-Transesophageal echocardiography (TEE) and 12-lead electrocardiography (ECG) are sophisticated techniques that are increasingly being used to monitor for myocardial ischemia during noncardiac surgery. We examined whether the routine use of these techniques has incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes when compared with preoperative clinical data and intraoperative monitoring using continuous two-lead bipolar ECG. Design.-Cohort study. Setting.-Veterans Affairs medical center. Patients.-A total of 332 men undergoing noncardiac surgery who had or were at high risk for coronary artery disease. Interventions.-TEE, 12-lead ECG, and two-lead ECG were performed continuously during noncardiac surgery (47% vascular, 53% nonvascular). Monitoring results were not available to anesthesiologists or surgeons, and data were blindly analyzed after surgery. Main Outcome Measure.-Perioperative ischemic outcomes (cardiac death, nonfatal myocardial infarction, unstable angina). Results.-In a subset of 285 patients who were adequately studied by all three techniques, 111 patients (39%) were identified as having intraoperative myocardial ischemia (by one or more monitoring techniques). By univariate analysis, intraoperative ischemia was associated with all perioperative cardiac outcomes, including ischemic outcomes, congestive heart failure, and ventricular tachycardia (P less-than-or-equal-to .02 for each of the three monitoring techniques). However, when monitoring results for TEE and 12-lead ECG were added to a multivariate model that included preoperative clinical data and continuous two-lead ECG results, the incremental value of TEE was small (odds ratio, 2.6; 95% confidence interval [CI], 1.2 to 5.7; P=.02) and that of 12-lead ECG was not significant (odds ratio, 1.5; 95% CI, 0.6 to 3.8). Furthermore, when the multivariate analysis was repeated with only ischemic outcomes, neither TEE nor 12-lead ECG retained significant associations (odds ratio, 2.2; 95% CI, 0.5 to 9.4, and odds ratio, 1.1; 95% CI, 0.2 to 6.1, respectively). Conclusion.-When compared with preoperative clinical data and intraoperative monitoring using two-lead ECG, routine monitoring for myocardial ischemia with TEE or 12-lead ECG during noncardiac surgery has little incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes.	UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [HL 07192, R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, T32HL007192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUPRE PN, 1984, AM HEART J, V107, P1021, DOI 10.1016/0002-8703(84)90844-5; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CHAITMAN BR, 1978, CIRCULATION, V57, P71, DOI 10.1161/01.CIR.57.1.71; CHUNG F, 1991, CAN J ANAESTH, V38, P98, DOI 10.1007/BF03009170; CLEMENTS FM, 1987, ANESTH ANALG, V66, P249; COHEN M, 1987, J AM COLL CARDIOL, V10, P17, DOI 10.1016/S0735-1097(87)80154-7; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; GEWERTZ BL, 1987, J VASC SURG, V5, P607, DOI 10.1067/mva.1987.avs0050607; GIANNUZZI P, 1989, EUR HEART J, V10, P880, DOI 10.1093/oxfordjournals.eurheartj.a059396; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAGGMARK S, 1989, ANESTHESIOLOGY, V70, P19; HAUSER AM, 1985, J AM COLL CARDIOL, V5, P193, DOI 10.1016/S0735-1097(85)80036-X; KREMER P, 1983, CIRCULATION, V68, P332; KREMER P, 1982, AM J CARDIOL, V49, P956, DOI 10.1016/0002-9149(82)92230-5; KRUCOFF MW, 1987, J ELECTROCARDIOL, V20, P15; LEUNG JM, 1989, ANESTHESIOLOGY, V71, P16, DOI 10.1097/00000542-198907000-00004; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MATSUMOTO M, 1980, AM J CARDIOL, V46, P95, DOI 10.1016/0002-9149(80)90611-6; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROIZEN MF, 1984, J VASC SURG, V1, P300, DOI 10.1067/mva.1984.avs0010300; ROY WL, 1979, ANESTHESIOLOGY, V51, P393, DOI 10.1097/00000542-197911000-00005; SHIVELY B, 1986, J AM COLL CARDIOL, V7, pA2; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002; SMITH JS, 1985, CIRCULATION, V72, P1015, DOI 10.1161/01.CIR.72.5.1015; TOPOL EJ, 1984, J AM COLL CARDIOL, V4, P1123, DOI 10.1016/S0735-1097(84)80131-X; VONKNORRING J, 1986, SURGERY, V99, P610; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7; 1989, PHS891232 DEP HLTH H; 1978, MANUAL OPERATIONS, V2	36	102	105	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					210	216		10.1001/jama.268.2.210	http://dx.doi.org/10.1001/jama.268.2.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608139				2022-12-24	WOS:A1992JB27900027
J	AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG				AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG			INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	SCIENCE			English	Article							PERSISTENT INFECTION; RHESUS-MONKEYS; HIV INFECTION; MOLECULAR CLONE; CD4 RECEPTOR; T-CELL; AIDS; CHIMPANZEES; MACAQUES; RETROVIRUSES	After observations that Macaca nemestrina were exceptionally susceptible to simian immunodeficiency virus and human immunodeficiency virus type-2 (HIV-2), studies of HIV-1 replication were initiated. Several strains of HIV-1, including a recent patient isolate, replicated in vitro in peripheral blood mononuclear cells (PBMCs) and in CD4-positive M. nemestrina lymphocytes in a CD4-dependent fashion. Eight animals were subsequently inoculated with either cell-associated or cell-free suspensions of HIV-1. All animals had HIV-1 isolated by cocultivation, had HIV-1 DNA in their PBMCs as shown by polymerase chain reaction, and experienced sustained seroconversion to a broad spectrum of HIV-1 proteins. Macaca nemestrina is an animal model of HIV-1 infections that provides opportunities for evaluating the pathogenesis of acute HIV-1 replication and candidate vaccines and therapies.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University			Wolinsky, Steven/B-2893-2012; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI27757, AI26503] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGY MB, 1990, VIROLOGY, V177, P251, DOI 10.1016/0042-6822(90)90478-A; AGY MB, 1991, VIROLOGY, V183, P170, DOI 10.1016/0042-6822(91)90130-4; AGY MB, UNPUB; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHAFFEE S, 1988, J EXP MED, V168, P605, DOI 10.1084/jem.168.2.605; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMATO JJ, 1988, LAB MED, V19, P753; DORMONT D, 1989, INTERVIROLOGY, V30, P59, DOI 10.1159/000150125; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FRANCHINI G, 1990, J VIROL, V64, P4462, DOI 10.1128/JVI.64.9.4462-4467.1990; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; GAJDUSEK DC, 1985, LANCET, V1, P55; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KOEHLER JA, UNPUB; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kraiselburd E N, 1990, P R Health Sci J, V9, P161; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LUSSO P, 1988, J IMMUNOL, V141, P2467; MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; MORTON WR, UNPUB; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NARA P, 1989, J MED PRIMATOL, V18, P343; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHNEIDER J, 1988, AIDS, V2, P1, DOI 10.1097/00002030-198802000-00001; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992	47	161	172	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					103	106		10.1126/science.1621083	http://dx.doi.org/10.1126/science.1621083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621083				2022-12-24	WOS:A1992JC16500041
J	FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM				FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM			THE ARGOS GENE ENCODES A DIFFUSIBLE FACTOR THAT REGULATES CELL FATE DECISIONS IN THE DROSOPHILA EYE	CELL			English	Article							SEGMENT POLARITY GENE; NERVOUS-SYSTEM; RECEPTOR; HOMOLOG; MELANOGASTER; WINGLESS; CLONING; EMBRYOS; PROTEIN; DIFFERENTIATION	The argos gene encodes a protein that is required for viability and that regulates the determination of cells in the Drosophila eye. A developmental analysis of argos mutant eyes indicates that the mystery cells, which are usually nonneuronal, are transformed into extra photoreceptors, and that supernumerary cone cells and pigment cells are also recruited. Clonal analysis indicates that argos acts nonautonomously and can diffuse over the range of several cell diameters. Conceptual translation of the argos gene suggests that it encodes a secreted protein.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703; Freeman, Matthew/0000-0003-0410-5451				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMAYA E, 1991, CELL, V66, P257; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; DANIELS SB, 1985, GENETICS, V109, P95; FISCHERVIZE JA, 1992, IN PRESS DEVELOPMENT; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAY RP, 1991, DEVELOPMENT, V113, P35; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wieschaus E., 1986, P199; WOLFF T, 1991, DEVELOPMENT, V113, P825	59	218	222	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					963	975		10.1016/0092-8674(92)90615-J	http://dx.doi.org/10.1016/0092-8674(92)90615-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606617				2022-12-24	WOS:A1992HY79200008
J	HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD				HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD			TRANSIENT TRANSLATIONAL SILENCING BY REVERSIBLE MESSENGER-RNA DEADENYLATION	CELL			English	Article							XENOPUS OOCYTE MATURATION; MOUSE OOCYTES; PLASMINOGEN-ACTIVATOR; MEIOTIC MATURATION; POLY(A) ADDITION; RICH SEQUENCES; CYTOPLASMIC POLYADENYLATION; SPISULA OOCYTES; DEGRADATION; FERTILIZATION	Tissue-type plasminogen activator (tPA) mRNA is stored, stable and untranslated, in the cytoplasm of fully grown primary mouse oocytes. Dormancy is associated with an unusually short poly(A) tail, and poly(A) tail elongation controls tPA mRNA translational activation during meiotic maturation. Here we show that the nuclear transcript of this mRNA is extensively polyadenylated and that primary oocytes contain a deadenylating activity capable of silencing the cytoplasmic message. The sequence determinants that control deadenylation and polyadenylation overlap; this AU-rich region thus serves as an adenylation control element (ACE). The translation of a reporter mRNA in primary oocytes is prevented upon inclusion of an ACE in its 3' untranslated region. Therefore, the stage-specific regulation of poly(A) tail length accounts for the regulated synthesis of tPA in oocytes, and reversible deadenylation provides a mechanism for the translational control of dormant mRNAs.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; UNIV GENEVA, SCH MED, DEPT PATHOL, CH-1211 GENEVA 4, SWITZERLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Geneva	HUARTE, J (corresponding author), UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017875, R01HD025922] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25922, HD-17875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; BACHVAROVA R, 1985, DEV BIOL, V108, P325, DOI 10.1016/0012-1606(85)90036-3; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; FENG P, 1990, J BIOL CHEM, V265, P2022; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; HAN J, 1991, J IMMUNOL, V146, P1843; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; ROSENTHAL ET, 1983, J MOL BIOL, V166, P309, DOI 10.1016/S0022-2836(83)80087-4; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; SALES FJ, 1992, IN PRESS GENES DEV; Sambrook J., 1989, MOL CLONING LAB MANU; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	35	208	209	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1021	1030		10.1016/0092-8674(92)90620-R	http://dx.doi.org/10.1016/0092-8674(92)90620-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606611				2022-12-24	WOS:A1992HY79200013
J	DIRICK, L; MOLL, T; AUER, H; NASMYTH, K				DIRICK, L; MOLL, T; AUER, H; NASMYTH, K			A CENTRAL ROLE FOR SWI6 IN MODULATING CELL-CYCLE START-SPECIFIC TRANSCRIPTION IN YEAST	NATURE			English	Article							HO GENE; CEREVISIAE; SEQUENCE	MOST genes involved in DNA replication in the yeast Saccharomyces cerevisiae are transcribed transiently during late G1 as cells become committed to a new cell cycle at Start 1. Their promoters all contain one or more versions of an 8-base-pair motif (ACGCGTNA) containing an MluI restriction enzyme site and called the MluI cell-cycle box (MCB) 2. MCBs are both necessary and sufficient for the late G1-specific transcription of the TMP1 thymidylate synthase and POL1 DNA polymerase genes 3,4. A different late G1-specific 8-base-pair transcription element called the SCB (CACGAAAA; ref. 5) is bound by a factor containing the Swi4 and Swi6 proteins 6,7. We describe here the formation in vitro of complexes on TMP1 MCBs that contain the Swi6 protein and, we suggest, a protein of relative molecular mass 120,000 (p120) that is distinct from Swi4. Transcription due to SCBs and MCBs occurs in the absence of Swi6 but it is no longer correctly regulated in the cell cycle. We suggest that Swi6 is an essential regulatory subunit of two different Start-dependent transcription factors. One factor (SBF) contains Swi4 and binds to SCBs, whereas the other (MBF) contains the protein p120 and binds MCBs.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Auer, Herbert/AAV-2332-2020	Nasmyth, Kim/0000-0001-7030-4403				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P803; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Maxam A M, 1980, Methods Enzymol, V65, P499; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MOLL T, IN PRESS J CELL SCI; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000	26	163	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					508	513		10.1038/357508a0	http://dx.doi.org/10.1038/357508a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608451				2022-12-24	WOS:A1992HY05200067
J	PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR				PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR			AMINOACYL ESTERASE-ACTIVITY OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; GROUP-I INTRON; BINDING-SITE; ENDORIBONUCLEASE ACTIVITY; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; RIBONUCLEASE-P; CATALYSIS; CLEAVAGE; SUBSTRATE	Several classes of ribozymes (catalytic RNA's) catalyze reactions at phosphorus centers, but apparently no reaction at a carbon center has been demonstrated. The active site of the Tetrahymena ribozyme was engineered to bind an oligonucleotide derived from the 3' end of N-formyl-methionyl-tRNA(fMet). This ribozyme catalyzes the hydrolysis of the aminoacyl ester bond to a modest extent, 5 to 15 times greater than the uncatalyzed rate. Catalysis involves binding of the oligonucleotide to the internal guide sequence of the ribozyme and requires Mg2+ and sequence elements of the catalytic core. The ability of RNA to catalyze reactions with aminoacyl esters expands the catalytic versatility of RNA and suggests that the first aminoacyl tRNA synthetase could have been an RNA molecule.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of California System; University of California Santa Cruz								ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Benkovic S. J, 1973, ENZYMES, P201; Benkovic S. J., 1978, TRANSITION STATES BI, P493; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BUERGI HB, 1973, J AM CHEM SOC, V95, P5605; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DESLONGC.P, 1972, CAN J CHEMISTRY, V50, P3405, DOI 10.1139/v72-549; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FORSTER AC, 1990, SCIENCE, V249, P784; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, UNPUB; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; Monro RE., 1971, METHOD ENZYMOL, V20, P472; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PACE NR, 1990, J BIOL CHEM, V265, P3587; PICCIRILLI JA, UNPUB; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SYMONS RH, 1991, CRIT REV PLANT SCI, V10, P189, DOI 10.1080/07352689109382312; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TAIJI M, 1985, BIOCHEMISTRY-US, V24, P5776, DOI 10.1021/bi00342a013; VISSER CM, 1984, ORIGINS LIFE EVOL B, V14, P291, DOI 10.1007/BF00933670; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WESTHEIMER FH, 1986, NATURE, V319, P534, DOI 10.1038/319534a0; White H. I., 1982, PYRIDINE NUCLEOTIDE; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C.R., 1967, MOL BASIS GENETIC EX, P186; WOLFENDEN R, 1963, BIOCHEMISTRY-US, V2, P1090, DOI 10.1021/bi00905a031; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	61	165	176	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1420	1424		10.1126/science.1604316	http://dx.doi.org/10.1126/science.1604316			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604316				2022-12-24	WOS:A1992HX33700027
J	HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK				HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK			REPRODUCIBLE IMAGING AND DISSECTION OF PLASMID DNA UNDER LIQUID WITH THE ATOMIC FORCE MICROSCOPE	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; NUCLEIC-ACIDS; WATER; RESOLUTION; SURFACE; IMAGES; AIR	Reproducible images of uncoated DNA in the atomic force microscope (AFM) have been obtained by imaging plasmid DNA on mica in n-propanol. Specially sharpened AFM tips give images with reproducible features several nanometers in size along the DNA. Plasmids can be dissected in propanol by increasing the force applied by the AFM tip at selected locations.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; DIGITAL INSTRUMENTS INC,SANTA BARBARA,CA 93117	University of Oregon	HANSMA, HG (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106, USA.			Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032543, R37GM032543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAMA Y, 1990, J VAC SCI TECHNOL A, V8, P429, DOI 10.1116/1.576413; ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ALLEN MJ, IN PRESS ULTRAMICROS; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, EUROPHYS LETT, V3, P1281, DOI 10.1209/0295-5075/3/12/006; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HANSMA HG, 1991, J VAC SCI TECHNOL B, V9, P1282, DOI 10.1116/1.585221; HECKL WM, 1991, P NATL ACAD SCI USA, V88, P8003, DOI 10.1073/pnas.88.18.8003; HECKL WM, IN PRESS ULTRAMICROS; HECKL WM, 1992, NONLINEAR OPTICS, V1, P53; HENDERSON E, IN PRESS NUCLEIC ACI; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Israelachvili JN, 1985, INTERMOLECULAR SURFA; JEFFREY GA, 1991, HYDROGEN BONDONG BIO; KELLER D, IN PRESS SURF SCI; KOLLER T, 1974, BIOPOLYMERS, V13, P995, DOI 10.1002/bip.1974.360130514; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LEE KL, 1989, J VAC SCI TECHNOL B, V7, P1941, DOI 10.1116/1.584652; LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694; LIU CY, 1991, LANGMUIR, V7, P1138, DOI 10.1021/la00054a020; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHNEIR J, 1986, PHYS REV B, V34, P4979, DOI 10.1103/PhysRevB.34.4979; VASILE MJ, 1991, REV SCI INSTRUM, V62, P2167, DOI 10.1063/1.1142334; VESENKA J, IN PRESS ULTRAMICROS; WEISENHORN AL, 1989, APPL PHYS LETT, V54, P2651, DOI 10.1063/1.101024; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003	33	484	497	0	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1180	1184		10.1126/science.256.5060.1180	http://dx.doi.org/10.1126/science.256.5060.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589799				2022-12-24	WOS:A1992HV19200028
J	HUME, RI; DINGLEDINE, R; HEINEMANN, SF				HUME, RI; DINGLEDINE, R; HEINEMANN, SF			IDENTIFICATION OF A SITE IN GLUTAMATE RECEPTOR SUBUNITS THAT CONTROLS CALCIUM PERMEABILITY	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; CENTRAL NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; CHLORIDE CURRENT; XENOPUS OOCYTES; CHANNELS; NEURONS; FAMILY; INJECTION; CLONING	The neurotransmitter glutamate mediates excitatory synaptic transmission throughout the brain. A family of genes encoding subunits of the non-N-methyl-D-aspartate (non-NMDA) type of glutamate receptor has been cloned. Some combinations of these subunits assemble into receptors with a substantial permeability to calcium, whereas others do not. To investigate the structural features that control ion permeation through these ligand-gated channels, mutant receptors subunits with single-amino acid changes were constructed. Mutation of a certain amino acid that results in a net charge change (from glutamine to arginine or vice versa) alters both the current-voltage relation and the calcium permeability of non-NMDA receptors. A site has thus been identified that regulates the permeation properties of these glutamate receptors.	SALK INST BIOL STUDIES, MOLEC NEUROBIOL LAB, LA JOLLA, CA 92037 USA; UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Salk Institute; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill			, Richard/AAI-5000-2020; dingledine, Ray/F-5173-2011	Dingledine, Ray/0000-0001-7128-4520; Hume, Richard/0000-0001-9807-112X	NINDS NIH HHS [NS25782, NS28709, NS21043] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021043, R01NS025782, R01NS028709] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; BOTON R, 1989, J PHYSIOL-LONDON, V408, P511, DOI 10.1113/jphysiol.1989.sp017473; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DASCAL N, 1986, SCIENCE, V231, P1147, DOI 10.1126/science.2418503; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DINGLEDINE R, UNPUB; GILBERTSON TA, 1991, SCIENCE, V251, P1613, DOI 10.1126/science.1849316; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; MURPHY SN, 1987, J NEUROSCI, V7, P4145; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3	23	621	634	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 30	1991	253	5023					1028	1031		10.1126/science.1653450	http://dx.doi.org/10.1126/science.1653450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	GC982	1653450				2022-12-24	WOS:A1991GC98200045
J	GOODWIN, FK				GOODWIN, FK			ALCOHOL, CAFFEINE, AND FETAL CELLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											GOODWIN, FK (corresponding author), ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,ROCKVILLE,MD 20857, USA.							HENDERSON GI, 1991, ALCOHOL CLIN EXP RES, V15, P175, DOI 10.1111/j.1530-0277.1991.tb01850.x	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	1991	266	8					1056	1056						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GB975	1650851				2022-12-24	WOS:A1991GB97500008
J	CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M				CORDONCARDO, C; TAPLEY, P; JING, SQ; NANDURI, V; OROURKE, E; LAMBALLE, F; KOVARY, K; KLEIN, R; JONES, KR; REICHARDT, LF; BARBACID, M			THE TRK TYROSINE PROTEIN-KINASE MEDIATES THE MITOGENIC PROPERTIES OF NERVE GROWTH-FACTOR AND NEUROTROPHIN-3	CELL			English	Article							FACTOR NGF RECEPTORS; MOLECULAR-CLONING; FACTOR FAMILY; GENE-TRANSFER; HIGH-AFFINITY; PC12 CELLS; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; EXPRESSION; ONCOGENE	The product of the trk proto-oncogene encodes a receptor for nerve growth factor (NGF). Here we show that NGF is a powerful mitogen that can induce resting NIH 3T3 cells to enter S phase, grow in semisolid medium, and become morphologically transformed. These mitogenic effects are absolutely dependent on expression of gp140trk receptors, but do not require the presence of the previously described low affinity NGF receptor. gp140trk also serves as a receptor for the related factor neurotrophin-3 (NT-3), but not for brain-derived neurotrophic factor. Both NGF and NT-3 induce the rapid phosphorylation of gp140trk receptors and the transient expression of c-Fos proteins. However, NT-3 appears to elicit more limited mitogenic responses than NGF. These results indicate that the product of the trk proto-oncogene is sufficient to mediate signal transduction processes induced by NGF and NT-3, at least in proliferating cells.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,GROWTH REGULAT LAB,PRINCETON,NJ 08543; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,BIOTECHNOL LAB,PRINCETON,NJ 08543; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	Bristol-Myers Squibb; Bristol-Myers Squibb; Howard Hughes Medical Institute; University of California System; University of California San Francisco	CORDONCARDO, C (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,MOLEC ONCOL LAB,POB 4000,PRINCETON,NJ 08543, USA.		Klein, Ruediger/C-6147-2008; Kovary, Karla/E-3979-2013; Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017	Klein, Ruediger/0000-0002-3109-0163; Lamballe, Fabienne/0000-0001-7631-942X; JONES, KEVIN/0000-0002-3802-7562	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016033] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016033-190014, P01 NS016033] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; BARBACID M, 1991, IN PRESS ACTA REV CA; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURSTEIN DE, 1982, DEV BIOL, V94, P477, DOI 10.1016/0012-1606(82)90364-5; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HEMPSTEAD B, 1988, COLD SPRING HARB SYM, V53, P477, DOI 10.1101/SQB.1988.053.01.055; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, SCIENCE, V243, P373, DOI 10.1126/science.2536190; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOSANG M, 1985, J BIOL CHEM, V260, P655; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1987, BIOCHEM PHARMACOL, V36, P4189, DOI 10.1016/0006-2952(87)90658-7; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1991, BIOCHEM BIOPH RES CO, V174, P379, DOI 10.1016/0006-291X(91)90531-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; KLEIN R, 1991, IN PRESS CELL, V66; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LILLIEN LE, 1985, NATURE, V317, P632, DOI 10.1038/317632a0; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASSAGUE J, 1981, J BIOL CHEM, V256, P9419; MATSUSHIMA H, 1990, MOL CELL BIOL, V10, P5015, DOI 10.1128/MCB.10.9.5015; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PLEASURE SJ, 1990, P NATL ACAD SCI USA, V87, P8496, DOI 10.1073/pnas.87.21.8496; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REPRESA J, 1989, DEV BIOL, V134, P21, DOI 10.1016/0012-1606(89)90074-2; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; ROSS R, 1987, ANNU REV MED, V38, P71, DOI 10.1146/annurev.med.38.1.71; SUTTER A, 1979, J BIOL CHEM, V254, P5972; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	59	499	513	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 12	1991	66	1					173	183		10.1016/0092-8674(91)90149-S	http://dx.doi.org/10.1016/0092-8674(91)90149-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	FW913	1649007	Green Accepted			2022-12-24	WOS:A1991FW91300019
